[
{"Name" : "ORZID GMENU ABX GENRL ALT AM LIST", "Contents" : [
{"Row" : 4, "Column" : 1, "Item" : "PSJIZID ALT ACYCLOVIR 500MG IV BID", "Text" : "Acyclovir IV", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "PSJZID ALT ACYCLOVIR 800MG PO TID", "Text" : "Acyclovir PO", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJIZID ALT AMIKACIN 250MG IV QDAY", "Text" : "Amikacin IV", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJZID ALT AMOXICILLIN 500MG PO TID", "Text" : "Amoxicillin PO", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJZID ALT AMOXICILLIN-CLAVULANATE 875MG PO BID", "Text" : "Amoxicillin-clavulanate PO", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX ALT AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "Amphotericin B Liposomal (Ambisome)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID ALT AMPICILLIN 2GM IV Q6H", "Text" : "Ampicillin IV", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID ALT AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam IV", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID ALT ATOVAQUONE SUSP 750MG PO BID", "Text" : "Atovaquone PO", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID ALT AZITHROMYCIN 500MG ONCE THEN 250MG QD 4DS", "Text" : "Azithromycin IV", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID ALT AZITHROMYCIN 500MG PO ONCE THEN 250 QD 4DS", "Text" : "Azithromycin PO", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID ALT AZTREONAM 2GM IV Q8H", "Text" : "Aztreonam IV", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID ALT BENZATHINE PENICILLIN 1.2MU IM ONCE", "Text" : "Benzathine Penicillin IM", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID ALT CEFADROXIL 500MG PO Q12H", "Text" : "Cefadroxil PO", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID ALT CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin IV", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "Text" : "Cefdinir PO", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID ALT CEFEPIME 2GM IV Q8H", "Text" : "Cefepime IV", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID ALT CEFOTETAN IV 2GM Q12H", "Text" : "Cefotetan IV", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID ALT CEFOXITIN 2GM IV Q6H", "Text" : "Cefoxitin IV", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID ALT CEFPODOXIME 200MG PO Q12H", "Text" : "Cefpodoxime PO", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID ALT CEFTAZIDIME 2GM IV Q8H", "Text" : "Ceftazidime IV", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID ALT CEFTRIAXONE 500MG IM ONCE", "Text" : "Ceftriaxone IM", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID ALT CEFTRIAXONE 2GM IV QDAY", "Text" : "Ceftriaxone IV", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID ALT CEFUROXIME 500MG PO BID", "Text" : "Cefuroxime PO", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID ALT CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin PO", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID ALT CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin IV", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ALT CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin PO", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID ALT CLARITHROMYCIN 500MG PO BID", "Text" : "Clarithromycin PO", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID ALT CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin IV", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID ALT CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin PO", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID ALT CLINDAMYCIN 2% CRM VAG APPLFUL QHS", "Text" : "Clindamycin Vaginal", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJZID ALT CLOTRIM 1% CRM TOP TO AFFECT AREA QID", "Text" : "Clotrimazole Topical", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID ALT CLOTRIMAZOLE 1% CRM VAG APPLFUL QHS", "Text" : "Clotrimazole Vaginal", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID ALT DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin PO", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID ALT DOXYCYCLINE 100MG IV Q12H", "Text" : "Doxycycline IV", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJZID ALT DOXYCYCLINE 100MG PO BID", "Text" : "Doxycycline PO", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID ALT ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem IV", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID ALT ERYTHROMYCIN 500MG IV Q6H", "Text" : "Erythromycin IV", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJZID ALT ERYTHROMYCIN 0.5% OINT OPH AFFECT EYE QID", "Text" : "Erythromycin OPTH", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJZID ALT ERYTHROMYCIN 500MG PO FQID", "Text" : "Erythromycin PO", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSJIZID ALT FLUCONAZOLE 400MG IV Q24H", "Text" : "Fluconazole IV", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJZID ALT FLUCONAZOLE 400MG PO QDAY", "Text" : "Fluconazole PO", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "ALTERNATIVE ANTIMICROBIALS",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : "PSJIZID ALT GANCICLOVIR 500MG IV Q12H", "Text" : "Ganciclovir IV", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : "PSJIZID ALT GENTAMICIN 5MG/KG IV Q24H", "Text" : "Gentamicin IV", "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : "PSJZID ALT ITRACONAZOLE 200MG PO QDAY", "Text" : "Itraconazole PO", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "PSJIZID ALT LEVOFLOXACIN 500MG IV Q24H", "Text" : "Levofloxacin IV", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "PSJZID ALT LEVOFLOX 500MG PO Q24H", "Text" : "Levofloxacin PO", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "PSJIZID ALT MEROPENEM 1GM IV Q8H", "Text" : "Meropenem IV", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "PSJIZID ALT METRONIDAZOLE 500MG IV Q6H", "Text" : "Metronidazole IV", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "PSJZID ALT METRONIDAZOLE 500MG PO TID", "Text" : "Metronidazole PO", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "PSJZID ALT METRONIDAZOLE 0.75% GEL VAG 1 APPLFUL QHS", "Text" : "Metronidazole Vaginal", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "PSJZID ALT MINOCYCLINE 100MG PO BID", "Text" : "Minocycline PO", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "PSJZID ALT MOXIFLOXACIN OPH 1 DROP TID", "Text" : "Moxifloxacin Ophthalmic", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "PSJIZID ALT NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin IV", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "PSJZID ALT NEOMYCIN 1000MG PO TID", "Text" : "Neomycin PO", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "PSJZID ALT NITROFURANTOIN SA 100MG PO BID", "Text" : "Nitrofurantoin PO", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "PSJZID ALT PENICILLIN 500MG PO QID", "Text" : "Penicillin PO", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "PSJIZID ALT PENICILLIN 4MU IV Q4H", "Text" : "Penicillin IV", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "PSJIZID ALT PIP/TAZO 3.375 GM IV Q6H", "Text" : "Piperacillin/Tazobactam IV", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "PSJZID ALT PYRIMETHAMINE 75MG PO QDAY", "Text" : "Pyrimethamine PO", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "PSJIZID ALT RIFAMPIN 300MG IV Q12H", "Text" : "Rifampin IV", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "PSJZID ALT RIFAMPIN 300MG PO BID", "Text" : "Rifampin PO", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "PSJZID ALT SULFACETAMIDE SOLN OPH 1 DRP QID", "Text" : "Sulfacetamide OPTH", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "PSJZID ALT SULFADIAZINE 1000MG PO QID", "Text" : "Sulfadiazine PO", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "PSJZID ALT TERBINAFINE 250MG PO QDAY", "Text" : "Terbinafine PO", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "PSJZID ALT TERCONAZOLE 0.4% CRM VAG 1 APPLFUL QHS", "Text" : "Terconazole 0.4% Vaginal", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "PSJIZID ALT TOBRAMYCIN 5 MG/KG IV Q24H", "Text" : "Tobramycin IV", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "PSJZID ALT TRIMETHOPRIM 100MG Q12H", "Text" : "Trimethoprim PO", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "PSJZID ALT TRIMETHOPRIM-SULFAMETHOXAZOLE 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole PO", "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : "PSJIZID ALT TRIMETH/SULFA 5MG/KG IV Q12H", "Text" : "Trimethoprim-sulfamethoxazole IV", "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : "PSJZID ALT VALACYCLOVIR 1000MG PO BID", "Text" : "Valacyclovir PO", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "PSJZID ALT VANCOMYCIN SOLN 125MG PO Q6H", "Text" : "Vancomycin PO", "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : "PSJIZID ALT VANCOMYCIN 1000MG IV Q12H", "Text" : "Vancomycin IV", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "Oseltamivir (see Influenza Menu)", "Header" : 0}
]},
{"Name" : "ORZID GMENU ABX GENRL ALTERNATIVE DRUG", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX ALLERGIC TO RECOMMENDED DRUGS", "Text" : "Allergic to recommended drug(s)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX DECREASED RENAL CLR", "Text" : "Decreased renal clearance", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX LIVER SECRETORY", "Text" : "Liver secretory or metabolic impairment", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX DRUG INTERACTION", "Text" : "Drug interaction", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX MULTIPLE INFECTIONS", "Text" : "Patient has multiple infections requiring antimicrobials", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX ISOLATE NOT SUSC TO RECOMD DRUG", "Text" : "Adjust therapy based on antimicrobial susceptibility", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OTHER ADVERSE DRUG AFFECT", "Text" : "Other adverse drug effect", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX ALTERNATIVE OTHER REASON", "Text" : "Other reason", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "Please Click Here to Send comments to the CDSS team", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "Text" : "Information about drug allergies", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEED AN ALERNATIVE ANTIMICROBIAL?",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If you cannot use the recommended antimicrobials or you believe another one",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "would be better for your patient, you can order another drug. Please indicate",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "the reason you need an alternative drug below.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Note: Alternative antimicrobial selections will be reviewed and we may contact",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "prescribers to learn more about situations that need alternatives, improve the",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "CDSS, and in some cases offer suggestions.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Clarification/Comments:", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help and Additional Information Menu", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZ GMENU CONSULTS MAIN IP", "Text" : "Inpatient Consult Menu - place consults to specialty service", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZ GMENU CONSULTS MAIN OP", "Text" : "Outpatient Consult Menu - place consults to specialty service", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Antibiogram", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID GMENU ABX GENRL ALTERNATIVE DRUG", "Text" : "Inpatient Alternative Antimicrobials to CDSS Recommendations - select here", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU NEED AN ALT ABX MAIN", "Text" : "Outpatient Alternative Antimicrobials to CDSS Recommendations - select here", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "Text" : "Contact Information", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "Antimicrobial Information", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "Text" : "Important Drug Properties", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "Text" : "Antimicrobial Cost Information", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "GENERAL INFORMATION",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "LEGEND ________________________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "[DI] = Important interactions between antimicrobial and other drugs",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "[H] = Hepatic excretion of antimicrobial",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "[M] = Minimal risk posed by antimicrobial",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "[O] = Other important antimicrobial property",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "[R] = Renal excretion of antimicrobial",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "($) = <10 dollars per day",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "($$) = 10-50 dollars per day",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "($$$) = 51-100 dollars per day",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "($$$$) = 101-400 dollars per day",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "($$$$$) = >400 dollars per day",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Beta-lactam Reaction Assessment", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC ABX LYME DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID GMENU ER/UC LYME DISEASE PROPHYLAXIS", "Text" : "Lyme Disease Prophylaxis", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU LYME ERYTHEMA MIGRANS", "Text" : "Erythema migrans associated with Lyme disease", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID GMENU ER/UC LYME ACUTE NEURO DISEASE", "Text" : "Acute neurological disease associated with Lyme disease", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU LYME ARTHRITIS ASSOC", "Text" : "Arthritis associated with Lyme disease", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID GMENU ER/UC LYME CARDIAC DISEASE", "Text" : "Cardiac disease associated with Lyme disease", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Lyme disease results from the transmission of Borrelia burgdorferi from an",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Ixodes spp. tick bite. Patients who display signs of illness or fever within 30",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "days of removing an attached tick should be evaluated for tick-borne illness.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "In the upper Midwest these are Lyme disease, human anaplasmosis, babesiosis, and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Powassan virus disease. Patients who have been bitten by an Ixodes spp. tick",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "(deer tick) but who do not display signs or symptoms of infection should not",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "be treated with antimicrobials.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Prophylactic antimicrobial treatment may be beneficial in certain patients who",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "have been bitten while in endemic areas.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Except for erythema migrans, Lyme disease is a complicated, difficult disease to",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "diagnose and treat. Infectious Diseases consultation is strongly encouraged.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC ACUTE SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS MILD TO MOD", "Text" : "[CLICK HERE] for treatment of mild to moderate bacterial sinusitis - Opt CDSS", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEVERE SINUSITIS", "Text" : "[CLICK HERE] for treatment of severe bacterial sinusitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACUTE SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases of acute sinusitis are viral and resolve within 10 days. Symptoms",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(nasal congestion, purulent nasal discharge, and tooth or facial pain) can be",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "treated with decongestants, analgesics, and nasal saline. Diagnosis of acute",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "sinusitis is based on the presence of at least 2 major or 1 major and at least 2",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "minor symptoms.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Major Symptoms",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "1. Purulent anterior nasal discharge",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "2. Purulent or discolored posterior nasal discharge",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "3. Nasal congestion or fullness",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "4. Facial pain or pressure",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "5. Hyposmia or anosmia",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "6. Fever",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Minor Symptoms",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "1. Headache",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "2. Ear pain, pressure or fullness",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "3. Halitosis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "4. Dental pain",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "5. Cough",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "6. Fatigue",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If patient meets criteria above for acute sinusitis, treat with antimicrobials",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "according to the following criteria for mild to moderate or severe bacterial",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "sinusitis.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mild to moderate bacterial sinusitis",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "1. Symptoms persisting beyond 10 days",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "2. Double-sickening - Symptoms typical of viral upper respiratory infection",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "initially improving for 5-6 days then worsening with new development of fever,",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "headache or increased nasal discharge.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Severe bacterial sinusitis",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Severe signs or symptoms of high fever (>/= 102 degrees Fahrenheit, >/= 39",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "degrees Celsius) and purulent nasal discharge for 3-4 consecutive days or facial",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "pain lasting for at least 3-4 consecutive days at the beginning of illness.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC APPENDICITIS W/O PERFORATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID GMENU ER/UC APPENDICITIS WITH PERFORATION", "Text" : "Link to appendicitis with perforation menu", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX CEFAZ 2GM METRO 500MG IV ONCE SURGERY ER/UC", "Text" : "Cefazolin 2 gm IV once STAT ($) [R] <AND> metronidazole 500 mg IV once STAT", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX GENT 5MG/KG METRO 500MG IV ONCE SURGERY ER/UC", "Text" : "Gentamicin 5 mg/kg IV once STAT ($) [R,O] <AND> metronidazole 500 mg IV once", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM ONCE ER/UC", "Text" : "Ertapenem 1 gm IV once STAT ($$) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPENDICITIS WITHOUT PERFORATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients with an acutely inflamed appendix and no gangrene or perforation are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "considered to have uncomplicated appendicitis. Patients with gangrene,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "perforation, peritonitis, or abscess have complicated appendicitis. Treatment",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "with antibiotics is an option for patients who are unfit for surgery or refuse",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "surgery. Treatment with antibiotics should not be used routinely as an",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "alternative to surgery.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Select for treatment of complicated appendicitis",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Surgical prophylaxis for uncomplicated appendicitis",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "($) [DI] infusion beginning 60 minutes before incision < OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "STAT ($) [DI] infusion beginning 60 minutes before incision",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment of patients who are unfit for surgery or refuse surgery",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Initial treatment",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Step down treatment after completion of initial intravenous treatment",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Appendicitis",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Salminen et al, JAMA, 2015, 313(23):2340-2348",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Appendicitis",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Management of acute appendicitis in adults", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC APPENDICITIS WITH PERFORATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] <AND> metronidazole 500 mg IV once", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "Text" : "Moxifloxacin 400 mg IV once STAT ($$) [R,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG METRO 500MG IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> Metronidazole 500 mg IV once", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPENDICITIS WITH PERFORATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treat until normalization of temperature, WBC and GI tract functioning",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "STAT ($) [DI]",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "once STAT ($) [DI]",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "who can tolerate oral therapy. Base selection on culture results.",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Appendicitis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Solomkin JS Clin Infect Dis 2003, 37: 997",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-to-date", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC ASPIRATION PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID GMENU ER/UC COM-ACQ PNEUMONIA", "Text" : "Community acquired pneumonia (CAP) < OR >", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID GMENU ER/UC NOSO PNEUMONIA NEW", "Text" : "Nosocomial pneumonia", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ASPIRATION PNEUMONIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Aspiration of oropharyngeal or gastric contents induces inflammation and is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "often accompanied by fever and/or an infiltrate. Bacterial pneumonia occurs in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "a minority of patients who aspirate, typically about 3 days later. The patient",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "usually improves for the first 2 days and then worsens as bacterial pneumonia",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "develops with increased fever, new or progressive infiltrates, leukocytosis, and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "newly purulent sputum.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antimicrobials have no role for treatment of aspiration and their use entails",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "risk of side effects and selection of resistant organisms.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Antimicrobials used for community-acquired pneumonia are appropriate for cases",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "that develop after an episode of aspiration. For more information, consult",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pulmonary or Infectious Diseases.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for patients with pneumonitis but without lung abscess or putrid",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "sputum",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Therapy directed towards anaerobic pathogens is usually unnecessary. If",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "pneumonia is confirmed, treat as",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treament for patients with LUNG ABSCESS",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Refer to Lung and Mediastinum section of the inpatient or outpatient",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Luna CM Crit Care Med 2003, 31: 676",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Lung Abscess",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell LA Clin Infect Dis 2003,37:1405",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Roig J J Antimicrob Chemother 2003, 51: 1119",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC BACT MENING W/O GRM STAIN RES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSCZID DEXAMETHASONE 10MG IV ONCE ER/UC", "Text" : "Dexamethasone 10 mg IV once STAT ($)", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] <AND> vancomycin 15mg/kg IV once STAT", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H STAT", "Text" : "Meropenem 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg once STAT ($) [R]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 2GM CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Ampicillin 2 gm IV once STAT ($$) [R] <AND> ceftriaxone 2 gm IV once STAT", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX MOXI 400MG VANCO 15MG/KG TMP/SMX 5-25MG/KG IV STAT", "Text" : "Moxifloxacin 400mg IV once STAT ($$) [R,DI] <AND> vancomycin 15mg/kg once", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS (WITHOUT GRAM STAIN RESULTS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid. Adjust",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial regimen to optimize therapy and treatment duration based on",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "pathogen once isolated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Intravenous dexamethasone therapy improves outcomes for meningitis with",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Streptococcus pneumoniae and is recommended for empirical treatment of all",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "community acquired cases that might be associated with S. pneumoniae.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Dexamethasone must be given before (1 to 20 minutes) or concurrent with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobials.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If meningococcal meningitis is identified, antimicrobial prophylaxis should be",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "considered for close contacts. Contact Infectious Diseases/Epidemiology for",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "advice and assistance.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Step 1 of Treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(Discontinue if isolated pathogen is not S. pneumoniae)",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Step 2 of Treatment, Select One of the Following:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment for Adults < 50 Years Without Alcoholism, Debilitating Disease, or",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Any Other Condition Associated with Impaired Cellular Immunity.",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treatment for Adults >= 50 Years or With Alcoholism, Debilitating Disease, or",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Impaired Cellular Immunity. Listeria Monocytogenes is One Important Pathogen.",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "($) [M] vancomycin 15mg/kg once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "STAT ($) [R] <AND> trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV once",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "STAT ($$$) [R,DI]",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, Age > 50 years",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, Age 1 mo to 50 years",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC BEBTELOVIMAB EUA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help page (instructions, microbiology, drug properties, etc.)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "Text" : "[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PATIENT EUA FACT SHEET", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Bebtelovimab", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Bebtelovimab", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Bebtelovimab (EUA)",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-Bebtelovimab is available via FDA Emergency Use Authorization (EUA)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "for treating patients that meet specific criteria. bebtelovimab is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "not FDA approved drug.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "-Bebtelovimab EUA does NOT include post-exposure prophylaxis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Bebtelovimab Emergency Use Authorization (EUA)",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "**Treatment:**",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "ID available to discuss if needed.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Inclusion Criteria",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "ALL of the following criteria must be met for a patient to receive:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "1) Patient has a laboratory-confirmed diagnosis of mild to moderate COVID-19.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "2) Patient is not hospitalized due to COVID-19.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Note: patient may be hospitalized for some other reason.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "increase in baseline oxygen flow rate due to COVID-19.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "4) Administration will begin within 7 days of symptom onset.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "5) Patient does not have known hypersensitivity to bebtelovimab or components.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "6) Patient has at least one risk factor for progression to severe disease",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "including hospitalization or death.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "See link below for complete list:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "The provider has communicated with the patient/caregiver regarding",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "unapproved drug that is authorized for use under an EUA, given information",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Exclusion Criteria",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "If patient recieved tixagevimab plus cilgavimab previously, discuss with ID.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "If patient agreeable and meets criteria, please contact Minneapolis VA Emergency",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Department charge nurse at 31-6736 to arrange for treatment if available. Click",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "*Patients treated with this drug should continue to self-isolate and use",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "infection control measures (wear mask, isolate, social distance, avoid",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "frequent handwashing) according to CDC guidelines.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "order set below to complete order form and place IV order for administration.",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Note: order does not contain medication order. ED provider will order.",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX BEBTELIVOMAB ED INFO", "Text" : "INV-Bebtelovimab 175 mg IV Push ONCE", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS EIKENELLA CORRODENS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Doxycycline 100mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV ONCE STAT", "Text" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV ONCE STAT", "Text" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH EIKENELLA CORRODENS", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS METH RES S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 10DS 100MG PO BID", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 14DS 100MG PO BID", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS METH SUSC S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 10DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 10DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 10DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 10DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV ONCE ER/UC", "Text" : "Nafcillin 2 gm IV once STAT ($$) [DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV ONCE ER/UC", "Text" : "Cefazolin 2 gm IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 14DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 14DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 DICLOX 14DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 DICLOX 14DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV ONCE ER/UC", "Text" : "Nafcillin 2 gm IV once STAT ($$) [DI]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV ONCE ER/UC", "Text" : "Cefazolin 2 gm IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treat for 14-21 days.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS P. MULTOCIDA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Doxycycline 100mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV ONCE STAT", "Text" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV ONCE STAT", "Text" : "Doxycycline 100mg IV once STAT ($$) [DI]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH PASTEURELLA MULTOCIDA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC BITE WNDS STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 10DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]< OR >", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 10DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 10DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($0.48/day) [DI]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 10DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV ONCE ER/UC", "Text" : "Cefazolin 2 gm IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 10DS 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID for 10 days ($) [H,O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 10DS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 14DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 14DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 DICLOX 14DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 DICLOX 14DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV ONCE ER/UC", "Text" : "Cefazolin 2 gm IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 14DS 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID for 14 days ($) [H,O]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 14DS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection but no arthritis - 10 days joint involved - 14-21 days",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH STREPTOCOCCI", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC BITE WOUNDS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "Text" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "Text" : "Moxifloxacin 400mg IV once STAT ($$) [R,DI]", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 10DS 400MG PO QDAY", "Text" : "Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 10DS 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS P. MULTOCIDA", "Text" : "Pasteurella multocida", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS EIKENELLA CORRODENS", "Text" : "Eikenella corrodens", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS METH SUSC S. AUREUS", "Text" : "Methicillin-susceptible Staphylococcus aureus", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS METH RES S. AUREUS", "Text" : "Methicillin-resistant Staphylococcus aureus", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : "ORZID GMENU ER/UC BITE WNDS STREPTOCOCCI", "Text" : "Streptococci", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Bite wounds are prone to infection because of the pathogenic oral flora carried",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "into tissuesby teeth.Common pathogens include Eikenella corrodens, usually",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "from human bites, and Pasteurella multocida, often from dog or cat bites,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "streptococci and staphylococci.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Clean wounds with soap and water as soon as possible, add local antiseptic",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "and debride non-viable tissue.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult orthopedic surgery for all bite wounds involving the hand.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antibiotic Prophylaxis Indications:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Severe injury less than 8 hours, Crush injury, Bone or joint penetration,",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Wound of the face or hands or genitals, Immunocompromised host, Asplenia,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Advanced liver disease",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "*Routine use of prophylactic antibiotics for non-immunocompromised patients",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "with superficial wounds with no puncture that do not involve the face/",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "genitals/hands is not recommended.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Treatment:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Empiric treatment for suspected or established infection following bite wound.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "In these cases, therapy should be directed against pathogen identified",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "by Gram stain and culture whenever possible.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Rabies Prophylaxis:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Consider rabies post-exposure prophylaxis for all animal bite cases.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Contact infectious diseases for assistance.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Consider tetanus immunization status:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "If immunization is up to date, nothing more needs to be done to prevent tetanus.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "If immunization is lacking, and:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "wound IS NOT tetanus prone, bring immunization up to date with Td",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "wound IS tetanus prone, bring immunization up to date with Td< AND >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Human Tetanus Immune Globulin Inject 250 units deeply into muscle (deep IM)",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Select below for Tetanus vaccination information page:",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Treat deep wounds for the first 3-5 days after a bite to prevent infection.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "For wounds that later develop evidence of infection but without arthritis, treat",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "with antimicrobials for 7-14.For wounds that develop infection of a joint,",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "treat 14 to 21 days.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Prophylaxis:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Duration 3 to 5 days:",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with penicillin allergy:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Empiric treatment for suspected or estabished infection:",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Duration 7 to 14 days:",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with penicillin allergy:",  "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Pathogen directed bite wound therapy:",  "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Abrahamian FM New Engl Journ Med 1999, 340:85", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC BRONCHITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "Text" : "Bronchitis-antibiotics not a benefit in otherwise healthy patient", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 5DS 100MG PO BID BRONCHITIS", "Text" : "Doxcycline 100 mg PO BID for 5 days ($) [DI]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 5DS 100MG PO BID BRONCHITIS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSOZID2 TMP/SMX 5DAYS 1DS TAB BID BRONCHITIS", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSHZID2 TMP/SMX 5DAYS 1DS TAB BID BRONCHITIS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO once on day one then 250 mg PO qday for 4 days ($) [M]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Amoxicillin-clavulanate 875-125 mg PO BID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSJIZID AZITHROMYCIN 500 MG IV ONCE ER/UC", "Text" : "Azithromycin 500 mg IV once STAT ($) [M< OR >", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "Text" : "Ampicillin-sulbactam 3 gm IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BRONCHITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis should not be treated with antimicrobials except in specific",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "circumstances. If pneumonia is suspected, order a chest x-ray. If an",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "infiltrate is not present, the patient does not have bacterial pneumonia and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "need not be treated for it.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis in an otherwise HEALTHY PATIENT",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobials provide no benefit. If bronchitis persists beyond 2 weeks,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "additional diagnostic workup is needed to find a cause. If a patient has",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "persistent cough with inspiratory whoop, consider a diagnosis of pertussis.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "For symptomatic treatment dextromethorphan and benzonatate combined with",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "guaifenesin has shown some benefit. Benzonatate and guaifenesin",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "alone did not show benefit. Also, allergy medicines and codeine",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "do not appear to help the symptoms.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Refer to the outpatient or inpatient Antimicrobial CDSS for treatment of",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Pertussis recommendations",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis in patients with COPD",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Symptoms of COPD exacerbation include dyspnea with increased sputum purulence",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "and volume, together with increased cough and wheeze. Co-morbidities are",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "common in COPD patients, thus exacerbations must be differentiated clinically",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "from other events such as acute coronary syndrome, worsening heart failure,",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "pulmonary embolism and pneumonia.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Cornerstones of therapy include oxygen, bronchodilators, and in some cases",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "corticosteroids. Recommend antibiotics for moderately or severely ill patient",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "with COPD exacerbation who have increased sputum purulence and volume.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Treatment for MILD DISEASE:",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "No antibiotics recommended",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment for MODERATE DISEASE",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treat for 5 to 7 days.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Treatment for SEVERE DISEASE",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "NOTE: Fluoroquinolones are not listed as a choice because the risk of serious",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "side effects outweigh the benefits.",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Access: http://www.goldcopd.org",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Wenzel WP et al NEJM 2006, 355: 2125",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bronchitis",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bronchitis",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Murphy TF Chest 2000, 118: 204",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Masterton RG Int J Antimicrob Agents 2001, 18: 503", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING NON-SEVERE CAP", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED IN AN INPATIENT SETTING",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Inpatient, non-severe CAP (NOTE: DURATION of therapy)",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFTRIAXONE 2GM IV AZITHROMYCIN 500MG PO STAT", "Text" : "Ceftriaxone 2GM IV STAT ($) [M] <AND> Azithromycin 500mg PO STAT ($) [M]", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Be sure of the diagnosis.Careful reviews have shown that over half of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "people treated for community-acquired pneumonia do not in fact have",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pneumonia.Pneumonia is likely in persons with 3 or more signs or symptoms",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "including a) new infiltrate (or, no prior film for comparison) b) new",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "crackles, egophony, or dullness c) pleuritic pain, d) fever and/or chills",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "e) leukocytosis f) cough g) purulent sputum and h) new or worsened dyspnea",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "or tachypnea, and no likely alternative explanation for the presentation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Common alternative explanations include heart failure, thromboembolic",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "disease, COPD exacerbation, viral pneumonitis, aspiration pneumonitis, or",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "tumor. Most of the latter conditions do NOT benefit from antimicrobials.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Recommendation for duration of antibiotic therapy for CAP:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Patients with CAP should be treated for a minimum of 5 days, should be",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "afebrile for 48-72 hours, and should have no more than 1 CAP-",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "associated sign of clinical instability before discontinuation",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "of therapy.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Criteria for clinical stability:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Temperature less than/equal to 100 degrees F",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Heart rate less than/equal to 100 beats/minute",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Respiratory rate less than/equal to 24 breaths/minute",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Systolic blood pressure greater than/equal to 90 mm Hg",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Ability to maintain oral intake",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Normal mental status",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Arterial oxygen saturation greater than/equal to 90% --OR--",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "PO2 greater than/equal to 60 mm Hg on room air",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Preferred: (no prior respiratory isolation of MRSA or P. aeruginosa)",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Sanford website",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSCZID PNA VANCOMYCIN 15MG/KG IV STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSCZID PNA LEVOFLOXACIN 750MG PO STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Obtain cultures BUT withhold MRSA coverage unless cultures or nasal carriage",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "positive for MRSA. (See below for prior respiratory isolation of MRSA)",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Obtain cultures BUT withhold anti-pseudomonal coverage unless cultures",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "are positive for P. aeruginosa. (See below for prior respiratory isolation",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZ SET ABX PNA PIPER-TAZO 4.5 GM + AZITHROMYCIN 500MG PO STAT", "Text" : "", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFEPIME 2GM IV STAT+AZITHROMYCIN 500MG PO STAT", "Text" : "", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Prior Respiratory Isolation of MRSA within last 12months: ADD MRSA COVERAGE",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Prior Respiratory Isolation of P.aeruginosa within last 12months: SELECT BELOW",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Select regimen below for P.aeruginosa, obtain cultures to allow deescalation",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "of P. aeruginosa)",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "PSCZID PNA LEVOFLOXACIN 750MG PO STAT ER/UC", "Text" : "Levofloxacin 750 mg PO STAT ($) [R,DI]", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Alternative for P. aeruginosa:",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "ADD MRSA coverage to above regimen, otain cultures/nasal PCR to allow",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "for deescalation",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING SEVERE CAP", "Contents" : [
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment on INTENSIVE CARE UNIT (ICU)",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Alternative Standard Regimen:",  "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Preferred Standard Regimen: (no MRSA or P. aeruginosa coverage)",  "Header" : 1}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Recommendation for duration of antibiotic therapy for CAP:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Patients with CAP should be treated for a minimum of 5 days, should be",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "afebrile for 48-72 hours, and should have no more than 1 CAP-",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "associated sign of clinical instability before discontinuation",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "of therapy.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Criteria for clinical stability:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Temperature less than/equal to 100 degrees F",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Heart rate less than/equal to 100 beats/minute",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Respiratory rate less than/equal to 24 breaths/minute",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Systolic blood pressure greater than/equal to 90 mm Hg",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Ability to maintain oral intake",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Normal mental status",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Arterial oxygen saturation greater than/equal to 90% --OR--",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "PO2 greater than/equal to 60 mm Hg on room air",  "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : null, "Text" : "Liu C Clin Inf Dis. 2011, 52:285",  "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : null, "Text" : "Mandell LA Clin Infect Dis 2007, 44:S27",  "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : null, "Text" : "Sanford website",  "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : null, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEVERE Community-Acquired Pneumonia (CAP) Treated in Intensive Care Unit (ICU)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Criteria for Defining SEVERE Community-acquired Pneumonia",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Validated definition includes either one major or three or more minor criteria",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "MAJOR CRITERIA:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Septic shock with need for vasopressors",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Respiratory failure requiring mechanical ventilation",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "MINOR CRITERIA:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Respiratory rate greater than or equal to 30 breaths/minute",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "PaO2/FiO2 ratio less than or equal to 250",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Multilobar infiltrates",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Confusion/disorientation",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Uremia (blood urea nitrogen level greater than 20 mg/dl)",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Leukopenia* (WBC less than 4,000 cells/microliter)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "*Due to infection alone (i.e., not chemotherapy induced)",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Thrombocytopenia (platelet count less than 100,000 microliters)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Hypothermia (core temperature less than 36 degrees C)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Hypotension requiring aggressive fluid resuscitation",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "PSCZID PNA LEVOFLOXACIN 750MG PO STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : "PSCZID PNA LEVOFLOXACIN 750MG PO STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : "ORZ SET ABX PNA PIPER-TAZO 4.5GM IV AZITH 500MG IV STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Prior respiratory isolation of MRSA in the last 12 months: ADD MRSA coverage",  "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Item" : "PSCZID PNA VANCOMYCIN 15MG/KG IV STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Prior respiratory isolation of P. aeurginosa in the last 12 months:",  "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "SELECT REGIMEN BELOW:",  "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "ADD MRSA COVERAGE. Obtain nasal PCR and cultures to allow deescalation or",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "confirmation of need for continued therapy. SEE MRSA Section below",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR-",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "COVER for P. aeruginosa. Obtain cultures to allow deescalation or",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "confirmation of need for continued therapy. SEE P. aeruginosa section below",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-",  "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR-",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Prior Respiratory Isolation of P. aeruginosa in the last 12 months:",  "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "ADD MRSA coverage to Standard Regimen above or Antipseudomonal regimen below:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Prior Respiratory Isolation of MRSA within last 12 months:",  "Header" : 1}, 
{"Row" : 85, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV AZITHROMYCIN 500MG IV STAT", "Text" : "", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFTRIAXONE 2GM AZITH 500MG IV STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "500 mg IV STAT ($) [M]",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Stepdown empiric treatment for CAP (Intravenous to Oral conversion)",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "(Specific therapy should be guided by culture results.)",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "Text" : "[Link] Stepdown empiric treatment for CAP with oral antibiotics", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Recommend blood and lower respiratory tract specimen cultures for all patients",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "with Severe CAP.",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET LAB SPUTUM CULT & GRAM STAIN", "Text" : "Lab Order: Sputum Culture & Gram Stain", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET LAB BLOOD CULTURE X2", "Text" : "Lab order: Blood culture x2", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Prior Respiratory Isolation of MRSA within last 12 months:",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "ADD MRSA COVERAGE. Obtain nasal PCR and cultures to allow deescalation or",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "confirmation of need for continued therapy. SEE MRSA Section below", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC CAP OUTPATIENT TREATED SETTING", "Contents" : [
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 PNA DOXYCYCLINE 100MG PO BID 5DAYS", "Text" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 PNA DOXYCYCLINE 100MG PO BID 5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSOZID2 PNA LEVOFLOXACIN 5DS 750MG PO QDAY", "Text" : "Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSHZID2 PNA LEVOFLOXACIN 5DS 750MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED IN AN OUTPATIENT SETTING",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Preferred outpatient treatment for PREVIOUSLY HEALTHY PATIENT:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(WITHOUT chronic obstructive pulmonary disease, diabetes, renal failure,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "conditions, or use of immunosuppressing drugs)",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Outpatient and UNcomplicated:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred outpatient treatment for PATIENTS WITH COMORBIDITIES:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "(WITH chronic obstructive pulmonary disease, diabetes, renal failure,",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "conditions, or use of immunosuppressing drugs)",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Sanford: Community Acquired Pneumonia",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Outpatient and comorbidity:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Azithromycin 500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 PNA AMOXICILLIN 1000MG PO TID X5DAYS", "Text" : "Amoxicillin 1000 mg PO TID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 PNA AMOXICILLIN 1000MG PO TID X5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX NV PNA AMOX-CLAV 875/125 BID AZITH 500 THEN 250", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200(7):e45",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP PNA CEFDINIR 300MG PO BID AZITH 500 THEN 250", "Text" : "Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Azithromycin", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX NV PNA CEFDINIR 300MG PO BID AZITH 500 THEN 250", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP PNA AMOX-CLAV 875/125 BID AZITH 500 THEN 250", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP PNA AMOX-CLAV 875/125 BID DOXY 100MG BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX NV PNA AMOX-CLAV 875/125 BID DOXY 100MG BID", "Text" : "", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX OP PNA CEFDINIR 300MG BID DOXY 100MG BID", "Text" : "Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Doxycycline", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "100 mg PO BID for 5 days ($) [DI]",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX NV PNA CEFDINIR 300MG BID DOXY 100MG BID", "Text" : "Non-VA for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "ER/UC MAY ADMINISTER AN INITIAL INTRAVENOUS DOSE STAT THEN DISPENSE RX FOR HOME",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID PNA CEFTRIAXONE 2GM STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "ORDER OUTPATIENT PRESCRIPTIONS BELOW:",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "ER/UC MAY ADMINISTER AN INITIAL INTRAVENOUS DOSE STAT THEN DISPENSE RX FOR HOME",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "ORDER OUTPATIENT PRESCRIPTION BELOW:",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV STAT ER/UC", "Text" : "", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID GMENU ER/UC MORE ABOUT CELLULITIS", "Text" : "More about cellulitis...", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 500MG PO QID 5DS", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 500MG PO QID 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 500MG PO QID 5DS", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 500MG PO QID 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV ONCE ER/UC", "Text" : "Nafcillin 2 gm IV once STAT ($$) [DI]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV ONCE ER/UC", "Text" : "Cefazolin 2 gm IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV ONCE ER/UC", "Text" : "Clindamycin 600mg IV STAT ($$) [H,O]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R] <AND> vancomycin IV", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG CIPRO 400MG METRO 500MG IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> Vancomycin 15 mg/kg IV", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL CELLULITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cellulitis refers to inflammation of the skin and subcutaneous tissue and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "often associated with bacterial pathogens. The most common pathogens are group",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "A streptococci and Staphylococcus aureus. Group B streptococci are associated",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "with cellulitis in elderly people, in those with diabetes mellitus, and on",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and legs of patients with athlete's foot (tinea pedis).",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Mild cases can be treated with oral antimicrobials. Moderate to severe cases",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "should be treated initially with intravenous antimicrobials. Switch to oral",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "drugs after clinical improvement.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Consider MRSA coverage for cellulitis associated with penetrating trauma, a",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "history of MRSA infection, injection drug use, or infections not responding",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "to first line beta-lactams.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Duration: Treat for 5 days. Re-evaluate the patient and extend/modify treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "if not improved in this time.",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mild: Cellulitis without systemic signs of infection",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for MILD cellulitis",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Alternative for Penicillin Allergy or MRSA suspected",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "MRSA Suspected Mild Cellulitis",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Moderate: Cellulitis with systemic signs of infection",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for MODERATE cellulitis",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy or MRSA suspected",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Severe: Cellulitis in patients with signs of deeper infections",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "(e.g. bullae, skin sloughing, hypotension, or evidence of organ dysfunction).",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Patients may also qualify as severe if they are neutropenic, have a",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "hematologic malignancy or congenital immunodeficiency, or are receiving",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "immunosuppressant therapy. Consider whether surgical drainage is necessary.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for SEVERE infection",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "15mg/kg once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy or MRSA suspected:",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "once STAT ($) [R] <AND> Metronidazole 500 mg IV once STAT ($) [DI,H]",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC CHOLANGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "Text" : "Moxifloxacin 400 mg IV q24h once STAT [R,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOX 750MG IV METRO 500MG IV ONCE STAT", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [DI,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> metronidazole 500 mg IV once", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHOLANGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are due to common bile duct obstruction. Obstruction (if present)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "must be relieved with an endoscopical, transcutaneous, or surgical procedure.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "The most common pathogens isolated are E. coli, Klebsiela, Enterococcus and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Enterobacter. Anaerobes such as Bacteriodes and Clostridia can be present as",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "part of a mixed infection.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "once STAT ($) [DI]",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Step down treatment for completion of antimicrobial course after initial",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "on culture results.",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Cholangitis, Cholecystitis)",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gallbladder Infections",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Acute cholangitis", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC CHOLECYSTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV ONCE ER/UC", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "Text" : "Moxifloxacin 400 mg IV once STAT ($$) [R,DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOX 750MG IV METRO 500MG IV ONCE STAT", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R,O]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> Metronidazole 500 mg IV once", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R] <AND> vancomycin 15", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV ONCE VANCO 15MG/KG IV ONCE STAT", "Text" : "Meropenem 1 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> Metronidazole 500 mg IV once", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHOLECYSTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Adequate biliary drainage is the definitive treatment. Antimicrobials should be",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "prescribed only if signs of infection like leukocytosis or fever are present or",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "if the patient is elderly. Surgery and Gastroenterology involvement are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "essential.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Most cases are associated with E. coli, Enterococcus, Klebsiella, and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Enterobacter. Anaerobic coverage is not indicated unless a biliary-enteric",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "anastomosis is present. For community-acquired acute cholecystitis, enterococcal",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "coverage is not required because Enterococcus has not been shown to be",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "pathogenic in these patients.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If needed, antimicrobial therapy should be continued only until adequate",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "drainage is established, then stopped.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Community-acquired acute cholecystitis",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate infection and biliary-enteric anastomosis present",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "once STAT ($) [DI]",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Treatment of severe infection, advanced age or immunocompromised patient",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Health care-associated infection",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "STAT ($) [R]",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Step down treatment for completion of antimicrobial course after initial",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "on culture results.",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimimicrobial CDSS",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Cholangitis, Cholecystitis)",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gallbladder Infections, Acute Cholecystitis",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of acute calculous cholecystitis", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC COM-ACQ PNEUMONIA", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Empirical regimens listed here cover the usual pathogens associated with CAP,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "including \"atypical\" pathogens.Specific therapy should be guided by culture",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "results.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "a patient with pneumonia.Pre-estimated risk can then be used to determine how",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "aggressively to treat the patient's pneumonia and whether the patient can be",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treated safely outside of the hospital.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX CAP PSI", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Empirical treatment",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "If a patient has taken an antimicrobial in the previous 3 months, it is prudent",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "to avoid giving the same or a similar drug for the current episode of pneumonia.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : ">> Setting-specific treatment regimens <<",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID GMENU ER/UC CAP OUTPATIENT TREATED SETTING", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "CAP Pneumonia Severity Index (PSI) or PORT Score",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "The CAP pneumonia severity index is useful for estimation of mortality risk f",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "The Community-Acquired Pneumonia Severity Index (PSI) is a guide and",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "should be used to augment clinical judgment. If social circumstances",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "or cognitive dysfunction would interfere with success of outpatient",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "treatment, the patient should be hospitalized.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING NON-SEVERE CAP", "Text" : "CAP treated in an Inpatient setting - NON-SEVERE CAP", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID GMENU ER/UC CAP INPATIENT TREATED SETTING SEVERE CAP", "Text" : "CAP treated in an Inpatient setting - SEVERE CAP (ICU)", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Note: Healthcare-associated pneumonia (HCAP) no longer used in 2019",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "ATS/IDSA CAP Guideline. Instead, prior history or risks for MRSA",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "and/or P. aeruginosa are use to guide whether to start appropriate",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "coverage empirically.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Fine MJ, et al. N Engl J Med (1997) 336: 243-250",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC COMP CYSTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet BID ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] for 7 days, CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 7DAYS", "Text" : "Cefdinir 300 mg PO BID ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO", "Text" : "Select for updated Ciprofloxacin Info Page", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 2 GM IV GENT 5MG/KG IV ONCE STAT", "Text" : "Ampicillin 2 gm IV once STAT ($$) [R] <AND> gentamicin 5 mg/kg IV once", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX CIPROFLOXACIN 400MG GENT 5MG/KG IV STAT", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI] < AND > gentamicin 5 mg/kg IV", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2GM IV ONCE ER/UC", "Text" : "Ampicillin 2 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 500MG TID 7DAYS", "Text" : "Amoxicillin 500 mg PO TID ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 500MG TID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "PSOZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] for 7 days, CrCl =/>60 mL/min", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IV ONCE ER/UC", "Text" : "Gentamicin 5 mg/kg IV once STAT ($) [R,O]", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO", "Text" : "Select for updated Ciprofloxacin Info Page", "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMPLICATED CYSTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cystitis is considered complicated when one or more of the following is present:",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "> Most men with cystitis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "> Pregnant women",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "> Structural abnormalities (e.g. presence of obstruction, catheter or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "nephrostomy tubes, neurogenic bladder)",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "> Metabolic abnormalities that reduce local host defenses (e.g. diabetes,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "pregnancy, neutropenia, pelvic irradiation)",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "> Unusual or resistant pathogen",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "> Treatment failure or relapse or recurrence of infection",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat for 7 days. If patient is febrile, may extend duration up to 14 days total",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Empirical treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Alternative (weigh risk for potential serious side effects vs benefit)",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Treatment for SEVERE DISEASE or if patient cannot take oral therapy",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "STAT ($) [R,O]",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "once STAT ($) [R,O]",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Treatment for specific pathogens",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Treatment if enterococcus identified",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Alternative for enterococcus",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Unable to use ampicillin or vancomycin",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Treatment if Pseudomonas identified",  "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "________________________________________________________________________________",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Conversion to oral therapy",  "Header" : 1}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "When patients who require parenteral therapy are substantially improved and can",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "take oral medication, finish the course with oral antimicrobials depending on",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "the identification and susceptibility of the isolate.",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "Alternative (weigh risk for potential serious side effects vs benefit)",  "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 94, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : null, "Text" : "Drekonja, Dimitri M., et al. JAMA 326.4 (2021): 324-331",  "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : null, "Text" : "Gupta K. et. al. IDSA Clinical Practice Guidelines (2011) 52.1",  "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cystitis",  "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC COVID-19 MPLS PHARMACOLOGIC GUIDELINES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZ GTX ABX URL MINNEAPOLIS COVID SHAREPOINT SITE", "Text" : "Minneapolis VAHCS COVID-19 SharePoint Site", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "Minneapolis On-Call Schedule - Infectious Disease", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 MONOCLONAL ANTIBODY SOP", "Text" : "Minneapolis VAHCS COVID Monocolonal Antibody and Antiviral Allocation SOP", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA", "Text" : "Paxlovid (EUA)", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ABX MOLNUPIRAVIR EUA", "Text" : "Molnupiravir (EUA)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OUTPATIENT COVID-19 PHARMACOLOGIC TREATMENT GUIDELINES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Minneapolis VAHCS COVID-19 SharePoint site for additional Informati",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "***COVID-19 therapy is a rapidly evolving field, including the widespread",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "dissemination of therapies with little or no evidence for benefit. Therapies an",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "dosages not specifically listed here or on the NIH clinical guidelines should b",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "discussed with the infectious diseases service. ***",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "OUTPATIENT TREATMENT OF COVID-19",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If you have any questions on the selection of therapy, please contact Infectious",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Disease.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "DECIDE ON APPROPRIATE TREATMENT PLAN BY REFERRING TO ALLOCATION SOP BELOW",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "ORAL COVID-19 ANTIVIRALS (Paxlovid or Molnupiravir):",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Outpatient Pharmacy - Mon-Fri 0800-2130 and Weekend/Holidays 0900-1700: 31-3144",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Inpatient Pharmacy - Off-Tours: 31-3128",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "*Please be ready to spend time on the phone with the pharmacist to complete EUA",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "documentation, address medication questions and determine the best method of",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "delivery.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "MONOCLONAL ANTIBODY:",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID GMENU ER/UC BEBTELOVIMAB EUA", "Text" : "Bebtelovimab (EUA)", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Please contact Pharmacy to determine supply and availability.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX URL COVID-19 MED INTERACTION CHECKER", "Text" : "Interaction checker for COVID-19 medications website link", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC CUTANEOUS ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS PO BID 7DS", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100 mg PO bid for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 CLINDAM 7DS 300MG PO QID", "Text" : "Clindamycin 300 mg po qid for 7 days ($) [H]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 CLINDAM 7DS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO qid for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 7DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO qid for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "Text" : "Vancomycin 15 mg/kg IV STAT ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CUTANEOUS ABSCESS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Incise and drain and cover the site with a dry dressing.For small abscesses,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "systemic antimicrobial therapy is rarely necessary.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "If the patient is neutropenic, has multiple lesions, or has fever or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "leukocytosis, antimicrobial treatment may be necessary.Contact Infectious",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diseases for assistance.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For the few CUTANEOUS ABSCESSES away from the rectal area that need a systemic",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "antimicrobial",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration: Treat for 5 to 7 days",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mild to Moderate Cases:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Moderate or high suspicion of MRSA",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Low suspicion of MRSA",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "For SEVERE cases empiric coverage with MRSA agent",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "For Perirectal/Anorectal Abscess",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Refer to the inpatient or outpatient Soft Tissue Section of the Antimicrobial",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Skin infections",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "CDSS", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC DIVERTICULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 to 10 days ($) [R]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP TRIMETH/SULFA 1DS BID METRO 1GM PO BID 7 DAYS", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX NV TRIMETH/SULFA 1DS BID METRO 1GM PO BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "Text" : "Moxifloxacin 400 mg PO QDAY for 7 to 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 7DS 500 BID METRO 7DS 1G BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 7DS 500 BID METRO 7DS 1G BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-Tazobactam 3.375g IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] <AND> metronidazole 500 mg IV once", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV ONCE ER/UC", "Text" : "Moxifloxacin 400 mg IV once STAT ($$) [R,DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG METRO 500MG IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> metronidazole 500 mg IV", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID PIPERACILLIN/TAZOBACTAM 4.5 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> metronidazole 500 mg IV once", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIVERTICULITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diverticulitis involves inflammation of an intestinal diverticulum, usually in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the colon, causing pain and disturbed bowel function.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Mild disease",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "metronidazole 1000 mg PO BID ($) [DI] for 7 to 10 days",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "BID ($) [DI] for 7 to 10 days",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Moderate disease",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If symptoms fail to respond within 48 to 72 hours, consult General Surgery.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "STAT ($) [DI]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Alternative for beta lactam allergy",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "once STAT ($) [DI]",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Severe, life-threatening disease",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Consult General Surgery.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "STAT ($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Diverticulitis and Typhlitis",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Diverticulitis",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Acute colonic diverticulitis: Medical management", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC EMERGENCY DEPARTMENT MAIN MENU", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID GMENU ER/UC SUSP BACT, BLD CX NOT YET POS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID GMENU ER/UC BRONCHITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU CONJUNCTIVITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID GMENU ER/UC APPENDICITIS WITH PERFORATION", "Text" : "Appenditicitis with perforation", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID GMENU ER/UC APPENDICITIS W/O PERFORATION", "Text" : "Appendicitis without perforation", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID GMENU ER/UC CHOLANGITIS", "Text" : "Cholangitis", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID GMENU ER/UC CHOLECYSTITIS", "Text" : "Cholecystitis", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID GMENU ER/UC DIVERTICULITIS", "Text" : "Diverticulitis", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID GMENU ER/UC SPON BACT PERITONITIS", "Text" : "Spontaneous Bacterial Peritonitis", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL TREATMENT", "Text" : "Antiviral treatment for influenza", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX LYME DISEASE", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID GMENU ER/UC BACT MENING W/O GRM STAIN RES", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID GMENU ER/UC IMMUNOCOM NEUT FEVER", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMERGENCY DEPARTMENT ANTIMICROBIAL CDSS MENU",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "This menu contains links to treatment recommendations",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "for the most common infections treated in the Emergency Dept.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "For infections not included in this menu, refer to full Outpatient or",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Inpatient Antimicrobial CDSS for recommendations.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Acute Respiratory Infection (ARI) Symptomatic Therapy",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Bacteremia",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Bronchitis",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Conjunctivitis",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Gastrointestinal",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "For infections not listed, see GI",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "section of the CDSS.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Influenza",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "For chemoprophylaxis see Lung and",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Mediastiunum section of the CDSS, use",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "ED order set for vaccination.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Lyme Disease",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Meningitis, Bacterial",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "For pathogen specific, nosocomial and",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "trauma associated treatement see CNS",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "section of the CDSS.",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Neutropenic Fever",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "For infections in other",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "immunocompromised conditions, see",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Immunocompromised Patients section of",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "the CDSS.",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID GMENU ER/UC PHARYNGITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID GMENU ER/UC ASPIRATION PNEUMONIA", "Text" : "Aspiration", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID GMENU ER/UC COM-ACQ PNEUMONIA", "Text" : "Community Acquired Pneumonia (CAP) (Updated Feb2020)", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID GMENU ER/UC NOSO PNEUMONIA NEW", "Text" : "Nosocomial", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID GMENU ER/UC SEPSIS AND SHOCK", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "ORZID GMENU ER/UC ACUTE SINUSITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : "ORZID GMENU ER/UC BITE WOUNDS", "Text" : "Bite wounds", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZID GMENU ER/UC CELLULITIS", "Text" : "Cellulitis", "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : "ORZID GMENU ER/UC CUTANEOUS ABSCESS", "Text" : "Cutaneous abcesses", "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : "ORZID GMENU ER/UC FOOT ULCER WITH DM", "Text" : "Diabetic foot ulcer", "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : "ORZID GMENU ER/UC FURUNCLES, CARBUNCLES, CUT ABSCESS", "Text" : "Furuncles and cabuncles", "Header" : 0}, 
{"Row" : 46, "Column" : 2, "Item" : "ORZID GMENU ER/UC SUPP ODONTOGENIC INFECT", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 52, "Column" : 2, "Item" : "ORZID GMENU ER/UC COMP CYSTITIS", "Text" : "Cystitis, complicated", "Header" : 0}, 
{"Row" : 53, "Column" : 2, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "Text" : "Cystitis, uncomplicated", "Header" : 0}, 
{"Row" : 54, "Column" : 2, "Item" : "ORZID GMENU ER/UC PYELONEPHRITIS", "Text" : "Pyelonephritis", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "Pharyngitis",  "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Pneumonia",  "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "Rabies Post-Exposure Prophylaxis",  "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "Sepsis and Septic Shock",  "Header" : 1}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "Sinusitis, Acute",  "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "For chronic, fungal and nosocomial",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "sinusitis, see Head and Neck section",  "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "of CDSS",  "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : "Skin and Soft Tissue Infections",  "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "For infections not listed, see Skin",  "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : "and Soft Tissue Infection sections of",  "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : null, "Text" : "CDSS. See above for rabies exposure.",  "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : null, "Text" : "Tooth Abcess and Other Suppurative",  "Header" : 1}, 
{"Row" : 43, "Column" : 2, "Item" : null, "Text" : "Odontogenic Infections",  "Header" : 1}, 
{"Row" : 44, "Column" : 2, "Item" : null, "Text" : "For other oral infections see Head",  "Header" : 0}, 
{"Row" : 45, "Column" : 2, "Item" : null, "Text" : "and Neck section of CDSS",  "Header" : 0}, 
{"Row" : 48, "Column" : 2, "Item" : null, "Text" : "Urinary Tract Infections",  "Header" : 1}, 
{"Row" : 49, "Column" : 2, "Item" : null, "Text" : "For urinary tract infections not",  "Header" : 0}, 
{"Row" : 50, "Column" : 2, "Item" : null, "Text" : "listed, see Genitourinary section of",  "Header" : 0}, 
{"Row" : 51, "Column" : 2, "Item" : null, "Text" : "CDSS",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "CDSS-MicroGuide Web and Mobile App",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX MICROGUIDE MOBILE APP INSTRUCTIONS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "[CLICK HERE]", "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "Help Page",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Text version", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Beta-lactam Allergy Assessment *Updated",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "PDF version *Preferred", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "Sexually Transmitted Infections (STI)",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 INFORMATION", "Text" : "Minneapolis VAHCS SharePoint Site", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "COVID-19",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID GMENU ER/UC COVID-19 MPLS PHARMACOLOGIC GUIDELINES", "Text" : "Outpatient COVID-19 Pharmacologic Treatment Guidelines", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "PSCZID TEST2 CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Test CEFTRIAXONE 2GM IV ONCE ER/UC clinic infusion order", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 MPLS PHARMACOLOGIC GUIDELINE", "Text" : "Inpatient COVID-19 Pharmacologic Treatment Guidelines", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC EMP INTRAV W/ VANCO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Vancomycin 15 mg/kg IV once STAT($) [R] <AND> cefepime 2 gm IV once STAT", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> vancomycin 15", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ 4.5GM GENT 5MG/KG VANCO 15MG/KG ONCE STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> gentamicin", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> vancomycin 15 mg/kg IV once STAT ($)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> gentamicin 5 mg/kg IV once STAT ($)", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMPIRICAL INTRAVENOUS REGIMENS WITH VANCOMYCIN",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Discontinue vancomycin after 3 days unless culture results indicate that",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "continued therapy is needed.Gentamicin is optional.Contact Hematology-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Oncology or Infectious Diseases for advice.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "($$) [R]",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "mg/kg IV once STAT ($) [R] < OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "5 mg/kg IV once STAT ($) [R] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternatives for penicillin allergy",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "[R] < OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "[R] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sipsas NVCancer 2005, 103: 1103", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC EMP INTRAV W/O VANCO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV ONCE ER/UC", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] < OR >", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PIPERACILLIN/TAZOBACTAM 4.5 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] < OR >", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM IV GENT 5MG/KG IV STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> gentamicin 5", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> vancomycin 15 mg/kg IV once STAT ($", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> gentamicin 5 mg/kg IV once STAT ($)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMPIRICAL INTRAVENOUS REGIMENS WITHOUT VANCOMYCIN",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Gentamicin is optional.Contact Hematology-Oncology or Infectious Diseases for",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "advice.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternatives for penicillin allergy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Vancomycin must be added to aztreonam for coverage of Gram-positive organisms.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "[R] < OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "[R] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Hughes WTClin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sipsas NVCancer 2005, 103: 1103",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-Date", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC FOOT ULCER W/ INFECT SURR TISSUES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU APPRO FOOT ULCER W/ INFECT", "Text" : "Approach to foot ulcers with infection", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV STAT ($) [M] < AND > Vancomycin 15mg/kg IV STAT ($) [R]", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL/SULBACT 3GM VANCO 15MG/KG STAT", "Text" : "Ampicillin-sulbactam 3 gm IV STAT ($) [R] <AND> Vancomycin 15 mg/kg IV", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375GM IV VANCO 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 3.375 gm IV STAT ($$) [R] <AND> vancomycin 15mg/kg", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZ 2GM VANCO 15MG/KG METRO 500MG IV STAT", "Text" : "Ceftazidime 2 gm IV STAT ($$) R <AND> vancomycin 15 mg/kg IV q12h ($)", "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : "ORZ SET ABX AZTR 2GM METRO 500MG VANCO 15MG/KG IV ONCE STAT", "Text" : "Aztreonam 2 gm IV STAT ($$$$) [R] <AND> metronidazole 500 mg IV STAT ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOOT ULCERS WITH INFECTION OF SURROUNDING TISSUES",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antibiotics may be stopped 24-48 hours following curative amputation.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Otherwise, continue antibiotics until signs of infection have resolved.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Typically, 1-2 weeks for mild, 1-3 weeks for moderate and 2-4 weeks for severe.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Mild: ulcer with superficial inflammation",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration: treat until resolution of symptoms usually 1-2 weeks",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Oral therapy, no MRSA coverage:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Oral therapy, MRSA coverage:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "________________________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Moderate: Ulcer with inflammation, extension into fascia",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Duration: treat to resolution of symptoms usually 1-3 weeks",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "For patients started on parenteral therapy, a switch to an oral regimen",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "is reasonable following clinical improvement.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Oral therapy with MRSA coverage:",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Intravenous regimens with MRSA coverage: (MRSA coverage until ruled out)",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "STAT ($) [R,DI]",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "________________________________________________________________________",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Severe: Extensive local inflammation plus systemic toxicity",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Intravenous regimens for SEVERE (limb-threatening) infections",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Duration: treat to resolution of symptoms usually 2-4 weeks",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "A switch to an oral regimen is reasonable following clinical improvement.",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "IV STAT ($) [R]",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "[R] <AND> metronidazole 500 mg IV STAT ($) [DI]",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV STAT ($) [R]",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID CEFADROXIL 500MG PO BID 7DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID CEFADROXIL 500MG PO BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data.",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data.",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX-CLAV 875 BID + TMP/SULFA 14DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 14 days ($) [R,DI]",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875/125 BID + TRIMETH SULF BID 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX CLAV 875 + DOXY 14DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND> Doxycycline", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "100 mg PO BID for 14 days ($) [DI]",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875/125 BID 14D+DOXY 100MG BID 14D", "Text" : "Non-VA order for above", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC FOOT ULCER WITH DM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER W/O INFECT SURR TISSUES", "Text" : "Foot ulcers WITHOUT infection of surrounding tissues", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID GMENU ER/UC FOOT ULCER W/ INFECT SURR TISSUES", "Text" : "Foot ulcers WITH infection of surrounding tissues", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOOT ULCER IN PATIENT WITH DIABETES MELLITUS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Foot ulcers in patients with diabetes mellitus are colonized with bacteria.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Antimicrobials should not be used to treat colonization.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Cases with infection of surrounding tissues signified by erythema, warmth, local",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "tenderness, or purulent discharge should be treated with antimicrobials. Pain",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "may not be present in patients with neuropathy. In patients with substantial",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "vascular disease, erythema and warmth may not be present and instead the tissues",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "will be dusky, mottled, or cool. Capillary refill may be impaired. Patiets",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "with diabetes and ulcers are at risk for gangrenous infections. If there is any",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "suggestion of gangrene, consult surgery immediately.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC FURUNCLES, CARBUNCLES, CUT ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Select here for Staphylococcus aureus Decolonization", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DICLOX 5DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DICLOX 5DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 500MG PO QID 5DS", "Text" : "Cephalexin 500 mg po qid for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 500MG PO QID 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Doxycycline 100 mg po BID ($) [DI]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 5DS 300MG PO QID", "Text" : "Clindamycin 300 mg PO qid for 5 days ($) [H]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 5DS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Doxycycline 100 mg po BID ($) [DI]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15 MG/KG IV ONCE STAT ER/UC", "Text" : "Vancomycin 15 mg/kg IV STAT ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FURUNCLES AND CARBUNCLES",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Localized purulent infections include furuncles, carbuncles and cutaneous",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "abscesses. Nearly all are caused by Staphylococcus aureus. A furuncle is a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "inflamed nodule that usually develops as a complication of folliculitis. A",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "carbuncle is a more extensive lesion that extends further into the subcutaneous",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "tissue.Contact a wound care nurse for more information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Incision and drainage is the mainstay of therapy for carbuncles, cutaneous",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "abscesses, and large furuncles.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "The decision to administer antibiotics directed against S. aureus as an adjunct",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "to incision and drainage should be made based on the presence of systemic",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "inflammatory response syndrome (SIRS) or in patients with markedly impaired",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "host defenses.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For recurrent skin abscesses in addition to culture and antibiotic therapy",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "recommended consider a decolonization regimen.",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mild infection: Purulent infection without systemic signs of infection",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Recommend incision and drainage. No antibiotic indicated.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Moderate Infection: Purulent infection with signs of systemic infection.",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Recommend incision and drainage. Culture material and use results to guide",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "therapy.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treat for 5 days and extend/modify treatment if not improved in this time.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Alternatives",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "If methicillin-RESISTANT Staphylococcus aureus (MRSA) is suspected or proved",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Severe Infections:",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Patients who have failed incision and drainage along with oral antibiotics",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "or those with SIRS or for infections in those with neutropenia or diminished",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "neutrophil function.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Recommend incision and drainage. Culture material and use results to guide",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "therapy.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Treat for 5 days. Reevaluate patient and extend or modify treatment if not",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "improved in this time.",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Furuncle, carbuncle",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC IMMUNOCOM NEUT FEVER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU NEUT CAND ORAL THERAPY", "Text" : "If patient IS a candidate for oral therapy", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID GMENU ER/UC NEUT FEVER CAND NOT ORAL THERA", "Text" : "If patient is NOT a candidate for oral therapy", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC FEVER",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The risk of severe, rapidly progressive infections increases when the absolute",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "neutrophil count (ANC, segmented neutrophils plus bands) is less than 500",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cells/microliter. The risk increases dramatically when the ANC is <100",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cells/microliter. Because of these risks, patients with fever and neutropenia",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "to this degree should receive empirical antimicrobial therapy immediately.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empirical therapy should also be given to patients with fever and ANC 500-1000",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "cells/microliter when the concentration is expected to be <500 cells/microliter",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "within the next 48 hours. For this purpose, fever is defined as a single",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "temperature greater than 38.3 degrees Celsius.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Initial therapy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Since infection can be rapidly progressive and severe, broad-spectrum",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "antimicrobials are given urgently to patients with neutropenic fever as defined",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "above. Vancomycin should only be given when there are clear indications for its",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "use.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Candidates for empirical treatment with oral antimicrobials include those who",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "are febrile but who have no evidence of focal infection or signs or symptoms of",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "severe disease, like hypotension. Outpatient antimicrobials for neutropenic",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "fever must be ordered only in consultation with Hematology-Oncology or",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Modification to therapy",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Refer to the Systemic Infections section of the Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sipsas NV Cancer 2005, 103: 1103", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC LYME ACUTE NEURO DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACUTE NEUROLOGICAL DISEASE ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treat isolated facial palsy (Bell palsy) with oral antimicrobials. Treat more",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "extensive neurological disease with intravenous antimicrobials.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment of isolated facial paresthesia (Bell palsy)",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment of neurological disease other than Bell palsy",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 28 days.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Halperin et. al., Neurology (2007) 69.91-102",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC LYME CARDIAC DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CARDIAC DISEASE ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days. Cardiology consult recommended.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment of first degree or second degree heart block",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment of third degree heart block or other manifestation",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC LYME DISEASE PROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX TICK IDENTIFICATION LINK", "Text" : "Ixodes scapularis identification", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX MN TICKBORNE RISK MAP", "Text" : "Tickborne Disease Risk in Minnesota", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSCZID DOXYCYCLINE 200MG STAT", "Text" : "Doxycycline PO 200mg once STAT ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LYME DISEASE PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients who have been bitten while in endemic areas of New England, Mid-",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Atlantic States, Minnesota and Wisconsin where local rate of Ixodes scapularis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "tick infection rate with Borrelia burgdorferi is equal to or greater than 20%",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "may be treated with prophylactic antibiotics for prevention of Lyme disease.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Using a wait and see method by monitoring for signs and symptoms of Lyme disease",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "is also an acceptable approach in patients who have been bitten by an Ixodes",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "scapularis tick.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "All following criteria must be met to be considered for prophylactic treatment:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "1. Doxyclycline is not contraindicated (i.e. allergy, pregnant, lactating)",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "2. Attached tick is reliably identified as an adult or nymphal Ixodes",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "scalpularis. Follow link below for identification guide:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "3. Tick is attached for greater than or equal to 36 hours based on degree of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "tick engorgement with blood or likely time of exposure to tick infested area.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "4. Prophylaxis must be started within 72 hours after time tick was removed.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "5. Patient was exposed to tick bite in endemic areas where rate of Ixodes",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "scapularis infection with Borrelia burgdorferi is greater than 20%. Minnesota",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "counties where there is high risk of tickborne disease are shown in the",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "following link:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Providers can call the Minnesota Department of Health (651-201-5414) or the",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Wisconsin Department of Health Services (608-266-1865) for specific rates of B.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "burdorferi infection of ixodes ticks in area where a patient was exposed.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Disease if patient was exposed to an Ixodes scapularis tick",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "bite in New England or Mid-Atlantic States.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Prophylactic treatment if all above criteria are met",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health, Lyme Disease Basics (2017)",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "http://www.health.state.mn.us/divs/idepc/diseases/lyme/basics.html",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Wisconsin Department of Health Services, Tickborne Illness in Wisconsin (2010)",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "bitehttps://www.dhs.wisconsin.gov/tickborne/lyme-training-071210.pdf",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Wisconsin Department of Health Services, Lyme Disease Trends in Wisconsin (2016)",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "https://www.dhs.wisconsin.gov/publications/p01295.pdf", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC MORE ABOUT CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID GMENU ER/UC FOOT ULCER WITH DM", "Text" : "Foot ulcer in patient with diabetes mellitus", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "THE APPROACH TO CELLULITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In addition to antimicrobial therapy, several non-pharmacological treatments",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "improve the outcome of cellulitis. Elevation and immobilization of the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "affected limb reduces swelling. Heat reduces discomfort.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Prevent tinea pedis infection by keeping feet clean and dry. In patients with",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "peripheral edema, good skin hygiene and support stockings reduce the incidence",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "of recurrent infection.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "In many cases of cellulitis, the affected area is usually not well-",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "differentiated from unaffected areas of the skin. Erysipelas is a special case",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "with typically a well-defined border and raised, orange-peel appearance.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "For treatment of erysipelas refer to the Soft Tissue Section of the inpatient or",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "outpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Use broad-spectrum therapy for cellulitis arising in feet of patients with",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "advanced diabetes.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Schwartz MN New Eng J Med 2004, 350: 904",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cellulitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC NEUT FEVER CAND NOT ORAL THERA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID GMENU ER/UC EMP INTRAV W/O VANCO", "Text" : "Empirical intravenous regimens WITHOUT vancomycin", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID GMENU ER/UC EMP INTRAV W/ VANCO", "Text" : "Empirical intravenous regimens WITH vancomycin", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC FEVER--PATIENT IS NOT A CANDIDATE FOR ORAL THERAPY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Vancomycin is not recommended as a standard part of the initial antibiotic",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sipsas NV Cancer 2005, 103: 1103",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "regimen.Consider adding Vancomycin for specific clinical indications:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : ">>Hemodynamic instability",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : ">>Pneumonia,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : ">>Skin or soft-tissue infection,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : ">>Suspected catheter-related infection,", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC NOSO PNEUMONIA NEW", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU ABX MORE ABOUT NOSOCOMIAL PNEUMO", "Text" : "More about Nosocomial pneumonia...", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID GMENU ER/UC PNEUMONIA HAP NEW", "Text" : "HOSPITAL ACQUIRED PNEUMONIA (HAP)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "Text" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL PNEUMONIA",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Local facility antibiogram and patient risk factors for multi-drug",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "resistant pathogens guide antimicrobial therapy.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "VENTILATOR ASSOCIATED PNEUMONIA (VAP) - Refer to Lung and Mediastinum section of",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "the inpatient or outpatient Antimicrobial CDSS for recommendations",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Empirical therapy must be re-evaluated at 72 hours.",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "covered the pathogen and the patient is clinically responding.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "culture and susceptibility tests.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Pathogen-specific treatment",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Certain respiratory pathogens that are usually treated in unique ways are listed",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "here. Other respiratory pathogens are treated with drugs effective for",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "pneumonia and active against identified organisms.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Recommended duration of therapy for more resistant pathogens",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "(e.g. MRSA, Pseudomonas, Acinetobacter) require longer treatment.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Refer to pathogen-specific treatment regimen below for recommendation.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Pathogen-specific nosocomial pneumonia treatment regimens",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Refer to Lung and Mediastinum section of the inpatient or outpatient",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Antimicrobial CDSS for recommendations.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Luna CM. Crit Care Med 2003. 31:676",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC OTITIS EXTERNA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID GMENU ER/UC FURUNCLES, CARBUNCLES, CUT ABSCESS", "Text" : "Furuncles and carbuncles", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 7DAYS", "Text" : "Neomycin-polymixin-hydrocortisone ear drops 4 drops in affected ear(s) QID", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 7DAYS", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID ($) [M]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OTITIS EXTERNA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute Localized Disease",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Often due to furunculosis and usually associated with Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treat mild cases with moist local heat. For cases with cellulitis or deep",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "invasion, incision and drainage as well as systemic antibiotics may be needed.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Refer to the Furuncules and Carbuncles page for antibiotic recommendations.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Acute diffuse and chronic otitis externa",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Most commonly associated with Pseudomonas aerogenosa and Staphylococcus",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "aureus/epidermidis. Irrigate to remove cerumen, desquamated skin and purulent",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "material which can improve effectiveness of topical antibiotics. Avoid products",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "that contain neomycin if the tympanic membrane is perforated.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treat for 7 to 10 days",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Preferred treatment if tympanic membrane is intact",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "($) [M]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative if tympanic membrane is perforated or allergy to preferred treatmen",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Complicated Cases",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "For cases resistant to topical therapy alone, diabetic patients,",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "immunocompromised patients, cases where infection has spread beyond ear canal",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "and in those where topical therapy cannot be delivered effectively. Culture",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "secretions to guide therapy.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "In addition to topical therapy above <ADD>",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al., Otolaryngology-Head and Neck Surgery (2014) 150.S1-S24",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Otitis Externa", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC PHARYNGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "Text" : "Treatment of Gonorrheal Infections - Opt CDSS, change parental orders to STAT", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "LRTZHIV (RAPID) QUALITATIVE", "Text" : "HIV Rapid Test", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU MORE ABOUT PHARYNGITIS", "Text" : "More About Pharyngitis/Tonsillitis and Modified Centor score - Opt CDSS", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "LRTZ STREP A PCR", "Text" : "Rapid Strep A throat PCR testing lab order", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 PENICILLIN V 500MG PO BID 10DS", "Text" : "Penicillin V 500 mg PO BID for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 PENICILLIN V 500MG PO BID 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSCZID BENZATHINE PENCIILLIN 1.2MU IM ONCE ER/UC", "Text" : "Benzathine penicillin 1.2 million units IM once STAT ($$$) [M]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO BID 10D", "Text" : "Cephalexin 500 mg PO BID for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO BID 10D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($)", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PHARYNGITIS AND TONSILLITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are viral, primarily due to adenovirus. Aside from streptococcal and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "gonococcal pharyngitis, antimicrobials are not indicated. For gonococcal",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pharyngitis, use link below for recommendations.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consider HIV screening for patients with pharyngitis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Streptococcal Pharyngitis and Tonsillitis",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Diagnosis of group A streptococcal (GAS) infection is made through detection by",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "rapid PCR and should be reserved for patients who have a moderate to high risk",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of GAS infection according to the Modified Centor Score. Use link below for",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Modified Centor score criteria and for more details.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "PCR Negative, Viral and Other Non-GAS Causes of Pharyngitis Treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are not indicated",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "GAS Pharyngitis and Tonsillitis Treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Primary alternative:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "[M]",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Pharyngitis",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcal Pharyngitis",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC PNEUMONIA HAP NEW", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "Text" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin/tazobactam 4.5 gm IV once STAT ($$) [R] <AND> vancomycin", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG VANCO 15MG/KG ONCE IV STAT", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI]] <AND> vancomycin 15 mg/kg IV", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM GENT 5MG/KG VANCO 15MG/KG IV STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R] <AND> gentamicin 5", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> gentamicin 5 mg/kg IV once STAT ($)", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG GENT 5MG/KG VANCO 15MG/KG STAT", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> gentamicin 5 mg/kg IV once", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX AZTREONAM 2GM GENT 5MG/KG VANCO 15MG/KG STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) <AND> gentamicin 5 mg/kg IV once STAT [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMPIRIC TREATMENT: Hospital Acquired Pneumonia (HAP)",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Development of pneumonia 48 hours or more after hospital admission.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Local facility antibiogram and patient risk factors for multi-drug",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "resistant pathogens guide antimicrobial therapy.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Risk Factors for Multi-Drug Resistant (MDR) Pathogen(s):",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Prior intravenous antibiotic use within 90 days",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "covered the pathogen and the patient is clinically responding.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "culture and susceptibility tests. Can discontinue MRSA coverage if no",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "MRSA isolated from respiratory cultures, if obtained, or if nasal",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "swab or throat cultures show no growth of MRSA, or if NAAT negative for",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "MRSA.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "No Risk of MDR Pathogen(s):",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Preferred Treatment:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "15 mg/kg IV once STAT ($) [R] < OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Risk of MDR Pathogen(s):",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Preferred Treatment:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "mg/kg IV once STAT ($) [R] <AND> vancomycin 15mg/kg once STAT ($) [R] <OR>",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "[R] <AND> vancomycin 15mg/kg once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy:",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "STAT ($) [R] <AND> vancomycin 15mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1.",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Boyce JM. Antimicrob Agents Chemother 2013. 57:1163",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Chastre J. JAMA 2003. 290:2588.",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371.",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Luna CM. Crit Care Med 2003. 31:676.",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Roig J. J Antimicrob Chemother 2003. 51:1119.",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC PYELONEPHRITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSCZID CEFTRIAXONE 1GM IM ONCE ER/UC", "Text" : "Ceftriaxone 1 gm IM once STAT ($) [M]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IM ONCE ER/UC", "Text" : "Gentamicin 5 mg/kg IM once STAT ($) [R,O]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet BID for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSOZID AMOXICILLIN-CLAVULANATE 875/125 MG PO BID X14DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSHZID AMOXICILLIN-CLAVULANATE 875/125 MG PO BID X14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 14DAYS", "Text" : "Cefdinir 300 mg PO BID for 14 days ($$) [R]", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV STAT ($$) [R]", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG GENT 5MG/KG IV ONCE STAT", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R] < AND > gentamicin 5 mg/kg", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 2 GM IV GENT 5MG/KG IV ONCE STAT", "Text" : "Ampicillin 1-2 gm IV once STAT ($$) [R] <AND> gentamicin 5 mg/kg IV once", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG GENT 5MG/KG IV ONCE STAT", "Text" : "Vancomycin 15 mg/kg IV once STAT ($) [R] < AND > gentamicin 5 mg/kg", "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IV ONCE ER/UC", "Text" : "Gentamicin 5 mg/kg IV once STAT ($) [R,O]", "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO Q8H ($) [R]", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : "PSOZID AMOXICILLIN-CLAVULANATE 875/125 MG PO BID X14DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO Q12H ($) [R]", "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : "PSHZID AMOXICILLIN-CLAVULANATE 875/125 MG PO BID X14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 14DAYS", "Text" : "Cefdinir 300 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PYELONEPHRITIS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Most cases are caused by Escherichia coli. Resistant organisms are more likely",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "if the patient has been in the hospital for more than 48 hours or received a",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "course of antibiotics.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Obtain a urine Gram stain immediately to guide therapy. Drugs active against",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "enterococci (ampicillin, piperacillin) or staphylococci needn't be used if Gram-",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "negative bacilli predominate on the smear.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Judge severity of infection based on clinical signs and symptoms, including",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "blood pressure, pulse, mental status, white blood count, and degree of fever.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Oral regimens are preferred over IV if severity is mild or moderate and patient",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "is able to tolerate oral antibiotics.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "In older men with pyelonephritis, obtain a renal ultrasound to rule out",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "obstruction. Consult urology if abnormalities are found.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treat for 7 to 14 days. In patients with a mild infection and a quick clinical",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "response, 7 days of treatment may be adequate. Severe infection, resistant",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "organisms or structural abnormality may require a longer duration. A 7-day",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "course of ciprofloxacin has been shown to be as effective as a 14-day course.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment for pyelonephritis is often a 3 step process.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Stage 1: Early empirical therapy",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Stage 2: If the patient rapidly becomes clinically stable and does not have",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "SIRS, narrow intravenous or oral therapy can be substituted before",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "susceptibility results are known.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Stage 3: Definitive therapy is based on susceptibility results.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "For treatment of specific pathogens, refer to the Genitourinary section of the",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "outpatient or inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Stage 1, Empirical treatment:",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "An initial dose of parental agent is recommended, then complete treatment course",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "with oral agent. It is imperative to confirm susceptibility to the prescribed",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "oral antibiotic when results are reported.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Parental Therapy x 1 dose:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Complete course with oral therapy:",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Alternatives for patients unable to tolerate usual therapy:",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "IV once STAT ($) [R,O]",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Severe disease",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "STAT ($) [R,O]",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "IV once STAT ($) [R,O]",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "Stages 2 and 3:",  "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 100, "Column" : 1, "Item" : null, "Text" : "Sanberg et al, Lancet (2012) 380.9840:4-10",  "Header" : 0}, 
{"Row" : 101, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pyelonephritis",  "Header" : 0}, 
{"Row" : 102, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS AND SHOCK", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX SOFA ONLINE CALCULATOR", "Text" : "SOFA Online Calculator", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GMENU UC/ED SEPSIS 2", "Text" : "ED sepsis order set", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS AND SEPTIC SHOCK",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Per the Sepsis-3 task force, sepsis is defined as life-threatening",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "organ dysfunction caused by dysregulated host response to infection.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "The Sequential Organ Failure Assessment (SOFA) score can be used to help",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "identify organ dysfunction. An acute increase of 2 or more points in a patient",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "with sepsis is associated with in-hospital mortality greater than 10%. Neither",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the SOFA nor the abbreviated qSOFA is sufficiently sensitive to be used as the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "sole method of identifying sepsis related organ dysfunction.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Septic shock is a subset of sepsis in which profound circulatory, cellular and",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "metabolic abnormalities occur. Septic shock is associated with in-hospital",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "mortality greater than 40%.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Early intervention is crucial to prevention of death from sepsis. Antimicrobials",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "active against likely pathogens and supportive treatment to maintain vascular",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "perfusion should be initiated immediately.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Reassess antimicrobial therapy daily to narrow therapeutic spectrum when culture",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "and susceptibility data are available.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment of Sepsis or Septic Shock",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Sepsis, Severe Sepsis and Septic Shock",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Rhodes et al., Intensive Care Medicine (2017), 45.3: 304-377",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Singer et al., JAMA (2016), 315(8) 801-810", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS EMPIRIC THERAPY SITE UNK", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin/tazobactam 4.5 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX AZTR2GM METRO1GM VANCO15MG/KG IV STAT", "Text" : "Aztreonam 2 gm IV once STAT ($$$$) [R] <AND> metronidazole 1 gm IV once STAT", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IV ONCE ER/UC", "Text" : "<ADD> Gentamicin 5 mg/kg IV once STAT", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "RAZ ABDOMINAL CT SEVERE SEPSIS PROTOCOL", "Text" : "Please Click Here To Order an Abdominal CT", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "For Severe Penicillin Allergy:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "($) [DI] <AND> vancomycin 15 mg/kg IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg once STAT",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "*Pharmacy to follow",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Consider abdominal CT",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH UNKNOWN INFECTIOUS SITE",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS PNEUMONIA", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM VANCO15MG/KG AZITHRO500MG IV ONCE STAT", "Text" : "Piperacillin/tazobactam 4.5 gm IV once STAT( $$) [R] <AND> vancomycin 15 mg/kg", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM VANCO 15MG/KG IV AZITH500MG ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND> vancomycin 15 mg/kg IV once STAT", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG VANCO 15MG/KG ONCE IV STAT", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI] <AND> vancomycin 15 mg/kg IV once", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IV ONCE ER/UC", "Text" : "<ADD> Gentamicin 5 mg/kg IV once STAT", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Nosocomial pneumonia preferred treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Community acquired pneumonia preferred treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "IV q12H ($) [R] <AND> Azithromycin 500 mg IV once STAT ($) [M]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "($) [R] <AND> Azithromycin 500 mg IV once STAT ($) [M]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "For severe penicillin allergy in nosocomial and community acquired pneumonia",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "STAT ($) [R]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg once STAT",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "*Pharmacy to follow",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED PNEUMONIA", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS PROTOCOL ANTIMICROBIALS", "Contents" : [
{"Row" : 4, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS EMPIRIC THERAPY SITE UNK", "Text" : "Unknown Infectious Site (see below for Intraabdominal Infection)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS PNEUMONIA", "Text" : "Suspected Pneumonia", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSPECTED MENINGITIS", "Text" : "Suspected Meningitis, CNS Infection", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSP NATIVE VALVE ENDOCARD", "Text" : "Suspected Native Valve Endocarditis", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSP PROS VALVE ENDOCARD", "Text" : "Suspected Prosthetic Valve Endocarditis", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSPECTED SKIN SOFT TISSUE", "Text" : "Suspected Skin Soft Tissue Infection", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSPECTED URO SEPSIS", "Text" : "Suspected Urinary Tract Infection (AKA Urosepsis)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSPECTED INTRAABDOMINAL INFECTION", "Text" : "Suspected Intraabdominal Infection", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID GMENU ER/UC SEPSIS SUSP C. DIFFICILE", "Text" : "Suspected Severe Clostridium Difficile Infection", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID GMENU ER/UC NEUT FEVER CAND NOT ORAL THERA", "Text" : "Suspected Neutropenic Fever", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "INITIAL EMPIRIC ANTIBIOTIC GUIDELINES FOR SEVERE SEPSIS", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSP C. DIFFICILE", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "PSCZID VANCOMYCIN 125MG/2.5ML PO ONCE ER/UC", "Text" : "Vancomycin 125MG PO once STAT", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX METRO 500MG IV VANCOMYCIN 500MG PR ENEMA ONCE STAT", "Text" : "Metronidazole 500MG IV once STAT AND Vancomycin Enema 500MG PR once STAT", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site: Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given: 1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "If No ileus:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "If ileus:",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED SEVERE CLOSTRIDIUM DIFFICILE INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSP NATIVE VALVE ENDOCARD", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ 4.5GM GENT 2MG/KG VANCO 15MG/KG ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX GENT 2MG/KG VANCO 15MG/KG IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site: Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given: 1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "No Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Piperacillin/Tazobactam 4.5GM IV once STAT AND",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Gentamicin 2 MG/KG once STAT AND",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "If Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Gentamicin 2 MG/KG once STAT AND",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED NATIVE VALVE ENDOCARDITIS",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSP PROS VALVE ENDOCARD", "Contents" : [
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5 GENT2MG/KG VANC RIFAMP300 IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX AZTR2 GENT2MG/KG VANC RIFAMP300 IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site: Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given: 1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "No Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Piperacillin/Tazobactam 4.5GM IV once STAT AND",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Gentamicin 2 MG/KG once STAT AND",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines) AND",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Rifampin 300MG IV once STAT",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Aztreonam 2GM IV once STAT AND",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Gentamicin 2 MG/KG once STAT AND",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines) AND",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Rifampin 300MG IV once STAT",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED PROSTHETIC VALVE ENDOCARDITIS", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSPECTED INTRAABDOMINAL INFECTION", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM METRO 1GM IV ONCE STAT", "Text" : "Cefepime 2 gm IV once STAT ($$) [R] <AND>metronidazole 1 gm IV once STAT", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG METRO 1GM IV ONCE STAT", "Text" : "Ciprofloxacin 400 mg IV once STAT ($) [R,DI] <AND> metronidazole 1 gm IV once", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSCZID GENTAMICIN 5MG/KG IV ONCE ER/UC", "Text" : "<ADD> Gentamicin 5 mg/kg IV once STAT", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "RAZ ABDOMINAL CT SEVERE SEPSIS PROTOCOL", "Text" : "Please Click Here To Order an Abdominal CT", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "For severe penicillin allergy",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "STAT ($) [DI]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg once STAT",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "*Pharmacy to follow",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Consider Abdominal CT",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED INTRAABDOMINAL INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIPERACILLIN/TAZOBACTAM 4.5 GM IV ONCE ER/UC", "Text" : "Piperacillin/tazobactam 4.5 gm IV once STAT ($$) [R]", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSPECTED MENINGITIS", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 2GM CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX TRIM/SULFAM 5MG/KG VANCO 15MG/KG IV ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site: Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given: 1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "No Penicillin Allergy and Listeria is NOT a concern:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Ceftriaxone 2GM IV once STAT AND Vancomycin 15 mg/kg IV once STAT",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "(Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "No Penicillin Allergy and Listeria IS a concern (Patient with age > 50",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "yrs, alcoholism, or impaired cellular immunity:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Ceftriaxone 2GM IV once STAT AND",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines) AND",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Ampicillin 2GM IV once STAT",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Definite, Severe Penicillin Allergy (Whether or not Listeria is a concern):",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Trimethoprim/Sulfamethoxazole 5mg/kg (TMP component) IV once STAT AND",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED MENINGITIS, CNS INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSPECTED SKIN SOFT TISSUE", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM CLINDA900MG VANCO15MG/KG IV ONCE STAT", "Text" : "Please Click Here to Order This Set.", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX MERO1GM CLINDA900MG VANCO15MG/KG IV ONCE STAT", "Text" : "Please Click Here to Order This Set.", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CIPROFLOXACIN 400MG VANCOMYCIN 15MG/KG IV ONCE STAT", "Text" : "Please Click Here to Order This Set", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site: Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given: 1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Aggressive surgical debridement is recommended.",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "No Pencillin Allergy:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Piperacillin/Tazobactam 4.5GM IV once STAT AND",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Clindamycin 900MG IV once STAT AND",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "If Penicillin Allergy= Non-type 1 allergy (e.g. rash, etc.)",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Meropenem 1 GM IV once STAT AND",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Clindamycin 900 MG IV once STAT AND",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Penicillin Allergy= Type 1 allergy (e.g. anaphylaxis, hives, angioedema,",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "hypotension, etc.)",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Ciprofloxacin 400 MG IV once STAT AND",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED SKIN SOFT TISSUE INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SEPSIS SUSPECTED URO SEPSIS", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ 3.375GM GENT 5MG/KG VANCO 15MG/KG ONCE STAT", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX CIPRO400MG GENT5MG/KG VANCO15MG/KG IV ONCE STAT", "Text" : "Please Click Here to Order This Set.", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site: Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given: 1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "No Pencillin Allergy:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Piperacillin/Tazobactam 4.5GM IV once STAT AND",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Gentamicin 5 mg/kg IV once STAT (If CrCl less than 50 ml/min: 2 mg/kg once",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "STAT, Pharmacy to follow) AND",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "If Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Ciprofloxacin 400 mg IV once STAT AND",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Gentamicin 5 mg/kg IV once STAT (if CrCl less than 50 ml/min: 2 mg/kg once",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "STAT, Pharmacy to follow) AND",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15 mg/kg IV once STAT (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED URINARY TRACT INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SEVERE SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 10 days", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 5DAYS", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 10 days", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID($) [DI] for 10 days", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "Text" : "Ampicillin-sulbactam 3gm IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSJIZID PIP/TAZO 3.375 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 3.375 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV ONCE ER/UC", "Text" : "Cefepime 2 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEVERE SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pneumoniae, Haemophilus influenza or Moraxella catarrhalis. Group A",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Streptococci, Staphylococcus aureus and anaerobes are isolated less frequently.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "For patients who present with severe symptoms (high fever (>/= 102 degrees",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Fahrenheit, >/= 39 degrees Celsius) and purulent nasal discharge for 3-4",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "consecutive days or facial pain lasting for at least 3-4 consecutive days at the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "beginning of illness), initiate empiric antimicrobials and obtain CT of sinuses",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "to determine the extent of infection. If the CT shows extension of sinusitis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "infection into surrounding structures (i.e. the cranium or orbit) consult ENT",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "immediately. Closely monitor all patients who present with severe signs and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "symptoms to ensure that signs and symptoms improve within 72 hours.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Outpatient Treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternatives:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Treatment of hospitalized patient",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treatment failure",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "If symptoms worsen or no improvement is seen after 3-5 days of treatment,",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "broaden coverage, switch to different antimicrobial class and treat 10 days. If",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "symptoms continue to worsen or there is no improvement after 3-5 more days of",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "treatment, obtain CT to investigate non-infectious or suppurative causes. ENT",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "consultation is recommended. If sinuses are aspirated, specimens should be",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "cultured.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Chronic",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "rhinosinusitis", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SPON BACT PERITONITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV ONCE ER/UC", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 90DAYS 1DS TAB PO QDAY", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO QDAY ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 90DAYS 1DS TAB PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "Text" : "Ciprofloxacin 500 mg PO QDAY ($) [R,DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV ONCE ER/UC", "Text" : "Levofloxacin 750 mg IV once STAT ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SPONTANEOUS BACTERIAL PERITONITIS (SBP)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "SBP is infection of the peritoneal cavity in the absence of apparent trauma or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "other obvious cause. SBP occurs primarily in people with end-stage liver disease",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "and ascites. The diagnosis is made when a peritoneal fluid sample has >/= 250",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "polymorphonuclear leukocyte cells per microliter, or when bacterial pathogens",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "are isolated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Long-term SBP prophylaxis is indicated for patients who experience a first",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "episode of SBP. Short-term SBP prophylaxis is indicated for patients with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "variceal bleeding, or for patients who have low-protein refractory ascites (<1",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "gm albumin/dl ascitic fluid). Some give long-term antimicrobials to patients",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "with low-protein refractory ascites. Consult Gastroenterology for more",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "SBP",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Prophylaxis in a patient with a previous SBP episode",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Prophylaxis in a patient with cirrhosis and variceal hemorrhage",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Treat initially with an intravenous antimicrobial then step down to an oral",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "antimicrobial when the patient can tolerate oral treatment.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treat for a total of 7 days (intravenous and oral)",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Preffered initial treatment",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Initial treatment, alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Step down treatment",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Refer to Intpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for hospitalized patients with refractory low-protein ascites",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "(less than 1 gm/dL peritoneal fluid)",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Refer to Intpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Peritonitis, Primary: Spontaneous, Bacterial",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Spontaneous bacterial peritonitis in adults: Treatment and",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "prophylaxis", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SUPP ODONTOGENIC INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (ER)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h for 7 to 14 days ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 450MG PO TID 7D", "Text" : "Clindamycin 450 mg PO q8h for 7 to 14 days ($) [H,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 450MG PO TID 7D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE ER/UC", "Text" : "Ampicillin-sulbactam 3gm IV once STAT ($) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV METRO 500MG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] <AND> metronidazole 500 mg IV once STAT", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID PIPERACILLIN/TAZOBACTAM 4.5 GM IV ONCE ER/UC", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) [R]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV ONCE ER/UC", "Text" : "Meropenem 1 gm IV once STAT ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TOOTH ABSCESS AND OTHER SUPPURATIVE ODONTOGENIC INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Surgical drainage, scaling and antimicrobial treatment are essential and tooth",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "extraction is required in most cases. All patients should be referred to the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "dental service for assessment and direction of treatment. Empirical coverage for",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "likely pathogens (streptococci, Peptostreptococcus, Finegoldia, Bacteriodes and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "other oral anaerobes is required. Immunocompromised patients need additional",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "coverage for Pseudomonas aeruginosa.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult Dental Service",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease in immunocompetent patients or step-down",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "therapy after initial intravenous therapy. Adjust duration for a total of 7-14",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "days of antimicrobial therapy.",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease in immunocompetent patients",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Treatment in immunocompromised patients",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Complications, diagnosis and treatment of odontogenic",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Infections", "Header" : 0}
]},
{"Name" : "ORZID GMENU ER/UC SURG GENTAMICIN SPECIFIC DOSING", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 240 MG DOSE LESS 50KG ER/UC", "Text" : "Gentamicin 240 mg IV beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 300 MG DOSE 50-75KG ER/UC", "Text" : "Gentamicin 300 mg IV beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 400 MG DOSE 75-100KG ER/UC", "Text" : "Gentamicin 400 mg beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 500 MG DOSE 100-125KG ER/UC", "Text" : "Gentamin 500 mg beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 600 MG 100-125 KG ER/UC", "Text" : "Gentamicin 600 mg IV beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Recommended Gentamicin Doses based on patient weight:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Weight equal/less 50kg:",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Weight greater 50 kg and less 75 kg",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Weight equal 75 kg and less than 100kg:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Weight equal to 100 kg and less than 120kg:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Weight equal/greater 120 kg:", "Header" : 1}
]},
{"Name" : "ORZID GMENU ER/UC SUSP BACT, BLD CX NOT YET POS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID GMENU ER/UC ABX GENERAL INFORMATION ED", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX BACTEREMIA", "Text" : "Link to Bacteremia order menus in the Inpatient Antimicrobial CDSS", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV ONCE ER/UC", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM VANCO 15MG/KG IV ONCE STAT", "Text" : "Ceftriaxone 2 gm IV once STAT ($) [M] < AND > Vancomycin 15mg/kg IV once", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM VANC 15MG/KG IV ONCE STAT", "Text" : "Piperacillin-tazobactam 4.5 gm IV once STAT ($$) <AND> vancomycin 15 mg/kg", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG GENT 5MG/KG IV ONCE STAT", "Text" : "vancomycin 15 mg/kg IV once STAT ($) [R] <AND> gentamicin 5 mg/kg once STAT", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SUSPECTED BACTEREMIA, BLOOD CULTURES NOT YET POSITIVE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If blood cultures are positive, refer to the Bacteremia order menus in the",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "inpatient Antimicrobial CDSS (link below).",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "***ALERT*** Leaving ED Antimicrobial CDSS! When ordering antimicrobials from the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inpatient Antimicrobial CDSS, STAT priority must be manually selected.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Choice of antimicrobials",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Select antimicrobials active against any suspected site of infection that may be",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "present. Return to main menu and refer to the source infection's page within",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "the Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For patients with an intravascular catheter, refer to the intravascular-",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "associated infection page in the Systemic Infections section of the Inpatient",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Antimicrobial CDSS",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Empirical therapy for mild to moderate infection, focal infection not found",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empirical therapy for severe infection",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "STAT ($) [R]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Empirical therapy for immunosuppressed patients",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "IV once STAT ($) [R]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "For patients with penicillin allergy",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "($) [R,O]",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Medical Letter Treatment Guidelines 2010, 8: 94",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pseudomonas aeruginosa",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococci",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococci",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococci",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABSCESSES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU CUTANEOUS ABSCESS", "Text" : "Cutaneous abscess", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal/Anorectal Abscess", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Furuncles and carbuncles", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU PYOMYOSITIS", "Text" : "Pyomyositis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ABSCESSES: CUTANEOUS ABSCESS, FURUNCLE, CARBUNCLE, AND PYOMYOSITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "This section describes management of skin and soft tissue infections.For",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "information on abscesses in other areas, please return to the main CDSS menu and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "choose the appropriate organ system.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Skin infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ABOUT THE CDSS", "Contents" : [
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "Text" : "More information on antimicrobial restriction policy", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU ABX HOW TO USE CDSS", "Text" : "How to use the CDSS", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ABOUT THE ANTIMICROBIAL COMPUTERIZED DECISION SUPPORT SYSTEM (CDSS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The Antimicrobial CDSS is a tool within the Computerized Patient Record System",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "that offers antimicrobial prescribing advice to clinicians at the point of order",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "entry. The system is structured as an order menu decision tree that contains",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "quick orders pre-programmed with appropriate antimicrobial regimens for specific",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "infectious diseases.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Goals",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Improve patient outcomes, reduce rates of microbial resistance, prevent adverse",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "patient outcomes, optimize costs and improve providers' lives. In addition to",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "these goals, the program fulfills antimicrobial stewardship quality standards",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "implemented by the Joint Commission.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Rationale",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "*Improved patient outcomes",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "In a 2013 study, Minneapolis Veterans Affairs Medical Center (MVAMC)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "antimicrobial courses ordered through the Antimicrobial CDSS were significantly",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "more likely to be appropriate from start to completion, (44%) compared to non-",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "CDSS courses (33%, P = 0.013). This is consistent with other studies that have",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "shown significant improvement in appropriate use of antimicrobials when CDSS",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "programs are utilized.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "*Restricted formulary",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "The Minneapolis VAHCS has a restricted antimicrobial formulary. A restricted",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "formulary reduces cost of health care and is an integral part of antimicrobial",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "stewardship. The Antimicrobial CDSS provides a method of formulary restriction",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "that doesn't require a call back from pharmacy or a prior authorization for the",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "antimicrobial to be approved.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "*Increased efficiency",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Along with being able to order restricted antimicrobials without a prior",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "authorization or call back from pharmacy, the Antimicrobial CDSS provides quick",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "orders pre-programmed with appropriate antimicrobial regimens for specific",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "infectious diseases. Using the system saves time and increases the efficiency of",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "the ordering provider.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Features",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "The CDSS has been developed locally with input from a broad, representative",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "group of clinicians. Recommendations have been based on local susceptibility",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "patterns, clinical evidence, local preferences, and national guidelines. The",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "CDSS provides a way for clinicians to select alternative drugs when the",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "recommended drugs are contraindicated.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Detailed instructions can be found in the link below.",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Dellit et al. Clinical Infectious Diseases 2007, 44:159-7",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Filice et al. Infection Control and Hospital Epidemiology. 2013, 34.6",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Rawson et al. Clinical Microbiology and Infection. 2017, 1e9", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIAL RESTRICTION POLICY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Medication orders placed using the CDSS system will NOT require Infectious",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Disease approval. Because prescribing advice within the system has been",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "developed with input from a broad, representative group of clinicians and the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "recommendations that have emerged are based on site-specific susceptibility",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "patterns, clinical evidence, local preferences, and national guidelines,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "INFECTIOUS DISEASE APPROVAL FOR RESTRICTED ANTIMICROBIALS WILL NOT BE NEEDED at",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "participating VA sites. Clinicians are still encouraged to seek advice from",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases whenever it would be helpful.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Restricted antimicrobials ordered outside the CDSS system will continue to need",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "ID approval.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ACKNOWLEDGEMENTS", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACKNOWLEDGEMENT",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "This project was funded as a VISN 23 Strategic Planning Project for FY2005-2007.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "It addresses the VISN's efforts to build a culture of continuous quality",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "improvement, evidence-based practice and optimal resource utilization.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "This project has been guided by our project collaborators as well as the efforts",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "of the guideline review committee members. We would like to thank these",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "individuals for their time and thoughtful input.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ACUTE BACT PROSTATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACUTE BACTERIAL PROSTATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute bacterial prostatitis typically presents with dysuria and fever. The",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "prostate gland is tense, boggy, and extremely tender. The urinalysis reveals",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pyuria, and the urine culture is positive. Most cases are associated with",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "aerobic Gram-negative rods. Men with dysuria and fever but without pyuria",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and/or bacteriuria should be seen by a urologist. If there is any suspicion of",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "abscess, especially in men older than 40 years, the patient should be seen by a",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "urologist and transurethral prostate resection for drainage should be",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "considered.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Hydration, bed rest and analgesics are recommended along with these",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "antimicrobials.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat for 10-14 days",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prostatitis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute Bacterial Prostatitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "Contents" : [
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "[CLICK HERE] to open email", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "[CLICK HERE] to open Infectious Diseases on call schedule", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "WHOM TO CONTACT FOR ADDITIONAL ASSISTANCE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "CDSS Program",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Contact for issues regarding",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "navigation or content of the CDSS",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Email: VISN23AntimicrobialCDSS@va.gov",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Phone: (612) 467-1781",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Erik Stensgard, PharmD, BCPS",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antimicrobial CDSS Program Manager",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Phone: (271) 1781-4121",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Email: Erik Stensgard@va.gov",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Bobbie Masoud, PharmD, BCPS",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Clinical Pharmacist",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Phone: (612) 719-6778",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Email: Bobbie.Masoud@va.gov",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Contact for issues regarding",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "antimicrobial treatment",  "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZ GTX ABX PHARMACIST NUMBERS PHONE/PAGER", "Text" : "[CLICK HERE] to open list of", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "Antimicrobial Stewardship",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "Contact for issues regarding",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "antimicrobial stewardship",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "Muthu Narayan, DO",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "Antimicrobial Stewardship Physician",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "Pager: 612-818-3936",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "Eric Geurkink, PharmD",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "Antimicrobial Stewardship Pharmacist",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "Pager: 612-818-0841",  "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "Pharmacy Staff",  "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "Contact for pharmacy related",  "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "antimicrobial issues",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "pharmacists' phone/pager numbers",  "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "Microbiology",  "Header" : 1}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : "Contact for microbiology issues",  "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : "Phone extension: 2408", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ADJ EXIST ABX THERAPY", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ADJUSTING EXISTING ANTIMICROBIAL THERAPY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "To change the DOSE of a CURRENTLY ACTIVE antimicrobial",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Right click on the active order and change the dose as needed.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "To change from the CURRENT ANTIMICROBIAL MEDICATION",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "We encourage clinicians to consult the CDSS when considering alternative",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy due to an adverse drug reaction, a culture result, or a",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "need to switch from intravenous to oral therapy. Many of the CDSS advice menus",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "contain more than one antimicrobial recommendation. If a suitable alternative",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "is not listed on the advice menu, clinicians have the additional resource of an",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "expanded menu of alternative medications that can be accessed by selecting the",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Need an alternative antimicrobial? link at the top of each advice menu. To",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "order an alternative medication using this link prescribers will need to",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "indicate the rationale behind the choice.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Note: Restricted antimicrobials ordered outside of the CDSS system will still",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "require Infectious Diseases approval.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX AEROMONAS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q24H FOR 3 DAYS", "Text" : "Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q12h for 3 days($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH AEROMONAS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8(94)",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Aeromonas sp.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Aeromonas infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Select individual antimicrobial listed below for current status on shortages.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Currently NO antimicrobial shortages.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX ANTIVIRAL TREATMENT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSJZID OSELTAMIVIR 75 MG PO BID 5DAYS", "Text" : "Oseltamivir 75 mg po bid for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Antiviral Therapy Recommendations:",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Who to Treat:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "The decision to treat should be based on clinical symptoms and/or presence of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "a high risk condition, and should NOT be delayed until laboratory test",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "results are available.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "It is important to use antiviral drugs early to treat influenza in people who",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "are very sick with influenza (for example hospitalized people) and people who",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "are sick with influenza and have a greater chance of getting severe",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "complications. If a patient is not in a high-risk group or is not hospitalized,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "healthcare providers should use clinical judgment to guide treatment decisions.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "People who have a greater chance of serious influenza complications include:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "*Persons who have chronic pulmonary (including asthma) or cardiovascular",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "*Persons who are immunocompromised due to any cause (including immunosuppresion",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "caused by medications or by HIV infection)",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "*Persons younger than 19 years of age who are receiving long-term aspirin-",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "or salicylate-containing medications and who might be at risk for experiencing",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Reye syndrome after influenza virus infection",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "*Residents of nursing homes and other long-term care facilities",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "*American Indians/Alaska Natives",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "*Persons who are extremely obese (BMI greater than or equal to 40)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Antiviral Treatment:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "If indicated, antivirals should be started as soon as possible.Maximal",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "benefit occurs when started within 48 hours of symptom onset.However,",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "antivirals should not be withheld if symptoms began more than 48 hours prior",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "and the patient meets criteria for treatment and remains severely ill.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "CDC is recommending for this influenza season.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "The adamantanes (amantadine and rimantadine) are not recommended for",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "treatment or chemoprophylaxis this influenza season.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Treatment Dosing:",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Zanamivir is not recommended for patients with chronic respiratory disease such",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "as asthma or chronic obstructive pulmonary disease. These patients may have",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "bronchospasm with zanamivir. If zanamivir must be used, and patients are using",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "an inhaled bronchodilator, zanamivir should be taken just after the",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "bronchodilator.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Requires Infectious Disease Approval",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Zanamivir 2 inhalations (2 x 5 mg) BID for 5 days ($) [O]",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to tolerate or absorb oral oseltamivir:",  "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Requires Infectious Disease Approval",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Peramivir 600 mg IV q24h for 5 to 10 days ($$$$$) [R]",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Centers for Disease Control (CDC) (Accessed 9/8/21)",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Up-to-date online: Treatment of seasonal influenza in adults",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "Yoo JW, J Med Virol. (2015) 87(10):1649-1655",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "*Adults aged 65 years or older",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(except isolated hypertension), renal, hepatic, hematologic, metabolic",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "disorders (including diabetes mellitus), neurologic and",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "neuro-developmental disorders",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "(https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm)",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Baloxavir 80 mg PO x1 dose patients wt 80kg or greater, 40mg PO x1dose for",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "patients wt <80kg ($$$) [DI]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "intravenous peramivir) and oral baloxavir are the antiviral medications the",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Hospitalized, high risk:",  "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Acute, uncomplicated:",  "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Peramivir 600mg IV Once ($$$$$) [R]",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "de Jong MD, Clin Infect Dis. (2014) 59(12):e172-e185",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Uyeki TM, Clin Infect Dis. (2019) 68(6):895-902",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "The neuraminidase inhibitors (oral oseltamivir, inhalded zanamivir, and",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Extending the duration of treatment for oseltamivir or peramivir may be",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "needed for those patients with prolonged illness or who are immunosuppressed.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "*Pregnant women and women up to 2 weeks after the end of pregnancy", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX APPRO TO BACTEREMIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Sepsis, severe sepsis, and septic shock", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS", "Text" : "Suspected bacteremia, blood cultures not yet positive", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "Text" : "Interim report of Gram-positive cocci in pairs", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS", "Text" : "Interim report of Gram-positive cocci in pairs and clusters", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS", "Text" : "Interim report of Gram-positive cocci in pairs and chains", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNB", "Text" : "Interim report of Gram-negative bacilli", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNC", "Text" : "Interim report of Gram-negative cocci", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPR", "Text" : "Interim report of Gram-positive bacilli", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT YEAST", "Text" : "Interim report of yeast", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPROACH TO BACTEREMIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Bacteremia usually results from a focal infection somewhere in the body. If a",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "focal infection is not obvious, a careful search should be made beginning with a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "detailed history and physical examination.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "If a focal infection seems to be the source of the bacteremia, select",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobials active against pathogens likely to be present in the focal",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "infection. Return to the main menu and select the relevant diagnosis or",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "syndrome.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "For infections with signs and/or symptoms of severe sepsis, like hypotension or",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "end organ dysfunction",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sequence of evaluation",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Obtain blood cultures before starting antibiotics when signs or symptoms suggest",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "bacteremia. Obtain 2 or 3 blood culture sets from different venipuncture sites",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "within a 24 hour period. When suspicion is strong and the patient's signs and",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "symptoms have not responded, obtain 2 blood culture sets the next day. For more",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "information about blood cultures, see recommendations on the Q-drive",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Q:\\MICROBIOL INFO FOR CLINICIANS\\BLOOD CULTURE Recommendations.doc",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected bacteremia if local infection is not apparent",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "and blood cultures are not yet positive",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Cultures usually become positive after 1 or more days. Usually interim results",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "are reported first, followed by final identification and sensitivities after",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "another day or two. Adjust antimicrobials as appropriate as this sequence",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "unfolds.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Preliminary results of a positive culture are available",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "When a focal infection is not apparent, the type of bacteria growing in blood",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "culture might suggest a focal infection and direct the search for a diagnosis.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "When a focal infection is apparent, it may suggest the identity of the bacteria",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "growing in blood cultures before the laboratory completes its identification.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Preliminary positive results should lead to changes in antimicrobial therapy to",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "target suspected pathogens, narrow the spectrum, reduce toxicity, and reduce",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "costs.",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter Sepsis, Severe Sepsis and Septic Shock", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX APPRO TO ENDOCARDITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX DUKE CRITERIA", "Text" : "Diagnosis with Duke Criteria", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "Text" : "Penicillin Desensitization protocol", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPROACH TO ENDOCARDITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases and Cardiology consults are essential for proved cases and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "encouraged for suspected cases. See diagnosis page for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Attempt to identify the pathogen before starting antimicrobials. At least three",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "sets of blood cultures should be obtained from different venipuncture sites.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "These cultures should be drawn at different times with the first and last",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "culture separated by at least one hour.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "For a patient who is not clinically stable, or if the progression of the illness",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "is rapid, draw 3 sets of blood cultures and then initiate empirical",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy and/or surgical intervention.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Ascertain whether any antimicrobials were taken during the previous 2 weeks to",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "help interpret culture results.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Penicillin susceptibility data are used to determine appropriate antimicrobial",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "therapy for streptococcal endocarditis. Because bacteria in cardiac vegetations",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "are not actively dividing, and are protected from host defense mechanisms,",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "bactericidal antimicrobial regimens are necessary to treat bacterial",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "endocarditis. The minimum inhibitory concentration (MIC) cut-off levels used to",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "select therapy for endocarditis differ from those used to select therapy for",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "other infectious diseases (see below).",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Beta-lactam antibiotics are more effective than vancomycin for treating",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "susceptible gram-positive pathogens. For patients with penicillin allergy that",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "is known or suspected to be class I (anaphylaxis, angioedema, or hives),",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "penicillin desensitization or therapy with a cephalosporin is usually the best",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "approach.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "When gentamicin is used for synergy against gram positive bacteria, serum",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "concentrations should be 3-4 mcg/ml peak and < 1 mcg/ml trough. Once daily",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "gentamicin dosing can be used for streptococcal cases but not for staphylococcal",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "or enterococcal cases.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX APPROACH TO ACUTE MENINGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING W/O GRM STAIN RES", "Text" : "Community acquired meningitis", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA", "Text" : "Meningitis associated with trauma or nosocomial infection", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO", "Text" : "Gram-positive diplococci suggesting Streptococcus pneumoniae", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING", "Text" : "Gram-negative diplococci suggesting Neisseria meningitidis", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "Text" : "Gram-positive bacilli/coccobacilli suggesting Listeria monocytogenes", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GNB", "Text" : "Gram negative bacilli", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "Text" : "S. pneumoniae", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS", "Text" : "N. meningitidis", "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES", "Text" : "L. monocytogenes", "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "Text" : "E. Coli, Pseudomonas, or another organism", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPROACH TO ACUTE MENINGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Meningitis is an inflammation of the meninges and tissues surrounding the brain",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "and spinal cord. It is characterized by an abnormal amount of white blood cells",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "in the cerebrospinal fluid (CSF) and symptoms include headache, fever, mental",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "status changes, nuchal rigidity, and nausea.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Acute Meningitis",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "The sudden onset of meningeal symptoms within hours to days caused by several",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "infectious etiologies, including bacterial, viral, fungal and protozoa, as well",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "as non-infectious etiologies. Bacterial meningitis is the most common type of",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "meningitis, accounting for up to 90% of cases where a CSF culture was obtained",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "prior to starting antimicrobials. Non-bacterial meningitis is commonly referred",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "to as aseptic meningitis (refer to \"Negative CSF culture\" below for",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "recommendations).",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Patients with acute bacterial meningitis often have severe symptoms and present",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "soon after onset of infection. The relationship between predisposing factors and",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "common bacterial pathogen are listed below.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Predisposing Factors and Common Bacterial Pathogens",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "*Age 2-50 years - S. pneumoniae, N. meningitidis",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "*Age > 50 years - S. pneumoniae, N. meningitidis, L. monocytogenes, aerobic",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "gram-negative bacilli",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "*Immunocompromised state - S. pneumoniae, N. meningitidis, L. monocytogenes,",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "aerobic gram-negative bacilli (including Pseudomonas aeruginosa)",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "*Basilar skull fracture - S. pneumoniae: H. influenzae, group A and",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "beta-hemolytic streptococci",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "*Head trauma: after neurosurgery - Staphylococcus aureus, coagulase-negative",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "staphylococci (especially Staphylococcus epidermidis), aerobic gram-negative",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "bacilli (including P. aeruginosa)",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Initial Management of Suspected Acute Bacterial Meningitis",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture (LP) to obtain CSF. Two blood cultures",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "should be drawn based on predisposing factors above. LP should be performed in",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "nearly all patients to obtain CSF for establishing diagnosis and determining",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "infectious organism/susceptibility. Computed tomography (CT) should be performed",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "prior to LP in some patients (see list below). If CT must be obtained prior to",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "LP or there is another delay in performing LP, empiric antimicrobials should not",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "be delayed and initiated immediately after obtaining blood cultures only.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Relative LP contraindications (no absolute contraindications exist):",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Anticoagulation therapy or bleeding disorder, spinal epidural abscess, raised",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "intracranial pressure.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Computed tomography scan should be performed prior to lumbar puncture in cases",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "with the following: Immunocompromise, history of CNS disease, new onset seizure,",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "papilledema, abnormal level of consciousness, focal neurologic deficit.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "LP and CSF Analysis",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "LP opening pressure is often elevated in bacterial meningitis. CSF findings",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "characteristic of bacterial meningitis include CSF glucose <40mg/dL, CSF to",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "serum glucose ratio </=0.4, CSF protein concentration >/=200 mg/dL and CSF WBC",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : ">100 microL.",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment After Blood Cultures are Drawn, and CSF is Obtained, or if LP",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Must be Delayed",  "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment Based on CSF Gram-Stain Results",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "When gram stain results are available, adjust antimicrobials to optimize therapy",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Treatment Based on CSF Isolated Organism",  "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "When infectious organism is identified, adjust antimicrobials to optimize therap",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Negative CSF Culture",  "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Patients who have a negative CSF culture, but have symptoms and CSF findings",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "consistent with bacterial meningitis should be treated based on likely pathogen.",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "Patients with negative CSF culture, symptoms of acute meningitis but have labs",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "inconsistent with bacterial meningitis should be considered to have aseptic",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "meningitis. Aseptic meningitis is caused by a variety of non-bacterial",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "infectious etiologies and non-infectious etiologies. Consult Infectious Disease",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "for more information.",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 90, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX APPROACH TO UTI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPROACH TO URINARY TRACT INFECTION (UTI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In most infants, children, and young adults, urine typically has few or no",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "detectable bacteria. When bacteriuria (>= 10,000 bacteria/ml urine) occurs in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "these groups, it often results from a recognizable risk factor like congenital",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "or acquired structural abnormalities in children or young adults or sexual",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "intercourse in young women. As men and women progress through middle age and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "beyond, bacteriuria is increasingly prevalent because of laxity of the urinary",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "sphincter and urethra or supporting pelvic structures and prostatic",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "hypertrophy. Asymptomatic bacteriuria is present in the majority of elderly",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "people with chronic illness. Asymptomatic bacteriuria is not harmful and should",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "not be treated with antimicrobials except in pregnant women or just before and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "during urological surgery.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "When patients present with urinary tract infection (UTI) symptoms, obtain",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "urinalysis with microscopic examination. Depending on symptoms and signs,",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "clinicians should also order semi-quantitative urine culture, blood cultures,",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "renal ultrasound, or cystoscopy.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Cystitis refers to infection of the urinary bladder, but inflammation often",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "extends into the urethra. Typical symptoms and signs include dysuria, increased",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "urinary frequency, urgency, and/or suprapubic tenderness.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Pyelonephritis refers to infection of the kidney, renal pelvis or ureter.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Typical symptoms and signs include flank pain or tenderness, chills and/or",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "fever. The urinalysis may have white cell casts. Signs or symptoms of cystitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "are often present also.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Complicated or uncomplicated?",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Treatment and follow-up plans depend on whether an infection is considered",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "complicated or uncomplicated. Infection is considered complicated when one",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "or more of the following is present:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "> Most men with cystitis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "> Pregnant women",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "> Structural abnormalities (e.g. presence of obstruction, catheter or",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "nephrostomy tubes, neurogenic bladder)",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "> Metabolic abnormalities that reduce local host defenses (e.g. diabetes,",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "pregnancy, neutropenia, pelvic irradiation)",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "> Unusual or resistant pathogen",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "> Treatment failure or relapse or recurrence of infection",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Prevention of urinary tract infections in patients who are incontinent of urine",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Use indwelling (Foley) catheters only when needed for careful fluid management",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "or in cases where diapers or intermittent straight-catheterization are not",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "possible. Indwelling catheters substantially increase the risk of symptomatic",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "urinary tract infection and subsequent septicemia and death. Treatment of",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "recurrent infections in people with indwelling catheters selects for resistant",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "organisms, which are difficult to treat. These resistant organisms represent a",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "threat to the catheterized patients and others in the environment.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Individuals who cannot drain their bladders are best managed with intermittent",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "straight catheterization. The bladder should be drained 5 or 6 times daily to",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "simulate normal bladder function and effectively prevent cystitis. Individuals",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "who are incontinent from structural, physiological, or mental dysfunction should",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "wear diapers. This keeps the bladder and urethra free of foreign bodies, allows",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "them to drain, and reduces the incidence of urinary tract infection to",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "background levels. Modern, disposable diapers are convenient, non-obtrusive,",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "and inexpensive.",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary Tract Infection",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nosocomial Urinary Tract Infection",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Hooten et al, Clinical Infectious Diseases (2010) 50.625-663", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "Text" : "Community acquired pneumonia (CAP)< OR >", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "Text" : "Nosocomial pneumonia", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX LUNG ABSCESS", "Text" : "Lung abscess", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ASPIRATION PNEUMONIA",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Aspiration of oropharyngeal or gastric contents induces inflammation and is",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "often accompanied by fever and/or an infiltrate.Bacterial pneumonia occurs in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "a minority of patients who aspirate, typically about 3 days later.The patient",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "usually improves for the first 2 days and then worsens as bacterial pneumonia",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "develops with increased fever, new or progressive infiltrates, leukocytosis, and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "newly purulent sputum.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobials have no role for treatment of aspiration and their use entails",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "risk of side effects and selection of resistant organisms.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antimicrobials used for community-acquired pneumonia are appropriate for cases",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "that develop after an episode of aspiration.For more information, consult",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Pulmonary or Infectious Diseases.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment for patients with pneumonitis but without lung abscess or putrid",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "sputum",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Therapy directed towards anaerobic pathogens is usually unnecessary.If",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "pneumonia is confirmed, treat as",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treament for patients with LUNG ABSCESS",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Luna CMCrit Care Med 2003, 31: 676",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Lung Abscess",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell LA Clin Infect Dis 2003,37:1405",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ASSOC COLITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX INI EPI ABX ASSOC COLITIS", "Text" : "Initial Episode", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX FIRST RECURRENCE ABX ASSOC", "Text" : "First Recurrence", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU ABX SECOND RECUR ABX ASSOC COLITIS", "Text" : "Second Recurrence", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CLOSTRIDIUM DIFFICILE INFECTION [CDI]",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Discontinue implicated antibiotic and avoid high risk antibiotic if antibiotic",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "therapy is still needed. Discontinue laxatives. Reassess need for tube feeds. C.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "difficile PCR testing should be completed to confirm diagnosis of C. difficile",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "infection.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Antibiotic risk (rank order):",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "High: clindamycin, fluoroquinolones, 2nd/3rd/4th generation cephalosporins,",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Medium: carbapenems, penicillins, 1st generation cephalosporins, macrolides,",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "vancomycin, metronidazole",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Low: tetracyclines, aminoglycosides, trimethoprim/sulfamethoxazole, rifampin",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Very low: sulfonamides, nitrofurantoin, fosfomycin, methenamine",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Avoid antiperistaltic agents (narcotics, loperamide, etc.). Increasing evidence",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "suggests that antacid therapy, especially with PPIs and H2 blockers, increases",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "the risk for C. difficile disease and recurrences. Avoid antacid therapy",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "without clear indication, especially in patients at risk for primary recurrent C",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "difficile disease.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "The preferred route of antimicrobial therapy for C. difficile infection is by",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "mouth. Intravenous metronidazole should be used only when oral therapy cannot",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "be used to deliver drug to the colon. Intravenous vancomycin does not get into",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "colonic contents and is not effective.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "C. difficile infection usually responds to antimicrobial therapy, especially if",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "other antimicrobial therapy has been stopped. Relapse is usually due to failure",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "of normal colonic flora to re-establish itself, rather than antimicrobial",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "treatment failure. If symptoms do not respond to appropriate antimicrobial",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "therapy, re-consider the diagnosis. Relapse occurs in 6% to 25% of people after",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "their first episode of C. difficile infection.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Third Recurrence: Consult Gastroenterology and/or Infectious Disease",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Clostridium difficile infection",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium difficile",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "CDI: Patient with clinical symptom onset (e.g., 3 or more unformed stools in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "24 hours after discontinuation of laxatives) and laboratory confirmation of CDI.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "CDI Recurrence: Typically defined as a repeated symptomatic, laboratory",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "case of CDI within 12 weeks after a prior episode.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ASYMP BACTERIURIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU SURG UROLOGICAL PROCED", "Text" : "Antimicrobial prophylaxis for urological procedures", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O] CrCl >30 mL/min", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 250MG PO ONCE POST COITUS", "Text" : "Cephalexin 250 mg PO once post-coitus ($) [R]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO X1 POST COITUS", "Text" : "Nitrofurantoin SA 100 mg PO once post-coitus ($) [R,O]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 250MG PO QHS", "Text" : "Cephalexin 250 mg PO QHS ($) [R]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100MG PO QHS", "Text" : "Nitrofurantoin SA 100 mg PO QHS($) [R,O] CrCl >30 mL/min", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ASYMPTOMATIC BACTERIURIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Asymptomatic bacteriuria is common and harmless in most people. Asymptomatic",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "bacteriuria is common in middle-aged and older people, especially in people with",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "chronic medical problems. Patients with no symptoms of cystitis (i.e., no",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "dysuria, pain, urgency) should not be treated. The presence of pyuria (>7",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "wbc/hpf) or positive leukocyte esterase, urine nitrate, or urine bacteria s not",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "a sufficient indication for antibiotic treatment. Treatment is indicated for",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "pregnant women, patients who will have urological procedures and post-renal",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "transplant patients. If a Foley catheter is in place and can be removed safely,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "it should be done. The bacteriuria may clear.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Patients having urological procedures",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Pregnant women",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Bacteriuria in pregnant women is associated with pyelonephritis, premature",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "delivery, and lower birth weight. Screening for bacteriuria is recommended at",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "least once early in pregnancy. If bacteriuria is not found upon initial",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "testing, further screening cultures are not needed. If bacteriuria (>10,000",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "CFU/mL) is present, the patient should be treated. Testing should be repeated",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "throughout the pregnancy to detect recurrences. Suppressive therapy (see below)",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "is used for patients with 2 or more recurrences of bacteriuria during a",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "pregnancy.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Initial treatment of pregnant women with bacteriuria",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Avoid nitrofurantoin in 3rd trimester due to risk of hemolytic anemia in newborn",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treat for 5 to 7 days",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Treat for 3 to 7 days.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Suppressive therapy treatment of pregnant women with bacteriuria",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Suppressive therapy is indicated for pregnant women with more than 2 or more",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "episodes of bacteriuria.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Use post-coital dosing if infection is associated with intercourse",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "If infection is not associated with intercourse",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary Tract Infections",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Nicolle LE Clin Infect Dis 2005, 40: 643",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bacteriuria, Asymptomatic",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Urinary tract infections and asymptomatic bacteriuria in",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "pregnancy",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Approach to the adult with asymptomatic bacteriuria",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "US Preventive Services Task Force (USPSTF): Final recommendation statement on",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "asymptomatic bacteriuria in adults - Screening (2008)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ GTX ABX RESOURCE QTC", "Text" : "Please Click Here for Resource for Drugs that Cause QTc Prolongation", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ GMENU COPD-EXACERBATION MAIN IP", "Text" : "Inpatient COPD Exacerbation Orders", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN LONGTERM COPD PULM", "Text" : "Azithromycin 250 mg po daily long-term for COPD ($) [DI]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Azithromycin for Prevention of Exacerbations in Advanced COPD",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Daily azithromycin prevents chronic obstructive pulmonary disease (COPD)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "exacerbations in people with advanced COPD (Albert et al, see below).",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Of note, in the study there was no benefit in the most severely ill",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "subgroup that was on the most pulmonary medications.People",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "with frequent exacerbations have more doctor visits and hospitalizations than",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "people with fewer or no exacerbations.Frequent exacerbations are associated",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with rapid decline in lung function and quality of life and increased risk of",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "death.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "To receive daily azithromycin, patients must meet the following criteria and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "receive approval from pulmonary service.The evidence that benefits of daily",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "azithromycin outweigh risks is limited to people who meet the following",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "criteria.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Eligibility Criteria:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "*Age >40 years",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "*Clinical diagnosis of COPD (>= 10 pack-years cigarette smoking, a ratio of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "postbronchodilator forced expiratory volume in 1 second [FEV1] to forced",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "vital capacity of <70%, and a postbronchodilator FEV1 of <80% of the",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "predicted value), *AND*",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "*Were either using continuous supplemental oxygen or had received systemic",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "glucocorticoids within the previous year, *OR*",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "*Had gone to an emergency room or had been hospitalized for an acute",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "exacerbation of COPD.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Exclusion criteria:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "*Asthma",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "*People with hearing impairments",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "*Congestive heart failure",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "*Resting heart rate > 100 beats per minute",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "*Use of medications that are associated with torsades de pointes (with the",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "exception of amiodarone)",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "*Prolonged QTc interval (>450 msec)",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "*Use of medications that prolong the QTc interval",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "If, after trying all of the standard treatments, patients are still having",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "acute exacerbations of COPD, long-term antibiotic treatment with Azithromycin",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "may be considered.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Note: Guidelines for COPD can be found on the CPRS Tools Menu.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Select below for Inpatient COPD order sets for comprehensive management:",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "If the patient meets the criteria and is willing to have audiometric testing",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "and an electrocardiogram, please place a Pulmonary Consult for long-term",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Azithromycin therapy for the prevention of exacerbations of COPD.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Pulmonary is the only approved provider for ordering long-term",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Azithromycin therapy for COPD.",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Albert, RK, et al, Azithromycin for Prevention of Exacerbations of COPD.New",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "England Journal of Medicine 2011, 365:689-698",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Ray, WA, et al, Azithromycin and the Risk of Cardiovascular Death.New",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "England Journal of Medicine 2012, 366:1881-1890", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX BACTEREMIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPRO TO BACTEREMIA", "Text" : "Approach to bacteremia...", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS", "Text" : "Suspected bacteremia, blood cultures not yet positive...", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNC", "Text" : "Interim report:Gram negative cocci", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNB", "Text" : "Interim report:Gram negative bacilli", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "Text" : "Interim report:Gram positive cocci in pairs", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS", "Text" : "Interim report:Gram positive cocci in pairs and chains", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS", "Text" : "Interim report:Gram positve cocci in pair and clusters", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPR", "Text" : "Interim report:Gram positive bacilli", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT YEAST", "Text" : "Interim report:Yeast", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Bacteremia",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Bacteremia, PRELIMINARY results",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Last reviewed July 2017",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA S. AUREUS", "Text" : "with Staphylococcus aureus", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH", "Text" : "with Coagulase-negative Staphylococci (CNS)", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "Text" : "with Candida spp.", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA LISTERIA", "Text" : "with Listeria monocytogenes", "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "Bacteremia, FINAL results (specific pathogens)",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "_____________________________________", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX BARICITINIB EUA COVID-19", "Contents" : [
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "1) The patient is hospitalized with a laboratory confirmed severe COVID-19",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "diagnosis, defined as one of the following:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "-room air oxygen saturation </= 94%",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "-requirement for supplemental oxygen",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "-requirement for invasive or non-invasive mechanical ventilation",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "-requirement for ECMO",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "2) eGFR at baseline is > 15 ml/min/1.73 m2 and appropriate dosing has been",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "confirmed based on renal function. (See dosing guidance below)",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "3) Absolute neutrophil count at baseline is >/= 500 cell/ul AND the",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "absolute lymphocyte count is >/= 200 cells/ul.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "4) Liver transaminases are normal at baseline, or if abnormal, drug-induced",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "liver injury has been ruled out.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "If above requirements are met, place order for Baricitinib:",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Lexicomp Online [Baricitinib] Accessed 8/12/21",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Patients with eGFR >/= 60 ml/min/1.73 m2:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID BARICITINIB EUA COVID 4MG PO QDAY X14DAYS", "Text" : "Baricitinib 4 mg PO qday for 14 days or until discharge (COVID-19) ($$$) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Patients with eGFR 30-59 ml/min/1.73 m2:",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Patients with eGFR 15-29 ml/min/1.73 m2:",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Patients with an eGFR < 15ml/min/1.73 m2 or those on dialysis:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Baricitinib is NOT recommended",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID BARICITINIB EUA COVID 2MG PO QDAY X14DAYS", "Text" : "Baricitinib 2 mg PO qday for 14 days or until discharge (COVID-19) ($$) [R]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJZID BARICITINIB EUA COVID 1MG PO QDAY X14DAYS", "Text" : "Baricitinib 1 mg PO qday for 14 days or until discharge (COVID-19) ($$) [R]", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "FDA Fact Sheet for Healthcare Providers for baricitinib, July 2021.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Baricitinib prescribing information, Eli Lilly and Company, 07/20.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Jorgensen S, et al. Baricitinib: a review of pharmacology, safety, and",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "and emerging clinical experience in COVID-19. Pharmacother (2020) 40:843-856",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207924s002lbl.pdf",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "https://www.fda.gov/media/143823/download",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "https://pubmed.ncbi.nlm.nih.gov/32542785/",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Baricitinib may be used only when ALL the following criteria are met:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Note: See below for inclusion criteria. Barcitinib does NOT require ID approval.",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Barcitinib Oral",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Baricitinib is FDA approved for the treatment of COVID-19 in hospitalized adults",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "5) The patient does not have active tuberculosis.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB NG 4MG + ADMINISTRATION INSTRUCTIONS", "Text" : "Baricitinib 4 mg NG qday for 14 days or until discharge (COVID-19) ($$$) [R]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB NG 2MG + ADMINISTRATION INSTRUCTIONS", "Text" : "Baricitinib 2 mg NG qday for 14 days or until discharge (COVID-19) ($$) [R]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB NG 1MG + ADMINISTRATION INSTRUCTIONS", "Text" : "Baricitinib 1 mg NG qday for 14 days or until discharge (COVID-19) ($$) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB GTUBE 4MG + ADMIN INSTRUCTIONS", "Text" : "Baricitinib 4 mg G Tube qday for 14 days or until discharge (COVID-19)", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "($$$) [R]",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB GTUBE 2MG + ADMIN INSTRUCTIONS", "Text" : "Baricitinib 2 mg G Tube qday for 14 days or until discharge (COVID-19)", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX BARICITINIB GTUBE 1MG+ ADMIN INSTRUCTIONS", "Text" : "Baricitinib 1 mg G Tube qday for 14 days or until discharge (COVID-19)", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "($$) [R]",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "($$) [R]",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "requiring supplemental oxygen, non-invasive or invasive mechanical ventilation,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "or ECMO.",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "Text" : "REQUIRED UNTIL 5/14/22 -PROVIDER/PHARMACIST to complete EUA prior to ordering", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX BEBTELOVIMAB EUA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help page (instructions, microbiology, drug properties, etc.)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "Text" : "[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PATIENT EUA FACT SHEET", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Bebtelovimab", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Bebtelovimab", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJZID INV-BEBTELOVIMAB 175 MG IV ONCE", "Text" : "INV-Bebtelovimab 175 mg IV Push ONCE", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Bebtelovimab (EUA)",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-Bebtelovimab is available via FDA Emergency Use Authorization (EUA)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "for treating patients that meet specific criteria. bebtelovimab is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "not FDA approved drug.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "-Bebtelovimab EUA does NOT include post-exposure prophylaxis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Bebtelovimab Emergency Use Authorization (EUA)",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "**Treatment:**",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "ID available to discuss if needed.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Inclusion Criteria",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "ALL of the following criteria must be met for a patient to receive:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "1) Patient has a laboratory-confirmed diagnosis of mild to moderate COVID-19.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "2) Patient is not hospitalized due to COVID-19.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Note: patient may be hospitalized for some other reason.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "increase in baseline oxygen flow rate due to COVID-19.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "4) Administration will begin within 7 days of symptom onset.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "5) Patient does not have known hypersensitivity to bebtelovimab or components.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "6) Patient has at least one risk factor for progression to severe disease",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "including hospitalization or death.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "See link below for complete list:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "The provider has communicated with the patient/caregiver regarding",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "unapproved drug that is authorized for use under an EUA, given information",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Exclusion Criteria",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "If patient received tixagevimab plus cilgavimab previously, discuss with ID.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "If above requirements are met, place medication order:",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Monitor patient during infusion and 1 hour after infusion completed.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "*Patients treated with this drug should continue to self-isolate and use",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "infection control measures (wear mask, isolate, social distance, avoid",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "frequent handwashing) according to CDC guidelines.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX BELL'S PALSY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "Text" : "Lyme Disease", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX PREDNISONE 60MG Q24H 7D VALACYCLOVIR 1000MG PO Q8H", "Text" : "Prednisone 60 mg q24h PO for 7 days <AND> valacyclovir 1000 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX PREDNISONE 60MG Q24H 7D ACYCLOVIR 400MG PO Q6H", "Text" : "Prednisone 60 mg q24h PO for 7 days <AND> acyclovir 400 mg PO q6h ($) [R] for 10", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BELL'S PALSY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Herpes simplex and varicella-zoster are possible causes of Bell's palsy. Others",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "include Borrelia burgdorferi trauma. Some cases are idiopathic. Risk factors for",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Bell's Palsy include pregnancy, diabetes, obesity, hypertension, and upper",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "respiratory infections. Neurology consult is encouraged.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "If Lyme disease is suspected, refer to the Lyme disease treatment page:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment with prednisone and an antiviral within 72 hours of symptoms onset",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "improves the chances of a complete recovery.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "for 7 days",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "days",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Baugh et al., Otolaryngology-Head and Neck Surgery, 2013, 149(3S)S1-S27",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Eviston et al., J Neurol Neurosurg Psychiatry, 2015, 56.1356-1361",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Jalali et al., Laryngoscope, 2021, 131.1615-1625",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Antivirals against Herpes Viruses",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes Simplex, Bell's Palsy",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Schwartz et al., Otolaryngology-Head and Neck Surgery, 2014, 150(5)709-711",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Bell's palsy: Treatment and prognosis in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of Beta-lactam Reaction [CLICK HERE]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT BETA-LACTAM ALLERGY FACTS", "Text" : "Important Beta-Lactam Allergy Facts and Obtaining a Detailed Reaction History", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ASSESSMENT OF BETA-LACTAM REACTION AND ALTERNATIVE TREATMENT",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "This guide is intended to aid clinicians in assessment of beta-lactam",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "reactions and selection of appropriate alternative therapy. It is not a",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "substitute for clinical judgment and should not be used as a sole resource when",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "selecting antimicrobial therapy.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Reaction Assessment and Selection of an Alternative Beta-lactam",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "- If the same or a different beta-lactam was subsequently tolerated without",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "reaction, that beta-lactam may be used.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "- If reaction was intolerance (e.g. headache, GI symptoms), family history of",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "reaction, or if the patient denies allergy, any beta-lactam may be used.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "- See below for treatment based on type of reaction (severe vs non-severe).",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "- If reaction is unknown and patient denies any severe reactions (see below for",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "list of severe reactions), reaction is considered non-severe.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "- If patient is in a suitable care setting, observation during the first 15",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "minutes to 1 hour after first dose of therapy may be performed to monitor for",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "signs/symptoms of an allergic reaction.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "SEVERE REACTION TO BETA-LACTAM:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "If the patient experienced a known severe reaction (use link below for severe",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "reaction list), AVOID ALL Beta-Lactam Antibiotics. If beta-lactam therapy is",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "ideal, contact Infectious Diseases for desensitization or alternative.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Severe Reaction Examples:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "- Anaphylaxis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "- Reaction needed medical intervention",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "- Mucosal, cardiovascular or respiratory system involvement",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "- Hemolytic anemia",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "- Immune hepatitis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "- Interstitial nephritis",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "- Acute interstitial nephritis (AIN)",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "- Skin desquamation",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "- Drug reaction with eosinophilia and systemic symptoms (DRESS)",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "- Stevens-Johnson syndrome (SJS)",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "- Generalized exanthematous pustulosis",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "- Toxic epidermal necrolysis (TEN)",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "NON-SEVERE REACTION TO BETA-LACTAM:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Select an alternative non-cross-reactive beta-lactam for therapy based on",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "beta-lactam class patient had a reaction to. Refer to PDF document above for",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "detailed cross-reactivity chart.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "PENICILLIN CLASS REACTION",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "(e.g. Amoxicillin, ampicillin, cloxacillin, dicloxacillin, nafcillin, oxacillin,",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "penicillin, piperacillin, ticarcillin)",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Use: Cefazolin, cefdinir, cefuroxime, ceftazidime, ceftriaxone, cefepime,",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "ertapenem, imipenem, or meropenem",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "1ST GENERATION CEPHALOSPORIN CLASS REACTION",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "(e.g. Cefadroxil, cefatrizine, cefazolin, ceftezole, cephalexin, cephalothin,",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "cephapirin)",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Use: Dicloxacillin, nafcillin, cefazolin (unless reaction was to cefazolin)",  "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "cefdinir, ceftazidime, ceftriaxone, cefuroxime, cefepime, ertapenem, imipenem,",  "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "or meropenem",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "2ND GENERATION CEPHALOSPORIN CLASS REACTION",  "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "(e.g. Cefaclor, cefamandole, cefonicid, cefotetan, cefoxitin, cefprozil,",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "cefuroxime)",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Use: Amoxicillin, ampicillin, dicloxacillin, nafcillin, piperacillin,",  "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "cefadroxil cefazolin, cefdinir, ceftazidime, ceftriaxone, cephalexin, cefepime,",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "ertapenem imipenem, or meropenem",  "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "3RD-5TH GENERATION CEPHALOSPORIN CLASS REACTION",  "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "(e.g. Cefdinir, cefditoren, cefepime, cefiderocol ,cefixime, cefpirome,",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "cefoperazone, cefotaxime, cefpodoxime, ceftaroline, ceftazidime, ceftibuten,",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "ceftizoxime, ceftolozane, ceftriaxone)",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Use: Amoxicillin, ampicillin, dicloxacillin, nafcillin, penicillin,",  "Header" : 1}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "piperacillin, cefadroxil, cefazolin, cephalexin, ertapenem, imipenem, or",  "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "meropenem",  "Header" : 1}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "CARBAPENEM CLASS REACTION",  "Header" : 1}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "(e.g. Ertapenem, imipenem and meropenem)",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "Use: Amoxicillin, ampicillin, dicloxacillin, nafcillin, penicillin,",  "Header" : 1}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "piperacillin, cefadroxil, cefazolin, cephalexin, cefdinir, ceftazidime,",  "Header" : 1}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "ceftriaxone, or cefepime",  "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 89, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 90, "Column" : 1, "Item" : null, "Text" : "Blumenthal et. al., Addressing Inpatient Beta-Lactam Allergies: A Multihospital",  "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "Implementation. J Allergy Clin Immunol Pract. 2017, 5(3)616-625",  "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : null, "Text" : "Is it Really a Penicillin Allergy? Centers for Disease Control and Prevention,",  "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : null, "Text" : "2017",  "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : null, "Text" : "Chaudhry et al., Cephalosporins: A Focus on Side Chains and Beta-Lactam Cross-",  "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : null, "Text" : "Reactivity. Pharmacy, 2019, 7(3)103",  "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : null, "Text" : "Collins, et al. Impact of an Antibiotic Side-Chain-Based Cross-reactivity Chart",  "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "Combined With Enhanced Allergy Assessment Processes for Surgical Prophylaxis",  "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : null, "Text" : "Antimicrobials in Patients With Beta-Lactam Allergies. Clinical Infectious",  "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : null, "Text" : "Diseases, 2020",  "Header" : 0}, 
{"Row" : 100, "Column" : 1, "Item" : null, "Text" : "Patrick et al., Beta-lactam allergy Benefits of de-labeling can be achieved",  "Header" : 0}, 
{"Row" : 101, "Column" : 1, "Item" : null, "Text" : "safely. BC Medical Journal, 2019, 61(9)350",  "Header" : 0}, 
{"Row" : 102, "Column" : 1, "Item" : null, "Text" : "Sakoulas et al., Is a Reported Penicillin Allergy Sufficient Grounds to Forgo",  "Header" : 0}, 
{"Row" : 103, "Column" : 1, "Item" : null, "Text" : "the Multidimensional Antimicrobial Benefits of Beta-Lactam Antibiotics?",  "Header" : 0}, 
{"Row" : 104, "Column" : 1, "Item" : null, "Text" : "Clinical Infectious Diseases, 2019, 68(1)157",  "Header" : 0}, 
{"Row" : 105, "Column" : 1, "Item" : null, "Text" : "Shenoy et al., Evaluation and Management of Penicillin Allergy. JAMA. 2019,",  "Header" : 0}, 
{"Row" : 106, "Column" : 1, "Item" : null, "Text" : "321(2)188",  "Header" : 0}, 
{"Row" : 108, "Column" : 1, "Item" : null, "Text" : "Immunol. 2010, 105(4)259",  "Header" : 0}, 
{"Row" : 109, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Drug Allergy, Beta-lactams",  "Header" : 0}, 
{"Row" : 110, "Column" : 1, "Item" : null, "Text" : "Tribiano et al. The Three C's of Antibiotic Allergy - Classification, Cross-",  "Header" : 0}, 
{"Row" : 111, "Column" : 1, "Item" : null, "Text" : "Reactivity and Collaboration. J Allergy Clin Immunol Pract, 2017, 5(6)1532-",  "Header" : 0}, 
{"Row" : 112, "Column" : 1, "Item" : null, "Text" : "1542",  "Header" : 0}, 
{"Row" : 113, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Cephalosporin-allergic patients: Subsequent use of",  "Header" : 0}, 
{"Row" : 114, "Column" : 1, "Item" : null, "Text" : "cephalosporins and related antibiotics",  "Header" : 0}, 
{"Row" : 115, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Drug allergy: Classification and clinical features",  "Header" : 0}, 
{"Row" : 116, "Column" : 1, "Item" : null, "Text" : "Zagursky et al., Cross-reactivity in b-Lactam Allergy. J Allergy Clin Immunol",  "Header" : 0}, 
{"Row" : 117, "Column" : 1, "Item" : null, "Text" : "Pract. 2018, 6(1)72",  "Header" : 0}, 
{"Row" : 107, "Column" : 1, "Item" : null, "Text" : "Solensky et al., Drug Allergy: An Updated Practice Parameter. Ann Allergy Asthma",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Streamlined Version (PDF form)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX BRONCHITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERTUSSIS", "Text" : "Pertussis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "Text" : "Bronchitis-antibiotics not a benefit in otherwise healthy patient", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO BID ($) [DI] < OR >", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500mg PO once on day one then 250mg PO qday for 4 days ($) [M]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID AZITHROMYC 500MG IV X1 THEN 250MG IV X4DAYS", "Text" : "Azithromycin 500 mg IV once on day 1, then 250 mg IV q24 for 4 days ($) [M< OR >", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($) [R]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BRONCHITIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis should not be treated with antimicrobials except in specific",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "circumstances. If pneumonia is suspected, order a chest x-ray.If an",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infiltrate is not present, the patient does not have bacterial pneumonia and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "need not be treated for it.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis in an otherwise HEALTHY PATIENT",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Antimicrobials provide no benefit.If bronchitis persists beyond 2 weeks,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "additional diagnostic workup is needed to find a cause.If a patient has",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "persistent cough with inspiratory whoop, consider a diagnosis of pertussis.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis in patients with COPD",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Symptoms of COPD exacerbation include dyspnea with increased sputum purulence",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "and volume, together with increased cough and wheeze. Co-morbidities are",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "common in COPD patients, thus exacerbations must be differentiated clinically",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "from other events such as acute coronary syndrome, worsening heart failure,",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "pulmonary embolism and pneumonia.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Cornerstones of therapy include oxygen, bronchodilators, and in some cases",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "corticosteroids. Recommend antibiotics for moderately or severely ill patients",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "with COPD exacerbation who have increased sputum purulence and volume.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment for MILD DISEASE:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "No antibiotics recommended",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Treatment for MODERATE DISEASE",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Treat for 5 to 7 days.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Treatment for SEVERE DISEASE",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "NOTE: Fluoroquinolones are not listed as a choice because the risk of serious",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "side effects outweigh the benefits.",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Access: http://www.goldcopd.org",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Wenzel WP et al NEJM 2006, 355: 2125",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bronchitis",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bronchitis",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Murphy TF Chest 2000, 118: 204",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Masterton RG Int J Antimicrob Agents 2001, 18: 503", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BRONCHITIS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis is a clinical syndrome with a brief, self-limited",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "pneumonia on chest radiograph. It is accompanied by dry or productive cough",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "lasting up to 3 weeks, is most prevalent in winter, and is primarily caused",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "by viruses. More than 1 in 20 people have acute bronchitis per year, with",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "highest rates during the winter months.This discussion does not pertain to",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "acute exacerbations of chronic bronchitis, a clinical syndrome also",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "frequently associated with viral infection, but in which bacteria play a more",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "important role.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Narcotic cough suppressants, expectorants, antihistamines,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "decongestants, and beta 2-agonists have been used to treat patients with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "acute bronchitis, but controlled trials have not clearly concluded that they",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "are beneficial.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Empirical antibacterial therapy has repeatedly been shown to provide no",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "benefit for most patients.Acute bronchitis remains one of the five most",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "frequently cited rationales for excessive antibiotic use in outpatients.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis and other acute respiratory syndromes (otitis media,",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "sinusitis, pharyngitis,upper respiratory infections) account for",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "approximately 75% of ambulatory prescriptions in the United States.Current",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "guidelines, endorsed by a number of national societies, including the",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases Society of America, do not recommend the routine use of",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "antibiotics for uncomplicated acute bronchitis in otherwise normal persons.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "If pertussis is suspected, early therapy with macrolides or",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "tetracyclines is indicated to prevent transmission, although the clinical",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "findings early in pertussis infection are indistinguishable from viral causes",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "of bronchitis, and the incidence of disease is very low.Treat for pertussis",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "only when a patient has likely been exposed to other cases.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Asthma attacks often have symptoms resembling bronchitis.Asthma",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "attacks do not benefit from antimicrobial therapy.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CAMPYLOBACTER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h for 3 days ($) [M]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h for 5 days ($)[R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CAMPYLOBACTER",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Fluoroquinolone resistance is increasing worldwide. Macrolide resistance is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "rare.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Campylobacter",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Campylobacter infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CANDIDA UTI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "Text" : "Fungemia Associated with Candida spp.", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "Text" : "Fluconazole 400 mg (6 mg/kg) PO q24h for 3 days before and 3 days after", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 400MG IV Q24H", "Text" : "Fluconazole 400 mg 6 mg/kg) IV q24h for 3 days before and 3 days after", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 200MG PO Q24H", "Text" : "Fluconazole 200 mg (3 mg/kg) PO q24h for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 200-400MG IV Q24H", "Text" : "Fluconazole 200 mg (3 mg/kg) IV q24h for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "Text" : "Fluconazole 400 mg (6 mg/kg) PO q24h for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 400MG IV Q24H", "Text" : "Fluconazole 400 mg (6 mg/kg) IV q24h for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA URINARY TRACT INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A positive urine culture for candida usually reflects colonization. Treat",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cystitis only if the patient has symptoms of urinary tract infection (e.g.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "dysuria, frequency, urgency, and/or suprapubic tenderness) or if the patient",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "will undergo invasive urological manipulation",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Asymptomatic candiduria in a patient with a urinary catheter should not be",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "treated without an additional indication. Removal of catheter is strongly",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "recommended. Contact Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Neutropenic patients with asymptomatic candiduria should be assessed for",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "candidemia because they are at risk of dissemintation. Obtain blood cultures and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "assess potential sources of candidemia such as central venous catheters. Refer",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "to fungemia page for treatment recommendations.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment of patient undergoing invasive urological manipulation",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "procedure ($) [R,DI]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "procedure ($) [R,DI]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment of symptomatic candida cystitis:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Treatment of pyelonephritis",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Alternative for resistant candida",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "IDSA Guidelines: Pappas et al, Clin Infect Dis (2016) 62.409",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary Tract Infections",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Candida Infections of the Bladder and Kidneys",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-To Date article: Epidemiology and pathogenesis of candidemia in adults",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Urinary Tract Infections",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 150MG PO ONCE", "Text" : "Fluconazole 150 mg PO once ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE VAGINAL CRM 1% 1 APPLFUL QHS", "Text" : "Clotrimazole vaginal 1% cream 1 applicator full QHS for 7 to 14 days ($) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID TERCONAZOLE 0.4% CRM VAG QHS", "Text" : "Terconazole 0.4% vaginal cream 1 applicator full QHS for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 150MG PO Q72H", "Text" : "Fluconazole 150 mg PO q72h for 7 days (3 doses) ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE VAGINAL CRM 1% 1 APPLFUL QHS", "Text" : "Clotrimazole vaginal 1% cream 1 applicator full QHS for 10-14 days ($) [M]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID TERCONAZOLE 0.4% CRM VAG QHS", "Text" : "Terconazole 0.4% vaginal cream 1 applicator full QHS for 10-14 days ($) [M]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 150MG PO QWEEK", "Text" : "Fluconazole 150 mg PO every 7 days for 6 months ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA VULVOVAGINITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "The vaginal pH is 3.5 to 3.8. The discharge is typically thick and curdy.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Diagnosis is confirmed by identifying fungus or yeast with KOH prep.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Recurrent candida vulvovaginitis is treated as complicated candida",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "vulvovaginitis for induction treatment, followed by maintenance regimen for 6",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "months.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Most non-C. albicans species respond to fluconazole treatment except C. krusei",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "and C. glabrata. C. krusei can be treated with topical agents as for complicated",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "candida vulvovaginitis below. C. glabrata treatment is complicated and azole",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "therapy is frequently unsuccessful. Consult Infectious Diseases (inpatient) in",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "patients with C. glabrata vulvovaginitis.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for uncomplicated candida vulvovaginitis",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treatment for complicated candida vulvovaginitis (immunocompromised, severe",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "disease) or recurrent infection induction treatment",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Recurrent candida vulvovaginitis maintenance regimen following induction",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "treatment above",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment for C. glabrate vulvovaginitis",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Failure of azole therapy is common, alternative topical treatments below require",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "compounding by a pharmacist. Please call pharmacy to order.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Topical flucytosine cream (17%) daily for 14 days",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Topical boric acid capsule 600 mg intravaginal daily for 14 days",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "IDSA Guidelines: Pappas et al, Clin Infect Dis (2016) 62.409",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Vulvovaginitis",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Candida Vulvovaginitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CARDIOVASCULAR", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPRO TO ENDOCARDITIS", "Text" : "Approach to Endocarditis", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX DIAGNOSIS OF ENDOCARDITIS", "Text" : "Diagnosis of Endocarditis", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU EC NV EMP THERA", "Text" : "Empirical Therapy", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU EC NV SEL PATH", "Text" : "Selected Pathogens", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU EC PV EMP THERAPY", "Text" : "Empirical Therapy", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU EC PV SEL PATH", "Text" : "Selected Pathogens", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU LYME CARDIAC DISEASE", "Text" : "Cardiac Lyme Disease", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFECT INVOLVES CARD DEVICES", "Text" : "Cardiovascular Device Infections (Excluding Valves)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Catheter-Related Bloodstream Infections", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX MYOCARDITIS", "Text" : "Myocarditis", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERICARDITIS", "Text" : "Pericarditis", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUPPURATIVE THROMBO EMP THERAPY", "Text" : "Suppurative Thrombophlebitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++CARDIOVASCULAR++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Endocarditis",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Native Valve Endocarditis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Prosthetic Valve Endocarditis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Other",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Section last reviewed9/2020", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX CDSS VERSION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "VERSION 1.0",  "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "3-5-2020",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "NEW TEXT",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "AUTOMATION",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "AUTOMATION", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU MORE ABOUT CELLULITIS", "Text" : "More about cellulitis...", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin 15mg/kg IV", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG CIPRO 400MG METRO 500MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> Vancomycin 15 mg/kg IV", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BACTERIAL CELLULITIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Cellulitis refers to inflammation of the skin and subcutaneous tissue and is",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "often associated with bacterial pathogens.The most common pathogens are group",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "A streptococci and Staphylococcus aureus.Group B streptococci are associated",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "with cellulitis in elderly people, in those with diabetes mellitus, and on feet",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "and legs of patients with athlete's foot (tinea pedis).",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Mild cases can be treated with oral antimicrobials.Moderate to severe cases",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "should be treated initially with intravenous antimicrobials.Switch to oral",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "drugs after clinical improvement.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consider MRSA coverage for cellulitis associated with penetrating trauma, a",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "history of MRSA infection, injection drug use, or infections not responding",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "to first line beta-lactams.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Duration: Treat for 5 days. Re-evaluate the patient and extend/modify treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "if not improved in this time.",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mild: Cellulitis without systemic signs of infection",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for MILD cellulitis",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative for Penicillin Allergy or MRSA suspected",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "MRSA Suspected Mild Cellulitis",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Moderate: Cellulitis with systemic signs of infection",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for MODERATE cellulitis",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy or MRSA suspected",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Severe: Cellulitis in patients with signs of deeper infections",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "(e.g. bullae, skin sloughing, hypotension, or evidence of organ dysfunction).",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Patients may also qualify as severe if they are neutropenic, have a",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "hematologic malignancy or congenital immunodeficiency, or are receiving",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "immunosuppressant therapy.Consider whether surgical drainage is necessary.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for SEVERE infection",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "q12h ($) [R]",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy or MRSA suspected:",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "q12h ($) [R] <AND> Metronidazole 500 mg IV q8h ($) [DI,H]",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC PCR TEST", "Text" : "Chlamydia & GC PCR/LCR test", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "Text" : "Treatment of recurrent or persistent cervicitis", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS", "Text" : "Treatment for chlamydial or non-gonococcal cervicitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "The main diagnostic signs that characterize cervicitis are 1)women who present",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "with purulent or mucopurulent exudate in the endocervical canal or on an",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "endocervical swab specimen and 2)sustained endocervical bleeding induced by",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "gentle passage of cotton swab through the cervical os. One or both signs may be",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "present.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Neisseria gonorrhoeae and Chlamydia trachomatis are the two most common sexually",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "transmitted cervicitis pathogens. Nucleic acid amplification tests for these",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "pathogens are more sensitive than culture and should be used for patients at",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "risk for sexually transmitted cervicitis.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For patients who have recently been treated for cervicitis",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "When diagnosed with sexually transmitted cervicitis, the patient's sexual",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "transmitted infection. If diagnostic tests for the cause of cervicitis are not",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "feasible, therapy for both N. gonorrhoeae and C. trachomatis should be given to",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "partners.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Initial treatment of patients and sex partners",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Patients and partners are often infected with both N. gonorrhoeae and C.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "trachomatis. Treat for both pathogens unless one is ruled out by lab test.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urethritis",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute cervicitis",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX GONOCOCCAL", "Text" : "Treatment for gonorrhea cervicitis", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1 gm PO ONCE ($) [M]", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "CHLAMYDIAL OR NON-GONOCOCCAL URETHRITIS OR CERVICITIS OR RECTAL",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment for chlamydial or non-gonococcal urethritis or cervicitis",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urethritis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and Cervicitis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Urethritis, cervicitis: chlamydial",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute cervicitis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Urethritis in men",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "< OR >", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CHOLANGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h for 7 to 10 days ($$) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "Text" : "Moxifloxacin 400 mg IV q24h for 7 to 10 days [R,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG IV AND METRO 500MG IV", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h ($)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG PO Q24H METRO 1 GM PO Q12H", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHOLANGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are due to common bile duct obstruction. Obstruction (if present)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "must be relieved with an endoscopical, transcutaneous, or surgical procedure.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "The most common pathogens isolated are E. coli, Klebsiela, Enterococcus and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Enterobacter. Anaerobes such as Bacteriodes and Clostridia can be present as",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "part of a mixed infection.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "[DI] for 7 to 10 days",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Step down treatment for completion of antimicrobial course after initial",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "on culture results.",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Cholangitis, Cholecystitis)",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gallbladder Infections",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Acute cholangitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CHOLECYSTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG IV AND METRO 500MG IV", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin 15 mg/kg", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG PO Q24H METRO 1 GM PO Q12H", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHOLECYSTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Adequate biliary drainage is the definitive treatment. Antimicrobials should be",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "prescribed only if signs of infection like leukocytosis or fever are present or",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "if the patient is elderly. Surgery and Gastroenterology involvement are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "essential.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Most cases are associated with E. coli, Enterococcus, Klebsiella, and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Enterobacter. Anaerobic coverage is not indicated unless a biliary-enteric",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "anastomosis is present. For community-acquired acute cholecystitis, enterococcal",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "coverage is not required because Enterococcus has not been shown to be",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "pathogenic in these patients.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If needed, antimicrobial therapy should be continued only until adequate",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "drainage is established, then stopped.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Community-acquired acute cholecystitis",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate infection without biliary-enteric anastomosis",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate infection and biliary-enteric anastomosis present",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment of severe infection, advanced age or immunocompromised patient",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Health care-associated infection",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Step down treatment for completion of antimicrobial course after initial",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "on culture results.",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess,",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Cholangitis, Cholecystitis)",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gallbladder Infections, Acute Cholecystitis",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of acute calculous cholecystitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CHOLERA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 300MG PO ONCE", "Text" : "Doxycycline 300 mg PO one-time dose ($) [DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID CIPROFLOX 1000MG PO ONCE", "Text" : "Ciprofloxacin 1000 mg PO one-time dose ($) [R,DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CHOLERA (VIBRIO CHOLERAE)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Primary Treatment",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Aggressive hydration and electrolyte replacement are essential",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Tetracycline intolerant patient",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For patients who are hospitalized or unable to take oral medications",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastroenteritis, Vibrio cholerae",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Cholera: Clinical features, diagnosis, treatment, and",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "prevention",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "**Duration: 3 days**", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZ IBUPROFEN 600MG Q8H", "Text" : "Ibuprofen 200-800 mg PO q8h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHRONIC PROSTATITIS / CHRONIC PELVIC PAIN SYNDROME",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "This syndrome presents with intermittent perineal and/or low back pain,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "obstructive voiding symptoms, relatively normal examination, and negative urine",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures. Suggest urology consult.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For pain control, try for symptomatic relief. Treat for 2 to 3 weeks.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prostatitis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Chronic prostatitis/chronic pelvic pain syndrome", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CHRONIC BACT PROSTATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHRONIC BACTERIAL PROSTATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Chronic bacterial prostatitis usually presents as recurrent urinary tract",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infections with the same strain. Pain, tenderness, and fever may accompany",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "intermittent episodes of cystitis, but men are usually asymptomatic between",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "episodes and the prostate examination may be normal. Non-steroidal anti-",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "inflammatory drugs (NSAIDs) often relieve pain. If the diagnosis is uncertain",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "or if the patient's symptoms do not respond to therapy, consult urology. The",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "presence of hematuria may be a sign of carcinoma, especially in older men, and",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "a urology consult should be requested.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treat for 1 to 3 months.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prostatitis",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Chronic bacterial prostatitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CHRONIC MENINGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHRONIC MENINGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Subacute meningeal symptoms, including headache, fever, and nausea for 4 weeks",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "or more. Chronic meningitis is caused by a long list of infectious and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "non-infectious etiologies. Treatment is based on etiology and empirical",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "treatment is not urgent unless tuberculosis is suspected. Consult Infectious",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Diseases for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Chronic meningitis",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Chronic meningitis",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Approach to the patient with chronic meningitis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CHRONIC SUP OTITIS MEDIA", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "* *THIS PAGE UNDER CONSTRUCTION* *", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CMV COLITIS OR ESOPHAGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900MG PO Q12H", "Text" : "Valganciclovir 900 mg PO q12h ($$$) [R,O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID GANCICLOVIR 5 MG/KG IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID FOSCARNET 90 MG/KG IV Q12H", "Text" : "Foscarnet 90 mg/kg IV q12h ($$$$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV COLITIS OR ESOPHAGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection in immunocompetent patients is rare and usually associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and requires Infectious Diseases consultation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for 3-6 weeks. Patients may be converted to oral therapy after initial",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "intravenous therapy and after clinical improvement of severe disease.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease or following clinical improvement of",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "severe disease",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CMV ENCEPHALITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX GANCICLOVIR 5MG/KG IV Q12H FOSCAR 90MG/KG IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O] <AND> foscarnet 90 mg/kg IV q12h", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900MG PO Q12H", "Text" : "Valganciclovir 900 mg PO q12h ($$$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV ENCEPHALITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection in immunocompetent patients is rare and usually associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and requires Infectious Diseases consultation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration is likely to be prolonged and is individualized based on response.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Patients may be converted to oral therapy after initial intravenous therapy and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "after clinical improvement of severe disease.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "($$$$) [R,O]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Oral treatment following clinical improvement",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CMV MAIN PAGE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV COLITIS OR ESOPHAGITIS", "Text" : "Colitis or esophagitis", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV ENCEPHALITIS", "Text" : "Encephalitis", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV POLYRADICULOPATHY", "Text" : "Polyradiculopathy", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV RETINITIS", "Text" : "Retinitis", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV PNEUMONIA", "Text" : "Pneumonia", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CYTOMEGALOVIRUS (CMV)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antiviral toxicity information",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "The major toxicities of both ganciclovir and valganciclovir are neutropenia.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Nephrotoxicity is the major toxicity associated with foscarnet, which may be",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "reduced by concomitant saline administration (generally 0.5-1L).",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patient",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Infection is rare and usually associated with minimal or no symptoms.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Mononucleosis can be associated with CMV, but is more commonly associated with",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Epstein Barr virus. Antiviral treatment is not usually necessary as most",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "patients recover without intervention.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patient",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Patients in whom the risk for CMV disease is increased include solid organ and",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "bone marrow transplant recipients, persons receiving prolonged immunosuppressive",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "chemotherapy, and persons with advanced HIV disease indicated by a CD4 count of",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "less than 50 cells/microliter.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "CMV treatment recommendations",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CMV PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX GANCICLOVIR 5 MG/KG IV Q12H IMMUNE IG 0.5 GM/KG", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O] <AND> intravenous immune globulin", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900 MG PO Q24H", "Text" : "Valganciclovir 900 mg PO Q24h ($$$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV PNEUMONIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "CMV pneumonia occurs almost exclusively in bone marrow transplant recipients,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "usually within the first 120 days after transplantation. In these patients, CMV",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pneumonia is severe and requires aggressive treatment. Treatment is complex and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "requires Infectious Diseases consultation.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Induction therapy is indicated for 3 to 6 weeks, followed by maintenance",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "therapy. Duration of maintenance therapy is not well established.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "0.5 grams/kg IV every other day",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Maintenance therapy",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CMV POLYRADICULOPATHY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900MG PO Q12H", "Text" : "Valganciclovir 900 mg PO q12h ($$$) [R,O]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID GANCICLOVIR 5 MG/KG IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID FOSCARNET 90 MG/KG IV Q12H", "Text" : "Foscarnet 90 mg/kg IV q12h ($$$$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV POLYRADICULOPATHY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection in immunocompetent patients is rare and usually associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and requires Infectious Diseases consultation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration is likely to be prolonged and is individualized based on response.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Patients may be converted to oral therapy after initial intravenous therapy and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "after clinical improvement of severe disease.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease or following clinical improvement of",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "severe disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CMV RETINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID GANCICLOVIR 5 MG/KG IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID FOSCARNET 90 MG/KG IV Q12H", "Text" : "Foscarnet 90 mg/kg IV q12h ($$$$) [R,O]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID GANCICLOVIR 4MG INTRAVITREOUS INJECT ONCE", "Text" : "Ganciclovir 4mg/0.1mL intravitreal injection STAT ($$$$) [R,O]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID FOSCARNET 2.4MG INTRAVITREOUS INJECT ONCE", "Text" : "Foscarnet 2.4mg/0.1 mL intravitreal injection STAT ($$$$) [R,O]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX GANCICLOVIR 5MG/KG IV Q12H FOSCAR 90MG/KG IV Q12H", "Text" : "Ganciclovir 5 mg/kg IV q12h ($$$$) [R,O] <AND> foscarnet 90 mg/kg IV q12h", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900MG PO Q12H", "Text" : "Valganciclovir 900 mg PO q12h($$$) [R,O]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSJZID VALGANCICLOVIR 900 MG PO Q24H", "Text" : "Valganciclovir 900 mg PO q24h ($$$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV RETINITIS AND ACUTE RETINAL NECROSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection in immunocompetent patients is rare and usually associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and requires Infectious Diseases consultation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For sight threatening lesions (lesions within 1500 microns of the fovea)",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "intravitreal infections of ganciclovir or foscarnet are recommended in addition",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "to systemic treatment. Contact Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat retinitis for 14 to 21 days. Patients may be converted to oral therapy",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "after initial intravenous therapy and after clinical improvement of severe",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "disease. Treat acute retinal necrosis with IV therapy for at least 7 days and",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "until disease stabilizes then oral therapy for a minimum of 6 weeks. Maintenance",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "therapy after completion of treatment is indicated when CD4 count <100.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Discontinue maintenance therapy when CD4 count is >100 for 6 months.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment acute retinal necrosis or severe disease",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Intravitreal antiviral in addition to systemic antiviral may provide added",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "therapeutic efficacy.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Optional add-on therapy for acute retinal necrosis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "For cases not responsive to Intravenous therapy with foscarnet and ganciclovir",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "used alone",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "($$$$) [R,O]",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "In cases not responsive to first-line therapy, second-line therapies may be",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "effective. Their use is highly specialized and must be done by someone",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "experienced with HIV/AIDS medicine.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate retinitis or after clinical improvement of severe",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "retinitis/acute retinal necrosis",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Maintenance therapy",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CNS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPROACH TO ACUTE MENINGITIS", "Text" : "Approach to acute meningitis", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING W/O GRM STAIN RES", "Text" : "Community acquired", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA", "Text" : "Associated with trauma or nosocomial infection", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO", "Text" : "Gram-positive diplococci suggesting Streptococcus pneumoniae", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING", "Text" : "Gram-negative diplococci suggesting Neisseria meningitidis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "Text" : "Gram-positive bacilli/coccobacilli suggesting Listeria monocytogenes", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING GNB", "Text" : "Gram negative bacilli", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "Text" : "S. pneumoniae", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS", "Text" : "N. meningitidis", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES", "Text" : "L. monocytogenes", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "Text" : "E. Coli, Pseudomonas, or another organism", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ CENTRAL NERVOUS SYSTEM ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute Meningitis",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment Prior to Gram Stain Results",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment Based on Gram Stain Results",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment Based on Isolated Pathogen",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Last reviewed 11/2021",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU APPROACH TO BRAIN ABSCESS", "Text" : "Approach to brain abscess", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT", "Text" : "Contiguous or hematogenous spread of infection", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC", "Text" : "Post-surgical or post-traumatic", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP", "Text" : "Nocardia spp.", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.", "Text" : "Pseudomonas spp.", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII", "Text" : "Toxoplasma gondii", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "Text" : "Bell's Palsy", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU ABX CHRONIC MENINGITIS", "Text" : "Chronic Meningitis", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS", "Text" : "Cranial epidural abscess", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU SURG NEUROSURGERY", "Text" : "Neurosurgery prophylaxis", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU ABX HSV ENCEPHALITIS", "Text" : "Herpes simplex encephalitis", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "Text" : "Lyme disease", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS", "Text" : "Spinal epidural abscess", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU SUBDURAL EMPYEMA", "Text" : "Subdural empyema", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU SUPP INTRACRANIAL THROMBOPH", "Text" : "Suppurative intracranial thrombophilia", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Brain abscess",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Treatment based on Isolated Pathogen",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "Other", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR", "Contents" : [
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "Text" : "Nosocomial Pneumonia", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COLONIZED RESPIRATORY TRACT IN A PATIENT ON A VENTILATOR",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The respiratory tracts of persons who are intubated, have a",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "tracheostomy, or have other abnormalities of the larynx or trachea are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "usually colonized with bacteria and often fungi. The bacteria can be of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "relatively low virulence (e.g. coagulase negative staphylococci, streptococci,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "candida) or of potentially greater virulence (Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "enterobacteriaceae, pseudomonas). Candida and enterococci are common",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "respiratory tract colonizers and they almost never cause pneumonia. There is",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "no benefit from treatment of patients with systemic antimicrobials simply",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "because the respiratory tract is colonized with a potential pathogen and there",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "is no evidence of an infiltrate. Systemic antimicrobial therapy will select for",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "resistant organisms and may lead to other adverse effects.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "See below for ventilator-associated pneumonia treatment recommendations in",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "patients with a new or progressive infiltrate and at least one of the following:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "fever greater than 100.4F, leukocytosis, leukopenia or purulent bronchial",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "secretions.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Kalil et al. Clin Infect Dis, 2016, 63(5): e61-e111.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX COLONIZED WOUNDS", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU DECUBITUS ULCERS", "Text" : "Decubitus ulcers", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "Text" : "Diabetic foot ulcers", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COLONIZED WOUNDS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Open wounds are usually colonized with bacteria and often fungi. This is true of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "ulcers (see below), post-operative wounds, traumatic wounds, and others. Then",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "bacteria can be of relatively low virulence (eg, coagulase negative",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "staphylococci, diphtheroids) or of potentially greater virulence (Staphylococcus",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "aureus, enterobacteriaceae, pseudomonas). Candida is commonly present on wounds",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "that are moist or covered. There is no need to treat patients with systemic",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobials simply because a wound culture is positive for a potential",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "pathogen. Topical antimicrobials are not effective in nearly all circumstances",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "and can select for resistant organisms or lead to other adverse effects.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Systemic antimicrobial therapy may be indicated if there are signs of infection.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Lipsky et al, Clin Infect Dis, 2012, 54(12): e132-e173",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clinical assessment of chronic wounds", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX CAP PSI", "Text" : "CAP Pneumonia Severity Index (PSI) Calculator", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU CAP INPATIENT TREATED SETTING NON-SEVERE CAP", "Text" : "CAP NON-SEVERE treated in an Inpatient Ward setting", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU CAP INPATIENT TREATED SETTING SEVERE CAP", "Text" : "CAP SEVERE treated in an ICU setting", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "Text" : "Stepdown empiric treatment for CAP with oral antibiotics", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Empirical regimens listed here cover the usual pathogens associated with CAP,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "including atypical pathogens.Specific therapy should be guided by culture",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "results.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "CAP Pneumonia Severity Index (PSI) or PORT Score",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "The CAP pneumonia severity index is useful for estimation of mortality risk for",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "a patient with pneumonia.Pre-estimated risk can then be used to determine how",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "aggressively to treat the patient's pneumonia and whether the patient can be",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treated safely outside of the hospital.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "The Community-Acquired Pneumonia Severity Index (PSI) is a guide and",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "should be used to augment clinical judgment. If social circumstances",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "or cognitive dysfunction would interfere with success of outpatient",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "treatment, the patient should be hospitalized.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empirical treatment",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If a patient has taken an antimicrobial in the previous 3 months, it is prudent",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "to avoid giving the same or a similar drug for the current episode of pneumonia.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Empiric treatment for CAP treated in an Inpatient setting:",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Stepdown empiric treatment for CAP (Intravenous to Oral conversion)",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Note: These regimens may also be used to convert patients to oral medications",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "prior to discharge.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Fine MJ, et al. N Engl J Med (1997) 336:243-250", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX COMP CYSTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O] for 7 days, CrCl =/>30mL/min", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID FOSFOMYCIN 3GM PO QOD 3 DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO", "Text" : "Select for updated Ciprofloxacin Info Page", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 1GM IV Q6H AND GENT 5MG/KG IV Q24H", "Text" : "Ampicillin 1-2 gm IV q6h ($$) [R] <AND> gentamicin 5 mg/kg IV q24h ($) [R,O] for", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] for 7 days", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 IV Q12H GENT 5MG/KG IV Q24H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] < AND > gentamicin 5 mg/kg IV q24h", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 1GM IV Q6H", "Text" : "Ampicillin 1-2 gm IV q6h ($$) [R] for 7 days", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSJZID FOSFOMYCIN 3GM PO QOD 3 DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O] for 7 days, CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] for 7 days", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O] for 7 days", "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : "PSJZID TMP/SULFA 1DS TABLET PO Q12H", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO", "Text" : "Select for updated Ciprofloxacin Info Page", "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMPLICATED CYSTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cystitis is considered complicated when one or more of the following is present:",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "> Most men with cystitis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "> Pregnant women",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "> Structural abnormalities (e.g. presence of obstruction, catheter or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "nephrostomy tubes, neurogenic bladder)",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "> Metabolic abnormalities that reduce local host defenses (e.g. diabetes,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "pregnancy, neutropenia, pelvic irradiation)",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "> Unusual or resistant pathogen",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "> Treatment failure or relapse or recurrence of infection",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat for 7 days. If patient is febrile, may extend duration up to 14 days total",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Empirical treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative (weigh risk for potential serious side effects vs benefit)",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment for SEVERE DISEASE or if patient cannot take oral therapy",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "7 days",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "($) [R,O] for 7 days",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Treatment for specific pathogens",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Treatment if enterococcus identified",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Alternative for enterococcus",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Unable to use ampicillin or vancomycin",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Treatment if Pseudomonas identified",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Conversion to oral therapy",  "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "When patients who require parenteral therapy are substantially improved and can",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "take oral medication, finish the course with oral antimicrobials depending on",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "the identification and susceptibility of the isolate.",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Alternative (weigh risk for potential serious side effects vs benefit)",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "Drekonja, Dimitri M., et al. JAMA 326.4 (2021): 324-331",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "Gupta K. et. al. IDSA Clinical Practice Guidelines (2011) 52.1",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cystitis",  "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX COST INFORMATION", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIAL COST INFORMATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cost is represented as dollar ($) signs in parenthesis following the antibiotic.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "The number of $ signs represent the cost ranges below:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "$ = Less than 10 dollars per day",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "$$ = 10-50 dollars per day",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "$$$ = 51-100 dollars per day",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "$$$$ = 101-400 dollars per day",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "$$$$ = Greater than 400 dollars per day",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "The displayed cost of an antibiotic is an estimate based on usual daily doses",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for an 80kg patient. Costs may change frequently due to VA contract negotiations",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "as well as supply and demand effects. Antibiotic cost and formulary are reviewed",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "by members of the Antimicrobial Subcommittee annually.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX COVID-19 MPLS PHARMACOLOGIC GUIDELINE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Select here for help, legend, consults, alternative antimicrobials and more (Ip)", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "[Link] Minneapolis On-Call Schedule-Infectious Disease", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZ GTX ABX URL MINNEAPOLIS COVID SHAREPOINT SITE", "Text" : "Minneapolis VAHCS COVID-19 SharePoint Site", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 PHARMACOLOGIC INPT TREATMENT GUIDELINES", "Text" : "Minneapolis VAHCS COVID Pharmacologic Inpatient Treatment Guidelines", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REMDESIVER FOR TREATMENT OF COVID-19", "Text" : "Remdesivir IV", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX DEXAMETHASONE FOR COVID", "Text" : "Dexamethasone IV/PO", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX BARICITINIB EUA COVID-19", "Text" : "Baricitinib PO/NG/GT (EUA)", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOCILIZUMAB FOR TREATMENT OF COVID-19", "Text" : "Tocilizumab IV (EUA)", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA", "Text" : "Paxlovid PO (EUA)", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU ABX REMDESIVER FOR TREATMENT OF COVID-19", "Text" : "Remdesivir IV", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "INPATIENT COVID-19 PHARMACOLOGIC TREATMENT GUIDELINES",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Refer to the Minneapolis VAHCS COVID-19 SharePoint site for additional info.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "***COVID-19 therapy is a rapidly evolving field, including the widespread",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "dissemination of therapies with little or no evidence for benefit. Therapies an",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "dosages not specifically listed here or on the NIH clinical guidelines should b",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "discussed with the infectious diseases service. ***",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "HOSPITALIZED DUE TO COVID-19",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Refer to COVID-19 Pharmacological Inpatient Treatment Guidelines to determine",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "whether monotherapy or combination therapy with remdesivir and dexamethasone is",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "appropriate. For patients on dexamethasone with rapidly increasing oxygen needs",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "and systemic inflammation, add a second immunomodulatory drug (see",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Immunomodulatory Treatment below)",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Immunomodulatory Treatment",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "MVAHCS recommends baricitinib over tocilizumab in patients on high flow nasal",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "cannula oxygen or non-invasive ventilated patients that can take PO or NG. For",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "patients who cannot take PO or NG, or for those who are mechanically ventilated,",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "we recommend tocilizumab.These treatments are to be added on to dexamethasone,",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "with or without remdesivir.Consult Infectious Diseases for more details.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "HOSPITALIZED FOR REASONS OTHER THAN COVID-19",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Treatment is recommended for patients with confirmed mild to moderate COVID-19",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "and are at high risk of progressing to severe COVID-19.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Preferred for patients within 5 days of symptom onset",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Alternatives for patients within 5-7 days of symptom onset or with",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Primary",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Secondary",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX BEBTELOVIMAB EUA", "Text" : "Bebtelovimab IV (EUA)", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "contraindications to above oral therapies",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ GTX ABX URL COVID-19 MED INTERACTION CHECKER", "Text" : "Interaction checker for COVID-19 medications website link", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX COVID-19 VACCINE CLC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACCINE CLC WITH 15 MINUTE MONITORING", "Text" : "First and Second Dose [CLICK HERE] to order COVID-19 Vaccine Series (Pfizer)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC 3RD DOSE CLC 15 MINUTE MONITORING", "Text" : "Third Dose, [CLICK HERE] to order third COVID-19 Vaccine dose (Pfizer)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 BOOSTER DOSE CLC 15 MINUTE MONITORING", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine Booster dose (Pfizer)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "GMRCTZ COVID-19 VACCINE VACCINATION APPROPR NURSING TEXT ORDER", "Text" : "<ADD> *For SCI/4J Pts Only* nursing text order for vaccine appropriateness", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACCINE CLC WITH 30 MINUTE MONITORING", "Text" : "First and Second Dose [CLICK HERE] to order COVID-19 Vaccine Series (Pfizer)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC 3RD DOSE CLC 30 MINUTE MONITORING", "Text" : "Third Dose, [CLICK HERE] to order third COVID-19 Vaccine dose (Pfizer)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 BOOSTER DOSE CLC 30 MINUTE MONITORING", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine Booster dose (Pfizer)", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "GMRCTZ COVID-19 VACCINE VACCINATION APPROPR NURSING TEXT ORDER", "Text" : "<ADD> *For SCI/4J Pts Only* nursing text order for vaccine appropriateness", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMMUNITY LIVING CENTER AND SPINAL CORD INJURY COVID-19 VACCINE ORDERS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients with NO history of anaphylaxis (to oral medication, food, insect,",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "etc.), and NO history of immediate allergic reaction to non-COVID vaccine or",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "injectable medication",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Patients with history of anaphylaxis (to oral medication, food, insect, etc.),",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "OR history of immediate allergic reaction to non-COVID vaccine or injectable",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "medication",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Centers for Disease Control and Prevention. COVID-19 Vaccination Clinical and",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Professional Resources. Atlanta, GA: U.S. Department of Health and Human Service",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "https://www.cdc.gov/vaccines/covid-19/index.html", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX COVID-19 VACCINE JANSSEN INPT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 VACCINE JANSSEN EUA", "Text" : "[CLICK HERE] for link to COVID-19 vaccine EUA", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 VACCINE BOOSTER DOSE ELIGIBILITY CRITERIA", "Text" : "[CLICK HERE] for a comprehensive list of eligibility criteria", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC JANSSEN WITH 15 MINUTE MONITORING", "Text" : "Initial Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC JANSSEN BOOSTER WITH 15 MIN MONITOR", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC JANSSEN WITH 30 MINUTE MONITORING", "Text" : "Initial Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC JANSSEN BOOSTER WITH 30 MIN MONITOR", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine dose (Janssen)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "JANSSEN (JOHNSON & JOHNSON) COVID-19 VACCINE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Generally, mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) are preferred",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "over Janssen (Johnson & Johnson) vaccine. Janssen may be preferred in those who",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "have a contraindication to mRNA vaccines or are at risk of not showing up for a",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "second dose. By placing this order, the patient will be administered the vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "dose the same day or the next business day when vaccine doses are available.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Prerequisites",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "All Orders:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Placing this order implies that you have already discussed the following with",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "the patient: The patient meets the below criteria and understands that",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "this vaccine is an unapproved vaccine under an Emergency Use Authorization",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "(EUA). The patient has been offered a copy of the EUA Fact Sheet:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Booster Dose Additional Prerequisites:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "o If first dose was Janssen (Johnson & Johnson) - patients are eligibile 2 month",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "after receiving the 1st dose",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "o If first dose was Pfizer (BioNTech) or Moderna - patients are eligible",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "5 months after the second dose.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Absolute:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "1. Already received a 3rd dose of COVID-19 mRNA vaccine or Janssen booster dose",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "2. Active infection with COVID-19",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "3. Received monoclonal antibody or convalescent plasma for COVID-19 treatment in",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "the last 90 days",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "4. History of anaphylaxis requiring treatment with epinephrine to any Janssen",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "COVID-19 vaccine ingredient",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "5. History of any allergic reaction to previous COVID-19 vaccine or ingredient",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "(including PEG) OR polysorbate",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Relative:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Active infection where vaccine side effects may confuse diagnostic or",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "treatment course",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Please Note:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Booster doses may NOT be given at CBOCs, other satellite clinics or another",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "VA/hospital.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "If a booster dose is indicated, it should be administered 5 months after the",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "2nd dose of an mRNA vaccine (Pfizer (BioNTech) or Moderna) or 2 months after the",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Janssen (Johnson & Johnson) vaccine.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Order COVID-19 Vaccine (Janssen) Dose:",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Patients with NO history of anaphylaxis (to oral medication, food, insect,",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "etc.), and NO history of immediate allergic reaction to non-COVID vaccine or",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "injectable medication",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Patients with history of anaphylaxis (to oral medication, food, insect, etc.),",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "OR history of immediate allergic reaction to non-COVID vaccine or injectable",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Medication",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Risks and Benefits:",  "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Benefits:",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "May prevent contracting a symptomatic COVID-19 infection",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Risks:",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Common Side Effects:",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "1. Injection site reactions: pain, redness of the skin and swelling",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "2. General side effects: headache, feeling very tired, muscle aches, nausea, and",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "fever",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Uncommon Anaphylactoid Reactions:",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "1. Dyspnea",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "2. Tachycardia",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "3. Severe rash",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "4. Angioedema",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "5. Syncope or pre-syncope",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Rare but Serious Adverse Events",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "1. Thrombosis with Thrombocytopenia",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "2. Guillian-Barre' Syndrome",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "_________________________________________________________________________",  "Header" : 1}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "Centers for Disease Control and Prevention. COVID-19 Vaccination Clinical and",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "Professional Resources. Atlanta, GA: U.S. Department of Health and Human Service",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "https://www.cdc.gov/vaccines/covid-19/index.html", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "Contents" : [
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 VACC IMMUNOCOMPROMISED INDIVIDUALS", "Text" : "[CLICK HERE] for link to CDC info on COVID-19 vaccination in immunocompromised", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC FIRST DOSE WITH 15 MINUTE MONITORING", "Text" : "First Dose, [CLICK HERE] to order first COVID-19 Vaccine dose (Pfizer)", "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC SECOND DOSE WITH 15 MINUTE MONITORING", "Text" : "Second Dose, [CLICK HERE] to order second COVID-19 Vaccine dose (Pfizer)", "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 BOOSTER DOSE WITH 15 MINUTE MONITORING", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine Booster dose (Pfizer)", "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC THIRD DOSE WITH 15 MINUTE MONITORING", "Text" : "Third Dose, [CLICK HERE] to order third COVID-19 Vaccine dose (Pfizer)", "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC FIRST DOSE WITH 30 MINUTE MONITORING", "Text" : "First Dose, [CLICK HERE] to order first COVID-19 Vaccine dose (Pfizer)", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC SECOND DOSE WITH 30 MINUTE MONITORING", "Text" : "Second Dose, [CLICK HERE] to order second COVID-19 Vaccine dose (Pfizer)", "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 BOOSTER DOSE WITH 30 MINUTE MONITORING", "Text" : "Booster Dose, [CLICK HERE] to order COVID-19 Vaccine Booster dose (Pfizer)", "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : "ORZ SET ABX COVID-19 VACC THIRD DOSE WITH 30 MINUTE MONITORING", "Text" : "Third Dose, [CLICK HERE] to order third COVID-19 Vaccine dose (Pfizer)", "Header" : 0}, 
{"Row" : 113, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE JANSSEN INPT", "Text" : "[CLICK HERE] for COVID-19 Janssen (Johnson & Johnson) Vaccine recommendations", "Header" : 0}, 
{"Row" : 120, "Column" : 1, "Item" : "ORZ GTX ABX MPLS COVID-19 VACCINE COMMUNICATION EMAIL", "Text" : "MPLSCOVIDVaccineCommunication@va.gov", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INPATIENT COVID-19 VACCINE RECOMMENDATIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "COMIRNATY (PFIZER-BIONTECH) COVID-19 VACCINE",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "By placing this order, the patient will be administered the vaccine dose",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "the same day or the next business day when vaccine doses are available.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Janssen (Johnson & Johnson) vaccine may be considered if patient has a",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "contraindication to mRNA vaccine or is at risk for not showing up to 2nd dose",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "follow up appointment (see below).",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Prerequisites",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "First Dose",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "The patient must return to the Minneapolis VA Vaccine Clinic for the second dose",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "of this vaccination series approximately 21 days after this dose (time and date",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "will be scheduled before discharge).",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Second Dose",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "The patient has already received their 1st dose of Comirnaty (Pfizer-Biontech)",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "vaccine and is due for 2nd dose.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Third Dose",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "The patient is moderately to severely immunocompromised who has received either",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Pfizer or Moderna 2nd dose at least 28 days ago. For more more information:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Booster Dose",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "o If first dose was Janssen (Johnson & Johnson) - patients are eligibile 2 month",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "after receiving the 1st dose",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "o If first dose was Pfizer (BioNTech) or Moderna - patients are eligible",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "5 months after the second dose.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Contraindications",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Absolute:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "1. Already completed any vaccination for COVID-19 (for first and second dose",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "only)",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "2. Active infection with COVID-19",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "3. Received monoclonal antibody or convalescent plasma for COVID-19 treatment in",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "the last 90 days",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "4. History of anaphylaxis requiring treatment with epinephrine to any Pfizer-",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "BioNTech mRNA COVID-19 vaccine ingredient",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "5. History of any allergic reaction to previous mRNA COVID-19 vaccine or",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "ingredient (including PEG)",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Relative:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "1. Active infection where vaccine side effects may confuse diagnostic or",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "treatment course",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "2. Allergy to Polyethylene Glycol or Polysorbate (structurally related)",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "The second dose of the Pfizer vaccine should be given 21 days after the first",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "dose and must be the same brand as the first dose. The second dose should be",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "administered as close to the recommended interval as possible. If the second",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "dose is administered within the 4 days before the recommended date of the second",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "dose, or any time after, the individual is considered fully vaccinated. If the",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "second dose is administered earlier than the 4-day grace period, the CDC does",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "not recommend repeating the dose.",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "In immunocompromised patients, the third dose of the COVID-19 vaccine should be",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "administered greater than 28 days after the second dose and must be the same",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "product as the initial 2-dose series whenever possible. The other mRNA product",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "may be administered if the first product is not available.",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "If a booster dose is indicated, it should be administered 5 months after the",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "2nd dose of an mRNA vaccine (Pfizer (BioNTech) or Moderna) or 2 months after the",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Janssen (Johnson & Johnson) vaccine.",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Acute Care Vaccine Orders",  "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "Patients with NO history of anaphylaxis (to oral medication, food, insect,",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "etc.), and NO history of immediate allergic reaction to non-COVID vaccine or",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "injectable medication",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "Patients with history of anaphylaxis (to oral medication, food, insect, etc.),",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "OR history of immediate allergic reaction to non-COVID vaccine or injectable",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "medication",  "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : null, "Text" : "Risks and Benefits:",  "Header" : 1}, 
{"Row" : 93, "Column" : 1, "Item" : null, "Text" : "Benefits: May prevent contracting a symptomatic COVID-19 infection",  "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : null, "Text" : "Risks:",  "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : null, "Text" : "Common Side Effects:",  "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : null, "Text" : "1. Injection site pain, swelling, redness",  "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "2. Fatigue, Malaise",  "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : null, "Text" : "3. Headache",  "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : null, "Text" : "4. Muscle pain",  "Header" : 0}, 
{"Row" : 100, "Column" : 1, "Item" : null, "Text" : "5. Chills, Fever",  "Header" : 0}, 
{"Row" : 101, "Column" : 1, "Item" : null, "Text" : "6. Joint pain",  "Header" : 0}, 
{"Row" : 102, "Column" : 1, "Item" : null, "Text" : "Uncommon Anaphylactoid Reactions:",  "Header" : 0}, 
{"Row" : 103, "Column" : 1, "Item" : null, "Text" : "1. Dyspnea",  "Header" : 0}, 
{"Row" : 104, "Column" : 1, "Item" : null, "Text" : "2. Tachycardia",  "Header" : 0}, 
{"Row" : 105, "Column" : 1, "Item" : null, "Text" : "3. Severe rash",  "Header" : 0}, 
{"Row" : 106, "Column" : 1, "Item" : null, "Text" : "4. Angioedema",  "Header" : 0}, 
{"Row" : 107, "Column" : 1, "Item" : null, "Text" : "5. Syncope or pre-syncope",  "Header" : 0}, 
{"Row" : 108, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 110, "Column" : 1, "Item" : null, "Text" : "JANSSEN (JOHNSON & JOHNSON) COVID-19 VACCINE",  "Header" : 1}, 
{"Row" : 111, "Column" : 1, "Item" : null, "Text" : "Pfizer product preferred, but if patient at risk for not showing up to follow up",  "Header" : 0}, 
{"Row" : 112, "Column" : 1, "Item" : null, "Text" : "appointment consider Janssen vaccine",  "Header" : 0}, 
{"Row" : 114, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 116, "Column" : 1, "Item" : null, "Text" : "MODERNA COVID-19 VACCINE",  "Header" : 1}, 
{"Row" : 117, "Column" : 1, "Item" : null, "Text" : "The MVAHCS does not carry the Moderna COVID-19 Vaccine.For extenuating",  "Header" : 0}, 
{"Row" : 118, "Column" : 1, "Item" : null, "Text" : "circumstances, it may be possible to procure a dose from the St. Cloud VA.To",  "Header" : 0}, 
{"Row" : 119, "Column" : 1, "Item" : null, "Text" : "inquire if this is possible please email:",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE CLC", "Text" : "[CLICK HERE] for vaccine orders", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "CLC and SCI Vaccine Orders",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 121, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 0}, 
{"Row" : 123, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 124, "Column" : 1, "Item" : null, "Text" : "Centers for Disease Control and Prevention. COVID-19 Vaccination Clinical and",  "Header" : 0}, 
{"Row" : 125, "Column" : 1, "Item" : null, "Text" : "Professional Resources. Atlanta, GA, US Department of Health and Human Services",  "Header" : 0}, 
{"Row" : 126, "Column" : 1, "Item" : null, "Text" : "https://www.cdc.gov/vaccines/covid-19/index.html", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CRYPTOSPORIDIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID NITAZOXANIDE 500MG PO Q12H", "Text" : "Nitazoxanide 500 mg PO q12h for 3 days ($$$) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CRYPTOSPORIDIUM PARVUM",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antibiotic therapy is usually used only for persons with severe disease or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "immunocompromised persons.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for patients without HIV/AIDS",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for patients with HIV/AIDS",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for patients with HIV/AIDS.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cryptosporidiosis",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of cryptosporidiosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX CYCLOSPORA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q12h for 7 to 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CYCLOSPORA CAYETANENSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for patients with allergy to sulfonamides.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for patients without HIV/AIDS",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for patients with HIV/AIDS",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for patients with HIV/AIDS.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cyclosporiasis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Cyclospora infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DELAYED STANDARD ABX CV SURG", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : "ORZ SET ABX VANCOMYCIN 1500MG PREOP AND 1000MG INTRAOPERATIVE", "Text" : "Vancomycin 1500mg PRE-OPERATIVE dose **AND** 1000mg INTRAOPERATIVE dose", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZ SET ABX CEFUROXIME 1500MG PRE-OP & INTRA-OP DOSES", "Text" : "Cefuroxime 1.5gm PRE-OPERATIVE dose **AND** 1.5gm INTRAOPERATIVE dose", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DERM HIGH RISK SITE PROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "List of MRSA risk factors", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 2GM PO ONCE 'C'", "Text" : "Cephalexin 2 gm PO 60 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP TMP/SMX 1 DS TAB PO ONCE PENVK 500MG PO ONCE", "Text" : "Trimethoprim/Sulfamethoxazole 1 DS tablet PO 60 minutes before incision ($)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 600MG PO ONCE 'C'", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 1GM IV ONCE 'C'", "Text" : "Cefazolin 1 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV ONCE 'C'", "Text" : "Clindamycin 600 mg IV over 30 minutes, 60 minutes before incision", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 mg/kg IV 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HIGH RISK FOR SURGICAL SITE INFECTIONS ANTIBIOTIC PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antibiotic prophylaxis is recommended for prevention of infection for the listed",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "high risk conditions:",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "1. Extensive inflammatory skin disease (e.g. high tension)",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "2. Groin or Lower Extremities",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "3. Skin flaps and grafts",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "4. Wedge excision of lip or ear",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Contaminated, dirty or infected wound may warrant antibiotic prophylaxis.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "MRSA risk factor",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "[R,DI] < AND > penicillin VK 500 mg PO 60 minutes before incision ($) [R]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Unable to take oral medications",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy and unable to take oral medications",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "MRSA risk factors and unable to take oral medications",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "infection in adults",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DERM IE JI PROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX PROCED FOR INFECTED SKIN, SKIN STRUCTURES", "Text" : "Antimicrobial Prophylaxis in Patients with Prosthetic Joints", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INFECTED SKIN SURGICAL SITE PROSTHETIC JOINT INFECTION PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is indicated in procedures involving infected skin",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "skin structures, or infected musculoskeletal tissue when the patient is at",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "high risk of hematogenous prosthetic joint infection.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Hematogenous prosthetic joint infection high risk conditions:",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "1. First two years following joint replacement",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "2. Previous prosthetic joint infection",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "3. Immunocompromised",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "4. Insulin dependent diabetes",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "5. HIV infection",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "6. Malignancy",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "7. Malnutrition",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "8. Hemophilia",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If patient has one or more of the above conditions, antimicrobial prophylaxis is",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "indicated. Use the following link for antimicrobial prophylaxis recommendations.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Nishimura et al, J Am Coll Cardiol (2014) 63, e57-185",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "infection in adults",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for the prevention of bacterial",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "endocarditis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Wilson et al, Circulation (2007) 116, 1736-1754",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DERM POST-OP INFECTIONS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 500MG PO QID 'THREE DOSES'", "Text" : "Cephalexin 500 mg PO QID, three doses post-operatively ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 500MG PO QID 'THREE DOSES'", "Text" : "Dicloxacillin 500 mg PO QID, three doses post-operatively ($) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 TMP/SMX 1DS PO BID 'ONE DOSE'", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 1GM IV Q8H '2 DOSES'", "Text" : "Cefazolin 1 gm IV q8h, two doses post-operatively ($) [R]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "Text" : "Vancomycin 15 mg/kg IV q12h, one dose post-operatively ($) [R]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP CEPHALEX 500MG Q6H X3 METRON 500MG Q8H X2", "Text" : "Cephalexin 500 mg PO QID, three doses post-operatively ($) [R] <AND>", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 500MG BID PO X1 METRON 500MG TID PO X2", "Text" : "Ciprofloxacin 500 mg PO BID, one dose post-operatively ($) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX OP TMP/SMX 1DS BID PO X1 METRON 500MG PO TID X2", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID METRONIDAZOLE 500MG IV Q8H X 2", "Text" : "Metronidazole 500 mg IV q8h, two doses post-operatively ($) [DI]", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG Q12H IV X1 METRON 500MG Q8H IV X2", "Text" : "Ciprofloxacin 400 mg IV q12h, one dose post-operatively ($) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "Text" : "Vancomycin 15 mg/kg IV q12h, one dose post-operatively ($) [R]", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 500MG BID PO 'ONE DOSE'", "Text" : "Amoxicillin 500 mg PO BID, one dose post-operatively ($) [R]", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX OP TMP/SMX 1DS TAB PO BID X1 PENVK 500MG PO TID X2", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID, one dose post-operatively ($)", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2GM IV Q6H 'THREE DOSES'", "Text" : "Ampicillin 2 gm IV q6h, 3 doses post-operatively ($$) [R]", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H 'TWO DOSES'", "Text" : "Clindamycin 600 mg IV q8h, 2 doses post-operatively ($$) [H,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DERMATOLOGIC SURGERY POST-OPERATIVE ANTIBIOTIC PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "RECOMMENDATIONS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Conditions that may warrant dermatologic surgery post-operative antibiotic",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "prophylaxis:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "1. Large wound (>5cm)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "2. Long procedure where wound is open for a long time",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "3. Wound near cartilage or bone (e.g. some nose, scalp or ear sites)",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "If patient received pre-operative antibiotics, select the same antibiotic for",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "post-operative prophylaxis. Duration of antimicrobial prophylaxis should not",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "exceed 24 hours. Durations longer than 24 hours have not been shown effective in",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "preventing surgical site infections.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "MRSA risk factors",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Operations involving trunk or extremity away from axilla or perineum",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy or MRSA risk factors",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "[R,DI]",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Severe infections or patients unable to take oral medications",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy or MRSA risk factors and severe infection or patient unable",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "to take oral medications",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Operations involving the axilla or perineum",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "metronidazole 500 mg PO TID, two doses post-operatively ($) [DI]",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "metronidazole 500 mg PO TID, two doses post-operatively ($) [DI]",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "MRSA risk factors",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "[R,DI] <AND> metronidazole 500 mg PO q8h, two doses post-operatively ($) [DI]",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Severe infections or unable to take oral medications",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Note: ceftriaxone does not require redosing due to it's long half-live",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy and severe infections or unable to take oral medications",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "metronidazole 500 mg IV q8h, two doses post-operatively ($) [DI]",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "MRSA risk factors and severe infections or unable to take oral medications",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "< ADD > to one of the above IV regimens for operations involving axilla or",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "perineum",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Continuation of pre-operative antibiotics that are not listed above",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Note: azithromycin and ceftriaxone do not require redosing due to their long",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "half-lives",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "[R,DI] < AND > Penicillin VK 500 mg PO TID, 2 doses post-operatively ($) [R]",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "Nishimura et al, J Am Coll Cardiol (2014) 63, e57-185",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Stevens et al, Clinical Infectious Diseases (2014) 59.2, e10-52",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "infection in adults",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for the prevention of bacterial",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "endocarditis",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "Wilson et al, Circulation (2007) 116, 1736-1754",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DERM PROPHYLAXIS", "Contents" : [
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIAL PROPHYLAXIS AND DERMATOLOGIC SURGERY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Antibiotics are used to prevent infections in patients undergoing surgery in",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "certain well-defined circumstances. They are used to prevent surgical site",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infection or to prevent endocarditis in circumstances where the risk of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "endocarditis is high. For many low-risk surgeries, the risks associated with",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antibiotic use, which can be severe or cause death, outweigh the benefits. The",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "following recommendations are consistent with guidelines published by the",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "American Heart Association and Infectious Disease Society of America.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "In general, antibiotics are used to prevent post-operative wound infection",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "in clean-contaminated surgery. Most dermatological surgery involves clean",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "sites, and the risks of antibiotics outweigh potential benefits. Antibiotics",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "are used to prevent endocarditis and hematogenous joint infection in procedures",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "involving infected skin structures. Antibitic prophylaxis is also",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "recommended to prevent surgical site infections in procedures involving high",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "risk surgical sites and conditions.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "When they are used, prophylactic oral antimicrobial agents should be",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "administered 30-60 minutes before the first tissue manipulation or incision.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials should be administered 60 minutes (120 minutes for",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "vancomycin) prior to procedure.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Antimicrobials should not be used to prevent infections in patients with",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "vascular grafts or orthopedic prostheses because the risk of bacteremia or",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "infection of these devices is tiny and antibiotic risks outweigh any theoretical",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "benefit.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "A full course of antibiotics should be used to treat skin infections where",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "infection is already present at the time of surgery.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Suggested antibiotic prophylaxis regimens should be targeted against the typical",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "pathogens likely to be present. A risk-based approach for coverage of MRSA",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "should be taken in patients with specific risk factors for MRSA.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Nishimura et al, J Am Coll Cardiol (2014) 63, e57-185",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Stevens et al, Clinical Infectious Diseases (2014) 59.2, e10-52",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "infection in adults",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for the prevention of bacterial",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "endocarditis",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Wilson et al, Circulation (2007) 116, 1736-1754",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DERM SURGICAL INFECTION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX OP CEPHALEXIN 500MG PO Q8H METRON 500MG PO Q8H", "Text" : "Cephalexin 500 mg PO QID ($) [R] <AND> metronidazole 500 mg PO TID ($) [DI", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP CIPROF 500MG PO BID METRO 500MG PO TID", "Text" : "Ciprofloxacin 50O mg PO q12h ($) [R,DI] <AND> metronidazole 500 mg PO q8h ($", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX OP TMP 1 DS TAB PO BID METRO 500MG PO TID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID ($) [R,DI] <AND> metronidazole", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h ($", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DERMATOLOGIC SURGICAL SITE INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If an infection develops, obtain a gram stain and/or culture. Suture removal,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "incision and drainage is recommended. Antimicrobials may be beneficial in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "surgical site infections with significant systemic response (i.e induration",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "greater than 5cm from wound edge, fever, tachycardia and leukocytosis).",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "In general, most post-op infections develop greater than 48 hours after surgery.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Start on antibiotics as below until culture result is available and then switch",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antibiotics, if indicated.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "MRSA risk factors",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treat for 5-7 days",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Operations involving trunk or extremity away from axilla or perineum",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy or MRSA risk factors",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Severe infections or unable to take oral medications",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy or MRSA risk factors and severe infection or unable to take",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "oral medications",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Operations involving the axilla, gastrointestinal tract, or perineum, or female",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "genital tract",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "[DI]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "MRSA risk factors",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "500 mg PO TID ($) [DI]",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Severe infections or unable to take oral medications",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Penicillin allergy and severe infections or unable to take oral medications",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "[DI]",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "MRSA risk factors and severe infections or unable to take oral medications",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "< ADD > to one of the above IV regimens for operations involving axilla or",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "perineum",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Stevens et al, Clinical Infectious Diseases (2014) 59.2, e10-52",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM PROPHYLAXIS", "Text" : "Antimicrobial Prophylaxis and Dermatologic Surgery", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM HIGH RISK SITE PROPHYLAXIS", "Text" : "Other high risk surgical sites and conditions", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM POST-OP INFECTIONS", "Text" : "Post-operative prophylaxis recommendations", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM SURGICAL INFECTION", "Text" : "Management of Post-Operative infections", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 400MG BID", "Text" : "Acyclovir 400 mg PO BID for 5 days ($) [R]-OUTPATIENT ORDER", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "DERMATOLOGICAL GUIDELINES",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Background information on antibiotic prophylaxis in dermatologic surgery:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Specific antibiotic prophylaxis recommendations in dermatologic surgery:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Dermatologic surgical site infection recommendations:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Photodynamic therapy and laser skin resurfacing HSV-1 prophylaxis",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Recommended in patients with history of HSV-1 infection. Initiate prophylaxis",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "24-48 hours prior to surgery and continue for 3-7 days.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Herpes Simplex Virus",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Prevention of herpes simplex virus type 1 infection in",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "immunocompetent patients",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU HIDRADENITIS SUPPURATIVA", "Text" : "[click here] for outpatients", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Hidradenitis Suppurativa",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "endocarditis",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU ABX DERM IE JI PROPHYLAXIS", "Text" : "[click here] for outpatients", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "infection",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM IE JI PROPHYLAXIS", "Text" : "[click here] for inpatients", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Infected skin surgical site with high risk of hematogenous prosthetic joint",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "Text" : "[click here] for inpatients", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT", "Text" : "[click here] for outpatients", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Oral mucosa or infected skin surgical site with high risk of infective",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU HIDRADENITIS SUPPURATIVA", "Text" : "[click here] for inpatients", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO BID", "Text" : "Acyclovir 400 mg PO BID for 5 days ($) [R]-INPATIENT ORDER", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "*Menu contains outpatient PO orders",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "*Menu contains outpatient PO orders",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "*Menu contains outpatient PO orders",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU PREV PROS JOINT DENTAL", "Text" : "Oral mucosa surgical site with high risk of hematogenous prosthetic joint", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DERMATOLOGY MAIN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPETIGO", "Text" : "Impetigo", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU FOLLICULITIS", "Text" : "Folliculitis", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELAS", "Text" : "Erysipelas", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Furuncles and carbuncles", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX CELLULITIS", "Text" : "Cellulitis", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "Text" : "Necrotizing infections", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ECTHYMA GANGRENOSUM", "Text" : "Ecthyma gangrenosum", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU STAPH SCALDED SYNDROME", "Text" : "Scalded Skin Syndrome", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU HIDRADENITIS SUPPURATIVA", "Text" : "Hidradenitis Suppurativa", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU TOXIC SHOCK SYNDROME", "Text" : "Toxic Shock Syndrome", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ERYTHRASMA", "Text" : "Erythrasma", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELOID", "Text" : "Erysipeloid", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU CAT-SCATCH DISEASE", "Text" : "Cat-scratch disease", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU LEISHMANIASIS", "Text" : "Leishmaniasis", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ROCKY MTN SPOT FEVER", "Text" : "Rocky Mountain Spotted Fever", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatology Post-Op Infection", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++DERMATOLOGICAL INFECTIONS ++",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Section reviewed January 2018",  "Header" : 1}, 
{"Row" : 5, "Column" : 2, "Item" : "ORZID2 GMENU CUTANEOUS CANDIDIASIS", "Text" : "Candidiasis", "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU PARONYCHIA", "Text" : "Paronychia", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID2 GMENU BED BUGS (HEMIPTERA)", "Text" : "Bed bugs (hemiptera)", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "Text" : "Head lice (Pediculosis Capitis)", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Text" : "Body lice (Pediculosis corporis)", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Pubic lice (Pediculosis pubis)", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU SCABIES", "Text" : "Scabies", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "Text" : "Lyme disease", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI BLASTOMYCES DERMATIDIS", "Text" : "Blastomycosis", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU SPOROTRICHOSIS", "Text" : "Sporotrichosis", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Sexually Transmitted Infections", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "Text" : "Herpes Whitlow (digit/hand cellulitis)", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU ABX OROLABIAL HERPES", "Text" : "Oral lesions: Mouth, Lips (Cold sores)", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU TINEA CAPITIS (RINGWORM)", "Text" : "Tinea capitis (ringworm)", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "Text" : "Tinea unguium (onychomycosis)", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Text" : "Tinea pedis, Tinea corporis, Tinea cruris", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU TINEA VERSICOLOR", "Text" : "Tinea versicolor", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX", "Text" : "Varicella/Chickenpox (primary infection)", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "Text" : "Zoster/Shingles (reactivation)", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "Herpes simplex virus infections",  "Header" : 1}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "Tinea fungal infections",  "Header" : 1}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "Varicella-Zoster virus infections", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX DEVICE-RELATED INFECTIONS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Intravascular catheter-related infection", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU EC PV EMP THERAPY", "Text" : "Prosthetic-valve endocarditis - Empirical therapy", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU EC PV SEL PATH", "Text" : "Prosthetic-valve endocarditis - Selected pathogens", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFECT INVOLVES CARD DEVICES", "Text" : "Infections involving cardiovascular devices (except valves)", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "Text" : "Infections in bone or joint prostheses", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++DEVICE-RELATED INFECTIONS++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If the desired syndrome is not listed below, return to the main menu and refer",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to the pertinent organ-system.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Last reviewed 11/17", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX DEXAMETHASONE FOR COVID", "Contents" : [
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Indications:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "COVID with hypoxia (<89% O2 at rest for more than an hour, not just a transient",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "episode or nocturnal hypoxia due to sleep apnea). May be discontinued early",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "if patient is no longer hypoxic.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Contraindications: Lack of hypoxia",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Dexamethasone (PO/IV):",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID DEXAMETHASONE 6MG PO QDAY FOR 10DAYS COVID", "Text" : "Dexamethasone 6 MG PO q24h for up to 10 days", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID DEXAMETHASONE 6MG IV QDAY FOR 10 DAYS COVID", "Text" : "Dexamethasone 6 MG IV q24h for up to 10 days", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-Dexamethasone (for up to 10 days) decreases mortality in patients with severe",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "or critical COVID-19 (RECOVERY trial).",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "-Dexamethasone may increase mortality in patients with mild/moderate COVID.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "-Dexamethasone is the preferred steroid, but a meta-analysis supports the use of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "other steroids (hydrocortisone, methylprednisolone, or hydrocortisone) if",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "dexamethasone is not available.",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DEXAMETHASONE (RECOVERY trial) for COVID-19",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "RECOVERY Collaborative Group, N Engl J Med. (2021) 384(8):693-704.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DIAGNOSIS OF ENDOCARDITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX DUKE CRITERIA", "Text" : "Modified Duke Diagnostic Criteria", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIAGNOSIS OF ENDOCARDITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis and management are complex. Cardiology, Infectious Disease, and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Surgery services should all be involved in diagnosis and management of infective",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "endocarditis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Endocarditis is the result of growth of microorganisms on endothelium of the",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "heart. The integrity of the endothelial surface must be compromised in order to",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "allow microorganisms to attach and proliferate. Often such lesions are caused by",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "abnormal blood flow or thrombi resulting from heart valvular disease, prosthetic",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "heart valves, or from foreign material or microorganisms introduced to the",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "bloodstream as byproducts of illicit intravenous drug use.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Endocarditis should be considered a possible diagnosis in a patient with",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "persistent bacteremia without an identifiable focal infection, especially when",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "the patient has a structural heart abnormality, prosthesis, or has a recent",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "history of intravenous illicit drug use.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Diagnosis of endocarditis can be based on several combinations of signs and",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "symptoms. The Duke criteria help categorize cases as definite or possible",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "endocarditis based on major and minor criteria. The Duke criteria also indicate",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "when a diagnosis of endocarditis can be excluded.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Severity of Disease",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Endocarditis is categorized by time course and severity of symptoms of illness",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "into acute and subacute. These classifications help suggest which pathogens may",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "be more likely associated with symptoms.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Acute",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Acute endocarditis is a rapidly progressing illness that often causes fever. It",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "can be associated with spread of infection to other parts of the body and can",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "cause death within a matter of weeks. In patient with suspected acute",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "endocarditis, three sets of blood cultures should be obtained with the first and",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "last cultures separated by at least one hour. Empiric antimicrobial therapy",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "should then be initiated as soon as possible.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Subacute",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Subacute endocarditis follows an indolent course. Generally, patients have had",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "some symptoms for at least 2 weeks. Symptoms are more subtle and spread of",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "infection to other systems is uncommon. In patients with suspected subacute",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "endocarditis, every attempt should be made to identify a pathogen prior to",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "initiating antimicrobial therapy. These patients should be observed carefully",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "for signs of heart failure or embolic complications, and if signs are noted,",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "surgery should be consulted immediately.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DIVERTICULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h for 7 to 10 days ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX TRIMETH/SULFA DS Q12H METRO 1 GM PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h for 7 to 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-Tazobactam 3.375g IV q6h for 7 to 10 days ($$) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2 GM IV QD METRONIDAZOLE 500 MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "Text" : "Moxifloxacin 400 mg IV q24h for 7 to 10 days ($$) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h for 10-14 days ($$) [R]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIVERTICULITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diverticulitis involves inflammation of an intestinal diverticulum, usually in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the colon, causing pain and disturbed bowel function.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Mild disease or Step-down treatment for completion of antimicrobial course",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "after initial intravenous treatment in patients who can tolerate oral therapy.",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Base selection on culture results.",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "metronidazole 1000 mg PO q12h ($) [DI] for 7 to 10 days",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "q12h ($) [DI] for 7 to 10 days",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Moderate disease",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "If symptoms fail to respond within 48 to 72 hours, consult General Surgery.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "for 7 to 10 days",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative for beta lactam allergy",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "($) [DI] for 7 to 10 days",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Severe, life-threatening disease",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Consult General Surgery.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Diverticulitis and Typhlitis",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Diverticulitis",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Acute colonic diverticulitis: Medical management", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DRUG ALLERGIES", "Contents" : [
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "Text" : "Link to penicillin desensitization protocol", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DRUG ALLERGIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Importance of history",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "The nature and circumstances of a possible previous reaction including the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "timing should be considered. In many cases, previous reactions are clearly",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "not due to drug allergy.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Types of reactions",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "*Immediate - within one hour of starting drug administration.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Type I reactions present with urticaria, hypotension, angioedema, bronchospasm,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "or anaphylaxis and occur within an hour of exposure. These reactions are",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "immunoglobulin E (IgE) and mast cell and/or basophil mediated.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "*Delayed - After one hour of starting administration (usually after 6 days)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "1) Type II reactions manifest as hemolytic anemia, thrombocytopenia and",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "neutropenia. They are caused by antibody (usually IgG)- mediated cell",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "destruction.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "2) Type III reactions can manifest as serum sickness, vasculitis or Arthus",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "reaction, and are caused by IgG:drug immune complex deposition and complement",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "activation.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "3) Type IV reactions typically manifest as contact dermatitis, morbilliform",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "reactions, severe exfoliative dermatoses (Stevens-Johnson syndrome/toxic",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "epidermal necrolysis) and other presentations. They are T-cell mediated.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Repeated exposures lead to reactions that are of the same type.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Beta-lactam allergies",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Approximately 10% of patients report a beta-lactam allergy. Up to 90% of these",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "patients can tolerate penicillin and have been designated penicillin allergic",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "unnecessarily. Patients allergic to cephalosporins will have a cross-reaction to",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "penicillins 3% to 5% of the time. Overall, patients with a history of penicillin",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "allergy can tolerate cephalosporins although there are rare reports to severe,",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "sometimes fatal anaphylactic reactions. Neither penicillin- or cephalosporin-",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "allergic patients will react to aztreonam. The degree of cross-reactivity of",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "penicillins and cephalosporins with carbapenems appears to be low.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Therapeutic implications",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "If a patient has had an immediate reaction to a drug in the past, an allergy",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "specialist should evaluate the patient before a drug of the same class is",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "administered to the patient. Patients with delayed onset reactions causing",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "fever, systemic symptoms or mucosal involvement should also be evaluated by an",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "allergy specialist before a drug of the same class is administered.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Desensitization",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "A patient with previous Type I reaction to a beta-lactam can be desensitized and",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "then receive therapeutic doses of the same class within a day. Severe",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "reactions during desensitization are uncommon. Pharmacy service must be",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "contacted for assistance and drug preparation. Infectious Disease consultation",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "strongly recommended.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "JAMA 2001, 285: 249",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Joint Task Force on Practice Parameters: Drug Allergy - An Updated Practice",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Parameter (2010)",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Kelkar PS NEJM 2001, 345: 804",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Mayo Clinic Proc 1999, 74: 290",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Cephalosporin-allergic patients: Subsequent use of",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "cephalosporins and related antibiotics",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Drug allergy: Classification and clinical features",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Weiss ME, Adkinson NF. Immediate hypersensitivity reactions to penicillin and",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "related antibiotics. Clin Allergy 1988, 18:515", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Acyclovir PO", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Acyclovir IV", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Albendazole PO", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Amantadine PO", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Amikacin IV", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Amoxicillin PO", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Amoxicillin-clavulanate PO", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Amphotericin B IV", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Ampicillin IV", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Ampicillin-sulbactam IV", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Atovaquone PO", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Azithromycin PO", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Azithromycin IV", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Aztreonam IV", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Benzathine penicillin IM", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Caspofungin IV", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Cefazolin IV", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Cefepime IV", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Cefixime PO", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Cefotetan IV", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Cefoxitin IV", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Cefpodoxime PO", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Ceftazidime IV", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Ceftriaxone IM", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Ceftriaxone IV", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Cefuroxime PO", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Cephalexin PO", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Chloramphenicol IV", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Ciprofloxacin PO", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Ciprofloxacin IV", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Clarithromycin PO", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Clindamycin PO", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Clindamycin IV", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Clindamycin Vaginal", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Clotrimazole Topical", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Clotrimazole Vaginal", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Daptomycin IV", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Dicloxacillin PO", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Dolutegravir PO", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Doxycycline PO", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Doxycycline IV", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Emtricitabine/Tenofovir PO", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Ertapenem IV", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Erythromycin Ophthalmic", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Erythromycin PO", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Erythromycin IV", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Ethambutol PO", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "++ IMPORTANT DRUG PROPERTIES PAGE ++",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Select below for drug info from online database", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DUKE CRITERIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX DUKE LISTING", "Text" : "Modified Duke Criteria Diagnostic Listing", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MODIFIED DUKE DIAGNOSTIC CRITERIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The Modified Duke criteria are used to diagnose endocarditis on clinical",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "grounds. Endocarditis may also be diagnosed by pathology results.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Requirements for definite diagnosis of endocarditis",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Two major criteria",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "One major criterion and three minor criteria",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Five minor criteria",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Requirements for possible diagnosis of endocarditis",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "One major criterion and one minor criterion",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Three minor criteria",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Requirements for rejection of diagnosis of endocarditis",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Firm alternative diagnosis explaining evidence of endocarditis",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Resolution of endocarditis syndrome with antibiotic therapy for less than 4 days",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "No pathological evidence of endocarditis at surgery or autopsy, with antibiotic",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "therapy for less than 4 days",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Does not meet criteria for possible endocarditis as above.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DUKE LISTING", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MODIFIED DUKE CRITERIA DIAGNOSTIC LISTING",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Major criteria",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Blood culture positive",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "*Typical microorganisms consistent with IE from 2 separate blood cultures:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Viridans streptococci, Streptococcus bovis, HACEK group organisms (Haemophilus",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "species, Aggregatibacter species, Cardiobacterium species, Eikenella corrodens,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and Kingella species), Staphylococcus aureus, or community-acquired enterococci",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "in the absence of a primary focus, or microorganisms consistent with IE from",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "persistently positive blood cultures defined as follows: at least 2 positive",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "cultures of blood samples drawn >12h apart or all 3 or a majority of >/= 4",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "separate cultures of blood (with first and last sample drawn at least 1 h apart)",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "*Single culture positive for Coxiella burnetii or anti-phase 1 IgG antibody",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "titer greater than or equal to 1:800",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Echocardiogram positive for endocarditis",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "*Echocardiographic evidence for endocarditis, defined as:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "An echo dense, intracardiac mass attached to valve or supporting structures, in",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "the path of regurgitant jets, or a mass present on implanted material in the",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "absence of an alternative anatomic explanation",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Paravalvular abscess",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "New partial dehiscence of prosthetic valve or new valvular regurgitation",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "(worsening or changing or preexisting murmur is not sufficient for a major",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "criterion)",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Note: Echocardiography should be performed in all patients suspected of having",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "endocarditis. Transesophageal echocardiograph (TEE) is recommended for patients",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "with prosthetic valves. Transthoracic echocardiograph (TTE) is often adequate",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "for patients suspected of having native valve endocarditis, especially on the",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "aortic valve, but TEE may be needed for these patients as well. Contact",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "infectious diseases or cardiology for more information.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Minor criteria",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Predisposing heart condition or intravenous drug user",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Fever",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Temperature over 38 degrees Celsius (100.4 degrees Fahrenheit)",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Vascular phenomena",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Major arterial embolus, septic pulmonary infarcts, mycotic aneurysm,",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "intracranial hemorrhage, conjunctival hemorrhages, or Janeway's lesions",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Immunologic phenomena",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Glomerulonephritis, Osler's nodes, Roth's spots, or rheumatoid factor",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Microbiological evidence",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "A case with a positive blood culture, but with results that don't meet the major",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "criterion blood culture criteria listed above or serological evidence of active",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "infection with organism consistent with endocarditis. Microbiological evidence",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "is not intended to include all positive blood cultures. For example, a single",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "positive culture for coagulase-negative staphylococci or a culture yielding an",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "organism that is not a cause of endocarditis would not support a diagnosis of",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "endocarditis.",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX DURATION OF ABX THERAPY", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DURATION OF ANTIMICROBIAL THERAPY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In general, duration of therapy is based on multiple factors, including",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infection severity, rapidity of improvement, and pathogen susceptibility. For a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "few diseases guidelines are established based on available evidence and opinion.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "For many more diseases, guidelines have not been established.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For outpatient prescriptions, when a range is recommended by CDSS, the",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "prescription order will default to the lowest dose and day supply. For inpatient",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "orders, durations are listed in the recommendations but are not included in the",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "quick order. The provider must select a duration, if desired, when completing an",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "inpatient quick order.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "For all cases clinical judgment is important. More information is given within",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "specific diagnoses or syndromes sections.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX E COLI INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q24H FOR 3 DAYS", "Text" : "Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID RIFAXAMIN 200MG PO Q8H FOR 3 DAYS", "Text" : "Rifaximin 200 mg q8h for 3 days ($$) [M]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "Text" : "Link to Shigella/Enteroinvasive E. coli menu", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH ESCHERICHIA COLI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Enteroaggretive E. coli (EAEC), Enteropathogenic E. coli (EPEC), and",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Enterotoxigenic E. coli (ETEC)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "EAEC infection can cause watery diarrhea with mucus that is occasionally bloody.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "It is more common in patients with HIV and those who have traveled to developing",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "regions. EPEC infection is associated with severe acute watery diarrhea that is",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "occasionally bloody. ETEC infection causes acute watery diarrhea that is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "occasionally severe. It is most common in travelers to tropical regions who are",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "exposed to contaminated food and water.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antibiotic therapy is not required for mild to moderate disease caused by these",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "organisms because diarrhea often resolves on its own. Do not use antimotility",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "agents in patients with bloody stool.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of severe diarrhea",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment in patients with AIDS",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Enterohemorrhagic E. coli (EHEC) and Shiga Toxin-producing E. coli (STEC)",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "EHEC and STEC disease often presents as bloody diarrhea. It is more common in",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "people who have consumed undercooked meats or poultry, fruits or unpasteurized",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "fruit juices, vegetables, leafy greens or seed sprouts. Exposure risks include",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "swimming in or drinking untreated fresh water and visiting a farm, petting zoo,",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "healthcare facility, prison or childcare facility.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treatment includes supportive measures such as volume repletion and",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "administering appropriate nutrition. Do not use antimotility or antimicrobial",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "agents as they can increase shiga-toxin release and increase the risk of",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "hemolytic uremia syndrome (HUS).",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Enteroinvasive E. coli (EIEC)",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "EIEC disease typically presents as watery diarrhea, sometimes progressing to",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "bloody diarrhea. Refer to Shigella/Enteroinvasive E. coli menu for",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "recommendations.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Brunette, Gary W. CDC Yellow Book 2018: Oxford University Press, 2017",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterohemorrhagic E. coli / Shiga toxin-producing E. coli",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Pathogenic Escherichia coli",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment is complex, consult Infectious Diseases", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ELEMENTS OF CDSS ADVICE PAGE", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ELEMENTS OF A CDSS ADVICE MENU",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Advice menus are comprised of the following elements:",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "TYPICALLY present on an advice menu",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "1) Diagnosis or condition label-at the top of each advice menu.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "2) Treatment. Empirical treatment as well as treatment for selected pathogens",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "is presented with links to antimicrobial quick orders unless stated otherwise.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "In addition to the drug, dose, and route, each quick order text includes the",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "drug's approximate cost per day and coding for important drug properties of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "note. Drugs clustered together are considered equivalent.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "3) Help. At the top of each advice menu. There are links to a variety of",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "resources (susceptibilities, important drug properties, section-specific",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "consults, etc.).",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "4) References. At the bottom on each advice menu. These are key references for",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "the recommendations on the menu.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "DISCRETIONARY advice menu components",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "1) (Treatment) Alternative. Following the (preferred) Treatment section with",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "quick orders for common alternative antimicrobials. Antimicrobial listed under",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "each alternative header are equivalents among those listed. A broader selection",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "of medications can be accessed through the Need an alternative menu within the",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "help section. For some conditions we recommend alternative antimicrobials when",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "recommended drugs are not suitable for an individual patient. Unless otherwise",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "stated drugs clustered together under Alternatives are considered equivalent.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "If none of the recommended or alternative drugs is suitable you can find more",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "drugs by clicking on the Need an alternative link at the top of the menu.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "2) Consults. At the top of the menu, these are consultation requests pertinent",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "to the clinical problem addressed by the menu. Links to context-specific",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "consults can be found on advice menus, as appropriate. For example, the herpes",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "simplex encephalitis menu contains a link to a request for neurology consult.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "3) Resources. Pertinent to the clinical problem and addressed by the menu is",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "provided for example. For some menus, supplemental resources have been",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "identified (e.g., PORT score calculator for Community Acquired Pneumonia,",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "diagnostic tools, Epidemiology, etc.) the information is included on the advice",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "menu.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX EMPYEMA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "Text" : "Levofloxacin 500 mg IV Q24H ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "Text" : "Levofloxacin 500 mg PO q24h ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($)[H,O]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($)[H,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID METRONIDAZOLE 500 MG IV Q8H", "Text" : "Metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 1000MG PO Q12H", "Text" : "Metronidazole 1000 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "EMPYEMA",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Empyema is usually a complication of pneumonia.Blood cultures should be drawn",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "and whenever possible, diagnostic thoracentesis should be performed before",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "antimicrobials are begun to guide therapy.Drainage is essential, and a chest",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "tube is often required.Pulmonary or Infectious Diseases consultation is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "essential.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "The duration of antibiotic therapy for bacterial empyema is determined on",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "a patient-by-patient basis based on clinical and radiographic improvement.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Choose two antimicrobials, one from Group A and one from Group B.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : ">>Group A<<",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : ">>Group B <<",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter:Principles and Practice of Infectious Diseases",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Harrison's chapter: Infections due to mixed organisms",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ENTAMOEBA HISTOLYTICA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX METRO 750MG PO Q8H PAROMOMYC 25-35MG/KG/DAY PO Q8H", "Text" : "Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTAMOEBA HISTOLYTICA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Primary treatment for gastroenteritis",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for gastroenteritis or extraintestinal disease",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases. Paromomycin is nonformulary and must",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "be ordered by Infectious Diseases.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "25-35 mg/kg/day PO q8h for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Amoebiasis, Entamoeba histolytica",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Intestinal Entamoeba histolytica amoebiasis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ENTERIC FEVER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h for 7-10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h for 7-10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM ONCE THEN 500MG PO Q24H 5DAYS", "Text" : "Azithromycin 1 gm PO once then 500 mg PO q24h for 5 to 7 days ($) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h for 7 to 14 days ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTERIC FEVER (INCLUDING TYPHOID AND PARATYPHOID FEVER)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Enteric fever is a systemic febrile illness caused by Salmonella enterica",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "serotypes Typhi and Paratyphi A, B, or C. It is characterized by dramatic fever",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "and abdominal pain. Enteric fever typically occurs in patients who have traveled",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "to impoverished areas where the organisms are endemic, but can also be acquired",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "within the United States. Treatment is based on location of acquisition due to",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "increasing rates of fluoroquinolone resistance in Asia.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for infection NOT acquired in Asia",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for infection acquired in Asia",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Typhoid Fever, Enteric Fever",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of enteric (typhoid and",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "paratyphoid) fever", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX EPIDIDYMITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 500MG PO QDAY", "Text" : "Levofloxacin 500mg PO Q24h for 10 days ($) [R, DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 500MG IM ONCE LEVOFLOX 500MG PO Q24H", "Text" : "", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EPIDIDYMITIS",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Most cases in men under age 35 are associated with N. gonorrhoeae and C.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "trachomatis. Most cases in older men are associated with enteric Gram-negative",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "rods. Resistant organisms are more likely if the patient has been in the",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "hospital for more than 48 hours or received a course of antibiotics. There is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "increasing resistance in urinary pathogens to ciprofloxacin.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Patients with bacterial epididymitis treated with antibiotics should improve",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "within two or three days. If no improvement is noted, other causes of scrotal",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "pain and referral to an urologist should be considered.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Management should include bed rest, analgesics, and scrotal elevation. Older",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "men should have their residual urinary volume checked. If the residual volume",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "is elevated, the patient should be seen by a urologist as epididymitis is",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "unlikely to respond if the prostate is blocking the vas deferens.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment in men < 35 years who do not practice insertive anal intercourse",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment in men >/= 35 years who do not practice insertive anal intercourse",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment in men who practice insertive anal intercourse",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "for 10 days ($) [R, DI]",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "If previous cultures indicate that the urinary pathogen is susceptible and oral",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "therapy is appropriate:",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Prostatitis, Epididymitis and Orchitis",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Epididymo-orchitis",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Evaluation of acute scrotal pain in adults",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX GONOCOCCAL", "Text" : "Gonococcal infections with/without Chlamydia", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX EPIGLOTTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX CETRIAX 2G Q24H VANCO 15MG/KG Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> vancomycin 15 mg/kg IV q 12h ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOX 500MG QD VANCO 15MG/KG Q12", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EPIGLOTTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Maintaining the airway is the key to management. Call ENT service and ask them",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to see the patient immediately. Blood cultures and epiglottal cultures (in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "intubated patients) should be used to direct antimicrobial therapy. Empirical",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "therapy should be initiated prior to results of cultures as infection is life",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "threatening and cover for likely pathogens (Moraxella catarrhalis, penicillin",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "resistant S. pneumonia, beta-hemolytic streptococci and possibly Staph. aureus)",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for 7 days",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "for 7 days",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Epiglottitis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Rafei et al., Pediatric Clinics 2006, 53.2, 215-242",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Epiglottitis, Supraglottis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Epiglottis (supraglottis): Management", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ESBL KPC ETC", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Gram-Negative Bacilli Drug Resistance",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In some Gram-negative bacilli, potent bacterial enzymes have emerged that",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "inactive many newer broad-spectrum beta lactam drugs. These include extended-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "spectrum beta-lactamases (ESBLs), serine carbapenemases, metallo-beta-",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "lactamases, AmpC beta-lactamases and oxacillinases. These enzymes are most",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "common in strains of Acinetobacter, Citrobacter, Enterobacter, Escherichia coli,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Klebsiella, Proteus, Pseudomonas aeruginosa, Salmonella, and Serratia",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "marcescens. The enzymes can be latent under many circumstances. However, in",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "patients receiving beta lactam antibiotics, the enzymes can be expressed and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "contribute to treatment failure. Because of this, and since the enzymes continue",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "to evolve, they are difficult to detect in clinical microbiology laboratories.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Bacteria carrying these enzymes are often also resistant to many other commonly",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "used antimicrobials, including trimethoprim-sulfamethoxazole, quinolones, and",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "others, through different mechanisms. Enterobacteriaceae, Pseudomonas and",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Acinetobacter are increasingly resistant to all antimicrobials.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Clinicians must be aware that these enzymes may not be detected in all strains",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "that carry them. If a Gram-negative infection is not responding to therapy with",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "a beta lactam drug, consider adding or switching to a drug that is not a beta",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "lactam and appears active in the susceptibility report.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If a patient is suspected of having a Gram-negative infection and is likely to",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "be colonized with bacteria carrying these enzymes, empirical therapy with",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "alternative drugs that are not inactivated by them should be considered.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Risk factors for colonization or infection with resistant gram-negative bacilli",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "1. Travel to Asia",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "2. Central venous catheters and other indwelling tube and drains",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "3. Recent surgical procedures",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "4. Recent antibiotic therapy",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "5. Long-term care facility residence",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "6. Multiple, severe chronic illnesses",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "7. Ventilator assistance",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "8. Hemodialysis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "9. Long hospital or ICU stay.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "AmpC beta-lactamases alternative antimicrobials",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Inactivate many cephalosporins, most penicillins, and beta-lactam inhibitor",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "combinations. Alternatives include aminoglycosides, carbapenems, cefepime and",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "colistin.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "ESBLs alternative antimicrobials",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Inactivate most cephalosporins, monobactams, and penicillins. Alternatives",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "include aminoglycosides, carbapenems and colistin.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Serine carbapenemases, metallo-beta-lactamases and oxacillinases alternative",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "antimicrobials",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Confer resistance to all beta-lactams. Most strains are also resistant to most",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "other antibiotic classes. Alternatives include aminoglycosides and colistin.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases consultation is recommended.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Additional alternative antimicrobials",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Trimethoprim-sulfamethoxazole and quinolones are non-beta-lactam alternative",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "antimicrobials, especially useful for IV to PO conversion. Gram negative bacilli",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "co-resistance to these antimicrobials is common however. Tigecycline (restricted",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "to ID) and ceftazidime-avibactam (non-formulary) are also potential options for",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "susceptible isolates. Infectious Diseases consultation is required for their",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "use.",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Molecular Mechanisms of Antibiotic Resistance in Bacteria",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Extended-spectrum beta-lactamases",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Overview of carbapenemase-producing gram-negative bacilli",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Rodrguez-Bano et al. Clinical microbiology reviews, 2018, 31(2): e00079-17",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Sanford guide keyword: Gram Negative Bacilli, Drug Resistance, Overview",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Last Reviewed 9/18", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX ESOPHAGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "Text" : "Candidiasis", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV COLITIS OR ESOPHAGITIS", "Text" : "CMV Esophagitis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "Text" : "Herpes Simplex Esophagitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ESOPHAGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Esophagitis is usually associated with non-infectious diseases like",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "gastroesophageal reflux disease, mucositis and pill-induced esophagitis.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Esophageal infection occurs primarily in immunosuppressed individuals (e.g.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "chemotherapy, transplantation, HIV) and rarely in healthy individuals. The",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "majority of infectious esophagitis is caused by Candida albicans,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus (CMV) and herpes simplex virus. Aphthous ulceration of the",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "esophagus is common in HIV infection. HIV screening is recommneded.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Esophagitis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Candidiasis",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Cytomegalovirus, Gastrointestinal Disease",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Herpes simplex virus infection of the esophagus", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX EXCLUSIONS", "Contents" : [
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "Email the VISN23 Antimicrobial CDSS Program Staff", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DISEASES AND SYNDROMES NOT COVERED",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Our system provides advice for the treatment of most infectious diseases likely",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to be encountered in our patient population. Diseases that do not require",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy are not included. For more information on a syndrome not",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "described in our system, please contact infectious diseases. If you feel that a",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "syndrome should be included in our system please contact us.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Erik Stensgard, PharmD: 612-467-1781",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Bobbie Masoud, PharmD: 612-467-4916", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX FIRST RECURRENCE ABX ASSOC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID VANCOMYCIN TAPER AND PULSE DOSING", "Text" : "Vancomycin Extended-Pulse Taper Regimen ($) [M]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXI MEGACOLON", "Text" : "Select for Fulminant CDI", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FIRST RECCURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Discontinue implicated antibiotic and avoid high-risk antibiotic if",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Clostridium difficile infection",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium difficile",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Treatment and",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "prevention",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID FIDAXOMICIN 200MG Q12H 10D", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "CDI Recurrence: Typically defined as a repeated symptomatic, laboratory",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "confirmed case of CDI within 12 weeks after a prior episode.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "First Recurrence CDI: *The REGIMEN should be different from initial treatment.*",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID VANCOMYCIN 125MG PO Q6H X10DAYS CDIFF", "Text" : "Vancomycin 125 mg PO q6h for 10 days ($) [M]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID FIDAXAMICIN EXTENDED-PULSE REGIMEN", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Fulminant CDI:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "125 mg po twice daily for seven days, then 125mg po qday for 7 days, then",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "125mg every other day for 6 weeks)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX FUNGUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI ASPERGILLUS SPP.", "Text" : "Aspergillus and other moulds", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI BLASTOMYCES DERMATIDIS", "Text" : "Blastomyces dermatitidis", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "Text" : "Candida albicans", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA GLABRATA", "Text" : "Candida glabrata", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA KRUSEI", "Text" : "Candida krusei", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI COCCIDIOIDOMYCES", "Text" : "Coccidioidomyces", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "Text" : "Cryptococcus neoformans", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI HISTOPLASMA CAPSULATUM", "Text" : "Histoplasma capsulatum", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "Pneumocystis (considered a fungus)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ FUNGI ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "into site, and whether organism is pathogen, colonizer, or contaminant. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Last reviewed 8/18", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX GASTROINTESTINAL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Hepatic abscess", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "Text" : "Intraabdominal abscess", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "Text" : "Intraperitoneal abscess", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perirectal/Anorectal abscess", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION", "Text" : "Appendicitis without perforation", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION", "Text" : "Appendicitis with perforation", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLECYSTITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLANGITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "Text" : "Mild to moderate disease", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXI MEGACOLON", "Text" : "Severe/life-threatening disease", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX DIVERTICULITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ GASTROINTESTINAL ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Abscess",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Appendicitis",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Cholecystitis",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Cholangitis",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Clostridium difficile disease",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "(shock, ileus and megacolon)",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Diarrhea, infectious",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Diverticulitis",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "SECTION LAST REVIEWED MAY 2018",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU H. PYLORI INFECT", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS A", "Text" : "Hepatitis A", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "Text" : "Hepatitis B", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS C", "Text" : "Hepatitis C", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU ABX TYPHLITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU ABX PANCREATITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "Text" : "Acute Spontaneous Bacterial Peritonitis (SBP)", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERI ASSOC W PERI DIAL", "Text" : "Peritonitis associated with", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "Text" : "Secondary peritonitis", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Helicobacter pylori infection",  "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "Hepatitis",  "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "Neutropenic enterocolitis",  "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "(Typhlitis)",  "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "Pancreatitis",  "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "Peritonitis",  "Header" : 1}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "peritoneal dialysis",  "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "Thrush",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Asplenia (Fever Tx/Vaccines/Abx Prophylaxis)",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "Esophagitis",  "Header" : 1}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "Text" : "Candidal", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU ABX ESOPHAGITIS", "Text" : "Other", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Enteric Fever", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help and Additional Information Menu", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZ GMENU CONSULTS MAIN IP", "Text" : "Consult Menu - place consults to specialty service", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Antibiogram", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID GMENU ABX GENRL ALTERNATIVE DRUG", "Text" : "Alternative Antimicrobials to CDSS Recommendations - select here", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "Text" : "Contact Information", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "Antimicrobial Information", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "Text" : "Important Drug Properties", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "Text" : "Antimicrobial Cost Information", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "GENERAL INFORMATION",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "LEGEND ________________________________________________________________________",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "[DI] = Important interactions between antimicrobial and other drugs",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "[H] = Hepatic excretion of antimicrobial",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "[M] = Minimal risk posed by antimicrobial",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "[O] = Other important antimicrobial property",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "[R] = Renal excretion of antimicrobial",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "($) = <10 dollars per day",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "($$) = 10-50 dollars per day",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "($$$) = 51-100 dollars per day",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "($$$$) = 101-400 dollars per day",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "($$$$$) = >400 dollars per day",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "Text" : "Infectious Diseases Consult", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Beta-lactam Reaction Assessment", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX GENITAL HERPES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "Text" : "Acyclovir 400 mg PO q8h for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "Text" : "Valacyclovir 1 gm PO q12h for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "Text" : "Acyclovir 400 mg PO q8h for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO TID", "Text" : "Acyclovir 800 mg PO q8h for 2 days ($) [R]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO BID", "Text" : "Valacyclovir 500 mg PO q12h for 3 days ($) [R]", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "Text" : "Acyclovir 400 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "Text" : "Valacyclovir 1 gm PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 5 MG/KG IV Q8H", "Text" : "Acyclovir 5 mg/kg IV q8h ($$) [R]", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO BID", "Text" : "Acyclovir 400 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO Q24H", "Text" : "Valacyclovir 500 mg PO Q24h ($) [R]", "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1000 MG PO Q24H", "Text" : "Valacyclovir 1000 mg PO Q24h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GENITAL HERPES",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment of the initial episode decreases the duration of pain, lesions, and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "viral shedding by 1 to 2 days. Treatment of the initial episode does not",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "decrease likelihood of recurrent episodes.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Episodic therapy for relapses",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treatment of recurrent episodes must be started within 24 hours of symptom",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "onset. Treatment decreases the duration of pain and lesions, and viral shedding",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "by 1 to 2 days. Consider suppressive treatment for patients with more than 6",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "episodes per year.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients in whom genital herpes simplex disease is often",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "severe include: patients with HIV infection, organ transplants, malnourishment,",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "eczema or severe burns, and in patients receiving immunosuppressive",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "chemotherapy.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Treat mild to moderate disease for 10 days. In severe disease, treat with",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "intravenous acyclovir for 2 to 7 days based on clinical response, then treat",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "with an oral antiviral for a total duration of 10 days.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease or after clinical improvement of severe",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "disease",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases consult encouraged.",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Chronic suppressive therapy",  "Header" : 1}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Suppressive therapy is indicated in patients with more than 6 episodes per year.",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Suppressive therapy is optional, and some patients may find episodic treatment",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "more convenient. The frequency of recurrences usually decreases after 1 to 5",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "years, and suppressive therapy should be stopped every few years to see if it is",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "still needed.",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "For a patient with more than 9 episodes per year",  "Header" : 1}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "Center for Disease Control. MMWR 55(RR 11) 1-94",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes simplex",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX GENITOURINARY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX UTI2", "Text" : "Urinary Tract Infection (UTI)", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASYMP BACTERIURIA", "Text" : "Asymptomatic bacteriuria", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX COMP CYSTITIS", "Text" : "Complicated cystitis", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX UNCOMP CYSTITIS", "Text" : "Uncomplicated cystitis", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX PYELONEPHRITIS", "Text" : "Pyelonephritis", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU UROSEPSIS", "Text" : "Bacteremia/sepsis urinary tract source,Urosepsis", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "Text" : "Candida Urinary Tract Infection", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX ACUTE BACT PROSTATITIS", "Text" : "Acute bacterial prostatitis", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHRONIC BACT PROSTATITIS", "Text" : "Chronic bacterial prostatitis", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN", "Text" : "Chronic prostatitis/Chronic pelvic pain syndrome", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX EPIDIDYMITIS", "Text" : "Epididymitis", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX VAGINITIS", "Text" : "Bacterial vaginosis", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS", "Text" : "Candida vulvo-vaginitis", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Trichomonas vaginitis", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Pelvic Inflammatory Disease (PID)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ GENITOURINARY ++",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Urinary tract infections, Bacterial",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Urinary tract infections, fungal",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Prostatitis/Epididymitis",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Vaginitis, vaginosis",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Pelvic Inflammatory Disease (PID)",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Last updated Dec 2017",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Sexually Transmitted Infections (STI)", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Cervicitis associated with sexually transmitted infections", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Epididymitis", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Genital Herpes", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Pelvic Inflammatory Disease (PID)", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Syphilis", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Urethritis associated with sexually transmitted infection", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Vaginitis Trichomonas", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "Text" : "Necrotizing infection", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "ORZID2 GMENU ABX PREVENTION OF INFECTION", "Text" : "Prevention of infection", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "ORZID3 GMENU SURG SITE INFECT", "Text" : "Surgical site infection", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Sexually Transmitted Infections (STI)",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "Chlamydia (See Cervicitis or Urethritis)",  "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "Necrotizing Infection (including Fournier gangrene)",  "Header" : 1}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "Prevention of Infection",  "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "Surgical Site Infection",  "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Gonorrhea infection with/without Chlamydia", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX GI EUS-FNA ENDO PROCED", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 500MG PO QDAY 4DAYS PROCEDURE", "Text" : "Levofloxacin 500 mg PO q24h for 4 days, beginning 60 minutes before", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID LEVOFLOXACIN 500MG PO ONCE THEN QDAY 3DAYS", "Text" : "Levofloxacin 500 mg PO q24h for 4 days, beginning 60 minutes before", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Antibiotic Prophylaxis for GI Endoscopic Ultrasound FNA Procedures",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The purpose of antibiotic prophylaxis during GI endoscopy is to reduce the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "risk of iatrogenic infectious complications.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Cystic lesions along GI tract including mediastinum:",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Antibiotic prophylaxis is recommended before a FNA for cystic lesions along",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "the GI tract to prevent cyst infection.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Recommendation:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "INPATIENT:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "endoscopic procedure ($) [R,DI]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "OUTPATIENT:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "endoscopic procedure ($) [R,DI]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Solid Lesions along the upper or lower GI tract:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Antibiotic prophylaxis is not recommended before a diagnostic EUS or EUS-FNA",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "of solid lesions along the upper or lower GI tract.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Endoscopy 2008, 67:791-795", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX GIARDIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID NITAZOXANIDE 500MG PO Q12H", "Text" : "Nitazoxanide 500 mg PO q12h for 3 days ($$$)[M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 250 MG PO Q8H", "Text" : "Metronidazole 250 mg PO q8h for 5 to 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH GIARDIA DUODENALIS (ALSO KNOWN AS G. LAMBLIA AND G.INTESTINALIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Illness with Giardia is typically subacute but varies widely in its time course.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment is necessary when the patient has symptomatic disease. Diarrhea,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "abdominal pain, bloating, belching, flatus, nausea, and vomiting are present",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "acutely and after several days give way to flatus, loose stools, belching, and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "weight loss.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Asymptomatic carriage of Giardia is common in household contacts of people who",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "are infected with Giardia. Treatment of asymptomatic patients can be considered",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "if they have contact with immunocompromised or pregnant people or live or work",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "in settings where there is risk of spreading infection to others (e.g., food",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "handlers, daycare, nursing home).",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Minetti et al, BMJ, 2016, 355.i5369",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Giardia duodenalis (G. intestinalis, G. lamblia)",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Giardiasis: Treatment and prevention", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX GONOCOCCAL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Uncomplicated gonococcal infections of the pharynx, cervix, urethra, or rectum:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "chlamydia.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Patients weighing less than 300lbs:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Patients weighing 300lbs or greater:",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "No reliable alternative treatments are available for pharyngeal gonorrhea.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "of the reaction is recommended. For persons with an anaphylactic or other",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "severe reaction to ceftriaxone, consult Infectious Disease for alternative",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "treatment recommendation.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 1GM IMX1 +DOXY 100MG BID X7D", "Text" : "Ceftriaxone 1 GM IM Once ($) [M] <AND> Doxycycline 100mg PO bid x7days($) [DI]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "-If chlamydial infection has not been excluded, recommend to treat for",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 500MG IM X1 +DOXY 100MG PO BIDX7D", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "-A test-of-cure is unnecessary for uncomplicated urogenital or rectal",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "gonorrhea for patients treated with the recommended or alternative regimen.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "of the reaction is recommended.",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX GENTAMICIN 240MG IM X1+AZITH 2000MG X1 GONOCOCCAL", "Text" : "", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Alternative treatment for beta-lactam allergy for pharynx:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Alternative treatment for beta-lactam allergy for cervix, urethra, or rectum:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "-A test-of-cure is recommended for patients with pharyngeal gonorrhea.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Obtain nucleic acid amplification test (NAAT) 7 to 14 days after initial",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treatment, regardless of regimen used for pharyngeal gonorrhea.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for patients and no chlamydial co-infection:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Preferred treatment with chlamydial co-infection or chlamydial infection has",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "not been excluded:",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Patient weighing less than 300lbs:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Patients weighing 300lbs or greater:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 500MG IM X1 GONOCOCCAL", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 1GM IM X1 GONOCOCCAL", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS", "Text" : "[Click here] Chlamydial infection and no co-infection", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Chlamydial infection and no co-infection:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC PCR TEST", "Text" : "[Click here] Place order for gonorrhea/chlamydia lab NAAT test", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Lab test:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-When diagnosed with sexually transmitted disease, the patient's sexual",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "transmitted infection.",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Gonococcal Infections:", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX HEAD AND NECK", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU MALIGNANT OTITIS EXTERNA", "Text" : "Malignant Otitis Externa", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU MASTOIDITIS", "Text" : "Mastoiditis", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU OTITIS EXTERNA", "Text" : "Otitis Externa", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU OTITIS MEDIA", "Text" : "Otitis Media", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU CONJUNCTIVITIS", "Text" : "Conjunctivitis", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ENDOOPTHALMITIS", "Text" : "Endophthalmitis", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU KERATITIS", "Text" : "Keratitis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU PERIOCULAR INFECTIONS", "Text" : "Periocular Infections", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU PROPHYLAXIS OPTH SURG", "Text" : "Prophylaxis for Ophthalmic Surgery", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU RETINITIS", "Text" : "Retinitis", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU UVEITIS", "Text" : "Uveitis", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "Text" : "Bell's Palsy", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU PRESEPTAL CELLULITIS", "Text" : "Pre-septal Cellulitis", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU POSTSEPTAL CELLULITIS", "Text" : "Post-septal Cellulitis (Orbital Cellulitis)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++HEAD AND NECK++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Ear/Otologic",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Eye/Ophthalmologic",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Facial",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Section last reviewed June 2021",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU ACUTE SINUSITIS", "Text" : "Acute Sinusitis", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID2 GMENU CHRONIC SINUSITIS", "Text" : "Chronic Sinusitis", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "Text" : "Fungal Sinusitis", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID2 GMENU ABX NASAL PACKING", "Text" : "Nasal Packing (to prevent infection)", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU NOSOCOMIAL SINUSITIS", "Text" : "Nosocomial Sinusitis", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU DEEP OROPHAR INFECT", "Text" : "Deep Oropharyngeal Infections", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Dental Infections", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX EPIGLOTTITIS", "Text" : "Epiglottitis", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU ABX ESOPHAGITIS", "Text" : "Esophagitis", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP", "Text" : "Laryngitis", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX PAROTITIS", "Text" : "Parotitis", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU PERIODENTAL DISEASE", "Text" : "Periodontal Disease", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERTUSSIS", "Text" : "Pertussis", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "Text" : "Pharyngitis", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "Text" : "Thrush", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "Text" : "Tonsillitis", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Tooth Abscess and other Suppurative Odonotogenic Infections", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Nasal/Sinus",  "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Throat/Oropharyngeal", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX HELP PAGE", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "Text" : "[Click Here]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX ANTIMICROBIAL FORMULARY", "Text" : "Formulary", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "Text" : "Important drug properties", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "Text" : "Pregnancy and lactation risk", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Susceptibilities (Antibiogram)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX RESOURCE QTC", "Text" : "QTc prolongation drug resource", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Warfarin interactions", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "Text" : "Additional assistance", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "Clinical on call schedule (ID)", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Comments or suggestions", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX EXCLUSIONS", "Text" : "[Click Here]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CDSS HELP AND ADDITIONAL INFORMATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Allergies",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Penicillin desensitization",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Alternative antimicrobials",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "When to use and how to find",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antimicrobial information",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Contact Information",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Excluded diseases and syndromes",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "Text" : "[Click Here]", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOW TO USE CDSS", "Text" : "[Click Here]", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "Text" : "[Click Here]", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "Text" : "[Click Here]", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU ABX ABOUT THE CDSS", "Text" : "About the CDSS", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU ABX ACKNOWLEDGEMENTS", "Text" : "Acknowledgements", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU ABX NEW UPDATES", "Text" : "New updates information", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZ GTX ABX LEXICOMP ONLINE", "Text" : "Lexicomp online", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZ GTX ABX MANDELL", "Text" : "Mandell's online", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZ GTX ABX UP TO DATE", "Text" : "Up-to-date online", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZ GTX ABX SANFORD", "Text" : "Sanford Guide online", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Home IV Treatment Information",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "How to use the CDSS",  "Header" : 1}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "Navigation, adjusting regimens, menu",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "elements",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "Infection Control",  "Header" : 1}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "Contact info, links, precautions",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "Restriction policy information",  "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "Other/additional resources",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "Text" : "Cost Information", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Beta-lactam reaction assessment", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "Text" : "History, types, implications,", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HEPATITIS A", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HEPATITIS A",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Disease Management",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Most acute disease is self-limited, and the virus does not cause chronic",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease. No specific antiviral therapy is available.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Patients who appear to be developing fulminant hepatitis, including those with",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "mental status changes should receive supportive treatment. Fulminant hepatitis",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "is suggested by increased prothrombin time, cholestasis, ascites, decreased",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "liver size, or decreasing serum albumin. Supportive treatment includes",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "maintenance of fluid and electrolyte balance, monitoring and possible correction",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "of coagulation defects, treatment of hepatic encephalopathy, and good nutrition",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "with a low-protein diet.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Prevention for persons with continuing high risk of disease",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Vaccine should be offered to persons at high risk of hepatitis A infection: men",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "who have sex with men, travelers to endemic areas likely to be exposed, illegal",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "drug users, persons at occupational risk of disease, persons with chronic liver",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "disease or clotting factor disorders.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Prevention for persons with a specific, defined exposure",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Post-exposure prophylaxis should be offered to persons with substantial exposure",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "to hepatitis A. Specifically, persons exposed to acute hepatitis through",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "household or sexual contact, persons who attend or work in a day care center",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "with a recent case, or employee or patron of a restaurant with a food handler",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "with hepatitis. Post exposure prophylaxis must be given within 2 weeks of",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "exposure. Vaccine can be given at the same time as immune-globulin.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Immune globulin 0.02 ml/kg IM x 1 <AND>",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute viral hepatitis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Hepatitis A, Acute, Treatment",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Hepatitis A virus infections: Treatment and prevention", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HEPATITIS B", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B Vaccine Information Page", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "Text" : "Hepatitis B Evaluation", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HEPATITIS B",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute disease management",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Most acute hepatitis B disease is mild and self-limited. Patients who appear to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "be developing fulminant hepatitis, including those with mental status changes",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "should receive supportive treatment. Fulminant hepatitis is suggested by",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "increased prothrombin time, cholestasis, ascites, decreased liver size, or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "decreasing serum albumin. Supportive treatment includes maintenance of fluid",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "and electrolyte balance, monitoring and possible correction of coagulation",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "defects, treatment of hepatic encephalopathy, and good nutrition with a low-",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "protein diet. Antiviral therapy is not indicated. Gastroenterology consult",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "encouraged.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Chronic disease management",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Antiviral therapy for chronic hepatitis B is a complicated, highly specialized",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "task. Consult with gastroenterology and infectious diseases.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Prevention",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Vaccinate persons at high risk of disease including men who have sex with men,",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "illegal drug users, and health care workers with substantial exposure to blood",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "or body fluids.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Select below for Hepatitis B evaluation for patients receiving Anti-CD20",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Antibody Treatment",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute viral hepatitis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Chronic viral hepatitis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Hepatitis B virus: Overview of management", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HEPATITIS C", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HEPATITIS C",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment of acute disease",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Most acute disease is asymptomatic or mild. Patients with acute hepatitis C",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "should be referred to the Hepatitis C clinic. Treatment may be indicated for",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "disease that persists beyond 2 months",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Chronic disease treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antiviral therapy for chronic hepatitis C is a complicated, highly specialized",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "task",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute viral hepatitis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Chronic viral hepatitis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Overview of the management of chronic hepatitis C virus",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HERPES KERATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "Text" : "Acyclovir 400 mg PO q8h for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO BID", "Text" : "Valacyclovir 500 mg PO q12h for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO 5X/D", "Text" : "Acyclovir 800 mg PO 5x/day for 14-21 days ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "Text" : "Valacyclovir 1 gm PO q8h for 14-21 days ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO BID", "Text" : "Acyclovir 400 mg PO Q12h for 12 months ($) [R]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO Q24H", "Text" : "Valacyclovir 500 mg PO Q24h for 12 months ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HERPES KERATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Ocular herpes infection can be caused by either HSV-1 or HSV-2. The majority of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cases are caused by HSV-1. The recurrence rate of ocular herpes is 40% over a 5",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "year period, less than that of oral or genital herpes. Ocular herpes is a",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "major cause of blindness and typically presents as infection of the epithelium",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "of the cornea but can also rarely involve the stroma and endothelium.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Ophthalmology consultation is recommended.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Involvement of the stroma or endothelium requires treatment with topical",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "steroid and close monitoring. For these cases, start oral antiviral and consult",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "ophthalmology for management.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Antiviral prophylaxis is recommended for patients with multiple recurrences,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "recurrent episodes with ulceration, recurrent inflammation with",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "scar/vascularization approaching visual axis, patients who have had keratoplasty",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "for HSV-related scarring/astigmatism, and patients who have had HSV keratitis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "while on immunosuppressive therapy. Post-surgical prophylaxis is not discussed",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "here. Please consult ophthalmology for more information.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treatment of acute infection",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Without epithelial ulceration",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Ulceration of epithelium (Geographic ulcer)",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Infection prophylaxis for prevention of recurrence",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Reassess need for prophylaxis every 12 months",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Baratz, Arch Ophthalmology, (2012) 130.1: 108-110",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Guess et al, The Ocular Surface, (2007) 5.3:240-250",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Wilhelmus, Cochrane Database of Systematic Reviews, (2015), 1:CD002898",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Miserocchi et al, Efficacy of Valacyclovir vs Acyclovir for the Prevention of",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Recurrent Herpes Simplex",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Virus Eye Disease: A Pilot Study, American Journal of Ophthalmology, 2007",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "144:547-551",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "White et al, Ocular Microbiology and Immunology Group and American Academy of",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Ophthalmology, (2014)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO 5X/DAYS", "Text" : "Acyclovir 400 mg PO 5x/day (Cost $) [R] < OR >", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "Text" : "Valacyclovir 1 gm PO q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO 5X/DAYS", "Text" : "Acyclovir 400 mg PO 5x/day (Cost $) [R] < OR >", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "Text" : "Valacyclovir 1 gm PO q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 5 MG/KG IV Q8H", "Text" : "Acyclovir 5 mg/kg IV q8h (Cost $) [R]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HERPES SIMPLEX ESOPHAGITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "HSV infection of the esophagus usually occurs in patients who are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "immunocompromised, typically solid organ and bone marrow transplant",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "recipients.In healthy patients HSV esophagitis occurs occasionally,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "usually in men under the age of 40.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Patients usually present with odynophagia and dysphagia.Fever",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "epigastric pain, nausea, vomiting, and heartburn are less frequent.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Some patients may have coexistent herpes labialis or oropharyngeal",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "ulcers.Diagnosis is usually established with an upper endoscopy.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Suggestive findings may also be seen during a barium swallow.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Spontaneous resolution usually occurs in immunocompetent patients after",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "one to two weeks. Patients may respond more quickly if treated with a",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "short course of oral acyclovir.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treat for 7-10 days",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treat for 14-21 days",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Treat for 7-14 days",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "John Hopkin's Guides keyword: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes simplex",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Herpes simplex virus infection of the esophagitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HERPES WHITLOW", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "Text" : "Acyclovir 400 mg PO q8h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "Text" : "Valacyclovir 1 gm PO q12h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HERPES WHITLOW (DIGIT OR HAND CELLULITIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Alternative for easier compliance schedule",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Whitlow, herpetic", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HIV-AIDS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "Text" : "ID consult", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "GMRCTZ MRTC - OUTPT", "Text" : "MRTC consult", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HIV",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "HIV infection and AIDS are associated with several host defense defects. Cell-",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "mediated immune defects render a patient more susceptible to opportunistic",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "infections with pathogens like Pneumocystis jirovecii (formerly Pneumocystis",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "carinii), Toxoplasma gondii, cytomegalovirus, mycobacterium-avium intracellulare",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "complex, and Candida spp.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Contact ID or HIV (MRTC) service for assistance.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds. Clinical Immunology",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Roitt l, et al, eds. Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HOME IV AT MPLS", "Contents" : [
{"Row" : 25, "Column" : 1, "Item" : "GMRCTZ HOME IV INFUSION COORDINATION", "Text" : "Home IV consult (or page 7253)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HOME IV AT THE MINNEAPOLIS VA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Minneapolis VA provides home IV therapy contracts with commercial providers. To",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "order home IV antimicrobials:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Step 1",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "An Infectious Disease staff physician must approve outpatient IV antimicrobials",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "in each case. Call x4185, or call the operator on off-tours to contact the ID",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "staff member on-call. If the ID service has been consulted, you must request",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Home IV approval and recommendations from the ID staff on-call.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Step 2",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Order a Home IV consult (click on quick order below). Note: Allow 24 hours for",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "home IV service assessment, teaching, etc to occur.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HOW TO FIND AN ALTERNATIVE ANTIMICROBIAL WITHIN THE CDSS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The CDSS has been developed locally with input from a broad, representative",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "group of clinicians. All antimicrobial recommendations within the Antimicrobial",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "CDSS are reviewed by a clinical pharmacist and an Infectious Diseases Medical",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Specialist. Recommendations provided are based on local susceptibility patterns,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "clinical evidence, local preferences, and national guidelines. In rare cases,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "the recommended antimicrobials and listed alternatives may not be preferred for",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the patient you are treating (e.g. isolate resistance, allergies, etc.). In",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "these cases, a broader set of alternative antimicrobials may be ordered through",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "the Antimicrobial CDSS. Like other antimicrobial orders in the CDSS,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "antimicrobials ordered through the Alternative Antimicrobials menu do on require",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "a prior authorization or ID approval.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "To access the Alternative Antimicrobials menu, navigate to the menu containing",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "antimicrobial recommendations for the infectious disease you are treating.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "The Alternative Antimicrobial menu contains antimicrobial regimens that have",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "been deemed appropriate for use as alternatives to recommended antimicrobials by",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "the Antimicrobial P&T Subcommittee. If the list does not contain the preferred",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "antimicrobial, contact or consult Infectious Diseases.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "The regimens provided in the Alternative Antimicrobial menu are not tailored for",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "a specific infectious disease. The dose, frequency, and duration must be changed",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "based on the infectious disease you are treating as well as for patient specific",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "factors. The usage of alternative antimicrobials are monitored by the",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Antimicrobial CDSS team for appropriateness and to identify infectious diseases",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "for addition to the system.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "At the top of the menu, select:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "2 Help legend, allergy info, consults, alternative antimicrobials and more",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Then select- Alternative Antimicrobials to CDSS Recommendations",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Select the reason an alternative antimicrobial is required then the Alternative",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Antimicrobial menu will display.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HOW TO USE CDSS", "Contents" : [
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX DURATION OF ABX THERAPY", "Text" : "More information on duration of antimicrobial therapy", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID2 GMENU ABX ELEMENTS OF CDSS ADVICE PAGE", "Text" : "[Click Here]", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADJ EXIST ABX THERAPY", "Text" : "Adjusting existing antimicrobial therapy", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "Text" : "How to find an alternative antimicrobial within the CDSS", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HOW TO USE THE CDSS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The CDSS has been designed to offer antimicrobial prescribing advice quickly and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "efficiently. Since inpatient and outpatient drugs are ordered differently, the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "CDSS has both and inpatient and outpatient versions for prescribing.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "The Antimicrobial CDSS is located within CPRS. When CPRS is open, click on the",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Orders tab at the bottom left hand side of the CPRS window.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For inpatients",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "On the left-hand side of the \"Orders\" tab, click on the \"Medicine Inpt Orders.\"",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "now be open.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "For outpatients",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "On the left-hand side of the \"Orders\" tab, click on the \"Medicine Outpt Orders.\"",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "now be open.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Navigating Within the CDSS",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "*Using the decision tree",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "The main menu of the Antimicrobial CDSS contains links to categories of",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "infectious diseases based on syndrome/organ system (e.g. cardiovascular,",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "genitourinary, etc.), organisms (e.g. gram-positive bacteria, gram-negative",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "bacteria, viruses, etc.) and other special cases. To navigate to specific",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "infectious disease, select the category the infectious disease is associated",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "with. Within the category menu, select the specific infectious disease sub-menu",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "for recommendations, quick orders and pertinent resources (e.g., section-",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "specific consults, important drug properties, CDSS system help resources, etc.).",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "*Using the Index",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "The Index is in the main menu at the top of the left-hand column under the",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "header Index of Antimicrobial CDSS content. The Index contains an alphabetized",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "list of Antimicrobial CDSS content. Find the infectious disease, organism or",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "other topic you are looking for by scrolling down the list. When you locate the",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "term you are looking for, click on it to be linked to the menu containing",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "specific recommendations, quick orders and pertinent resources.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Quick Orders",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Quick orders are preprogrammed with the usually recommended antimicrobial dose,",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "frequency and solution for the specific infectious disease.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Quick orders are not tailored to specific patient factors such as renal",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "insufficiency, comorbidities, contraindications, weight, allergies, etc. The",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "provider must assess every patient closely for these factors and modify",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "recommended antimicrobials if needed. To assist the provider, additional drug",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "information is provided within specific infectious diseases recommendation menus",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "and a link to more in depth information is provided at the top of these menus.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Alternatives to preferred antimicrobials quick orders are often provided in",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "recommendations, a broader selection of alternative antimicrobials is provided",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "in the Alternative Antimicrobial menu (see What if a Preferred Antimicrobial is",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "not Provided in the Recommendations?).",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Elements of a CDSS Advice Page",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "If you need to modify existing therapy",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "If you need an alternative antimicrobial",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "option.In the right-hand column of the window that pops up, select \" 77",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Antimicrobials (CDSS).\". The main menu of the Inpatient Antimicrobial CDSS will",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "option. In the right-hand column of the window that pops up, select \" 55",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Antimicrobial (CDSS).\". The main menu of the Outpatient Antimicrobial CDSS will", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX HSV ENCEPHALITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "Text" : "Acyclovir 10 mg/kg IV q8h ($$) [R,DI] for 14 to 20 days", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HERPES SIMPLEX ENCEPHALITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Herpes simplex virus (HSV) type 1 is the leading cause of sporadic fatal",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "encephalitis worldwide and should be suspected in patients who have symptoms",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "unexplained by other causes. Typical symptoms include acute alteration of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "consciousness for more than 24 hours, fever, new onset seizures and/or focal",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "neurologic deficits. Patients taking natalizumab are at increased risk of HSV",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "encephalitis. Early diagnosis and treatment are essential to achieve resolution",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "of infection and symptoms. If diagnosis is not certain and there is little",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "likelihood of herniation, obtain cerebrospinal fluid (CSF) sample for HSV",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "polymerase chain reaction (PCR). MRI without contrast nearly always show",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "abnormal signs in patients with HSV encephalitis. Neurology and Infectious",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "disease consultations are strongly encouraged.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment, Initiate Immediately When HSV Encephalitis is Suspected",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Rabinstein, Neurol Clin, 2017, 695-705",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Encephalitis",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Herpes simplex virus type 1 encephalitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "________________________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Ciprofloxacin PO",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "________________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Usual dose:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "250-500 mg q12h",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Dose adjustments for renal or hepatic insufficiency:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Creatinine clearance (ml/min) Dose adjustment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "< 30 250 mg q12h",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Hemodialysis250-500 mg q24h",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Drug Interactions:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Hypoglycemia that can lead to coma especially in diabetics taking",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "oral hypoglycemic medicine or insulin.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Calcium, dairy products, iron, zinc, magnesium, aluminuminhibit the absorption",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "of oral ciprofloxacin.Give ciprofloxacin 2 hours before or 6 hours after these",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "drugs.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Increases effects of caffeine and theophylline by inhibitingmetabolism.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Monitor the patient for signs of agitation or anxiety.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Increases the effect of warfarin.Monitor international normalized ratio (INR)",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "ratio (INR) frequently in patients taking warfarin.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Adverse Drug Reactions:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "FDA Drug Safety Communication",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "The U.S. Food and Drug Administration advised that the serious",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "side effects associated with fluoroquinolone antibacterial drugs",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "generally outweigh the benefits for patients with acute sinusitis, acute",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "bronchitis, and uncomplicated urinary tract infections who have other",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "treatment options. For patients with these conditions, fluoroquinolones should",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "be reserved for those who do not have alternative treatment options.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "An FDA safety review has shown that fluoroquinolones when used systemically",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "are associated with disabling and potentially permanent serious side effects",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "that can occur together. These side effects can involve the tendons,",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "muscles, joints, nerves, and central nervous system.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "FDA identified cases of hypoglycemic coma, resulting in death in some",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "instances. Most pateints had risk factors for hypoglycemia such as older age,",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "diabetes, renal insufficiency, and concomitant use of hypoglycemic drugs,",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "especally sulfonylureas.FDA also identified reports of additional mental",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "health side effects, and requires that all fluoroquinolones include six",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "psychiatric adverse reactions (disturbance in attention, memory impairment,",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "delirium, nervousness, agitation and disorientation).",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Other adverse reactions:",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Nausea/vomiting, diarrhea, dizziness, confusion, CNS",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "stimulation, rare seizures, rare QT interval prolongation, and",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "tendinitis/tendon rupture. Six psychiatric adverse reactions",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "including disturbance in attention, memory impairment, delirium,",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "nervousness, agitation and disorientation.",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Hypoglycemia that can lead to coma, occuring more frequently in",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "the elderly and those with diabetes.",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Pregnancy Risk Factor Category: C", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX IMMUNOCOMPROMISED PATIENT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS", "Text" : "Basic concepts", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM COMP DEFICIENCY", "Text" : "Complement deficiency", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Spleen absent or dysfunctional", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION", "Text" : "Malnutrition", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS", "Text" : "Diabetes Mellitus", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUROL DYSFUNCTION", "Text" : "Neurological dysfunction", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE", "Text" : "Tobacco smoke", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM STRESS", "Text" : "Stress", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA", "Text" : "Hypochlorhydria", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA", "Text" : "Altered microbial flora", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM MALIGNANCY", "Text" : "Malignancy", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA", "Text" : "Neutropenia", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "Text" : "Neutropenic fever", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND ORAL THERA", "Text" : "Oral therapy for neutropenic fever", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND NOT ORAL THERA", "Text" : "Empirical intravenous therapy for neutropenic fever", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER MOD THERAPY", "Text" : "Modification to neutropenic fever therapy", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "Pneumocystis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ INFECTIONS IN IMMUNOCOMPROMISED PATIENTS ++",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Innate defects",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "HIV", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID2 GMENU CMI DEFECTS", "Text" : "Cell-mediated immunity (CMI) defects", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU IG HIS DEFICIENCY", "Text" : "Immunoglobulin (humoral immune system) deficiency", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU TRANSPLANTATION", "Text" : "Transplantation", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "Immune defects", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX IMPETIGO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID MUPIROCIN 2% OINT TOP TO AFFECT AREA Q8H", "Text" : "Mupirocin ointment to affected area q8h for 5 days ($) [M]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 250MG PO Q6H", "Text" : "Cephalexin 250 mg PO q6h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 250MG PO Q6H", "Text" : "Dicloxacillin 250 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100MG PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100MG PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Impetigo and Ecthyma",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Impetigo is a superficial skin infection that rarely causes systemic",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "symptoms. Ecthyma is a skin infection characterized by crusted sores",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "beneath which ulcers form. It is a deep form of impetigo, as the same",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "bacteria causing the infection are involved. Ecthyma causes deeper",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "erosions of the skin into the dermis.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Gram stain and culture of the pus or exudates from skin lesions of",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "impetigo and ecthyma are recommended to help identify whether",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus and/or beta-hemolytic Streptococcus is the cause.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Bullous and non-bullous impetigo can be treated with oral or topical",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobials, but oral therapy is recommended for patients with",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "numerous lesions or in outbreaks affecting several people to help",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "decrease transmission of infection. Treatment for ecthyma should be an",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "oral antimicrobial.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment for impetigo with few lesions",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treatment for ecthyma and for impetigo with numerous lesions or",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "whose symptoms have not responded to topical treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treat orally for 7 days",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "IF MRSA confirmed or suspected:",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014 59: 147",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX IMPORTANT BETA-LACTAM ALLERGY FACTS", "Contents" : [
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Important Beta-lactam Allergy Facts",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "1. 10% of patients report an allergy to penicillin.",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "2. Less than 1% of patients are truly allergic to penicillin.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "3. 80% of patients who had an immediate allergic reaction (Type I,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Immunoglobulin E (IgE)-mediated) to penicillin lose sensitivity after 10",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "years.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "4. Cross-reactivity between penicillin and cephalosporins occurs in only 2% of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "patients and most patients do not have clinically significant reactions.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Obtaining a Detailed Reaction History",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "- Locate documented reaction information within the Computerized Patient Record",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "System (CPRS)",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "> Reported reactions can be found in the Cover Sheet under Allergies/Adverse",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Reactions. Double click on the specific reaction for more information,",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "including signs/symptoms and date of reaction.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "> A reaction report can also be found here: Reports tab -> Clinical Reports -",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Allergies.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "- Determine beta-lactam medication history. A list of all locally prescribed",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "medications can be found here: Reports tab -> Clinical Reports -> Pharmacy ->",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "All Medications.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "- Interview the patient or family for details about the reaction. Questions to",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "ask during the interview:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "> What medication were you taking when the reaction occurred? DO NOT accept",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Penicillin or Cephalosporin as an allergy, ensure specific offending",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "medication is identified.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "> How long after taking the medication did the reaction occur? Immediate",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "reactions typically occur within 1 hour and up to 72 hours after",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "administration. Delayed reactions occur after 72 hours.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "> How long ago did the reaction occur? Did it occur over 10 years ago?",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "> What kind of reaction occurred? Did the reaction require medical attention?",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Blumenthal et. al., Addressing Inpatient Beta-Lactam Allergies: A Multihospital",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Implementation. J Allergy Clin Immunol Pract. 2017, 5(3)616-625",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Is it Really a Penicillin Allergy? Centers for Disease Control and Prevention,",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "2017",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Chaudhry et al., Cephalosporins: A Focus on Side Chains and Beta-Lactam Cross-",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Reactivity. Pharmacy, 2019, 7(3)103",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Collins, et al. Impact of an Antibiotic Side-Chain-Based Cross-reactivity Chart",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Combined With Enhanced Allergy Assessment Processes for Surgical Prophylaxis",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Antimicrobials in Patients With Beta-Lactam Allergies. Clinical Infectious",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Diseases, 2020",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Patrick et al., Beta-lactam allergy Benefits of de-labeling can be achieved",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "safely. BC Medical Journal, 2019, 61(9)350",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Sakoulas et al., Is a Reported Penicillin Allergy Sufficient Grounds to Forgo",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "the Multidimensional Antimicrobial Benefits of Beta-Lactam Antibiotics?",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Clinical Infectious Diseases, 2019, 68(1)157",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Shenoy et al., Evaluation and Management of Penicillin Allergy. JAMA. 2019,",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "321(2)188",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Immunol. 2010, 105(4)259",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Drug Allergy, Beta-lactams",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Tribiano et al. The Three C's of Antibiotic Allergy - Classification, Cross-",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Reactivity and Collaboration. J Allergy Clin Immunol Pract, 2017, 5(6)1532-",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "1542",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Cephalosporin-allergic patients: Subsequent use of",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "cephalosporins and related antibiotics",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Drug allergy: Classification and clinical features",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Zagursky et al., Cross-reactivity in b-Lactam Allergy. J Allergy Clin Immunol",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Pract. 2018, 6(1)72",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Solensky et al., Drug Allergy: An Updated Practice Parameter. Ann Allergy Asthma", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX UP TO DATE", "Text" : "Up-to-Date online (Lexicomp)", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX SANFORD", "Text" : "Sanford online", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Alphabet: A-B (acyclovir-benzathine penicllin)", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Alphabet: C(caspofungin-clindamycin)", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Alphabet D-E-F(daptomycin-fosfomycin)", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ GTX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "Text" : "Alphabet: G-H-I-J-K-L (ganciclovir-linezolid)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ GTX URL IDP M-N-O SANFORD OR LEXI LINKS", "Text" : "Alphabet M-N-O(metronidazole-oseltamivir)", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ GTX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "Text" : "Alphabet: P-Q-R-S (paromomycin-sulfadiazine)", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ GTX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "Text" : "Alphabet: T-U-V-W-X-Y-Z (terconazole-zanamivir)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "IMPORTANT DRUG PROPERTIES CODING",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Next to each drug quick order in CDSS, there are letters alerting the user to",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "important properties associated with that drug:",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "[DI]= clinically important drug interactions",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "[H] = may require dose adjustment in patients with hepatic dysfunction",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "[R] = may require dose adjustment in patients with renal dysfunction",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "[O] = other important information",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "[M] = minimal",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "The Important Drug Properties menu contains valuable information on common or",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "severe adverse effects, drug interactions and dose adjustments for hepatic and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "renal failure. This list is not comprehensive. Refer to Up-to-date, found in",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Clinical Online Resources under the Tools menu in CPRS, or click on the ling",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "below for more information.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases and Pharmacy Services can help with dose adjustments.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Important Drug Properties Menu Select by Alphabet of Generic Name",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Links to Sanford and Up-to-Date (Lexicomp) for drug information", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX INDEX INPATIENT", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX CNS", "Text" : "Abscess, brain", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS", "Text" : "Abscess, cranial epidural", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU CUTANEOUS ABSCESS", "Text" : "Abscess, cutaneous", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Abscess, liver", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX LUNG ABSCESS", "Text" : "Abscess, lung", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Abscess, perianal/anorectal", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABSCESSES", "Text" : "Abscess, skin and soft tissue", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS", "Text" : "Abscess, spinal epidural", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL A. BAUMANNI", "Text" : "Acinetobacter baumannii, general", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL A. BAUMANNII", "Text" : "Acinetobacter baumannii, nosocomial pneumonia", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "Acquired immunodeficiency syndrome (AIDS)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI ACTINOMYCES SPP.", "Text" : "Actinomyces infections, general", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Adenovirus diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT", "Text" : "Aerobic bottle, large uniform bacilli", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS AEROBIC BOT", "Text" : "Aerobic bottle, small pleomorphic bacilli", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX AEROMONAS", "Text" : "Aeromonas diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Aggregatibacter native valve endocarditis", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Aggregatibacter prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "Text" : "Allergy information", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA", "Text" : "Altered microbial flora", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX LIVER AMEBIC ABSCESS", "Text" : "Amebic liver abscess", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT", "Text" : "Anaerobic bottle, large uniform bacilli", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT", "Text" : "Anaerobic bottle, small pleomorphic bacilli", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI", "Text" : "Anaerobic gram-positive cocci", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ANAPLASMA PHATOCYTOPHILUM", "Text" : "Anaplasma phagocytophilum (human granulocytotropic anaplasmosis)", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Anorectal abscess", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT BACT PROPHYL", "Text" : "Antibacterial prophylaxis in malignancy", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Antibiogram", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL", "Text" : "Antifungal prophylaxis in malignancy", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Antimicrobial interactions with warfarin", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Antimicrobial shortages updates", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Antimicrobial susceptibilities", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Antiviral prophylaxis in malignancy", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION", "Text" : "Appendicitis with perforation", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION", "Text" : "Appendicitis without perforation", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU LYME ARTHRITIS", "Text" : "Arthritis associated with Lyme disease", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI ASPERGILLUS SPP.", "Text" : "Aspergillus infections, general", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "Text" : "Aspiration pneumonia", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Asplenia [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Astrovirus diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "Text" : "Asymptomatic bacteriuria", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "Text" : "Asymptomatic candiduria", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "Text" : "Asymptomatic pyuria", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU BABESIA SPP.", "Text" : "Babesia infections, general", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "Text" : "Bacillary dysentery", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT", "Text" : "Bacilli, large uniform, aerobic bottle", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT", "Text" : "Bacilli, large uniform, anaerobic bottle", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS AEROBIC BOT", "Text" : "Bacilli, small pleomorphic, aerobic bottle", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT", "Text" : "Bacilli, small pleomorphic, anaerobic bottle", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI BACILLUS SPP.", "Text" : "Bacillus infections, general", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID2 GMENU ABX BACTEREMIA", "Text" : "Bacteremia", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID2 GMENU GRAM NEGATIVE BACTERIA", "Text" : "Bacteria, Gram-Negative section", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID2 GMENU GRAM POS BACTERIA", "Text" : "Bacteria, Gram-Positive section", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "Text" : "Bacteriuria", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.", "Text" : "Bacteroides infections, general", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID2 GMENU BED BUGS (HEMIPTERA)", "Text" : "Bed bugs", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "Text" : "Bell's palsy", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU BITE WOUNDS", "Text" : "Bite wounds", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI BLASTOMYCES DERMATIDIS", "Text" : "Blastomycosis infections, general", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Text" : "Body lice", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "Text" : "Bone and Joint section", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "ORZ GMENU BONE MARROW MAIN", "Text" : "Bone marrow transplant immunizations", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J ENTEROCOCCI", "Text" : "Bone prosthesis infection", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BORDETELLA SPP.", "Text" : "Bordetella infections, general", "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT", "Text" : "Brain abscess from contiguous or hematogenous spread", "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP", "Text" : "Brain abscess with Nocardia spp.", "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.", "Text" : "Brain abscess with Pseudomonas spp.", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII", "Text" : "Brain abscess with Toxoplasma gondii", "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC", "Text" : "Brain abscess, post-surgical or post-traumatic", "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "Text" : "Bronchitis", "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "Text" : "Bronchitis in otherwise healthy patient", "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BRUCELLA SPP.", "Text" : "Brucella infections, general", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BRUCELLA SPP.", "Text" : "Brucella spp.", "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC BURSITIS", "Text" : "Bursitis, septic", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "ORZID2 GMENU ABX CAMPYLOBACTER", "Text" : "Campylobacter diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN CAMPYLOBACTER SPP.", "Text" : "Campylobacter, general", "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM MALIGNANCY", "Text" : "Cancer [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "Text" : "Candida albicans infections, general", "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA GLABRATA", "Text" : "Candida glabrata infections, general", "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH CANDIDA SPP", "Text" : "Candida intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CANDIDA KRUSEI", "Text" : "Candida krusei infections, general", "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : "ORZID2 GMENU RETINITIS", "Text" : "Candida retinitis", "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "Text" : "Candida urinary tract infection", "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS", "Text" : "Candida vulvo-vaginitis", "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "Text" : "Candidemia", "Header" : 0}, 
{"Row" : 100, "Column" : 1, "Item" : "ORZID2 GMENU CUTANEOUS CANDIDIASIS", "Text" : "Candidiasis", "Header" : 0}, 
{"Row" : 101, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "Text" : "Candiduria", "Header" : 0}, 
{"Row" : 102, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Carbuncles", "Header" : 0}, 
{"Row" : 103, "Column" : 1, "Item" : "ORZID2 GMENU LYME CARDIAC DISEASE", "Text" : "Cardiac disease associated with Lyme disease", "Header" : 0}, 
{"Row" : 104, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Cardiobacterium native valve endocarditis", "Header" : 0}, 
{"Row" : 105, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Cardiobacterium prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 106, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFECT INVOLVES CARD DEVICES", "Text" : "Cardiovascular device infections (excluding valves)", "Header" : 0}, 
{"Row" : 108, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Catheter-associated infection, intravascular", "Header" : 0}, 
{"Row" : 109, "Column" : 1, "Item" : "ORZID2 GMENU CAT-SCATCH DISEASE", "Text" : "Cat-scratch disease", "Header" : 0}, 
{"Row" : 110, "Column" : 1, "Item" : "ORZID2 GMENU CMI DEFECTS", "Text" : "Cell-mediated immunity (CMI) defects", "Header" : 0}, 
{"Row" : 111, "Column" : 1, "Item" : "ORZID2 GMENU ABX CELLULITIS", "Text" : "Cellulitis", "Header" : 0}, 
{"Row" : 112, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "Text" : "Cellulitis, herpes whitlow", "Header" : 0}, 
{"Row" : 113, "Column" : 1, "Item" : "ORZID2 GMENU POSTSEPTAL CELLULITIS", "Text" : "Cellulitis, postseptal (orbital)", "Header" : 0}, 
{"Row" : 114, "Column" : 1, "Item" : "ORZID2 GMENU PRESEPTAL CELLULITIS", "Text" : "Cellulitis, preseptal", "Header" : 0}, 
{"Row" : 115, "Column" : 1, "Item" : "ORZID2 GMENU ABX CNS", "Text" : "Central Nervous System section", "Header" : 0}, 
{"Row" : 116, "Column" : 1, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "Text" : "Cervicitis associated with sexually transmitted diseases", "Header" : 0}, 
{"Row" : 117, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Chickenpox vaccination", "Header" : 0}, 
{"Row" : 118, "Column" : 1, "Item" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX", "Text" : "Chickenpox, primary infection", "Header" : 0}, 
{"Row" : 119, "Column" : 1, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "Text" : "Chickenpox, reactivation of primary infection", "Header" : 0}, 
{"Row" : 120, "Column" : 1, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "Text" : "Chlamydia urethritis", "Header" : 0}, 
{"Row" : 121, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLANGITIS", "Text" : "Cholangitis", "Header" : 0}, 
{"Row" : 122, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLECYSTITIS", "Text" : "Cholecystitis", "Header" : 0}, 
{"Row" : 123, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL CITROBACTER SPP.", "Text" : "Citrobacter infections, general", "Header" : 0}, 
{"Row" : 124, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Clostridium difficile suspected, sepsis", "Header" : 0}, 
{"Row" : 125, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "Text" : "Clostridium difficile, mild to moderate disease", "Header" : 0}, 
{"Row" : 126, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXI MEGACOLON", "Text" : "Clostridium difficile, severe/life-threatening disease", "Header" : 0}, 
{"Row" : 127, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI CLOSTRIDIUM SPP.", "Text" : "Clostridium infections, general", "Header" : 0}, 
{"Row" : 128, "Column" : 1, "Item" : "ORZID2 GMENU ABX POSITIVE BLOOD CULTURE COAG NEG STAPH", "Text" : "Coagulase negative staphylococci, single blood culture positive", "Header" : 0}, 
{"Row" : 129, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH", "Text" : "Coagulase-negative Staphylococci (CNS) bacteremia", "Header" : 0}, 
{"Row" : 130, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FIN COAG-NEG STAPH", "Text" : "Coagulase-negative staphylococci, general", "Header" : 0}, 
{"Row" : 131, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH COAG-NEG STAPH", "Text" : "Coagulase-negative staphylococci, intravascular catheter-associated infectio", "Header" : 0}, 
{"Row" : 132, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI COCCIDIOIDOMYCES", "Text" : "Coccidioides infections, general", "Header" : 0}, 
{"Row" : 133, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV COLITIS OR ESOPHAGITIS", "Text" : "Colitis, cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 134, "Column" : 1, "Item" : "ORZID2 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR", "Text" : "Colonized respiratory tract patient on a ventilator", "Header" : 0}, 
{"Row" : 135, "Column" : 1, "Item" : "ORZID2 GMENU ABX COLONIZED WOUNDS", "Text" : "Colonized wound", "Header" : 0}, 
{"Row" : 136, "Column" : 1, "Item" : "ORZID2 GMENU COMM ACQ DIARRHEA", "Text" : "Community-acquired diarrhea", "Header" : 0}, 
{"Row" : 137, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "Text" : "Community-acquired pneumonia (CAP)", "Header" : 0}, 
{"Row" : 138, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "Text" : "Community-acquired pneumonia (CAP), inpatient treatment setting", "Header" : 0}, 
{"Row" : 139, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM COMP DEFICIENCY", "Text" : "Complement deficiency", "Header" : 0}, 
{"Row" : 140, "Column" : 1, "Item" : "ORZID2 GMENU ABX COMP CYSTITIS", "Text" : "Complicated cystitis", "Header" : 0}, 
{"Row" : 141, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT REQUIRED MAIN", "Text" : "Conditions not benefitted by antimicrobials", "Header" : 0}, 
{"Row" : 142, "Column" : 1, "Item" : "ORZID2 GMENU CONJUNCTIVITIS", "Text" : "Conjunctivitis", "Header" : 0}, 
{"Row" : 143, "Column" : 1, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Contact CDSS staff", "Header" : 0}, 
{"Row" : 144, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT", "Text" : "Contiguous or hematogenous spread brain abscess", "Header" : 0}, 
{"Row" : 145, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "Text" : "COPD exacerbation", "Header" : 0}, 
{"Row" : 146, "Column" : 1, "Item" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "Text" : "COPD, prevention of exacerbations", "Header" : 0}, 
{"Row" : 147, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI CORYNEBACTERIUM SPP.", "Text" : "Corynebacterium spp.", "Header" : 0}, 
{"Row" : 148, "Column" : 1, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Crabs", "Header" : 0}, 
{"Row" : 149, "Column" : 1, "Item" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS", "Text" : "Cranial epidural abscess", "Header" : 0}, 
{"Row" : 150, "Column" : 1, "Item" : "ORZID2 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "Text" : "Cryptococcus neoformans", "Header" : 0}, 
{"Row" : 151, "Column" : 1, "Item" : "ORZID2 GMENU ABX CRYPTOSPORIDIA", "Text" : "Cryptosporidium parvum diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 152, "Column" : 1, "Item" : "ORZID2 GMENU ABX CYCLOSPORA", "Text" : "Cyclospora cayetanensis diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 153, "Column" : 1, "Item" : "ORZID2 GMENU ABX COMP CYSTITIS", "Text" : "Cystitis, complicated", "Header" : 0}, 
{"Row" : 154, "Column" : 1, "Item" : "ORZID2 GMENU ABX UNCOMP CYSTITIS", "Text" : "Cystitis, uncomplicated", "Header" : 0}, 
{"Row" : 155, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV MAIN PAGE", "Text" : "Cytomegalovirus (CMV) [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 160, "Column" : 1, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Decolonization of Staphylococcus aureus", "Header" : 0}, 
{"Row" : 161, "Column" : 1, "Item" : "ORZID2 GMENU DECUBITUS ULCERS", "Text" : "Decubitus ulcers", "Header" : 0}, 
{"Row" : 162, "Column" : 1, "Item" : "ORZID2 GMENU DEEP OROPHAR INFECT", "Text" : "Deep oropharyngeal infections", "Header" : 0}, 
{"Row" : 163, "Column" : 1, "Item" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Dental infections", "Header" : 0}, 
{"Row" : 164, "Column" : 1, "Item" : "ORZID2 GMENU ABX STASIS DERMATITIS", "Text" : "Dermatitis, stasis", "Header" : 0}, 
{"Row" : 165, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatological surgery guidelines", "Header" : 0}, 
{"Row" : 166, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGY MAIN", "Text" : "Dermatological Infections section", "Header" : 0}, 
{"Row" : 167, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatology post-op infection", "Header" : 0}, 
{"Row" : 168, "Column" : 1, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "Text" : "Desensitization protocol, penicillin", "Header" : 0}, 
{"Row" : 169, "Column" : 1, "Item" : "ORZID2 GMENU ABX DEVICE-RELATED INFECTIONS", "Text" : "Device-related infections", "Header" : 0}, 
{"Row" : 170, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS", "Text" : "Diabetes Mellitus", "Header" : 0}, 
{"Row" : 171, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "Text" : "Diabetic foot ulcer", "Header" : 0}, 
{"Row" : 172, "Column" : 1, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "Text" : "Diarrhea, infectious/gastroenteritis", "Header" : 0}, 
{"Row" : 173, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Diphtheria vaccination", "Header" : 0}, 
{"Row" : 174, "Column" : 1, "Item" : "ORZID2 GMENU ABX EXCLUSIONS", "Text" : "Diseases and Syndromes not covered", "Header" : 0}, 
{"Row" : 175, "Column" : 1, "Item" : "ORZID2 GMENU VERTEBRAL (DISKITIS) OSTEOM", "Text" : "Diskitis and vertebral osteomyelitis", "Header" : 0}, 
{"Row" : 176, "Column" : 1, "Item" : "ORZID2 GMENU DISSEMINATED M. AVIUM", "Text" : "Disseminated Mycobacterium avium", "Header" : 0}, 
{"Row" : 177, "Column" : 1, "Item" : "ORZID2 GMENU ABX DIVERTICULITIS", "Text" : "Diverticulitis", "Header" : 0}, 
{"Row" : 178, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "Text" : "Drug allergy information", "Header" : 0}, 
{"Row" : 179, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "Drug Information", "Header" : 0}, 
{"Row" : 180, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "Text" : "Drug properties, important", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "INPATIENT ANTIMICROIBAL CDSS INDEX",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "A through F",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "A______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "antimicrobial prophylaxis, management of fever,",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "patient initiated antibiotics, vaccines",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "B______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "C______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "antimicrobial prophylaxis, neutropenic fever",  "Header" : 0}, 
{"Row" : 156, "Column" : 1, "Item" : null, "Text" : "colitis, esophagitis, encephalitis, polyradiculopathy",  "Header" : 0}, 
{"Row" : 157, "Column" : 1, "Item" : null, "Text" : "retinitis, and pneumonia",  "Header" : 0}, 
{"Row" : 159, "Column" : 1, "Item" : null, "Text" : "D______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 183, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEAD AND NECK", "Text" : "Ear, nose, throat (ENT)/Head and Neck section", "Header" : 0}, 
{"Row" : 184, "Column" : 1, "Item" : "ORZID2 GMENU ECTHYMA GANGRENOSUM", "Text" : "Ecthyma gangrenosum", "Header" : 0}, 
{"Row" : 185, "Column" : 1, "Item" : "ORZID2 GMENU EHRLICHIA CHAFFEENSIS", "Text" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Header" : 0}, 
{"Row" : 186, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS EIKENELLA CORRODENS", "Text" : "Eikenella corrodens, bite wound", "Header" : 0}, 
{"Row" : 187, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Eikenella native valve endocarditis", "Header" : 0}, 
{"Row" : 188, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Eikenella prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 189, "Column" : 1, "Item" : "ORZID2 GMENU ABX EMPYEMA", "Text" : "Empyema", "Header" : 0}, 
{"Row" : 190, "Column" : 1, "Item" : "ORZID2 GMENU SUBDURAL EMPYEMA", "Text" : "Empyema, subdural", "Header" : 0}, 
{"Row" : 191, "Column" : 1, "Item" : "ORZID2 GMENU ABX HSV ENCEPHALITIS", "Text" : "Encephalitis", "Header" : 0}, 
{"Row" : 192, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV ENCEPHALITIS", "Text" : "Encephalitis, Cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 193, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Endocarditis with sepsis", "Header" : 0}, 
{"Row" : 194, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPRO TO ENDOCARDITIS", "Text" : "Endocarditis, approach to", "Header" : 0}, 
{"Row" : 195, "Column" : 1, "Item" : "ORZID2 GMENU ABX DIAGNOSIS OF ENDOCARDITIS", "Text" : "Endocarditis, diagnosis of", "Header" : 0}, 
{"Row" : 196, "Column" : 1, "Item" : "ORZID2 GMENU EC NV SEL PATH", "Text" : "Endocarditis, native valve [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 200, "Column" : 1, "Item" : "ORZID2 GMENU EC NV EMP THERA", "Text" : "Endocarditis, native valve empirical therapy", "Header" : 0}, 
{"Row" : 201, "Column" : 1, "Item" : "ORZID2 GMENU EC PV SEL PATH", "Text" : "Endocarditis, prosthetic valve [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 205, "Column" : 1, "Item" : "ORZID2 GMENU EC PV EMP THERAPY", "Text" : "Endocarditis, prosthetic valve empirical therapy", "Header" : 0}, 
{"Row" : 206, "Column" : 1, "Item" : "ORZID2 GMENU ENDOOPTHALMITIS", "Text" : "Endophthalmitis", "Header" : 0}, 
{"Row" : 207, "Column" : 1, "Item" : "ORZID2 GMENU ABX ENTAMOEBA HISTOLYTICA", "Text" : "Entamoeba histolytica diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 208, "Column" : 1, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "Text" : "Enteric fever", "Header" : 0}, 
{"Row" : 209, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN ENTEROBACTER SPP.", "Text" : "Enterobacter species, general", "Header" : 0}, 
{"Row" : 210, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL ESBL ENTEROBACT", "Text" : "Enterobacteriaceae (ESBL+) nosocomial pneumonia", "Header" : 0}, 
{"Row" : 211, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI ENTEROCOCCI", "Text" : "Enterococcal infections, general", "Header" : 0}, 
{"Row" : 212, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH ENTEROCOCCUS", "Text" : "Enterococcal intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 213, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH ENTEROCOCCI", "Text" : "Enterococcal native joint infection", "Header" : 0}, 
{"Row" : 214, "Column" : 1, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "Text" : "Enterococcal native valve endocarditis", "Header" : 0}, 
{"Row" : 215, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J ENTEROCOCCI", "Text" : "Enterococcal prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 216, "Column" : 1, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "Text" : "Enterococcal prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 217, "Column" : 1, "Item" : "ORZID2 GMENU ABX PYELO SPECIFIC PATHOGENS", "Text" : "Enterococcal pyelonephritis", "Header" : 0}, 
{"Row" : 218, "Column" : 1, "Item" : "ORZID2 GMENU ABX EPIDIDYMITIS", "Text" : "Epididymitis", "Header" : 0}, 
{"Row" : 219, "Column" : 1, "Item" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS", "Text" : "Epidural abscess, cranial", "Header" : 0}, 
{"Row" : 220, "Column" : 1, "Item" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS", "Text" : "Epidural abscess, spinal", "Header" : 0}, 
{"Row" : 221, "Column" : 1, "Item" : "ORZID2 GMENU ABX EPIGLOTTITIS", "Text" : "Epiglottitis", "Header" : 0}, 
{"Row" : 222, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELAS", "Text" : "Erysipelas", "Header" : 0}, 
{"Row" : 223, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELOID", "Text" : "Erysipeloid", "Header" : 0}, 
{"Row" : 224, "Column" : 1, "Item" : "ORZID2 GMENU LYME ERYTHEMA MIGRANS", "Text" : "Erythema migrans, Lyme disease", "Header" : 0}, 
{"Row" : 225, "Column" : 1, "Item" : "ORZID2 GMENU ERYTHRASMA", "Text" : "Erythrasma", "Header" : 0}, 
{"Row" : 226, "Column" : 1, "Item" : "ORZID2 GMENU ABX E COLI INFECT", "Text" : "Escherichia coli diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 227, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FINAL ESCHERICHIA COLI", "Text" : "Escherichia coli infections, general", "Header" : 0}, 
{"Row" : 228, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "Text" : "Escherichia coli meningitis", "Header" : 0}, 
{"Row" : 229, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESOPHAGITIS", "Text" : "Esophagitis", "Header" : 0}, 
{"Row" : 230, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "Text" : "Exacerbation of COPD", "Header" : 0}, 
{"Row" : 231, "Column" : 1, "Item" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "Text" : "Exacerbations of COPD, prevention of", "Header" : 0}, 
{"Row" : 234, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA 2021-2022", "Text" : "Flu", "Header" : 0}, 
{"Row" : 235, "Column" : 1, "Item" : "ORZID2 GMENU FOLLICULITIS", "Text" : "Folliculitis", "Header" : 0}, 
{"Row" : 236, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "Text" : "Foot ulcer in patient with diabetes", "Header" : 0}, 
{"Row" : 237, "Column" : 1, "Item" : "ORZID2 GMENU EC FUNGI", "Text" : "Fungal native valve endocarditis", "Header" : 0}, 
{"Row" : 238, "Column" : 1, "Item" : "ORZID2 GMENU EC FUNGI", "Text" : "Fungal prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 239, "Column" : 1, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "Text" : "Fungal sinusitis", "Header" : 0}, 
{"Row" : 240, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "Text" : "Fungemia associated with Candida spp.", "Header" : 0}, 
{"Row" : 241, "Column" : 1, "Item" : "ORZID2 GMENU ABX FUNGUS", "Text" : "Fungi section", "Header" : 0}, 
{"Row" : 242, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Furuncles", "Header" : 0}, 
{"Row" : 182, "Column" : 1, "Item" : null, "Text" : "E______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 197, "Column" : 1, "Item" : null, "Text" : "culture negative, enterococci, fungi,",  "Header" : 0}, 
{"Row" : 198, "Column" : 1, "Item" : null, "Text" : "gram-negative bacilli, streptococci, staphylococci,",  "Header" : 0}, 
{"Row" : 199, "Column" : 1, "Item" : null, "Text" : "and HACEK bacteria",  "Header" : 0}, 
{"Row" : 202, "Column" : 1, "Item" : null, "Text" : "culture negative, enterococci, fungi,",  "Header" : 0}, 
{"Row" : 203, "Column" : 1, "Item" : null, "Text" : "gram-negative bacilli, Streptococcus bovis,",  "Header" : 0}, 
{"Row" : 204, "Column" : 1, "Item" : null, "Text" : "staphylococci, HACEK bacteria, and Viridans group streptococci",  "Header" : 0}, 
{"Row" : 233, "Column" : 1, "Item" : null, "Text" : "F______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 1, "Column" : 2, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Contact CDSS staff", "Header" : 0}, 
{"Row" : 2, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "Text" : "Gastroenteritis/infectious diarrhea", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU ABX GASTROINTESTINAL", "Text" : "Gastrointestinal and Intraabdominal section", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID2 GMENU ABX GENITAL HERPES", "Text" : "Genital herpes", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU ABX GENITOURINARY", "Text" : "Genitourinary section", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU ABX GIARDIA", "Text" : "Giardia lamblia diarrhea", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU ABX GIARDIA", "Text" : "Giardia lamblia infections, general", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "Text" : "Gonococcal urethritis", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GNB", "Text" : "Gram-negative bacilli bacteremia", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU GN INT RS GNB", "Text" : "Gram-negative bacilli interim culture results", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU INTRAVAS CATH GNB", "Text" : "Gram-negative bacilli intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GNB", "Text" : "Gram-negative bacilli meningitis", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU EC GNB", "Text" : "Gram-negative bacilli, non-HACEK, native valve endocarditis", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU EC GNB", "Text" : "Gram-negative bacilli, non-HACEK, prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU OSTEOM WITH GNB", "Text" : "Gram-negative bacilli, non-pseudomonas, osteomyelitis", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU PROS B/J GNB", "Text" : "Gram-negative bacilli, non-pseudomonas, prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTH GNB", "Text" : "Gram-negative bacilli, non-pseudomonas, native joint infection", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU GRAM NEGATIVE BACTERIA", "Text" : "Gram-Negative Bacteria section", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GNC", "Text" : "Gram-negative cocci bacteremia", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU GN INT RS GNC", "Text" : "Gram-negative cocci interim culture results", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING", "Text" : "Gram-negative diplococci meningitis", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPR", "Text" : "Gram-positive bacilli bacteremia", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "Text" : "Gram-positive bacilli meningitis", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPR", "Text" : "Gram-positive bacilli, interim culture results", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "ORZID2 GMENU GRAM POS BACTERIA", "Text" : "Gram-positive bacteria, section", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS", "Text" : "Gram-positive cocci in pairs and chains bacteremia", "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS", "Text" : "Gram-positive cocci in pairs and clusters bacteremia", "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "Text" : "Gram-positive cocci in pairs bacteremia", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "Text" : "Gram-positive cocci in pairs interim culture results", "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI", "Text" : "Gram-positive cocci, anaerobic", "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "Text" : "Gram-positive coccobacilli meningitis", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO", "Text" : "Gram-positive diplococci meningitis", "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN S. PYOGENES", "Text" : "Group A streptococci", "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FINAL S. AGALACTIAE", "Text" : "Group B Streptococci", "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN S. BOVIS", "Text" : "Group D Streptococci", "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN STREP C,F,G", "Text" : "Groups C, F, G Streptococci", "Header" : 0}, 
{"Row" : 44, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "HACEK bacteria native valve endocarditis", "Header" : 0}, 
{"Row" : 45, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "HACEK bacteria prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 46, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL HAEMOPHILUS SPP.", "Text" : "Haemophilus infections, general", "Header" : 0}, 
{"Row" : 47, "Column" : 2, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae B vaccination", "Header" : 0}, 
{"Row" : 48, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Haemophilus native valve endocarditis", "Header" : 0}, 
{"Row" : 49, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Haemophilus prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 50, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEAD AND NECK", "Text" : "Head and Neck/ENT section", "Header" : 0}, 
{"Row" : 51, "Column" : 2, "Item" : "ORZID2 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "Text" : "Head lice", "Header" : 0}, 
{"Row" : 52, "Column" : 2, "Item" : "ORZID2 GMENU H. PYLORI INFECT", "Text" : "Helicobacter pylori", "Header" : 0}, 
{"Row" : 53, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help", "Header" : 0}, 
{"Row" : 54, "Column" : 2, "Item" : "ORZID2 GMENU BED BUGS (HEMIPTERA)", "Text" : "Hemiptera", "Header" : 0}, 
{"Row" : 55, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Hemodialysis immunizations", "Header" : 0}, 
{"Row" : 56, "Column" : 2, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Hepatic abscess", "Header" : 0}, 
{"Row" : 57, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "Text" : "Hepatic disease immunizations", "Header" : 0}, 
{"Row" : 58, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS A", "Text" : "Hepatitis A", "Header" : 0}, 
{"Row" : 59, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A vaccination", "Header" : 0}, 
{"Row" : 60, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A/Hepatitis B vaccination", "Header" : 0}, 
{"Row" : 61, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "Text" : "Hepatitis B", "Header" : 0}, 
{"Row" : 62, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B vaccination", "Header" : 0}, 
{"Row" : 63, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS C", "Text" : "Hepatitis C", "Header" : 0}, 
{"Row" : 64, "Column" : 2, "Item" : "ORZID2 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "Text" : "Herpes esophagitis", "Header" : 0}, 
{"Row" : 65, "Column" : 2, "Item" : "ORZID2 GMENU ABX HERPES KERATITIS", "Text" : "Herpes keratitis", "Header" : 0}, 
{"Row" : 66, "Column" : 2, "Item" : "ORZID2 GMENU RETINITIS", "Text" : "Herpes retinitis", "Header" : 0}, 
{"Row" : 67, "Column" : 2, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "Text" : "Herpes whitlow (digit or hand cellulitis)", "Header" : 0}, 
{"Row" : 68, "Column" : 2, "Item" : "ORZID2 GMENU ABX GENITAL HERPES", "Text" : "Herpes, genital", "Header" : 0}, 
{"Row" : 69, "Column" : 2, "Item" : "ORZID2 GMENU ABX OROLABIAL HERPES", "Text" : "Herpes, orolabial", "Header" : 0}, 
{"Row" : 70, "Column" : 2, "Item" : "ORZID2 GMENU HIDRADENITIS SUPPURATIVA", "Text" : "Hidradenitis suppurativa", "Header" : 0}, 
{"Row" : 71, "Column" : 2, "Item" : "ORZID2 GMENU FUNGI HISTOPLASMA CAPSULATUM", "Text" : "Histoplasma capsulatum", "Header" : 0}, 
{"Row" : 72, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "Text" : "HIV patient immunization", "Header" : 0}, 
{"Row" : 73, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "HIV infection, general", "Header" : 0}, 
{"Row" : 74, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "Text" : "Home IV therapy at MVAMC", "Header" : 0}, 
{"Row" : 75, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "Text" : "Hospital-acquired pneumonia (HAP)", "Header" : 0}, 
{"Row" : 76, "Column" : 2, "Item" : "ORZ GMENU BONE MARROW MAIN", "Text" : "HSCT immunizations", "Header" : 0}, 
{"Row" : 77, "Column" : 2, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papilloma virus vaccination", "Header" : 0}, 
{"Row" : 78, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA", "Text" : "Hypochlorhydria", "Header" : 0}, 
{"Row" : 81, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "Text" : "Immunization of immunocompromised patients (except HIV)", "Header" : 0}, 
{"Row" : 82, "Column" : 2, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "Text" : "Immunization of patients at high-risk of rabies exposure", "Header" : 0}, 
{"Row" : 83, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Immunization of patients in kidney failure/HD", "Header" : 0}, 
{"Row" : 84, "Column" : 2, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Immunization of patients with asplenia", "Header" : 0}, 
{"Row" : 85, "Column" : 2, "Item" : "ORZ GMENU BONE MARROW MAIN", "Text" : "Immunization of patients with bone marrow transplant", "Header" : 0}, 
{"Row" : 86, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "Text" : "Immunization of patients with chronic liver disease", "Header" : 0}, 
{"Row" : 87, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "Text" : "Immunization of patients with HIV", "Header" : 0}, 
{"Row" : 88, "Column" : 2, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Immunization of patients with pregnancy", "Header" : 0}, 
{"Row" : 89, "Column" : 2, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "Text" : "Immunization, adult [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 94, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS", "Text" : "Immunocompromised patients basic concepts", "Header" : 0}, 
{"Row" : 95, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMMUNOCOMPROMISED PATIENT", "Text" : "Immunocompromised Patients section", "Header" : 0}, 
{"Row" : 96, "Column" : 2, "Item" : "ORZID2 GMENU IG HIS DEFICIENCY", "Text" : "Immunoglobulin (Humoral immune system) deficiency", "Header" : 0}, 
{"Row" : 97, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMPETIGO", "Text" : "Impetigo", "Header" : 0}, 
{"Row" : 98, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "Text" : "Important drug properties", "Header" : 0}, 
{"Row" : 99, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "Text" : "Infection control department information", "Header" : 0}, 
{"Row" : 100, "Column" : 2, "Item" : "ORZID2 GMENU ABX PREVENTION OF INFECTION", "Text" : "Infection Prevention section", "Header" : 0}, 
{"Row" : 101, "Column" : 2, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "Text" : "Infectious diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 102, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFLUENZA 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 103, "Column" : 2, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 104, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "Text" : "Intravenous therapy at home, MVAMC", "Header" : 0}, 
{"Row" : 105, "Column" : 2, "Item" : "ORZID2 GMENU ABX ISOSPORA", "Text" : "Isospora diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 108, "Column" : 2, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "Text" : "Joint and Bone section", "Header" : 0}, 
{"Row" : 109, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Text" : "Joint infection, native [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 113, "Column" : 2, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "Text" : "Joint infection, prosthetic [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 119, "Column" : 2, "Item" : "ORZID2 GMENU KERATITIS", "Text" : "Keratitis", "Header" : 0}, 
{"Row" : 120, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Kidney failure immunizations", "Header" : 0}, 
{"Row" : 121, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Kingella native valve endocarditis", "Header" : 0}, 
{"Row" : 122, "Column" : 2, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "Kingella prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 123, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL KLEBSIELLA SPP.", "Text" : "Klebsiella infections, general", "Header" : 0}, 
{"Row" : 126, "Column" : 2, "Item" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT", "Text" : "Large uniform bacilli, aerobic bottle", "Header" : 0}, 
{"Row" : 127, "Column" : 2, "Item" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT", "Text" : "Large uniform bacilli, anaerobic bottle", "Header" : 0}, 
{"Row" : 128, "Column" : 2, "Item" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP", "Text" : "Laryngitis", "Header" : 0}, 
{"Row" : 129, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL LEGIONELLA SPP.", "Text" : "Legionella infections, general", "Header" : 0}, 
{"Row" : 130, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL L. PNEUMOPHILA", "Text" : "Legionella pneumophila nosocomial pneumonia", "Header" : 0}, 
{"Row" : 131, "Column" : 2, "Item" : "ORZID2 GMENU LEISHMANIASIS", "Text" : "Leishmaniasis", "Header" : 0}, 
{"Row" : 132, "Column" : 2, "Item" : "ORZID2 GMENU LEUKOCYTOSIS", "Text" : "Leukocytosis", "Header" : 0}, 
{"Row" : 133, "Column" : 2, "Item" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Text" : "Lice, body", "Header" : 0}, 
{"Row" : 134, "Column" : 2, "Item" : "ORZID2 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "Text" : "Lice, head", "Header" : 0}, 
{"Row" : 135, "Column" : 2, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Lice, pubic", "Header" : 0}, 
{"Row" : 136, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI LISTERIA SPP.", "Text" : "Listeria infections, general", "Header" : 0}, 
{"Row" : 137, "Column" : 2, "Item" : "ORZID2 GMENU BACTEREMIA LISTERIA", "Text" : "Listeria monocytogenes bacteremia", "Header" : 0}, 
{"Row" : 138, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES", "Text" : "Listeria monocytogenes meningitis", "Header" : 0}, 
{"Row" : 139, "Column" : 2, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Liver abscess", "Header" : 0}, 
{"Row" : 140, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "Text" : "Liver disease immunizations", "Header" : 0}, 
{"Row" : 141, "Column" : 2, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "Text" : "Liver disease, prevention of spontaneous bacterial peritonitis", "Header" : 0}, 
{"Row" : 142, "Column" : 2, "Item" : "ORZID2 GMENU ABX LUNG ABSCESS", "Text" : "Lung abscess", "Header" : 0}, 
{"Row" : 143, "Column" : 2, "Item" : "ORZID2 GMENU ABX LUNG AND MEDIASTINUM", "Text" : "Lungs and Mediastinum section", "Header" : 0}, 
{"Row" : 144, "Column" : 2, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "Text" : "Lyme disease [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 149, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM MALIGNANCY", "Text" : "Malignancy [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 151, "Column" : 2, "Item" : "ORZID2 GMENU MALIGNANT OTITIS EXTERNA", "Text" : "Malignant otitis externa", "Header" : 0}, 
{"Row" : 152, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION", "Text" : "Malnutrition", "Header" : 0}, 
{"Row" : 153, "Column" : 2, "Item" : "ORZID2 GMENU MASTOIDITIS", "Text" : "Mastoiditis", "Header" : 0}, 
{"Row" : 154, "Column" : 2, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles vaccination", "Header" : 0}, 
{"Row" : 155, "Column" : 2, "Item" : "ORZID2 GMENU ABX MEDIASTINITIS", "Text" : "Mediastinitis", "Header" : 0}, 
{"Row" : 156, "Column" : 2, "Item" : "ORZID2 GMENU ABX LUNG AND MEDIASTINUM", "Text" : "Mediastinum and Lung section", "Header" : 0}, 
{"Row" : 157, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA", "Text" : "Meningitis associated with trauma or nosocomial infection", "Header" : 0}, 
{"Row" : 158, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "Text" : "Meningitis with E. coli, Pseudomonas or other organism", "Header" : 0}, 
{"Row" : 159, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "Text" : "Meningitis with Escherichia coli", "Header" : 0}, 
{"Row" : 160, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GNB", "Text" : "Meningitis with gram-negative bacilli", "Header" : 0}, 
{"Row" : 161, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING", "Text" : "Meningitis with gram-negative diplococci", "Header" : 0}, 
{"Row" : 162, "Column" : 2, "Item" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "Text" : "Meningitis with gram-positive bacilli/coccobacilli", "Header" : 0}, 
{"Row" : 163, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO", "Text" : "Meningitis with gram-positive diplococci", "Header" : 0}, 
{"Row" : 164, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES", "Text" : "Meningitis with Listeria monocytogenes", "Header" : 0}, 
{"Row" : 165, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS", "Text" : "Meningitis with Neisseria meningitidis", "Header" : 0}, 
{"Row" : 166, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "Text" : "Meningitis with pseudomonas", "Header" : 0}, 
{"Row" : 167, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Meningitis with sepsis", "Header" : 0}, 
{"Row" : 168, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "Text" : "Meningitis with Streptococcus pneumoniae", "Header" : 0}, 
{"Row" : 169, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING W/O GRM STAIN RES", "Text" : "Meningitis without gram stain results", "Header" : 0}, 
{"Row" : 170, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "Text" : "Meningitis, other organism", "Header" : 0}, 
{"Row" : 171, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal conjugate (MENACWY) vaccination", "Header" : 0}, 
{"Row" : 172, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MENB) vaccination", "Header" : 0}, 
{"Row" : 173, "Column" : 2, "Item" : "ORZID2 GMENU BITE WNDS S. AUREUS", "Text" : "Methicillin-resistant Staphylococcus aureus bite wounds", "Header" : 0}, 
{"Row" : 174, "Column" : 2, "Item" : "ORZID2 GMENU ABX MICROSPORIDIA", "Text" : "Microsporidia diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 175, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN M. CATARRHALIS", "Text" : "Moraxella catarrhalis infections, general", "Header" : 0}, 
{"Row" : 176, "Column" : 2, "Item" : "ORZID2 GMENU BITE WNDS S. AUREUS", "Text" : "MRSA bite wounds", "Header" : 0}, 
{"Row" : 177, "Column" : 2, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "MRSA risk factors", "Header" : 0}, 
{"Row" : 178, "Column" : 2, "Item" : "ORZID2 GMENU BITE WNDS S. AUREUS", "Text" : "MSSA bite wounds", "Header" : 0}, 
{"Row" : 179, "Column" : 2, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Mumps vaccination", "Header" : 0}, 
{"Row" : 180, "Column" : 2, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "Text" : "Muscle and Soft Tissue section", "Header" : 0}, 
{"Row" : 181, "Column" : 2, "Item" : "ORZID2 GMENU M. AVIUM INTRACELLULARE", "Text" : "Mycobacterium avium intracellular complex (MAI or MAC)", "Header" : 0}, 
{"Row" : 182, "Column" : 2, "Item" : "ORZID2 GMENU M. AVIUM PNEUMONIA", "Text" : "Mycobacterium avium pneumonia", "Header" : 0}, 
{"Row" : 183, "Column" : 2, "Item" : "ORZID2 GMENU PROPHYLAXIS M. AVIUM", "Text" : "Mycobacterium avium prophylaxis", "Header" : 0}, 
{"Row" : 184, "Column" : 2, "Item" : "ORZID2 GMENU DISSEMINATED M. AVIUM", "Text" : "Mycobacterium avium, disseminated", "Header" : 0}, 
{"Row" : 185, "Column" : 2, "Item" : "ORZID2 GMENU M. TUBERCULOSIS", "Text" : "Mycobacterium tuberculosis", "Header" : 0}, 
{"Row" : 186, "Column" : 2, "Item" : "ORZID2 GMENU M. PNEUMONIAE", "Text" : "Mycoplasma pneumonia infections, general", "Header" : 0}, 
{"Row" : 187, "Column" : 2, "Item" : "ORZID2 GMENU ABX MYOCARDITIS", "Text" : "Myocarditis", "Header" : 0}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "G through Pn",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "G______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 43, "Column" : 2, "Item" : null, "Text" : "H______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 80, "Column" : 2, "Item" : null, "Text" : "I______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 90, "Column" : 2, "Item" : null, "Text" : "diphtheria, Haemophilus influenza B, Hepatitis A and B,",  "Header" : 0}, 
{"Row" : 91, "Column" : 2, "Item" : null, "Text" : "human papilloma virus, influenza, measles, mumps,",  "Header" : 0}, 
{"Row" : 92, "Column" : 2, "Item" : null, "Text" : "meningococcal, pneumococcal, pertussis, rubella,",  "Header" : 0}, 
{"Row" : 93, "Column" : 2, "Item" : null, "Text" : "tetanus, varicella, zoster",  "Header" : 0}, 
{"Row" : 107, "Column" : 2, "Item" : null, "Text" : "J______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 110, "Column" : 2, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 111, "Column" : 2, "Item" : null, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,",  "Header" : 0}, 
{"Row" : 112, "Column" : 2, "Item" : null, "Text" : "Staphylococcus aureus, streptococcus",  "Header" : 0}, 
{"Row" : 114, "Column" : 2, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 115, "Column" : 2, "Item" : null, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 116, "Column" : 2, "Item" : null, "Text" : "and streptococcus",  "Header" : 0}, 
{"Row" : 118, "Column" : 2, "Item" : null, "Text" : "K______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 125, "Column" : 2, "Item" : null, "Text" : "L______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 145, "Column" : 2, "Item" : null, "Text" : "arthritis, carditis, erythema migrans,",  "Header" : 0}, 
{"Row" : 146, "Column" : 2, "Item" : null, "Text" : "neurological complications, prophylaxis",  "Header" : 0}, 
{"Row" : 148, "Column" : 2, "Item" : null, "Text" : "M______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 150, "Column" : 2, "Item" : null, "Text" : "antimicrobial prophylaxis, neutropenic fever",  "Header" : 0}, 
{"Row" : 190, "Column" : 2, "Item" : "ORZID2 GMENU ABX NASAL PACKING", "Text" : "Nasal packing", "Header" : 0}, 
{"Row" : 191, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Text" : "Native joint infection [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 195, "Column" : 2, "Item" : "ORZID2 GMENU EC NV SEL PATH", "Text" : "Native valve endocarditis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 199, "Column" : 2, "Item" : "ORZID2 GMENU EC NV EMP THERA", "Text" : "Native valve endocarditis empirical therapy", "Header" : 0}, 
{"Row" : 200, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Native valve endocarditis with sepsis", "Header" : 0}, 
{"Row" : 201, "Column" : 2, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "Text" : "Necrotizing infections", "Header" : 0}, 
{"Row" : 202, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. GONORRHOEAE", "Text" : "Neisseria gonorrhoeae infections, general", "Header" : 0}, 
{"Row" : 203, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTH N. GONORRHOEAE", "Text" : "Neisseria gonorrhoeae native joint infection", "Header" : 0}, 
{"Row" : 204, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. MENINGITIDIS", "Text" : "Neisseria meningitidis infections, general", "Header" : 0}, 
{"Row" : 205, "Column" : 2, "Item" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS", "Text" : "Neisseria meningitidis meningitis", "Header" : 0}, 
{"Row" : 206, "Column" : 2, "Item" : "ORZID2 GMENU LYME ACUTE NEURO DISEASE", "Text" : "Neurological disease associated with Lyme disease", "Header" : 0}, 
{"Row" : 207, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUROL DYSFUNCTION", "Text" : "Neurological dysfunction", "Header" : 0}, 
{"Row" : 208, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA", "Text" : "Neutropenia", "Header" : 0}, 
{"Row" : 209, "Column" : 2, "Item" : "ORZID2 GMENU ABX TYPHLITIS", "Text" : "Neutropenic enterocolitis", "Header" : 0}, 
{"Row" : 210, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "Text" : "Neutropenic fever", "Header" : 0}, 
{"Row" : 211, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Neutropenic fever with sepsis", "Header" : 0}, 
{"Row" : 212, "Column" : 2, "Item" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP", "Text" : "Nocardia spp. brain abscess", "Header" : 0}, 
{"Row" : 213, "Column" : 2, "Item" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION", "Text" : "Non-perforated appendicitis", "Header" : 0}, 
{"Row" : 214, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "Text" : "Non-streptococcal pharyngitis", "Header" : 0}, 
{"Row" : 215, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "Text" : "Nosocomial pneumonia", "Header" : 0}, 
{"Row" : 216, "Column" : 2, "Item" : "ORZID2 GMENU NOSOCOMIAL SINUSITIS", "Text" : "Nosocomial sinusitis", "Header" : 0}, 
{"Row" : 219, "Column" : 2, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "Occupational post-exposure prophylaxis", "Header" : 0}, 
{"Row" : 220, "Column" : 2, "Item" : "ORZID2 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "Text" : "Onychomycosis", "Header" : 0}, 
{"Row" : 221, "Column" : 2, "Item" : "ORZID2 GMENU POSTSEPTAL CELLULITIS", "Text" : "Orbital cellulitis", "Header" : 0}, 
{"Row" : 222, "Column" : 2, "Item" : "ORZID2 GMENU ABX OROLABIAL HERPES", "Text" : "Orolabial herpes", "Header" : 0}, 
{"Row" : 223, "Column" : 2, "Item" : "ORZID2 GMENU DEEP OROPHAR INFECT", "Text" : "Oropharyngeal infections, deep", "Header" : 0}, 
{"Row" : 224, "Column" : 2, "Item" : "ORZID2 GMENU OSTEOMYELITIS", "Text" : "Osteomyelitis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 227, "Column" : 2, "Item" : "ORZID2 GMENU OTHER PATHOGENS", "Text" : "Other Pathogens section", "Header" : 0}, 
{"Row" : 228, "Column" : 2, "Item" : "ORZID2 GMENU OTITIS EXTERNA", "Text" : "Otitis externa", "Header" : 0}, 
{"Row" : 229, "Column" : 2, "Item" : "ORZID2 GMENU MALIGNANT OTITIS EXTERNA", "Text" : "Otitis externa, malignant", "Header" : 0}, 
{"Row" : 230, "Column" : 2, "Item" : "ORZID2 GMENU OTITIS MEDIA", "Text" : "Otitis media", "Header" : 0}, 
{"Row" : 233, "Column" : 2, "Item" : "ORZID2 GMENU ABX PANCREATITIS", "Text" : "Pancreatitis", "Header" : 0}, 
{"Row" : 234, "Column" : 2, "Item" : "ORZID2 GMENU ABX PARAINFLUENZA", "Text" : "Parainfluenza", "Header" : 0}, 
{"Row" : 235, "Column" : 2, "Item" : "ORZID2 GMENU PARASITES", "Text" : "Parasites", "Header" : 0}, 
{"Row" : 236, "Column" : 2, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "Text" : "Paratyphoid fever", "Header" : 0}, 
{"Row" : 237, "Column" : 2, "Item" : "ORZID2 GMENU PARONYCHIA", "Text" : "Paronychia", "Header" : 0}, 
{"Row" : 238, "Column" : 2, "Item" : "ORZID2 GMENU ABX PAROTITIS", "Text" : "Parotitis", "Header" : 0}, 
{"Row" : 239, "Column" : 2, "Item" : "ORZID2 GMENU BITE WNDS P. MULTOCIDA", "Text" : "Pasteurella multocida bite wounds", "Header" : 0}, 
{"Row" : 240, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN P. MULTICIDA", "Text" : "Pasteurella multocida infections, general", "Header" : 0}, 
{"Row" : 241, "Column" : 2, "Item" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Text" : "Pediculosis corporis", "Header" : 0}, 
{"Row" : 242, "Column" : 2, "Item" : "ORZID2 GMENU ABX PID", "Text" : "Pelvic inflammatory disease (PID)", "Header" : 0}, 
{"Row" : 243, "Column" : 2, "Item" : "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN", "Text" : "Pelvic pain syndrome/prostatitis, chronic", "Header" : 0}, 
{"Row" : 244, "Column" : 2, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "Text" : "Penicillin desensitization protocol", "Header" : 0}, 
{"Row" : 245, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI", "Text" : "Peptostreptococcus infections, general", "Header" : 0}, 
{"Row" : 246, "Column" : 2, "Item" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION", "Text" : "Perforated appendicitis", "Header" : 0}, 
{"Row" : 247, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal abscess", "Header" : 0}, 
{"Row" : 248, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERICARDITIS", "Text" : "Pericarditis", "Header" : 0}, 
{"Row" : 249, "Column" : 2, "Item" : "ORZID2 GMENU PERIOCULAR INFECTIONS", "Text" : "Periocular infections", "Header" : 0}, 
{"Row" : 250, "Column" : 2, "Item" : "ORZID2 GMENU PERIODENTAL DISEASE", "Text" : "Periodontal disease", "Header" : 0}, 
{"Row" : 251, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERI ASSOC W PERI DIAL", "Text" : "Peritoneal dialysis peritonitis", "Header" : 0}, 
{"Row" : 252, "Column" : 2, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "Text" : "Peritonitis, acute spontaneous bacterial", "Header" : 0}, 
{"Row" : 253, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERI ASSOC W PERI DIAL", "Text" : "Peritonitis, peritoneal dialysis associated", "Header" : 0}, 
{"Row" : 254, "Column" : 2, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "Text" : "Peritonitis, secondary", "Header" : 0}, 
{"Row" : 255, "Column" : 2, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "Text" : "Persistent or recurrent urethritis", "Header" : 0}, 
{"Row" : 256, "Column" : 2, "Item" : "ORZID2 GMENU ABX PERTUSSIS", "Text" : "Pertussis", "Header" : 0}, 
{"Row" : 257, "Column" : 2, "Item" : "ORZID2 GMENU PREV OF PERTUSSIS", "Text" : "Pertussis post-exposure prophylaxis", "Header" : 0}, 
{"Row" : 258, "Column" : 2, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Pertussis vaccination", "Header" : 0}, 
{"Row" : 259, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "Text" : "Pharyngitis, non-streptococcal", "Header" : 0}, 
{"Row" : 260, "Column" : 2, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "Text" : "Pharyngitis, streptococcal", "Header" : 0}, 
{"Row" : 261, "Column" : 2, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal vaccination", "Header" : 0}, 
{"Row" : 262, "Column" : 2, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "Pneumocystis", "Header" : 0}, 
{"Row" : 263, "Column" : 2, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "Pneumocystis prophylaxis", "Header" : 0}, 
{"Row" : 264, "Column" : 2, "Item" : "ORZID2 GMENU ABX PNEUMONIA", "Text" : "Pneumonia", "Header" : 0}, 
{"Row" : 265, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Pneumonia with sepsis", "Header" : 0}, 
{"Row" : 266, "Column" : 2, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "Text" : "Pneumonia, aspiration", "Header" : 0}, 
{"Row" : 267, "Column" : 2, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "Text" : "Pneumonia, community-acquired (CAP)", "Header" : 0}, 
{"Row" : 268, "Column" : 2, "Item" : "ORZID2 GMENU ABX CMV PNEUMONIA", "Text" : "Pneumonia, Cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 269, "Column" : 2, "Item" : "ORZID2 GMENU M. AVIUM PNEUMONIA", "Text" : "Pneumonia, Mycobacterium avium", "Header" : 0}, 
{"Row" : 270, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "Text" : "Pneumonia, nosocomial [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 189, "Column" : 2, "Item" : null, "Text" : "N______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 192, "Column" : 2, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 193, "Column" : 2, "Item" : null, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,",  "Header" : 0}, 
{"Row" : 194, "Column" : 2, "Item" : null, "Text" : "Staphylococcus aureus, streptococcus",  "Header" : 0}, 
{"Row" : 196, "Column" : 2, "Item" : null, "Text" : "culture negative, enterococci, fungi,",  "Header" : 0}, 
{"Row" : 197, "Column" : 2, "Item" : null, "Text" : "gram-negative bacilli, streptococci, staphylococci,",  "Header" : 0}, 
{"Row" : 198, "Column" : 2, "Item" : null, "Text" : "and HACEK bacteria",  "Header" : 0}, 
{"Row" : 218, "Column" : 2, "Item" : null, "Text" : "O______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 225, "Column" : 2, "Item" : null, "Text" : "empirical therapy, gram-negative bacilli, Pseudomonas aeruginosa,",  "Header" : 0}, 
{"Row" : 226, "Column" : 2, "Item" : null, "Text" : "Staphylococcus aureus, and streptococci",  "Header" : 0}, 
{"Row" : 232, "Column" : 2, "Item" : null, "Text" : "Pa-Pn__________________________________________________________________________",  "Header" : 1}, 
{"Row" : 271, "Column" : 2, "Item" : null, "Text" : "72 hour re-evaluation, Acinetobacter baumannii,",  "Header" : 0}, 
{"Row" : 272, "Column" : 2, "Item" : null, "Text" : "empirical therapy, Enterobacteriaceae, HAP, Legionella pneumophila,",  "Header" : 0}, 
{"Row" : 273, "Column" : 2, "Item" : null, "Text" : "Pseudomonas aeruginosa, Staphylococcus aeruginosa, and VAP",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "Drug Information", "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : "ORZID2 GMENU ABX CMV POLYRADICULOPATHY", "Text" : "Polyradiculopathy, Cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.", "Text" : "Porphyromonas infections, general", "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "Post-exposure prophylaxis, occupational", "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : "ORZID2 GMENU PREV OF PERTUSSIS", "Text" : "Post-exposure prophylaxis, pertussis", "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "Text" : "Post-operative antimicrobial prophylaxis", "Header" : 0}, 
{"Row" : 14, "Column" : 3, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Post-operative dermatology infection", "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "Text" : "Post-operative wound infection", "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : "ORZID2 GMENU POSTSEPTAL CELLULITIS", "Text" : "Postseptal cellulitis", "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC", "Text" : "Post-surgical or post-traumatic brain abscess", "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Pregnancy immunizations", "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "Text" : "Pregnancy risk factors for antimicrobials", "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "Text" : "Pre-operative antimicrobial prophylaxis", "Header" : 0}, 
{"Row" : 21, "Column" : 3, "Item" : "ORZID2 GMENU PRESEPTAL CELLULITIS", "Text" : "Preseptal cellulitis", "Header" : 0}, 
{"Row" : 22, "Column" : 3, "Item" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "Text" : "Prevention of COPD exacerbations", "Header" : 0}, 
{"Row" : 23, "Column" : 3, "Item" : "ORZID2 GMENU ABX PREVENTION OF INFECTION", "Text" : "Prevention of Infection section", "Header" : 0}, 
{"Row" : 24, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.", "Text" : "Prevotella infections, general", "Header" : 0}, 
{"Row" : 25, "Column" : 3, "Item" : "ORZID2 GMENU PREV INFECT BACT PROPHYL", "Text" : "Prophylactic antibiotics in malignancy", "Header" : 0}, 
{"Row" : 26, "Column" : 3, "Item" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL", "Text" : "Prophylactic antifungals in malignancy", "Header" : 0}, 
{"Row" : 27, "Column" : 3, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Prophylactic antimicrobials for asplenia", "Header" : 0}, 
{"Row" : 28, "Column" : 3, "Item" : "ORZID2 GMENU LYME DISEASE PROPHYLAXIS", "Text" : "Prophylactic antimicrobials for Lyme disease", "Header" : 0}, 
{"Row" : 29, "Column" : 3, "Item" : "ORZID2 GMENU PROPHYLAXIS M. AVIUM", "Text" : "Prophylactic antimicrobials for Mycobacterium avium", "Header" : 0}, 
{"Row" : 30, "Column" : 3, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "Prophylactic antimicrobials for occupational post-exposure", "Header" : 0}, 
{"Row" : 31, "Column" : 3, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "Prophylactic antimicrobials for Pneumocystis", "Header" : 0}, 
{"Row" : 32, "Column" : 3, "Item" : "ORZID2 GMENU PREV OF PERTUSSIS", "Text" : "Prophylactic antimicrobials for post-exposure pertussis", "Header" : 0}, 
{"Row" : 33, "Column" : 3, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "Text" : "Prophylactic antimicrobials for spontaneous bacterial peritonitis", "Header" : 0}, 
{"Row" : 34, "Column" : 3, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "Text" : "Prophylactic antimicrobials, post-operative", "Header" : 0}, 
{"Row" : 35, "Column" : 3, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "Text" : "Prophylactic antimicrobials, pre-operative", "Header" : 0}, 
{"Row" : 36, "Column" : 3, "Item" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Prophylactic antivirals in malignancy", "Header" : 0}, 
{"Row" : 39, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FI PROPIONIBACT SPP.", "Text" : "Propionibacterium infections, general", "Header" : 0}, 
{"Row" : 40, "Column" : 3, "Item" : "ORZID2 GMENU ABX ACUTE BACT PROSTATITIS", "Text" : "Prostatitis, acute", "Header" : 0}, 
{"Row" : 41, "Column" : 3, "Item" : "ORZID2 GMENU ABX CHRONIC BACT PROSTATITIS", "Text" : "Prostatitis, chronic", "Header" : 0}, 
{"Row" : 42, "Column" : 3, "Item" : "ORZID2 GMENU ABX CHRON PROS/PELVIC PAIN SYN", "Text" : "Prostatitis/pelvic pain syndrome, chronic", "Header" : 0}, 
{"Row" : 43, "Column" : 3, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "Text" : "Prosthetic bone/joint infection [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 47, "Column" : 3, "Item" : "ORZID2 GMENU EC PV SEL PATH", "Text" : "Prosthetic valve endocarditis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 51, "Column" : 3, "Item" : "ORZID2 GMENU EC PV EMP THERAPY", "Text" : "Prosthetic valve endocarditis empirical therapy", "Header" : 0}, 
{"Row" : 52, "Column" : 3, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Prosthetic valve endocarditis with sepsis", "Header" : 0}, 
{"Row" : 53, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FINAL PROTEUS SPP.", "Text" : "Proteus infections, general", "Header" : 0}, 
{"Row" : 54, "Column" : 3, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "Text" : "Protocol for Penicillin Desensitization", "Header" : 0}, 
{"Row" : 55, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC ARTH P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa native joint infection", "Header" : 0}, 
{"Row" : 56, "Column" : 3, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa nosocomial pneumonia", "Header" : 0}, 
{"Row" : 57, "Column" : 3, "Item" : "ORZID2 GMENU OSTEOM WITH P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa osteomyelitis", "Header" : 0}, 
{"Row" : 58, "Column" : 3, "Item" : "ORZID2 GMENU PROS B/J P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 59, "Column" : 3, "Item" : "ORZID2 GMENU ABX PYELO SPECIFIC PATHOGENS", "Text" : "Pseudomonas aeruginosa pyelonephritis", "Header" : 0}, 
{"Row" : 60, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN PSEUDOMONAS SPP.", "Text" : "Pseudomonas infections, general", "Header" : 0}, 
{"Row" : 61, "Column" : 3, "Item" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "Text" : "Pseudomonas meningitis", "Header" : 0}, 
{"Row" : 62, "Column" : 3, "Item" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.", "Text" : "Pseudomonas spp. brain abscess", "Header" : 0}, 
{"Row" : 63, "Column" : 3, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Pubic lice", "Header" : 0}, 
{"Row" : 64, "Column" : 3, "Item" : "ORZID2 GMENU ABX PYELONEPHRITIS", "Text" : "Pyelonephritis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 66, "Column" : 3, "Item" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Text" : "Pyogenic liver abscess", "Header" : 0}, 
{"Row" : 67, "Column" : 3, "Item" : "ORZID2 GMENU PYOMYOSITIS", "Text" : "Pyomyositis", "Header" : 0}, 
{"Row" : 68, "Column" : 3, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "Text" : "Pyuria", "Header" : 0}, 
{"Row" : 75, "Column" : 3, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "Text" : "Rabies vaccination", "Header" : 0}, 
{"Row" : 76, "Column" : 3, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "Text" : "Recurrent or persistent urethritis", "Header" : 0}, 
{"Row" : 77, "Column" : 3, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Renal failure immunizations", "Header" : 0}, 
{"Row" : 78, "Column" : 3, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "Resistant bacteria, more about", "Header" : 0}, 
{"Row" : 79, "Column" : 3, "Item" : "ORZID2 GMENU ABX RSV", "Text" : "Respiratory syncytial virus (RSV)", "Header" : 0}, 
{"Row" : 80, "Column" : 3, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "Text" : "Restrictions on antimicrobials", "Header" : 0}, 
{"Row" : 81, "Column" : 3, "Item" : "ORZID2 GMENU RETINITIS", "Text" : "Retinitis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 83, "Column" : 3, "Item" : "ORZID2 GMENU TINEA CAPITIS (RINGWORM)", "Text" : "Ringworm", "Header" : 0}, 
{"Row" : 84, "Column" : 3, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "Risk factors for MRSA", "Header" : 0}, 
{"Row" : 85, "Column" : 3, "Item" : "ORZID2 GMENU ROCKY MTN SPOT FEVER", "Text" : "Rocky mountain spotted fever", "Header" : 0}, 
{"Row" : 86, "Column" : 3, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Rubella vaccination", "Header" : 0}, 
{"Row" : 89, "Column" : 3, "Item" : "ORZID2 GMENU ABX SALMONELLA SPECIES", "Text" : "Salmonella diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 90, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN SALMONELLA SPP.", "Text" : "Salmonella infections, general", "Header" : 0}, 
{"Row" : 91, "Column" : 3, "Item" : "ORZID2 GMENU SCABIES", "Text" : "Scabies", "Header" : 0}, 
{"Row" : 92, "Column" : 3, "Item" : "ORZID2 GMENU STAPH SCALDED SYNDROME", "Text" : "Scalded skin syndrome", "Header" : 0}, 
{"Row" : 93, "Column" : 3, "Item" : "ORZID2 GMENU ABX INFLUENZA 2021-2022", "Text" : "Seasonal influenza", "Header" : 0}, 
{"Row" : 94, "Column" : 3, "Item" : "ORZID2 GMENU ABX SECOND PERITONITIS", "Text" : "Secondary peritonitis", "Header" : 0}, 
{"Row" : 95, "Column" : 3, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Sepsis and septic shock", "Header" : 0}, 
{"Row" : 96, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Text" : "Septic arthritis, native joint [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 100, "Column" : 3, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "Text" : "Septic arthritis, prosthetic joint [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 104, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC BURSITIS", "Text" : "Septic bursitis", "Header" : 0}, 
{"Row" : 105, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FINAL SERRATIA SPP.", "Text" : "Serratia infections, general", "Header" : 0}, 
{"Row" : 106, "Column" : 3, "Item" : "ORZID2 GMENU ABX VAGINITIS", "Text" : "Sexually transmitted infection, bacterial vaginitis", "Header" : 0}, 
{"Row" : 107, "Column" : 3, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "Text" : "Sexually transmitted infection, cervicitis", "Header" : 0}, 
{"Row" : 108, "Column" : 3, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "Text" : "Sexually transmitted infection, chlamydia cervicitis", "Header" : 0}, 
{"Row" : 109, "Column" : 3, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "Text" : "Sexually transmitted infection, chlamydia urethritis", "Header" : 0}, 
{"Row" : 110, "Column" : 3, "Item" : "ORZID2 GMENU ABX GENITAL HERPES", "Text" : "Sexually transmitted infection, genital warts", "Header" : 0}, 
{"Row" : 111, "Column" : 3, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "Text" : "Sexually transmitted infection, gonorrhea cervicitis", "Header" : 0}, 
{"Row" : 112, "Column" : 3, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "Text" : "Sexually transmitted infection, gonorrhea urethritis", "Header" : 0}, 
{"Row" : 113, "Column" : 3, "Item" : "ORZID2 GMENU ABX PID", "Text" : "Sexually transmitted infection, pelvic inflammatory disease", "Header" : 0}, 
{"Row" : 114, "Column" : 3, "Item" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Sexually transmitted infection, pubic lice (crabs)", "Header" : 0}, 
{"Row" : 115, "Column" : 3, "Item" : "ORZID2 GMENU ABX SYPHILIS", "Text" : "Sexually transmitted infection, syphilis", "Header" : 0}, 
{"Row" : 116, "Column" : 3, "Item" : "ORZID2 GMENU ABX TRICH VAGINITIS", "Text" : "Sexually transmitted infection, trichomoniasis", "Header" : 0}, 
{"Row" : 117, "Column" : 3, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "Text" : "Sexually transmitted infection, urethritis", "Header" : 0}, 
{"Row" : 118, "Column" : 3, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "Text" : "Shigella diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 119, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-NEG FIN SHIGELLA SPP.", "Text" : "Shigella infections, general", "Header" : 0}, 
{"Row" : 120, "Column" : 3, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "Text" : "Shingles", "Header" : 0}, 
{"Row" : 121, "Column" : 3, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Shingles vaccination", "Header" : 0}, 
{"Row" : 122, "Column" : 3, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Shortages of antimicrobials updates", "Header" : 0}, 
{"Row" : 123, "Column" : 3, "Item" : "ORZID2 GMENU ACUTE SINUSITIS", "Text" : "Sinusitis, acute", "Header" : 0}, 
{"Row" : 124, "Column" : 3, "Item" : "ORZID2 GMENU CHRONIC SINUSITIS", "Text" : "Sinusitis, chronic", "Header" : 0}, 
{"Row" : 125, "Column" : 3, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "Text" : "Sinusitis, fungal", "Header" : 0}, 
{"Row" : 126, "Column" : 3, "Item" : "ORZID2 GMENU NOSOCOMIAL SINUSITIS", "Text" : "Sinusitis, nosocomial", "Header" : 0}, 
{"Row" : 127, "Column" : 3, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Skin and soft tissue infection with sepsis", "Header" : 0}, 
{"Row" : 128, "Column" : 3, "Item" : "ORZID2 GMENU ABX DERMATOLOGY MAIN", "Text" : "Skin Infections section", "Header" : 0}, 
{"Row" : 129, "Column" : 3, "Item" : "ORZID2 GMENU INT SM RODS AEROBIC BOT", "Text" : "Small pleomorphic bacilli, aerobic bottle", "Header" : 0}, 
{"Row" : 130, "Column" : 3, "Item" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT", "Text" : "Small pleomorphic bacilli, anaerobic bottle", "Header" : 0}, 
{"Row" : 131, "Column" : 3, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "Text" : "Soft Tissue and Muscle section", "Header" : 0}, 
{"Row" : 132, "Column" : 3, "Item" : "ORZID2 GMENU INTRO SPEC PATHOGEN", "Text" : "Specific pathogen introduction", "Header" : 0}, 
{"Row" : 133, "Column" : 3, "Item" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS", "Text" : "Spinal epidural abscess", "Header" : 0}, 
{"Row" : 134, "Column" : 3, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Spleen absent or dysfunctional [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 137, "Column" : 3, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "Text" : "Spontaneous bacterial peritonitis prevention", "Header" : 0}, 
{"Row" : 138, "Column" : 3, "Item" : "ORZID2 GMENU SPOROTRICHOSIS", "Text" : "Sporotrichosis infections, general", "Header" : 0}, 
{"Row" : 139, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN STAPHYLOCOCCI", "Text" : "Staphylococcal infections, general", "Header" : 0}, 
{"Row" : 140, "Column" : 3, "Item" : "ORZID2 GMENU EC NV STAPHYLOCOCCI", "Text" : "Staphylococcal native valve endocarditis", "Header" : 0}, 
{"Row" : 141, "Column" : 3, "Item" : "ORZID2 GMENU EC PV STAPHYLOCOCCI", "Text" : "Staphylococcal prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 142, "Column" : 3, "Item" : "ORZID2 GMENU TOXIC SHOCK SYNDROME", "Text" : "Staphylococcal toxic shock syndrome", "Header" : 0}, 
{"Row" : 143, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN COAG-NEG STAPH", "Text" : "Staphylococci, coagulase-negative", "Header" : 0}, 
{"Row" : 144, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN S. AUREUS", "Text" : "Staphylococcus aureus infections, general", "Header" : 0}, 
{"Row" : 145, "Column" : 3, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL STAPHYLOCOCCUS PNEUMONIA", "Text" : "Staphylococcus aureus nosocomial pneumonia", "Header" : 0}, 
{"Row" : 146, "Column" : 3, "Item" : "ORZID2 GMENU OSTEOMYELITIS WITH S. AUREUS", "Text" : "Staphylococcus aureus osteomyelitis", "Header" : 0}, 
{"Row" : 147, "Column" : 3, "Item" : "ORZID2 GMENU BACTEREMIA S. AUREUS", "Text" : "Staphylococcus aureus bacteremia", "Header" : 0}, 
{"Row" : 148, "Column" : 3, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Staphylococcus aureus decolonization", "Header" : 0}, 
{"Row" : 149, "Column" : 3, "Item" : "ORZID2 GMENU INTRAVAS CATH S. AUREUS", "Text" : "Staphylococcus aureus intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 150, "Column" : 3, "Item" : "ORZID2 GMENU PROS BONE/JOINT S. AUREUS", "Text" : "Staphylococcus aureus prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 151, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC ARTH S. AUREUS", "Text" : "Staphylococcus aureus, native joint infection", "Header" : 0}, 
{"Row" : 152, "Column" : 3, "Item" : "ORZID2 GMENU BACTEREMIA S. LUGDUNENSIS", "Text" : "Staphylococcus lugdunensis bacteremia", "Header" : 0}, 
{"Row" : 153, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN STAPH LUGDUNENSIS", "Text" : "Staphylococcus lugdunensis infections, general", "Header" : 0}, 
{"Row" : 154, "Column" : 3, "Item" : "ORZID2 GMENU ABX STASIS DERMATITIS", "Text" : "Stasis dermatitis", "Header" : 0}, 
{"Row" : 155, "Column" : 3, "Item" : "ORZID2 GMENU BITE WNDS STREPTOCOCCI", "Text" : "Streptococcal bite wounds", "Header" : 0}, 
{"Row" : 156, "Column" : 3, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "Text" : "Streptococcal native valve endocarditis (highly resistant isolate)", "Header" : 0}, 
{"Row" : 157, "Column" : 3, "Item" : "ORZID2 GMENU EC NV STREPTOCOCCI", "Text" : "Streptococcal native valve endocarditis (sensitive isolate)", "Header" : 0}, 
{"Row" : 158, "Column" : 3, "Item" : "ORZID2 GMENU OSTEOM WITH STREPTOCOCCI", "Text" : "Streptococcal osteomyelitis", "Header" : 0}, 
{"Row" : 159, "Column" : 3, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "Text" : "Streptococcal pharyngitis", "Header" : 0}, 
{"Row" : 160, "Column" : 3, "Item" : "ORZID2 GMENU PROS B/J STREPTOCOCCI", "Text" : "Streptococcal prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 161, "Column" : 3, "Item" : "ORZID2 GMENU EC PV VGS/S. BOVIS", "Text" : "Streptococcal prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 162, "Column" : 3, "Item" : "ORZID2 GMENU TOXIC SHOCK SYNDROME", "Text" : "Streptococcal toxic shock syndrome", "Header" : 0}, 
{"Row" : 163, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN STREP C,F,G", "Text" : "Streptococci Groups C, F, G infections, general", "Header" : 0}, 
{"Row" : 164, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN VIRIDANS STREP", "Text" : "Streptococci viridans infections, general [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 166, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FINAL S. AGALACTIAE", "Text" : "Streptococcus agalactiae (Group B)", "Header" : 0}, 
{"Row" : 167, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FI S. ANGINOSUS", "Text" : "Streptococcus anginosus (formerly S. milleri)", "Header" : 0}, 
{"Row" : 168, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN S. BOVIS", "Text" : "Streptococcus bovis (Group D)", "Header" : 0}, 
{"Row" : 169, "Column" : 3, "Item" : "ORZID2 GMENU SEPTIC ARTH STREPTOCOCCI", "Text" : "Streptococcus native joint infection", "Header" : 0}, 
{"Row" : 170, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FI S. PNEUMONIAE", "Text" : "Streptococcus pneumoniae infections, general", "Header" : 0}, 
{"Row" : 171, "Column" : 3, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "Text" : "Streptococcus pneumoniae meningitis", "Header" : 0}, 
{"Row" : 172, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN S. PYOGENES", "Text" : "Streptococcus pyogenes (Group A) infections, general", "Header" : 0}, 
{"Row" : 173, "Column" : 3, "Item" : "ORZID2 GMENU IMMUNOCOM STRESS", "Text" : "Stress", "Header" : 0}, 
{"Row" : 174, "Column" : 3, "Item" : "ORZID2 GMENU SUBDURAL EMPYEMA", "Text" : "Subdural empyema", "Header" : 0}, 
{"Row" : 175, "Column" : 3, "Item" : "ORZID2 GMENU SUPP INTRACRANIAL THROMBOPH", "Text" : "Suppurative intracranial thrombophlebitis", "Header" : 0}, 
{"Row" : 176, "Column" : 3, "Item" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Suppurative odontic infections", "Header" : 0}, 
{"Row" : 177, "Column" : 3, "Item" : "ORZID2 GMENU ABX SUPPURATIVE THROMBO EMP THERAPY", "Text" : "Suppurative thrombophlebitis", "Header" : 0}, 
{"Row" : 178, "Column" : 3, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "Text" : "Surgical site infection", "Header" : 0}, 
{"Row" : 179, "Column" : 3, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Susceptibilities, antimicrobial", "Header" : 0}, 
{"Row" : 180, "Column" : 3, "Item" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS", "Text" : "Suspected bacteremia, blood cultures not yet positive", "Header" : 0}, 
{"Row" : 181, "Column" : 3, "Item" : "ORZID2 GMENU ABX SYPHILIS", "Text" : "Syphilis", "Header" : 0}, 
{"Row" : 182, "Column" : 3, "Item" : "ORZID2 GMENU ABX SYSTEM INFECTIOUS DISEASES", "Text" : "Systemic Infections section", "Header" : 0}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "Po through Z",  "Header" : 1}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "Po-Py__________________________________________________________________________",  "Header" : 1}, 
{"Row" : 44, "Column" : 3, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 45, "Column" : 3, "Item" : null, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 46, "Column" : 3, "Item" : null, "Text" : "and streptococcus",  "Header" : 0}, 
{"Row" : 48, "Column" : 3, "Item" : null, "Text" : "culture negative, enterococci, fungi,",  "Header" : 0}, 
{"Row" : 49, "Column" : 3, "Item" : null, "Text" : "gram-negative bacilli, Streptococcus bovis,",  "Header" : 0}, 
{"Row" : 50, "Column" : 3, "Item" : null, "Text" : "staphylococci, HACEK bacteria, and Viridans group streptococci",  "Header" : 0}, 
{"Row" : 65, "Column" : 3, "Item" : null, "Text" : "empiric therapy, enterococcus, pseudomonas",  "Header" : 0}, 
{"Row" : 70, "Column" : 3, "Item" : null, "Text" : "Q______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 72, "Column" : 3, "Item" : null, "Text" : "R______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 82, "Column" : 3, "Item" : null, "Text" : "candida, Cytomegalovirus, herpes, zoster, and others",  "Header" : 0}, 
{"Row" : 88, "Column" : 3, "Item" : null, "Text" : "S______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 97, "Column" : 3, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 98, "Column" : 3, "Item" : null, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,",  "Header" : 0}, 
{"Row" : 99, "Column" : 3, "Item" : null, "Text" : "Staphylococcus aureus, streptococcus",  "Header" : 0}, 
{"Row" : 101, "Column" : 3, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 102, "Column" : 3, "Item" : null, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 103, "Column" : 3, "Item" : null, "Text" : "and streptococcus",  "Header" : 0}, 
{"Row" : 135, "Column" : 3, "Item" : null, "Text" : "antimicrobial prophylaxis, management of fever,",  "Header" : 0}, 
{"Row" : 136, "Column" : 3, "Item" : null, "Text" : "patient initiated antibiotics, vaccines",  "Header" : 0}, 
{"Row" : 165, "Column" : 3, "Item" : null, "Text" : "S. mutans, S. mitis, S. sanguis",  "Header" : 0}, 
{"Row" : 185, "Column" : 3, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus vaccination", "Header" : 0}, 
{"Row" : 186, "Column" : 3, "Item" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "Text" : "Thrush", "Header" : 0}, 
{"Row" : 188, "Column" : 3, "Item" : "ORZID2 GMENU TINEA CAPITIS (RINGWORM)", "Text" : "Tinea capitis", "Header" : 0}, 
{"Row" : 189, "Column" : 3, "Item" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Text" : "Tinea corporis", "Header" : 0}, 
{"Row" : 190, "Column" : 3, "Item" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Text" : "Tinea cruris", "Header" : 0}, 
{"Row" : 191, "Column" : 3, "Item" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Text" : "Tinea pedis", "Header" : 0}, 
{"Row" : 192, "Column" : 3, "Item" : "ORZID2 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "Text" : "Tinea unguium", "Header" : 0}, 
{"Row" : 193, "Column" : 3, "Item" : "ORZID2 GMENU TINEA VERSICOLOR", "Text" : "Tinea versicolor", "Header" : 0}, 
{"Row" : 194, "Column" : 3, "Item" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE", "Text" : "Tobacco smoke", "Header" : 0}, 
{"Row" : 195, "Column" : 3, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "Text" : "Tonsillitis", "Header" : 0}, 
{"Row" : 196, "Column" : 3, "Item" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Tooth abscess and other suppurative odontic infections", "Header" : 0}, 
{"Row" : 197, "Column" : 3, "Item" : "ORZID2 GMENU TOXIC SHOCK SYNDROME", "Text" : "Toxic shock syndrome", "Header" : 0}, 
{"Row" : 198, "Column" : 3, "Item" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII", "Text" : "Toxoplasma gondii brain abscess", "Header" : 0}, 
{"Row" : 199, "Column" : 3, "Item" : "ORZID2 GMENU TOXOPLASMA SPP.", "Text" : "Toxoplasma infections, general", "Header" : 0}, 
{"Row" : 200, "Column" : 3, "Item" : "ORZID2 GMENU TRANSPLANTATION", "Text" : "Transplantation", "Header" : 0}, 
{"Row" : 201, "Column" : 3, "Item" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA", "Text" : "Trauma or nosocomial infection associated meningitis", "Header" : 0}, 
{"Row" : 202, "Column" : 3, "Item" : "ORZID2 GMENU TRAVELERS DIARRHEA", "Text" : "Traveler's diarrhea", "Header" : 0}, 
{"Row" : 203, "Column" : 3, "Item" : "ORZID2 GMENU ABX TRICH VAGINITIS", "Text" : "Trichomonas vaginitis", "Header" : 0}, 
{"Row" : 204, "Column" : 3, "Item" : "ORZID2 GMENU ABX TUBERCULOSIS", "Text" : "Tuberculosis", "Header" : 0}, 
{"Row" : 205, "Column" : 3, "Item" : "ORZID2 GMENU ABX TYPHLITIS", "Text" : "Typhlitis", "Header" : 0}, 
{"Row" : 206, "Column" : 3, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "Text" : "Typhoid fever", "Header" : 0}, 
{"Row" : 209, "Column" : 3, "Item" : "ORZID2 GMENU DECUBITUS ULCERS", "Text" : "Ulcer, decubitus", "Header" : 0}, 
{"Row" : 210, "Column" : 3, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "Text" : "Ulcer, diabetic foot", "Header" : 0}, 
{"Row" : 211, "Column" : 3, "Item" : "ORZID2 GMENU ABX UNCOMP CYSTITIS", "Text" : "Uncomplicated cystitis", "Header" : 0}, 
{"Row" : 212, "Column" : 3, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Updates on antimicrobial shortages", "Header" : 0}, 
{"Row" : 213, "Column" : 3, "Item" : "ORZID2 GMENU ABX UPPER RESPIRATORY INFECTIONS (URI)", "Text" : "Upper respiratory infections (URI)", "Header" : 0}, 
{"Row" : 214, "Column" : 3, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "Text" : "Urethritis associated with STIs [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 216, "Column" : 3, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "Text" : "Urethritis, recurrent or persistent", "Header" : 0}, 
{"Row" : 217, "Column" : 3, "Item" : "ORZID2 GMENU ABX UTI2", "Text" : "Urinary tract infection (UTI), bacterial", "Header" : 0}, 
{"Row" : 218, "Column" : 3, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "Text" : "Urinary tract infection (UTI), candida", "Header" : 0}, 
{"Row" : 219, "Column" : 3, "Item" : "ORZID2 GMENU UROSEPSIS", "Text" : "Urinary tract infection with sepsis", "Header" : 0}, 
{"Row" : 220, "Column" : 3, "Item" : "ORZID2 GMENU UROSEPSIS", "Text" : "Urosepsis", "Header" : 0}, 
{"Row" : 221, "Column" : 3, "Item" : "ORZID2 GMENU UVEITIS", "Text" : "Uveitis", "Header" : 0}, 
{"Row" : 225, "Column" : 3, "Item" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS", "Text" : "Vaginitis, Candida", "Header" : 0}, 
{"Row" : 226, "Column" : 3, "Item" : "ORZID2 GMENU ABX TRICH VAGINITIS", "Text" : "Vaginitis, Trichomonas", "Header" : 0}, 
{"Row" : 227, "Column" : 3, "Item" : "ORZID2 GMENU ABX VAGINITIS", "Text" : "Vaginosis, bacterial", "Header" : 0}, 
{"Row" : 228, "Column" : 3, "Item" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX", "Text" : "Varicella", "Header" : 0}, 
{"Row" : 229, "Column" : 3, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella vaccination", "Header" : 0}, 
{"Row" : 230, "Column" : 3, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "Text" : "Ventilator-associated pneumonia (VAP)", "Header" : 0}, 
{"Row" : 231, "Column" : 3, "Item" : "ORZID2 GMENU VERTEBRAL (DISKITIS) OSTEOM", "Text" : "Vertebral osteomyelitis and diskitis", "Header" : 0}, 
{"Row" : 232, "Column" : 3, "Item" : "ORZID2 GMENU ABX CHOLERA", "Text" : "Vibrio cholerae diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 233, "Column" : 3, "Item" : "ORZID2 GMENU ABX NON-CHOLERA", "Text" : "Vibrio non-cholerae, diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 234, "Column" : 3, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Viral diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 235, "Column" : 3, "Item" : "ORZID2 GMENU GRAM-POS FIN VIRIDANS STREP", "Text" : "Viridans streptococci", "Header" : 0}, 
{"Row" : 236, "Column" : 3, "Item" : "ORZID2 GMENU ABX VIRUSES", "Text" : "Viruses section", "Header" : 0}, 
{"Row" : 237, "Column" : 3, "Item" : "ORZID2 GMENU ABX CANDIDA VULVO-VAGINITIS", "Text" : "Vulvo-vaginitis, candida", "Header" : 0}, 
{"Row" : 240, "Column" : 3, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Warfarin interactions with antimicrobials", "Header" : 0}, 
{"Row" : 241, "Column" : 3, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "Text" : "Wound infection, post-op", "Header" : 0}, 
{"Row" : 242, "Column" : 3, "Item" : "ORZID2 GMENU BITE WOUNDS", "Text" : "Wound, bite", "Header" : 0}, 
{"Row" : 243, "Column" : 3, "Item" : "ORZID2 GMENU ABX COLONIZED WOUNDS", "Text" : "Wound, colonized", "Header" : 0}, 
{"Row" : 248, "Column" : 3, "Item" : "ORZID2 GMENU INT RPT YEAST", "Text" : "Yeast bacteremia", "Header" : 0}, 
{"Row" : 249, "Column" : 3, "Item" : "ORZID2 GMENU YERSINIA ENTEROCOLITICA", "Text" : "Yersinia enterocolitica diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 252, "Column" : 3, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "Text" : "Zoster", "Header" : 0}, 
{"Row" : 253, "Column" : 3, "Item" : "ORZID2 GMENU RETINITIS", "Text" : "Zoster retinitis", "Header" : 0}, 
{"Row" : 254, "Column" : 3, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Zoster vaccination", "Header" : 0}, 
{"Row" : 184, "Column" : 3, "Item" : null, "Text" : "T______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 208, "Column" : 3, "Item" : null, "Text" : "U______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 215, "Column" : 3, "Item" : null, "Text" : "chlamydia and gonococcal",  "Header" : 0}, 
{"Row" : 223, "Column" : 3, "Item" : null, "Text" : "V______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 224, "Column" : 3, "Item" : null, "Text" : "Vaccination: see immunization, specific organism or condition",  "Header" : 0}, 
{"Row" : 239, "Column" : 3, "Item" : null, "Text" : "W______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 245, "Column" : 3, "Item" : null, "Text" : "X______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 247, "Column" : 3, "Item" : null, "Text" : "Y______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 251, "Column" : 3, "Item" : null, "Text" : "Z______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 73, "Column" : 3, "Item" : null, "Text" : "Rabies post-exposure prophylaxis - see Emergency",  "Header" : 0}, 
{"Row" : 74, "Column" : 3, "Item" : null, "Text" : "Department CDSS or contact ID for more information",  "Header" : 0}, 
{"Row" : 37, "Column" : 3, "Item" : null, "Text" : "Prophylaxis for post-exposure, Rabies - see Emergency",  "Header" : 0}, 
{"Row" : 38, "Column" : 3, "Item" : null, "Text" : "Department CDSS or contact ID for more information",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "Post-exposure prophylaxis, Rabies - see Emergency",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "Department CDSS or contact ID for more information",  "Header" : 0}, 
{"Row" : 107, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "Text" : "Cardiovascular Section", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "Text" : "Bite, tick", "Header" : 0}, 
{"Row" : 187, "Column" : 3, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "Text" : "Tick Bite", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX INFECT INVOLVES CARD DEVICES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX VANCO+RIFAMP 300MG PO Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> rifampin 300 mg PO/NG q8h ($)", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 1 MG/KG IV Q8H", "Text" : "< ADD > gentamicin 1 mg/kg IV q8h ($) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INFECTIONS INVOLVING CARDIOVASCULAR DEVICES (EXCLUDING VALVES)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most infections are associated with Staphylococcus aureus and coagulase-negative",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "staphylococci.Many of these staphylococci are resistant to methicillin, so",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "initial empiric therapy with vancomycin is required. Consultation with",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases is encouraged for patients with severe allergies to",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "vancomycin or for those who have vancomycin-resistant infections.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "At least 3 blood cultures should be drawn prior to the initiation of empirical",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "antimicrobial. Modify antimicrobial regimen and narrow coverage based on results",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "of culture and susceptibility tests Infectious Disease and Cardiothoracic",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "surgery consultations are encouraged.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Device removal is necessary for cure in most cases.However, it may be",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "difficult depending on the nature of the device and specific clinical",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "circumstances.Device removal should be discussed with Cardiology, Infectious",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Disease, or Cardiothoracic surgery consultants.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "If the device removal is not possible add rifampin.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Duration of therapy should be determined in concert with Cardiology, Infectious",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Disease, or Cardiothoracic surgery consultants.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Empiric treatment in cases where device removal is planned",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Empiric treatment in cases where surgery cannot be performed",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "[DI,O]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "For hemodynamically unstable patients, add gentamicin to one of the above",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "treatment regimens",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2010, 121.458-477",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Kusumoto et al., Heart Rhythm 2017, 14.15",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pacemaker/Defibrillator Infections",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of Nonvalvular Cardiovascular Devices",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Infections involving cardiac implantable electronic devices:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Treatment and prevention",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX INFECTION CTRL", "Contents" : [
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX ABX MVAMC INTRANET INFECT CTRL", "Text" : "[Click here] Minneapolis VAMC Infection Prevention & Control SharePoint site", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX CDC WEBSITE", "Text" : "[Click here] CDC website", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "Text" : "[Click here] Consult Infectious Diseases (inpatient)", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ GTX ABX ISOLATION SIGNS", "Text" : "[Click here] Minneapolis VAMC Isolation Precautions", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INFECTION CONTROL",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Minneapolis VAMC infection control policies and practices are designed to",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "prevent infection and infectious diseases among patients, employees, visitors,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "families and friends. This section briefly summarizes key infection control",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "practices.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "____________________________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For more information",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "____________________________________________",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : ">> Infection Prevention is available via phone (612-467-6888) during",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "duty hours Monday to Friday. (Internal extension 31-6888)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : ">> During nights, weekends, and holidays, contact the on-call person for",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : ">> Minneapolis VAMC Infection Prevention and Control SharePoint site",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : ">> CDC web site (www.cdc.gov)",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "____________________________________________",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Standard and special precautions",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "____________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "Text" : "[Click here] Consult Infectious Diseases (outpatient)", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : ">> Place consults for ID",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "[Click here] Minneapolis Clinical On-Call Schedule", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX INFLUENZA 2021-2022", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza Vaccination Recommendations", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX ANTIVIRAL TREATMENT", "Text" : "Antiviral Treatment Recommendations", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA CHEMOPROPHYLAXIS", "Text" : "Chemoprophylaxis Recommendations", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GMENU LAB NASOPHARYNGEAL TESTING MAIN", "Text" : "Lab Influenza Testing Menu", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Seasonal Influenza",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Last reviewed September 2021", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX INFLUENZA CHEMOPROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Early treatment as alternative to chemoprophylaxis:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "In most cases, if a person is suspected of having been exposed to influenza,",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "early treatment should signs or symptoms develop is preferred rather than",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "chemoprophylaxis.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "The provider should explain the early signs and symptoms of influenza to the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "patient and advise the patient to immediately contact a health care provider",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "for evaluation and possible early treatment if these symptoms or signs",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "develop. Influenza-like symptoms or signs include fever, cough, sore throat,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "runny or stuffy nose, body aches, headache, chills, fatigue, vomiting, and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "diarrhea. Influenza can present without fever.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Health care providers should use clinical judgment regarding situations where",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "early recognition of illness and treatment might be an appropriate",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "alternative to chemoprophylaxis.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Early treatment alternative or chemoprophylaxis may be considered:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "*Persons who are part of a high-risk group and are household or close",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "contacts of someone with influenza-like illness",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "*Health care personnel who have occupational exposures",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Chemoprophylaxis recommended:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Chemoprophylaxis considered:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "*Atypical situations (such as case clusters). Contact state health department",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "for consultation.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Zanamivir is not recommended for patients with chronic respiratory disease such",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "as asthma or chronic obstructive pulmonary disease. These patients may have",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "bronchospasm with zanamivir. If zanamivir must be used, and patients are using",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "an inhaled bronchodilator, zanamivir should be taken just after the",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "bronchodilator.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Requires Infectious Disease Approval",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Zanamivir 2 inhalations (2 x 5 mg)daily ($) [O]",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Centers for Disease Control (CDC) (Accessed 9/8/21)",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "(https://www.cdc.gov/flu/index.htm)",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Up-to-date online: Prevention of seasonal influenza",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "with antiviral drugs in adults",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "*For control of outbreaks in institutional settings (long-term care",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "facilities and hospitals)",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Antiviral Prophylaxis Recommendations:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJZID OSELTAMIVIR 75 MG PO DAILY PROPHY", "Text" : "", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "(See information above for length of prophylaxis)",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "(See information above for length of prophylaxis)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Chemoprophylaxis duration: 7 days after last known exposure",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Chemoprophylaxis duration: minimum of 2 weeks and continuing up to 1 week",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "after the last known case identified.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Note: Antiviral chemoprophylaxis is recommended for all residents, including",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "those who have received influenza vaccination.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Preferred treatment:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Alternative treatment:", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX INFLUENZA EGG ALLERGY ACIP", "Contents" : [
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Influenza Vaccine for Patients with Egg Allergies",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Previously the ACIP had recommended that persons with serious egg allergies",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "receive the egg-free influenza vaccine- i.e FluBlok. In 2016-2017 the ACIP",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "changed the recommendation for persons with egg-allergies to state that",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "all persons should receive any formulation of age-appropriate flu vaccine",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "regardless of egg allergy.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "This change was based on data from large studies of greater than 4000 egg",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "allergic patients with 500 of them having severe egg allergy who received",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "the influenza vaccine with no anaphylactic reactions. Egg-allergic patients",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "should be monitored just like everyone else for 15 minutes after influenza",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "vaccine receipt.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Grohskopf LA, MMWR Recommendations and Reports 2021, 70(5):1-28",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Up-to-date online: Influenza vaccination in individuals with egg allergy", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX INFLUENZA VACCINATION 2021-2022", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA EGG ALLERGY ACIP", "Text" : "ACIP Information on Influenza Vaccination and Egg Allergies", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MVAHCS Vaccination Recommendations for Inpatients:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Annual influenza vaccination is recommended for all persons aged 6",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "months and older without a specific contraindication. The Quadrivalent",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "influenza vaccine is made up of the four flu strains most likely to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cause the flu during the upcoming season (H1N1, H3N2, and two",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "group B viruses).",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Quadrivalent influenza vaccine will be administered at MVAHCS",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "for seasonal influenza 2021-2022.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "The Advisory Committee on Immunization Practices (ACIP) does not express a",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "preference for use of any particular product over another, for persons for",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "whom more than one type of influenza vaccine is appropriate.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Flu shot information:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "The influenza vaccine dispensed at MVAHCS is latex and preservative free.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Recommended administration to pregnant women during any trimester per CDC.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "All Veterans should receive flu vaccine regardless of egg allergyor",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "present illness.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "History of Guillain Barre Syndrome or previous flu shot reaction more severe",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "than mild-moderate arm pain, swelling, fatigue, or low grade fever, is",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "a contraindication to future receipt of the vaccine.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Recommend observing all patients for 15 minutes after receipt of any",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "influenza vaccine. A previous severe allergic reaction to influenza vaccine,",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "regardless of the component suspected of being responsible for the reaction,",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "is a contraindication to future receipt of ANY influenza vaccine.",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Recommended for all patients (including patients with egg allergies):",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "** Influenza vaccine is a Standing Order, thus does not need an order placed **",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Administer: Standard Dose Quadrivalent Influenza Vaccine Once",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Additional information regarding influenza vaccine for patients with",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "egg allergies.",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "It was once believed that patients with egg allergies were at risk of",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "allergic reaction to traditional influenza vaccines.However, in 2016-2017",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "the ACIP changed the recommendation for persons with egg allergies to state",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "that they can receive any formulation of age-appropriate flu vaccine",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "regardless of severity of egg allergy. To read more about reason for this",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "change select below.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Grohskopf LA, MMWR Recommendations and Reports 2021, 70(5):1-28",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Minneapolis VAHCS Influenza Committee 2021-2022",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Up-to-date online: Influenza vaccination in individuals with egg allergy", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX INI EPI ABX ASSOC COLITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID VANCOMYCIN 125MG PO Q6H X10DAYS CDIFF", "Text" : "Vancomycin 125mg PO q6h for 10 days ($) [M]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXI MEGACOLON", "Text" : "Select for severe/life-threatening disease", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INITIAL EPISODE OF CLOSTRIDIUM DIFFICILE INFECTION (CDI)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Discontinue implicated antibiotic and avoid high-risk antibiotic if antibiotic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "therapy is still needed. Discontinue antacid therapy if possible.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Clostridium difficile infection",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium difficile",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID FIDAXOMICIN 200MG PO Q12H 10DAYS", "Text" : "Fidaxomicin 200 mg PO q12h for 10 days ($$) [M]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Patient at increased risk of CDI recurrence:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "(e.g., age >65 years old, concomitant antibiotic use during CDI treatment,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "and/or immunosuppression)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Patient not meeting criteria above for increased risk of CDI recurrence:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Initial Episode Preferred Treatment:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Patient with clinical symptom onset (e.g. 3 or more unformed stools in 24 hours",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "after discontinuation of laxatives) and laboratory confirmation of CDI.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX INPT MAIN", "Contents" : [
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX INDEX INPATIENT", "Text" : "[CLICK HERE]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "Text" : "By Organism/Vaccine", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX CNS", "Text" : "Central Nervous System", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEAD AND NECK", "Text" : "Head and Neck", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX LUNG AND MEDIASTINUM", "Text" : "Lungs & Mediastinum", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA 2021-2022", "Text" : "[b] Influenza Seasonal 2021-2022", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMONIA", "Text" : "[c] Pneumonia", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "Text" : "Cardiovascular", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU ABX GASTROINTESTINAL", "Text" : "GI & Intraabdominal", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "Text" : "[a] C. difficile Colitis Mild/Moderate", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENITOURINARY", "Text" : "Urogenital", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "[a] Sexually Transmitted Infections (STI)", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "Text" : "Soft Tissue, Muscle, Bone and Joint Infection", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGY MAIN", "Text" : "Skin", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU ABX SYSTEM INFECTIOUS DISEASES", "Text" : "Systemic Infections", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU ABX BACTEREMIA", "Text" : "[a] Bacteremia", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "[b] Sepsis and Septic Shock", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "Text" : "[c] Neutropenic Fever", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU INTRO SPEC PATHOGEN", "Text" : "Introduction to Specific Pathogen", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU GRAM NEGATIVE BACTERIA", "Text" : "Gram-negative Bacteria", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU GRAM POS BACTERIA", "Text" : "Gram-positive Bacteria", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU ABX VIRUSES", "Text" : "Viruses", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID2 GMENU ABX FUNGUS", "Text" : "Fungi", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID2 GMENU PARASITES", "Text" : "Parasites", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID2 GMENU OTHER PATHOGENS", "Text" : "Other Pathogens", "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : "ORZID2 GMENU ABX TESTING INPATIENT MENU", "Text" : "Inpatient Testing Menu", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "*******************************************************",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "* ANTIMICROBIAL DECISION SUPPORT *",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "* >>>>>>>>INPATIENT<<<<<<<<<*",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "*******************************************************",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Welcome.Please click on the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "diagnosis or syndrome you wish to treat.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "**********************",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Index of Antimicrobial CDSS content",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Immunization Information and Vaccine Orders",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Syndromes and diseases, by body systems",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Specific organisms",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Medicine is an inexact and rapidly",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "changing discipline.The developers of",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "this system have made every effort to",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "provide current, accurate information.",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "However, in view of the possibility of",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "human error or changes in medical",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "service, readers are encouraged to",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "confirm the information contained",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "herein with other sources.In",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "particular, readers are encouraged to",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "check the product information for",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "antimicrobials to be certain that",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "information in this system is accurate",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "and current, especially for new or",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "infrequently used drugs.",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "Contact CDSS Staff", "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help page...", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZ GTX ABX CDSS FAQ", "Text" : "Frequently Asked questions (FAQ)", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Comments or Suggestions about this CDSS", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZ GTX ABX ANTIMICROBIAL FORMULARY", "Text" : "Antimicrobial Formulary (Restricted)", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "Text" : "Restrictions on Antimicrobials", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU ABX ADJ EXIST ABX THERAPY", "Text" : "Adjust Existing Antimicrobial Therapy", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "Text" : "How to Find Alternative Antimicrobials", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "Clinical On-Call Schedule (Infectious Disease)", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZ GTX ABX UP TO DATE", "Text" : "Up-to-date Online (Clinical Resource)", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "Text" : "Infection Control/Prevention Information", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatological Guidelines", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU ABX DEVICE-RELATED INFECTIONS", "Text" : "Device-related Infections", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU ABX PREVENTION OF INFECTION", "Text" : "Prevention of Infection", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "HIV-AIDS", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMMUNOCOMPROMISED PATIENT", "Text" : "Immunocompromised Patients", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "Text" : "Antimicrobial Prophylaxis Pre-op", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "Text" : "Antimicrobial Prophylaxis Post-op", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "Text" : "Surgical Site Infections", "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "Important Drug (Abx) Properties", "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : "ORZ GTX ABX LEXICOMP ONLINE", "Text" : "Lexicomp Online Drug Information", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "ORZ GTX ABX RESOURCE QTC", "Text" : "QT Prolongation Drug Resource", "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "DDI Warfarin and Antimicrobials", "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "Text" : "Pregnancy Risk Factors for Antibiotics", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Shortages of Antimicrobials", "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT REQUIRED MAIN", "Text" : "Conditions NOT benefitted by antibiotics", "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "ESBLs, Amp-C beta-lactamases and Carbapenemases", "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : "ORZ GTX ABX MEASLES OUTBREAK INFO", "Text" : "Measles Outbreak Information", "Header" : 0}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "HELP",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "Important Antimicrobial Information",  "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "General",  "Header" : 1}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "Surgical: Antimicrobial Prophylaxis and Site Infections",  "Header" : 1}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "Drug Information Links",  "Header" : 1}, 
{"Row" : 39, "Column" : 2, "Item" : null, "Text" : "Miscellaneous/Emerging Topics",  "Header" : 1}, 
{"Row" : 94, "Column" : 1, "Item" : "ORZID2 GMENU ABX CDSS VERSION", "Text" : "", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXI MEGACOLON", "Text" : "[b] C. difficile Fulminant (severe/complicated)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "COVID-19",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 MPLS PHARMACOLOGIC GUIDELINE", "Text" : "Pharmacologic Treatment Guidelines", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 MPLS PHARMACOLOGIC GUIDELINE", "Text" : "[a] COVID-19 Pharmacologic Inpatient Recs", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "CDSS-MicroGuide Web and Mobile App",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX MICROGUIDE MOBILE APP INSTRUCTIONS", "Text" : "[CLICK HERE]", "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "TESTING MENU ONLY- DO NOT USE TO PLACE ORDERS",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 INFORMATION", "Text" : "SharePoint Site and More Info", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Text version", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Beta-lactam Reaction Assessment *Updated",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "PDF version *Preferred", "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : "LRTZ SET PAN CULTURE", "Text" : "", "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : "ORZ SET LOWER EXTREMITY BYPASS PREOP VASCULAR SURGERY", "Text" : "", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX UTI2", "Text" : "[b] Urinary Tract Infections", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "Testing Menu:Restricted to ID/ED",  "Header" : 1}, 
{"Row" : 90, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "Text" : "COVID-19 Vaccine Inpt Testing Menu", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "Text" : "Vaccination of Acute and Long Term Care Patients", "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE CLC", "Text" : "CLC COVID-19 VACCINES", "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOCILIZUMAB FOR TREATMENT OF COVID-19", "Text" : "Tocilizumab COVID-19 Treatment", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Call Ext 313144 to expedite URGENT Outpatient prescriptions",  "Header" : 1}, 
{"Row" : 43, "Column" : 2, "Item" : "ORZID2 GMENU ABX VANCO + MRSA NARES INFORMATION", "Text" : "MRSA Nares Screening-Vanco New Start", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "(List starts at top and goes down body systems)",  "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : "PSJIZID TEST QOA", "Text" : "TEST", "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 8MG/KG IV X1 COVID-19 DOSE 2", "Text" : "TESTING DOSE 2 TOCI", "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : "ORZID2 GMENU ABX SOTROVIMAB EUA", "Text" : "Sotrovimab (EUA) Menu/orders", "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : "PSJZID2 NIRMATRELVIR 150MG RITONAVIR 100MG PO BID 5D", "Text" : "Inpatient Paxlovid Renally Dosed UD Order", "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : "PSJZID2 MOLNUPIRAVIR 800 MG PO BID 5DS", "Text" : "Inpatient Molnupiravir UD Order", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "**FOR INPATIENT PHARMACY USE ONLY**",  "Header" : 1}, 
{"Row" : 82, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "Text" : "Emergency Use Authorization (EUA) SharePoint Site", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 MPLS PHARMACOLOGIC GUIDELINE", "Text" : "COVID-19 Inpt Treatment Guidelines Edits", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY AGE", "Text" : "By Age", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY INDICATION", "Text" : "By Indication", "Header" : 0}, 
{"Row" : 100, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX ISOSPORA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO Q12H for 7 to 10 days ($)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETHAMINE 75MG PO Q24H LEUCOVORIN 25MG PO Q24H", "Text" : "Pyrimethamine 75 mg PO q24h ($$) [DI,O] <AND> leucovorin 25 mg q24h ($) for", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB PO Q6H", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS q6h for 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETHAMINE 75MG PO Q24H LEUCOVORIN 25MG PO Q24H", "Text" : "Pyrimethamine 75 mg PO q24h ($$) [DI,O] <AND> leucovorin 25 mg PO q24h ($)", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB Q72H", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO QOD ($) [R,DI]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETHAMINE 25MG PO Q24H LEUCOVORIN 10MG PO Q24H", "Text" : "Pyrimethamine 25 mg PO q24h ($$) [DI,O] <AND> leucovorin PO mg PO q24h ($)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CYSTOISOSPORA BELLI (FORMALLY ISOSPORA BELLI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "C. belli is associated with diarrhea in persons with HIV/AIDS and only rarely in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "immunocompetent persons.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of persons without HIV/AIDS",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "[R,DI]",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "for 21-28 days",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of persons with HIV/AIDS",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases involvement is essential. Initial treatment of acute",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "infection is followed by secondary prophylaxis until CD4 count is >200 for >6",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "months in response to ART without evidence of active C. belli.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Initial treatment",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "for 21 to 28 days",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Secondary prophylaxis",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cystoisospora belli",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Management of Cystoisospora (Isospora) infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LARYNGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cases are almost always viral (e.g. rhinovirus, influenza, adenovirus,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "coronavirus). Treatment is based on symptomatic therapy alone.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute laryngitis",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Hoarseness in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX LIVER AMEBIC ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX METRO 750MG PO Q8H PAROMOMYC 25-35MG/KG/DAY PO Q8H", "Text" : "Metronidazole 750 mg PO q8h for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "AMEBIC LIVER ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Serological testing for amoebiasis should be obtained in all patients with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "suspected amebic liver abscess. Multiple sets of anaerobic and aerobic blood",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures should also be obtained prior to starting antibiotics to exclude",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "pyogenic liver abscess, which is a much more common cause of liver abscess.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Serologic testing can be negative in a small number of patients with acute",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "presentation (symptoms <2 weeks). Repeat serology is usually positive. If repeat",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "serological testing is negative for amoebiasis or patient does not respond to",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "treatment of amebic liver abscess, patient should have further diagnostic",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "testing completed to exclude pyogenic liver abscess.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Drainage of amebic liver abscess should be considered in patients with large",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "lesions at risk of rupture.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Due to complicated treatment and follow up, Infectious Diseases consultation",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "is recommended in all patients with liver abscess.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment of patients with confirmed or suspected amebic liver abscess (obtain",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "blood cultures prior to starting in suspected cases)",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Paromomycin is nonformulary and must be ordered by Infectious Diseases.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "25-35 mg/kg/day PO q8h for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Liver and Biliary System",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Amoebiasis, Entamoeba histolytica",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Extraintestinal Entamoeba histolytica amoebiasis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX LIVER PYOGENIC ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX LIVER AMEBIC ABSCESS", "Text" : "Link to Amebic Liver Abscess menu", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 750MG IV AND METRO 500MG IV", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV q8h ($)", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG PO Q24H METRO 1 GM PO Q12H", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LIVER ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Liver abscess should be suspected in all patients with fever, leukocytosis, and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "a space-occupying liver lesion. Liver abscesses fall broadly into two",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "categories: pyogenic and amebic. In the United States, pyogenic liver abscess is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "much more common. Amebic liver abscess occurs almost exclusively in travelers",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and immigrants. If amebic liver abscess is suspected, select the link below.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Due to complicated treatment and follow up, Infectious Diseases consultation is",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "recommended in patients with pyogenic liver abscess.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment of pyogenic liver abscess",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "A typical course for pyogenic liver abscess is 4 to 6 weeks.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Initial treatment",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with mild to moderate disease and beta lactam allergy",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "[DI]",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with severe disease and beta lactam allergy",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Step down treatment for completion of antimicrobial course after initial",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "on culture results.",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Liver and Biliary System",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Hepatic Abscess",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Pyogenic liver abscess", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX LUNG ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] < OR >", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2 GM IV QD METRONIDAZOLE 500 MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] < AND > metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($) [H,O]< OR >", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "LUNG ABSCESS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Pulmonary and/or Infectious Diseases consultations are strongly encouraged for",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "all cases.Obtain samples for gram stain and culture from fine needle",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "aspiration whenever possible.Sputum culture is less helpful because it will be",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "contaminated with upper respiratory flora.Classically, lung abscess is a",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "complication of mixed anaerobic and aerobic pulmonary infection. The initial",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "infection may or may not be clinically apparent.Malaise, weight loss, fever,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "chills, and malodorous sputum typically develop over a period of weeks.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Cavitation and/or abscess can occur in cases of pneumonia from a single",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "pathogen, commonly Staphylococcus aureus or Pseudomonas aeruginosa.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment should be directed against the specific pathogen.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treat for 6 to 8 weeks and adjust treatment based on clinical response.Oral",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "medications should be used in patients who can take them.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred intravenous treatment",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Preferred oral treatment",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternatives for patient with severe penicillin allergy",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "If Staphloccus aureus MRSA suspected:",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Bartlett JG Anaerobe 2012, 18:235",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword lung abscess",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter:Principles and Practice of Infectious Diseases",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Harrison's chapter: Infections due to mixed organisms",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX LUNG AND MEDIASTINUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "Text" : "Bronchitis", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX EMPYEMA", "Text" : "Empyema", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "Text" : "Exacerbation of chronic obstructive pulmonary disease (COPD)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA 2021-2022", "Text" : "Influenza Seasonal", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX LUNG ABSCESS", "Text" : "Lung abscess", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDIASTINITIS", "Text" : "Mediastinitis", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERTUSSIS", "Text" : "Pertussis", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX TUBERCULOSIS", "Text" : "Tuberculosis", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX AZITHROMYCIN PREVENTION OF EXACERBATIONS COPD", "Text" : "Azithromycin for prevention of COPD exacerbations", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++LUNGS AND MEDIASTINUM++",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Last Reviewed July 2019",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "Text" : "Aspiration pneumonia", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "Text" : "Community-acquired pneumonia (CAP)", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "Text" : "Nosocomial pneumonia (including HAP and VAP)", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Pneumonia", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX LYME DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU LYME DISEASE PROPHYLAXIS", "Text" : "Lyme Disease Prophylaxis", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU LYME ERYTHEMA MIGRANS", "Text" : "Erythema migrans associated with Lyme disease", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU LYME ACUTE NEURO DISEASE", "Text" : "Acute neurological disease associated with Lyme disease", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU LYME ARTHRITIS", "Text" : "Arthritis associated with Lyme disease", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU LYME CARDIAC DISEASE", "Text" : "Cardiac disease associated with Lyme disease", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Lyme disease results from the transmission of Borrelia burgdorferi from an",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Ixodes spp. tick bite. Patients who display signs of illness or fever within 30",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "days of removing an attached tick should be evaluated for tick-borne illness.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "In the upper Midwest these are Lyme disease, human anaplasmosis, babesiosis, and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Powassan virus disease. Patients who have been bitten by an Ixodes spp. tick",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "(deer tick) but who do not display signs or symptoms of infection should not",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "be treated with antimicrobials.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Prophylactic antimicrobial treatment may be beneficial in certain patients who",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "have been bitten while in endemic areas.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Except for erythema migrans, Lyme disease is a complicated, difficult disease to",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "diagnose and treat. Infectious Diseases consultation is strongly encouraged.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX MANAGEMENT OF FEBRILE EPISODE ASPLENIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX MOXIFLOXACIN 400MG IV Q24H VANCO IV Q12H", "Text" : "Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "Text" : "Bacterial meningitis with S. pneumoniae", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Fever in an Asplenic Patient",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Patients with impaired splenic function are at risk for severe and",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "and overwhelming infection with encapsulated bacteria. Streptococcus",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "pneumoniae is the most common cause of fulminant sepsis in patients with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "impaired splenic function, followed by Haemophilus influenzae and Neisseria",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "meningitidis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "If fever develops in an asplenic patient, immediate administration of an",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobial agent is indicated, because fever can be the initial",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "manifestation of a fulminant infection and prompt administration of an",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "antimicrobial agent may prevent the development of clinical sepsis.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Administration of antibiotics should not be delayed in order to perform",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "diagnostic studies, including lumbar punture.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Recommended Empiric Therapy:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin/beta lactam allergy:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Streptococcus pneumoniae meningitis suspected:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rubin LG, N Engl J Med 2014, 371:349-356",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-date online", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX MEDIASTINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2 gm Iv q8h ($$)[R] <AND> Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG IV Q24H AND VANCO 15MG/KG IV Q12H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R] <AND> Vancomycin 15 mg/kg IV q12h ($)[R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600mg IV q8h ($$) [H,O]< OR >", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 4MU Q4H METRONIDAZOLE 500 MGM IV Q8H", "Text" : "Penicillin G 4 million units IV q4h ($) [R] <AND> metronidazole 500 mg", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG IV Q24H METRONIDAZOLE 500 MG IV Q8H", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI] <AND> metronidazole 500 mg IV", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI BACILLUS SPP.", "Text" : "Anthrax section", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "MEDIASTINITIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Mediastinitis occurs after cardiothoracic procedures or less commonly after",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "esophageal perforation.Rarely, infectious diseases of the head, neck or thorax",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "spread into the mediastinum.Surgical drainage and antimicrobial therapy are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "both essential.Specific management depends on the source of infection.Obtain",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "aerobic and anaerobic cultures in all cases.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Inhalational anthrax (due to Bacillus anthracis) typically presents as",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "mediastinitis with cough productive of hemorrhagic secretions.This disease",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "should be considered in a patient without typical risk factors for mediastinitis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "or in the setting of suspected or confirmed bioterrorism.If anthrax is",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "suspected, page the Infectious Diseases service.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment AFTER CARDIOTHORACIC SURGERY",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treat for 2 to 3 weeks:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment associated WITH MOUTH/THROAT INFECTION",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mixed aerobic/anaerobic infection is often present.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "IV q8h ($) [DI]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Treatment AFTER ESOPHAGEAL PERFORATION OR RUPTURE",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mixed aerobic/anaerobic infection is often present.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "q8h ($) [DI]",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Treatment if B. anthracis is suspected",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials should be used initially for treatment.Contact",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "infectious diseases immediately.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX MEDS DELAYED PRE-OP ANTIBIOTICS CV SURGERY2", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : "ORZID2 GMENU ABX DELAYED STANDARD ABX CV SURG", "Text" : "Standard (Non PCN allergic)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU DELAYED PCN ALLERGIC CV SURG", "Text" : "Severly PCN allergic", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Delayed Antibiotic Orders CV Surgery",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Minneapolis VA facility specific recommendations for open-heart surgery", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX MICROGUIDE MOBILE APP INSTRUCTIONS", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "DIRECTIONS TO INSTALL MICROGUIDE ON MOBILE DEVICE",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Within the Apple or Google app store on your mobile device, search for the term",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "\"MicroGuide\" and download the app. When opening the app, you will be prompted to",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "submit information about yourself and institution (this is for tracking usage of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "the system by CDSS personal). Select the Minneapolis VA Health Care System as",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "your institution. You will then be prompted to download the Minneapolis VA",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Health Care System CDSS specific guide content.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "When updates to the CDSS MicroGuide are made, you will be prompted to update",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "the content on your mobile device when opening the app.",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : "ORZ GTX ABX MICROGUIDE WEB APP", "Text" : "[CLICK HERE]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "MicroGuide Web App Link", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX MICROSPORIDIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID ALBENDAZOLE 400MG PO Q12H", "Text" : "Albendazole 400 mg PO q12h for 7 to 14 days ($$) [O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID ALBENDAZOLE 400MG PO Q12H", "Text" : "Albendazole 400 mg PO q12h ($$) [O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH MICROSPORIDIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In patients without HIV/AIDs, antimicrobial treatment may not be necessary",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "because symptoms can resolve without antimicrobial therapy. In persons with",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "AIDS, highly active anti-retroviral therapy (HAART) is beneficial because",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "recovery of host defenses helps to control microsporidial disease. Treatment",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "must include dietary supplementation for weight loss. Infectious Diseases",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "involvement is essential in patients with HIV/AIDS.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of persons without HIV/AIDS",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of persons with HIV/AIDS",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Continue treatment until CD4 count is >200 for >6 months after initiation of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "ART.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Microsporidiosis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Microsporidiosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX MORE ABOUT NOSOCOMIAL PNEUMO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "Text" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MORE ABOUT NOSOCOMIAL PNEUMONIA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Types of nosocomial pneumonia",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Hospital acquired pneumonia (HAP):",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Development of pneumonia 48 hours or more after hospital admission.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Ventilator-associated pneumonia (VAP):",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Pneumonia occurring 48 hours or more after endotracheal intubation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Criteria for diagnosis of pneumonia",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "1.Presence of new or progressive infiltrate <AND>",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "2.At least two of the following:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "> Fever greater than 38 C (100.4 F)",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "> Leukocytosis or leukopenia",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "> Purulent bronchial secretions",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "HAP OR VAP suspected:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Gram stain and culture of lower respiratory tract secretions and blood",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "cultures are important for guiding therapy. If a patient with no change in",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy during the previous 72 hours has few bacteria on gram",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "stain of secretions, bacterial pneumonia is unlikely.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "covered the pathogen and the patient is clinically responding.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "culture and susceptibility tests.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Longer duration of therapy is recommended for more resistant organisms",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "(e.g. Pseudomonas aeruginosa , Acinetobacter baumanni, and",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Legonella pneumophila).",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Kalil AC Clin Infect Dis 2016, 63:1",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Luna CMCrit Care Med 2003, 31: 676",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "MRSA RISK FACTORS",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Patients with one or more of the following risk factors are at increased risk of",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "MRSA infection:",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "1. Recent hospitalization",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "2. Residence in a long-term care facility",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "3. Recent surgery",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "4. Hemodialysis",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "5. History of MRSA colonization or infection within the last year",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "6. Recent antibiotic use",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "7. Human immunodeficiency virus (HIV) infection",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "8. Injection drug use",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "9. Contact with person colonized with MRSA",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "adults: Epidemiology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX MYOCARDITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MYOCARDITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Myocarditis is most commonly associated with enterovirus or coxsackie virus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infection. Less common pathogens include pyogenic bacteria, rickettsia,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "toxoplasmosis, and fungi.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobial treatment is not indicated. Supportive care and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "treatment of CHF are essential. Consult Cardiology and/or Infectious Diseases",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "for more assistance.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Avoid non-steroidal anti-inflammatory drugs (NSAIDS) and corticosteroids in",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "these patients, as the use of NSAIDs in myocarditis has been associated with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "worse outcomes.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Myocarditis and Pericarditis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment and prognosis of myocarditis in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NASAL PACKING", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF INFECTION IN PATIENTS WITH NASAL PACKING",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis to prevent infection and toxic shock syndrome in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "patients with nasal packing is not recommended. Antibiotics increase the risk of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "adverse events in patients with nasal packing with no proven effectiveness in",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "preventing infection.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Cohn, Annals of emergency medicine 2015, 1.65, 109-111",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Kucik et al, Am Fam Physician 2005, 71.2, 305-311",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Approach to the adult with epistaxis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NEW UPDATES", "Contents" : [
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "Email the Antimicrobial CDSS Program Staff", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEW UPDATES INFORMATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Section titles that are labeled with *New Updates* have been recently updated",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "according to current literature and guidelines. All updates are reviewed by a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Minneapolis VAHCS Infectious Diseases staff physician and a clinical pharmacist.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "If you have any questions or concerns please contact the VISN23 CDSS team:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Erik Stensgard, PharmD: 612-467-1781",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Bobbie Masoud, PharmD: 612-467-4916", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL PAXLOVID PATIENT EUA FACT SHEET", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Paxlovid", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX URL PAXLOVID PROVIDER FACT SHEET EUA", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Paxlovid", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX PAXLOVID INPT AND OPT ORDERS", "Text" : "INV-Nirmatrelvir 300 mg and ritonavir 100 mg (Paxlovid) PO BID for 5 days", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PAXLOVID (EUA)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Paxlovid (nirmatrelvir-ritonavir) is available via FDA Emergency Use",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Authorization (EUA) for treating patients that meet specific criteria. Paxlovid",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "is not an FDA approved drug.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "**Treatment:**",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "ID available to discuss if needed.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Inclusion Criteria, ALL the following criteria must be met for a patient to",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "receive:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "1) Patient has tested positive for COVID-19 with a lab-confirmed test",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "2) Patient is not hospitalized due to COVID-19. Note: patient may be",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "hospitalized for some other reason.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "4) Administration will begin within 5 days of symptom onset.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "5) Patient does not have known hypersensitivity to Paxlovid or components.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Contraindications, NONE of the following must be met for patient to receive:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "1) Severe renal impairment (eGFR <30 mL/min).",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "2) Severe hepatic impairment (Child-Pugh Class C).",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "3) History of clinically significant hypersensitivity reactions to the active",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "ingredients (nirmatrelvir or ritonavir) or any other components.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "4) Co-administration with drugs highly dependent on CYP3A for clearance and for",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "which elevated concentrations are associated with serious and/or",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "life-threatening reactions.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "5) Co-administration with potent CYP3A inducers where significantly reduced",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "nirmatrelvir or ritonavir plasma concentrations may be associated with the",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "potential for loss of virologic response and possible resistance.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Warnings and Precautions:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "1) The concomitant use of PAXLOVID and certain other drugs may result in",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "potentially significant drug interactions. Consult the full prescribing",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "information prior to and during treatment for potential drug interactions.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "2) Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "jaundice have occurred in patients receiving ritonavir.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "3) HIV-1 Drug Resistance: PAXLOVID use may lead to a risk of HIV-1 developing",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "resistance to HIV protease inhibitors in individuals with uncontrolled or",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "undiagnosed HIV-1 infection.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "If all above criteria above are met and there are no contraindications, place",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "medication order:",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "*Dose reduction for moderate renal impairment (eGFR =30 to <60 mL/min): 150 mg",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "nirmatrelvir (one 150 mg tablet) with 100 mg ritonavir (one 100 mg tablet), with",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "both tablets taken together twice daily for 5 days.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "*Patients treated with this drug should continue to self-isolate and use",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "infection control measures (wear mask, isolate, social distance, avoid sharing",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "personal items, clean and disinfect \"high touch\" surfaces, and frequent",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "handwashing) according to CDC guidelines.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "6) Patient must be able to take PO and swallow tablets whole",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "**Place medication orders for inpatient and outpatient (included in order set)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NON-CHOLERA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h for 3-5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg BID for 3-5 days ($) [DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h for 3-5 days ($) [M]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM Q24H DOXY IV 100MG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg IV q12h ($$) [DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM DOXI 100MG PO", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "Text" : "Levofloxacin 750 mg IV q24h for 7 to 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NON-CHOLERA VIBRIO",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Non-cholera vibrio is associated with gastroenteritis, septicemia, and wound",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infections. Vibrio vulnificans infections are acquired from contact with",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "seawater or seafood, especially raw oysters. V. vulnificans cases are more",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "severe than cases with other species. V. parahaemolyticus causes",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "gastroenteritis and milder wound infections.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobials do not shorten the course of disease in immunocompetent patients",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "with mild gastroenteritis.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Primary treatment for gastroenteritis",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of minor wound infection, severe gastroenteritis or",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "immunocompromised patient with gastroenteritis",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative for patient intolerant of fluoroquinolones",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "For patients who are hospitalized or unable to take oral medications",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of severe wound infection or septicemia",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for advice on duration of treatment.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "for 7 to 14 days",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "for 7 to 14 days",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Vibrio parahaemolyticus",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Vibrio vulnificus: Cellulitis, Sepsis",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Vibrio parahaemolyticus infections",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Vibrio vulnificus infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU ABX MORE ABOUT NOSOCOMIAL PNEUMO", "Text" : "More about Nosocomial pneumonia...", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMONIA HAP NEW", "Text" : "Hospital Acquired Pneumonia (HAP)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMONIA VAP", "Text" : "VENTILATOR ASSOCIATED PNEUMONIA (VAP)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "Text" : "Re-evaluate Nosocomial pneumonia at 72 hours", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL A. BAUMANNII", "Text" : "Acinetobacter baumannii", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL ESBL ENTEROBACT", "Text" : "Extended-spectrum beta-lactamase producing (ESBL+) Enterobacteriaceae", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL L. PNEUMOPHILA", "Text" : "Legionella pneumophila", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSOCOMIAL STAPHYLOCOCCUS PNEUMONIA", "Text" : "Staphylococcus aureus", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL PNEUMONIA",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Local facility antibiogram and patient risk factors for multi-drug",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "resistant pathogens guide antimicrobial therapy.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Empirical therapy must be re-evaluated at 72 hours.",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "covered the pathogen and the patient is clinically responding.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "culture and susceptibility tests.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Pathogen-specific treatment",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Certain respiratory pathogens that are usually treated in unique ways are listed",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "here.Other respiratory pathogens are treated with drugs effective for",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "pneumonia and active against identified organisms.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Recommended duration of therapy for more resistant pathogens",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "(e.g. MRSA, Pseudomonas, Acinetobacter) require longer treatment.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Refer to pathogen-specific treatment regimen below for recommendation.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Pathogen-specific nosocomial pneumonia treatment regimens",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Luna CM. Crit Care Med 2003. 31:676",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL A. BAUMANNII", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL PNEUMONIA WITH ACINETOBACTER BAUMANNII",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases consultation is essential for cases with Acinetobacter which",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "are often resistant to most therapies.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is unclear and should be guided by clinical response.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Luna CMCrit Care Med 2003, 31: 676",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL ESBL ENTEROBACT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,O]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL PNEUMONIA WITH EXTENDED-SPECTRUM BETA-LACTAMASE PRODUCING (ESBL+)",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTEROBACTERIACEAE",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The microbiology laboratory tests for ESBL production in all E. coli and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Klebsiella isolates. Proteus isolated from blood samples are also tested for",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "ESBL production.Other Enterobacteriaceae produce ESBL less commonly but",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "practical tests are not available for these. If ESBL is suspected regardless of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "testing, consult Infectious Diseases and/or the microbiology laboratory for more",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Craven DE Infect Dis Clin N Am 2004, 18: 939",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Luna CMCrit Care Med 2003, 31: 676",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Mandell LA Clin Infect Dis 2003,37: 1405",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Singh N Am J Resp Crit Care Med 2000, 162: 505",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "AnonymousAm J Respir Crit Care Med 2005, 171: 388", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL L. PNEUMOPHILA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID AZITH 500MG IV Q24H", "Text" : "Azithromycin 500 mg IV q24h ($) [M]< OR >", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h ($) [M]< OR >", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL PNEUMONIA WITH LEGIONELLA PNEUMOPHILA",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Intravenous therapy preferred initially until signs and symptoms improve.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treat for 7 to 10 days. Consider longer courses of therapy in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "immunocompromised patients with severe illness.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Recommend to start with parenteral therapy:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Switch to oral to complete therapy:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mandell LA Clin Infect Dis 2007, 44: S27",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Phin N Lancet Infectious Diseases 2014, 14:1011",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford: Pneumonia Legionella",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Stout JE, Yu VL: Legionellosis. N Engl J Med 337:682, 1997",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL P. AERUGINOSA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZIDIME 2GM IV Q8H GENT 5MG IV QD", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R] <AND> gentamicin 5mg/kg IV q24h", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX CIP 400MG IV Q8H GENT 5MG IV QD", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> gentamicin 5mg/kg IV q24h", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > gentamicin 5", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CEFTA 2GM IV Q8H CIPRO 400MG IV Q8H", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R] <AND> Ciprofloxacin 400 mg", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]< OR >", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID CIPROFLOX 400MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL PNEUMONIA WITH PSEUDOMONAS AERUGINOSA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Single drug therapy is as effective as combination therapy once susceptibility",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "results are known.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment:",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "($) [R,O]< OR >",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "($) [R,O] < OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "mg/kg IV q24h ($) [R,O] < OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "IV q8h ($) [R,DI]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Narrow therapy to single active antibiotic once susceptibility results are",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "available:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Oral therapy (usually given after several days of intravenous therapy)",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "if isolate known sensitive to fluoroquinolone:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Craven DE Infect Dis Clin N Am 2004, 18: 939",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Garnacho-Montero J Crit Care Med. 2007, 35:1888",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Kalil AC Clin Infect Dis 2016 63:1",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Singh N Am J Resp Crit Care Med 2000, 162: 505",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NOSOCOMIAL STAPHYLOCOCCUS PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcilin 2 gm IV q4h ($$) [DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O] < OR >", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI] < OR >", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO bid ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL PNEUMONIA WITH STAPHYLOCOCCUS AUREUS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Known Methicillin-SUSCEPTIBLE Staphylococcus aureus pneumonia",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Duration of therapy 7-14 days.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Oral therapy (usually given after several days of intravenous therapy):",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "A patient who is substantially improved, without fever for at least 2 days",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "can be treated with an oral agent to which the isolate is susceptible.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "_________________________________________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Methicillin-RESISTANT or Susceptibilities Unknown Staphylococcus aureus",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "In patients with MRSA pneumonia complicated by empyema, antimicrobial therapy",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "should be used in conjunction with drainage procedures.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "NOTE: A prospective trial comparing Linezolid to Vancomycin for MRSA",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "pneumonia, including ventilator-associated pneumonia, showed higher clinical",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "cure rate (p=0.042) for linezolid (95/165, 57.6%) than for vancomycin",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "(81/174, 46.6%) but no difference in mortality (15.7% for linezolid vs. 17%",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "for vancomycin).Other factors to consider are the drug-drug interactions",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "associated with linezolid and cost.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Duration of therapy 7-14 days",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Oral therapy (usually given after several days of intravenous therapy:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "In cases when a patient has substantially improved and has not had a fever",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "for at least 2 days, it may be appropriate to treat with an oral agent to",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "which the isolate is susceptible to complete therapy.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Liu C, Clin Infect Dis. 2011:52:285",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Wunderink RG, Clin Infect Dis. 2012: 54:621",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Rybak MJ, Clin Infect 2009: Dis 49:325",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword:Staphlococcus aureus pneumonia",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "John Hopkins Antimicrobial Guidewww.johnhopkinsguides.com", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "Contents" : [
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References:", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PHARYNGITIS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Acute pharyngitis is common, accounting for 2 percent of all",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "ambulatory visits in the United States.The major treatable pathogen, group",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "A streptococcus (GAS), is the cause of pharyngitis in only approximately 10",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "percent of adults who seek medical care.The vast majority of patients",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "receive presumptive antibiotic therapy for pharyngitis which in most cases is",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "unnecessary and results in adverse effects including death, increases costs,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and adds to pressure on antimicrobial resistance.Typical causes of",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "pharyngitis include viruses in about , beta-hemolytic streptococci other",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "than group A in 18%, Mycoplasma pneumoniae in 10%, Chlamydophila pneumoniae",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "in 8%, Group A streptococci in 5%, and no microbe identified in 1/3.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Rheumatic fever is rare in the United States, especially in adults, so",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "that some authorities recommend no treatment even if GAS is a potential cause",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "of pharyngitis. Others feel it is important to detect GASsince antibiotic",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "therapy can slightly shorten the acute illness, prevent acute rheumatic fever",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "and possibly prevent suppurative sequelae.Other potential causes of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "pharyngitis that should be considered and diagnosed if likely include",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Epstein-Barr virus (EBV) mononucleosis, primary HIV infection, influenza,",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "gonococcal pharyngitis, diphtheria, and suppurative pharyngeal infections.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "The Centor criteria are used to predict whether GAS pharyngitis is present.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "*Tonsillar exudates",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "*Tender anterior cervical adenopathy",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "*Fever by history",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "*Absence of cough",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "If three or four of these criteria are met, the positive predictive value is",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "40 to 60 percent.If fewer than three criteria are present, the likelihood",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "GAS is causing pharyngitis is less than 20 percent.If 3 or > Centor criteria",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "are met, obtain a throat culture for group A streptococcus.Treat",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "empirically for GAS if the patient has severe symptoms or treat later for GAS",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "if the throat culture is positive.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Pharyngitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "Contents" : [
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASYMP BACTERIURIA", "Text" : "Treatment of Asymptomatic Bacteriuria", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "Text" : "Treatment of Candida Urinary Tract Infections", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIURIA, CANDIDURIA, AND PYURIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Asymptomatic bacteriuria (>= 100,000 bacteria per ml of urine) is common in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "middle aged and older people, especially those who have chronic medical",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "conditions. Pyuria is common in persons with bacteriuria and individuals with",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "indwelling catheters in place. By itself, the presence of pyuria is not",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "sufficient to diagnose bacteriuria, and the presence or absence of pyuria does",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "not differentiate symptomatic from asymptomatic urinary infection. Candiduria is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "less common than bacteriuria, but the implications of candiduria are similar to",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "those of bacteriuria.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Many studies, including randomized clinical trials have shown that",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treatment of asymptomatic bacteriuria and candiduria, with or without pyuria is",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of no benefit, except in certain well-defined circumstances. Antimicrobial",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "therapy is always accompanied by risk of harms, including drug reactions,",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Clostridium difficile colitis, anaphylaxis and death. Except in circumstances",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "specified below, it is best to not order urinalysis or urine culture in",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "asymptomatic persons. If bacteriuria, candiduria or pyuria is discovered in an",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "asymptomatic person for some reason, antimicrobial therapy should not be given",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "except as specified below.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Pregnant women or patients undergoing urological procedures with bacteriuria",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Patients undergoing urological procedures or neutropenic patients with",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "candiduria",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Pappas et al, Clin Infect Dis, 2016, 62.409",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Nicolle et al, Clin Infect Dis, 2005, 40:643", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX NOT REQUIRED MAIN", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX UPPER RESPIRATORY INFECTIONS (URI)", "Text" : "Upper Respiratory Infections (URI)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR", "Text" : "Colonized Respiratory Tract in a Patient on a Ventilator", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX STASIS DERMATITIS", "Text" : "Stasis Dermatitis", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX COLONIZED WOUNDS", "Text" : "Colonized Wounds", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITTED BACTERIURIA", "Text" : "Asymptomatic Bacteriuria, cadiduria and pyuria", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX POSITIVE BLOOD CULTURE COAG NEG STAPH", "Text" : "Blood culture positive for coagulase negative staphylococci", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CONDITIONS NOT BENEFITTED BY ANTIMICROBIAL THERAPY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Several common conditions associated with inflammation or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "microorganisms do not benefit from antibiotic therapy in most or all cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Yet, antimicrobials are frequently prescribed for these conditions leading to",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "unnecessary toxicity and costs, rare deaths, and the relentless increase in",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antimicrobial resistance. Please review these conditions and do not give",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobials for these conditions unless there are extraordinary",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "circumstances that make your situation different. If you have any questions,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "please contact the infectious disease physician on call.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Lungs and Mediastinum",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Skin and Soft Tissue",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Genitourinary",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Miscellaneous",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Last reviewed 9-2018",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "Text" : "Pharyngitis, non-streptococcal", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "Text" : "Bronchitis in an Otherwise Healthy Patient", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX OROLABIAL HERPES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "Text" : "Acyclovir 400 mg PO q8h for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 2GM PO Q12H 1 DAY", "Text" : "Valacyclovir 2 gm q12h for 1 day ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO Q8H", "Text" : "Acyclovir 400 mg PO q8h for 7-14 days($) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "Text" : "Valacyclovir 1 gm q12h for 7-14 days ($) [R]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 5 MG/KG IV Q8H", "Text" : "Acyclovir 5 mg/kg IV q8h for 7-14 days ($$) [R]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG PO BID", "Text" : "Acyclovir 400 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 500MG PO Q24H", "Text" : "Valacyclovir 500 mg PO Q24h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OROLABIAL HERPES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Antiviral therapy is not beneficial after formation of vesicles. However, when",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "started as soon as prodromal symptoms of burning or tingling occur, antivirals",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "reduce duration of pain and lesions.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients in whom herpes simplex infections can be more severe",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "include: patients with HIV infection, organ transplant recipients, patients",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "undergoing chemotherapy, malnourished patients, and those with compromised skin",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "integrity.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Chronic suppressive therapy",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Indicated for patients with greater than 6 recurrences or severe recurrences,",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "immunocompromised patients or as adjunct to prevent transmission. Suppressive",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "therapy is optional, and some patients may find episodic treatment more",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "convenient. Patients should be reassessed every few years to evaluate if chronic",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "suppressive therapy is still necessary.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes simplex",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment of herpes simplex virus type 1 infection in",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "immunocompetent patients", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PANCREATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG IV Q24H METRONIDAZOLE 500 MG IV Q8H", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI] < AND > metronidazole 500 mg IV q8h", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX LEVOFL 500MG PO Q24H METRO 1 GM PO Q12H", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI] < AND > metronidazole 1 gm PO q12h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PANCREATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are not indicated for uncomplicated pancreatitis.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "In cases of necrotizing pancreatitis without infection, antimicrobial",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "prophylaxis does not improve patient outcomes. Antimicrobials increase the risk",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "of fungal superinfection and should not be used.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are indicated for cases with pancreatic abscess, infected",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "pancreatic pseudocyst, or infected necrotic pancreas (phlegmon). The diagnosis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "of infection can be difficult and may require aspiration. Consultation with",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Gastroenterology and/or Infectious Diseases is encouraged.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Uncomplicated pancreatitis",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "No antimicrobials are indicated.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Cases with necrosis",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "In cases with necrosis, aspirate necrotic material (fine needle under CT or",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "ultrasound guidance) for smear and culture. Uninfected cases should not receive",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "antimicrobials.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Pancreatic abscess, infected pancreatic pseudocyst, or infected necrotic",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "pancreas (phlegmon)",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Total duration of antimicrobial therapy is typically 2 to 4 weeks",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy in patients with mild or moderate disease",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Step down treatment for completion of antimicrobial course after initial",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "on culture results.",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Pancreatic Infection",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Sanford Guide keyword: Pancreatitis",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Management of acute pancreatitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PARAINFLUENZA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PARAINFLUENZA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "No specific antimicrobial therapy is indicated. Contact Infectious Diseases for",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "more information on management of this disease.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Parainfluenza virus", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PAROTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX PAROTITIS MORE INFORMATION", "Text" : "More information on Parotitis", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX NAFCILLIN 2 GRAMS Q4 AND METRON 500 Q8", "Text" : "Nafcillin 2 grams IV q4h ($$) [DI] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX NAFCIL 2GM IV Q4H METRO 500MG PO Q8H", "Text" : "Nafcillin 2 grams IV q4h ($$) [DI] <AND> metronidazole 500 mg PO q8h ($) [DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG Q12 METRON 500 MG Q8", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG Q12H METRO 500MG PO Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> metronidazole 500 mg PO q8h ($) [DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PAROTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection of salivary tissue is a relatively common disease. It is usually",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "caused by a stone in the parotid duct, dehydration, or a viral infection.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Sialolithiasis in elderly patients often leads to ductal obstruction and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "secondary infection. Other predisposing factors for ductal occlusion include",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "dehydration, anticholinergic medications such as tricyclics and diphenhydramine,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "general disability and trauma. Once culture results are available adjust",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy based on specific etiologic organism.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "For more information click on the link below",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Suppurative Parotitis or Chronic Bacterial Parotitis Exacerbation Empiric",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Immunocompetent Patient",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "If MRSA suspected or alternative:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Immunocompromised Patient",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Viral Parotitis",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Suspect mumps parotitis if there is fever, malaise, earache and bilateral tender",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "swelling of the parotid glands. For mumps parotitis treat with warm compresses",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "and analgesics and maintain good hydration to prevent secondary bacterial",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "infection. Other viral causes of parotitis include influenza and enteroviruses.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Am Fam Physician. 2014, 89(11)882-888",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Parotitis",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-To-Datearticle: Suppurative parotitis in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PAROTITIS MORE INFORMATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MORE ABOUT PAROTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Suppurative Parotitis. Acute bacterial parotitis affects primarily elderly,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "malnourished, dehydrated or post-operative patients. Symptoms include fever,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "toxicity, and tender swelling along the mandible with purulent drainage from the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "parotid duct. Suppurative parotitis is usually unilateral whereas viral",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "parotitis is usually bilateral. Pain is intense and aggressive, analgesic",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "therapy is required. Progression of infection may lead to massive swelling of",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the neck, respiratory obstruction, septicemia and osteomyelitis of adjacent",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "facial bones. Empiric antibiotics are required for coverage of Staphylococcus",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "aureus if bacterial, and surgical drainage is usually necessary.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Chronic Parotitis. Parotitis is recurrent with intermittent acute exacerbations.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Chronic, low-grade bacterial infection results in functional destruction of the",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "salivary gland. It may be confused with Sjogren's syndrome, a noninfectious",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "illness. Therapy includes systemic antibiotics. Parotidectomy may eventually be",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "required for patients with long-standing infection.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Viral Parotitis. Mumps parotitis is characterized by the rapid, painful swelling",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "of one or both parotid glands within 2 to 3 weeks after exposure to the mumps",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "virus. Mumps usually involves both parotid glands whereas bacterial parotitis is",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "unilateral. Other viral causes of parotitis include influenza and enteroviruses.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mumps parotitis usually resolves spontaneously in 5 to 10 days. Provide",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "symptomatic relief of pain and fever and maintain hydration to prevent secondary",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "bacterial infection.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Am Fam Physician. 2014, 89(11)882-888",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Parotitis",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-To-Datearticle: Suppurative parotitis in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PENICILLIN DESENSITIZATION PROTOCOL",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pharmacy Service must be involved. Contact satellite pharmacist at ext. 2040 or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "menu 648-6746. Infectious Diseases Consult strongly recommended.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "When penicillin is the drug of choice for an infectious disease in a patient",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with Type I penicillin allergy, one option is to desensitize the patient.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Severe reactions cannot be predicted accurately with skin testing in the",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "clinical setting.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Penicillin Desensitization",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "> Perform in an ICU or similar setting.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "> Discontinue all beta-adrenergic antagonists.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "> Have IV line in place and EKG and spirometer ready.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "> Once desensitization has been accomplished, therapy with this drug must not",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "lapse or the risk of allergic reactions increases.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "> A history of Stevens Johnson syndrome, exfoliative dermatitis, or erythroderma",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "are nearly absolute contraindications to desensitization.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "ORAL ROUTE",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Oral route is preferred if oral preparation is available and GI tract is",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "functional. 1/3 of patients will develop transient reaction, usually mild.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "[Step, 15 minute intervals] concentration, volume",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "[1] 0.5mg/ml, 0.1ml",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "[2] 0.5mg/ml, 0.2ml",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "[3] 0.5mg/ml, 0.4ml",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "[4] 0.5mg/ml, 0.8ml",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "[5] 0.5mg/ml, 1.6ml",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "[6] 0.5mg/ml, 3.2ml",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "[7] 0.5mg/ml, 6.4ml",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "[8] 5mg/ml, 1.2ml",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "[9] 5mg/ml, 2.4ml",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "[10] 5mg/ml, 4.8ml",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "[11] 50mg/ml, 1ml",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "[12] 50mg/ml, 2ml",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "[13] 50mg/ml, 4ml",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "[14] 50mg/ml, 8ml",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "After step 14, observe 30 minutes. If no reaction, give 1 gm IV.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "PARENTERAL ROUTE",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "[Step, 15 minute intervals] concentration, volume",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "[1] 0.1mg/ml, 0.1ml",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "[2] 0.1mg/ml, 0.2ml",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "[3] 0.1mg/ml, 0.4ml",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "[4] 0.1mg/ml, 0.8ml",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "[5] 1mg/ml, 0.16ml",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "[6] 1mg/ml, 0.32ml",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "[7] 1mg/ml, 0.64ml",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "[8] 10mg/ml, 0.12ml",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "[9] 10mg/ml, 0.24ml",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "[10] 10mg/ml, 0.48ml",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "[11] 100mg/ml, 0.1ml",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "[12] 100mg/ml, 0.2ml",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "[13] 100mg/ml, 0.4ml",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "[14] 100mg/ml, 0.8ml",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "[15] 1000mg/ml, 0.16ml",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "[16] 1000mg/ml, 0.32ml",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "[17] 1000mg/ml, 0.64ml",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "After step 17, observe 30 minutes. If no reaction, give 1 gm IV.",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Sanford key term: allergy",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Allergy: Principles and Practice 1993, p1726",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Curr Clin Topics Inf Dis 1993, 13:131", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PERI ASSOC W PERI DIAL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 200MG PO Q48H", "Text" : "Fluconazole 200 mg PO every other day ($) [R,DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 100MG PO Q24H", "Text" : "Fluconazole 100 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFEPIME 1 GM Q24H", "Text" : "Cefepime 1 gm PD q24h ($$) [R]", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H AND GENT 0.6MG/KG Q24H", "Text" : "Cefazolin 15 mg/kg ($) [R] <AND> gentamicin 0.6 mg/kg ($) [R,O] PD q24h", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFEPIME 1GM Q24H VANCO 15-30MG/KG Q5-7D", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D AND GENT 0.6MG/KG Q24H", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H", "Text" : "Cefazolin 15 mg/kg PD q24h ($) [R]", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFEPIME 1 GM Q24H", "Text" : "Cefepime 1 gm PD q24h ($$) [R]", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "ORZID2 GMENU PD GENTAMICIN 0.6MG/KG Q24H", "Text" : "Gentamicin 0.6 mg/kg PD q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H", "Text" : "Cefazolin 15 mg/kg PD q24h ($) [R]", "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFTAZIDIME 1GM Q24H", "Text" : "Ceftazidime 1 gm PD q24h ($) [R]", "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : "ORZID2 GMENU PD CEFTRIAXONE 1GM Q24H", "Text" : "Ceftriaxone 1 gm PD q24h ($) [M]", "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : "ORZID2 GMENU PD GENTAMICIN 0.6MG/KG Q24H", "Text" : "Gentamicin 0.6 mg/kg PD q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Peritonitis associated with peritoneal dialysis usually presents with abdominal",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "pain, fever, nausea or vomiting, and cloudy effluent. The leukocyte",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "concentration is greater than 100 cells/microliter of dialysate, with more than",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "50% neutrophils.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Obtain Gram stain, culture, and cell count with differential of dialysate before",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobials are given. Nephrology consultation is essential. If cultures",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "show Gram-negative or mixed bacterial infection, a gastrointestinal tract",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "infectious source is more likely. Gram-positive organisms like staphylococci",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "usually result from external contamination. Fungal peritonitis is rare and",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "requires immediate catheter removal.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "**Antimicrobial recommendations are for empirical therapy only. Regimens should",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "be tailored according to patient response and microbiology results in",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "consultation with Nephrology and/or Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "To prevent catheter occlusion by turbid dialysate, add 1,000 units of heparin",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "per dialysis bag each day until one day after the dialysate is clear.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "If vancomycin is used, trough serum concentrations should be kept above 15",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "mcg/ml to ensure adequate intraperitoneal levels. Usually vancomycin must be",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "given every 3 to 7 days. Contact Nephrology and/or Pharmacy for more",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Antifungal prophylaxis:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Antifungal prophylaxis may be used for the duration of antimicrobial therapy to",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "possibly reduce the risk of fungal peritonitis.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Antimicrobial therapy",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Duration",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Duration of therapy depends on the pathogen identified. Treat staphylococcal and",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "streptococcal infections for 2 weeks and all other gram-positive infections for",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "3 weeks. In patients who have Staphylococcus isolated and had a previous",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "staphylococcal infection, treat for 3 weeks",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "All antimicrobials below are administered via peritoneal dialysate bag over 6",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "hours with the option to include heparin 1000 units.",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Empirical treatment while waiting for results of gram stain",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "MRSA risk factors",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "cefepime 1 gm PD q24h ($) [R]",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Alternative for severe penicillin or cephalosporin allergy",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "gentamicin 0.6 mg/kg PD q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Gram positive organism",  "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Gram negative organism",  "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Alternative for severe penicillin allergy",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Alternative treatments for narrowing coverage based on isolate susceptibilities",  "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "De Vin et al, Peritoneal Dialysis International, 2009, Vol. 39, pp. 5-15",  "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : null, "Text" : "Li et al, Peritoneal Dialysis International, 2016, Vol. 36, pp. 481-508",  "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses",  "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Peritonitis, Dialysis (CAPD) Associated",  "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Microbiology and therapy of peritonitis in peritoneal",  "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : null, "Text" : "dialysis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX DERM IE JI PROPHYLAXIS", "Text" : "High risk of hematogenous prosthetic joint infection", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "Link to MRSA Risk Factors menu", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX TRIMETH/SULFA DS Q12H METRO 1 GM PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-Tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2 GM IV QD METRONIDAZOLE 500 MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERIANAL/ANORECTAL ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Primary therapy: abscess drainage",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Prompt surgical drainage is important. Antibiotics have a limited role in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "treatment of uncomplicated anorectal abscess. In general, the addition of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antibiotics to routine incision and drainage of uncomplicated anorectal abscess",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "does not improve healing time or reduce recurrences. Antibiotics may be",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "considered in patients with significant cellulitis, underlying",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "immunosuppression, concomitant systemic illness, or failure to improve with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "drainage alone.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Antibiotic prophylaxis for prevention of infective endocarditis or hematogenous",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "prosthetic joint infection is recommended for procedures involving infected skin",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "or skin structures in patient with underlying cardiac or high-risk prosthetic",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "joint conditions. Click on link below for list of conditions and",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "recommendations.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Although culture of abscess fluid in patients who undergo drainage is rarely",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "helpful, it may be considered in patients who will be treated with adjunctive",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "antibiotic treatment, recurrent infection or nonhealing wounds, substantial host",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "defense deficiency, and patients with MRSA risk factors. Click on the link below",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "for list of MRSA risk factors.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Duration of adjunctive antimicrobial therapy",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "After adequate drainage, 5-14 days of antibiotic coverage is indicated for those",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "who receive adjunctive antimicrobial therapy, with duration in part based on",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "resolution of fever and leukocytosis, severity of infection, and additional",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "indicators of clinical response.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Adjunctive antibiotic treatment for drained perirectal abscess in patients with",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "significant cellulitis, underlying immunosuppression, concomitant systemic",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "illness, or failure to improve with drainage alone",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Mild disease",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "metronidazole 1000 mg PO q12h ($) [DI]",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Moderate disease",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta-lactam allergy",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Severe, life-threatening disease",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with penicillin allergy",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Steele et al, Dis Colon Rectum 54(12):1465-74, 2011",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Wilson et al, Circulation 116:1736, 2007",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Perianal and perirectal abscess",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Cellulitis and skin abscess in adults: Treatment",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "Text" : "High risk of infective endocarditis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PERICARDITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> piperacillin-tazobactam 4.5 gm", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERICARDITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases arise from non-infectious causes or are associated with viruses.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Antimicrobial therapy is not indicated unless pericardial fluid is purulent. If",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "fluid is purulent, pericardial drainage is required in most cases. Modify",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial regimen and narrow coverage based on results of culture and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "susceptibility tests.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Cardiology consultation is essential for management of therapy. Infectious",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Diseases consultation is recommended if an infectious origin is suspected.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration is based on patient specific factors such as resolution of fever and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "clinical signs of infection. Generally, duration is 2 to 4 weeks depending on",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "how adequacyof drainage of pericardial fluid and susceptibility of infectious",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "organism.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "IV q6h ($$) [R]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Adler et al., European Heart Journal 2015, 36.2921-2964",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Myocarditis and Pericarditis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pericarditis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Purulent pericarditis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PERTUSSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU DIAGNOSIS PERTUSSIS", "Text" : "Diagnosis of pertussis", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF PERTUSSIS", "Text" : "Prevention of pertussis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500 mg PO x 1 then 250 mg QD for 4 days ($)[M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERTUSSIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pertussis is associated with persistent cough in adolescents and adults.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Immunity conferred by pertussis vaccine wanes after about 10 years. The first 1",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "to 2 weeks of disease resembles viral upper respiratory infection.After this,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "the characteristic cough with whoop is present for 1 to 6 weeks, followed by a",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "2 to 3 week period of gradual resolution.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative for macrolide intolerant or allergic patients",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Kline et al, Am Fam Physician (2013) 88.8, 507-514",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Langley et al, Pediatrics (2004), e96-e101",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pertussis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bordetella species", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PHARYNGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX GONOCOCCAL", "Text" : "Treatment of Gonorrheal Infections", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "LRTZHIV (RAPID) QUALITATIVE", "Text" : "HIV Rapid Test", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU MORE ABOUT PHARYNGITIS", "Text" : "More About Pharyngitis/Tonsillitis and Modified Centor score", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "LRTZ STREP A PCR", "Text" : "Rapid Strep A throat PCR testing lab order", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500 MG PO Q12H", "Text" : "Penicillin V 500 mg PO q12h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID BENZATHINE PENICILLIN 1.2MU IM ONCE", "Text" : "Benzathine penicillin 1.2 million units IM x 1 ($$$) [M]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG Q12H", "Text" : "Cephalexin 500 mg PO q12h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500 mg PO once on day one then 250mg PO q24h for 4 days ($)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PHARYNGITIS AND TONSILLITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are viral, primarily due to adenovirus. Aside from streptococcal and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "gonococcal pharyngitis, antimicrobials are not indicated. For gonococcal",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pharyngitis, use link below for recommendations.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consider HIV screening for patients with pharyngitis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Streptococcal Pharyngitis and Tonsillitis",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Diagnosis of group A streptococcal (GAS) infection is made through detection by",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "rapid PCR and should be reserved for patients who have a moderate to high risk",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of GAS infection according to the Modified Centor Score. Use link below for",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Modified Centor score criteria and for more details.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "PCR Negative, Viral and Other Non-GAS Causes of Pharyngitis Treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are not indicated",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "GAS Pharyngitis and Tonsillitis Treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Primary alternative:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "[M]",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Pharyngitis",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcal Pharyngitis",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PID", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 500MG IM DOXYC 100MG PO METRO 500MG PO", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > doxycycline 100 mg q12h for 14", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CEF 500MG IM ONCE DOXYCL 100MG PO Q12H", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > doxycycline 100 mg PO q12h for 7", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 500MG IM ONCE AZITHROMYCIN 1GM PO ONCE", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > azithromycin 1 gm PO once ($) [M]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX CEFOTETAN 2GM IV Q12H DOXYCL 100MG PO Q12H", "Text" : "Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX CEFOT 2GM IV Q12H DOXYCL 100MG IV Q12H", "Text" : "Cefotetan 2 gm IV q12h ($$) [R] < AND > doxycycline 100 mg IV q12h ($) [DI]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG IV Q8H GENT 5 MG/KG QD", "Text" : "Clindamycin 900 mg IV q8h ($$) [H,O] < AND > gentamicin 5 mg/kg q24h ($) [R,", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PELVIC INFLAMMATORY DISEASE (PID)",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Pelvic inflammatory disease (PID) refers to bacterial infection of the upper",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "female reproductive tract. Likely bacterial pathogens include Neisseria",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "gonorrhoeae, Chlamydia trachomatis, anaerobes, enteric Gram-negative rods, and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Streptococcus agalactiae. PID should be considered in sexually active women",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "with pelvic tenderness and signs of lower genital tract inflammation. Signs and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "symptoms may be mild or non-specific, and providers should have a low threshold",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "to initiate treatment. All women who are diagnosed with acute PID should be",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "tested for N. gonorrohoeae, C. trachomatis, and HIV. Male sex partners of",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "patients with PID should be examined and treated (see below) if they had sexual",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "contact within the 60 days before onset of the patient's symptoms.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Judge severity of infection based on clinical signs and symptoms, including",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "blood pressure, pulse, mental status, and degree of fever.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "days ($) [DI] < OPTIONAL > metronidazole 500 mg PO q12h ($) [DI]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For patients who cannot take ceftriaxone and doxycycline, call ID",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment of sex partner who is a veteran",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treat for both Chlamydia and Gonorrhea",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "days ($) [DI]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "O]",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Neisseria gonorrheoeae (Gonorrhea)",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pelvic inflammatory disease",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Pelvic inflammatory disease: Treatment",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pelvic inflammatory disease",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Pelvic inflammatory disease: Treatment",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TABLET PO Q24H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet QD ($) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID TMP/SMX SS Q24H", "Text" : "Trimethoprim-sulfamethoxazole 1 SS tablet QD ($) [R,DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID DAPSONE 100MG PO QDAY PCP PROPHLAXIS", "Text" : "Dapsone 100mg PO QD ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PNEUMOCYSTIS JIROVECII PROPHYLAXIS (PCP Prophylaxis)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Indications for primary prophylaxis of P. jirovecii include:",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "1) HIV/AIDS patients with CD4 count <200 cells/microliter",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "2) Hematopoietic or organ transplantation patients during immunosuppression",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "3) Patients receiving Alemtuzumab, temozolomide or fludarabine",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "4) Patients receiving >/= 20mg equivalent of prednisone per day for over 1 month",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "5) Patients with acute lymphocytic leukemia, rheumatologic disease receiving",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "immunosuppressive therapy and certain primary immunodeficiencies (e.g. severe",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "combined immunodeficiency, idiopathic CD4 T-lymphocytopenia, hyper-IgM",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Dose and duration of prophylaxis varies with the indication. Please contact",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases or Hematology/Oncology for more information.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Prophylaxis should be discontinued when host defenses are restored. In persons",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "with AIDS on highly active antiretroviral therapy, Prophylaxis should be",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "discontinued when the CD4 cell concentrations remain over 200 cells/microliter",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "for 3 to 6 months in patients, except that prophylaxis should be continued for",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "life in those who have had P. jirovecii disease.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2018)",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pneumocystis pneumonia, Adult",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of Pneumocystis pneumonia in HIV-",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "uninfected patients",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Recommended FIRST-LINE prophylaxis:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "**Patient should be tested for glucose-6-phosphate dehydrogenase (G6-PD)",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "deficiency before starting dapsone. Individuals deficient in G6-PD",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJZID ATOVAQUONE 1500MG QDAY PCP PROPHYLAXIS", "Text" : "Atovaquone 1500mg qday for PCP prophylaxis ($$) [DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Atovaquone is alternative for patient for clinical reason:",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "(e.g. patients with SLE, hematologic concerns, G6PD deficiency)",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Alternative to the above preferred regimens:",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : "LRTZ G6-PD SCREEN", "Text" : "[Click here] G6-PD Screen Lab Order", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "syndrome)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "show about a 2-fold increase in sensitivity toward dapsone-induced hemolytic",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "anemia.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "G6-PD lab test are resulted the same day or next day. May be add on lab.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "G6-PD lab result should be \"normal\" to start dapsone therapy.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative when trimethoprim/sulfa is poorly tolerated or contraindicated:",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Maertens J, et al. J Antimicrob Chemother. 2016, 71(9): 2397-404",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Martin SI, et al. Am J Transplant. 2013, 13 Suppl 4:272-9",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Alternative to the above regimens:",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX PENTAMIDINE NEB INPT", "Text" : "Pentamidine 300mg Inhalation QMONTH ($) [DI,O] <AND> Albuterol 0.083%", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "inhalation QMONTH ($) [M] clinic orders (call 612-467-5193 for 3V LPN",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "appointment)",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Due to efficacy and complicated logistics for administration, alternative",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "when above recommendations not appropriate for patient.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "Text" : "Aspiration Pneumonia", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "Text" : "Community-acquired pneumonia (CAP)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOSO PNEUMONIA NEW", "Text" : "Nosocomial pneumonia (including HAP, AND VAP)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ PNEUMONIA - INPATIENT ++",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Note: Healthcare-associated pneumonia (HCAP), no longer used in the 2019",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "ATS/IDSA CAP Guideline. Instead, prior history or risks for MRSA",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and/or P. aeruginosa are used to guide whether to start",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "appropriate coverage empirically. (See CAP above)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PNEUMONIA HAP NEW", "Contents" : [
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ 4.5GM IV Q6H VANCO 15MG/KG IV Q12H", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "15 mg/kg IV q12h ($) [R] < OR >",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMPIRIC TREATMENT: Hospital Acquired Pneumonia (HAP)",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG IV Q24H AND VANCO 15MG/KG IV Q12H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]] <AND> vancomycin 15 mg/kg IV", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "q12h ($) [R]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Chastre J. JAMA 2003. 290:2588.",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Luna CM. Crit Care Med 2003. 31:676.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Roig J. J Antimicrob Chemother 2003. 51:1119.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Risk Factors for Multi-Drug Resistant (MDR) Pathogen(s):",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Prior intravenous antibiotic use within 90 days",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "covered the pathogen and the patient is clinically responding.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Preferred Treatment:",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Boyce JM. Antimicrob Agents Chemother 2013. 57:1163",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "culture and susceptibility tests. Can discontinue MRSA coverage if no",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "MRSA isolated from respiratory cultures, if obtained, or if nasal",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "swab or throat cultures show no growth of MRSA, or if NAAT negative for",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "MRSA.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "resistant pathogens guide antimicrobial therapy.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Local facility antibiogram and patient risk factors for multi-drug",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Development of pneumonia 48 hours or more after hospital admission.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "Text" : "", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Conditions that increase risk for Pseudomonas infections:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : ">Bronchiectasis or Bronchomalacia",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : ">Lung Cancer",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : ">Pneumonectomy",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : ">Bronchoesophageal fistula",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : ">Cystic Fibrosis",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : ">Chronic pleural effusions with chest tubes",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : ">Severe obstructive Lung Disease with FEV1%<31",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If no risk factors for pseudomonas:",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "If risk factors for Pseudomonas *ADD* additional coverage to above regimens:",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PNEUMONIA VAP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG IV Q24H AND VANCO 15MG/KG IV Q12H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX PIPER/TZ 4.5 GENT 5M/KG VANCO 15MG/KG Q12H", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin 5", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM GENT 5M/KG VANCO 15MG/KG Q12H", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> gentamicin 5", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2G Q8H GENT 5MG/KG VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($$$$) <AND> gentamicin 5 mg/kg IV", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX LEVO 750MG GENT 5M/KG VANCO 15MG/KG Q12H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h ($)", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "EMPIRIC TREATMENT: Ventilator Associated Pneumonia (VAP)",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Pneumonia occurring 48 hours or more after endotracheal intubation",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Local facility antibiogram and patient risk factors for multi-drug",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "resistant pathogens guide antimicrobial therapy.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Risk factors for Multi-Drug Resistant VAP:",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Prior intravenous antibiotic use within 90 days",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Septic shock at the time of VAP",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "ARDS preceding VAP",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "5 or more days of hospitalization prior to the occurrence of VAP",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Acute renal replacement therapy prior to VAP onset",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Local resistance pattern",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment for 7 days is generally sufficient if the initial empiric therapy",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "covered the pathogen and the patient is clinically responding.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Narrow therapy to treat specific pathogen(s) based on results of",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "culture and susceptibility tests. Can discontinue MRSA coverage if no",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "MRSA isolated from respiratory cultures, if obtained, or if nasal",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "swab or throat cultures show no growth of MRSA, or if NAAT negative for",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "MRSA.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "No Risk of MDR Pathogen(s):",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "15mg/kg IV q12h ($) [R]<OR>",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "q12h ($) [R]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative for Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "q12h ($) [R]",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Risk of MDR Pathogens:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Preferred Treatment:",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]<OR>",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "mg/kg IV q24h ($) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy:",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]<OR>",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Boyce JM. Antimicrob Agents Chemother 2013. 57:1163",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Chastre J. JAMA 2003. 290:2588.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ. Am J Respir Crit Care Med 2001. 163:1371.",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Luna CM. Crit Care Med 2003. 31:676.",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Roig J. J Antimicrob Chemother 2003. 51:1119.",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX POSITIVE BLOOD CULTURE COAG NEG STAPH", "Contents" : [
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH", "Text" : "Treatment of CNS Bacteremia", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH COAG-NEG STAPH", "Text" : "Treatment of CNS Infected Intravascular Catheters", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BLOOD CULTURE POSITIVE FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "CNS are the most common contaminants isolated from blood cultures. When CNS",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "isolated from blood cultures represent true bacteremia, the blood is usually",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "obtained from a patient with plastic or metal in the body. The most common",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "source of coagulase negative staphylococcal bacteremia is an infected",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "intravascular catheter.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "When CNS are isolated from blood, the physician should carefully assess the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "patient to decide whether the isolation represents disease or colonization.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Colonization is more likely if a single bottle is positive or both bottles from",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "a single blood draw are positive. If multiple bottles are positive from separate",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "blood draws, it is more likely that the isolates reflect disease or colonization",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of an intravascular device. Isolates from contaminated bottles often take",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "several days to become positive. If the patient has risk factors for true",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "coagulase negative staphylococcal bacteremia, catheter-related blood stream",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "infection and/or the patient is severely ill, antimicrobials should be given",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "(see below). If there is a plastic or metal prosthesis in the body, the",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "physician should evaluate the site for possible infection. If the isolates are",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "likely to represent contamination and the patient does not seem ill with CNS,",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy would not be helpful and should not be given.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus epidermis and Other Coagulase-Negative",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Staphylococci",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mermel et al, Clin Infect Dis, 2009, 49", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PREVENTION OF INFECTION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "Text" : "Prevention of bacterial endocarditis", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU PREV PROS JOINT DENTAL", "Text" : "Before dental procedures", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT BACT PROPHYL", "Text" : "Antibacterial prophylaxis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL", "Text" : "Antifungal prophylaxis", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Antiviral prophylaxis", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "Text" : "Spontaneous bacterial peritonitis", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "Pneumocystis jirovecii prophylaxis", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Click Here", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++PREVENTION OF INFECTION++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Prevention of bacterial endocarditis",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Prevention of prosthetic joint infection",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Prevention of infection in patient with malignancy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Prevention of infection in patients with liver disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Prevention of Pneumocystis infection",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Prevention of recurrent Staphylococcus aureus skin infection",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Section reviewed January 2019",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERM IE JI PROPHYLAXIS", "Text" : "Before procedures involving infected skin, skin structures or muskuloskeletal", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "tissue", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO 5X/D", "Text" : "Acyclovir 800 mg PO 5x/d for 5-7 days ($) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "Text" : "Valacyclovir 1 gm PO q8h for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO 5X/D", "Text" : "Acyclovir 800 mg PO 5x/day for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "Text" : "Valacyclovir 1000 mg PO q8h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "Text" : "Acyclovir 10 mg/kg IV q8h for 7 days ($$) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PRIMARY INFECTION (CHICKENPOX)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Prevention",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Vaccinate all adults without evidence of immunity except for pregnant women.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Test antibody first in adults who have uncertain history of chickenpox or",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "vaccination.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Give Varicella vaccine x 2, 2nd dose 4-8 weeks after 1st dose",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Therapy must be started within 24 hrs onset of rash.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Therapy must be started within 24 hrs onset of rash.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Prevention",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients without prior immunity to varicella who are at risk",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "for disease include: patients with malignancy, current immunosuppressive",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "therapy, or HIV infection. Vaccination is not recommended while patients are",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "immunocompromised.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease, or if mild to moderate disease doesn't improve on",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "above therapy",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Kim et al. Annals Intern Med. 2018, 168(3):210-220",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Varicella-Zoster Virus",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PROCED FOR INFECTED SKIN, SKIN STRUCTURES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 2GM PO ONCE 'C'", "Text" : "Cephalexin 2 gm PO 1 hour before procedure ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 1GM IV ONCE 'C'", "Text" : "Cefazolin 1 gm IV over 20 minutes, beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID TRIMETHOPRIM/SULFA 1 DS PO (PRE-OP)", "Text" : "Trimethoprim/Sulfamethoxazole 1 DS table PO 1 hour before incision", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100 MG PO (PRE-OP)", "Text" : "Minocycline 100 mg PO 1 hour before incision ($) [DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15mg/kg IV over 60 minutes, beginning 120 minutes before incision", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIALS FOR PATIENTS UNDERGOING PROCEDURES THAT INVOLVE INFECTED SKIN,",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "SKIN STRUCTURES, OR INFECTED MUSCULOSKELETAL TISSUE TO PREVENT ENDOCARDITIS OR",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "PROSTHETIC JOINT INFECTION",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pathogen unknown or possibly MSSA or beta-hemolytic streptococcus",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Patients unable to take oral medications",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Suspected MRSA",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "($) [R,DI]",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "infection in adults",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PYELO SPECIFIC PATHOGENS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 1GM IV Q6H", "Text" : "Ampicillin 1-2 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "Text" : "Linezolid 600 mg PO Q12h ($) [DI,O]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "Text" : "Linezolid 600 mg IV Q12h ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PYELONEPHRITIS WITH SPECIFIC PATHOGEN",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment regimens apply to mild, moderate, and severe cases.",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Infections with enterococcus and pseudomonas require specific therapy.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "If enterococcus identified",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy or ampicillin-resistant enterococci",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative for vancomycin-resistant enterococci (VRE)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Linezolid should be used only for patients who cannot tolerate vancomycin",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "because of its drug interactions, high cost, and to avoid selection of",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "resistance.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "If Pseudomonas identified",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pyelonephritis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX PYELONEPHRITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX PYELO SPECIFIC PATHOGENS", "Text" : "Treatment for specific pathogens", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX GENTAMICIN 5 MG/KG Q24H/VANCO 15MG/KG", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < AND > gentamicin 5 mg/kg", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 1GM IV Q6H AND GENT 5MG/KG IV Q24H", "Text" : "Ampicillin 1-2 gm IV q6h ($$) [R] <AND> gentamicin 5 mg/kg IV Q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV Q24h ($) [M]", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZ SET ABX GENTAMICIN 5 MG/KG Q24H/VANCO 15MG/KG", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < AND > gentamicin 5 mg/kg", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV Q24H ($) [M]", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV Q24H ($) [R,O]", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO Q8H ($) [R]", "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO Q12H ($) [R]", "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PYELONEPHRITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are caused by Escherichia coli. Resistant organisms are more likely",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "if the patient has been in the hospital for more than 48 hours or received a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "course of antibiotics.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Obtain a urine Gram stain immediately to guide therapy. Drugs active against",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "enterococci (ampicillin, piperacillin) or staphylococci needn't be used if Gram-",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "negative bacilli predominate on the smear.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Judge severity of infection based on clinical signs and symptoms, including",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "blood pressure, pulse, mental status, white blood count, and degree of fever.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Oral regimens are preferred over IV if severity is mild or moderate and patient",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "is able to tolerate oral antibiotics.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "In older men with pyelonephritis, obtain a renal ultrasound to rule out",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "obstruction. Consult urology if abnormalities are found.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treat for 7 to 14 days. In patients with a mild infection and a quick clinical",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "response, 7 days of treatment may be adequate. Severe infection, resistant",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "organisms or structural abnormality may require a longer duration. A 7-day",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "course of ciprofloxacin has been shown to be as effective as a 14-day course.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment for pyelonephritis is often a 3 step process.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Stage 1: Early empirical therapy",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Stage 2: If the patient rapidly becomes clinically stable and does not have",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "SIRS, narrow intravenous or oral therapy can be substituted before",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "susceptibility results are known.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Stage 3: Definitive therapy is based on susceptibility results.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Stage 1, Empirical treatment:",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mild to moderate disease",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Usual therapy:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "If previous cultures indicate that the urinary pathogen is susceptible to",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "trimethoprim/sulfamethoxazole or ciprofloxacin and oral therapy is appropriate",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Alternatives for patients unable to tolerate usual therapy:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "IV q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Severe disease",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "IV q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Stages 2 and 3:",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "Sanberg et al, Lancet (2012) 380.9840:4-10",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pyelonephritis",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX RE-EVALUATE 72HRS N. PNEUMO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "RE-EVALUATE NOSOCOMIAL PNEUMONIA AT 72 HOURS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Step 1.Evaluate the patient",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Assess for favorable clinical response indicated by improvement in one or more",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "of the following: fever, mental status, appetite, ability to eat, oxygenation,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "blood pressure, pulse, leukopenia.If the patient has improved, continue to",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "step 2.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "If the patient has not improved, consider the following",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "1. The patient has pneumonia with a pathogen resistant to empirical",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "antimicrobials (e.g., resistant bacteria, fungi, mycobacteria)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "2. The patient does not have bacterial pneumonia.Consider alternative",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "diagnoses including pulmonary edema, atelectasis, pulmonary embolus, ARDS,",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "pulmonary hemorrhage, underlying disease, and neoplasm.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "3. The patient has infectious disease outside the lungs.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "4. The patient has one or more complications of pneumonia (e.g., empyema, lung",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "abscess, mediastinitis, or pericarditis)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "5. The patient has an adverse drug event",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Infectious Disease or Pulmonary consult is strongly encouraged for patients who",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "do not respond to initial therapy.If bacterial pneumonia is still considered",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "likely, continue to step 2.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "____________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Step 2.Evaluate microbiology results",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "____________________________________________________",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Decide whether a likely pathogen has been identified from respiratory secretions",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "or blood.The clinician must decide whether any organisms identified on smear",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "or culture of respiratory tract secretions reflect disease, colonization, or",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "contamination based on clinical and microbiological information.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "The quality of a respiratory secretion sample must be evaluated.Sputum samples",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "with fewer than 25 polymorphonuclear leukocytes per high power field (hpf) are",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "unlikely to be from a site of bacterial infection unless the patient is",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "profoundly neutropenic.Sputum samples with more than 10 epithelial cells/hpf",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "are likely to be contaminated with upper respiratory tract secretions.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "In cases of bacterial pneumonia, a gram stain of a high quality respiratory",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "tract secretion usually contains 3+ or 4+ of bacteria with morphology and",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "staining characteristics consistent with the pathogen.Culture of the",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "respiratory tract secretion indicates the species and susceptibilities of the",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "bacteria seen on gram stain.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Step 3.Adjust or discontinue antimicrobial therapy",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Decide whether to continue, modify, or discontinue antimicrobials.If an",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "organism likely to be a respiratory pathogen is isolated from a patient thought",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "to have bacterial pneumonia, adjust therapy if necessary to treat this pathogen.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "If the patient does not have convincing evidence for bacterial pneumonia and/or",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "a likely pathogen has not been isolated from respiratory secretions then stop",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "antimicrobials for pneumonia.",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al. Clin Infect Dis 2016. 63:1",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Luna CMCrit Care Med 2003, 31: 676",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "Text" : "Valacyclovir 1000 mg PO q8h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJZID PREDNISONE TAPER HERPES ZOSTER TX", "Text" : "Prednisone 60 mg daily for 7 days then 30 mg daily for 7 days, then 15 mg", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "Text" : "Valacyclovir 1000 mg PO q8h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "Text" : "Acyclovir 10 mg/kg IV q8h for 7-14 days ($$) [R]", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 7.5 MG/KG IV Q8H", "Text" : "Acyclovir 7.5 mg/kg IV q8h for 7-14 days($$) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "REACTIVATION OF PRIMARY INFECTION (ZOSTER OR SHINGLES)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Zoster represents reactivation of varicella-zoster virus. After primary",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infection, virus remains latent in the sensory dorsal root ganglia.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Reactivation syndrome is characterized by painful, unilateral, vesicular,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "dermatomal rash.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Prevention",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Vaccinate all adults greater than or equal to 50 years of age with the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "recombinant zoster vaccine regardless of past episode or receipt of the live",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "zoster vaccine.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Give recombinant zoster vaccine x2, 2nd dose 2-6 months after the first",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment in persons <50 years",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment is not beneficial, none is recommended.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment in persons >=50 years",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment with antivirals can shorten duration of pain and rash in patients over",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "50 years old. Treatment must be started within 72 hours of onset.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "There is evidence that addition of corticosteroids to antiviral",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "therapy decreases pain and duration of rash and improves quality of life",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "modestly during the acute shingles episode. Corticosteroids do not decrease the",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "incidence of post-herpetic neuralgia. Some authorities recommend addition of",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "corticosteroid therapy to antiviral therapy for patients over age 50 years.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Corticosteroids are not recommended for patients at greater risk for steroid",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "toxicities (e.g., insulin-dependent diabetes mellitus, hypertension, peptic",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "ulcer disease) or for immunocompromised patients.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Optional Recommendation:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "daily for 7 days. ($)",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients at increased risk for complications of VZV disease",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "include: patients with malignancy, current immunosuppressive therapy, or HIV",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "infection. Treatment with antivirals shortens duration of symptoms and reduces",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "incidence of complications. In immunocompromised patients, treatment is",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "recommended to be started at any point during an active infection.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease or progression from mild to moderate disease in",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "patients <=65 years",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease or progression from mild to moderate disease in",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "patients >65 years",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Kim et al. Annals Intern Med. 2018, 168(3):210-220",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Varicella-Zoster Virus",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (A-C)", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Anonymous.Antibiotic prophylaxis for urological patients with total joint",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "replacement.Advisory statement, American Urological Association And",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "American Academy Of Orthopaedic Surgeons.J Urol 2003, 169: 1796",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Anonymous.Antifungal drugs.Med Letter Treatment Guidelines 2005, 3: 7",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Anonymous.Antimicrobial prophylaxis in surgery.Med Lett 2001, 43: 92",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Anonymous.ASHP Therapeutic Guidelines on Antimicrobial Prophylaxis in Surgery.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Am J Health-Syst Pharm 1999, 56: 1839",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Anonymous.Choice of antibacterial drugs.Med Letter Treatment Guidelines",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "2004, 2: 13",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Anonymous.Guidelines for the management of adults with hospital-acquired,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "ventilator-associated, and healthcare-associated pneumonia.Am J Respir",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Crit Care Med 2005, 171: 388",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Anonymous.Prevention of wound infection and sepsis in surgical patients.Med",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Lett 2001, 43: 92",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Baddour et al. Infective endocarditis: diagnosis, antimicrobial therapy, and",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "management of complications.AHA scientific statement.Circulation 2005,",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "111: e394-e433.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Baddour LM, et al.Nonvalvular cardiovascular device-related infections.AHA",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Scientific Statement.Circulation 2003, 108: 2015-31.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Bartlett JG.Antibiotic-associated diarrhea.NEJM 2002, 346:334",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Baum J.Infections of the eye.Clin Infect Dis 1995, 21: 479",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Beutner KR, et al.Valacyclovir compared with acyclovir for improved therapy",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "for herpes zoster in immunocompetent adults.Antimicrob Ag Chemother 1995,",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "39:1546.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Bisno AL , et al.Practice guidelines for the diagnosis and management of group",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "A streptococcal pharyngitis.Clin Infect Dis 2002, 35: 113",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Boivin G, et al.Predicting influenza infections during epidemics with use of a",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "clinical case definition. Clin Infect Dis 2000, 31: 1166.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Bratzler, DW, et al.Antimicrobial prophylaxis for surgery: an advisory",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "statement from the national surgical infection prevention project.Clin",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Infect Dis 2004, 38: 1706",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Byl B, et al.Antibiotic prophylaxis for infectious complications after",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "therapeutic endoscopic retrograde cholangiopancreatography: a randomized,",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "double-blind, placebo-controlled study.Clin Infect Dis 1995, 20: 1236",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Calderone RR, et al.Overview and classification of spinal infections.Ortho",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Clin N Amer 1996, 27: 1",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Casburn-Jones AC, et al.Management of infectious diarrhea.Gut 2004, 53:296-",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "305",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Center for Disease Control.MMWR 2002, 51: 73-6",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Center for Disease Control and Prevention. Sexually transmitted diseases",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "treatment guidelines 2002. MMWR Morb Mortal Wkly Rep 2002, 51(No. RR-6):1",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Chastre J et al.Comparison of 8 vs 15 days of antibiotic therapy for",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "ventilator-associated pneumonia in adults.JAMA 2003, 290: 2588",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "prophylactic administration of antibiotics and the risk of surgical-wound",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "infection. New England Journal of Medicine. 1992,326(5):281-286",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Cohen JI, et al.Recent advances in varicella-zoster infection.Ann Intern Med",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "1999,130:922.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Couch RB.Prevention and treatment of influenza.N Engl J Med 2000, 343: 1778.",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Cox NJ, Subbaro K. Influenza.Lancet 354:1277, 1999.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Craven DE et al.Healthcare-associated pneumonia in adults: management",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "principles to improve outcomes. Infect Dis Clin N Am 2004, 18:939",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Cunha BA.Osteomyelitis in elderly patients.Clin Infect Dis 2002, 35: 287",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "CDSS Journal References (Author Lastname: A-C)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (D-J)", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Delzell JE et alUrinary tract infections during pregnancy.Am Fam Physician",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "2000, 61: 713",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ et al.Resolution of infectious parameters after antimicrobial",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "therapy in patients with ventilator-associated pneumonia.Am J Respir Crit",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Dryden MS, et al.Empirical treatment of severe community-acquired diarrhea",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with ciprofloxacin.Clin Infect Dis 1996, 22: 1019",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Dupont HL, et al.Persistent diarrhea in travelers.Clin Infect Dis 1996,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "22:124",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Dupont HL, et al.Rifaximin versus ciprofloxacin for the treatment of",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "traveler's diarrhea.Clin Infect Dis 2001, 33: 1807",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Dworkin RH.Prevention of postherpetic neuralgia.Lancet 1999, 353:1636.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Frazee LA, et al.Long-term prophylaxis of spontaneous bacterial peritonitis in",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "patients with cirrhosis.Ann Pharmacother 2005, 39: 908",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Gerding D, et al.Clostridium-difficile associated diarrhea and colitis.Inf",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Cont Hosp Epi 1995, 16:459",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Gorecki P, Schein M, Rucinski JC, Wise L. Antibiotic administration in patients",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "undergoing common surgical procedures in a community teaching hospital: the",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "chaos continues. World Journal of Surgery. 1999,23(5):429-432, discussion",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "433.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Gould IM. A review of the role of antimicrobial policies in the control of",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "antibiotic resistance. Journal of Antimicrobial Chemotherapy. 1999,43:459-",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "465.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Guerrant RL, et al.Practice guidelines for the management of infectious",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "diarrhea.Clin Infect Dis 2001, 32: 331",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Hanssen AD, Osmon DR. The use of prophylactic antimicrobial agents during and",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "after hip arthroplasty. Clinical Orthopaedics & Related Research.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "1999(369):124-138.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Harris A, et al.Meta-analysis of antibiotic prophylaxis in endoscopic",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "retrograde cholangiopancreatography (ERCP).Endoscopy 1999, 31: 718",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Hewlett EL, et al.Pertussis - not just for kids.NEJM 2005, 352: 1215",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Hooton et al.Acute uncomplicated cystitis in an era of increasing antibiotic",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "resistance: a proposed approach to empiric therapy.Clin Infect Dis",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "2004:39:75",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Hughes WT, et al.2002 guidelines for the use of antimicrobial agents in",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "neutropenic patients with cancer.Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Interagency Task Force on Antimicrobial Resistance. A public health action plan",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "to combat antimicrobial resistance.Part I:Domestic issues. Centers for",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Disease Control and Prevention, Atlanta, Georgia. 2000.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Jaeckel et al.Treatment of acute hepatitis C with interferon alfa-2b.NEJM",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "2001, 345: 1452.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Jensen L et al.Oral antivirals for the acute treatment of recurrent herpes",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "labialis.Ann Pharmacother 2004, 38:705.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Johnson RT.Acute encephalitis. Clin Infect Dis 1996, 23:219.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Joshi N, et al.Infections in patients with diabetes mellitus.New Eng J Med",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "1999, 341: 1906.",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "CDSS Journal References (Author Lastname: D-J)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (K-N)", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Lew DP, et al.Osteomyelitis.Lancet 2004, 364: 369",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Lipsky BA et al.Diagnosis and treatment of diabetic foot infections.Clin",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infect Dis 2004, 39: 885",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Little P et al.Information leaflet and antibiotic prescribing strategies for",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "acute lower respiratory tract infection.JAMA 2005, 293: 3029",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Ljungman P, et al.Treatment of interstitial pneumonitis due to cytomegalovirus",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with ganciclovir and intravenous immune globulin: experience of European",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "bone marrow donor transplant group.Clin Infect Dis 1992 14:831-5.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Luna CM, et al.Resolution of ventilator-associated pneumonia: prospective",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "evaluation of the clinical pulmonary infection score as an early clinical",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "predictor of outcome.Crit Care Med 2003, 31: 676",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Madigosky WS.Does acyclovir help herpes simplex virus cold sores if treatment",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "is delayed?J Fam Prac 2004, 53: 923.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Magnus G.Perioperative antibiotic prophylaxis in urology.Curr Opin Urol",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "2001, 11: 81",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Maki DG, Schuna AA. A study of antimicrobial misuse in a university hospital.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "American Journal of the Medical Sciences. 1978,275:271-282.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mandell LA, Bartlett JG, Dowell SF, et al, Update of practice guidelines for the",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "management of community-acquired pneumonia in immunocompetent adults., Clin",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Infect Dis 2003,37:1405",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mangram AJ, et al.Guideline for Prevention of Surgical Site Infection, Infect",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Control Hosp Epidemiol 1999, 20: 247",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "of Surgical Site Infection, 1999. Infection Control and Hospital",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Epidemiology. 1999,20(4):250-278.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mathisen GE, et al.Brain abscess.Clin Infect Dis 1997, 25: 763.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "McDonald M, Grabsch E, Marshall C, Forbes A. Single- versus multiple-dose",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "antimicrobial prophylaxis for major surgery:a systematic review.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Australia & New Zealand Journal of Surgery. 1998,68:388-396.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "McGowan JE, Jr. Do intensive hospital antibiotic control programs prevent the",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "spread of antibiotic resistance? Infection Control & Hospital Epidemiology.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "1994,7:478-483.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Merrill et al Treating postoperative mediastinitis.Ann Thorac Surg 2004, 78:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "608-12.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Morris A, Kellner JD, Low DE. The superbugs: evolution, dissemination and",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "fitness. [Review] 70. Current Opinion in Microbiology. 1998,1(5):524-529.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mulhern JG, et al.Trough serum vancomycin levels predict the relapse of gram-",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "positive peritonitis in peritoneal dialysis patients.Am J Kidney Dis",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "1995, 25: 611",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Murphy TF, et al.The role of bacteria in exacerbations of COPD.Chest 2000,",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "118:204",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Naber et al. Chronic prostatitis - an infectious disease?JAC 2000, 46:157",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Nathens AB et al.Management of the critically ill patient with severe acute",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "pancreatitis.Crit Care Med 2004, 32: 2524-2536",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Nichols RL. Preventing surgical site infections: a surgeon's perspective.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Emerging Infectious Diseases. 2001,7(2):220-224.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Nicolle et al IDSA guidelines for the diagnosis and treatment of asymptomatic",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "bacteriuria in adults.Clin Infect Dis 2005, 40: 643",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Novella M, et al.Continuous versus inpatient prophylaxis of the first episode",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "of spontaneous bacterial peritonitis with norfloxacin.Hepatol 1997, 25:",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "532",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "CDSS Journal References (Author Lastname: K-N)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (P-R)", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Pappas PG, et al.Guidelines for treatment of candidiasis.Clin Infect Dis",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "2004, 38: 161",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Parish LC et al.Controversies about the decubitus ulcer.Dermatol Clin 2004,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "22: 87.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Parsi MA, et al.Spontaneous bacterial peritonitis: recent data on incidence",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "and treatment.Clev Clin J Med 2004, 71: 569",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Payne TH. Computer decision support systems. Chest. 2000,118:47S-52S.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Peterson LR.Penicillins for treatment of pneumococcal pneumonia: does in vitro",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "resistance really matter?Clin Infect Dise 2006, 42: 224",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Pharmacy Benefits Management-Medical Advisory Panel. The Pharmacologic",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Management of Helicobacter pylori in Peptic Ulcer Disease and Dyspepsia.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "VHA PBM-SHG Publication No. 98-0009.Hines, IL: Pharmacy Benefits",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Management Strategic Health Group, Veterans Health Administration,",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Department of Veterans Affairs. February 1998.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Piraino B, et al.Peritoneal dialysis-related infections recommendations: 2005",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "update.Perit Dial Int 2005, 25: 107.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Ray S, et al.Neuroretinitis.Int Ophth Clin 2001, 41: 83.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology.2nd ed.London, UK: Mosby",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "International Limited 2001.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Roig J, et al.Legionnaire's disease: a rational approach to therapy.J",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Antimicrob Chemother 2003, 51: 1119-29",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Roitt I, Brostoff J, Male D, eds.Immunology.5th ed.London, UK: Mosby",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "International Limited 1998.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Rolston KVI.The infectious diseases society of America 2002 guidelines for the",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "use of antimicrobial agents in neutropenic patients with cancer and",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "neutropenia: salient features and comments.Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Ronald A The etiology of urinary tract infection: traditional and emerging",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "pathogens.Dis Mon 2003, 49: 71",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Runyon BA, et al.Short course versus long course antibiotic treatment of",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "spontaneous bacterial peritonitis.Gastroenterol 1991, 100: 1737",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "CDSS Journal References (Author Lastname: P-R)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (S-V)", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Saag MS, et al.Practice guidelines for the management of cryptococcal disease.",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Clin Infect Dis 2000, 30: 710",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Sapico FL.Microbiology and antimicrobial therapy of spinal infections.Ortho",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Clin N Amer 1996, 27:9",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Scheid DC, et al.Acute bacterial rhinosinusitis in adults.Am Fam Phys 2004,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "70: 1697",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Scher KS. Studies on the duration of antibiotic administration for surgical",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "prophylaxis. The American Surgeon. 1997,63:59-63.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Schwartz MN.Cellulitis.New Eng J Med 2004, 350: 904",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology of",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "America and Infectious Diseases Society of American Joint Committee on the",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "prevention of antimicrobial resistance:guidelines for the prevention of",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobial resistance in hospitals. Infection Control & Hospital",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Epidemiology. 1997,18:275-291.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Singh N et al.Short-course empiric antibiotic therapy for patients with",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "pulmonary infiltrates in the intensive care unit.Am J Resp Crit Care Med",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "2000, 162: 505",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sipsas NV, et al.Perspectives for the management of febrile neutropenic",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "patients with cancer in the 21st century.Cancer 2005, 103: 1103.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Snow V, et al. Principles of appropriate antibiotic use for acute sinusitis in",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "adults. Ann Intern Med 2001, 1234: 495",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Snow V, et al.Principles of appropriate antibiotic use for acute pharyngitis",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "for adults.Ann Intern Med 2001, 134: 506",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Soares-Weiser K, et al.Antibiotic prophylaxis for cirrhotic patients with",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "gastrointestinal bleeding.Cochrane Database of Systematic Reviews 3, 2005",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Solomkin JS, et al.Guidelines for the selection of anti-infective agents for",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "complicated intra-abdominal infections.Clin Infect Dis 2003, 37: 997",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Song F, Glenny AM. Antimicrobial prophylaxis in colorectal surgery: a systematic",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "review of randomized controlled trials. British Journal of Surgery.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "1998,85(9):1232-1241.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Stevens DL, et al.Practice guidelines for the diagnosis and management of skin",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "and soft-tissue infections.Clin Infect Dis 2005, 41: 1373.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Strader DB, et al.Diagnosis, management, and treatment of hepatitis C.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Hepatology 2004, 39:1147-71.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Stulberg DL, et al.Common bacterial skin infections.Am Fam Phys 2002, 66:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "119",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Such J et al.Spontaneous bacterial peritonitis.Clin Infect Dis 1998, 27: 669",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Tay BK et al.Spinal infections.J Amer Acad Ortho Surg 2002, 10: 188",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Thielman, NM.Acute infectious diarrhea.NEJM 2004, 350: 38",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Tunkel et al.Practice guidelines for the management of bacterial meningitis.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Clin Infect Dis 2004, 39: 1267-84.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Van der Valk P et al.Clinical predictors of bacterial involvement in",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "exacerbations of chronic obstructive pulmonary disease.CID 2004, 39: 980",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Vincent MT, et al.Pharyngitis.Am Fam Phys 2004, 69: 1465",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "CDSS Journal References (Author Lastname: S-V)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REF JOURN (W-Z)", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Weinstein L, et al.Gas gangrene.New Eng J Med 1973, 289: 1129",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Westphal JF.Biliary tract infections.Drugs 1999, 57: 81-91.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Wheat J, et al.Practice guidelines for the management of patients with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Histoplasmosis.Clin Infect Dis 2000, 30: 688",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Whitely RJ, et al.Herpes simplex virus infections.Lancet 2001, 357: 1513.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Whitely RJ, et al.Herpes zoster: risk categories for persistent pain.J",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Infect Dis 1999,179:9.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Wald A.New therapies and prevention strategies for genital herpes.Clin",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Infect Dis 1999, 28(Suppl 1):S4.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Wallace MR, et al.Treatment of adult varicella with acyclovir.Ann Int Med",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "1992, 117:358.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Warren et al.Guidelines for antimicrobial treatment of uncomplicated acute",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "bacterial cystitis and acute pyelonephritis in women.Clin Infect Dis",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "1999, 29:745",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Woods RK, et al.Current guidelines for antibiotic prophylaxis of surgical",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "wounds.Am Fam Phys 1998, 57:2731",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Wormser GP, et al.Duration of antibiotic therapy for early Lyme disease.Ann",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Intern Med 2003, 138: 697.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Wormser GP, et al.Practice guidelines for the treatment of Lyme disease.Clin",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Infect Dis 2000, 31 (Supp 1): S1",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Zimmerli W, et al.Prosthetic-joint infections.New Eng J Med 2004, 351:1645",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "CDSS Journal References (Author Lastname: W-Z)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REFERENCES", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES BOOK", "Text" : "Book references", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES WEBSITE", "Text" : "Website references", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES JOURNAL", "Text" : "Journal references", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX REFERENCES BOOK", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CDSS Book References (common to most CDSS guidelines)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA. The Sanford Guide to",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Therapy. 35th ed. Hyde Park, VT: Antimicrobial Therapy Inc,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "2005.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Kasper DL, Braunwald E, Fauci AS, et al., eds. Harrison's Principles of Internal",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Medicine. 16th ed. Mcgraw-Hill, 2005.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Diseases. 6th ed. Philadelphia, PA: Churchill-Livingston, 2005.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Johns Hopkins Point of Care Information Technology (POC-IT): ABX Guide.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "www.hopkins-abxguide.org", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX REFERENCES JOURNAL", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CDSS Journal References",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (A-C)", "Text" : "Go to CDSS Journal References (Author Lastname: A-C)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (D-J)", "Text" : "Go to CDSS Journal References (Author Lastname: D-J)", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (K-N)", "Text" : "Go to CDSS Journal References (Author Lastname: K-N)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (P-R)", "Text" : "Go to CDSS Journal References (Author Lastname: P-R)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (S-V)", "Text" : "Go to CDSS Journal References (Author Lastname: S-V)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX REF JOURN (W-Z)", "Text" : "Go to CDSS Journal References (Author Lastname: W-Z)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX REFERENCES WEBSITE", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Up-to-date (view up-to-date web site)www.uptodate.com",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CDSS Website References (common to most CDSS guidelines)", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX REMDESIVER FOR TREATMENT OF COVID-19", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Select here for help, legend, consults, alternative antimicrobials and more (Ip)", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX REMDESIVIR 200MG LOAD THEN 100MG Q24H 5DAYS", "Text" : "Remdesivir 200mg IV once on day 1, then 100mg IV daily for 4 additional days", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Note: Consult Infectious Disease for approval to extend therapy beyond 5 days",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "1. Requirement: PCR-confirmed COVID-19",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "(maximum 10 days total therapy)",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Remdesivir is FDA approved for treatment of COVID-19 in hospitalized patients:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Monitoring required for Remdesivir:",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "***If above requirements are met, place order for labs and Remdesivir***",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "1. Daily laboratory monitoring includes:",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "See below for full prescribing information including WARNINGS and PRECAUTIONS",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Relative contraindications:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "2. Consider discontinuing drug if ALT levels increase to greater than 10 times",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "upper limit of normal",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "3. Discontinue drug if ALT elevation is accompanied by signs or symptoms of",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "liver inflammation",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "1. Hepatic impairment (pharmacokinetics and need for dose adjustment unclear)",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "3. Pregnancy (maternal and fetal risks unknown)",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Note: Consult Infectious Disease for COVID-19 negative patients, but",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "clinically very consistent with COVID-19",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Use not recommended unless potential benefit outweighs potential risk.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZ GTX ABX URL REMDESIVIR PI", "Text" : "[Link] Remdesivir Package Insert (FDA approved Oct 2020)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Comprehensive Metabolic Profile, CBC with Diff, and INR",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Note: Discuss with Infectious Disease patients with these contraindications:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "2. Renal impairment: not recommended in patients with eGFR less than 30ml/min",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "-Remdesivir can shorten COVID symptom duration but does not affect mortality. It",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "appears most effective for patients needing supplemental oxygen but not",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "receiving mechanical ventilation. It has little benefit for patients not",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "requiring oxygen.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "approval from ID staff.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Please Note:",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "REMDESIVIR COVID-19 REGIMEN",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "-Remdesivir may be discontinued early in patients who are minimally symptomatic",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "and ready for discharge.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "-The default duration of therapy is 5 days and DOES NOT require Infectious",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Disease approval, extending therapy is of minimal benefit and DOES require",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Note: May be given to patients on dialysis at recommended dose.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Monitor Labs Daily: Comprehensive Metabolic Profile, CBC with Diff, and INR",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Place medication order:",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : "LRTZ SET REMDESIVIR X5 DAYS", "Text" : "[Click here] Place lab orders for Remdesivir daily x 5 days", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX RSV", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "RESPIRATORY SYNCYTIAL VIRUS (RSV)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "No specific antimicrobial therapy is indicated. Contact Infectious Diseases for",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "more information on management of this disease.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Respiratory Syncytial Virus", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SALMONELLA SPECIES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX ENTERIC FEVER", "Text" : "Link to Enteric Fever Menu", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h for 14 days ($) [M]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h for 14 days ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH SALMONELLA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For systemic febrile illness or typhoidal Salmonella, refer to Enteric Fever",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Menu:",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment is not recommended for mild or moderately severe disease in otherwise",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "healthy individuals <50 years old, because the disease is self-limiting and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobials can prolong the carrier state and increase the risk of relapse.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "By contrast, treatment should be considered for severe disease, and if the",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "patient is > 50 years old, is immunocompromised, or has another debilitating",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "underlying disease.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of immunocompetent patients",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "If infection acquired in Asia or patient is intolerant to fluoroquinolones",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "For patients who are hospitalized or unable to take oral medications",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of immunocompromised patients",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "If infection acquired in Asia or patient is intolerant to fluoroquinolones",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "For patients who are hospitalized or unable to take oral medications",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastroenteritis, Salmonella: Non-typhi",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Nontyphoidal Salmonella: Gastrointestinal infection and",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "carriage", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SECOND PERITONITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SECONDARY PERITONITIS, INTRAABDOMINAL ABSCESS, INTRAPERITONEAL ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Secondary peritonitis occurs after spillage of colonic flora into the peritoneum",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "due to ruptured viscus, perforated appendicitis, gastrointestinal trauma, or",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "diverticulitis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Intraperitoneal or intraabdominal abscess can complicate secondary or primary",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "peritonitis. Abscess location is generally related to primary disease site.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Primary therapy: abscess drainage",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "CT or US-guided percutaneous or surgical drainage should be considered in all",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "cases for diagnostic confirmation, microbiologic evaluation, and therapy.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "After adequate drainage, 4 days of antibiotic coverage is indicated, with",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "duration in part based on resolution of fever, leukocytosis, ileus severity of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "infection, and additional indicators of clinical response. Inadequately drained",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "abscess with residual fluid may require prolonged therapy with follow-up imaging",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "to ensure resolution.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease (typically necessitating ICU admission)",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "< AND > vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "who can tolerate oral therapy. Base selection on culture results.",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Peritonitis, Secondary: rupture, perforation, abscess",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Sawyer et al, N Engl J Med, 2015, 372:1996-2005",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial approach to intra-abdominal infections in",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SECOND RECUR ABX ASSOC COLITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID VANCOMYCIN TAPER AND PULSE DOSING", "Text" : "Vancomycin Extended Pulse-Taper Regimen ($) [M]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXI MEGACOLON", "Text" : "Select for Fulminant CDI", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SECOND RECCURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients with more than one recurrence of C. difficile infection are complex and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "difficult.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Discontinue any antibiotics if possible and avoid high-risk antibiotic if",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Second Recurrence:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Clostridium difficile infection",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium difficile",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Treatment and",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "prevention",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID FIDAXOMICIN 200MG Q12H 10D", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID FIDAXAMICIN EXTENDED-PULSE REGIMEN", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "125 mg po twice daily for seven days, then 125mg po qday for 7 days, then",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "125mg every other day for 6 weeks)",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "*Infectious Disease or Gastroenterology consultation is recommended*",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Fulminant CDI:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Third or more recurrence: Consult Gastroenterology or Infectious Disease", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A diagnosis of a sexually transmitted infection can suggest sexual activity",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Sexually Transmitted Infections (STI)",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "consult to MRTC clinic for further discussion and evaluation for PrEP.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX EPIDIDYMITIS", "Text" : "", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX PID", "Text" : "Pelvic Inflammatory Disease (PID)", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX SYPHILIS", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX CERVICITIS ASSOC STD", "Text" : "Cervicitis", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENITAL HERPES", "Text" : "", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "Text" : "Urethritis", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sexually Transmitted Infections (STIs)",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "Human Immunodeficiency Virus (HIV)", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "Text" : "HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Chlamydia (see Cervicitis or Urethritis or Gonorrhea)",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX TRICH VAGINITIS", "Text" : "Trichomonas Vaginitis, Urethritis and Male Sex Partners", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "that could result in HIV exposure. Recommendation is for the provider to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "HIV acquisition.If the patient is interested, the provider should place a",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Pre-exposure prophylaxis (or PrEP) is a way for people who do not have",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "HIV but who are at high risk of getting HIV to prevent HIV infection by",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "taking a pill every day. When someone is exposed to HIV through sex or",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "injection drug use, these medicines can work to keep the virus from",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "establishing a permanent infection.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "When taken daily, PrEP is highly effective for preventing HIV. Studies",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "have shown that PrEP reduces the risk of getting HIV from sex by about",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "99% when taken daily. PrEP is much less effective if not taken consistently.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "As PrEP only protects against HIV, condoms are important for the protection",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "against other STIs. Condoms are also an important prevention strategy",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "if PrEP is not taken consistently.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX GONOCOCCAL", "Text" : "Gonorrhea", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q24H FOR 3 DAYS", "Text" : "Ciprofloxacin 750 mg PO q24h for 3 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h for 3 days ($) [M]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h for 5 days ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH SHIGELLA (BACILLARY DYSENTERY) OR ENTEROINVASIVE E. COLI (EIEC)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Shigellosis is generally a self-limited infection lasting 5-7 days.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Antimicrobial resistance is common and continues to rise for all recommended",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antimicrobials. Treatment should be reserved for patients who are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "immunocompromised, or who develop severe illness (e.g., requiring",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "hospitalization, invasive, or with complications) or live or work in settings",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "where there is risk of spreading infection to others (e.g., food handlers,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "daycare, nursing home).",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "For patients who are hospitalized or unable to take oral medications",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "CDC advisory: https://emergency.cdc.gov/han/han00401.asp",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastroenteritis, Shigella",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Shigella infection: Treatment and prevention in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SOFT TISSUE, MUSCLE, BONE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU BITE WOUNDS", "Text" : "Bite wounds", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC BURSITIS", "Text" : "Septic bursitis", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABSCESSES", "Text" : "Abscesses", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU CUTANEOUS ABSCESS", "Text" : "Cutaneous abscess", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perirectal/Anorectal Abscess", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU PYOMYOSITIS", "Text" : "Pyomyositis", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU DECUBITUS ULCERS", "Text" : "Decubitus ulcers", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "Text" : "Surgical wound infections", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ SOFT TISSUE, MUSCLE, BONE AND JOINT INFECTIONS++",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Section reviewed Dec 2018",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "Text" : "Foot ulcer in patient with diabetes mellitus", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID2 GMENU OSTEOMYELITIS", "Text" : "Osteomyelitis", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU VERTEBRAL (DISKITIS) OSTEOM", "Text" : "Diskitis and vertebral osteomylitis", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "Text" : "Infections in bone or joint prostheses", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Text" : "Septic arthritis (Native joint)", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "Text" : "Prosthetic joint", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "Septic arthritis", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX SOTROVIMAB EUA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "If above requirements are met, place medication order:",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "infection control measures (wear mask, isolate, social distance, avoid",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "frequent handwashing) according to CDC guidelines.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Monitor patient during infusion and 1 hour after infusion completed.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Inclusion Criteria",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "ALL of the following criteria must be met for a patient to receive:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "2) Patient is not hospitalized due to COVID-19.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "increase in baseline oxygen flow rate due to COVID-19.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "4) Administration will begin within 7 days of symptom onset.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "5) Patient does not have known hypersensitivity to sotrovimab or components.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "The provider has communicated with the patient/caregiver regarding",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "unapproved drug that is authorized for use under an EUA, given information",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "1) Patient has a laboratory-confirmed diagnosis of mild to moderate COVID-19.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "Text" : "[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "ID available to discuss if needed.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX INV-SOTROVIMAB NURSING INST", "Text" : "INV-Sotrovimab 500mg IVPB ONCE", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "including hospitalization or death.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "6) Patient has at least one risk factor for progression to severe disease",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "See link below for complete list:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "**Treatment:**",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Note: patient may be hospitalized for some other reason.",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Sotrovimab (EUA)",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Sotrovimab Emergency Use Authorization (EUA)",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-Sotrovimab is available via FDA Emergency Use Authorization (EUA)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "for treating patients that meet specific criteria. Sotrovimab is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "not FDA approved drug.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "-Sotrovimab EUA does NOT include post-exposure prophylaxis.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "*Patients treated with this drug should continue to self-isolate and use",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PATIENT EUA FACT SHEET", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Sotrovimab", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Sotrovimab", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Exclusion Criteria",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "If patient recieved tixagevimab plus cilgavimab previously, discuss with ID.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SPLENECTOMY CHART", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZ SET ABX SPLENECTOMY VACCINE INPT + OUTPT FOLLOW-UP", "Text" : "CLICK HERE TO ORDER SPLENECTOMY VACCINES", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus B conjugate vaccine", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroup Vaccine", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal Serogroup B vaccine", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal conjugate 13-valent vaccine", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal polysaccharide 23-valent vaccine", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroups Vaccine", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Functional or Anatomical Asplenia Vaccine Guidelines",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "ORDER SPLENECTOMY VACCINES:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "DOSE 1 AS INPATIENT & DOSE 2 AS OUTPATIENT",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "*CLICK THE INDIVIDUAL VACCINES BELOW FOR",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "INFO PAGE AND ORDER OUTPATIENT VACCINES*",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Dose1______________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "day 1",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Dose3_________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "5 years",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "MMWR Morb Mortal Wkly Rep 2018:66(5)",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Clin Infect Dis 2014,58:e44-100",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal Serogroup B vaccine", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroups Vaccine", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Dose2_______________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "4 weeks",  "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "Dose4__________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "10 years",  "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroups Vaccine", "Header" : 0}, 
{"Row" : 21, "Column" : 3, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal polysaccharide 23-valent vaccine", "Header" : 0}, 
{"Row" : 29, "Column" : 3, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroups Vaccine", "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "Dose2____________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "8 weeks",  "Header" : 1}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 24, "Column" : 3, "Item" : null, "Text" : "Dose5 and above_______________",  "Header" : 1}, 
{"Row" : 25, "Column" : 3, "Item" : null, "Text" : "REPEAT every 5 years",  "Header" : 1}, 
{"Row" : 27, "Column" : 3, "Item" : null, "Text" : "n/a", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SPLENECTOMY DAILY ANTIBIOTICS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO BID FOR DAILY PROPHY ASPLENIA", "Text" : "Amoxicillin 500MG PO bid for daily prophylaxis asplenic patient ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 250MG PO BID FOR DAILY PROPHY ASPLENIA", "Text" : "Cephalexin 250MG PO bid for daily prophylaxis asplenic patient ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 250MG PO QDAY DAILY PROPHY ASPENIA", "Text" : "Azithromycin 250MG PO qday for daily prophylaxis for asplenic pateints ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Daily Antibiotic Prophylaxis for Asplenia",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "The need for daily antibiotic prophylaxis and its duration is typically",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "determined individually based on patient age, immune status, history of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infection, potential for adverse drug reactions and other factors.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Consider Prophylaxis:",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "1) Approximately 1 year prophylaxis for all patients following splenectomy.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "2) Lifelong prophylaxis for patients with history of sepsis or other severe",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "infections caused by encapsulated organisms.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "3) Prophylaxis for as long as the patient is immunocompromised or for life",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "for patients with concurrent immunocompromising conditions (e.g. hematologic",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "malignancy, hypogammaglobulinemia, solid-organ transplant, advanced liver",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "disease, or HIV infection).",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Daily antibiotic prophylaxis is in addition to the emergency supply.",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Recommended:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin and beta lactam allergy:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-Date online", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX MANAGEMENT OF FEBRILE EPISODE ASPLENIA", "Text" : "Management of an Episode of Fever in an Asplenic Patient", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY CHART", "Text" : "[click here] Place Order for Vaccines for Inpatient", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY DAILY ANTIBIOTICS", "Text" : "Daily Antibiotic Prophylaxis INPATIENT", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY EMPIRIC ABX", "Text" : "Self-medicate Empiric Antibiotics", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Asplenia Functional or Anatomical",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Following a splenectomy there is considerably increased risk of developing",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "septicemia from invasive encapsulated organisms, namely Streptococcus pneumonia,",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Haemophilus inluenza type b and meningococcus. Key measures to prevent",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "such infections include education, vaccination, prophylactic antimicrobial",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "therapy in selected patients, and early empirical therapy for febrile",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "epsisodes. It is critically important to educate patients regarding the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "lifelong risk of postsplenectomy sepsis, the importance of vaccinations,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and the need for urgent action in response to a febrile episode.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Management of an Episode of Fever in an Asplenic Patient",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Initiation of vaccine regimen:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Routine vaccines should be up to date including influenza, Tdap, Zoster,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "HPV, MMR, Varicella. See CDSS Immunization section to order.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Ideally splenectomy vaccinations should be given 10 to 12 weeks before",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "elective splenectomy.Where this is not possible they can be given up to",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "two weeks before or at least two weeks post-splenectomy.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Use of Antibiotic Prophylaxis for Asplenia:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Use of antibiotic prophylaxis, in addition to vaccination, further reduces",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "the risk of infection and poor outcomes.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Daily Antibiotic Prophylaxis: (in addition to emergency supply)",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Emergency Supply Empiric Abx for Fever or Other Signs of Systemic Infection:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "**OUTPATIENT ORDERS**",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "MMWR Morb Mortal Wkly Rep 2018:66(5)",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Clin Infect Dis 2014, 58:e44-100",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-to-Date", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SPON BACT PERITONITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h for 5 days ($) [M]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "Text" : "Levofloxacin 750 mg IV q24h for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TABLET PO Q24H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "Text" : "Ciprofloxacin 500 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TABLET PO Q24H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q24h until discharge from", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "Text" : "Ciprofloxacin 500 mg PO q24h until discharge from hospital ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SPONTANEOUS BACTERIAL PERITONITIS (SBP)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "SBP is infection of the peritoneal cavity in the absence of apparent trauma or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "other obvious cause. SBP occurs primarily in people with end-stage liver disease",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "and ascites. The diagnosis is made when a peritoneal fluid sample has >/= 250",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "polymorphonuclear leukocyte cells per microliter, or when bacterial pathogens",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "are isolated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Long-term SBP prophylaxis is indicated for patients who experience a first",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "episode of SBP. Short-term SBP prophylaxis is indicated for patients with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "variceal bleeding, or for patients who have low-protein refractory ascites (<1",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "gm albumin/dl ascitic fluid). Some give long-term antimicrobials to patients",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "with low-protein refractory ascites. Consult Gastroenterology for more",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "SBP",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Prophylaxis in a patient with a previous SBP episode",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Prophylaxis in a patient with cirrhosis and variceal hemorrhage",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Treat initially with an intravenous antimicrobial then step down to an oral",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "antimicrobial when the patient can tolerate oral treatment.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treat for a total of 7 days (intravenous and oral)",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Preffered initial treatment",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Initial treatment, alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Step down treatment",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for hospitalized patients with refractory low-protein ascites",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "(less than 1 gm/dL peritoneal fluid)",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "hospital ($) [R,DI]",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Peritonitis, Primary: Spontaneous, Bacterial",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Spontaneous bacterial peritonitis in adults: Treatment and",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "prophylaxis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "Text" : "Mupirocin 2% ointment topically q12h ($) [M] <AND> chlorhexidine 4% liquid", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "Text" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STAPHYLOCOCCUS AUREUS DECOLONIZATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "From 10% to 40% of adults are colonized with Staphylococcus aureus, and the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "anterior nares is the most common site of colonization. The great majority of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "people never have disease with S. aureus, but a tiny fraction of people develop",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "clinical infections with the S. aureus that has colonized their skin or anterior",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "nares. Steps to decolonize the skin and anterior nares can transiently diminish",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "or eradicate S. aureus colonization and can prevent post-operative wound",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "infection in certain high-risk circumstances. For people who have other forms",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "of recurrent S. aureus disease, not associated with an operation, results with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "decolonization have been disappointing, and decolonization is not routinely",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "recommended. Colonization typically reappears in most patients within a few",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "days or weeks after decolonization has been attempted. Clinicians occasionlly",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "wish to attempt decolonization for patients with frequent, troublesome",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "recurrences. The procedure here is one of several that have been studied, but",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "none have been particularly effective over the long run.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Consultation with Infectious Diseases is recommended.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Inpatient Decolonization Order Set:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "topically q24h nursing text order ($) [M] for 5 days",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Outpatient Decolonization Order Set:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Order if patient is being discharged within 5 days",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "topically qday ($) [M] for 5 days",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Instructions",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "* Patient must wear clean clothes after bathing to prevent recontaminat",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "* Bedding and linens must be changed/cleaned daily until the end of the",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "decolonization protocol.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Bradley S Clin Infect Dis 2007, 44: 186",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Lonneke G NEJM 2010, 362: 9",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Schweizer et al, JAMA 2015, 313.212:162-2171",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "adults: Prevention and control", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX STASIS DERMATITIS", "Contents" : [
{"Row" : 68, "Column" : 1, "Item" : "ORZID2 GMENU ABX CELLULITIS", "Text" : "Bacterial Cellulitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STASIS DERMATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Stasis dermatitis is a common condition that is often confused with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "bacterial cellulitis. Stasis dermatitis does not benefit from antimicrobial",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "therapy. It is important to distinguish between the two. The provider",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "should be mindful of the fact that bacterial cellulitis can occur on skin",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with underlying stasis dermatitis. (See link below for bacterial cellulitis)",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Common risk factors for venous stasis include advancing age, family",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "history of venous disease, increased body mass index, smoking, a history of",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "trauma, prior venous thrombosis and pregnancy. Chronic venous disease and",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "arterial vascular disease have some common risk factors (eg, smoking,",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "obesity) and pathophysiological processes. The most common symptoms reported",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "by patients with chronic venous disease are limb discomfort (tired, heavy",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "legs), pain, and limb swelling. Swelling is often worse with prolonged",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "standing and improves with leg elevation and walking. The skin of the",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "anterior surfaces of the lower legs often has brown or blue-grey",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "hyperpigmentation.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "People with venous stasis are prone to develop stasis dermatitis which",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "is one of the most common and earliest dermatologic signs of chronic venous",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "insufficiency. Stasis dermatitis is an inflammatory process that presents as",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "an eczematous rash characterized by itching, erythema, scaling, weeping,",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "erosions, and crusting. Longstanding cases may develop lipodermatosclerosis",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "a fibrosing panniculitis of the subcutaneous tissue. Lipodermatosclerosis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "typically starts with a firm area of induration at the medial ankle. As the",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "process progresses, the entire leg lower leg can become involved with",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "extension up to the mid leg in more advanced cases. The skin overlying the",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "panniculitis is typically heavily pigmented and bound down to the",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "subcutaneous tissues. Brawny edema above the fibrotic area and on the foot",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "below is seen in advanced cases. Leukocytosis and fever are common in people",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "with stasis dermatitis.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Chronic venous disease is the most common cause of leg ulcers. They",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "are usually found low on the medial ankle over a perforating vein, or along",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "the course of the great or small saphenous veins. They occur more proximally",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "if precipitated by trauma. Venous ulcers are not found on the forefoot or",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "above the level of the knee. Venous ulcers can be multiple or single, and",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "can be exquisitely tender, shallow, exudative and have a granulation base.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "The ulcer borders are usually irregular but not undermined. They can extend",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "circumferentially around the leg if left untreated.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Arterial ulcers are typically painful, and punched out or stellate. The",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "surrounding skin is red and taut. Some arterial ulcers are pale - others have",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "a black or yellow eschar. They are often associated with trauma and commonly",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "occur on the foot over pressure points. There may be other signs of arterial",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "insufficiency on the lower limb including thin atrophic or hairless skin,",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "poor pedal pulses, diminished capillary refill, or hypertrophic deformed",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "nails.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Patients with stasis or lipodermatosclerosis are prone to bouts of",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "bacterial cellulitis, usually caused by Staphylococcus aureus or encapsulated",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "streptococci. Typically, stasis dermatitis develops slowly, over a week or",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "more. It is often bilateral. The onset of bacterial cellulitis is usually",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "abrupt, typically developing over 1 or 2 days. Bacterial cellulitis often",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "starts in one area and spreads to adjacent areas. Bacterial cellulitis is",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "unilateral. Both can present with fever and leukocytosis.",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "In a patient with stasis and cellulitis and the physician is uncertain",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "about whether bacterial cellulitis is present, the physician should consider",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "a trial of bed rest, leg elevation, and if there is fluid overload, diuresis",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "If the cellulitis improves in 24-48 hours, antibacterial therapy and the",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "attendant adverse reactions can be avoided. If it is clear that bacterial",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "cellulitis has occurred, antimicrobial therapy should be given.",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Stevens et al, Clin Infect Dis, 2014, 59(2): e10-52",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Stasis dermatitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SUPPURATIVE THROMBO EMP THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX VANC 15 mg/kg IV Q12H CEFTRIAX 2 GM IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 mg/kg IV Q12H GENT 5 MG/KG IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg IV q24h ($)", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "< ADD > Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SUPPURATIVE THROMBOPHLEBITIS - EMPIRICAL THERAPY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Obtain blood cultures before starting empirical antimicrobials.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Peripheral vein suppurative thrombophlebitis may require surgical intervention",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "in addition to antimicrobial therapy. The usual treatment for jugular vein",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "suppurative thrombophlebitis (Lemierre's syndrome) and vena cava suppurative",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "thrombophlebitis is prolonged antimicrobial therapy, with or without",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "radiological or thrombolytic clot removal. Consult Infectious Diseases and",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Vascular Surgery for more information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Modify antimicrobial regimen and narrow coverage based on results of culture and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "susceptibility tests.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "A minimum of 4 to 6 weeks of antimicrobial therapy is appropriate and may be",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "abbreviated in peripheral vein infections based on patient specific factors.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Antimicrobial therapy should be continued until there is definite clinical",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "response and oral antimicrobial therapy may be used after completion of initial",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "course of intravenous therapy.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for peripheral vein infections and central vein infections",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "associated with a venous catheter",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "[R,O]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for jugular vein infection (also known as Lemierre's) or",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "suppurative pelvic vein infection",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Consultation with Surgery and Infectious Diseases is encouraged.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "For catheter-associated infection, add vancomycin to one of the above treatment",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "regimens",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Suppurative Thrombophlebitis",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Mermel et al., Clinical Infectious Diseases 2009, 49.1-45",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Up-To-date article: Suppurative (septic) thrombophlebitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Contents" : [
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX ABX MPLS VAMC ABX SENSITIVITIES", "Text" : "Or Click Here to go directly to the Antibiotic Susceptibilities.", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ GTX ABX MDH ANTIBIOGRAM", "Text" : "Please Click Here For the MDH website", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ GTX ABX SANFORD", "Text" : "Click Here for link to Sanford Guide online access", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZ GTX ABX MANDELL", "Text" : "Click Here for link to Principles and Practice of Infectious Diseases online", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIAL SUSCEPTIBILITIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial selection should be based on likely susceptibilities of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "anticipated or proven pathogens. Clinicians should be aware of local, regional,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "and national susceptibility patterns. Several sources for susceptibility",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "patterns are listed below.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "LOCAL",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Minneapolis VAMC Network W-Drive",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "With any thin client or PC in the Minneapolis VAMC, use Microsoft Explorer or My",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Computer to open a Microsoft Word document summarizing antimicrobial",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "suscepti bilities in the following path:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "W:\\LABORATORY\\MICROBIOL INFO FOR CLINICIANS-Lab\\Antibiotic Susceptibilities",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Minneapolis VAMC CPRS Help",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "From the menu bar at the top, select",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "-->[Tools]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "---->[CPRS and BCMA Help/What's New?]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "------>[CPRS Help]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "-------->[Placing Orders]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "---------->[CURRENT SUSCEPTIBILITIES]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Minneapolis VAMC Microbiology Laboratory",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Call (ext. 2408) or visit (room BB-127) the Microbiology Laboratory and ask for",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "the most recent summary.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "REGIONAL",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "NATIONAL",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "_____________________________________",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Sanford Guide",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Gilbert DN et al: The Sanford Guide to Antimicrobial Therapy, published",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "annually by Antimicrobial Therapy, Inc., Hyde Park, VT.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Mandell, Douglas, and Bennett Textbook",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "access",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Mandell et al: Principles and Practice of Infectious Diseases, Churchill",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Livingstone", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Intravascular Catheter-Associated Infection", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) <AND> vancomycin 15 mg/kg IV q12h", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 mg/kg IV Q12H GENT 5 MG/KG IV Q24H", "Text" : "vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SUSPECTED BACTEREMIA, BLOOD CULTURES NOT YET POSITIVE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If blood cultures are positive, return to the previous menu and make a selection",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "based on the interim results.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Choice of antimicrobials",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Select antimicrobials active against any suspected site of infection that may be",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "present. Return to main menu and refer to the source infection's page within",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "For patients with an intravascular catheter, refer to the intravascular-",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "associated infection page",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Empirical therapy for mild to moderate infection, focal infection not found",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Empirical therapy for severe infection",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empirical therapy for immunosuppressed patients",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "For patients with penicillin allergy",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Medical Letter Treatment Guidelines 2010, 8: 94",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pseudomonas aeruginosa",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococci",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococci",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococci",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX SYPHILIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "LRTZ SYPHILIS AB W/REFLEX TO RPR W/TITER", "Text" : "Syphilis antibody test with reflex to rapid plasma reagin (RPR)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "LRTZ FTA-ABS", "Text" : "Fluorescent treponemal antibody absorbed (FTA-ABS)", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJZID BENZATHINE PENICILLIN 2.4MU IM ONCE", "Text" : "Benzathine Penicillin 2.4 million units IM once ($$$) [M]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Beta-lactam Reaction Assessment", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 14 days", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSJZID2 BENZATHINE PENICILLIN 2.4MU IM QWEEK X3 SYPHILIS", "Text" : "Benzathine Penicillin 2.4 million units IM qweek ($$$) [M] x3 doses", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Beta-lactam Reaction Assessment", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 28 days", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SYPHILIS",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Syphilis is a sexually transmitted disease caused by the spirochete Treponema",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "pallidum that can manifest as a variety of signs or symptoms. Primary syphilis",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "typically consists of painless ulcers or chancre at the site of infection with",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "regional adenopathy. Secondary syphilis often includes a skin rash (disseminated",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "and/or including the palms and soles), fever, malaise, mucocutaneous lesions and",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "lymphadenopathy. Tertiary syphilis includes those with cardiovascular or",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "gummatous disease.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Latent syphilis is a period of disease when a patient does not have symptoms but",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "is found to be infected through serologic testing. Early latent syphilis refers",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "to latent syphilis acquired within the preceding year and late latent syphilis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "refers to all other cases of latent syphilis. Neurosyphilis, Ocular syphilis or",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Otosyphilis, can occur at any stage of syphilis with early manifestations (e.g.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "meningitis, stroke, vision or hearing loss) occurring within the first months to",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "years of infection and late manifestations (e.g. dementia, tabes dorsalis)",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "occurring after 10-30 years.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "A presumptive diagnosis is made through use of a nontreponemal or serologic test",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "(i.e. rapid plasma reagin [RPR]) and a treponemal test (i.e. fluorescent",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "treponemal antibody absorbed [FTA-ABS]). Direct methods through darkfield",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "microscopy and direct fluorescent antibody (DFA) must be used for definitive",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "diagnosis since T. pallidum cannot be cultured.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Management of sex partners",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Persons with sexual contact with a person with primary, secondary or early",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "latent syphilis within the last 90 days should be presumptively treated even if",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "serologic test is negative.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Primary, Secondary and Early Latent Syphilis",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Secondary treatment for patients who are not pregnant",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Tertiary and Late Latent Syphilis",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Secondary treatment for patients who are not pregnant",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Neurosyphilis, Ocular syphilis or Otosyphilis",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Disease for treatment",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines MMWR (2021) 70.4",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Syphilis (Treponema pallidum)",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Syphilis",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Syphilis: Screening and diagnostic testing",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Syphilis: Treatment and monitoring",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases. Evaluation and management are complex.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX SYSTEM INFECTIOUS DISEASES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX APPRO TO BACTEREMIA", "Text" : "Approach to bacteremia", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSP BACT, BLD CX NOT YET POS", "Text" : "Suspected bacteremia, blood cultures not yet positive", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNC", "Text" : "Interim report of Gram-negative cocci", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GNB", "Text" : "Interim report of Gram-negative bacilli", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "Text" : "Interim report of Gram-positive cocci in pairs", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS", "Text" : "Interim report of Gram-positive cocci in pairs and chains", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS", "Text" : "Interim report of Gram-positive cocci in pairs and clusters", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPR", "Text" : "Interim report of Gram-positive bacilli", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT YEAST", "Text" : "Interim report of yeast", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA S. AUREUS", "Text" : "Bacteremia associated with Staphylococcus aureus", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH", "Text" : "Bacteremia associated with Coagulase-negative Staphylococci (CNS)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA S. LUGDUNENSIS", "Text" : "Bacteremia associated with Staphylococcus lugdunensis", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA LISTERIA", "Text" : "Bacteremia associated with Listeria monocytogenes", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "Text" : "Fungemia associated with Candida spp.", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++SYSTEMIC INFECTIOUS DISEASES++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Bacteremia",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Bacteremia, preliminary results",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Bacteremia, final results (specific pathogens)",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Last reviewed July 2017",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU SEPSIS AND SHOCK", "Text" : "Sepsis and septic shock", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU LEUKOCYTOSIS", "Text" : "Leukocytosis", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU FEVER OF UNK ORIGIN", "Text" : "Fever of unknown origin", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "Text" : "Neutropenic fever", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "Text" : "Lyme disease", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "Other systemic diseases", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX TESTING INPATIENT MENU", "Contents" : [
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX THERADOC HYPERLINK", "Text" : "CLICK HERE FOR THERADOC", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX URINARY CATHETER", "Text" : "Urinary catheters", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "Important Drug Properties A-B", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX URL IDP C SANFORD OR LEXI LINKS", "Text" : "Important Drug Properties C", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ GTX URL IDP D-E-F SANFORD LEXI LINKS", "Text" : "Important Drug Properties D-E-F", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX URL IDP G-H-I-J-K-L SANFORD LEXI LINKS", "Text" : "Important Drug Propertie G-L", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX URL IDP M-N-O SANFORD OR LEXI LINKS", "Text" : "Important Drug Properties M-N-O", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ GTX URL IDP P-Q-R-S SANFORD LEXICOMP LINKS", "Text" : "Important Drug Properties P-Q-R-S", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX URL IDP T-U-V-W-X-Y-Z SANFORD LEXI LINKS", "Text" : "Important Drug Properties T-U-V-W-X-Y-Z", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "testing drug info", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX CDSS 2.0 TEST", "Text" : "Peritonitis Associated with Peritoneal Dialysis Outpatient", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "MENINGOCOCCAL VACCINE INFO PAGE", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ GTX POST SCT VACCINATIONS BLOOD 2016", "Text" : "Test Post SCT Blood", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ GTX URL ANTIMICROBIAL CDSS WEBSITE LINK", "Text" : "Antimicrobial CDSS Website Link", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU SURG ORTHO ALBC HIP AND KNEE JOINT INFECTIONS", "Text" : "TEST ortho", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ GTX URL IDP A-B SANFORD OR LEXI LINKS", "Text" : "SANFORD LINKS", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "CDSS TESTING ONLY BELOWS",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "THERADOC:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMONIA HAP NEW", "Text" : "Pneumonia HAP (new page Pseudomonas)", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSHZID TEST MED", "Text" : "test non-va", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID TEST AZITHROMYCIN 500MG PO QDAY", "Text" : "TEST NON-VA", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Beta-lactam allergy guidance", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ZZPSJIZID VANCOMYCIN 1 GM PREOP CDSS IVPB DELAYED", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID TESTING INDICATIONS (CEF 1GM IV Q8H)AZOLIN 1GM IV Q8H", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID TESTING INDICATIONS (CEF 1GM IV Q8H)AZOLIN 1GM IV Q8H", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : "PSCZID ABX MOXIFL 400MG PO ONCE ER/UC", "Text" : "Verify -yes, auto accept - no", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "PSCZID ALT BENZATHINE PENICLLIN 1.2", "Text" : "verify no, auto accept no", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSCZID AZITHROMYCIN 1GM PO ONCE ER/UC", "Text" : "verify yes, auto accept yes", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "PSCZID AZITHROMYCIN 500MG PO ONCE ER/UC", "Text" : "verify no, auto accept yes", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : "PSJIZID TEST ALT NAFCILLIN 2GM IV Q4H", "Text" : "Ind test", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "PSOZID2 TEST AMOXICILLIN 500MG PO TID 10DS", "Text" : "Indication test", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX THRUSH", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX FUNGUS", "Text" : "Link to candida in specific pathogen", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID NYSTATIN SWISH AND SWALLOW 5ML Q6H", "Text" : "Nystatin swish and swallow QID for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE TROCHE 10MG PO 5X/DAY", "Text" : "Clotrimazole troche 10 mg PO 5X/day for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 200MG PO ONCE THEN 100MG PO Q24H", "Text" : "Fluconazole 200 mg PO once, then 100 mg PO QD for 6 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 200MG PO ONCE THEN 100MG PO Q24H", "Text" : "Fluconazole 200 mg PO once, then 100 mg PO QD for 13 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "THRUSH (OROPHARYNGEAL AND ESOPHAGEAL CANDIDIASIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For information on other types of candidal infections",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Candidal infections of the mouth, throat, or esophagus usually occur in patients",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "on corticosteroid therapy, those who wear dentures, patients treated with",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antibiotics, chemotherapy or head/neck radiation therapy, and those with",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "cellular immune deficiency states, such as AIDS.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Oropharyngeal candidal disease may present in different patterns, like white",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "plaques in the oropharyngeal area, erythematous macules (often in patients with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "dentures), or as pseudomembranes.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Thrush infection often recurs, especially in patients with AIDS. Consult",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases (MRTC may also be consulted in the MVAHCS)for more",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "information on treatment of recurrent infection.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Oral or pharyngeal candidiasis in patients without HIV",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with HIV, or whose disease fails to respond to the",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "above therapies",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Esophageal candidiasis",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Esophageal infection requires systemic therapy.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Oropharyngeal",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment of oropharyngeal and esophageal candidiasis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX TOCILIZUMAB FOR TREATMENT OF COVID-19", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 800MG IV X1 COVID-19 DOSE 1", "Text" : "Tocilizumab 800 mg IV x 1 ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 600MG IV X1 COVID-19 DOSE 1", "Text" : "Tocilizumab 600 mg IV x 1 ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 400MG IV X1 COVID-19 DOSE 1", "Text" : "Tocilizumab 400 mg IV x 1 ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "PSJIZID TOCILIZUMAB 8MG/KG IV X1 COVID-19 DOSE 1", "Text" : "Tocilizumab 8 mg/kg IV x 1 ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TOCILIZUMAB (IL- 6 RECEPTOR BLOCKER) FOR TREATMENT OF COVID-19",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The RECOVERY Trial: Tocilizumab",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "In hospitalized patients with COVID-19 who are hypoxic and have evidence of",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "systemic inflammation, tocilizumab improved mortality. These benefits were seen",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "regardless of the level of respiratory support and were additional to the",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "benefits of systemic corticosteroids.",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "The FIRST dose of tocilizumab DOES NOT require ID approval. Patient must meet",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "all inclusion criteria. If any questions, please page ID on call. Due to",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "current shortage, and uncertainty of benefit of second dose, would",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Inclusion Criteria:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "o Confirmed COVID-19 <AND>",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "o Hospitalized <AND>",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "o Clinical evidence of progressive COVID-19 (supplemental oxygen, high-flow",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "oxygen, or noninvasive or invasive ventilation) <AND>",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Exclusion Criteria:",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "o Outpatient",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "o Current documented or suspected bacterial or fungal infection",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "o Active tuberculosis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "o ANC < 1000/mm3, platelet count < 50,000/mm3, ALT/AST> 10x ULN",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "**1ST DOSE**",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "If all the above inclusion criteria are met and no exclusion criteria, the 1st",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "dose of tocilizumab may be ordered below based on patient's weight.",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Patient weight >/= 90 kg",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Patient weight >/= 65 kg and < 90 kg",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Patient weight >/= 40 kg and < 65 kg",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Patient weight < 40 kg",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "**2ND DOSE**",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "If the patient's condition has not improved in 12-24 hours after receiving the",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "1st dose, a second dose may be considered in select patients. Please page ID for",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Horby, Peter W., et al. Tocilizumab in patients admitted to hospital with",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "COVID-19 (RECOVERY): preliminary results of a randomized, controlled, open-",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "label, platform trial. Medrxiv (2021).",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Tocilizumab Emergency Use Authorization (EUA)",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "Text" : "[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "o Patient does not have a known hypersensitivity to tocilizumab",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "o Counseling is provided and documented in the electronic health record per EUA.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "The provider has communicated with the patient/caregiver regarding",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "caregiver has been given the Fact sheet, informed that the drugs are",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "unapproved drugs that are authorized for use under an EUA, given information",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "discussion of 2nd dose.",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX TOCILIZUMAB FACT SHEET FOR PATIENTS", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Tocilizumab", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX TOCILIZUMAB FACT SHEET FOR PROVIDERS", "Text" : "[Click here] Fact Sheet for Providers EUA Tocilizumab", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "suggest no second doses.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX TOXI MEGACOLON", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX METRONIDAZOLE 500MG IV Q8H VANCO 500MG CAPS PO Q6H", "Text" : "Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg PO q6h ($) [M]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX METRO 500MG IV Q8h VANCO 500MG PO/NG Q6H", "Text" : "Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg NG soln q6h ($)", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX METRO 500MG IV Q8H VANCO CAP 500MG Q6H W/O ENEMA", "Text" : "Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg PO q6h ($) [M]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX METRO 500MG IV Q8H VANCO 500MG NG Q6H W/O ENEMA", "Text" : "Metronidazole 500 mg IV q8h ($) [DI] <AND> vancomycin 500 mg NG q6h ($) [M]", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Discontinue any antibiotics if possible and avoid high risk antibiotic if",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible.",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "An enteral dose of 125mg of vancomycin results in colonic vancomycin",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "concentrations hundreds of times greater than needed to inhibit Clostridium",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "difficile. Only with toxic megacolon or ileus is a higher dose of vancomycin",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "(500mg) administered by enteral route.",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Antimicrobial therapy should be continued for 10 days but may be prolonged",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "considering clinical circumstances. In patients being treated with antibiotics",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "for predisposing infections, continue treatment for 7 days after completion of",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "those antibiotics. If patient is being treated for C. difficile recurrence,",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "pulse taper therapy is indicated after resolution of severe disease. Refer to",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "mild to moderate C. difficile treatment menu for recommendations.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment if ileus is present",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Deliver antimicrobials by intravenous, oral, and rectal routes.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin enema 500 mg in 100 ml normal saline q6h ($) [M]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "**ONLY for Vancomycin NG administration**",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "[M] <AND> vancomycin enema 500 mg in 100 ml normal saline q6h ($) [M]",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treatment if ileus is not present",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "**ONLY for Vancomycin NG administration**",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Clostridium difficile infection",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "McDonald et al, Clin Inf Dis, 2018, (00)1-48",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium difficile",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FULMINANT CLOSTRIDIUM DIFFICILE INFECTION (CDI)",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Definition of fulminant CDI is supported by:",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Hypotension or shock, ileus, megacolon",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Gastroenterology and/or Infectious Diseases consults are essential.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Johnson et al, Clin Inf Dis,2021,73(5):e1029-e1044",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Note: there are no available data supporting the use of fidaxomicin for",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "treatment of fulminant CDI.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX TRICH VAGINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 500MG PO Q12H", "Text" : "Metronidazole 500 mg PO q12h for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 500MG PO Q12H", "Text" : "Metronidazole 500 mg PO q12h for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID METRONIDAZOLE 2GM PO Q24H", "Text" : "Metronidazole 2 gm PO q24h for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TRICHOMONAS VAGINITIS AND URETHRITIS",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Male sexual partners of women with trichomonas vaginitis will not have symptoms",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "but should be treated to prevent recurrent vaginitis in the female sexual",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "partner.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "The discharge is purulent, malodorous, and thin. The vaginal pH is greater",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "than 4.5. Nucleic Acid amplification test (NAAT) for trichomonas has improved",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "sensitivities and specifities compared to wet mount.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment of Initial Episode in Men and Woman",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pregnant women with trichomonas infection may be treated with metronidazole",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "during any trimester.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment of Veteran Male Sex Partners (Non-Veteran Sex Partners Should Be",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Referred to Non-VA Care)",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "1st failure",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "2nd failure",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "3rd failure",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Disease",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Trichomoniasis",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2021) 70.4",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Trichomoniasis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX TUBERCULOSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TUBERCULOSIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Evaluation and management are complex.Consult pulmonary and/or infectious",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diseases.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Patients with suspected or proven pulmonary tuberculosis must be in respiratory",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "isolation.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Centers for Disease Control (CDC). Tuberculosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX TYPHLITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "Text" : "Clostridium difficile infection", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV Q8H METRONIDAZOLE 500 MG IV Q8H", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC ENTEROCOLITIS (TYPHLITIS)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "patients, especially in those with acute leukemia. Send stool for C. difficile",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "PCR testing to exclude of C. difficile infection.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Hematology-oncology, Infectious Diseases and general surgery consults",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "are essential.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Broad spectrum antimicrobials that include anaerobic coverage should be",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "initiated promptly.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Continue antimicrobial therapy until normalization of body temperature, recovery",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "of neutropenia and thrombocytopenia, return of normal gastrointestinal function",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "and resolution of bacteremia if initially present.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< AND > Vancomycin 15 mg/kg ($)[R]",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "who can tolerate oral therapy. Base selection on culture results.",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Diverticulitis and typhlitis",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Nesher and Rolston, Clinical Infectious Diseases, 2013, 56(5):711-7",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neutropenic Enterocolitis, Typhlitis",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Neutropenic enterocolitis (typhlitis)",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Freifeld AG Clin Infect Dis 2011, 52: e56",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Neutropenic enterocolitis, also known as \"typhlitis\" or \"necrotizing",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "enterocolitis\", is a severe intraabdominal infection that occurs in neutropenic", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX UNCOMP CYSTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASYMP BACTERIURIA", "Text" : "Asymptomatic bacteriuria", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID TMP/SULFA 1DS TABLET PO Q12H", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID AMOXI-CLAV 500/125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 500/125 mg PO q12h ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO", "Text" : "Select for updated Ciprofloxacin Info Page", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 5 days", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O] for 5 days, CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] for 3 days", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJZID FOSFOMYCIN 3 GM PO ONCE", "Text" : "Fosfomycin 3GM sachet PO ($$)[M] once", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJZID AMOXI-CLAV 500/125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 500/125 mg PO q12h ($) [R] for 5 days", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] for 3 days", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSJZID TMP/SMX SS Q24H", "Text" : "Trimethoprim/sulfamethoxazole 1 SS tablet PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "PSJZID TMP/SMX 2DS PO ONCE", "Text" : "Trimethoprim/sulfamethoxazole 2 DS tablets PO once as a single patient-", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSJZID TMP/SULFA 1 DS TAB ONCE POST-COITUS", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO once post-coitus ($) [R,DI]", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100MG PO QHS", "Text" : "Nitrofurantoin SA 100 mg PO qHS ($) [R,O] CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "UNCOMPLICATED CYSTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Uncomplicated cystitis refers to symptomatic bladder inflammation from bacterial",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infection. Symptoms usually include dysuria, lower abdominal pain, urgency.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Bacterial cystitis in people with obstruction to urine flow, abnormalities of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "the urine collecting system, indwelling urinary catheters, or symptoms lasting",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "more than a week are considered complicated. Most cases of uncomplicated",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "cystitis occur in healthy adolescent or young adult females.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "A word about asymptomatic bacteriuria or pyuria. With just a few exceptions,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "patients with no symptoms of cystitis should not be treated. The presence of",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "pyuria (>7 wbc/hpf) or positive leukocyte esterase, urine nitrate, or urine",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "bacteria is not a sufficient indication for antibiotic treatment. See page on",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "asymptomatic bacteriuria.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "The prevalence of antimicrobial resistance among bacteria associated with",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "uncomplicated cystitis has increased. A urine culture should be considered in a",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "patient who has had substantial involvement with healthcare or exposure to",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "antimicrobials. If a patient fails to respond to therapy, a urine culture",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "should be done.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Men, preferred treatment for symptomatic cystitis",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative (weigh risk for potential serious side effects vs benefit)",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Women, preferred treatment for symptomatic cystitis",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Alternatives",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Alternative (weigh risk for potential serious side effects vs benefit)",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Suppression",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "For pre-menopausal women with 3 or more episodes per year of recurrent",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "uncomplicated cystitis, suppressive therapy is indicated after infection is",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "eradicated.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "initiated dose at onset of symptoms ($) [R,DI]",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Drekonja, Dimitri M., et al. JAMA 326.4 (2021): 324-331",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Gupta K. et. al. IDSA Clinical Practice Guidelines (2011) 52.1",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cystitis",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: UTI, Recurrent, Cystitis, Urethritis",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute uncomplicated cystitis and pyelonephritis in women",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute uncomplicated cystitis and pyelonephritis in men", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX UPPER RESPIRATORY INFECTIONS (URI)", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS", "Text" : "Bronchitis", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ACUTE SINUSITIS", "Text" : "Sinusitis", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX PHARYNGITIS", "Text" : "Pharyngitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "UPPER RESPIRATORY INFECTION (URI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Upper respiratory infections include several common syndromes including",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the common cold, bronchitis (see below), pharyngitis (see below) and sinusitis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(see below). Most are caused by viruses and there is no benefit from",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy. If a patient presents with a URI, consider specific",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "infections that do respond to antimicrobial therapy like herpes simplex",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "stomatitis, pertussis or thrush. If no condition that benefits from",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy is present, antimicrobials will almost certainly not help",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "but will likely select for antimicrobial resistance and may lead to other",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "adverse effects.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Kogawa et al, General medicine, 2009, 10:7-15", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX URETHRITIS ASSOC STD", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC PCR TEST", "Text" : "Chlamydia & GC PCR/LCR test", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "Text" : "Treatment of recurrent or persistent urethritis", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX GONOCOCCAL", "Text" : "Treatment for gonococcal urethritis", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHLAMYDIA URETHRITIS", "Text" : "Treatment for chlamydial or non-gonococcal urethritis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "URETHRITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "The main differential in a person who presents with dysuria is between cystitis",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "and urethritis. Bacterial urethritis is more likely in people with mild",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "dysuria, onset over a few days, or recent sexual contact.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "The two most common sexually transmitted urethritis pathogens are Neisseria",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "gonorrhoeae and Chlamydia trachomatis. Nucleic acid amplification tests for",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "these pathogens are more sensitive than culture and should be used for patients",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "at risk for sexually transmitted urethritis.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For patients who have recently been treated for urethritis",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "When dysuria is from a sexually transmitted disease, the patient's sexual",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "transmitted infection.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "If diagnostic tests for the cause of urethritis are not feasible, therapy for",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "both N. gonorrhoeae and C. trachomatis should be given to partners.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Initial treatment of patients and sex partners",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Patients and partners are often infected with both N. gonorrhoeae and C.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "trachomatis. Treat for both pathogens unless one is ruled out by lab test.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urethritis",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Urethritis in men",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX URINARY CATHETER", "Contents" : [
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "1) Urinary blockage due to clots",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "2) Urinary blockage due to urinary obstruction (not clots)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "3) Urinary retention due to neurological condition",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "4) Urinary incontinence",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "5) Prolonged surgical procedure",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "6) Monitoring of urinary output",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "7) Open sacral wound",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "8) Suprapubic catheter",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "9) Nephrostomy tubes present",  "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : "GMRCTZ UROLOGY INPT", "Text" : "Consult Urology (inpatient)", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "HELP, additional information:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Urinary Catheters:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Bladder catheters are used for urinary drainage, or as a means to collect",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "urine for measurement. Many clinical situations are appropriate for the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "placement of catheters, BUT too frequently they are used without proper",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "indication or continued longer than needed.Unwarranted urinary catheters",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Daily evaluation of the ongoing need for the catheter is essential to reduce",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "complications including catheter-assosciated urinary tract infection.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternatives to indwelling urethral catheterization should be considered",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "and include intermittent catheterization, external sheath (ie,condom)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "catheters, suprapubic catheters, and in some cases, supportive management",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "with protective garments.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Hospital-acquired urinary tract infection is the most common type of",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "nosocomial infection.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "are placed in 21 to 50 percent of hospitalized patients.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Indications for Catheterization:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU URINARY CATHETER DUE TO IMMOBILIZATION", "Text" : "Management of immobilized patients (eg, stroke, pelvic fracture)", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX URINARY CATHETER NEUROGENIC BLADDER", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "04 Description of types of catheters and insertion", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX URINARY CATHETER NEUROGENIC BLADDER", "Contents" : [
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Management of patients with neurogenic bladder/spinal cord injury",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The goal of an SCI bladder program is to preserve renal function while",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "eliminating urine at regular and socially acceptable times, avoiding high",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "bladder pressures, retention, incontinence, and infection.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Clean intermittent catheterization, which is the removal of the catheter",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "immediately after bladder decompression with recatheterization on a scheduled",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Clean technique intermittent catheterization has a lower infection rate",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "compared with with the use of indwelling catheters.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "basis ispreferred. Clean intermittent catheterization is performed at regular",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "intervals, usually every 4 hours. A bladder volume of less than 500 mls",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "of urine is targeted in order to avoid bladder distention, pressure, and reflux",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "as well as to reduce the incidence of infections.",  "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : "GMRCTZ UROLOGY INPT", "Text" : "Urology Consult (Inpatient)", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "HELP, additional information:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "08 Order forIntermittent Catheterization Q4Hours",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Intermittent urinary incontinence is expected. Condom catheters (for men)",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "and adult diapers are important short-term interventions. Recommend rule",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "out infection and adjust the frequency of intermittent catheterization",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "and fluid intake.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "10 Order for condom catheter for men",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "12 Order for adult diapers",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-to-date online",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "available caregivers, a chronic indwelling catheter may be necessary.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "The indwelling catheter should be changed each month to minimize infections.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "13 Order for indwelling catheter",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "For admitted patients who normally use chronic indwelling catheter:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "For patients unable to perform intermittent catheterization and without", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX URINE CULTURE MENU", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "URINE CULTURE MAIN ORDER MENU",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "-Cloudy urine",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "-Malodorous urine",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "-Discolored urine",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "-When a urinary catheter is placed",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "-Automatic on admission",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (FEVER/SEPSIS NO OTHER CAUSE)", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (DYSURIA,FREQ,URG)", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (PAIN:FLANK,SUPRAPUBIC,PELVIC", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (CVA tenderness)", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Urine Culture is NOT indicated for the following conditions alone:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (ACUTE HEMATURIA)", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (PRE-0P SCREENING UROLOGIC)", "Text" : "", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (PREGNANT SCREENING)", "Text" : "", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (SCI OR NEUROGENIC BLADDER)", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Urine cultures should be ordered in patients with symptoms of a urinary tract",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "infection, during pregnancy at appropriate screening intervals, and prior",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "to an invasive urologic procedure.",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Select indication for urine culture your patient has to place lab order:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "-End of therapy re-testing",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "LRTZ MB URINE CULTURE CLEAN CATCH (ALTERED MENTAL STATUS)", "Text" : "", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "(note that UC not usually indicated, call ID with questions)",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "Minneapolis Clinical On-Call Schedule (Infectious Disease)", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "spinal cord injury or neurologic deficit",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "LRTZ SET OR/IR STERILE ASPIRATE COLLECTION ONLY 2", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX UTI2", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX UNCOMP CYSTITIS", "Text" : "Treatment for uncomplicated cystitis", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU ABX COMP CYSTITIS", "Text" : "Treatment for complicated cystitis", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX PYELONEPHRITIS", "Text" : "Treatment for pyelonephritis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "URINARY TRACT INFECTION (UTI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cystitis refers to infection of the urinary bladder, but inflammation often",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "extends into the urethra. Typical symptoms and signs include dysuria, increased",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "urinary frequency, urgency, and/or suprapubic tenderness.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Most cases of uncomplicated cystitis occur in pre-menopausal, non-pregnant,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "sexually active young women.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Most cases of complicated cystitis are associated with Escherichia coli, but",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "more resistant pathogens occur, including the Gram-positive pathogens",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "staphylococci and enterococci. Urine culture should be obtained before",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobials are given.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Complicating conditions",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Cystitis is considered complicated when one or more of the following is present",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "> Most men with cystitis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "> Pregnant women",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "> Structural abnormalities (e.g. presence of obstruction, catheter or",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "nephrostomy tubes, neurogenic bladder)",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "> Metabolic abnormalities that reduce local host defenses (e.g. diabetes,",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "pregnancy, neutropenia, pelvic irradiation)",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "> Unusual or resistant pathogen",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "> Treatment failure or relapse or recurrence of infection",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "When a patient presents with symptoms of cystitis, urinalysis should be",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "performed to check for the presence of white blood cells. Increased numbers of",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "leukocytes (usually >25) in the presence of cystitis symptoms indicates",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "inflammation and thus cystitis. The bacterial etiology is so predictable that",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "urine culture is unnecessary and empirical treatment is indicated. The",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "clinical significance of pyuria in the absence of cystitis symptoms is unclear.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Antimicrobial therapy is not indicated for pyuria in the absence of symptoms.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary Tract Infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX VAGINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 500MG PO Q12H", "Text" : "Metronidazole 500 mg PO q12h for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 0.75% GEL VAGINAL QHS", "Text" : "Metronidazole topical gel, contents of 1 applicator intravaginally QHS for 5", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q12H", "Text" : "Clindamycin 300 mg PO q12h for 7 days ($) [H,O]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 2% CRM VAG 1APPLFUL CREAM QHS", "Text" : "Clindamycin phosphate vaginal cream 5 gram (contents of 1 applicator)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL VAGINOSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Vaginitis usually presents with discharge, itching, irritation, odor, or pain.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Bacterial vaginosis is the most common form of vaginitis. The vaginal flora is",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disrupted by one or more of the following common pathogens: Gardnerella",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "vaginalis, Mycobacterium hominis, or Gram-negative anaerobes. Vaginal pH should",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "be measured and the specimen should be examined under the microscope.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "The vaginal pH is greater than 4.5, the discharge is homogenous and gray-white,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "and the specimen has a positive amine or whiff test characterized by a fishy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "odor before or after addition of 10% KOH.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "days ($)[DI]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternatives",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "intravaginally QHS for 7 days ($) [H,O]",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bacterial Vaginosis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Bacterial Vaginosis Treatment", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ABX VANCO + MRSA NARES INFORMATION", "Contents" : [
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "MRSA nares screening will be ordered on all new IV Vancomycin starts.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "MRSA nares may be a helpful tool in identifying patients with low risk of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "MRSA infection in whom empiric vancomycin may not be required.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "A negative MRSA nares does not definitively rule out the presence of MRSA",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "elsewhere and is one factor to consider in the de-escalation of vancomycin",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "(and other anti-MRSA antimicrobials).",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Parente DM, Cunha CB, Mylonakis E, Timbrook TT. The Clinical Utility of",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Out MRSA Pneumonia: A Diagnostic Meta-analysis With AntimicrobialStewardship",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Implications. Clin Infect Dis. (2018) 67(1):1-7",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "doi: 10.1093/cid/ciy024. PMID: 29340593.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Jones BE, Ying J, Stevens V, et al. Empirical Anti-MRSA vs Standard Antibiotic",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "JAMA Intern Med. (2020) 180(4):552-560. doi:10.1001/jamainternmed.2019.7495",  "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Information on adding MRSA nares screening with new IV Vancomycin starts:", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ABX VIRUSES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV MAIN PAGE", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEPATITIS A", "Text" : "Hepatitis A", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "Text" : "Hepatitis B", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEPATITIS C", "Text" : "Hepatitis C", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "Text" : "Bell's palsy", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX HSV ENCEPHALITIS", "Text" : "Encephalitis", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX SEXUALLY TRANSMITTED INFECTION", "Text" : "Genital herpes", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "Text" : "Herpes Whitlow (digit or hand", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES KERATITIS", "Text" : "Keratitis", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX OROLABIAL HERPES", "Text" : "Oral lesions: Mouth,Lips (Cold sores)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ VIRUSES ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cytomegalovirus (CMV)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Diarrhea, viral",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Hepatitis",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Herpes Simplex",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "cellulitis)",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Last reviewed 8/2018",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFLUENZA 2021-2022", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID2 GMENU ABX PARAINFLUENZA", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX RSV", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX BELL'S PALSY", "Text" : "Bell's palsy", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU ABX PRIM INFECT CHICKENPOX", "Text" : "Varicella/Chickenpox (primary infection)", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU ABX REACT PRIM INFECT ZOSTER", "Text" : "Zoster/Shingles (reactivation)", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Human Immunodeficiency Virus (HIV)",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "Influenza, Seasonal",  "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "Parainfluenza",  "Header" : 1}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "Respiratory Syncytial Virus (RSV)",  "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "Varicella-zoster", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU ACUTE SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU MILD TO MOD SINUSITIS", "Text" : "[CLICK HERE] for treatment of mild to moderate bacterial sinusitis", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU SEVERE SINUSITIS", "Text" : "[CLICK HERE] for treatment of severe bacterial sinusitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACUTE SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases of acute sinusitis are viral and resolve within 10 days. Symptoms",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(nasal congestion, purulent nasal discharge, and tooth or facial pain) can be",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "treated with decongestants, analgesics, and nasal saline. Diagnosis of acute",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "sinusitis is based on the presence of at least 2 major or 1 major and at least 2",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "minor symptoms.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Major Symptoms",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "1. Purulent anterior nasal discharge",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "2. Purulent or discolored posterior nasal discharge",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "3. Nasal congestion or fullness",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "4. Facial pain or pressure",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "5. Hyposmia or anosmia",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "6. Fever",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Minor Symptoms",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "1. Headache",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "2. Ear pain, pressure or fullness",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "3. Halitosis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "4. Dental pain",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "5. Cough",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "6. Fatigue",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If patient meets criteria above for acute sinusitis, treat with antimicrobials",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "according to the following criteria for mild to moderate or severe bacterial",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "sinusitis.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mild to moderate bacterial sinusitis",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "1. Symptoms persisting beyond 10 days",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "2. Double-sickening - Symptoms typical of viral upper respiratory infection",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "initially improving for 5-6 days then worsening with new development of fever,",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "headache or increased nasal discharge.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Severe bacterial sinusitis",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Severe signs or symptoms of high fever (>/= 102 degrees Fahrenheit, >/= 39",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "degrees Celsius) and purulent nasal discharge for 3-4 consecutive days or facial",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "pain lasting for at least 3-4 consecutive days at the beginning of illness.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ANAPLASMA PHATOCYTOPHILUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h for 10 days ($) [DI]", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "Text" : "Doxycycline 100 mg IV q12h for 10 days ($$) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANAPLASMA PHAGOCYTOPHILUM (HUMAN GRANULOCYTOTROPIC ANAPLASMOSIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "MMWR RR. 2016, 65 (2) 1-44",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Ehrlichia sp., Anaplasma sp.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Human ehrlichiosis and anaplasmosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL IMMUNOSUPPRESSIVE MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800 MG PO BID PROPHYLAXIS", "Text" : "Acyclovir 800 MG PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800 MG PO BID PROPHYLAXIS", "Text" : "Acyclovir 800 MG PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Severly Immunosuppressive Chemo-immunotherapy",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Purine Analogues",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Chemotherapy with purine analogues such as fludarabine, cladribine, or",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "pentostatin results in major cellular-immunodeficiency that may outlast the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "exposure by months and enhances the risk for viral infections.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Recommend antiviral prophylaxis for patients treated with purine analogues,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "if at least one of the following risk factors is present:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "a) Second-line chemotherapy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "b) Treatment with corticosteroids",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "c) CD4 cell count <50/ul",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "d) Age >65 years",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "e) Prolonged Mild or Moderate Neutropenia: Mild<1000 Neutrophils /",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "L (Grade III neutropenia) OR Moderate: <500 Neutrophils/L",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(Grade IV neutropenia)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Recommendations:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Duration: Antiviral prophylaxis should be initiated in the first week of",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "therapy and continued until 2 months after completion of therapy.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Alemtuzumab Therapy:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alemtuzumab is a potent reactivator of latent intracellular pathogens,",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "including CMV. Chemotherapy with alemtuzumab results in major cellular-",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "immunodeficiency that may outlast the exposure by months and enhances the",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "risk for viral infections. The risk of viral disease increases with the",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "intensity and duration of functional T-cell suppression experienced with",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "recipients of alemtuzumab.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Recommendations:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Duration: Initiate antiviral prophylaxis with alemtuzumab therapy and",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "continue therapy for at least 2 months after last dose or until CD4 counts",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "are greater than or equal to 200 cells/ul, whichever is later.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Taplitz RA Journal of Clinical Oncology 2018, 36:3043",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Cancer Patients",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sandherr M Annals of Oncology 2006, 17:1051", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL IMMUNOSUPPRESSIVE MALIGNANCY", "Text" : "Select for recommendations for antiviral prophylaxis", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA 2021-2022", "Text" : "Seasonal Influenza Recommendations", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "Text" : "Consult Infectious Disease", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "Text" : "Hepatitis B Evaluation Anti-CD20 Antibody", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "Text" : "Consult Infectious Disease", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Influenza and Other Respiratory Viruses",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Yearly influenza vaccination with inactivated vaccine is recommended for all",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "patients receiving chemotherapy for malignancy and all family and household",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "contacts and health care providers.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Optimal timing of vaccination for patients being treated for cancer is not",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "established, but serologic responses may be best between chemotherapy cycles",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "(greater than 7 days after the last treatment) or greater than 2 weeks",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "before chemotherapy starts.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Patients with active malignant disease are at higher risk for upper",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "respiratory infections due to influenza, parainfluenza or respiratory",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "syncytial virus (RSV). Although response to vaccination with the attenuated",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "influenza vaccine in patients on chemotherapy is variable, ranging",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "from 24-75%, immnunoprophylaxis with the influenza vaccine is recommended for",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "patients with active malignant disease or chemotherapy, lymphoproliferative",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "disease, or multiple myeloma. In areas and seasons where influenza is",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "endemic, chemoprophylaxis can be considered in addition to vaccination in",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "exposed patients with a high risk of influenza complications.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Recommendations:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Cytomegalovirus (CMV)",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Prophylaxis and monitoring for CMV reactivation is not recommended unless the",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "patient has received an allogeneic HSCT. Usually the recommendations for",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "surveillance and prophylaxis of CMV infections from the institution",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "performing the HSCT will be followed.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Recommendations:",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Chronic Hepatitis B",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Reactivation of chronic hepatitis B in patients undergoing immunosuppressive",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "or antineoplastic treatment is a severe complication. Patients with positive",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "HBsAg, chronic hepatitis B infection, or a previous episode of HBV",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "reactivation who will receive immunosuppressive therapy should receive",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "prophylaxis.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Recommend routine testing for Hepatitis B prior to initiating Rituximab",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "(Anti-CD20 antibody) therapy in patients.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Recommendations:",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Cancer Patients",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Taplitz RA Journal of Clinical Oncology 2018, 36:3043",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Sandherr M Annals of Oncology 2006, 17: 1051", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL TYPE OF MALIGNANCY", "Text" : "Solid Tumors, Acute Leukemia, or Lymphoma", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL IMMUNOSUPPRESSIVE MALIGNANCY", "Text" : "Purine analogues or Alemtuzumab", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Text" : "Stem cell transplant recipients (autologous or allogeneic)", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Text" : "Rituximab therapy", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Influenza and Other Respiratory Viruses", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Hepatitis B", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF VIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Viral infections reactivate in a small percentage of people with malignancy.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most viral infections in patients with hematologic malignancies or solid",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "tumors result from reactivation of asymptomatic latent infections,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "predominantly of herpes viruses, including herpes simplex virus (HSV),",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "varicella zoster virus (VZV) and cytomegalovirus (CMV). Exogenous",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "respiratory tract infections caused by influenza, parainfluenza",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "or respiratory syncytial virus (RSV) are less common.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "The main risk factor for clinically relevant reactivation is profound",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "disruption of cellular immune response, usually due to chemotherapy.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "The duration and severity of neutropenia are of lesser importance.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "The risk of viral disease increases with the intensity and duration",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of functional T-cell suppression. Patients receiving conventionally",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "dosed chemotherapy regimens for solid tumors experience no major",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "T-cell suppression and do not have a higher incidence of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "invasive viral infections.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "This section is organized mainly by type of malignancy.",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "There are separate sections for purine analogues (fludarabine,",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "cladribine, pentostatin), alemtuzumab and rituximab.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Select below for recommended antiviral prophylaxis:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "This section is organized by virus.",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Select below for recommended antiviral prophylaxis:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Cancer Patients",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sandherr M Annals of Oncology 2006, 17:1051", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Select for Hepatitis B recommendations", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "**Stem cell transplant recipients (autologous or allogeneic)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Usually the standard prophylaxis and monitoring strategies recommended",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "by the institution performing the stem cell transplant will be",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "followed.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Consult Hematology-Oncology or Infectious Disease for recommendations.",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Rituximab Therapy",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Recommend routine testing for Hepatitis B prior to initiating treatment",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "with Rituximab.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Vega, J et al, J Clin Oncol 26: 2008 (May 20 suppl, abstract 8558)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ANTIVIRAL TYPE OF MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800 MG PO BID PROPHYLAXIS", "Text" : "Acyclovir 800 MG PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "Text" : "Hepatitis B information page", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "Text" : "Hepatitis B Evaluation Anti-CD20 Antibody", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "**Solid Tumors**",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "No Antiviral Prophylaxis Recommended",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Solid tumors do not significantly compromise the cellular immune system.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Therefore, patients are at low risk for opportunistic viral infections.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Documented invasive viral infections are very rare. Coincidental",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "mucocutaneous infections by herpes simplex are easily treated and do not",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "result in life-threatening invasive infections. Reactivation of",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) is rarely observed.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "**Acute Leukemia**",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Herpes simplex virus-seronegative patients",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "No Antiviral Prophylaxis Recommended",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "In patients with acute leukemia, treatment is highly aggressive and consists",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "of a combination of various cytotoxic agents administered in sequential",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "cycles as induction, consolidation and maintenance therapy. Persistent, i.e.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : ">10 days and profound neutropenia (<500 neutrophils) regularly occurs and",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "correlates with the risk of developing fever and infections. Almost all viral",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "infections during neutropenia constitute reactivations of herpes viruses.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "None of the available studies demonstrated an effect of antiviral prophylaxis",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "on the initiation of antibiotic treatment, number of febrile days, duration",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "of antibiotic treatment, and onset of opportunistic infections. Therefore, no",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "recommendation for antiviral prophylaxis in patients with acute leukemia can",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "be given.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Herpes simplex virus-seropostive patients",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Patients undergoing leukemia induction therapy should receive prophylaxis.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "**Lymphoma**",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "No Antiviral Prophylaxis Recommended",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Rituximab is a monoclonal anti-CD-20 antibody used for treatment of",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "lymphomas. It leads to a profound depletion of circulating B-cells. B-cells",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "recover usually within 3-6 months after treatment. Prolonged administration",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "of rituximab (e.g., maintenance treatment >12 months) may result in a",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "significant decrease of levels of immunoglobulin M. Parvovirus B19 and JC-",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "papovavirus infections have been reported with maintenance rituximab therapy,",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "but drugs that would prevent these infections are not available. There is no",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "substantial increase in risk of reactivation of herpes viruses (including",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "HSV, VZV, and CMV).",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Recommend routine testing for Hepatitis B virus prior to initiating Rituximab",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "therapy in patients.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Cancer Patients",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-to-Date",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION", "Text" : "Link to appendicitis with perforation menu", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX CEFAZ 2GM IV X1 METRO 500MG IV X1", "Text" : "Cefazolin 2 gm IV ($) [R] <AND> metronidazole 500 mg IV ($) [DI] both given", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX GENTAM 5 MG/KG IV 30MIN METRO 500MG IV X1", "Text" : "Gentamicin 5 mg/kg IV ($) [R,O] <AND> metronidazole 500 mg IV ($) [DI] both", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem 1 gm IV Q24h for 3 days ($$) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h for 3 days ($$) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPENDICITIS WITHOUT PERFORATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients with an acutely inflamed appendix and no gangrene or perforation are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "considered to have uncomplicated appendicitis. Patients with gangrene,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "perforation, peritonitis, or abscess have complicated appendicitis. Treatment",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "with antibiotics is an option for patients who are unfit for surgery or refuse",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "surgery. Treatment with antibiotics should not be used routinely as an",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "alternative to surgery.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Select for treatment of complicated appendicitis",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Surgical prophylaxis for uncomplicated appendicitis",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "over 30 minutes beginning 60 minutes before incision",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "given over 30 minutes beginning 60 minutes before incision",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treatment of patients who are unfit for surgery or refuse surgery",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Initial treatment",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Step down treatment after completion of initial intravenous treatment",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "($) [DI] for 7 days",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Appendicitis",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Salminen et al, JAMA, 2015, 313(23):2340-2348",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Appendicitis",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Management of acute appendicitis in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU APPENDICITIS WITH PERFORATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 400MG IV Q12 METRON 500MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg IV q8h", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> Metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CIPROF 500MG PO Q12H METRO 1G PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> metronidazole 1000 mg PO q12h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPENDICITIS WITH PERFORATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treat until normalization of temperature, WBC and GI tract functioning",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "who can tolerate oral therapy. Base selection on culture results.",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Appendicitis",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Appendicitis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Management of acute appendicitis in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU APPRO FOOT ULCER W/ INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPROACH TO FOOT ULCER WITH INFECTION",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Whenever possible, material should be obtained for Gram stain and culture.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Specimens from deep ulcer biopsy, aspiration, or bone biopsy are superior to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "wound swab or drainage.Pathogen identification is especially important because",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "therapy is often given for weeks.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "While foot ulcers in patients with diabetes typically have many bacterial",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "species on the surface, disease is usually caused by only one or two.When",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is present in a surface culture, it is usually a pathogen",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "in the deeper tissues.Therapy can usually be directed against the predominant",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "or virulent organisms found on surface cultures and need not be active against",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "every isolate.To reduce uncertainty it is better to obtain deeper cultures.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Bacteria that are most likely to be responsible for invasive infection include",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "S. aureus, streptococci, enteric gram-negative bacilli, Pseudomonas aeruginosa,",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "and anaerobes typical of the human enteric flora.When there is no evidence",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "that would direct therapy to any single organism, empirical therapy should be",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "directed against these organisms.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU APPRO INTRAVAS CATH-ASSOC INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUPPURATIVE THROMBO EMP THERAPY", "Text" : "Suppurative thrombophlebitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPROACH TO INTRAVASCULAR CATHETER-ASSOCIATED INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The likelihood of colonization of an intravenous catheter increases with time,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "increasing noticeably after 3 days. Patients whose catheters become colonized",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "may or may not develop local or systemic signs or symptoms. All types of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "catheters are associated with risk of local and catheter-associated bacteremia.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Since central catheters are usually used for more days than peripheral",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "catheters, central catheters have a greater risk of catheter-associated",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "bacteremia.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "When catheter-related bacteremia is suspected, draw blood cultures from both the",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "catheter and a peripheral vein. Growth rate between the two cultures may be used",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "to determine if the source of bacteremia is likely catheter-associated. If the",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "catheter obtained culture's time to positivity is 2 hours or more before the",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "peripheral vein obtained culture's time to positivity, this suggests catheter-",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "associated infection. Sample any exudate at the catheter site for gram stain and",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "culture.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Suppurative thrombophlebitis presents with inflammation in and around a vein.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "There may be local thrombosis and/or bacteremia. Cases may be life-threatening",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "and can require surgical drainage.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For patients with catheter-associated bacteremia with virulent pathogens like",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus, gram-negative bacilli, or candida, catheter removal is",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "almost always necessary. For mild or moderate cases with less virulent",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "organisms like coagulase-negative staphylococci, antimicrobial therapy is",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "successful without catheter removal about half of the time. The decision about",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "whether to remove the catheter depends on severity of illness, the need for the",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "catheter, and how difficult catheter replacement would be.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Antimicrobial lock therapy",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "For cases in which an infected catheter is not removed, the success rate is",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "improved when the infected catheter is filled with an antimicrobial solution",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "during periods when the catheter is not used. Consult Infectious Diseases or",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Pharmacy for information.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "In Staphylococcus aureus cases, document that bacteremia has cleared during",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy. Infectious Disease consultation is required for all",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "cases of S. aureus bacteremia.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "For a patient whose blood cultures remain positive for more than 3 days or with",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "a catheter tunnel abscess or who has a prosthetic device, contact Infectious",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "diseases.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Gaur et al., Clinical infectious diseases 2003, 37.4",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Mandell chapter Sepsis, Severe Sepsis and Septic Shock",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Prevention of Intravascular Catheter Associated Infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU APPROACH TO BRAIN ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT", "Text" : "Brain abscess from contiguous or hematogenous spread of infection", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC", "Text" : "Post-surgical or post-traumatic brain abscess", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP", "Text" : "Nocardia spp.", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.", "Text" : "Pseudomonas spp.", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII", "Text" : "Toxoplasma gondii", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPROACH TO BRAIN ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Brain abscess is a focal infection of the brain parenchyma. Symptoms often",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "include headache, fever, altered mental status, seizures, and focal neural",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "deficits. Pathogens vary based on primary site of infection and patient's immune",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "status. Bacteria cause most infections in immunocompetent patients whereas a",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "wider array of pathogens, including fungi, cause infection in immunocompromised",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "patients.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Streptococci are the most isolated pathogen, often isolated from mixed",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "infections. Bacteroides are also commonly isolated in mixed cultures. Enteric",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "gram-negative bacilli are typically isolated in patients with otitic foci,",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "bacteremia, or post-neurosurgery. Staphylococcus aureus is commonly isolated in",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "a pure culture and in patients with endocarditis or cranial trauma. Brain",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "abscess caused by Listeria and Nocardia may occur in patients who are",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "immunocompromised.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Magnetic resonance imaging (MRI) should be obtained in all patients with",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "suspected brain abscess for diagnosis and determining number of lesions. Prior",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "to beginning antimicrobial therapy, when possible, computed topographic (CT) -",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "guided aspiration or surgery should be performed to obtain abscess material for",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "determination of infectious pathogen.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Solitary brain abscesses usually result from the spread of focal ear, sinus, or",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "dental infection (contiguous source). Cases with multiple abscesses often result",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "from hematogenous spread from infections such as endocarditis, abdominal",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "infection, or lung abscess.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment After Obtaining Abscess Sample, When Possible",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treatment Based on Isolated Pathogen",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "When infectious organism is identified, adjust antimicrobials to optimize",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "therapy",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Brain Abscess",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Brain Abscess",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and Prognosis of Bacterial Brain Abscess",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Pathogenesis, clinical manifestations, and diagnosis of",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "brain abscess", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BABESIA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX AZITHRO 500 THEN 250 Q24H ATOVAQUONE 750 Q12H", "Text" : "Azithromycin 500 mg PO once ($) on day 1, then 250 mg PO q24h ($) [M] for 6", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX AZITHRO 500MG IV Q24H ATOVA 750MG PO Q12H", "Text" : "Azithromycin 500 IV q24h ($) [M] <AND> atovaquone 750 mg PO q12h ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BABESIA SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treat for 7-10 days. If patient has persistent relapsing disease, treat for 6",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "weeks including 2 weeks after babesia are no longer detected in blood smear.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "days <AND> atovaquone 750 mg PO q12h ($) [M] for 7 days",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "*Consult Infectious Diseases, requires NF consult for quinine.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Clindamycin 600 mg PO q8h <AND> quinine 650 mg PO q8h",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "*Consult Infectious diseases, requires NF consult for quinine.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Clindamycin 600mg IV q6h <AND> quinine 650 mg PO q8h",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Babesia Species",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Babesiosis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Babesiosis: Treatment and prevention",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Vannier et al. N Engl J Med. 2012 (366)2397-407", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BAC MENING GRM POS BACILLI L. MONOCYTO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID GENT 2MG/KG IV ONCE THEN 1.7MG/KG IV Q8H", "Text" : "Gentamicin 2 mg/kg IV x 1 then 1.7 mg/kg IV q8h ($) [R,O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID TRIMETH/SULFA 5-25 MG/KG IV Q6H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS WITH GRAM-POSITIVE BACILLI/COCCOBACILLI SUGGESTING LISTERIA",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "MONOCYTOGENES",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid. Adjust",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antimicrobial regimen to optimize therapy and treatment duration based on",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "pathogen once isolated.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OPTIONAL ADD ON TO ONE OF THE AGENTS ABOVE FOR SYNERGY >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACT MENING ASSOC TRAUMA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2gm IV q8h ($$) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R] for 10-14", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R] for", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS ASSOCIATED WITH TRAUMA OR NOSOCOMIAL INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid. Adjust",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial regimen to optimize therapy and treatment duration based on",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "pathogen once isolated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery and Infectious Diseases",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Removal of Infected Shunt, Drain, and Other Hardware is Required for Source",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Control",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment duration is typically 10-14 days depending on infection type,",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "organism, severity, and source control.A shorter duration may be used in",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "infections caused by P. acnes, coagulase-negative staphylococci, diptheroids,",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "and infections with minimal CSF abnormalities.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "days",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "10-14 days",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clinical Infectious Diseases, 2017, 64(6)e34-e65",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACT MENING E.COLI, PSEUDOMONAS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS WITH E. COLI, PSEUDOMONAS, OR ANOTHER ORGANISM",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment is complicated and non-standardized. Consult Infectious Diseases to",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "assist in treatment in all cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACT MENING GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H GENT 2MG/KG X1 1.7MG/KG IV Q8H", "Text" : "Cefepime 2gm IV q8h ($$) [R] <AND> gentamicin 2 mg/kg IV x 1 then 1.7 mg/kg IV", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS WITH GRAM-NEGATIVE BACILLI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid. Adjust",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial regimen to optimize therapy and treatment duration based on",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "pathogen once isolated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "q8h ($) [R,O]",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, Gram-negative Bacilli",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACT MENING GRM NEG DIPL N. MENING", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS WITH GRAM-NEGATIVE DIPLOCOCCI SUGGESTING NEISSERIA",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "MENINGITIDIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid. Adjust",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antimicrobial regimen to optimize therapy and treatment duration based on",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "pathogen once isolated.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "If meningococcal meningitis is identified, antimicrobial prophylaxis should be",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "considered for close contacts. Contact Infectious Diseases/Epidemiology for",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "advice and assistance.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACT MENING GRM POS DIPLO S. PNEUMO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID DEXAMETHASONE 10MG IV Q6H SYRINGE", "Text" : "Dexamethasone 10 mg IV q6h ($) for 4 days", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS WITH GRAM-POSITIVE DIPLOCOCCI SUGGESTING STREPTOCOCCUS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "PNEUMONIAE",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid. Adjust",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antimicrobial regimen to optimize therapy and treatment duration based on",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "pathogen once isolated.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Intravenous dexamethasone therapy improves outcomes for meningitis with some",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "bacteria and by extrapolation is recommended for all community acquired cases.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Dexamethasone must be given before (1 to 20 minutes) or concurrent with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobials.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Step 1 of Treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Step 2 of Treatment",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empirical Antimicrobials",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACT MENING L. MONOCYTOGENES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] for 21 days", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID GENT 2MG/KG IV ONCE THEN 1.7MG/KG IV Q8H", "Text" : "Gentamicin 2 mg/kg IV x 1 then 1.7 mg/kg IV q8h ($) [R,O] for 7 days", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID TRIMETH/SULFA 5-25 MG/KG IV Q6H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS WITH L. MONOCYTOGENES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 21 days. If gentamicin is added for synergy, treat",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "for at least 1 week. May be extended for up to 3 weeks in those who are poor",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "responders and do not have signs of toxicity.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OPTIONAL ADD ON TO ONE OF THE AGENTS ABOVE FOR SYNERGY >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, Listeria monocytogenes",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACT MENING N. MENINGITIDIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Penicillin MIC <0.1 mcg/mL: Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Penicillin MIC 0.1-1.0 mcg/mL: Meropenem 2 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS WITH N. MENINGITIDIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Meningococcal disease prophylaxis should be given to close contacts. Contact",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases/Epidemiology for advice and assistance.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 7 days.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Preferred treatment:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, Neisseria meningitidis",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACT MENING S. PNEUMONIAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID DEXAMETHASONE 10MG IV Q6H SYRINGE", "Text" : "Dexamethasone 10 mg IV q6h ($) for 4 days", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Meropenem 2 gm IV q8h ($$) [R]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX MOXIFLOXACIN 400MG IV Q24H VANCO IV Q12H", "Text" : "Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15 mg/kg q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS WITH S. PNEUMONIAE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Some evidence suggests that intravenous dexamethasone therapy improves outcomes",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "for pneumococcal meningitis. Dexamethasone must be given before (1 to 20",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "minutes) or concurrent with antimicrobials.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "If Initiating Therapy, Give:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Note: Antimicrobials depend on S. pneumoniae MIC results. In most cases results",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "will usually be known only after 2 or 3 days of therapy.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 10-14 days.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treatment if Penicillin MIC < or = 0.1 mcg/mL",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Treatment if Penicillin MIC > or = 0.1 mcg/mL and Ceftriaxone MIC < or = 0.5",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "mcg/mL",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Treatment if Penicillin MIC > or = 0.1 mcg/mL and Ceftriaxone MIC > 0.5 mcg/mL",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Treat as listed below, and obtain another CSF specimen in 24 to 48 hours.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, Streptococcus pneumoniae",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACT MENING W/O GRM STAIN RES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID DEXAMETHASONE 10MG IV Q6H SYRINGE", "Text" : "Dexamethasone 10 mg IV q6h ($) for 4 days", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg q12h ($) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN+CEFTRIAX+VANCOMYCIN", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> ceftriaxone 2 gm IV q12h ($) [M] <AND>", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX MOXIFLOX IV Q24H VANCO IV Q12H TMP/SULFA IV Q6H", "Text" : "Moxifloxacin 400mg IV q24h ($$) [R,DI] <AND> vancomycin 15mg/kg q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL MENINGITIS (WITHOUT GRAM STAIN RESULTS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Once a diagnosis of acute bacterial meningitis is considered likely,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "antimicrobials should be initiated as soon as possible after obtaining blood",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures and performing a lumbar puncture to obtain cerebrospinal fluid. Adjust",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial regimen to optimize therapy and treatment duration based on",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "pathogen once isolated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Intravenous dexamethasone therapy improves outcomes for meningitis with",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Streptococcus pneumoniae and is recommended for empirical treatment of all",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "community acquired cases that might be associated with S. pneumoniae.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Dexamethasone must be given before (1 to 20 minutes) or concurrent with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobials.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If meningococcal meningitis is identified, antimicrobial prophylaxis should be",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "considered for close contacts. Contact Infectious Diseases/Epidemiology for",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "advice and assistance.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Step 1 of Treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(Discontinue if isolated pathogen is not S. pneumoniae)",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Step 2 of Treatment, Select One of the Following:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment for Adults < 50 Years Without Alcoholism, Debilitating Disease, or",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Any Other Condition Associated with Impaired Cellular Immunity.",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment for Adults >= 50 Years or With Alcoholism, Debilitating Disease, or",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Impaired Cellular Immunity. Listeria Monocytogenes is One Important Pathogen.",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "vancomycin 15mg/kg q12h ($) [R]",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "<AND> trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute meningitis",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, Age > 50 years",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, Age 1 mo to 50 years",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Meningitis, bacterial, positive gram stain",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Tunkel et al., Clin Infect Dis, 2004, 39.1267-84",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Clinical features and diagnosis of acute bacterial",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "meningitis in adults",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Treatment of bacterial meningitis caused by specific",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "pathogens in adults",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Van de Beek et al., Clin Microbiol Infect, 2016, 22.S37-S62", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 800MG PO ONCE THEN 400MG Q24H", "Text" : "Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX FLUCONAZOLE IV 800MG ONCE THEN 400MG Q24H", "Text" : "Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "Text" : "Micafungin 100 mg IV q24h ($$$) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FUNGEMIA ASSOCIATED WITH CANDIDA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases. Antifungal treatment is indicated for all cases of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "candidemia. Treat until 14 days after the last positive blood culture.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Most Candida can be treated with fluconazole. If the patient is critically ill,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "if the patient has recently taken an azole antifungal, or if Candida krusei or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "C. glabrata are present, micafungin should be used initially.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "If the patient has substantial renal disease, but is not dialysis-dependent,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "consider micafungin. Call Infectious Diseases for advice.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment for Candida albicans, Candida parapsilosis and",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Candida tropicalis",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For patients who cannot take oral medication",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment for Candida glabrata and Candida krusei",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Andes et al, Clinical Infectious Diseases 2012, 54.8",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Pappas et al, Clinical Infectious Diseases 2016, 62.4e1-50",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA COAG NEG STAPH", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA S. LUGDUNENSIS", "Text" : "Bacteremia associated with Staphylococcus lugdunensis", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTEREMIA ASSOCIATED WITH COAGULASE-NEGATIVE STAPHYLOCOCCI (CNS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Commonly isolated CNS are S. epidermidis, S. haemolyticus, S. lugdunensis and S.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "saprophyticus. Less commonly isolated CNS are S. auricularis, S capitis, S.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "caprae, S. carnosus, S. cohnii, S. hominis, S. pasteuri, S. petrasii, S.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "pettenkoferi, S. pulvereri, S. saccharolyticus, S. schleiferi, S. simulans, S.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "warneri and S. xylosus.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Unlike other CNS, S. lugdunensis can cause severe disease like S. aureus. Refer",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "to Bacteremia Associated S. lugdunensis page for treatment.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "CNS are present in 50% of positive blood cultures, and 90% are contaminants. In",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "a patient without signs or symptoms of infection, a single positive blood",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "culture for CNS often represents contamination and not infection. CNS are more",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "likely to be pathogens in patients with a prosthetic device. Contact Infectious",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Diseases for more information.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "For patients with catheter-related bacteremia or those with suspected",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "endocarditis, please return to the main menu and proceed to the appropriate",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "advice page.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Most isolates are methicillin-resistant. Use vancomycin empirically, but switch",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "to the more effective beta-lactam antimicrobials if the isolate is susceptible.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of coagulase-negative staphylococci",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-susceptible staphylococci",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "For patients with non-severe penicillin allergy",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-resistant staphylococci or for patients with severe",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "penicillin allergy",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus, Coagulase-negative species", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA LISTERIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2G Q4H GENT 1.7MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h ($$$) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTEREMIA ASSOCIATED WITH LISTERIA MONOCYTOGENES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment of listeria infection",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For immunocompromised patients and for patients with meningitis or endocarditis",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "($) [R,O]",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "For patients with penicillin allergy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Listeria Monocytogenes",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Listeria monocytogenes", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "Text" : "CARDIOVASCULAR", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTEREMIA ASSOCIATED WITH STAPHYLOCOCCUS AUREUS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases. Empirical therapy should cover",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "methicillin-resistant Staphylococcus aureus. If an isolate susceptible to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "beta-lactams is identified, use one of these drugs because they are more",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "effective.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "If there is an easily removable or drainable focus (e.g. infected intravenous",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "catheter, minor abscess, urinary cystitis, or mild to moderate pneumonia), and",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "this focus has been treated, give parenteral antimicrobials for 2 weeks.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Consider echocardiogram to assess for associated endocarditis, which would",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "require 4-6 weeks of therapy. Consult Cardiology or Infectious Diseases for more",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Refer to cardiovascular section for suspected endocarditis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-susceptible staphylococci",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-resistant staphylococci",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Antimicrobial Therapy",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BACTEREMIA S. LUGDUNENSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "Text" : "CARDIOVASCULAR", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTEREMIA ASSOCIATED WITH STAPHYLOCOCCUS LUGDUNENSIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Severity of S. lugdenensis infections vary from moderate to severe.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Approximately 25% of isolates are resistant to penicillin, but methicillin",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "resistance is uncommon. Since optimal duration of therapy has not been",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "established, treat until patient is clearly improved and has been free of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "symptoms or signs of S. lugdunensis infection for several days.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Refer to cardiovascular section for suspected endocarditis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-susceptible S. lugdunensis",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-resistant S. lugdunensis",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Staphylococci",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Staphylococcus lugdunensis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus lugdunensis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BED BUGS (HEMIPTERA)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJZID TRIAMCINOLONE 0.1% CRM TOP BID PRN", "Text" : "Triamcinolone 0.1% cream apply to affected area BID PRN for itching ($)[M]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID HYDROXYZINE PAMOATE 25MG PO TID", "Text" : "Hydroxyzine pamoate 25 mg PO TID until symptoms resolve, then take 25 mg PO", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BED BUGS (HEMIPTERA)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment is not indicated.Treat itching with topical",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "corticosteroids or systemic antihistamines.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "TID PRN for itching ($) [H]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BILIARY SURGERY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG GENTAMICIN 5MG/KG PREOP", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BILIARY SURGERY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Surgical prophylaxis is indicated for open procedures and high risk",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "laparoscopic procedures.Additional doses should not be given after",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "incisions are closed. Surgical prophylaxis is not indicated in elective",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "low risk laparoscopic procedures.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "The risk of infectious complications after laparoscopic cholecystectomy is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "increased after emergent procedures, procedures lasting more than 120 minutes,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "intraoperative gall bladder rupture or bile spillage, conversion from",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "laparoscopic to open cholecystectomy, and insertion of a prosthetic device.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "The risk is increased in patients who have had an episode of colic or a",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "biliary procedure within 30 days before the procedure, patients with acute",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "cholecystitis or jaundice, patients with a nonfunctional gallbladder, patients",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "with immunosuppression, pregnancy, diabetes, age greater than 70 years, or",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "American Society of Anesthesiologists classification of 3 or greater.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "If one of these risk factors exists, prophylaxis is indicated for laparoscopic",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "cholecystectomy.If there is a substantial likelihood that one of these risk",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "factors will develop during a procedure, the surgeon may elect to order",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "prophylaxis.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Open procedure or high-risk laparoscopic procedure:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Preferred prophylaxis",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "($) [R] < OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative in patients with beta lactam allergy",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "($) [H,O] <AND> Gentamicin 5 mg/kg IV over 30 minutes beginning 60",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "minutes before incision ($) [R,O]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BITE WNDS EIKENELLA CORRODENS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100MG PO Q12H", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH EIKENELLA CORRODENS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bites",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BITE WNDS P. MULTOCIDA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100mg PO q12h ($) [DI] < OR >", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "Text" : "Doxycycline 100mg IV q12h ($$) [DI]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH PASTEURELLA MULTOCIDA",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bites",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BITE WNDS S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]< OR >", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI]< OR >", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH STAPHYLOCOCCUS AUREUS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "_________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Methicillin-SUSCEPTIBLE S. aureus",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Methicillin-RESISTANT S. aureus",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bites",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BITE WNDS STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 MU IV q4h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH STREPTOCOCCI",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergic patients:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bites",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BITE WOUNDS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400MG PO Q24H", "Text" : "Moxifloxacin 400mg po q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN 400MG IV Q24H", "Text" : "Moxifloxacin 400 mg IV q24h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 400 MG PO Q24H", "Text" : "Moxifloxacin 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS P. MULTOCIDA", "Text" : "Bite wounds with Pasteurella multocida", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS EIKENELLA CORRODENS", "Text" : "Bite wounds with Eikenella corrodens", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS S. AUREUS", "Text" : "Bite wounds with Staphylococcus aureus", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU BITE WNDS STREPTOCOCCI", "Text" : "Bite wounds with Streptococci", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Bite wounds are prone to infection because of the pathogenic oral flora carried",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "into tissuesby teeth.Common pathogens include Eikenella corrodens, usually",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "from human bites, and Pasteurella multocida, often from dog or cat bites,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "streptococci and staphylococci.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Clean wounds with soap and water as soon as possible, add local antiseptic",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "and debride non-viable tissue.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult orthopedic surgery for all bite wounds involving the hand.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antibiotic Prophylaxis Indications:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Severe injury less than 8 hours, Crush injury, Bone or joint penetration,",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Wound of the face or hands or genitals, Immunocompromised host, Asplenia,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Advanced liver disease",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "*Routine use of prophylactic antibiotics for non-immunocompromised patients",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "with superficial wounds with no puncture that do not involve the face/",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "genitals/hands is not recommended.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Treatment:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Empiric treatment for suspected or established infection following bite wound.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "In these cases, therapy should be directed against pathogen identified",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "by Gram stain and culture whenever possible.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Rabies Prophylaxis:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Consider rabies post-exposure prophylaxis for all animal bite cases.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Contact infectious diseases for assistance.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Consider tetanus immunization status:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "If immunization is up to date, nothing more needs to be done to prevent tetanus.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "If immunization is lacking, and:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "wound IS NOT tetanus prone, bring immunization up to date with Td",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "wound IS tetanus prone, bring immunization up to date with Td< AND >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Human Tetanus Immune Globulin Inject 250 units deeply into muscle (deep IM)",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Select below for Tetanus vaccination information page:",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Treat deep wounds for the first 3-5 days after a bite to prevent infection.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "For wounds that later develop evidence of infection but without arthritis, treat",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "with antimicrobials for 7-14.For wounds that develop infection of a joint,",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "treat 14 to 21 days.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Prophylaxis:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Duration 3 to 5 days:",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with penicillin allergy:",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Empiric treatment for suspected or estabished infection:",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Duration 7 to 14 days:",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with penicillin allergy:",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Pathogen directed bite wound therapy:",  "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Abrahamian FM New Engl Journ Med 1999, 340:85", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID PERMETHRIN 1% LOTION TO AFFECT AREA 10MIN", "Text" : "Permethrin 1% lotion Apply to affected area for 10 minutes then comb out", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BODY LICE (PEDICULOSIS CORPORIS)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Body lice proliferate in places where crowding of persons with poor hygiene is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "common, especially homeless persons.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Infested clothing and bed linen should be heat washed or discarded.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Itching is the most common symptom, but some patients present only with",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "excoriations and inflammation on the neck and trunk.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "A repeat application may be used if live lice are seen 7-10 days after",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "treatment.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "nits ($) [M]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: lice",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BRN ABSC CONT HEMATO SPRD INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM IV Q12H METRO 15 MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 15 mg/kg IV q12h ($) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM METRO 15MG/KG VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm q12h ($) [M] <AND> metronidazole 15 mg/kg IV q12h ($) [DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX CEFE2GMIVQ8H METRO15MG/KGIVQ12H VANCO15MG/KGIVQ12H", "Text" : "Cefepime 2gm IV Q8h <AND> metronidazole 15 mg/kg IV q12h ($) [DI] <AND>", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] ] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BRAIN ABSCESS FROM CONTIGUOUS OR HEMATOGENOUS SPREAD OF INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Prior to beginning antimicrobial therapy, when possible, computed topographic",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(CT) - guided aspiration or surgery should be performed to obtain abscess",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "material for determination of infectious pathogen. Adjust antimicrobial regimen",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "to optimize therapy and treatment duration to optimize therapy based on pathogen",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "once isolated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Broad spectrum empiric antimicrobials are indicated initially for brain abscess.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is a common pathogen. Beta-lactam antibiotics are more",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "effective than vancomycin for susceptible Staphylococci. If Staphylococcus is",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "isolated, once methicillin- resistance is ruled out, switch to an",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "anti-staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "in post-surgical patients, and those who are known to be colonized with",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pseudomonas.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment for Solitary Brain Abscess from Contiguous Source",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment for Solitary Brain Abscess from Unknown Source, From",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Hematogenous Spread, Multiple Brain Abscesses or History of MRSA Infection or",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Colonization",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Preferred if Pseudomonas is not likely:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Preferred if Pseudomonas is likely:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Brain Abscess",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Brain Abscess",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and Prognosis of Bacterial Brain Abscess",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Pathogenesis, clinical manifestations, and diagnosis of",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "brain abscess", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BRN ABSC NOCARDIA SPP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX TRIM 5MG/KG SULFA 25MG/KG IV Q8H IMIP 500MG IV Q6H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q8h ($$$) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX TRIM 5MG/KG SULFA 25MG/KG IV Q8H CEFTRI 2GM IV Q12H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q8h ($$$) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID AMIKACIN 7.5 MG/KG IV Q12H", "Text" : "< ADD > Amikacin 7.5 mg/kg q12h ($$)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX TRIM 5MG/KG SULFA 25MG/KG PO MINO 100MG PO Q12H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BRAIN ABSCESS WITH NOCARDIA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Magnetic resonance imaging (MRI) should be obtained in all patients with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "suspected brain abscess for diagnosis and determining number of lesions. Prior",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "to beginning antimicrobial therapy, when possible, computed topographic (CT) -",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "guided aspiration or surgery should be performed to obtain abscess material for",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "determination of infectious pathogen.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Nocardia brain abscess typically occur in immunocompromised patients and is",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "often concomitant with disseminated or pulmonary infection.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat with IV therapy for total duration of 3-6 weeks in immunocompetent and 6",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "weeks in immunocompromised patients. Switch to oral antimicrobials after",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "completing IV therapy and treat for an additional 3 months or more.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Initial IV Therapy",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "imipenem 500 mg q6h ($$) [R]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If Nocardia isolate is susceptible to third generation cephalosporins",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "ceftriaxone 2 gm IV q12h ($) [M]",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "If multiorgan or rapidly progressive disease, in addition to above therapy",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Oral Therapy, After Completing IV Therapy Above",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "minocycline 100 mg q12h ($) [DI]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Brain Abscess",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Brain Abscess",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of Nocardiosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BRN ABSC POST SURG POST TRAUMATIC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2gm IV Q8h ($$) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15mg/kg IV Q12H CEFT 2GM IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2gm IV Q8h ($$) [R] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "POST-SURGICAL OR POST-TRAUMATIC BRAIN ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Prior to beginning antimicrobial therapy, when possible, computed topographic",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(CT) - guided aspiration or surgery should be performed to obtain abscess",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "material for determination of infectious pathogen. Adjust antimicrobial regimen",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "to optimize therapy based on pathogen once isolated.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Broad spectrum empiric antimicrobials are indicated initially for brain abscess.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is a common pathogen. Beta-lactam antibiotics are more",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "effective than vancomycin for susceptible Staphylococci. If Staphylococcus is",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "isolated, once methicillin- resistance is ruled out, switch to an",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "anti-staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "in post-surgical patients, and those who are known to be colonized with",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Pseudomonas.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Post-Surgical Empiric Treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Post Traumatic Empiric Treatment",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Preferred if pseudomonas is not suspected and paranasal sinuses are not",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "involved:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Preferred if Pseudomonas is suspected and paranasal sinuses are not involved:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "If paranasal sinuses are involved or alternative:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Brain Abscess",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Brain Abscess, Post-traumatic or Post-surgical",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and Prognosis of Bacterial Brain Abscess", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BRN ABSC PSEUDOMONAS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "Text" : "Cefepime 2gm IV Q8h ($$) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BRAIN ABSCESS WITH PSEUDOMONAS SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Prior to beginning antimicrobial therapy, when possible, computed topographic",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(CT) - guided aspiration or surgery should be performed to obtain abscess",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "material for determination of infectious pathogen. Adjust antimicrobial regimen",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "to optimize therapy based on pathogen once isolated.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 6-8 weeks",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Brain abscess",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Pseudomonas aeruginosa infections of the eye, ear, urinary",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "tract, gastrointestinal tract and central nervous system", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU BRN ABSC TOXOPLASMA GONDII", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETH 200MG PO SULFAD 1GM LEUCOVORIN 10MG", "Text" : "Pyrimethamine 200 mg PO x 1 ($$$$$) [DI,O] then 75 to 100 mg PO QD ($$$$$)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h ($$$) [R,DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BRAIN ABSCESS WITH TOXOPLASMA GONDII",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Prior to beginning antimicrobial therapy, when possible, computed topographic",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(CT) - guided aspiration or surgery should be performed to obtain abscess",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "material for determination of infectious pathogen. Adjust antimicrobial regimen",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "to optimize therapy based on pathogen once isolated.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Central nervous system toxoplasmosis occurs mostly in HIV-infected patients.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Continue treatment for 4 to 6 weeks after resolution of symptoms, then continue",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "suppressive therapy in HIV patients until sustained immune reconstitution",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "occurs.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "[DI,O] <AND> sulfadiazine 1 to 1.5 gm PO q6h ($$) [DI,O] <AND> leucovorin 10 to",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "15 mg PO QD ($)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Brouwer et al. N Engl J Med, 2014, 371(5)447-56",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Brain Abscess",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Brain Abscess, Toxoplasmosis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Toxoplasmosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CAP INPATIENT TREATED SETTING NON-SEVERE CAP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "Text" : "[Link] Stepdown empiric treatment for CAP with oral antibiotics", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFTRIAXONE 2GM IV QD AND AZITHROMYCIN 500MG PO", "Text" : "Ceftriaxone 2 gm IV q24h for 5 days ($) [M] <AND> azithromycin 500 mg PO x1", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750MG PO Q24H X5DAYS", "Text" : "Levofloxacin 750 mg PO Q24H for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZ SET ABX PNA PIPERACILLIN-TAZO AND AZITHROMYCIN 500/250 PO", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> Azithromycin", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFEPIME 2GM Q8H AND AZITH 500/250 PO", "Text" : "Cefepime 2 gm IV Q8H ($$) [R] <AND> Azithromycin 500 mg PO x1 on", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750 MG PO Q24H", "Text" : "Levofloxacin 750 mg PO Q24H ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NON-SEVERE COMMUNITY-ACQUIRED PNEUMONIA TREATED IN AN INPATIENT SETTING",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Be sure of the diagnosis.Careful reviews have shown that over half of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "people treated for community-acquired pneumonia do not in fact have",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pneumonia.Pneumonia is likely in persons with 3 or more signs or symptoms",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "including a) new infiltrate (or, no prior film for comparison) b) new",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "crackles, egophony, or dullness c) pleuritic pain, d) fever and/or chills",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "e) leukocytosis f) cough g) purulent sputum and h) new or worsened dyspnea",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "or tachypnea, and no likely alternative explanation for the presentation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Common alternative explanations include heart failure, thromboembolic",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "disease, COPD exacerbation, viral pneumonitis, aspiration pneumonitis, or",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "tumor. Most of the latter conditions do NOT benefit from antimicrobials.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Recommendation for duration of antibiotic therapy for CAP:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Patients with CAP should be treated for a minimum of 5 days, should be",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "afebrile for 48-72 hours, and should have no more than 1 CAP-",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "associated sign of clinical instability before discontinuation",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "of therapy.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Criteria for clinical stability:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Temperature less than/equal to 100 degrees F",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Heart rate less than/equal to 100 beats/minute",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Respiratory rate less than/equal to 24 breaths/minute",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Systolic blood pressure greater than/equal to 90 mm Hg",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Arterial oxygen saturation greater than/equal to 90% --OR--",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "PO2 greater than/equal to 60 mm Hg on room air",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Ability to maintain oral intake",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Normal mental status",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Inpatient, non-severe CAP (NOTE: DURATION of therapy)",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Stepdown empiric treatment for CAP (Intravenous to Oral conversion)",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Note: These regimens may also be used to convert patients to oral medications",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "prior to discharge.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Obtain cultures BUT withhold MRSA coverage unless cultures or nasal carriage",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "positive for MRSA. (See below for prior respiratory isolation of MRSA)",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa:",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Obtain cultures BUT withhold anti-pseudomonal coverage unless cultures",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "are positive for P. aeruginosa. (See below for prior respiratory isolation",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "of P. aeruginosa)",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Preferred: (no prior respiratory isolation of MRSA or P. aeruginosa)",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "on day 1, then 250 mg PO Q24H for 4 days ($) [M]< OR >",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Prior Respiratory Isolation of MRSA within last 12months: ADD MRSA COVERAGE",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "ADD MRSA coverage to Standard Regimen above or Antipseudomonal Regimen below:",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Prior Respiratory Isolation of P.aeruginosa within last 12months: SELECT BELOW",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Select regimen below for P.aeruginosa, obtain cultures to allow deescalation",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "500mg PO x1 on day 1, then 250 mg PO Q24H for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "day 1, then 250 mg PO Q24H for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Alternative for P. aeruginosa:",  "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "Sanford website",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Obtain cultures/nasal PCR to allow for deescalation.",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZ SET ABX VANCO PNA NEW START + MRSA NARES", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CAP INPATIENT TREATED SETTING SEVERE CAP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "Text" : "[Link] Stepdown empiric treatment for CAP with oral antibiotics", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET LAB SPUTUM CULT & GRAM STAIN", "Text" : "Lab Order: Sputum Culture & Gram Stain", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET LAB BLOOD CULTURE X2", "Text" : "Lab order: Blood culture x2", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZ SET ABX PNA CEF 2GM IV AND AZITHROMYCIN 500MG IV", "Text" : "Ceftriaxone 2 gm IV q24h($) [M] <AND> azithromycin 500 mg IV once", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV Q24H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750 MG PO Q24H", "Text" : "Levofloxacin 750 mg po q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "ORZ SET ABX VANCO PNA NEW START + MRSA NARES", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : "ORZ SET ABX PNA PIPERACILLIN-TAZO AND AZITHROMYCIN 500/250 IV", "Text" : "Piperacillin-tazobactam 4.5 gm IV Q6H ($$) [R] <AND> Azithromycin 500 mg IV", "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFEPIME AND AZITHROMYCIN IV", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> Azithromycin 500 mg IV x1 on day 1,", "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : "PSJIZID PNA LEVOFLOXACIN 750MG IV Q24H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750 MG PO Q24H", "Text" : "Levofloxacin 750 mg po q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEVERE Community-Acquired Pneumonia (CAP) Treated in Intensive Care Unit (ICU)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Criteria for Defining SEVERE Community-acquired Pneumonia",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Validated definition includes either one major or three or more minor criteria",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "MAJOR CRITERIA:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Septic shock with need for vasopressors",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Respiratory failure requiring mechanical ventilation",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "MINOR CRITERIA:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Respiratory rate greater than or equal to 30 breaths/minute",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "PaO2/FiO2 ratio less than or equal to 250",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Multilobar infiltrates",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Confusion/disorientation",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Uremia (blood urea nitrogen level greater than 20 mg/dl)",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Leukopenia* (WBC less than 4,000 cells/microliter)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "*Due to infection alone (i.e., not chemotherapy induced)",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Thrombocytopenia (platelet count less than 100,000 microliters)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Hypothermia (core temperature less than 36 degrees C)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Hypotension requiring aggressive fluid resuscitation",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Recommendation for duration of antibiotic therapy for CAP:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Patients with CAP should be treated for a minimum of 5 days, should be",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "afebrile for 48-72 hours, and should have no more than 1 CAP-",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "associated sign of clinical instability before discontinuation",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "of therapy.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Criteria for clinical stability:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Temperature less than/equal to 100 degrees F",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Heart rate less than/equal to 100 beats/minute",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Respiratory rate less than/equal to 24 breaths/minute",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Systolic blood pressure greater than/equal to 90 mm Hg",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Arterial oxygen saturation greater than/equal to 90% --OR--",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "PO2 greater than/equal to 60 mm Hg on room air",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Ability to maintain oral intake",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Normal mental status",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment on INTENSIVE CARE UNIT (ICU)",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Stepdown empiric treatment for CAP (Intravenous to Oral conversion)",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "(Specific therapy should be guided by culture results.)",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Recommend blood and lower respiratory tract specimen cultures for all patients",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "with Severe CAP.",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Prior Respiratory Isolation of MRSA within last 12 months:",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "ADD MRSA COVERAGE. Obtain nasal PCR and cultures to allow deescalation or",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "confirmation of need for continued therapy. SEE MRSA Section below",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Prior Respiratory Isolation of P. aeruginosa in the last 12 months:",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "COVER for P. aeruginosa. Obtain cultures to allow deescalation or",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "confirmation of need for continued therapy. SEE P. aeruginosa section below",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Preferred Standard Regimen: (no MRSA or P. aeruginosa coverage)",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "on day 1, then 250 mg IV Q24H for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Alternative Standard Regimen:",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for MRSA -OR-",  "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Prior respiratory isolation of MRSA in the last 12 months: ADD MRSA coverage",  "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "ADD MRSA coverage to Standard Regimen above or Antipseudomonal regimen below:",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Recent hospitalization and IV antibiotics and risk factors for P. aeruginosa-OR",  "Header" : 1}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Prior respiratory isolation of P. aeruginosa in the last 12 months:",  "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "SELECT REGIMEN BELOW:",  "Header" : 1}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "on day 1, then 250 mg IV Q24H for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "then 250 mg IV Q24H for 4days ($) [M]",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200:e45",  "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : null, "Text" : "Sanford website",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU CAP OUTPATIENT TREATED SETTING", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID2 PNA DOXYCYCLINE 100MG PO Q12H X5DAYS", "Text" : "Doxycycline 100 mg PO Q12H for 5 days ($) [DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID2 PNA AMOXICILLIN 1000MG PO Q8H X5DAYS", "Text" : "Amoxicillin 1000 mg PO Q8H for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX PNA AMOX-CLAV 875 PO Q12H AZITH 500MG PO THEN 250MG", "Text" : "Amoxicillin-clavulanate 875/125 mg PO Q12H for 5 days ($) [R] <AND> Azithromycin", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFDINIR 300MG BIDX5D AZITH 500MG PO THEN 250MG", "Text" : "Cefdinir 300 mg PO Q12H for 5 days ($) [R] <AND> Azithromycin", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX PNA AMOX-CLAV 875 PO Q12H DOXY 100MG PO Q12H 5DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO Q12H for 5 days ($) [R] <AND> Doxycycline", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX PNA CEFDINIR 300MG PO BID DOXY 100MG PO Q12H 5DAYS", "Text" : "Cefdinir 300 mg PO q12h for 5 days ($) [R] <AND> Doxycycline", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJZID2 PNA LEVOFLOXACIN 750MG PO Q24H X5DAYS", "Text" : "Levofloxacin 750 mg PO q24h for 5 days ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED WITH ORAL ANTIBIOTICS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "NOTE: These are INPATIENT orders.To transfer these orders to outpatient for",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "discharge, highlight the order in the MEDS tab of CPRS, click on the",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "heading ACTION then click on Transfer to Outpatient.",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred oral treatment for PREVIOUSLY HEALTHY PATIENTS:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "(WITHOUT chronic obstructive pulmonary disease, diabetes, renal failure,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "conditions, or use of immunosuppressing drugs)",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "No comorbidities: (Note: duration of therapy)",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred oral treatment for PATIENTS WITH COMORBIDITIES:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "(WITH chronic obstructive pulmonary disease, diabetes, renal failure, congestive",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "heart failure, malignancy, alcoholism, asplenia, immunosuppressing conditions",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "or use of immunosuppressing drugs)",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Comorbidities: (Note: duration of therapy)",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "po once on day 1, then 250 mg PO QDAY for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "once on day 1, then 250 mg PO QDAY for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "100 mg PO Q12H for 5 days ($) [DI]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "100 mg PO Q12H for 5 days ($) [DI]",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200(7):e45",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Sanford: Community Acquired Pneumonia",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CAT-SCATCH DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500 mg PO x 1on day 1, then 250 mg PO QDAY for 4 days ($) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CAT-SCRATCH DISEASE",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Cat-scratch disease occurs when a cat infected with Bartonella henselae",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "scratches or bites a person or licks a person's open wound.A local pustule",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "develops followed by lymphadenopathy, typically on the same side of the body as",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "the scratch or bite.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Infections associated with other pathogens such as Francisella tularemia,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Coxiella burnetiid and other slow-growing bacteria may present with similar",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "symptoms.Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "About 10% of cases of cat-scratch disease present atypically with symptoms",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "involving the eye, nervous system, or lungs.Consult Infectious Diseases in",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "these cases.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bartonella, including cat-scratch disease",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: cat-scratch disease",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CHRONIC SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SEVERE SINUSITIS", "Text" : "Severe Sinusitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHRONIC SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis of chronic sinusitis is based on presence of at least 2 of the 4",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cardinal signs/symptoms lasting >/= 12 weeks. In addition, diagnosis requires",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "objective evidence of mucosal inflammation using nasal endoscopy and/or CT",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "imaging. The initial therapy for chronic sinusitis is treatment with intranasal",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "corticosteroids and saline. For patients with severe nasal blockage by polyps,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "treat with a short course of oral glucocorticoids. Reassess patient after 1 to 3",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "months of intranasal therapy or after completion of glucocorticoid therapy. If",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "signs/symptoms have not improved, consult surgery, ENT and Infectious Diseases",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "as treatment is complex.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Acute exacerbations of chronic sinusitis can be caused by discontinuing medical",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "therapy, viral infections, allergens, noxious inhalants and bacterial or fungal",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "infections. Bacterial infections should be suspected when the patient has",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "increased signs/symptoms persisting for more than 10 days. Refer to Severe",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sinusitis recommendations for choice of antimicrobial therapy in these patients.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Repeated use of the same agent should be avoided to prevent promotion of drug",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "resistant bacteria or increased fungal colonization.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Cardinal Signs/Symptoms of Chronic Sinusitis",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "1. Anterior and/or posterior nasal mucopurulent drainage",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "2. Nasal obstruction/nasal blockage/congestion",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "3. Facial pain, pressure, and/or fullness",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "4. Reduction or loss of sense of smell",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Objective Evidence mucosal inflammation",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "1. Purulent (not clear) mucus or edema in the middle meatus or ethmoid regions",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "2. Polyps in the nasal cavity or the middle meatus",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "3. Radiographic imaging demonstrating mucosal thickening or partial or complete",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "opacification of the paranasal sinuses",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Rudmik et al., JAMA. 2015, 314(9) 926-939",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Chronic",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Chronic rhinosinusitis: Clinical manifestations,",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "pathophysiology, and diagnosis",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "rhinosinusitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CMI DEFECTS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CELL-MEDIATED IMMUNITY (CMI) DEFECTS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients with reduced CMI include those with HIV/AIDS, hematologic malignancies,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cytotoxic chemotherapy, and congenital abnormalities.Patients with cell-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "mediated immune defects are more susceptible to infections from ubiquitous",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "microorganisms that do not usually cause infection in healthy patients.The",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "specific organisms that are more likely to be associated with disease vary",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "depending on the specific type of immune defect present, but include:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Pneumocystis jirovecii (formerly Pneumocystis carinii), Mycobacterium avium,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Mycobacterium tuberculosis, Salmonella spp., Candida spp., Aspergillus spp.,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Toxoplasma gondii, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "and Cryptosporidium parvum.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "These infectious diseases usually have a subacute or chronic presentation.The",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "best approach in most circumstances is for the clinician to conduct a methodical",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "diagnostic workup to identify the specific pathogen and guide therapy.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobials are not indicated for patients with CMI defects who",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "present only with fever.Contact Infectious Disease for more information.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU COMM ACQ DIARRHEA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "Text" : "Clostridium difficile", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h for 3-5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h for 3 days ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMMUNITY ACQUIRED DIARRHEA (NO RECENT TRAVEL)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Acute diarrhea (< 14 days of symptoms)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobials should be given only in cases of severe acute disease",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "or high-risk conditions: fever, >/= 6 stools in 24 hours, volume depletion",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "requiring hospitalization, severe abdominal pain, immune compromise, cardiac",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "disease, >/= 70 years old.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "If in the preceding two months the patient has taken a PPI or has been",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "hospitalized for three or more days, consider Clostridium difficile infection.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "For more information on when an antimicrobial is indicated or if the patient has",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Empiric antimicrobial treatment for non-bloody severe acute diarrhea",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Subacute or chronic (>/= 14 days of symptoms)",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Primary treatment is hydration and electrolyte replacement. Empiric",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy is not indicated. Investigate for the cause of diarrhea.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Gastroenterology and/or Infectious Diseases involvement is encouraged.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "settings", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "VIRAL GASTROENTERITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infectious diarrhea caused by viral pathogens such as Adenovirus, Astrovirus,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Norovirus, Rotavirus, and Sapovirus is usually self-limited. Treatment includes",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "supportive measures such as oral rehydration and unrestricted nutrition.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antiviral therapy is not recommended and for most viruses is unavailable.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Antimotility agents may be used for one or two days in patients with mild to",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "moderate volume depletion. Antiemetic agents may be used for one or two days in",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "patients with vomiting.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute viral gastroenteritis in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CONJUNCTIVITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID TRIMETHOPRIM/POLYMIXIN B OPHTH 1 DROP Q3H", "Text" : "Trimethoprim/polymixin B ophthalmic solution 1 drop in affected eye(s)", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID OFLOXACIN OPTH 2 DRPS Q2H X2D THEN QID X5D", "Text" : "Ofloxacin 0.3% ophthalmic solution 2 drops in affected eye q2h while awake for 2", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CONJUNCTIVITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Conjunctivitis is associated with viral or bacterial pathogens. Viral",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "conjunctivitis presents with watery discharge. Bacterial infections are more",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "likely to present with thick exudate and conjunctival injection. Allergic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "conjunctivitis typically presents with stringy mucus. If there is pus",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "(hypopion), corneal involvement, possible bacterial conjunctivitis, or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "keratitis, consult ophthalmology.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Viral conjunctivitis is most commonly caused by adenovirus. It is self-limited",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "and antivirals provide no benefit. Symptomatic treatment with ophthalmic",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "antihistamine/decongestants and warm or cool compresses may relieve symptoms.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Bacterial conjunctivitis is most commonly associated with Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Streptococcus pneumoniae, Haemophilus spp., Moraxella catarrhalis,",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Corynebacterium diphtheriae, Neisseria spp. or enteric gram-negative rods. It is",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "generally self-limited, but topical antimicrobials reduce duration of symptoms",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "and limit person-to-person spread of infection. If symptoms do not improve after",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "2 days of antimicrobial therapy, the patient should be seen by an",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "ophthalmologist.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment for acute bacterial conjunctivitis",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "q3h for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment for severe cases of bacterial conjunctivitis involving suppuration or",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "contact lens wearers",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Consult ophthalmology and begin topical antimicrobials.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "days then 2 drops QID for 5 days ($) [M]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Azari eta al, JAMA (2013) 1721-1730",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Microbial conjunctivitis",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Conjunctivitis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Conjunctivitis, Bacterial", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CONTACT CDSS STAFF", "Contents" : [
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "Contact CDSS Staff", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX EXCLUSIONS", "Text" : "Exclusions- recommendations for additions to CDSS", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The CDSS Project Team can be contacted in Outlook using the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "group Email: VISN23AntimicrobialCDSS@va.gov", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CRANIAL EPIDURAL ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM METRO 15MG/KG VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 15 mg/kg IV q12h", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX CEFE2GMIVQ8H METRO15MG/KGIVQ12H VANCO15MG/KGIVQ12H", "Text" : "Cefepime 2gm IV Q8h ($$) [R] <AND> metronidazole 15 mg/kg IV q12h ($) [DI] <AND>", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CRANIAL EPIDURAL ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment involves source control by drainage procedure and antimicrobial",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "therapy.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Beta-lactam antibiotics are more effective than vancomycin against susceptible",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Staphylococci. If Staphylococcus is isolated, once methicillin-resistance is",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "ruled out, switch to an anti-staphylococcal beta-lactam antibiotic. Pseudomonas",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "is a potential pathogen in post-surgical patients or patients with known",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Pseudomonas colonization.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat for 3 to 6 weeks after surgical drainage.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Preferred if Pseudomonas is not suspected:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "($) [DI] <AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Preferred if Pseudomonas is suspected:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Treatment if methicillin-sensitive S. aureus is isolated",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Intracranial Thrombophlebitis",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Pradilla et al, Lancet Neurol, 2009, 8(3)292-300",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Up-To-Date Article: Intracranial Epidural Abscess", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CUTANEOUS ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100MG PO Q12H", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal/Anorectal Abscess", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CUTANEOUS ABSCESS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Incise and drain then cover the site with a dry dressing. For small abscesses,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "systemic antimicrobial therapy is rarely necessary.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "If the patient is neutropenic, has multiple lesions, or has fever or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "leukocytosis, antimicrobial treatment may be necessary.Contact Infectious",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diseases for assistance.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For the few CUTANEOUS ABSCESSES away from the rectal area that need a systemic",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "antimicrobial",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration: Treat for 5 to 7 days",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mild to Moderate Cases:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Moderate or high suspicion of MRSA",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Low suspicion of MRSA",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "For SEVERE cases empiric coverage with MRSA agent",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "For Perirectal/Anorectal Abscess Select Below",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Skin infections",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU CUTANEOUS CANDIDIASIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE 1% CREAM TOPICAL BID", "Text" : "Clotrimazole 1% cream apply to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID NYSTATIN CREAM BID", "Text" : "Nystatin Cream to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CUTANEOUS CANDIDIASIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Cutaneous candidiasis is a superficial fungal infection of the epidermis.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Presents with red, erythematous patches, often in areas where skin contacts",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "skin, including axillae, groin, and abdominal folds.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Keep affected areas dry and clean.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Sanford: Cutaneous Candidiasis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU DECUBITUS ULCERS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI] < OR >", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal/Anorectal Abscess", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX CELLULITIS", "Text" : "Cellulitis", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOMYELITIS", "Text" : "Osteomyelitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DECUBITUS ULCERS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Relieve pressure and friction, provide good nutrition, and debride the ulcer.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Decubitus ulcers are colonized with bacteria.Antimicrobial therapy is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "unnecessary unless the patient has infection of surrounding tissues signified by",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "erythema, warmth, local tenderness, or purulent discharge.Rectal or groin",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "decubitus ulcers with surrounding infection need broad spectrum antimicrobials.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Ulcers located in other sites are usually treated with antimicrobials for",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "staphylococci and streptococci.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration of therapy usually 7-14 days, but adjust to clinical response",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For deep abscesses away from the rectal area, obtain material for Gram stain an",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "culture to guide therapy.",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For severe cases",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "For deep PERIRECTAL ABSCESSES that need a systemic antimicrobial SELECT BELOW:",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "If there are signs and/or symptoms of cellulitis or osteomyelitis, refer to the",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "advice page for the appropriate syndrome.Contact the ET nurse, Infectious",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Diseases, Dietician, or Vascular surgery for more information.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Parish LC Dermatol Clin 2004, 22: 87",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU DEEP OROPHAR INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "MRSA risk factors", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "< ADD > vancomycin 15 mg/kg IV q12 hours ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "Text" : "", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV Q12H VANCO 15MG/KG Q12H", "Text" : "Cefepime 2 gm IV q12h ($$) [R] < AND > vancomycin 15 mg/kg IV q 12 hours ($) [R]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DEEP OROPHARYNGEAL INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Deep oropharyngeal infections may threaten life and must be treated immediately.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Assess the risk of airway compromise and monitor the airway if it is threatened.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "These infections are more common in people with diabetes mellitus and are caused",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "by mixed organisms including streptococcus sp., Staphylococcus aureus and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "anaerobes . Perform CT scan to diagnose abscess. ENT and Infectious Diseases",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "consults are essential.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "If the patient's condition worsens or does not improve during the first 48 hours",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "of antimicrobial therapy, surgical drainage is indicated. If surgical drainage",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "is done, antimicrobials are usually continued for 48 hours after the procedure.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "If surgical drainage is not done, 2 weeks of antimicrobial therapy until",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "clinical improvement is observed (e.g. resolution of fever and leukocytosis) is",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "appropriate.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative: Assessment of Beta-lactam Reaction",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Risk factors for MRSA or gram-positive cocci in clusters on gram stain, in",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "addition to one of the above antimicrobial regimens",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patient or severe infection",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients require additional coverage for Staphylococcus aureus",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "and Pseudomonas aeruginosa.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "< AND > vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "for 7 days",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Step-down treatment after initial intravenous therapy. Adjust duration based on",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "criteria above.",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Submandibular space infections (Ludwig's angina)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU DELAYED PCN ALLERGIC CV SURG", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : "ORZ SET ABX VANCOMYCIN 1500MG PREOP AND 1000MG INTRAOPERATIVE", "Text" : "Vancomycin 1500mg PREOPERATIVE dose **AND** 1000mg INTRAOPERATIVE dose", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750 MG DELAYED ORDER", "Text" : "Levofloxacin 750mg IV once Pre-op Delayed Order", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Severly PCN Allergic Pre-op Antibiotic Delayed Order", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU DIAGNOSIS PERTUSSIS", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Td/Tdap Immunization Menu", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ LAB MICROBIOLOGY", "Text" : "Obtain nasopharyngeal sample for PCR", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ LAB MICROBIOLOGY", "Text" : "Obtain nasopharyngeal sample for PCR", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "LRTZID IGG ABY BORDETELLA PERTUSSIS", "Text" : "Obtain serum sample for IgG antibodies to Bordetella pertussis", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "LRTZID IGG ABY BORDETELLA PERTUSSIS", "Text" : "Obtain serum sample for IgG antibodies to Bordetella pertussis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIAGNOSIS OF PERTUSSIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Laboratory testing is recommended to confirm a clinical diagnosis of pertussis.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Nasopharyngeal samples should be obtained with calcium alginate swabs.The",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "appropriate diagnostic strategy depends upon the duration of coughing symptoms.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "For previously unvaccinated individuals, the three-dose serious of Td/Tdap",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "should be administered. A Tdap booster should be administered every 10 years",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "after completion of the series.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : ">>During the first 2 weeks of coughing",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : ">>Between 2 and 4 weeks of coughing",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : ">>More than 4 weeks of coughing",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Pertussis infection in adolescents and adults: Clinic",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pertussis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bordetella species", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU DISSEMINATED M. AVIUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CLARITHROMYCIN 500 PO Q12H EHTAMBUTOL 15 Q24H", "Text" : "Clarithromycin 500 mg PO q12h ($) [R,DI] <AND> ethambutol 15 mg/kg PO q24h", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX AZITHRO 250MG PO Q24H ETHAMBUTOL 15 PO Q24H", "Text" : "Azithromycin 250 mg PO q24h ($) [M] <AND> ethambutol 15 mg/kg PO q24h [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX CLARITHROMYCIN, ETHAMBUTOL, RIFABUTIN", "Text" : "Clarithromycin 500 mg PO q12h($) [R,DI] <AND> ethambutol 15 mg/kg PO q24h", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX AZITH 250, ETHAMBUTOL, RIFABUTIN 300", "Text" : "Azithromycin 250 mg PO q24h ($) M <AND> ethambutol 15 mg/kg PO q24h [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DISSEMINATED MYCOBACTERIUM AVIUM DISEASE TREATMENT",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Many of these patients have HIV/AIDS. Management is complex. Consult",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Rifabutin is optional for disseminated disease. Rifabutin can improve cure",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "rates, but may decrease blood concentrations of many drugs. Consult Infectious",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diseases or Pharmacy for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment is continued for 12 months and until CD4 count is >100 cells per",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "microliter for at least 6 months.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Two-drug treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "($$) [R]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Three-drug treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "($$) [R] <AND> rifabutin 300 mg PO q24h ($$) [R,DI]",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "<AND> rifabutin 300 mg q24h ($$) [R,DI]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Mycobacterium avium complex",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "patients", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU DRUG PT UNDERGO DENTAL PROC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 2GM PO ONCE 'C'", "Text" : "Amoxicillin 2 gm PO 1 hour before procedure ($) [R]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2GM IV ONCE 'C'", "Text" : "Ampicillin 2 gm IV over 20 minutes, beginning 60 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 2GM PO ONCE 'C'", "Text" : "Cephalexin 2 gm PO 1 hour before procedure ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 1GM IV ONCE 'C'", "Text" : "Cefazolin 1 gm IV over 20 minutes, beginning 60 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500 MG PO ONCE 'C'", "Text" : "Azithromycin 500mg PO 1 hour before procedure ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIALS FOR PATIENTS UNDERGOING DENTAL OR ORAL MUCOSA TO PREVENT",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "BACTERIAL ENDOCARDITIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Primary Alternative",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Secondary Alternative, after assessment of beta-lactam reaction above",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "endocarditis",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC CX NEG", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENDOCARDITIS WITH CULTURE-NEGATIVE RESULTS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cultures are often negative in cases of infection with fastidious organisms like",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Abiotrophia (formerly nutritionally variant Streptococci), Bartonella, Coxiella,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Chlamydia, Legionella spp., or Trophyrema or when antimicrobials are given",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "before blood cultures are obtained. Consult Infectious Diseases and Cardiology.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC ENTEROCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2GM IV Q4H CEFTRIAXONE 2G Q12H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] < AND > ceftriaxone 2 gm IV q12h ($) for 6", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX PENICIL 4MU IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Penicillin G 4 MU IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV q8h ($)", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX AMPICI 2GM IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV q8h ($) [R,O]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2GM IV Q4H CEFTRIAXONE 2G Q12H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] < AND > ceftriaxone 2 gm IV q12h ($) for 6", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX VANC Q12H 15MG/KG GENT 1MG/KG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < AND > gentamicin 1 mg/kg IV q8h ($)", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI] for 6 weeks", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 10-12MG/KG Q24H", "Text" : "Daptomycin 10-12 mg/kg IV q24h ($$$$) [R,DI] for 6 weeks", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENDOCARDITIS WITH ENTEROCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infectious diseases and cardiology should be consulted in all cases",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Native valve endocarditis (NVE):",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of therapy depends on duration of symptoms, susceptibility of the",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "enterococcus isolate to antimicrobials, and the effectiveness of the",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobials that can be used. For patients who have experienced symptoms for",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "less than 3 months and who can be treated with ampicillin or penicillin plus",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "gentamicin, treat for 4. Treat all other patients including any patient",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "receiving vancomycin for at least 6 weeks. Duration should be determined with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "input from Infectious Diseases.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Prosthetic Valve endocarditis (PVE):",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treat for at least 6 weeks, duration should be determined with input from",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Organism Susceptibility",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Isolate is susceptible to penicillin (MIC </= 16 mcg/mL) and high concentration",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "gentamicin (MIC </= 500 mcg/mL)",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "weeks",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "[R,O] for 4 to 6 weeks (NVE) for 6 weeks (PVE)",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "for 4 to 6 weeks (NVE) for 6 weeks (PVE)",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Isolate is resistant to gentamicin (MIC > 500 mcg/mL)",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "weeks",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Isolate is penicillin-resistant (MIC > 16 mcg/mL)",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "[R,O] for 6 weeks",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Isolate is penicillin resistant (MIC > 16 mcg/mL), gentamicin resistant (MIC >",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "500 mcg/mL) and vancomycin resistant",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Fernandez-Hidalgo, Clinical Infectious Diseases 2013, 56: 1261",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC FUNGI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENDOCARDITIS WITH FUNGI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases, Cardiology, and Cardiothoracic surgery.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 6 weeks", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "Text" : "Cefepime2 gm IV q8h ($$) [R] for 6 weeks", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENDOCARDITIS WITH GRAM NEGATIVE BACILLI OTHER THAN HACEK ORGANISMS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pseudomonas aeruginosa and various Enterobacteriaceae are uncommon endocarditis",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pathogens. Risk factors include cirrhosis, IV drug use and prosthetic valve.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Choice of agents should be based on in vitro susceptibilities.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases and Cardiothoracic surgery in all cases.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment for Enterobacteriaceae",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment for Pseudomonas",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Most cases of pseudomonas endocarditis occur in IV drug users.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Begin treatment with a beta-lactam agent, and when appropriate, Infectious",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diseases will initiate treatment with add-on aminoglycoside or fluroquinolone",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "agent for additional coverage.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC HACEK", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 4 weeks (NVE) or 6 weeks (PVE)", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($) [R] for 4 weeks (NVE) or 6 weeks (PVE)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENDOCARDITIS WITH HACEK BACTERIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "HACEK bacteria are the fastidious Gram-negative bacilli, including Haemophilus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "parainfluenzae, Haemophilus paraphrophilus, Haemophilus influenzae,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Aggregatibacter aphrophilus (Haemophilus aphrophilus), Actinobacillus",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "kingae and Kingella denitrificans. It may take up three weeks for the",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "microbiology laboratory to isolate these organisms.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment options are limited for patients with allergies to beta-lactam",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "antibiotics. Consult Infectious Diseases for advice.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Native valve endocarditis (NVE): 4 weeks",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Prosthetic valve endocarditis (PVE): 6 weeks",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Isolate is susceptible to ampicillin",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC NV EMP THERA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> ceftriaxone 2 gm IV q24h ($)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX VAN 15 MG/KG IV Q12H GENT 1 MG/KG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 1 mg/kg IV q8h ($)", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX VAN 15 MG/KG IV Q12H GENT 1 MG/KG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 1 mg/kg IV q8h ($)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NATIVE VALVE ENDOCARDITIS--EMPIRICAL THERAPY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Empirical treatment in a non-intravenous drug user",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Wait for identification of pathogen before initiating antimicrobial therapy in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "most cases. If empiric antimicrobial treatment is necessary, due to hemodynamic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "instability or other severe disease, use:",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "[R,O]",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Empirical treatment in an intravenous drug user",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is the most likely pathogen, followed by streptococci and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "enterococci. However, gram negative pathogens are often associated with",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "endocarditis in these patients. Culture results are key for appropriate therapy.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Consult Cardiology and Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "[R,O]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC NV SEL PATH", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU EC CX NEG", "Text" : "Culture-negative endocarditis", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "Text" : "Enterococci", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU EC FUNGI", "Text" : "Fungi", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU EC GNB", "Text" : "Gram negative bacilli (other than HACEK organisms)", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "HACEK bacteria", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU EC NV STAPHYLOCOCCI", "Text" : "Staphylococci", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU EC NV STREPTOCOCCI", "Text" : "Streptococci", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NATIVE VALVE ENDOCARDITIS--SELECTED PATHOGENS", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU EC NV STAPHYLOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI] for 6 weeks", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R] for 6 weeks", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 8-12MG/KG Q24H", "Text" : "Daptomycin 8-12mg/kg q24h ($$$$) [R,DI] for 6 weeks", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NATIVE VALVE ENDOCARDITIS WITH STAPHYLOCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Endocarditis with Staphylococcus aureus and coagulase-negative staphylococci are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "treated similarly.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Retrospective studies show that patients with native valve staphylococcal",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "endocarditis treated with valve replacement and antimicrobials have a lower",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "mortality rate than those treated with antimicrobials alone. Consult",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "cardiothoracic surgery for all patients with staphylococcal endocarditis.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Most patients need 6 weeks of antimicrobial treatment. For vancomycin-resistant",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "strains Infectious Disease consultation is recommended.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-susceptible strains",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Primary alternative:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-resistant strains",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC NV STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "Text" : "Penicillin G 3 million units IV q4h ($$) [R] for 4 weeks", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 3MU IV Q4H GENT 3 MG/KG ONCE DAILY", "Text" : "Penicillin G 3 million units IV q4h ($$) [R] for 2 weeks <AND> gentamicin", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 4 weeks", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 2 weeks <AND> gentamicin 3 mg/kg IV once", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 4 weeks", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 4 weeks", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] for 4 weeks <AND> gentamicin", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 4 weeks <AND> gentamicin 3 mg/kg IV q24h", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 4 weeks", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX PENICIL 4MU IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q24h", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX AMPICI 2GM IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q8h ($) [R,O]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 4 weeks", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NATIVE VALVE ENDOCARDITIS WITH STREPTOCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Selection is based on susceptibility to penicillin.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment of highly susceptible viridians streptococci or Streptococcus",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "gallolyticus (bovis) (penicillin MIC less than or equal to 0.12 mcg/ml)",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "The addition of gentamicin provides a synergistic effect and is reasonable to",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "add in patients with uncomplicated endocarditis, rapid response to therapy and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "no underlying renal disease",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "3 mg/kg IV q24h ($) [R,O] for 2 weeks",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Primary alternatives:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "daily ($) [R,O] for 2 weeks",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment of relatively resistant viridians streptococci or S. gallolyticus",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "(bovis) (penicillin MIC greater than 0.12 and less than or equal to 0.5 mcg/ml)",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "For ceftriaxone susceptible isolates (MIC < 0.5 mcg/mL):",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "For ceftriaxone resistant isolates (MIC >/= 0.5 mcg/mL):",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "3 mg/kg IV q24h ($) [R,O] for first 2 weeks",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "($) [R,O] for first 2 weeks",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Treatment of highly resistant viridians streptococci or S. gallolyticus (bovis)",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "(penicillin MIC greater than or equal to 0.5 mcg/mL)",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "($) [R,O] for 4 weeks",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR>",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "for 4 weeks",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Treatment of Streptococci pneumonia, Streptococcus pyogenes, and Groups B, C, F",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "and G beta-hemolytic streptococci",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Treatment is non-standardized and must be tailored to each patient. Consult",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases.",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC PV EMP THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG IV Q12H RIFAMP 300MG PO GENT 1MG/KG", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 1 mg/kg IV q8h ($)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROSTHETIC VALVE ENDOCARDITIS--EMPIRICAL THERAPY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Early surgical consultation is essential.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "If a patient is hemodynamically stable and the diagnosis is uncertain,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy can safely be withheld until the diagnosis is clear and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "blood culture results are available to guide therapy. In all cases, be sure",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "adequate numbers of blood cultures are obtained before antimicrobials are given.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "[R,O] <AND> rifampin 300 mg PO/NG q8h ($) [DI,O]",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC PV SEL PATH", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU EC CX NEG", "Text" : "Culture-negative endocarditis", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU EC ENTEROCOCCI", "Text" : "Enterococci", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU EC FUNGI", "Text" : "Fungi", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU EC GNB", "Text" : "Gram negative bacilli (other than HACEK organisms)", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU EC HACEK", "Text" : "HACEK bacteria", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU EC PV STAPHYLOCOCCI", "Text" : "Staphylococci", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU EC PV VGS/S. BOVIS", "Text" : "Streptococci", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROSTHETIC VALVE ENDOCARDITIS--SELECTED PATHOGEN", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU EC PV STAPHYLOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX NAFCIL 2GM IV Q4H RIFAMP 300MG Q8H GENT 1MG/KG Q8H", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI] x 6 weeks <AND> rifampin 300 mg PO/NG q8h", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG IV Q12H RIFAMP 300MG PO GENT 1MG/KG", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] x 6 weeks <AND> rifampin 300 mg PO/NG", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROSTHETIC VALVE ENDOCARDITIS WITH STAPHYLOCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Endocarditis with Staphylococcus aureus and coagulase-negative staphylococci are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "treated similarly. Surgery is required frequently in these patients.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-susceptible strains",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "($) [DI,O] for 6 weeks <AND> gentamicin 1 mg/kg IV q8h ($) [R,O] for initial 2",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "weeks",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-resistant strains",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "($) [DI,O] q8h for 6 weeks <AND> gentamicin 1 mg/kg IV q8h ($) [R,O] for initial",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "2 weeks",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EC PV VGS/S. BOVIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] for 6 weeks", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] for 6 weeks <AND> gentamicin", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 6 weeks", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "Text" : "Ceftriaxone 2 gm IV q24h ($) for 6 weeks <AND> gentamicin 3 mg/kg IV q24h", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PENICILLIN 4MU IV Q4H GENT 3 MG/KG IV QD", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q24h", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H GENT 3 MG/KG IV ONCE DAILY", "Text" : "Ceftriaxone 2 gm IV q24h ($) <AND> gentamicin 1 mg/kg IV QD($) R,O] both", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX AMPICI 2GM IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1 mg/kg IV q8h ($) [R,O]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction [CLICK HERE]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] for 6 weeks", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROSTHETIC VALVE ENDOCARDITIS WITH STREPTOCOCCUS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment of highly susceptible viridians streptococci or Streptococcus",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "gallolyticus (bovis) (penicillin MIC less than or equal to 0.12 mcg/ml)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Addition of gentamicin to penicillin or ceftriaxone is optional, as combination",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "therapy has not demonstrated superior outcomes. Contact Infectious Diseases for",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "3 mg/kg IV q24h($) [R,O] for 2 weeks",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "($) [R,O] for 2 weeks",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment of relatively resistant viridians streptococci or S. gallolyticus",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "(bovis) (penicillin MIC greater than 0.12 and less than or equal to 0.5 mcg/ml)",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "($) [R,O] both drugs for 6 weeks",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "drugs for 6 weeks",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment of highly resistant viridians streptococci or S. gallolyticus (bovis)",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "(penicillin MIC greater than or equal to 0.5 mcg/mL)",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "($) [R,O] for 6 weeks",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "< OR>",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "for 6 weeks",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Treatment of Streptococci pneumonia, Streptococcus pyogenes, and Groups B, C, F",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "and G beta-hemolytic streptococci",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Treatment is non-standardized and must be tailored to each patient. Consult",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Baddour et al., Circulation 2015, 132:1-52",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and intravascular infections",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endocarditis",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of management of infective endocarditis in adults",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Wang et al., JAMA 2018, 320.1:72-83", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ECTHYMA GANGRENOSUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CIPROFLOX 400MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > gentamicin", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CIP 400MG IV Q8H GENT 5MG IV QD", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] < AND > gentamicin 5 mg/kg", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ECTHYMA GANGRENOSUM",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Ecthyma gangrenosum lesions commonly begin as painless red macules which",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "rapidly evolve into areas of induration that develop into pustules and-or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "bullae. Ultimately, these become gangrenous ulcers. Ecthyma lesions",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "typically progress rapidly within 12 to 18 hours. They are often associated",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "with Pseudomonas aeruginosa bacteremia, especially in neutropenic patients.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Recommend blood cultures and culture of skin exudates.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Infectious disease consult is suggested.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consider combination therapy in patients with severe infections.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for 7 days.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative for severe infections",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "5 mg/kg IV q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "IV q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Pseudomonas aeruginosa",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EHRLICHIA CHAFFEENSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EHRLICHIA CHAFFEENSIS (HUMAN MONOCYTOTROPIC EHRLICHIOSIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treat for at least 5 to 7 days, up to 10 days may be required for more severe or",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "complicated cases",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "MMWR RR. 2016, 65 (2) 1-44",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Ehrlichiosis: Human monocytic ehrlichiosis (HME)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Human ehrlichiosis and anaplasmosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EMP INTRAV W/ VANCO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Vancomycin 15 mg/kg IV q12h ($6/day) [R] <AND> cefepime 2 gm IV q8h", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] <AND> vancomycin 15mg/kg", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX PIPER/TZ 4.5 GENT 5M/KG VANCO 15MG/KG Q12H", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] <AND> gentamicin 5", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2GM Q8H VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($50/day) <AND> vancomycin 15mg/kg IV q12h", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2G Q8H GENT 5MG/KG VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($50/day) <AND> gentamicin 5 mg/kg IV q24h ($3/day)", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMPIRICAL INTRAVENOUS REGIMENS WITH VANCOMYCIN",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Discontinue vancomycin after 3 days unless culture results indicate that",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "continued therapy is needed.Gentamicin is optional.Contact Hematology-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Oncology or Infectious Diseases for advice.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "($35/DAY) [R]",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "IV q12h ($6.00/day) [R] < OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "mg/kg IV q24h ($3/day) [R] <AND> vancomycin 15mg/kg q12h ($6.00/day) [R]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternatives for penicillin allergy",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "($6/day) [R] < OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($6.00/day) [R]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sipsas NVCancer 2005, 103: 1103", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU EMP INTRAV W/O VANCO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "Text" : "Cefepime 2 gm IV q8h ($35/day) [R]< OR >", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] < OR >", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($33/day) [R] <AND> gentamicin 5", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2GM Q8H VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($50/day) <AND> vancomycin 15mg/kg IV q12h", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX AZTREON 2G Q8H GENT 5MG/KG VANCO 15MG/KG Q12H", "Text" : "Aztreonam 2 gm IV q8h ($50/day) <AND> gentamicin 5 mg/kg IV q24h ($3/day)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMPIRICAL INTRAVENOUS REGIMENS WITHOUT VANCOMYCIN",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Gentamicin is optional.Contact Hematology-Oncology or Infectious Diseases for",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "advice.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "mg/kg IV q24h ($3/day) [R]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternatives for penicillin allergy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Vancomycin must be added to aztreonam for coverage of Gram-positive organisms.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "($6/day) [R] < OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "[R] <AND> vancomycin 15mg/kg IV q12h ($6.00/day) [R]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Hughes WTClin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sipsas NVCancer 2005, 103: 1103", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ENDOOPTHALMITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX VANCO 1MG INTRA INJ CEFTAZ 2.25MG INTRA INJ", "Text" : "Vancomycin 1 mg/0.1 mL intravitreal injection STAT ($) [R] < AND > ceftazidime", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX VANCO 1MG INTRAVITREOUS AMIK 0.4MG INTR INJ", "Text" : "Vancomycin 1 mg/0.1 mL intravitreal injection STAT ($) [R] < AND > amikacin 0.4", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID AMPHO B 5MCG INTRAVITREOUS INJECTION ONCE", "Text" : "Amphotericin B 5mcg/0.1mL intravitreal injection STAT ($$$) [R,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID VORICONAZOLE 100MCG INTRAVITREOUS INJECTION ONCE", "Text" : "Voriconazole 100 mcg/0.1mL intravitreal injection STAT ($$$$) [R,H,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENDOPHTHALMITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Endophthalmitis is a medical emergency and presents with eye pain and visual",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "loss. It may be associated with gram positive or gram-negative bacteria,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "including Staphylococcus aureus and Pseudomonas aeruginosa, or with fungi.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Consult ophthalmology immediately. The ophthalmologist will obtain an aqueous or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "vitreous fluid sample for gram stain and culture and begin intravitreal",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobials.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment with intravitreal antimicrobials",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "2.25 mg/0.1 mL intravitreal injection STAT ($$) [M]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "mg/0.1 mL intravitreal injection STAT ($$) [M]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Fungal endophthalmitis",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Fungal endophthalmitis is rarely diagnosed in temperate climates and treatment",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "is complicated. Ophthalmology and Infectious Diseases involvement is essential.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endophthalmitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endophthalmitis, Hematogenous or Endogenous",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Tranos et al., Advances in therapy. 2016, 33(5)727-746",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Bacterial endophthalmitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ERYSIPELAS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "Text" : "Penicillin VK 250 - 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID ERYTHROMYCIN 500MG PO Q6H", "Text" : "Erythromycin 500 mg po q6h ($) [DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID PENICILLIN 3 MILLION UNITS IV Q6H", "Text" : "Penicillin 3 million units IV q6h ($) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($) [H,O]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ERYSIPELAS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "In contrast to cellulitis, erysipelas has sharply demarcated borders and a",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "characteristic raised, orange-peel appearance.Most cases are associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "streptococcus.In a minority of cases, especially those involving the face,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is also a potential pathogen.In severe cases,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "methicillin-resistant Staphylococcus aureus (MRSA) coverage must be provided",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "until microbiology results are available.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treat for 5 to 10days, longer if patient is bacteremic.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Facial",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sudden onset of rapidly spreading red edematous tender plaque-like skin on the",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "face in an otherwise healthy host.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If erysipelas-like on the face treat as if MRSA is present:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Non-facial",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "MILD TO MODERATE disease",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "SEVERE disease",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy or MRSA suspected",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Erysipelas",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ERYSIPELOID", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "Text" : "Penicillin V 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID ERYTHROMYCIN 500MG PO Q6H", "Text" : "Erythromycin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 GM IV q24h ($$) [M]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 750MG IV Q24H", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ERYSIPELOID (ERYSIPELOTHRIX RHUSOPATHIAE INFECTION)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Erysipeloid is a localized cutaneous infection with Erysipelothrix rhusopathiae.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "It is a zoonotic infection of fisherman, fish handlers, and butchers acquired by",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "direct animal contact, most commonly with fish, but also with other animals",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(e.g., swine). It usually affects the hand or fingers and is characterized by",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "throbbing pain and a red rash with a purple center and an elevated border.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Localized infections can be treated with oral antimicrobials.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Severe, diffuse cutaneous infections or systemic infections with E.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "rhusopathiae occur rarely after ingestion of undercooked pork or contaminated",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "seafood in immunosuppressed individuals.These infections are treated",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "initially with intravenous antimicrobials.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment of localized infection (erysipeloid)",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treat for 7 days",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "___________________________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment of systemic or severe diffuse cutaneous infection with E.",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "rhusopathiae.",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "___________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment duration is at least 4 weeks. Infectious Disease Consult recommended.",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Erysipelothrix",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ERYTHRASMA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 1% TOPICAL SOLN Q12H", "Text" : "Clindamycin 1% topical solution apply twice daily ($) [M]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CLARITHROMYCIN 500MG PO Q12H", "Text" : "Clarithromycin 500 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ERYTHRASMA",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Erythrasma presents as brownish-red, well circumscribed, irregularly shaped",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "patches in or near skin folds.Patches in the groin often itch.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Most cases respond to topical therapy.Systemic antibiotics are used for more",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "severe cases or those that do not respond to topical therapy.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: erythrasma",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Holdiness MR Drugs 2002, 62:1131", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FEVER OF UNK ORIGIN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "Text" : "NEUTROPENIC FEVER", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FEVER OF UNKNOWN ORIGIN",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Fever of unknown origin (FUO) is the occurrence of several episodes of fever",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "greater than 101 degrees Fahrenheit over a time period of at least 3 weeks",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "despite 1 week of hospital evaluation. Cases with FUO are often classified in",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "four categories: (1) classical, (2) neutropenic, (3) nosocomial, and (4) fever",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "in persons with HIV/AIDS. Empirical antimicrobial therapy is rarely indicated",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "in patients with FUO.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Note that FUO in neutropenic patients refers to persistent fever that has",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "remained undiagnosed after extensive diagnostic work and empirical antimicrobial",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "therapy. New fever in patients with profound neutropenia is a different",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "syndrome and does require empirical antimicrobial therapy. Infectious Diseases",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "should be involved in any case where empirical treatment for fever of unknown",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "origin is being considered.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Fever of Unknown Origin", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FOLLICULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID MUPIROCIN 2% OINT TOP TO AFFECT AREA Q8H", "Text" : "Mupirocin ointment to affected area q8h for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE 1% CRM TOP Q8H", "Text" : "Clotrimazole cream q8h for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "FOLLICULITIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Folliculitis is an infection of the hair follicle with purulent exudate in the",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "epidermis. It is usually associated with Staphylococcus aureus.In patients",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "exposed to swimming pools or hot tubs, folliculitis may be associated with",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pseudomonas aeruginosa. Candida albicans can cause folliculitis in patients",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "receiving antimicrobials and/or corticosteroids. For folliculitis in patients",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with severe acne, consult Dermatology.For extensive folliculitis or in",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "patients with HIV, consult Infectious Diseases.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Usually self-limiting. For most cases, treat with daily saline compresses until",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "symptoms resolve.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For moderate to severe cases associated with Staphylococcus aureus:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For cases associated with Candida albicans",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Folliculitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FOOT ULCER DRUG SELECTION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DRUG SELECTION",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "MILD TO MODERATE INFECTIONS are treated with drugs that cover Gram positive",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cocci such as S. aureus and Streptococcus spp unless there is reason to suspect",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "a different pathogen.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "SEVERE INFECTIONS or infections that have failed previous antimicrobial therapy",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "should be treated initially with broad-spectrum intravenous antimicrobials.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "If methicillin-resistant S. aureus (MRSA) is suspected, use vancomycin for",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "severe cases and trimethoprim-sulfamethoxazole or doxycycline for mild or",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "moderate cases.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Use oral antimicrobial therapy for mild-moderate cases.Use intravenous therapy",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "for severe cases or when oral therapy is not feasible.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54: e132", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FOOT ULCER W/ INFECT SURR TISSUES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU APPRO FOOT ULCER W/ INFECT", "Text" : "Approach to foot ulcers with infection", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX AMOX-CLAV 875 PO Q12H TRIMETH-SULFA 1DS PO Q12", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R] <AND> Trimethoprim-", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] < AND > Vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX AMPI/SULB 3GM IV Q6H VANCO 15MG/KG IV Q12H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($) [R] <AND> Vancomycin 15 mg/kg IV", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin 15mg/kg", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZ 2GM VANCO 15MG/KG METRO 500MG IV Q8H", "Text" : "Ceftazidime 2 gm IV q8h ($$) R <AND> vancomycin 15 mg/kg IV q12h ($)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2GM METRONI 500MG VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOOT ULCERS WITH INFECTION OF SURROUNDING TISSUES",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antibiotics may be stopped 24-48 hours following curative amputation.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Otherwise, continue antibiotics until signs of infection have resolved.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Typically, 1-2 weeks for mild, 1-3 weeks for moderate and 2-4 weeks for severe.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Mild: ulcer with superficial inflammation",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Oral therapy, no MRSA coverage:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Oral therapy, MRSA coverage:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "________________________________________________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Moderate: Ulcer with inflammation, extension into fascia",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Duration: treat to resolution of symptoms usually 1-3 weeks",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "For patients started on parenteral therapy, a switch to an oral regimen",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "is reasonable following clinical improvement.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Oral therapy with MRSA coverage: (MRSA coverage until ruled out)",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "sulfamethoxazole 1 DS tablet po q12h ($) [R,DI]",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Intravenous regimens with MRSA coverage: (MRSA coverage until ruled out)",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "q12h ($) [R,DI]",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Severe: Extensive local inflammation plus systemic toxicity",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Intravenous regimens for SEVERE (limb-threatening) infections",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Duration: treat to resolution of symptoms usually 2-4 weeks",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "A switch to an oral regimen is reasonable following clinical improvement.",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "[R] <AND> metronidazole 500 mg IV q8h ($) [DI]",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration: treat until resolution of symptoms usually 1-2 weeks",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data.",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID CEFADROXIL 500MG PO BID", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX AMOX CLAV 875 Q12H + DOXYCYCLINE 100MG Q12H", "Text" : "", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "PO BID for 14 days ($) [DI]",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data.",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Preferred:", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU FOOT ULCER W/O INFECT SURR TISSUES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOOT ULCERS WITHOUT INFECTION OF SURROUNDING TISSUES",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Clinically uninfected wounds do not need antibiotic treatment.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Topical antimicrobials are not helpful, are associated with allergic reactions,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "and select for resistant organisms.In general, local treatment should consist",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "of dressings with frequent changes, soaks, and debridement. Patients with",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "edema or impaired venous return should keep the limb elevated.Wound care and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "improved control of diabetes can improve outcomes of infection and prevent",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "future complications.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2004, 39: 885",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FOOT ULCER WITH DM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER W/O INFECT SURR TISSUES", "Text" : "Foot ulcers WITHOUT infection of surrounding tissues", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER W/ INFECT SURR TISSUES", "Text" : "Foot ulcers WITH infection of surrounding tissues", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOOT ULCER IN PATIENT WITH DIABETES MELLITUS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Foot ulcers in patients with diabetes mellitus are colonized with bacteria.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Antimicrobials should not be used to treat colonization.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Cases with infection of surrounding tissues signified by erythema, warmth, local",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "tenderness, or purulent discharge should be treated with antimicrobials. Pain",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "may not be present in patients with neuropathy.In patients with substantial",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "vascular disease, erythema and warmth may not be present and instead the tissues",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "will be dusky, mottled, or cool.Capillary refill may be impaired.Patients",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "with diabetes and ulcers are at risk for gangrenous infections.If there is any",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "suggestion of gangrene, consult surgery immediately.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FUNGAL SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FUNGAL SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Fungal sinusitis mainly affects immunocompromised patients, but occasionally it",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "occurs in immunocompetent hosts. Drainage is essential. Consult ENT and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Infectious Disease.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Aspergillosis, Allergic Fungal Sinusitis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Fungal rhinosinusitis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FUNGI ASPERGILLUS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID VORICONAZOLE 6MG/KG Q12H THEN 4MG/KG IV Q12H", "Text" : "Voriconazole 6 mg/kg IV q12h for 2 doses, then 4 mg/kg IV q12h ($$$$) [R,H,", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VORICONAZOLE 200MG PO BID", "Text" : "Voriconazole 200 mg PO q12h ($$) [R,H,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ASPERGILLUS SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For localized disease (fungus ball), antifungal therapy is ineffective.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Consult Surgery and Pulmonary for cases of localized disease without systemic",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "infection. Consult Infectious Diseases in all cases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat invasive disease with intravenous antifungals initially, then",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "switch to oral antifungals for a total duration of therapy of 6-12",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "weeks dependent on the degree and duration of immunosuppression, site of disease",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "and evidence of disease improvement.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred intravenous therapy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative intravenous therapy for patients intolerant to voriconazole",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Oral therapy after disease has stabilized",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Aspergillus Species",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Patterson et al. Clinical Infectious Diseases. 2016, 63(4): e1-60",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Aspergillosis, Invasive",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of invasive aspergillosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FUNGI BLASTOMYCES DERMATIDIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200 PO TIDX3DAYS THEN 200 BID", "Text" : "Itraconazole 200 mg PO q8h for 3 days then q12h ($) [DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "Text" : "Fluconazole 400-800 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 800MG PO Q24H", "Text" : "Fluconazole 800 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BLASTOMYCES DERMATITIDIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Diseases in all cases. Lifelong suppressive therapy may be",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "required in immunosuppressed patients if immunosuppression cannot be reversed.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Disease outside of the central nervous system",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat for 6-12 months. It is recommended that immunocompromised patients be",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treated with at least 1-2 weeks of intravenous treatment and a total treatment",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "duration of 12 months.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Change to oral itraconazole after the patient's condition has stabilized.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Oral therapy after disease has stabilized",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Central nervous system infection",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Treat with intravenous therapy for 4-6 weeks followed by oral azole for at least",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "12 months.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Initial intravenous treatment",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Oral therapy after disease has stabilized",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Stanley et al. Clinical Infectious Diseases. 2008, (46)1801-12",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Blastomycosis",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of blastomycosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FUNGI CANDIDA ALBICANS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID NYSTATIN SWISH AND SWALLOW 5ML Q6H", "Text" : "Nystatin swish and swallow q6h for 7-14 days ($) [M]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE TROCHE 10MG PO 5X/DAY", "Text" : "Clotrimazole troche 10 mg PO 5X/day for 7-14 days ($) [M]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 200MG PO Q24H", "Text" : "Fluconazole 200 mg PO q24h for 7-14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "Text" : "Fluconazole 400 mg PO q24h for 14-21 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 400MG IV Q24H", "Text" : "Fluconazole 400 IV q24h for 14-21 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 800MG PO ONCE THEN 400MG Q24H", "Text" : "Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX FLUCONAZOLE IV 800MG ONCE THEN 400MG Q24H", "Text" : "Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "Liposomal amphotericin (Ambisome) 3-5 mg/kg IV q24h ($$$$) [R,O]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "Text" : "Micafungin 100-150 mg IV q24h ($$$) [H,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA ALBICANS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Avoid using fluconazole empirically to treat candidal infections in patients who",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "have received an imidazole in the previous year.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment of thrush or oropharyngeal candidiasis",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Oropharyngeal candidal disease may present in different patterns, like white",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "plaques in the oropharyngeal area, erythematous macules (often in patients with",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "dentures), or as pseudomembranes.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Thrush infection often recurs, especially in patients with AIDS. Consult MRTC",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "clinic or Infectious Diseases (MRTC may also be consulted in the MVAHCS) for",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "more information on treatment of recurrent infection.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mild disease.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Moderate to severe disease",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Esophageal candidiasis",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Esophageal infection requires systemic therapy.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Alternative for patient who cannot swallow tablets",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Systemic candidal infection",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Fluconazole is preferred empirical therapy in most cases. Amphotericin B should",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "be used empirically in patients who have received an azole antifungal drug",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "recently, or in patients who are critically ill.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location, severity of infection,",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Recent azole antifungal treatment",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FUNGI CANDIDA GLABRATA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "Text" : "Micafungin 100-150 mg IV q24h ($$$) [H,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID VORICONAZOLE 6MG/KG Q12H THEN 4MG/KG IV Q12H", "Text" : "Voriconazole 6mg/kg IV q12h for 2 doses, then 4mg/kg IV q12h ($$$$) [R,H,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VORICONAZOLE 400MG PO Q12H THEN 200MG Q12H", "Text" : "Voriconazole 400 mg PO q12h for 2 doses, then 200 mg PO q12h ($$) [R,H,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA GLABRATA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "C. glabrata is often resistant to fluconazole and occasionally has some degree",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "of resistance to amphotericin. Higher doses of amphotericin are recommended due",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "to delayed killing effects against Candida glabrata.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location and severity of infection,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "*150mg q24h for esophageal candidiasis, 100mg q24h for other indications",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative for susceptible isolates",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FUNGI CANDIDA KRUSEI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "Text" : "Micafungin 100-150 mg IV q24h ($$$) [H,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID VORICONAZOLE 6MG/KG Q12H THEN 4MG/KG IV Q12H", "Text" : "Voriconazole 6mg/kg IV q12h for 2 doses, then 4mg/kg IV q12h ($$$$) [R,H,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID VORICONAZOLE 400MG PO Q12H THEN 200MG Q12H", "Text" : "Voriconazole 400 mg PO q12h for 2 doses, then 200 mg PO q12h ($$) [R,H,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA KRUSEI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "C. krusei is resistant to fluconazole, and often has some degree of resistance",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to amphotericin. Higher doses of amphotericin are recommended for treatment of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "C. krusei due to decreased susceptibility.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location and severity of infection,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "*150mg q24h for esophageal candidiasis, 100mg q24h for other indications",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FUNGI COCCIDIOIDOMYCES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "Text" : "Fluconazole 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID FLUCONAZOLE 400MG IV Q24H", "Text" : "Fluconazole 400-800 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COCCIDIOIDOMYCES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pulmonary and Infectious Diseases consultations are essential for diagnosis and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "treatment.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location and severity of infection,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Mild to moderate disease",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Observation alone is indicated for some cases. Consult Infectious Diseases for",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "more information. If antifungal treatment is indicated:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Severe disease (diffuse pneumonia, rapid progression or central nervous system",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "infection)",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Galgiani et al. Clinical Infectious Diseases. 2016, 63(6) e112-46",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Coccidioidomycosis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford guide keyword: Coccidioidomycosis",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "Text" : "Fluconazole 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CRYPTOCOCCUS NEOFORMANS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location and severity of infection,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate infection outside of the central nervous system",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "or step-down treatment once disease has stabilized",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment of central nervous system infection or severe infection outside",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "central nervous system",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases, recommended combination therapy",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "with flucytosine requires ID approval",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cryptococcosis (Cryptococcus neoformans and Cryptococcus",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "gattii)",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Perfect et al. Clinical Infectious Diseases 2010, (50) 291-322",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cryptococcus",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Amphotericin B Liposomal (Ambisome) 3-5 mg/kg IV q24h ($$$$) [R,O] <AND>",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "flucytosine 25 mg/kg PO q6h ($$$$$) [R,O]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(Reminder: for Ampho B add NS 500 ml hydration BEFORE & AFTER.)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FUNGI HISTOPLASMA CAPSULATUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "Text" : "Itraconazole 200 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "Text" : "Fluconazole 400-800 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HISTOPLASMA CAPSULATUM",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Intravenous antifungals are indicated initially for severe or progressive",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "disease. After disease has stabilized, oral antifungals may be used to complete",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "the course. Contact Infectious Diseases and Pulmonary services for advice.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Contact HIV expert for advice on cases involving patients with HIV.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location and severity of infection,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Preferred initial therapy for meningitis, severe pulmonary or disseminated",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "disease",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment after disease has stabilized",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Itraconazole is more effective than fluconazole, but fluconazole may be used in",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "patients who cannot tolerate itraconazole.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Histoplasma capsulatum (Histoplasmosis)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Histoplasmosis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Diagnosis and treatment of pulmonary histoplasmosis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Wheat et al. Clinical Infectious Diseases. 2007 (45) 807-25", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Select here for Staphylococcus aureus Decolonization", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg po q12h ($) [DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "FURUNCLES AND CARBUNCLES",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Localized purulent infections include furuncles, carbuncles and cutaneous",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "abscesses. Nearly all are caused by Staphylococcus aureus. A furuncle is an",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "inflamed nodule that usually develops as a complication of folliculitis.A",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "carbuncle is a more extensive lesion that extends further into the subcutaneous",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "tissue.Contact a wound care nurse for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Incision and drainage is the mainstay of therapy for carbuncles, cutaneous",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "abscesses, and large furuncles.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "The decision to administer antibiotics directed against S. aureus as an adjunct",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "to incision and drainage should be made based on the presence of systemic",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "inflammatory response syndrome (SIRS) or in patients with markedly impaired",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "host defenses.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "For recurrent skin abscesses in addition to culture and antibiotic therapy",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "recommended consider a decolonization regimen.",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Mild infection: Purulent infection without systemic signs of infection",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Recommend incision and drainage. No antibiotic indicated.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Moderate Infection: Purulent infection with signs of systemic infection.",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Recommend incision and drainage. Culture material and use results to guide",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "therapy.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treat for 5 days and extend/modify treatment if not improved in this time.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Preferred treatment:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "If methicillin-RESISTANT Staphylococcus aureus (MRSA) is suspected or proved",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Severe Infections:",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Patients who have failed incision and drainage along with oral antibiotics",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "or those with SIRS or for infections in those with neutropenia or diminished",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "neutrophil function.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Recommend incision and drainage. Culture material and use results to guide",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "therapy.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Treat for 5 days. Reevaluate patient and extend or modify treatment if not",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "improved in this time.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Furuncle, carbuncle",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GI ENDOSCOPIC PROCEDURES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU SURG ERCP", "Text" : "Endoscopic Retrograde Cholangiopancreatography (ERCP)-Inpatient", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX GI EUS-FNA ENDO PROCED", "Text" : "Endoscopic Ultrasound-FNA Gastrointestinal Tract", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU GI PEG TUBE PLACEMENT", "Text" : "Placement of Percutaneous Gastrostomy (PEG) Tube", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANTIBIOTIC PROPHYLAXIS FOR GI ENDOSCOPIC PROCEDURES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The purpose of antibiotic prophylaxis during GI endoscopy is to reduce the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "risk of iatrogenic infectious complications.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GI PEG TUBE PLACEMENT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV ONCE 'C'", "Text" : "Clindamycin 600 mg IV over 30 minutes beginning 60 minutes", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Antibiotic Prophylaxis for Placement of Percutaneous Gastrostomy (PEG) Tube",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antibiotics are recommended for all patients prior to placement of PEG tube",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to reduce the risk of peristomal wound infection.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred Prophylaxis:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "($$) [R]",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with severe penicillin allergy:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "before incision ($$) [H,O]",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Endoscopy 2008, 67:791-795", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GN INT RS GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM RESULTS: GRAM-NEGATIVE BACILLI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pseudomonas, Bordetella, and Brucella spp. usually grow aerobically (but can",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "show up in an anaerobic bottle). Bacteroides, Fusobacterium, Porphyromonas, and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Prevotella spp. usually grow anaerobically (but can show up in an aerobic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "bottle). Most other gram-negative bacilli are facultative, i.e. they can grow",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "in aerobic or anaerobic culture conditions.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Some antimicrobial combinations are synergistic in vitro against some Gram-",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "negative bacilli. Combination therapy has not been shown to improve outcomes",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "in most circumstances. Single drug therapy is used in most cases. Contact",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Use susceptibility information to select an antimicrobial when a pathogen is",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "identified.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment before pathogen is identified",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment if Pseudomonas is suspected",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative for critically ill patients",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "IV q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Antibacterial Activity Spectra",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Pseudomonas aeruginosa",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Principles of antimicrobial therapy of Pseudomonas",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "aeruginosa infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GN INT RS GNC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 3-4 million units IV q4 hr ($$) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM RESULTS: GRAM-NEGATIVE COCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Gram-negative cocci may represent meningococci, gonococci, or Moraxella. This",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "page recommends empirical therapy before the final identification of the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pathogen,based on the clinical situation.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "If meningococci are suspected",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "If gonoccoci are suspected",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "If Moraxella is suspected",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neisseria meningitidis",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neisseia gonorrhoeae",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Moraxella catarrhalis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM NEGATIVE BACTERIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU GN INT RS GNB", "Text" : "Gram-negative bacilli", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU GN INT RS GNC", "Text" : "Gram-negative cocci", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ GRAM-NEGATIVE BACTERIA ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "site of infection, penetration of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "drug(s)into site, and whether",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "organism is pathogen, colonizer, or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "contaminant. See disease/syndrome",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "section for more information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Interim culture results",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "++ MULTIDRUG RESTANT ORGANISMS ++",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "ESBLS, Amp-C beta-lactamases, and",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Carbapenemases",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Gram-negative bacilli carrying",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "extended-spectrum beta-lactamases",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(ESBLs), AmpC beta-lactamases, or",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "carbapenemases.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "lactamases, and carbapenemases.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Last Reviewed December 2017",  "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL A. BAUMANNI", "Text" : "Acinetobacter baumanni", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL CITROBACTER SPP.", "Text" : "Citrobacter spp.", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN ENTEROBACTER SPP.", "Text" : "Enterobacter spp.", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL ESCHERICHIA COLI", "Text" : "Escherichia coli", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL KLEBSIELLA SPP.", "Text" : "Klebsiella spp.", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL PROTEUS SPP.", "Text" : "Proteus spp.", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL SERRATIA SPP.", "Text" : "Serratia spp.", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BORDETELLA SPP.", "Text" : "Bordetella spp.", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL BRUCELLA SPP.", "Text" : "Brucella spp.", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN CAMPYLOBACTER SPP.", "Text" : "Campylobacter spp.", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL HAEMOPHILUS SPP.", "Text" : "Haemophilus spp.", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU H. PYLORI INFECT", "Text" : "Helicobacter pylori", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FINAL LEGIONELLA SPP.", "Text" : "Legionella spp.", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN P. MULTICIDA", "Text" : "Pasteurella multocida", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN PSEUDOMONAS SPP.", "Text" : "Pseudomonas spp.", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN SALMONELLA SPP.", "Text" : "Salmonella spp.", "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "Text" : "Shigella spp (bacillary dysentery)", "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. MENINGITIDIS", "Text" : "Neisseria meningitidis", "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. GONORRHOEAE", "Text" : "Neisseria gonorrhoeae", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN M. CATARRHALIS", "Text" : "Moraxella catarrhalis", "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.", "Text" : "Bacteriodes, Porphyromonas,", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Final culture results",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : ">> Gram-negative bacilli <<",  "Header" : 1}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : ">> Gram-negative cocci <<",  "Header" : 1}, 
{"Row" : 36, "Column" : 2, "Item" : null, "Text" : "Prevotella", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM POS BACTERIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "Text" : "Gram-positive cocci", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU INT RPT GPR", "Text" : "Gram-positive bacilli", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ GRAM-POSTITIVE BACTERIA ++",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "site of infection, penetration of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "drug(s) into site, and whether",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "organism is pathogen, colonizer, or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "contaminant. See disease/syndrome",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "section for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Interim culture results",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Last Reviewed December 2017",  "Header" : 1}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN STAPHYLOCOCCI", "Text" : "Staphylococci", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN S. PYOGENES", "Text" : "Group A (S. pyogenes)", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FINAL S. AGALACTIAE", "Text" : "Group B (S. agalactiae)", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN STREP C,F,G", "Text" : "Groups C, F, G", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN S. BOVIS", "Text" : "Group D (S. bovis)", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FIN VIRIDANS STREP", "Text" : "Viridans streptococci (including S. mutans, S. mitis, S. sanguis)", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI S. PNEUMONIAE", "Text" : "Streptococcus pneumoniae", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI S. ANGINOSUS", "Text" : "Streptococcus anginosus (formerly S. milleri)", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI", "Text" : "Anaerobic Gram-positive cocci (including Peptostreptococcus)", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ENTEROCOCCI", "Text" : "Enterococci", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI BACILLUS SPP.", "Text" : "Bacillus spp.", "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI CLOSTRIDIUM SPP.", "Text" : "Clostridium spp.", "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI CORYNEBACTERIUM SPP.", "Text" : "Corynebacteriium spp.", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI PROPIONIBACT SPP.", "Text" : "Cutibacterium (formerly Propionibacterium) spp.", "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI ACTINOMYCES SPP.", "Text" : "Actinomyces spp.", "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : "ORZID2 GMENU GRAM-POS FI LISTERIA SPP.", "Text" : "Listeria spp.", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "Final culture results",  "Header" : 1}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : ">> Gram-positive cocci <<",  "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "Streptococci",  "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : ">> Gram-positive bacilli <<", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN BACTEROIDES SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID METRONIDAZOLE 1000MG PO Q12H", "Text" : "Metronidazole 1000 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID METRONIDAZOLE 1000MG IV Q12H", "Text" : "Metronidazole 1000 mg IV q12h ($) [DI]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTEROIDES SPP. (INCLUDING PREVOTELLA, PORPHYROMONAS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "These bacteria are strict anaerobes and will only grow in anaerobic media.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bacteriodes sp., Overview",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Anaerobic bacterial infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN CAMPYLOBACTER SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h ($) [O]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID AZITH 500MG IV Q24H", "Text" : "Azithromycin 500 mg IV q24h ($) [O]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CAMPYLOBACTER SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal Optimal therapy depends on both the disease or syndrome and the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pathogen. See diagnosis/syndrome section for more information. Drugs",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "recommended below are best for most cases. If susceptibility results or other",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "factors make these inappropriate for this case, click need an alternative",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For information on gastroenteritis (usually involving C. jejuni), refer to the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Gastrointestinal and Intraabdominal infection section.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment of extraintestinal infectious not involving the central nervous",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "system infections",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment of central nervous system infections",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Campylobacter jejuni, Campylobacter coli",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Campylobacter infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN ENTEROBACTER SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PIPER/TAZO 3.375 Q6H GENT 5MG/KG Q24H", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> gentamicin 5 mg/kg IV", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 IV Q12H GENT 5MG/KG IV Q24H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> gentamicin 5 mg/kg IV q24h", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTEROBACTER SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "($) [R,O]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterobacter sp.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN M. CATARRHALIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID TMP/SULFA 1DS TABLET PO Q12H", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MORAXELLA CATARRHALIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Moraxella catarrhalis",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Moracella catarrhalis infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN N. GONORRHOEAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEISSERIA GONORRHOEAE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for disseminated gonococcal infection:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Disseminated gonococcal infection",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neisseria gonorrhoeae",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treat for at least 7 days. Need susceptibility testing of the bloodstream",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "isolate to guide potential switch to an oral medication.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "of the reaction is recommended.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "-Consult Infectious Disease to determine best alternative to cephalosporin.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 1GM IV Q24H", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "All gonorrhea patients should be tested for HIV, syphilis, and Chlamydia",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "trachomatis. Sexual partners should be evaluated.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN N. MENINGITIDIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 1 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CHLORAMPHENICOL 12.5 MG/KG IV Q6H", "Text" : "Chloramphenicol 12.5 mg/kg IV q6h ($$) [O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEISSERIA MENINGITIDIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Central nervous system infections require higher doses of antimicrobials.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment for infections outside of the central nervous system",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment for central nervous system infections",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "For patients intolerant to cephalosporins",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Call pharmacy, chloramphenicol is not regularly stocked and will need to be",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "special ordered.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neisseria meningitidis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment and prevention of meningococcal infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN P. MULTICIDA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 1.5-3 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PASTEURELLA MULTOCIDA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pasteurella multocida",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Pasteurella infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN PSEUDOMONAS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID AZTREONAM 2GM IV Q8H", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5GM Q6H TOBRA 5MG/KG Q24H", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > tobramycin 5 mg/kg IV", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZ 2GM Q8H TOBRA 5MG/KG Q24H", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R] < AND > tobramycin 5 mg/kg IV q24h ($) [R,O", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX AZTREO 2G Q8H TOBRA 5MG/KG Q24H", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] < AND > tobramycin 5 mg/kg IV q24h ($)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PSEUDOMONAS SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "In severe cases, addition of an aminoglycoside to a beta",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "lactam may be beneficial. Aminoglycoside monotherapy is effective only in",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "treatment of UTI. Refer to genitourinary section for treatment of UTI due to",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "pseudomonas. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Oral treatment for mild infections",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "For patients with Beta-lactam allergy",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for severe infections",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "For patients with Beta-lactam allergy",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "[R,O]",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pseudomonas aeruginosa",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Principles of antimicrobial therapy of Pseudomonas",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "aeruginosa infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN SALMONELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SALMONELLA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For gastroenteritis antimicrobials are not usually indicated. Please refer to",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the Gastrointestinal and Intra-abdominal infections section for more",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "salmonella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "For localized or systemic extraintestinal infections",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Salmonella sp.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FIN SHIGELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h ($) [O]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SHIGELLA SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "infections section for more information. antibiotic resistance is increasing,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "especially among men who have sex with men. Drug selection should be based on",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "antimicrobial susceptibility tests.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for systemic infections",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "MMWR (2015) 64.318",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Shigella Sp.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Shigella infection: Treatment and prevention in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL A. BAUMANNI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases.", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "Text" : "Cefepime 2 gm IV q8h ($$) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CEFTAZ 2GM Q8H AMIK 7.5 MG/KG Q12H", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R] <AND> amikacin 7.5 mg/kg IV q12h ($$) [R,O]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACINETOBACTER BAUMANNII",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Isolation of Acinetobacter baumannii from a culture often represents",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "contamination or colonization and not disease. For questions about whether a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "patient should be treated, contact Infectious Diseases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Many isolates are resistant to multiple antimicrobials. If susceptibilities are",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "not known, start therapy with imipenem or amikacin.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "If susceptibities are known, use appropriate antimicrobial.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Acinetobacter carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sulbactam is active against some strains of ESBLs",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Acinetobacter baumannii",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acinetobacter infection: Treatment and prevention", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL BORDETELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID AZITHROMYC 500MG IV X1 THEN 250MG IV X4DAYS", "Text" : "Azithromycin 500 mg IV once ($) [O] on day 1, then 250 mg IV q24h ($) [O]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID TMP/SULFA 1DS TABLET PO Q12H", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h ($$$) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BORDETELLA SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bordetella pertussis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL BRUCELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX DOXYCY 100MG PO Q12H RIFAMP 600MG PO Q24H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] < AND > rifampin 600 mg PO q24h ($)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BRUCELLA SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment for non-localizing disease only. Consult Infectious Diseases for",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "specifc clinical syndrome since regimens vary (e.g. arthritis, neurobrucellosis,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "endocarditis, etc.)",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat with both drugs for 45 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "[DI,O]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Brucellosis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "brucellosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL CITROBACTER SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CITROBACTER SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Citrobacter sp.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL ESCHERICHIA COLI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID FOSFOMYCIN 3 GM PO ONCE", "Text" : "Fosfomycin 3 gm sachet PO ($$) [M] once", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJZID FOSFOMYCIN 3GM PO QOD 3 DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSJZID FOSFOMYCIN 3GM PO QOD 3 DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ESCHERICHIA COLI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "infections section.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "E. coli carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections including cystitis",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "E. coli carrying ESBL:",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "E. coli carrying carbapenemase:",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Escherichia coli",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL HAEMOPHILUS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID AZITHROMYC 500MG IV X1 THEN 250MG IV X4DAYS", "Text" : "Azithromycin 500 mg IV once ($) [O] on day 1, then 250 mg IV q24h ($) [O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HAEMOPHILUS SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Haemophilus influenzae",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL KLEBSIELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "Text" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID FOSFOMYCIN 3 GM PO ONCE", "Text" : "Fosfomycin 3 gm sachet PO ($$) [M] once", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "KLEBSIELLA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "klebsiella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections including cystitis",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Klebsiella sp.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL LEGIONELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h ($) [O]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID AZITH 500MG IV Q24H", "Text" : "Azithromycin 500 mg IV q24h ($) [O]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 500MG PO QDAY", "Text" : "Levofloxacin 500 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LEGIONELLA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Consider treating for up to 21 days in immunosuppressed patients who are",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "severely ill upon presentation.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative for patients intolerant to macrolides",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Legionella sp.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment and prevention of Legionella infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL PROTEUS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "Text" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROTEUS SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "proteus carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections including cystitis",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Allergy to penicillin",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Proteus sp.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-NEG FINAL SERRATIA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "Text" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID MEROPENEM 1GM IV Q8H", "Text" : "Meropenem 1 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SERRATIA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Serratia marcescens",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Infections due to Serratia species", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI ACTINOMYCES SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACTINOMYCES SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta-lactam allergy",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Actinomycosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI ANAEROBIC COCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "Text" : "Penicillin G 3 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID AMPICIL 2GM IV Q6H", "Text" : "Ampicillin 2 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANAEROBIC GRAM-POSITIVE COCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Anaerobic Gram-positive cocci, including peptostreptococci, are often involved",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "in mixed aerobic/anaerobic infections. Beta-lactams (like ampicillin and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "penicillin) and clindamycin are the drugs of choice against anaerobic gram-",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "positive cocci. Beta-lactam/beta-lactamase inhibitors are active against",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "peptostreptococci, so no additional anaerobic antimicrobials are needed",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "specifically to cover peptostreptococcus when drugs such as ampicillin-sulbactam",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "or piperacillin-tazobactam are used.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Anaerobic Cocci and Anaerobic Gram-Positive Nonsporulating",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Bacilli",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Peptostreptococcus sp.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI BACILLUS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 Q8H MERO 2 Q8H LINEZOLID 600 Q12H", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> Meropenem 2 gm IV q8h", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG IV Q8H CLINDA 900MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <AND> clindamycin 900mg IV q8h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACILLUS SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "B. cereus",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease/syndrome sections for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "If isolate is clindamycin-susceptable",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "B. anthracis",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Start combination therapy and contact Infectious Diseases immediately.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If meningitis has not been ruled out",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treat for 6 weeks",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "($$) [R,O] < AND > linezolid 600 mg IV q12h ($$$$) [DI]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "If meningitis has been ruled out",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If isolate is penicillin-susceptible",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Isolate is not penicillin susceptible or susceptibility unknown",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Hendricks et al., Emerg Infect Dis 2014, 20.2",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI CLOSTRIDIUM SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "Text" : "Clostridium difficile disease", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "Text" : "Penicillin G 3 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 900MG IV Q8H", "Text" : "Clindamycin 900 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CLOSTRIDIUM SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For Clostridium difficile disease refer to",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections may be treated with oral antimicrobials. For",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "neutropenic enterocolitis, gas gangrene, or other necrotizing infection,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "intravenous therapy is indicated. Combination therapy may be preferred. Refer",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "to the appropriate section of the CDSS or contact Infectious Diseases for more",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "C. perfringens food poisoning is treated with supportive care. Diarrhea resolves",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "within 24 hours.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "For severe infection with Clostridium spp. other than perfringens, septicum or",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "sordellii, call Infectious Diseases.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Preferred empirical treatment for mild to moderate infections",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergic patients",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Preferred empirical therapy for severe infections",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergic patients",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Sanford Table 2: Recommended antimicrobial agents",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI CORYNEBACTERIUM SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 6 MG/KG IV Q24H", "Text" : "Daptomycin 4-6 mg/kg IV q24h ($$$$) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID ERYTHROM 500MG PO Q8H", "Text" : "Erythromycin 500 mg PO q8h ($$) [DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID ERYTHROMYCIN 500MG IV Q6H", "Text" : "Erythromycin 500 mg IV q6h ($$) [DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 500,000 UNITS IV Q4H", "Text" : "Penicillin G 500,000 units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID PENICILLIN VK 250MG PO Q6H", "Text" : "Penicillin VK 250 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CORYNEBACTERIUM SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Corynebacterium jeikeium",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease/syndrome sections for more information.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative for patients intolerant of vancomycin",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Corynebacterium diphtheriae",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Diphtheria is usually severe and often fatal. Antitoxin is the most important",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "treatment. Contact Infectious Diseases immediately.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative for patients intolerant of erythromycin",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Corynebacterium diptheriae",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Corynebacterium jeikeium",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "diptheria", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI ENTEROCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FI TREAT ENTEROCOCCI", "Text" : "Treatment for enterococcal infections", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTEROCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The important human pathogens are Enterococcus faecium and Enterococcus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "faecalis. The antimicrobial susceptibilities that are reported for enterococci",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "depend on the site of the sample. For all enterococci the microbiology",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "laboratory reports susceptibility for ampicillin and vancomycin. Additionally",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "the lab reports fluoroquinolone susceptibility for urinary isolates and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "susceptibility to gentamicin synergy for bloodstream isolates. For more",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "information on culture and susceptibilities, contact the microbiology laboratory",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Ampicillin is the drug of choice for enterococcal infections. Piperacillin is",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "also active against enterococcus. Cephalosporins are ineffective as single",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "agents for enterococcal infections. For patients who are allergic to penicillin",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "or infected with penicillin-resistant enterococcus, vancomycin is the preferred",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "drug. Nitrofurantoin is effective in urinary tract infections only. Linezolid",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "must be reserved for cases where no other drug can be used as it has many side",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "effects and drug interactions, is expensive, is bacteriostatic rather than",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "bactericidal, and its use promotes resistance.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Combination regimens include a primary anti-enterococcal agent (ampicillin or",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "vancomycin) plus gentamicin or streptomycin are synergistic in vitro and are",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "needed for severe infections like endocarditis or prosthetic joint infections.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "See relevant disease/syndrome sections for more information. Milder diseases",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "like cystitis or wound infection can usually be treated with a single drug. For",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "more information on treatment of enterococcal infections, contact Infectious",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Enterococcus Species, Streptococcus gallolyticus Group, and",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Leuconostoc Species",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococcus faecalis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococcus faecium",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment of enterococcal infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI LISTERIA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2G Q4H GENT 1.7MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> gentamicin 1.7 mg/kg IV q8h ($) [R,O]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID TRIMETH/SULFA 5-25 MG/KG IV Q6H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q6h ($$$) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LISTERIA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "For meningitis, please refer to the meningitis section for treatment advice.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta-lactam allergy or intolerant of gentamicin",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Listeria monocytogenes",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment, prognosis, and prevention of Listeria",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "monocytogenes infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI PROPIONIBACT SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID PENICILLIN 2MU IV Q4H", "Text" : "Penicillin G 2 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CUTIBACTERIUM (FORMERLY PROPIONIBACTERIUM) SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Isolation of Propionibacterium species from a culture often represents",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "contamination or colonization and not disease. For questions about whether a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "patient should be treated, contact Infectious Diseases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "disease/syndrome sections for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta-lactam allergy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Propionibacterium acnes",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Invasive Cutibacterium (formerly Propionibacterium)",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI S. ANGINOSUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STREPTOCOCCUS ANGINOSUS (FORMERLY S. MILLERI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Ceftriaxone or penicillin are preferred for central nervous system infection.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Cefazolin or penicillin are preferred for infection outside of the central",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "nervous system.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Central nervous system infections",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Diseases for advice.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Infections outside of the central nervous system",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "If isolate is clindamycin-susceptable",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Streptococcus anginosus group",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus anginosus group",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Infections due to the Streptococcus anginosus (Streptococcus",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "milleri) group", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI S. PNEUMONIAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX CNS", "Text" : "Central Nervous System section", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 1000MG PO Q8H", "Text" : "Amoxicillin 1000 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STREPTOCOCCUS PNEUMONIAE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Refer to Central Nervous System section for treatment of meningitis",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for infections outside of the central nervous system",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta-lactam allergy, or when beta-lactam resistance",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "is suspected or proved",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Streptococcus pneumoniae",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus pneumoniae",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Invasive pneumococcal (Streptococcus pneumoniae) infections",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "and bacteremia", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FI TREAT ENTEROCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 8-12MG/KG Q24H", "Text" : "Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TREATMENT FOR ENTEROCOCCAL INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Isolation of enterococci in wounds often represents colonization rather than",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "infection. When colonization is suspected, enterococci need not be treated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment for urinary tract infections",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for systemic infections",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative for resistant organisms",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to take vancomycin or vancomycin resistant",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "enterococci",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "promotes bacterial resistance. It should only be used in cases where other",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "options are not feasible. Contact Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Enterococcus Species, Streptococcus",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "gallolyticus Group, and Leuconostoc Species",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococcus faecalis",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococcus faecium",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment of enterococcal infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN COAG-NEG STAPH", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FIN STAPH LUGDUNENSIS", "Text" : "Treatment for Staphylococcus lugdunensis", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 3 MILLION UNITS IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO q12h ($) [R,O]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TREATMENT FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Commonly isolated CNS are S. epidermidis, S. haemolyticus, S. lugdunensis and S.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "saprophyticus. Less commonly isolated CNS are S. auricularis, S capitis, S.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "caprae, S. carnosus, S. cohnii, S. hominis, S. pasteuri, S. petrasii, S.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "pettenkoferi, S. pulvereri, S. saccharolyticus, S. schleiferi, S. simulans, S.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "warneri and S. xylosus",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Unlike other CNS, S. lugdunensis can cause severe disease like S. aureus. Refer",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "to S. lugdunensis page for treatment.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Isolation of coagulase-negative staphylococci from a culture often represents",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "contamination or colonization and not disease. For questions about whether a",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "patient should be treated, contact Infectious Diseases.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "If susceptibility results are known, use them to select one of the following",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "drugs.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "If not, use vancomycin empirically until final culture and susceptibilities are",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "available.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for urinary tract infection associated with S. saprophyticu",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Alternative for resistant organisms",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to take vancomycin",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "promotes bacterial resistance. It should only be used in cases where other",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "options are not feasible. Contact Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Staphylococci",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus sp., Coagulase-negative",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus epidermidis",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Infection due to coagulase-negative staphylococci: Treatment", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TREATMENT FOR STAPHYLOCOCCUS AUREUS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If susceptibility results are known, use them to select one of the following",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "drugs.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "If not, use vancomycin empirically until final culture and susceptibilities are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "available.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative for resistant organisms",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to take vancomycin",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "promotes bacterial resistance. It should only be used in cases where other",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "options are not feasible. Contact Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus aureus",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus aureus", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN S. BOVIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID AMPICIL 2GM IV Q6H", "Text" : "Ampicillin 2 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GROUP D STREPTOCOCCI (S. BOVIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Bacteremia with Streptococcus bovis is associated with malignancy of the colon.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Resistance to penicillin is uncommon. Vancomycin should only be used in a",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "patient with beta-lactam allergy, or if beta-lactam resistance is strongly",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "suspected.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "infections due to group D streptococci (Streptococcus bovis/Streptococcus",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "equinus complex)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN S. PYOGENES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID PENICILLIN VK 250MG PO Q6H", "Text" : "Penicillin VK 250 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] <AND> clindamycin 900 mg IV q8h", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM Q12H CLINDAMYCIN 900MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> clindamycin 900 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX VANCOMYCIN 15MG/KG IV Q12H CLINDAMYCIN 900MG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> clindamycin 900 mg IV q8h ($$)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GROUP A STREPTOCOCCI (S. PYOGENES)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Group A streptococcus (Streptococcus pyogenes) is the most virulent",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "streptococcal species. Important syndromes include pharyngitis, cellulitis,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "streptococcal toxic shock syndrome, necrotizing fasciitis, erysipelas, rheumatic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "fever, and post-streptococcal glomerulonephritis. Optimal therapy depends on",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "both the disease or syndrome and the pathogen. See diagnosis/syndrome section",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections (non-necrotizing)",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Bacteremia, toxic shock syndrome and necrotizing infections",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "If isolate is sensitive to clindamycin",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "[H,O]",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Streptococcus pyogenes",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Strep",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Group A streptococcal (Streptococcus pyogenes) bacteremia in",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN STAPH LUGDUNENSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI,O]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TREATMENT FOR STAPHYLOCOCCUS LUGDUNENSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Severity of S. lugdunensis infections vary from moderate to severe.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Approximately 25% of isolates are resistant to penicillin, but methicillin",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "resistance is uncommon.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "If susceptibility results are known, use them to select one of the following",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "drugs. If not, use vancomycin empirically until final culture and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "susceptibilities are available.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for resistant organisms",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to take vancomycin",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "promotes bacterial resistance. It should only be used in cases where other",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "options are not feasible. Contact Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Staphylococci",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus lugdunensis",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Staphylococcus lugdunensis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN STAPHYLOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FIN S. AUREUS", "Text" : "for Staphylococcus aureus", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-POS FIN COAG-NEG STAPH", "Text" : "for coagulase-negative staphylococci", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU ABX STAPHYLOCOCCUS AUREUS DECOLONIZATION", "Text" : "Click Here", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STAPHYLOCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is a virulent pathogen, and staphylococcal disease tends",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to relapse. Optimal therapy often involves intravenous therapy for defined",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "durations. See sections on specific syndromes (e.g., bacteremia or",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "endocarditis) for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Coagulase-negative staphylococci, including Staphylococcus epidermidis and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "several less common species, are less virulent than S. aureus and are most",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "commonly pathogenic when they colonize plastic or metal devices in a patient",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "(e.g., intravenous catheters, prosthetic joints or heart valves). S.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "lugdunensis is an uncommon but virulent coagulase-negative staphylococcus",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "species. S. saprophyticus is associated with urinary tract infections in women.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Beta-lactam antimicrobials are the most active drugs against beta-lactam",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "susceptible staphylococci. Penicillin is superior for penicillin-susceptible",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "staphylococci, but most strains are resistant. Nafcillin and oxacillin are",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "nearly as active as penicillin. Cefazolin or ceftriaxone (also beta-lactams are",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "next best. Vancomycin, a glycopeptide, is less active than the beta-lactams.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Trimethoprim-sulfamethoxazole, minocycline, and clindamycin are less effective",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "than beta-lactams for treatment of methicillin-susceptible staphylococcal",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "infections, but may be useful in patients with severe penicillin allergy. For",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "methicillin-resistant staphylococcal infections, trimethoprim-sulfamethoxazole,",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "minocycline, and clindamycin are useful alternatives to to vancomycin, as they",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "are inexpensive and available in both intravenous and oral formulations. They",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "are preferred over linezolid in most circumstances because linezolid is",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "expensive, toxic with long-term use, and needed for treatment of highly",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "resistant bacteria like vancomycin-resistant enterococci.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Combination regimens include a primary anti-staphylococcal agent (beta-lactam or",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "vancomycin) plus one or more supplemental drugs (e.g. gentamicin and/or",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "rifampin) often synergistic against staphylococci in vitro, but there is no",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "evidence that combination therapy improves outcomes in staphylococcal infections",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "in humans. Combination therapy has become the community standard for treatment",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "of prosthetic-valve staphylococcal endocarditis based on experimental models and",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "limited clinical data that combination therapy is superior (see endocarditis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "section for details).",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Decolonization",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Baddour, et al. Circulation 2015, 132.15",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and Intravascular Infections",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus aureus", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN STREP C,F,G", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500 mg PO once ($) [O] on day 1, then 250 mg PO q24h ($) [O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STREPTOCOCCI GROUPS C, F, G",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "If isolate is clindamycin-susceptable",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "If isolate is clindamycin-susceptable",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Groups C and G Streptococci, and Other Related Organisms",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Strep",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Group C and group G streptococcal infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FIN VIRIDANS STREP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX CARDIOVASCULAR", "Text" : "Cardiovascular", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX PENICIL 4MU IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "VIRIDANS STREPTOCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Viridans streptococci are a heterogeneous group defined by their production of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "green pigment on blood agar. Clinically important members of this group include",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "S. mutans, S. mitis, and S. sanguis. S. anginosus (formerly S. milleri) and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Streptococcus bovis are described separately. Viridans streptococci are",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "important, common pathogens in endocarditis and can also be contaminants in",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "cultures of blood and other specimens. Consult Infectious Diseases for more",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Refer to Cardiovascular Section for diagnosis and treatment of endocarditis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Preferred treatment is penicillin or cefazolin. Vancomycin should be used only",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "in patients with beta-lactam allergy, or if beta-lactam resistance is strongly",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "suspected. For serious disease, consider addition of gentamicin for synergy.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "q8h ($) [R,O]",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with penicillin allergy, or if beta-lactam resistance",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "is suspected",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Groups C and G Streptococci, and Other Related Organisms",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococci, viridans group", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU GRAM-POS FINAL S. AGALACTIAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin 2-4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin 600 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GROUP B STREPTOCOCCI (S. AGALACTIAE)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Group B streptococci (Streptococcus agalactiae) are associated most commonly",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "with bacteremia and meningitis in infants and bacteremia and urinary tract",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "infections in elderly people and people with diabetes mellitus.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If isolate is clindamycin-susceptable",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "If isolate is clindamycin-susceptable",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR>",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Streptococcus agalactiae (Group B Streptococcus)",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus agalactiae, Group B Strep",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Group B streptococcal infections in nonpregnant adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU H. PYLORI INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX CLARITH AMOX METRO OMEPRO H PYLORI", "Text" : "Clarithromycin 500 mg PO q12h ($)[R,DI] <AND> Amoxicillin 1000 mg PO q12h", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX BIS SUBSAL METRO DOXY OMEP H PYLORI", "Text" : "Bismuth subsalicylate 524 mg PO q6h <AND> doxycycline 100 mg q12h ($)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HELICOBACTER PYLORI INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "H. pylori infection is associated with peptic ulcers, gastritis, gastric",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "adenocarcinoma, and gastric lymphoma. Antimicrobials should be given to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "patients with confirmed H. pylori infection. Antisecretory therapy should be",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "given concurrently. Contact Gastroenterology for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "($)[R] <AND> metronidazole 500 mg PO q12h ($) [DI] <AND> omeprazole 20",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "mg PO q12h for 14 days",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "[DI]<AND> metronidazole 500mg PO q12h ($) [DI] <AND> omeprazole 20 mg PO q12h fo",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "14 days",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Fallone et al, Gastroenterology, 2016,151:61-69",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Helicobacter pylori and Other Gastric Helicobacter Species",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastric/Duodenal Ulcer, Helicobacter pylori",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment regimens for Helicobacter pylori", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX TREAT HEAD LICE URL", "Text" : "https://www.cdc.gov/parasites/lice/head/index.html", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID PERMETHRIN 1% LOTION TO AFFECT AREA 10MIN", "Text" : "Permethrin 1% lotion Apply to affected area for 10 minutes then comb out", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "HEAD LICE (PEDICULOSIS CAPITIS)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "To make a diagnosis, use a nit comb, bright light, or lens to find a louse",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "living on the scalp.Dead nits may remain for months after successful",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "treatment.Dead nits are usually located more than 6 mm from the scalp.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Lice are often transmitted by infected clothing and bedclothes but not by",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "ordinary furniture that is not typically in contact with hair or scalp.Refer",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "to the following for advice on household cleaning for lice infestations:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Repeat if live lice are seen 7-10 days after treatment.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "nits ($) [M]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: lice",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU HIDRADENITIS SUPPURATIVA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID CHLORHEXIDINE GLUCONATE WASH QDAY", "Text" : "Chlorhexidine gluconate 4% liquid topically wash affected area q24h ($) [M]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJZID BENZOYL PEROXIDE 10% WASH TOPICALLY Q24H", "Text" : "Benzoyl peroxide 10% soap topically wash affected area q24h ($) [M]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 1% TOPICAL SOLN Q12H", "Text" : "Clindamycin 1% solution topically to affected areas q12h prn for flares ($) [M]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI] for 12 weeks", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q12H", "Text" : "Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O]", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX MOXI400MGPOQ24H METRO500MGPOQ8H RIFAMP300MGPOQ12H", "Text" : "Moxifloxacin 400 mg PO q24h ($)[R,DI] for 12 weeks <AND> metronidazole 500", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HIDRADENITIS SUPPURATIVA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A chronic inflammatory condition that typically involves occlusion, rupture,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "abscess formation and infection of hair follicles as well as secondary infection",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "of apocrine glands/surrounding tissues. Lesions most often occur in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "intertriginous areas (axillae, inguinal and anogenital) in is associated with",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "smoking and obesity. There is a 40% genetic predisposition for hidradenitis",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "suppurativa (HS) and is often accompanied by pain, malodor, and drainage.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Cultures are negative 50% of the time and often are polymicrobial with S.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "epidermidis and S. aureus most isolated. The Hurley Staging System is often used",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "to determine severity of HS.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Therapy generally consists of treatment of comorbidities that can exacerbate HS,",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "avoidance of triggers, pain management, wound care, and topical/oral",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "antimicrobials. Hormonal agents, steroids, retinoids, and surgery can also be",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "used to treat certain patients. Biologics may be considered in Stage II-III HS.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Consult Dermatology in all cases",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Hurley Staging System:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Stage I: recurrent nodules and abscesses with minimal scarring",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Stage II: limited number of sinuses and/or scarring within a body region",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Stage III: multiple or extensive sinuses and/or scarring",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment is typically for 12 weeks but may require longer durations in certain",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "cases. Metronidazole should only be used for a maximum of 6 weeks to avoid",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "neurologic toxicity.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Interventions for All Patients:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Smoking cessation, weight loss, avoidance of triggers, and pain management",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "should be part of all treatment plans. Consult Dermatology for use of hormonal",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "agents, steroids, retinoids, and surgery.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Optional Topical Treatment, May be Used in Addition to Oral Therapies Below:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "< ADD ON THERAPY FOR FLARES - MUST USE IN ADDITION TO ONE OF THE AGENTS ABOVE>",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Stage I-II Initial Treatment:",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Stage III Initial Treatment and Stage I-II Failure of Oral Doxycycline:",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Stage II-III Failure of Oral Clindamycin:",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "mg q8h ($) [DI] for 6 weeks <AND> rifampin 300 mg PO q12h ($) [DI,O] for 12",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "weeks",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Alikhan, Ali, et al. Journal of the American Academy of Dermatology 81.1 (2019):",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "76-90",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "John Hopkins ABX Guide Keyword: Hidradenitis Suppurativa",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Hidradenitis suppurativa: Management",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Hidradenitis suppurativa: Pathogenesis, clinical features,",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "and diagnosis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IG HIS DEFICIENCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($5.71/day) [M]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "IMMUNOGLOBULIN DEFICIENCY (HUMORAL IMMUNE SYSTEM)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antibody deficiency typically leads to recurrent, severe respiratory tract",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infections associated with encapsulated bacteria, especially Streptococcus",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pneumoniae and Haemophilus influenzae, and to a lesser extent, Staphylococcus",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "aureus. Recurrent otitis media, sinusitis, and pneumonia are common syndromes.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Gastrointestinal disease associated with Salmonella, Shigella, Campylobacter, or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "rotavirus is also common in some patients.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred empirical treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative for severe penicillin allergy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Chloramphenicol is not currently available.Contact Infectious Diseases for",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "advice.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ALTERED MICROBIAL FLORA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A rich, diverse microbial flora lives on or in skin, mucosal surfaces, and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "respiratory and gastrointestinal tracts of healthy people.This flora prevents",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease by inhibiting the growth of potential pathogens.Disruption of the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "normal flora, usually by antimicrobial therapy, reduces this barrier and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "increases the risk of infectious disease.Patients exposed to broad-spectrum",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobials are at greater risk for colonization with resistant bacteria,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "fungal infections, and Clostridium difficile colitis.During hospitalization,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "many patients become colonized with more resistant organisms like methicillin-",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "resistant Staphylococcus aureus and resistant Gram-negative bacilli.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BASIC CONCEPTS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Humans are protected by a broad array of host defenses that fall into two major",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "categories: innate and immune host defenses.Innate defense operate",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "continuously without specific antigenic stimulation and immune defenses are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "primed by and respond to antigenic stimulation.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Each type of host defense protects against a specific set of organisms.As a",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "result, infectious diseases more common because of host defense defects in an",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "individual patient are usually predictable from that patient's host defense",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "defects.For example, antibody or complement deficiencies predispose patients",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "to disease with encapsulated organisms but not fungi.Defects in cell-mediated",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "immunity predispose patients to infections with mycobacteria or cytomegalovirus",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "but not Escherichia coli or influenza virus.Suspected cases of infectious",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "disease must be evaluated in the context of the patient's host defects.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Management, including possible antimicrobial therapy, should be initiated on the",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "basis of the most likely offending pathogens.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM COMP DEFICIENCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($5.71/day) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMPLEMENT DEFICIENCY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Complement deficiency can be inherited or acquired.Acquired defects are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "usually a consequence of other diseases like systemic lupus erythematosus.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Complement deficiency leads to increased rates of infections, usually of the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "upper respiratory tract, but also occasionally with bacteremia or meningitis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Pathogens are usually Streptococcus pneumoniae, Neisseria meningitidis, and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Neisseria gonorrhea.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Patients presenting with fever or other symptoms suggesting systemic bacterial",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "infection should be treated immediately with antimicrobials active against these",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "pathogens.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred empirical treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative for severe penicillin allergy",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Chloramphenicol is not currently available.Contact Infectious Diseases for",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "advice.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIABETES MELLITUS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Hyperglycemia increases the risk of infectious diseases in diabetic patients,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "and increased blood glucose slows infection resolution.Diabetic patients are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "prone to a variety of infections including urinary tract infections,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cholecystitis, and bacteremia.Peripheral neuropathy and arterial insufficiency",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "predispose to infections of skin, soft tissue, and bone infection in the lower",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "legs and feet.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Joshi NNew Eng J Med 1999, 341: 1906", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HYPOCHLORHYDRIA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diminished gastric acid allows increased numbers of bacteria in the stomach and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "predisposes to infection with several potentially pathogenic bacterial species.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "These changes increase the risk of nosocomial pneumonia and possibly the risk of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "community-acquired respiratory infections.However, interventions to",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "decontaminate the upper gastrointestinal tract do not prevent infectious",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "disease.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "Text" : "Neutropenic fever", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT BACT PROPHYL", "Text" : "Prevention of bacterial infections in a patient with malignancy", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL", "Text" : "Prevention of fungal infections in a patient with malignancy", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Prevention of viral infection in a patient with malignancy", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MALIGNANCY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Malignancies affect host defenses in many ways.Hematogenous malignancies can",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diminish the effectiveness of neutrophils and other cells involved in host",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "defense.Tumors often disrupt mucous membranes or blood vessels and allow",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "contaminating organisms into hollow cavities or the bloodstream.Chemotherapy",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "used to treat these malignancies often impairs mucus membranes and suppresses",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "neutrophil production and function.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Ordinarily, empirical antimicrobials are not indicated for patients with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "malignancy and fever unless they have neutropenia or a specific infectious",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "disease.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MALNUTRITION",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Adequate nutrition is necessary for optimal host defense function.A few days",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "of malnutrition can decrease host defenses, mainly cell-mediated immunity. The",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "degree of compromised immunity increases with the duration of malnutrition.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "However, nutritional replacement has not been shown to improve outcomes in",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "patients with mild-moderate malnutrition.Enteral nutritional replacement is",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "far superior to and safer than intravenous hyperalimentation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobials are not indicated for malnourished patients with fever",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "but without evidence of a specific infectious disease.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM NEUROL DYSFUNCTION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASPIRATION PNEUMONIA", "Text" : "Aspiration pneumonia", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUROLOGICAL DYSFUNCTION",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Several types of neurological dysfunction predispose patients to infectious",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diseases.Comatose patients are unable to keep weight off dependent tissues,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "predisposing them to decubitus ulcers and pressure necrosis.Atelectasis is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "common in obtunded patients who cannot cough or breathe deeply.When patients",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "require artificial ventilation, intubation compounds the risk of respiratory",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "infection.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Neurological dysfunction of the bladder can interfere with normal bladder",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "emptying and predisposes patients to bacteriuria.The risk of bacteruria",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "increases if patients are catheterized.Antimicrobial treatment is not",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "indicated for asymptomatic bacteriuria.It provides no benefit and increases",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "risk of colonization with resistant organisms.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Neurological dysfunction predisposes patients to aspiration of oropharyngeal or",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "gastric contents.Aspiration causes fever, inflammation, and/or pulmonary",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "infiltrate, but does not require antimicrobial treatment. Bacterial pneumonia",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "occurs in a minority of patients who experience significant aspiration,",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "typically about 3 days later.Typically, the patient improves for the first 2",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "days and then worsens as bacterial pneumonia develops with increased fever, new",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "or progressive infiltrates, leukocytosis, and newly purulent sputum.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM NEUT FEVER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND ORAL THERA", "Text" : "If patient IS a candidate for oral therapy", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND NOT ORAL THERA", "Text" : "If patient is NOT a candidate for oral therapy", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER MOD THERAPY", "Text" : "Modification to neutropenic fever therapy", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC FEVER",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The risk of severe, rapidly progressive infections increases when the absolute",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "neutrophil count (ANC, segmented neutrophils plus bands) is less than 500",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cells/microliter.The risk increases dramatically when the ANC is <100",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cells/microliter.Because of these risks, patients with fever and neutropenia",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "to this degree should receive empirical antimicrobial therapy immediately.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empirical therapy should also be given to patients with fever and ANC 500-1000",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "cells/microliter when the concentration is expected to be <500 cells/microliter",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "within the next 48 hours.For this purpose, fever is defined as a single",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "temperature greater than 38.3 degrees Celsius.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Initial therapy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Since infection can be rapidly progressive and severe, broad-spectrum",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "antimicrobials are given urgently to patients with neutropenic fever as defined",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "above.Vancomycin should only be given when there are clear indications for its",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "use.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Candidates for empirical treatment with oral antimicrobials include those who",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "are febrile but who have no evidence of focal infection or signs or symptoms of",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "severe disease, like hypotension.Outpatient antimicrobials for neutropenic",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "fever must be ordered only in consultation with Hematology-Oncology or",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Modifcation to therapy",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Hughes WTClin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sipsas NVCancer 2005, 103: 1103", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients with neutropenia are at risk of infection from pyogenic organisms",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "including Staphylococcus aureus, streptococci, Gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pseudomonas aeruginosa, candida, and certain filamentous fungi, most notably",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Aspergillus and the zygomycetes.The risk is inversely related to the absolute",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "neutrophil count (ANC), the disease or condition associated with neutropenia,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "duration of neutropenia, and the presence of other host defense defects or",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "underlying diseases.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM STRESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STRESS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute psychological stress is associated with immune stimulation and increased",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cellular host defenses.However, chronic stress decrease humoral and cell-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "mediated immunity.Chronic stress has been correlated with increased risk of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "respiratory tract infection.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Critically ill patients are usually profoundly stressed.The risk of infection",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "is subtle and the defects are non-specific.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TOBACCO SMOKE",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Active or passive exposure to tobacco smoke is associated with increased",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "susceptibility to respiratory infectious diseases and several systemic",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "infectious diseases with bacterial and viral pathogens.Compounds found in",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "tobacco or tobacco smoke interfere with several host defense mechanisms in the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "respiratory tract and elsewhere in the body.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU COMM ACQ DIARRHEA", "Text" : "Community acquired diarrhea (no recent travel)", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU TRAVELERS DIARRHEA", "Text" : "Traveler's diarrhea", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX AEROMONAS", "Text" : "Aeromonas", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Adenovirus", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Astrovirus", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU ABX CAMPYLOBACTER", "Text" : "Campylobacter", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZID2 GMENU ABX ASSOC COLITIS", "Text" : "[CLICK HERE] for mild to moderate disease", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID2 GMENU ABX TOXI MEGACOLON", "Text" : "[CLICK HERE] for severe/life-threatening disease (shock, ileus and megacolon)", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU ABX ISOSPORA", "Text" : "Cystoisospora belli", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU ABX CRYPTOSPORIDIA", "Text" : "Cryptosporidium parvum", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU ABX CYCLOSPORA", "Text" : "Cyclospora cayetanensis", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU ABX ENTAMOEBA HISTOLYTICA", "Text" : "Entamoeba histolytica", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID2 GMENU ABX E COLI INFECT", "Text" : "Escherichia coli [CLICK HERE], including varieties listed below:", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU ABX GIARDIA", "Text" : "Giardia duodenalis", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID2 GMENU ABX MICROSPORIDIA", "Text" : "Microsporidia", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Norovirus", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Rotavirus", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID2 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Sapovirus", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU ABX SALMONELLA SPECIES", "Text" : "Salmonella", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID2 GMENU ABX SHIGELLA SPECIES", "Text" : "Shigella", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "ORZID2 GMENU ABX CHOLERA", "Text" : "Vibrio cholerae", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "ORZID2 GMENU ABX NON-CHOLERA", "Text" : "Vibrio non-cholerae", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "ORZID2 GMENU YERSINIA ENTEROCOLITICA", "Text" : "Yersinia enterocolitica", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INFECTIOUS DIARRHEA / GASTROENTERITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most episodes of acute diarrhea are self limited and do not need to be evaluated",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "or treated. In most mild to moderate cases, antimicrobial therapy does not",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "provide benefit and may prolong symptoms or shedding. Antimicrobial therapy is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "detrimental in cases involving enterohemorrhagic Escherichia coli.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "The decision for whether to test stool depends on illness severity and duration,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the likelihood of specific infectious agents and the severity of any underlying",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "diseases. Send stool sample for enteric pathogen PCR testing if the patient has",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "volume depletion warranting hospitalization, bloody stool, >/= 6 stools in 24",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "hours, temperature >38.4 C, or severe abdominal pain or signs of sepsis, or is",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : ">/= 70 years old or substantially immunocompromised. Replace fluid losses and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "correct electrolyte imbalances. Patients with diarrhea who were potentially",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "exposed during a community outbreak of infectious diarrhea should be tested for",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "the suspected bacterial, viral, and parasitic agents regardless of symptom",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "severity.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Obtain blood cultures if patients have signs of septicemia, suspected enteric",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "fever (e.g., fever plus recent travel to an endemic area or contact with someone",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "who has enteric fever), other systemic symptoms, immune compromise, or other",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "high-risk conditions.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "For more information on when an antimicrobial is indicated or if the patient has",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobial treatment of diarrhea",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Treatment of diarrhea caused by specific bacteria, parasites, and viruses",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Clostridium difficile:",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Enteroaggretive E. coli (EAEC), Enterotoxigenic E. coli (ETEC),",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Enterohemorrhagic E. coli (EHEC), Shiga Toxin-producing E. coli (STEC),",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Enteropathogenic E. coli (EPEC), Enteroinvasive E. Coli (EIEC)",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "settings", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h (Cost $$)[R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h (Cost $) [M]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "Text" : "Penicillin G 4 million units IV q4h (Cost $$) [R] <AND> clindamycin 900 mg", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LARGE UNIFORM BACILLI IN AN ANAEROBIC BOTTLE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Large uniform bacilli in an anaerobic bottle usually suggest clostridium, a",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "potentially severe pathogen. Combination therapy is recommended for necrotizing",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "infections as clindamycin has the theoretical benefit of inhibiting toxin",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "production.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of mild to moderate infection",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "For patients with non-severe penicillin allergy",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For patients with severe penicillin allergy",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of severe or necrotizing infection",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "IV q8h (Cost $$) [H,O]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium perfingens",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Stevens et al., Clinical Infectious Diseases 2014 59.2", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 Q8H MERO 2 Q8H LINEZOLID 600 Q12H", "Text" : "Ciprofloxacin 400 mg IV q8h (Cost $) [R,DI] <AND> Meropenem 2 gm IV q8h", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "Text" : "Penicillin 4 million units IV q4H (Cost $$) [R,DI] <AND> clindamycin 900mg", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400MG IV Q8H CLINDA 900MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q8h (Cost $) [R,DI] <AND> clindamycin 900mg IV q8h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LARGE UNIFORM BACILLI IN AN AEROBIC BOTTLE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Large uniform bacilli in an aerobic bottle usually suggest Bacillus species.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Bacillus subtilis is usually a contaminant, Bacillus cereus is uncommon but",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "usually pathogenic. If Bacillus anthracis is suspected or isolated contact",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases immediately.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected non-anthracis Bacillus spp. associated with",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "disease",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected Bacillus anthracis",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Start combination therapy and contact Infectious Diseases immediately.",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If meningitis has not been ruled out",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treat for 6 weeks",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "(Cost $$) [R,O] < AND > linezolid 600 mg IV q12h (Cost $$$$) [DI]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "If meningitis has been ruled out",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Isolate is penicillin-susceptible",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "IV q8h (Cost $$) [H,O]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Isolate is not penicillin susceptible or susceptibility unknown",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "(Cost $$) [H,O]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Hendricks et al., Emerg Infect Dis 2014, 20.2",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT RPT GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h (Cost $$) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "Text" : "Cefepime 2 gm IV q8h (Cost $$) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID AZTREONAM 2GM IV Q8H", "Text" : "Aztreonam 2 gm IV q8h (Cost $$$$) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "Text" : "Gentamicin 5 mg/kg IV q24h (Cost $) [R,O] <AND> piperacillin-tazobactam", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM REPORT OF GRAM-NEGATIVE BACILLI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most Gram-negative bacilli grow in aerobic or anaerobic bottles. Pseudomonas",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "nearly always grows in aerobic bottles. One drug is sufficient to treat Gram-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "negative bacillus bacteremia, unless the patient is critically ill.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Empirical treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Empirical treatment if pseudomonas is suspected",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For patients with non-severe penicillin allergy",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For patients with severe penicillin allergy",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for critically ill patients or resistant organism likely",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "4.5 gm q6h (Cost $$) [R]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pseudomonas aeruginosa",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Gram-negative bacillary bacteremia in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT RPT GNC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h (Cost $$) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h (Cost $) [M]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID AZITH 500MG IV Q24H", "Text" : "Azithromycin 500mg IV q24h (Cost $) [O]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. MENINGITIDIS", "Text" : "NEISSERIA MENINGITIDIS", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN N. GONORRHOEAE", "Text" : "NEISSERIA GONORRHOEAE", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU GRAM-NEG FIN M. CATARRHALIS", "Text" : "MORAXELLA CATARRHALIS", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM REPORT OF GRAM-NEGATIVE COCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Gram-negative cocci may represent meningococci, gonococci, or moraxella. Based",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "on the clinical situation, select from following possibilities:",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Empirical treatment if meningococci are suspected",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Empirical treatment if gonococci, moraxella are suspected or if unknown",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "suspected organism",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For suspected meningococci or gonococci and severe penicillin allergy",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For suspected moraxella and severe penicillin allergy",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Refer to specific organism page when final culture results are available",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Warkowski et al, MMWR Recomm Rep 2015, 64.3",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Neisseria Meningitidis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neisseria Meningitidis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neisseria Gonorrhoeae", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT RPT GPC IN PAIRS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID PENICILLIN 2MU IV Q4H", "Text" : "Penicillin G 2 million units IV q4h (Cost $) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h (Cost $) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h (Cost $$) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A preliminary report of gram-positive cocci in pairs suggests staphylococci,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "streptococci, or enterococci. If the patient is severely ill, is likely",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "colonized with resistant organisms, or if staphylococci or enterococci are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "likely, treat with vancomycin until susceptibility results are known.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Cephalosporins are not active against enterococci or methicillin-resistant",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected streptococci",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "For patients with non-severe penicillin allergy",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "For severe disease, resistance to beta lactams likely or patient with severe",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "penicillin allergy",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected enterococci",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For severe disease, resistance to beta-lactams likely or patient with",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "penicillin allergy",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected staphylococci",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococci",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococci",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococci", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT RPT GPC PAIRS/CLUSTERS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS AND CLUSTERS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "This suggests staphylococci. Empirical therapy should cover methicillin-",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "resistant Staphylococcus aureus. If a susceptible isolate is identified, beta-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "lactam antimicrobials should be used as they are most effective at killing",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "staphylococci. When a final pathogen is identified, treatment depends on which",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "specific bacterium is identified.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected staphylococcus infection",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococci", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT RPT GPC PRS/CHAINS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PENICILLIN 2MU IV Q4H", "Text" : "Penicillin G 2 million units IV q4h (Cost $) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h (Cost $) [M]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h (Cost $$) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS AND CHAINS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If chains are reported, streptococci are likely. If short chains are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "reported, enterococci are likely. Beta-lactam antimicrobials are more effective",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "than vancomycin in killing susceptible streptococci and enterococci, so",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "penicillin or ampicillin should be used if resistance is unlikely.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "If the patient is severely ill or is likely to be colonized with resistant",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "organisms, treat with vancomycin until susceptibility results are known.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected streptococcus infection",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For patients with non-severe penicillin allergy",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For patients with severe-penicillin allergy",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected enterococcal infection",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For patients with severe disease, resistance to beta-lactams is likely or",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "patient with penicillin allergy",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococci",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococci", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT RPT GPR", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG UNIF RDS AEROBIC BOT", "Text" : "LARGE UNIFORM BACILLI in an AEROBIC bottle", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU INT LRG RODS ANAEROBIC BOT", "Text" : "LARGE UNIFORM BACILLI in an ANAEROBIC bottle", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS AEROBIC BOT", "Text" : "SMALL PLEOMORPHIC BACILLI in AEROBIC bottle", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT", "Text" : "SMALL PLEOMORPHIC BACILLI in ANAEROBIC bottle", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM REPORT OF GRAM-POSITIVE BACILLI",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "There are three typical morphologies (1)large and regular, (2)medium sized and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "variable, and (3)small and pleomorphic.The large, uniformly rod-shaped Gram-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "positive bacilli are usually Bacillus spp. (aerobic) or Clostridium species",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "(anaerobic).Bacillus spp. include Bacillus subtilis (usually a contaminant),",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Bacillus cereus, and Bacillus anthracis.Medium-sized Gram-positive bacilli are",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "usually Lactobacilli (anaerobic).Small and pleomorphic bacilli are usually",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Listeria (aerobic), diphtheroids (aerobic), Propionibacteria (anaerobic), and",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Corynebacteria (aerobic).", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT RPT YEAST", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX FUNGUS", "Text" : "Fungi", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 800MG PO ONCE THEN 400MG Q24H", "Text" : "Fluconazole 800 mg PO once then 400 mg PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX FLUCONAZOLE IV 800MG ONCE THEN 400MG Q24H", "Text" : "Fluconazole 800 mg IV once then 400 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID MICAFUNGIN 100MG IV Q24H", "Text" : "Micafungin 100 mg IV q24h ($$$) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM REPORT OF YEAST",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases. If the yeast appear to be or are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "known to be Candida species treat as follows. If other yeasts (e.g.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Cryptococcus, Histoplasma) are suspected, contact Infectious Diseases for",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "treatment advice.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Refer to specific organism for yeasts other than candida",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Most Candida can be treated with fluconazole. If the patient is critically ill",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "or neutropenic or has recently taken an azole antifungal, or if Candida krusei",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "or C. glabrata are suspected, micafungin should be used initially. Removal of",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "central venous catheter is associated with decreased mortality. Call Infectious",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Diseases for advice.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for patients with mild to moderate illness who have no",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "prior azole antifungal therapy",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "For patients who cannot take oral medication",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for critically ill patients, neutropenic patients, patients",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "who have recently taken azole antifungals, or if C. glabrata or C. krusei are",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "suspected",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Andes et al, Clinical Infectious Diseases 2012, 54.8",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Pappas et al, Clinical Infectious Diseases 2016, 62.4e1-50",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT SM RODS AEROBIC BOT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h (Cost $$) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2G Q4H GENT 1.7MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h (Cost $$) [R] and gentamicin 1.7 mg/kg IV q8h (Cost", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "Text" : "Trimethoprim 5 mg/kg - sulfamethoxazole 25 mg/kg IV q12h (Cost $$$) [R,DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SMALL PLEOMORPHIC BACILLI IN AEROBIC BOTTLE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Small pleomorphic bacilli in aerobic bottle are usually diphtheroids. These are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "usually contaminants. Uncommonly such organisms prove to be Listeria",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "monocytogenes, which when present in a blood culture is likely a pathogen.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Listeria is more likely in patients with impaired cell-mediated immunity,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "pregnant women, elderly and patients on immunosuppressive therapy for",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "transplantation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Empirical treatment if there is a strong suspicion of listeria",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "For immunocompromised, meningitis or endocarditis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "$) [R,O]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For patients with penicillin allergy",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empirical treatment if therapy is indicated and listeria is not suspected",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Listeria Monocytogenes",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Other Coryneform Bacteria and Rhodococci",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Listeria monocytogenes",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Propionibacterium acnes",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Corynebacterium", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INT SM RODS ANAEROBIC BOT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h (Cost $$)[R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h (Cost $) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h (Cost $) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SMALL PLEOMORPHIC BACILLI IN AN ANAEROBIC BOTTLE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Small pleomorphic bacilli in anaerobic bottle usually suggest propionibacteria.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "These are often contaminants.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment if therapy is indicated",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For penicillin allergy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "For severe penicillin allergy",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Other Coryneform Bacteria and Rhodococci",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Propionibacterium acnes",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Corynebacterium", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH CANDIDA SPP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU BACTEREMIA CANDIDA SPP.", "Text" : "FUNGEMIA ASSOCIATED WITH CANDIDA SPP.", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED CANDIDA SPP. INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Remove catheter and Consult Infectious Diseases",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Refer to candidemia page for antifungal choice and duration of treatment", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH COAG-NEG STAPH", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFAZO 2GM Q8H CEFAZ ABX LOCK THERAPY", "Text" : "Cefazolin 2 gm IV q8h ($) [R] for <AND> cefazolin antibiotic lock therapy", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG Q12H VANCO ABX LOCK THERAPY", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED COAGULASE-NEGATIVE STAPHYLOCOCCUS INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Catheter removal is optional.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment if the catheter is removed",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treat for 7 days.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Methicillin-susceptible isolate",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For patients with non-severe penicillin allergy",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Methicillin-resistant isolate or alternative for patients with severe",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "penicillin allergy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment if the catheter is retained",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treat concurrently with systemic therapy and antibiotic lock therapy for 10 to",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "14 days.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Methicillin susceptible isolate",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Methicillin resistant isolate or alternative for patients with",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "penicillin/cephalosporin allergy",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Treatment of Intravascular Catheter-Related Infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH ENTEROCOCCUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID LINEZOLID 600MG IV Q12H", "Text" : "Linezolid 600 mg IV q12h ($$$$) [DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID DAPTOMYCIN 8-12MG/KG Q24H", "Text" : "Daptomycin 8-12 mg/kg IV q24h ($$$$) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX AMPICIL 2G Q4H AMPICIL ABX LOCK THERAPY", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] <AND> ampicillin antibiotic lock therapy", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG Q12H VANCO ABX LOCK THERAPY", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> vancomycin antibiotic lock therapy", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED ENTEROCOCCUS INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Remove catheter and treat for 7-14 days for uncomplicated catheter-associated",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "bacteremia. Document that bacteremia clears on therapy. If there is evidence of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "deep-seated infection or endocarditis refer to pertinent sections.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment if the catheter is removed (preferred)",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treat for 7-14 days",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment for ampicillin-resistant isolates or alternative for patients with",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "penicillin allergy",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for ampicillin and vancomycin resistant isolate",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treat for 6 weeks",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treatment if catheter removal is not possible (less desirable)",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Use concurrent systemic AND antibiotic lock therapy, both for 14 days.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treatment for ampicillin resistant isolates or alternative for patients with",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "penicillin allergy",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Treatment for ampicillin and vancomycin resistant isolate",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "If catheter removal is not possible, discuss options with Infectious Diseases",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of intravascular catheter-related infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q8H", "Text" : "Cefepime 2 gm IV q8h ($$) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID AZTREONAM 2GM IV Q8H", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 GM IV Q6H GENT 5MG IV QD", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < AND > Gentamicin 5mg/kg", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 4.5 Q6H GENT ABX LOCK THERAPY", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> gentamicin antibiotic", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED GRAM-NEGATIVE BACILLI INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Adjust initial antibiotics to narrow spectrum when cultures and susceptibility",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "data are available.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment if the catheter is removed (preferred)",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 10 to 14 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with non-severe penicillin allergy",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with severe penicillin allergy",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Critically ill patient or resistant organism likely",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "IV q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treatment if catheter removal is not possible (less desirable)",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Use concurrent systemic AND antibiotic lock therapy, both for 14 days.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "lock therapy",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of intravascular catheter-related infections",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article gram-negative bacillary bacteremia in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INTRAVAS CATH S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED STAPHYLOCOCCUS AUREUS INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Remove catheter and treat for 2 weeks. Duration should be extended to 4 to 6",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "weeks in complicated cases. Document that bacteremia clears on therapy. If",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "there is evidence of deep-seated infection or endocarditis refer to pertinent",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "sections.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consult infectious Diseases in all cases.",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment for methicillin-susceptible isolates",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Methicillin resistant isolate or alternative for patient with severe penicillin",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "allergy",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of intravascular catheter-related infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INTRAVASC CATH-ASSOC INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU APPRO INTRAVAS CATH-ASSOC INFECT", "Text" : "Approach to intravascular catheter-associated infection and antimicrobial", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] <AND> vancomycin 15 mg/kg IV", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 mg/kg IV Q12H GENT 5 MG/KG IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> gentamicin 5 mg/kg q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH COAG-NEG STAPH", "Text" : "Coagulase-negative staph. intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH S. AUREUS", "Text" : "Staphyloccus aureus intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH ENTEROCOCCUS", "Text" : "Enterococcus intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH GNB", "Text" : "Gram-negative Bacilli intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU INTRAVAS CATH CANDIDA SPP", "Text" : "Candida Spp. intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED INFECTION",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "lock therapy",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "When catheter-related bacteremia is suspected, draw blood cultures from both the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "catheter and a peripheral vein. If patient is seriously ill (hypotension,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "hypoperfusion, signs and symptoms of organ failure) remove catheter and culture",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "tip. In patients who are moderately ill (e.g. hypotension, organ failure),",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "remove catheter and culture tip if patient has a prosthetic valve, pacemaker or",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "vascular graft. Start empirical antibiotics while awaiting culture results.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Narrow therapeutic spectrum based on sensitivities of cultured pathogens.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Empirical therapy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Empirical therapy for immunosuppressed patients",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "q12h ($) [R]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "For patients with penicillin allergy",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Pathogen-directed therapy",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections Caused by Percutaneous Intravascular Devices",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mermel et al., Clinical Infectious Diseases 49 (2009)",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Treatment of Intravascular Catheter-Related Infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU INTRO SPEC PATHOGEN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ GTX ABX MANDELL", "Text" : "Mandell's Principles and Practice of Infectious Disease Online Access", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTRODUCTION TO SPECIFIC PATHOGEN SECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "This section gives brief advice on antimicrobial treatment for specific",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pathogens. Colonization by pathogens in most non-sterile sites rarely requires",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy. If there is a question about whether an isolate should",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "be treated, contact Infectious Diseases.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "If culture and susceptibility results are available, use them to select",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy. If culture and susceptibility results are not available,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "use clinical judgment to decide the appropriate spectrum of coverage. If you",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "need advice on a disease or syndrome, return to the main menu and proceed to",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "that disease or syndrome. In most cases, culture and susceptibility results",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "should be used when they become available to select antimicrobials. This",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "section gives the most common drugs to treat most microorganisms. Contact",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases or consult a textbook such as Mandell's Principles and",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Practice of Infectious Disease for more information.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Microbiology results often become available in stages. Interim reports",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "typically indicate the morphology and staining properties of an organism before",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "final identification and susceptibility reports are available. Use an interim",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "report along with the patient's presenting syndrome to refine the empirical",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "therapy regimen pending final results. Use this section to adjust antimicrobial",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "therapy based on an interim report.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU KERATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES KERATITIS", "Text" : "Herpes keratitis", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID MOXIFLOXACIN 0.5% OPTH 1 DROP Q1H", "Text" : "Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) q1h ($) [M]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CEFZ 50MG/ML OPH GENT 15MG/ML OPH Q1H", "Text" : "Cefazolin 50 mg/ml ophthalmic drops: 1-2 drops q1h <AND> gentamicin 15 mg/ml", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "KERATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Keratitis is an emergency requiring prompt treatment to prevent vision loss.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Contact Ophthalmology immediately.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Keratitis is associated with viral or bacterial infection, trauma, foreign",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "bodies, or allergies. About half of cases of infectious keratitis are caused by",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "bacterial pathogens, most commonly Staphylococcus spp., Streptococcus spp., and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "gram-negative bacilli. Viruses are the second leading cause. Fungi and parasites",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "have also been associated with corneal infection. Obtain corneal scrapings for",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "gram stain and bacterial and viral cultures and start empirical therapy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "immediately.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Link to herpes keratitis page",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If bacterial keratitis is likely, contact ophthalmology to obtain a corneal",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "scraping and give empirical antibacterial drops immediately. Modify therapy",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "based on Ophthalmology and/or Infectious Diseases recommendations. Ophthalmic",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "corticosteroids are contraindicated in patients with keratitis.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment should be continued until ulcer and other signs of infectious",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "keratitis have resolved. A minimum of two weeks and in rare cases, up to a month",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "of therapy may be required.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mild to moderate bacterial keratitis empirical treatment",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Severe (vision-threatening) bacterial keratitis empirical treatment",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "ophthalmic drops: 1-2 drops q1h ($) [M] in affected eye(s)",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Suspected MRSA",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Patient may require vancomycin 50mg/mL eye drops q1h in addition to gentamicin",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "eye drops. Vancomycin eye drops must be specially compounded and managed by",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Ophthalmology.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Lin et al., Ophthalmology. 2019,126(1):1-55",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Microbial keratitis",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Keratitis",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article:Complications of contact lenses", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU LEISHMANIASIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LEISHMANIASIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis and treatment are complex.Consult Infectious Diseases and/or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Dermatology in all cases.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU LEUKOCYTOSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LEUKOCYTOSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The majority of leukocytosis cases are due to infection but a sizable minority",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "are associated with physiological stress, inflammation, medications (e.g",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "glucosteroids), and hematological conditions. In a review of 100 cases of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "extreme leukocytosis (more than 25000 leukocytes per microliter with more than",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "50% granulocytes) at the Minneapolis VA, only 48 were from infectious problems.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Infection should be considered as a possible stimulus for leukocytosis in a",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "patient with leukocytosis. Antimicrobials should be administered if the patient",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "has a syndrome or disease that calls for antimicrobials. Antimicrobials should",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "not be administered solely to treat a patient with leukocytosis and no other",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "sign or symptom of infection.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Wanahita et al., Clinical Infectious Diseases (2002), 34.1585-92",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Reding et al., The American Journal of Medicine (1998), 104.12-16", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU LYME ACUTE NEURO DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACUTE NEUROLOGICAL DISEASE ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treat isolated facial palsy (Bell palsy) with oral antimicrobials. Treat more",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "extensive neurological disease with intravenous antimicrobials.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment of isolated facial paresthesia (Bell palsy)",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment of neurological disease other than Bell palsy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 28 days.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Halperin et. al., Neurology (2007) 69.91-102",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU LYME ARTHRITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ARTHRITIS ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases respond to a 28 day course of oral antimicrobials. If symptoms",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "persist or recur, Consult Infectious Diseases or Rheumatology.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU LYME CARDIAC DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CARDIAC DISEASE ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days. Cardiology consult recommended.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment of first degree or second degree heart block",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment of third degree heart block or other manifestation",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU LYME DISEASE PROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX TICK IDENTIFICATION LINK", "Text" : "Ixodes scapularis identification", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX MN TICKBORNE RISK MAP", "Text" : "Tickborne Disease Risk in Minnesota", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 200MG PO ONCE", "Text" : "Doxyclycline PO 200mg once ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LYME DISEASE PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients who have been bitten while in endemic areas of New England, Mid-",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Atlantic States, Minnesota and Wisconsin where local rate of Ixodes scapularis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "tick infection rate with Borrelia burgdorferi is equal to or greater than 20%",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "may be treated with prophylactic antibiotics for prevention of Lyme disease.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Using a wait and see method by monitoring for signs and symptoms of Lyme disease",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "is also an acceptable approach in patients who have been bitten by an Ixodes",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "scapularis tick.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "All following criteria must be met to be considered for prophylactic treatment:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "1. Doxyclycline is not contraindicated (i.e. allergy, pregnant, lactating)",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "2. Attached tick is reliably identified as an adult or nymphal Ixodes",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "scalpularis. Follow link below for identification guide:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "3. Tick is attached for greater than or equal to 36 hours based on degree of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "tick engorgement with blood or likely time of exposure to tick infested area.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "4. Prophylaxis must be started within 72 hours after time tick was removed.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "5. Patient was exposed to tick bite in endemic areas where rate of Ixodes",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "scapularis infection with Borrelia burgdorferi is greater than 20%. Minnesota",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "counties where there is high risk of tickborne disease are shown in the",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "following link:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Providers can call the Minnesota Department of Health (651-201-5414) or the",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Wisconsin Department of Health Services (608-266-1865) for specific rates of B.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "burdorferi infection of ixodes ticks in area where a patient was exposed.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Disease if patient was exposed to an Ixodes scapularis tick",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "bite in New England or Mid-Atlantic States.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Prophylactic treatment if all above criteria are met",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health, Lyme Disease Basics (2017)",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "http://www.health.state.mn.us/divs/idepc/diseases/lyme/basics.html",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Wisconsin Department of Health Services, Tickborne Illness in Wisconsin (2010)",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "bitehttps://www.dhs.wisconsin.gov/tickborne/lyme-training-071210.pdf",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Wisconsin Department of Health Services, Lyme Disease Trends in Wisconsin (2016)",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "https://www.dhs.wisconsin.gov/publications/p01295.pdf", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU LYME ERYTHEMA MIGRANS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ERYTHEMA MIGRANS ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Erythema migrans is the first manifestation of Lyme disease in 70-80% of cases.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "It is typically an erythematous circular rash, 5cm or larger in diameter, with",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "induration and central clearing (although other patterns occur). It usually",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "develops at the site of the bite and/or in one or more distant locations. The",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "rash occurs 3 to 30 days after the bite. Rashes with onset less than 3 days",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "after a tick bite are not from Lyme disease.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU M. AVIUM INTRACELLULARE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU M. AVIUM PNEUMONIA", "Text" : "Treatment for pneumonia", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU DISSEMINATED M. AVIUM", "Text" : "Treatment for disseminated disease", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU PROPHYLAXIS M. AVIUM", "Text" : "Prophylaxis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MYCOBACTERIUM AVIUM INTRACELLULARE (MAI OR MAC)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "MAI colonization in patients with chronic lung disease is common. These",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "patients should not be treated with antimicrobials.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Occasionally, MAI causes pulmonary disease in patients who are not",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "immunosuppressed. Diagnosis and management are complex. Consult Infectious",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diseases and/or Pulmonary.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "MAI causes systemic disease commonly in patients with HIV/AIDS. Most of these",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "cases do not involve the lungs. After treatment, long-term prophylaxis is",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "usually given. Consult Infectious Diseases in all cases.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU M. AVIUM PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CLARITHROMYCIN, ETHAMBUTOL, RIFABUTIN", "Text" : "Clarithromycin 500 mg PO q12h ($) [R,DI] <AND> ethambutol 15 mg/kg PO q24h", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX AZITH 250, ETHAMBUTOL, RIFABUTIN 300", "Text" : "Azithromycin 250 mg PO q24h ($) M <AND> ethambutol 15 mg/kg PO q24h [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MYCOBACTERIUM AVIUM PNEUMONIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis and treatment are complex. Regimens containing 3 or 4 drugs are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "usually recommended, but two drug regimens may be sufficient in some cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases and/or Pulmonary in all cases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treatment is continued until sputum cultures are consecutively negative for 12",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "months.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Three-drug regimens",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "($$) [R] <AND> rifabutin 300 mg PO q24h ($$) [R,DI]",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "<AND> rifabutin 300 mg q24h ($$) [R,DI]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Four-drug regimens may be recommended for advanced (severe) or previously",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "treated disease-Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Mycobacterium avium Complex",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of Mycobacterium avium complex lung infection in",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU M. PNEUMONIAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO BID for 7 to 14 days ($) [DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500 mg PO x 1 ($) on day 1, then 250 mg PO QD ($) for 4 days", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "Text" : "Levofloxacin 500 mg PO q24h for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MYCOPLASMA PNEUMONIAE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Intolerance to doxycycline and azithromycin",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Mycoplasma pneumoniae and Atypical Pneumonia",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mycoplasma pneumoniae",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Mycoplasma pneumoniae infection in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU M. TUBERCULOSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MYCOBACTERIUM TUBERCULOSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Management of tuberculosis is complex. Contact Infectious Diseases and/or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Pulmonary service for more information.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU MALIGNANT OTITIS EXTERNA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "Text" : "Cefepime 2 gm IV q12h for 6 weeks ($$) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q8h for 6 weeks ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "Text" : "Ciprofloxacin 750 mg PO q12h for 6 weeks ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MALIGNANT OTITIS EXTERNA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Those who are elderly, diabetic, immunocompromised and debilitated are at",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "highest risk. Most cases are associated with Pseudomonas aeruginosa, but other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pathogens can be involved. Obtain culture to identify etiologic agent and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "susceptibilities. Obtain a CT scan to determine whether osteomyelitis is",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "present. ENT and Infectious Disease consultations are recommended.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for 6 weeks",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment of early infection or step-down treatment after initial intravenous",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy. Adjust for a total duration of 6 weeks of antimicrobial",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "therapy.",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Evans, Journal of Laryngology and Otology. 2011, 125(12)1212-1217Mandell",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "chapter: Otitis Externa, Otitis Media, and Mastoiditis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mahdyoun et al., Otol Neurotol. 2013, 34(4)620-629",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Otitis Externa",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Malignant (necrotizing) external otitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU MASTOIDITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV Q12H VANCO 15MG/KG Q12H", "Text" : "Vancomycin 15 mg/kg IV q 12 hours ($) [R] < AND > cefepime 2 gm IV q12h ($$) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CEFUROXIME 500MG Q12H", "Text" : "Cefuroxime 500mg PO q12h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN/DEXAMETHASONE OTIC 4 DRPS BID", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 4 weeks ($)", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSJZID NEOMYCIN/POLYMIXIN/HC OTIC 4 DRPS QID", "Text" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MASTOIDITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute Mastoiditis",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Acute mastoiditis most commonly occurs as a suppurative complication of acute",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "otitis media. Diagnosis is supported by CT or MRI imaging and culture of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "drainage. Antibiotics and drainage of middle ear are sufficient treatment in",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "most cases. Mastoidectomy is necessary if abscess has formed in the mastoid",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "bone. If complication of first episode of acute otitis media, etiologies",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "typically include Streptococcus pneumonia (most common), Streptococcus pyogenes,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "or Staphylococcus aureus. If secondary to chronic otitis media, etiologies",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "typically include Staphylococcus aureus or Pseudomonas aeruginosa. Patients",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "usually too ill for outpatient therapy. ENT consultation recommended. Obtain",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "cultures of auditory canal or middle ear fluid (preferred).",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q 12 hours ($) [R] for 7 days",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "for 7 days",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "who can tolerate oral therapy. Base selection on culture results. Adjust for a",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "total duration of 7 days of antimicrobial therapy.",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Chronic Mastoiditis",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Chronic mastoiditis is usually the result of chronic otitis media with",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "perforation of the tympanic membrane. There is often associated formation of a",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "cholesteatoma (keratoma). Diagnosis is supported by CT or MRI imaging and",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "culture of drainage. Long term treatment with topical antimicrobials is first",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "line therapy. Infection is often polymicrobial, including Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Pseudomonas aeruginosa and anaerobes. Treatment should be managed in",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "collaboration with otolaryngology and includes topical antimicrobials, care of",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "external auditory canal, and is some cases mastoidectomy. If possible, withhold",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "therapy until a pathogen is identified by culture of drainage to direct therapy.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Specific drug choice dictated by culture results.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "[M]",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "weeks ($) [M]",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Loh et. al., The Journal of Laryngology & Otology. 2018, 132(2)96-104.",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mastoiditis",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Chronic otitis media, cholesteatoma, and mastoiditis in",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "Contents" : [
{"Row" : 2, "Column" : 1, "Item" : "ORZID2 GMENU SURG PROPHYL GENRL INFO", "Text" : "Surgical prophylaxis general information", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : "ORZID2 GMENU SURG WND CLASS PROPHYL REC", "Text" : "Surgical wound classification and prophylaxis recommendations", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZID2 GMENU SURG TIMING DOSING PROPHYL ABX", "Text" : "Timing of prophylactic antibiotics", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SURG PROPHYLAXIS DOSES AND REDOSING", "Text" : "CHART: Doses and Redosing Interval for NORMAL renal function", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU SURG ANTIBIOTIC RENAL REDOSING", "Text" : "CHART: Redosing Interval for Normal and ESRD renal function", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX SURGICAL PROPHYLAXIS", "Text" : "<Hyperlink> Surgical Antimicrobial Prophylaxis Guidelines 2013", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "Text" : "Inpatient status", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT", "Text" : "Outpatient status", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SURG NEUROSURGERY", "Text" : "Neurosurgery", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU SURG HEAD AND NECK SURG", "Text" : "Head and neck surgery (See Thoracic for esophageal procedures)", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU SURG OPHTHALMIC SURG", "Text" : "Ophthalmology Surgery- Moxifloxacin Intracameral for Cataract Surgery", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDS DELAYED PRE-OP ANTIBIOTICS CV SURGERY2", "Text" : "CV Surgery (open heart)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU SURG CARDIAC SURG", "Text" : "Cardiac Procedures", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED PREOP", "Text" : "Cardiac Implantable Electronic Devices Surgery", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU SURG THORACIC SURGERY", "Text" : "Thoracic surgery (See CV surgery for heart)", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX CARD SURGERY DECOLON", "Text" : "Cardiovascular surgery decolonization", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU SURG GASTRODUODENAL SURG", "Text" : "Gastroduodenal surgery", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU GI ENDOSCOPIC PROCEDURES", "Text" : "GI Endoscopic Procedures", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU SURG VASCULAR SURG", "Text" : "Vascular surgery", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU APPENDICITIS W/O PERFORATION", "Text" : "Appendectomy", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU BILIARY SURGERY", "Text" : "Biliary surgery", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU SURG COLON AND RECTAL SURG", "Text" : "Colon and rectal surgery", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU SURG HERNIA REPAIR", "Text" : "Hernia repair surgery with abdominal mesh", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU SURG GYNECOL SURG", "Text" : "Gynecological surgery", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU SURG UROLOGICAL PROCED", "Text" : "Urological Procedures", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU SURG ORTHO SURG JOINT ARTHRO", "Text" : "Orthopedic surgery,including joint arthroplasty", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU SURG ORTHO ALBC HIP AND KNEE JOINT INFECTIONS", "Text" : "Orthopedic surgery ALBC Joint Infections", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatologic surgery", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU SURG PLASTIC SURGERY", "Text" : "Plastic surgery", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID2 GMENU SURG OTHER PROCEDURES", "Text" : "Other procedures", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "++Surgical Prophylaxis++",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "For the complete guideline follow the link below:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Endocarditis Prophylaxis",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Patients receiving preop antibiotics to prevent an SSI generally",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "do NOT need additional antibiotics for endocarditis prophylaxis.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Surgical Prophylaxis Specific Surgeries",  "Header" : 1}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "__Oral Medications and Nasal Spray__",  "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "Do NOT use Delayed Orders",  "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "Go to Surgery Outpt Orders",  "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "then56 Pre Op Clinic Medications",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU SURG SPINAL CORD STIMULATOR TRIAL", "Text" : "Pain Clinic-Spinal Cord Stim Trial", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU SURG PODIATRY", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU MILD TO MOD SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 5 days", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 5 days", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 5 days", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID LEVOFLOXACIN 750MG PO Q24H", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MILD TO MODERATE SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pneumoniae, Haemophilus influenzae or Moraxella catarrhalis. Streptococci,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus and anaerobes are isolated less frequently.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment for first 10 days of illness",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat with decongestants, analgesics, and nasal saline spray.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment of cases that have not improved in 10 days despite",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "treatment with decongestants, analgesics, and nasal saline.",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternatives:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment Failure",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If symptoms worsen despite 72 hours orfail to improve after 3-5 days of",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "initial empirical antimicrobial therapy, broaden coverage, switch to different",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "antimicrobial class and treat 7-10 days. If symptoms continue to worsen or there",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "is no improvement after 3-5 more days of treatment, obtain CT to investigate",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "non-infectious or suppurative causes. ENT consultation is recommended. If",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "sinuses are aspirated, specimens should be cultured.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU MORE ABOUT CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ERYSIPELAS", "Text" : "Erysipelas", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU FOOT ULCER WITH DM", "Text" : "Foot ulcer in patient with diabetes mellitus", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "THE APPROACH TO CELLULITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In addition to antimicrobial therapy, several non-pharmacological treatments",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "improve the outcome of cellulitis. Elevation and immobilization of the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "affected limb reduces swelling.Heat reduces discomfort.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Prevent tinea pedis infection by keeping feet clean and dry.In patients with",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "peripheral edema, good skin hygiene and support stockings reduce the incidence",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "of recurrent infection.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "In many cases of cellulitis, the affected area is usually not well-",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "differeniated from unaffected areas of the skin. Erysipelas is a special case",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "with typically a well-defined border and raised, orange-peel appearance.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Use broad-spectrum therapy for cellulitis arising in feet of patients with",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "advanced diabetes.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Schwartz MN New Eng J Med 2004, 350: 904",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cellulitis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU MORE ABOUT PHARYNGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MORE ABOUT PHARYNGITIS/ TONSILLITIS AND THE MODIFIED CENTOR SCORE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "As most cases are of viral origin, antimicrobials are not indicated in these",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cases. Warm saltwater gargle rinses and throat lozenges provide temporary relief",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "of throat pain. Five to 10% of cases are caused by group A Streptococcus.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment reduces symptoms by one day, prevents suppurative",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "complications and prevents acute rheumatic fever, an uncommon disease in US",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "adults.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Streptococcal pharyngitis or tonsillitis should be suspected when patients have",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "fever and exudate on the pharyngeal wall or tonsils without symptoms like cough,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "nasal congestion, or runny nose that suggest viral infection or common cold. If",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "streptococcal pharyngitis is suspected in adults, perform PCR testing for group",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "A streptococci and treat only if positive.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Neisseria gonorrhoeae is a rare cause of pharyngitis. N. gonorrhoeae should be",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "considered for patients with risk factors for sexually transmitted diseases. N.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "gonorrhoeae infections must be reported to the state health department and this",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "will be done by Infection Control if the culture is positive.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "The Modified Centor score",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Used to estimate the likelihood that a patient with sore throat has",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "streptococcal pharyngitis and whether rapid PCR testing should be performed.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "1) Absence of cough = 1 point",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "2) Swollen and tender anterior cervical nodes = 1 point",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "3) Temperature greater than 100.4 degrees Fahrenheit (38 degrees Centigrade) = 1",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "point",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "4) Tonsillar exudates or swelling = 1 point",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "5) Age: 3-14 years = 1 point",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "15-44 years = 0 points",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "45 years and older = -1 point",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Patients with a score of 0 or 1 are at very low risk. PCR testing and antibiotic",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "treatment are not indicated. Patients with a score of 2 to 4 are at moderate to",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "high risk. PCR testing should be obtained in these patients to determine if GAS",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "is present. In patients with a score of 4 or greater, consider empiric",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "antibiotic treatment.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Pharyngitis",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcal Pharyngitis",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NECROT INFECT DIRECT THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "Text" : "Penicillin 4 million units IV q4h ($) [R] <AND> clindamycin 900 mg", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 900MG IV Q8H", "Text" : "Clindamycin 900 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "Text" : "Penicillin 4 million units IV q4h ($) [R] <AND> clindamycin 900 mg", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 900MG IV Q8H", "Text" : "Clindamycin 900 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375 CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> clindamycin 900 mg", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX CEFT CLINDA 900MG IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> clindamycin 900 mg IV q8h", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 1 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> clindamycin 900 mg IV", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX GENT 5MG/KG CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O] <AND> clindamycin 900 mg IV q8h", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "NECROTIZING INFECTIONS--PATHOGEN-DIRECTED THERAPY",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Clostridial infections",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "IV q8h ($$) [H,O]",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "_______________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Group A Streptococcal infections (S. pyogenes)",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "_______________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "IV q8h ($$) [H,O]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "______________________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Polymicrobial infections",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "______________________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "These are more common in injection drug users, or in patients who have had",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "recent abdominal surgery or trauma, vulvo-vaginal infection, or genital or",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "rectal abscess.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Preferred Treatment:",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "IV q8h ($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R] < OR >",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Alternatives for penicillin allergy",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "q8h ($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]< OR >",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gas gangrene",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NECROT INFECT EMP THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZO 3.375 CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> clindamycin 900 mg", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX CEFT CLINDA 900MG IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> clindamycin 900 mg IV q8h ($$)", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 1GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 1gm IV q8h ($$) <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> clindamycin 900 mg IV", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX GENT 5MG/KG CLINDA 900 VANCO 15MG/KG IV Q12H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O] <AND> clindamycin 900 mg IV q8h", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "EMPIRICAL THERAPY FOR NECROTIZING INFECTIONS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Preferred treatment:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "IV q8h ($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "($$) [H,O] <AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternatives for penicillin allergy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "q8h ($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "($$) [H,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gas gangrene",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NECROTIZING INFECTIONS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU NECROT INFECT EMP THERAPY", "Text" : "Empirical therapy of necrotizing infections", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU NECROT INFECT DIRECT THERAPY", "Text" : "Pathogen-directed therapy of necrotizing infections", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NECROTIZING INFECTIONS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Call Surgery immediately and consult Infectious Diseases in all cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Necrotizing infections involve tissues skin and/or deeper structures, including",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "fascia and muscle.These infections destroy tissue, often rapidly, and are",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "often fatal if not treated promptly and appropriately.Necrotizing infections",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "usually result from trauma, surgery, and/or ischemia.These infections can be",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "monomicrobial (e.g., with streptococci or clostridia) or polymicrobial (usually",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "with a mixture of aerobes and anaerobes).Fournier gangrene is usually",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "associated with mixed infection.Myonecrosis is most commonly associated with",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Clostridium species.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Necrotizing infections differ from cellulitis in several ways.Necrotic",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "infections typically have one or more of the following: (1) severe, constant",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "pain, (2) bullae, (3) bruising or necrosis of overlying skin, (4) gas in tissues",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "which can be felt or seen on images, (5) edema that extends beyond areas of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "erythema, (6) local anesthesia, and (7) signs of systemic toxicity, such as",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "fever, leukocytosis, delirium, or renal failure.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Necrotizing infections must be treated with both antimicrobial therapy and",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "surgical procedures (excision and/or drainage).Call surgery to see the patient",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "immediately in all cases.Obtain tissue and blood cultures and begin empirical",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "antimicrobials.For several necrotic diseases and/or pathogens, a combination",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "of two antimicrobials is recommended including a bactericidal antimicrobial",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "active at the cell wall or membrane (e.g., beta-lactam or glycopeptide) and an",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "antimicrobial that rapidly inhibits protein synthesis and thus inhibits toxin",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "production, typically clindamycin.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Repeat debridement should be performed daily until no further debridement is",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "necessary. Antibiotic therapy should be tailored as soon as culture results",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "become available.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Administer antibiotics until further debridement is no longer necessary, the",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "patient has improved clinically, and fever has been absent for 48-72 hours.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobials",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Pathogen-directed treatment regimens",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gas gangrene",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER CAND NOT ORAL THERA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU EMP INTRAV W/O VANCO", "Text" : "Empirical intravenous regimens WITHOUT vancomycin", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU EMP INTRAV W/ VANCO", "Text" : "Empirical intravenous regimens WITH vancomycin", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC FEVER--PATIENT IS NOT A CANDIDATE FOR ORAL THERAPY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Vancomycin is not recommended as a standard part of the initial antibiotic",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "regimen.Consider adding Vancomycin for specific clinical indications:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : ">>Suspected catheter-related infection,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : ">>Skin or soft-tissue infection,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : ">>Pneumonia,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : ">>Hemodynamic instability",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sipsas NVCancer 2005, 103: 1103", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER CAND ORAL THERA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 500MG Q12H AMOX-CLAV 875/125 Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] <AND> amoxicillin-clavulanate", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX CIPROFLOX 500MG PO BID CLINDAMYCIN 300MG PO Q6H", "Text" : "Ciprofloxacin 500mg PO q12h ($) [R,DI] <AND> Clindamycin 300mg po q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC FEVER--PATIENT IS A CANDIDATE FOR ORAL THERAPY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Can the patient be treated with oral therapy?",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "875/125 mg PO q12h ($) [R]",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Freifeld AG Clinical Infectious Disease 2011, 52: 427-431",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Taplitz RA, J Clin Oncol 2018, 36: 1443-1453",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanford: Neutropenia, Febrile, Low-Risk",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Related Infections. Version 1.2019. nccn.org", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER MOD THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER PT BECOME AFEBRILE", "Text" : "Patients who BECOME AFEBRILE in the first 3 to 5 days of treatment", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER PT FEVER PERSISTS", "Text" : "Patients whose FEVER PERSISTS throughout the first 3 to 5 days of treatment", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MODIFICATION TO NEUTROPENIC FEVER THERAPY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Determine efficacy of the initial regimen during the first 3 to 5 days.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Decisions about therapy should be made based on (1) whether an infectious",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease has been diagnosed (e.g., pneumonia or cellulitis), (2) whether the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "fever has resolved, and (3) the clinical course.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "If a specific infectious disease and/or pathogen is identified, ensure that the",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobial regimen is adequate to treat that pathogen or disease, and",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "continue broad-spectrum antimicrobial therapy.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "(www.journals.uchicago.edu/doi/pdf/10.1086/339215)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sipsas NVCancer 2005, 103: 1103", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER PT BECOME AFEBRILE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "Text" : "Scoring tool to identify low risk febrile neutropenic patients", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 500MG Q12H AMOX-CLAV 875/125 Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h($0.18/day) [R,DI] <AND> amoxicillin-", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PATIENTS WITH NEUTROPENIC FEVER WHO BECOME AFEBRILE IN THE FIRST 3 TO 5 DAYS OF",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "TREATMENT",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : ">>Treatment if an INFECTIOUS CAUSE WAS IDENTIFIED and has resolved",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(The infectious disease associated with the fever has resolved, the pathogen has",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "been controlled or eradicated, and the patient seems well)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Stop antimicrobials after treatment for pathogen/disease is completed, often",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "after 7 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : ">>Treatment if infectious cause of fever WAS NOT identified",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "To determine a patients risk level refer to",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment for low risk patients",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Consider a change to oral therapy",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "clavulanate 875/125 mg PO q12h($1.56/day) [R]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment for high risk patients",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Continue same antimicrobials for 7 days",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sipsas NVCancer 2005, 103: 1103", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER PT FEVER PERSISTS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PATIENTS WITH NEUTROPENIC FEVER WHOSE FEVER PERSISTS THROUGHOUT THE FIRST 3 TO 5",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "DAYS OF TREATMENT",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "If no infectious disease has been diagnosed but the patient is clinically",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "stable, continue the current regimen.If vancomycin was part of initial therapy",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "but culture results have not yielded a pathogen that must be treated with",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "vancomycin, discontinue it to minimize development of resistance.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Consider adding amphotericin B for empirical antifungal therapy.Hematology-",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "oncology or Infectious Diseases may recommend another antifungal like",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "micafungin or voriconazole.Contact Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "If the patient is receiving prophylactic fluconazole, stop it when empirical",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "antifungals are started.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Rolston KVIClin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sipsas NVCancer 2005, 103: 1103",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX AMPHOTERICIN LIPOSOMAL+FLUID+FLUSH ORDERS", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "MASCC RISK INDEX FOR FEBRILE NEUTROPENIA",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SCORING TOOL TO IDENTIFY LOW RISK FEBRILE NEUTROPENIC PATIENTS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients with minimal risk of severe or rapidly progressive infection can be",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "treated with oral antimicrobials safely.Many can be treated as outpatients.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Use the scoring index to identify febrile neutropenic patients who at",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "sufficiently low risk for severe infections and can be treated with outpatient",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "oral antimicrobials.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "SCORING INDEX",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "CharacteristicScore",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Severity of symptoms of illness (choose one only)",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "No symptoms or mild symptoms 5",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Moderate symptoms3",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "No hypotension 5",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "No chronic obstructive pulmonary disease4",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Solid tumor or no previous fungal infection4",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "No dehydration 3",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Outpatient status at onset of fever3",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Age less than 60 years2",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sum total __",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Interpretation",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "The highest possible score is 26. A risk index score of 21 or greater indicates",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "that the patient is likely to be at LOW RISK for complications and morbidity.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "This is a guide.Always use clinical judgement.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Klastersky, J Clin Oncol 2000, 18: 3038", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU NOSOCOMIAL SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "Text" : "Cefepime 2 gm IV q12h ($$) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "< ADD > Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Nasogastric tubes increase the risk of bacterial sinus infection associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus, streptococcus, and gram-negative bacilli, including",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pseudomonas aeruginosa. Aspirate sinuses for gram stain and culture to direct",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy. Adequate sinus drainage is vital to treatment.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobial treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "MRSA suggestive on gram-stain",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Intubation Associated",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Complications of the endotracheal tube following initial",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "placement: Prevention and management in adult intensive care unit patients", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU OSTEOM EMPIRICAL THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID TMP/SULFA 1DS TABLET PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "Text" : "Levofloxacin 500 mg PO q24h ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX LEVOFLOXACIN 500MG PO Q24H RIFAMPIN 600 MG PO Q24H", "Text" : "Levofloxacin 500mg po q24h ($) [R] <AND> Rifampin 600 mg po", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CEFT 2GM IV Q24H VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ3.375GM(NE-EXTINF,CI-CEFEP/METRO)VANC15MG/KG", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R] <AND> vancomycin", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMPIRICAL THERAPY FOR OSTEOMYELITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Therapy should be modified when culture results and patient response to therapy",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "are known.If cultures cannot be obtained, the oral regimens listed below can",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "be used for empirical therapy or to complete a treatment course after the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "patient's disease has improved. Consult Infectious Diseases for more",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Duration of treatment 4 to 6 weeks.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "ORAL treatment for MILD disease or for completion of treatment course",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "q24h ($) [DI,O]",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "INTRAVENOUS treatment for MODERATE to SEVERE disease",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford: key term: Osteomyelitis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Calhoun JH Infect Dis Clin North AM 2005, 19:765",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:393", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU OSTEOM WITH GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]< OR >", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]< OR >", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS WITH GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Osteomyelitis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Lew DP Lancet 2004, 364: 369",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU OSTEOM WITH P. AERUGINOSA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS WITH PSEUDOMONAS AERUGINOSA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Osteomyelitis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Lew DP Lancet 2004, 364: 369",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID CIPROFLOX 400MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI] <OR>", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacilin-tazobactam 4.5 gm IV q6h ($$) [R]<OR>", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU OSTEOM WITH STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID TMP/SULFA 1DS TABLET PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS WITH STREPTOCOCCI",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Osteomyelitis",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Lew DP Lancet 2004, 364: 369",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU OSTEOMYELITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOM EMPIRICAL THERAPY", "Text" : "Empirical therapy for osteomyelitis", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOMYELITIS WITH S. AUREUS", "Text" : "Osteomyelitis with Staphylococcus aureus", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOM WITH STREPTOCOCCI", "Text" : "Osteomyelitis with Streptococci", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOM WITH GNB", "Text" : "Osteomyelitis with Gram negative bacilli (other than Pseudomonas)", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU OSTEOM WITH P. AERUGINOSA", "Text" : "Osteomyelitis with Pseudomonas aeruginosa", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "Text" : "Infections in bone or joint prostheses", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDIASTINITIS", "Text" : "Mediastinitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In acute osteomyelitis, symptoms have been present for several days to weeks.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Chronic osteomyelitis is characterized by a longer duration of symptoms,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "sometimes months or years, and often dead, necrotic bone is present.There is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "considerable overlap between the syndromes of acute and chronic osteomyelitis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Symptom duration may be unreliable in a patient with neuropathy.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Obtain material for gram stain and culture before initiating antimicrobials.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Blood and bone cultures are ideal.Sinus tracts are often colonized with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "multiple species and usually only one or two are pathogens in bone.If",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is present, it is likely to be a pathogen in bone.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobial therapy is the same for acute and chronic osteomyelitis,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "but necrotic bone must often be removed for cure of chronic osteomyelitis.If",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "complete debridement is not possible, long-term suppressive antimicrobials may",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "be needed.Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "The most important pathogens are S. aureus and streptococci.Gram negative",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "bacilli are common pathogens in osteomyelitis associated with diabetic foot",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "infection.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Duration of treatment and route will vary with differences in location of",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "infection, infecting organism, and host comorbidities.In general treat",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "for 4 to 6 weeks.For difficult location (e.g. spine) or difficult bacteria",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "(e.g. staphylococcus, pseudomonas) give intravenous therapy for 4 to 6 weeks.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "For moderate cases, give intravenous therapy for 1 to 2 weeks followed",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "by oral therapy for the balance of 4 to 6 weeks.For mild cases, start with",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "intravenous therapy for only a few days followed by oral therapy for the",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "balance of 4 to 6 weeks.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Empirical treatment regimens",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Pathogen-directed treatment regimens",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Recommend Orthopedic, Neurosurgery (for spine or skull osteomyelitis), Podiatry",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "(for foot infections), and Infectious Diseases consults.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Treat for 4 to 6 weeks.Do not place a long-term intravascular access device",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "(e.g. a PICC line) until it is clear the patient will need long-term intravenous",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "therapy.Consult Infectious Diseases or Orthopedic Surgery for more",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : ">>For patients with infections associated with prosthetic materials see",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : ">>For patients with sternal infection associated with chest surgery see",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Disease 2012, 54:393", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU OSTEOMYELITIS WITH S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($) [DI] < OR >", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID TMP/SULFA 1DS TABLET PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID TMP/SULFA 1DS TABLET PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS WITH STAPHYLOCOCCUS AUREUS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Methicillin-SUSCEPTIBLE S. aureus",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Methicillin-RESISTANT S. aureus",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Osteomyelitis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Spellberg B Clin Infect Dis 2012, 54:393",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Calhoun JH Infect Dis Clin North Am 2005,19:765", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU OTHER PATHOGENS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU EHRLICHIA CHAFFEENSIS", "Text" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ANAPLASMA PHATOCYTOPHILUM", "Text" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "Text" : "Lyme disease", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU M. TUBERCULOSIS", "Text" : "Mycobacterium tuberculosis", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU M. AVIUM INTRACELLULARE", "Text" : "Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU M. PNEUMONIAE", "Text" : "Mycoplasma pneumonia", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "Pneumocystis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ OTHER PATHOGENS ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "into site, and whether organism is pathogen, colonizer, or",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "contaminant. See disease/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Coxiella and Ehrlichia",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Lyme Disease",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mycobacteria",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mycoplasma",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Pneumocystis infection",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Last reviewed 8/2018", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU OTITIS EXTERNA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Furuncles and Carbuncles", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID NEOMYCIN/POLYMIXIN/HC OTIC 4 DRPS QID", "Text" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN/DEXAMETHASONE OTIC 4 DRPS BID", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 7 days ($)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID CIPROFL 500MG PO Q12H", "Text" : "< ADD > ciprofloxacin 500 mg PO q12h for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OTITIS EXTERNA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute Localized Disease",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Often due to furunculosis and usually associated with Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treat mild cases with moist local heat. For cases with cellulitis or deep",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "invasion, incision and drainage as well as systemic antibiotics may be needed.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Refer to the Furuncles and Carbuncles page for antibiotic recommendations.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Acute diffuse and chronic otitis externa",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Most commonly associated with Pseudomonas aeruginosa, Staphylococcus aureus and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Staphylococcus epidermidis. Irrigate to remove cerumen, desquamated skin and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "purulent material which can improve effectiveness of topical antibiotics. Avoid",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "products that contain neomycin if the tympanic membrane is perforated.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred treatment if tympanic membrane is intact",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative if tympanic membrane is perforated or allergy to preferred treatmen",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "[M]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Complicated Cases",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "For cases resistant to topical therapy alone, patients with poorly controlled",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "diabetes mellitus, immunocompromised patients, cases where infection has spread",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "beyond ear canal and in those where topical therapy cannot be delivered",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "effectively. Culture secretions to guide therapy.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "In addition to topical therapy above",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al., Otolaryngology-Head and Neck Surgery. 2014, 150(2)161-168",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Otitis Externa",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: External otitis: Treatment", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU OTITIS MEDIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 1000MG PO Q8H", "Text" : "Amoxicillin 1000 mg PO q8h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "Text" : "Cefdinir 300 mg PO q12h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "Text" : "Cefpodoxime 200 mg PO BID for 10 days ($$) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OTITIS MEDIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the most common bacteria to cause otitis media.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Patient has NOT received antibiotics in the prior month",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Patient has received antibiotics in the prior month",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternatives",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Harmes et al, American Family Physician. 2013, 88(7)435-440",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Otitis media",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Online: Acute otitis media in adults", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PARASITES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU BABESIA SPP.", "Text" : "Babesia spp.", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU INFECT DIARRHEA/GASTRO", "Text" : "Diarrhea, parasitic", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "Pneumocystis", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU TOXOPLASMA SPP.", "Text" : "Toxoplasma", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ PARASITES ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "into site, and whether organism is pathogen, colonizer, or contaminant. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Last reviewed 8/2018", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PARONYCHIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID CLOTRIM 1% CREAM TOPICAL QDAY", "Text" : "Clotrimazole 1% apply to affected area once daily ($) [M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID NYSTATIN CREAM BID", "Text" : "Nystatin Cream to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX HERPES WHITLOW", "Text" : "Link to Herpes whitlow", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PARONYCHIA",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Cutaneous infection of the hand, cuticle or fingers usually occurring near OR",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "around the nail.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment depends on etiology.Candida spp. are commonly involved when the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "patient has extensive exposure to water (e.g. dishwashers).Staphylococcus",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "aureus is more commonly after manicures or nail biting.Herpes simplex",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "(whitlow) usually follows exposure to oral mucosa (e.g. wrestlers, dentists, or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "anesthetists).",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment for paronychia associated with Candida",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment for paronychia associated with Staphylococcus",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Treatment for paronychia associated with Herpes whitlow",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: paronychia", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID PD CEFAZOLIN 15MG/KG Q24H LOW MAG 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID PD CEFAZOLIN 15MG/KG Q24H HEP LOW MAG 2.5%", "Text" : "[Click Here] to order WITH heparin", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CEFAZOLIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cefazolin 15 mg/kg PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PD CEFAZOLIN 15MG/KG Q24H AND GENT 0.6MG/KG Q24H", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID PD CEFAZ 1GM Q24H GENT Q24H LOW MAG 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID PD CEFAZ 1GM Q24H GENT Q24H HEP LOW MAG 2.5%", "Text" : "[Click Here] to order WITH heparin", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CEFAZOLIN AND GENTAMICIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cefazolin 15 mg/kg PD q24h and gentamicin 0.6 mg/kg PD q24h in 2000 mL",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "2.5% dextrose diaslyate solution (low mag)",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PD CEFEPIME 1 GM Q24H", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID PD CEFEPIME 1GM Q24H LOW MAG 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID PD CEFEPIME 1GM Q24H HEP LOW MAG 2.5%", "Text" : "[Click Here] to order WITH heparin", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CEFIPIME",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cefepime 1 gm PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PD CEFEPIME 1GM Q24H VANCO 15-30MG/KG Q5-7D", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "ORZ SET ABX PD CEFEPIME AND VANCO LOW MAG 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX PD CEFEPIME AND VANCO HEP LOW MAG 2.5%", "Text" : "[Click Here] to order WITH heparin", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CEFIPIME AND VANCOMYCIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cefepime 1 gm PD q24h and vancomycin 30 mg/kg PD loading dose followed by 15",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "mg/kg PD every 3 to 7 days in 2000 mL 2.5% dextrose diaslyate solution (low mag)",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PD CEFTAZIDIME 1GM Q24H", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID PD CEFTAZIDIME 1GM Q24H LOW MAG 2.5%", "Text" : "Low Mag 2.5%", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID PD CEFTAZIDIME 1GM Q24H HEP LOW MAG 2.5%", "Text" : "Low Mag 2.5% with heparin 1000 units daily", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CEFTAZIDIME",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Ceftazidime 1 gm PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PD CEFTRIAXONE 1GM Q24H", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID PD CEFTRIAXONE 1GM Q24H LOW MAG 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID PD CEFTRIAXONE 1GM Q24H HEP LOW MAG 2.5%", "Text" : "[Click Here] to order WITH heparin", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CEFTRIAXONE",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Ceftriaxone 1 gm PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low mag)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PD GENTAMICIN 0.6MG/KG Q24H", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID PD GENT 0.6MG/KG Q24H LOW MAG 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID PD GENT 0.6MG/KG Q24H HEP LOW MAG 2.5%", "Text" : "[Click Here] to order WITH heparin", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "GENTAMICIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Gentamicin 0.6 mg/kg PD q24h in 2000 mL 2.5% dextrose diaslyate solution (low ma",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "ORZ SET ABX PD VANCO 30MG/KG-15MG/KG Q5-7D LOW MAG 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX PD VANCO 30MG/KG-15MG/KG Q5-7D HEP LOW MAG 2.5%", "Text" : "[Click Here] to order WITH heparin", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "VANCOMYCIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Vancomycin 30 mg/kg PD loading dose followed by 15 mg/kg PD every 3 to 7 days",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "in 2000 mL 2.5% dextrose diaslyate solution (low mag)",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PD VANCO 15-30MG/KG Q5-7D AND GENT 0.6MG/KG Q24H", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX PD VANCO AND GENTAMICIN LOW MAG 2.5%", "Text" : "[Click Here] to order WITHOUT heparin", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX PD VANCO AND GENTAMICIN HEP LOW MAG 2.5%", "Text" : "[Click Here] to order WITH heparin", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "VANCOMYCIN AND GENTAMICIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Vancomycin 30 mg/kg PD loading dose followed by 15 mg/kg PD every 3 to 7 days",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "and gentamicin 0.6 mg/kg PD q24h in 2000 mL 2.5% dextrose diaslyate solution",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(low mag)",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU PERIOCULAR INFECTIONS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERIOCULAR INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Eyelid infections",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Patients with moderate or severe eyelid infections should be referred to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "ophthalmology.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Blepharitis",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Wash margins with baby shampoo daily and use warm compresses daily.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antimicrobials have no benefit.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Hordeolum (stye)",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For external disease (involving the gland of Zeis), daily hot pack massage",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "encourages drainage and relieves symptoms. For internal disease (involving",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Meibomian glands) ophthalmology consult is encouraged, as the infection seldom",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "drains without intervention.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Lacrimal infections",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Refer cases of lacrimal infection to ophthalmology, including infections of the",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "lacrimal gland (dacryoadenitis), lacrimal sac (dacrocystitis), or tear ducts",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(canaliculitis).",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Periocular infections",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Blepharitis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Eyelid lesions",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Blepharitis",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Hordeolum, Stye", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PERIODENTAL DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CHLORHEXIDINE 0.12% ORAL SWISH BID", "Text" : "Chlorhexidine 0.12% oral rinse swish for 30 seconds, then spit 15 ml twice", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERIODONTAL DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Periodontal disease, including gingivitis and periodontitis, may progress into",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "more severe disease or cause hematogenous spreading of bacteria if left",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "untreated. All patients with periodontal disease should be referred to the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "dental service for assessment and direction of treatment. In the presence of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "gingivitis, the most commonly isolated subgingival flora includes Prevotella",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "intermedia, Capnocytophaga spp, Finegoldia magna and Peptostreptococcus. In the",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "presence of periodontitis, flora increases in complexity to most commonly",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "include Porphyromonas gingivalis, P. intermedia, Aggregatibacter",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "actinomycetemcomitans, Tanneralla forsythensis and Treponema denticola.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consult Dental Service",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Non-severe periodontitis or acute simple gingivitis treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "daily for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Severe periodontitis or acute complicated gingivitis (ulceration, rapidly",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "advancing disease, severe pain, patients with immunocompromising conditions)",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "treatment",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Consult Dental Service",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Infections of the Oral Cavity, Neck and Head",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Complications, diagnosis, and treatment of odontogenic",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "infections",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of gingivitis and periodontitis in adults",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Vincent's Angina",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Slots et al., Periodontology. 2002, 28(1)106-176",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Tonetti et al., Journal of Periodontology, 2018, 89 S159-S172.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PNEUMOCYSTIS JIROVECII", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX PNEUMOCYSTIS JIROVECII PROPHYLAXIS", "Text" : "[CLICK HERE]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJZID TMP/SMX 2DS TAB PO Q8H", "Text" : "Trimethoprim-sulfamethoxazole 2 DS tablets PO q8h for 21 days ($)[R,DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX TRIMETHOPRIM 5 MG/KG DAPSONE 100MG PO QD", "Text" : "Trimethoprim-sulfamethoxazole 5mg/kg PO q8h ($)[R,DI] <AND> dapsone 100mg", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 450MG Q6H PRIMAQUINE 26.3MG QD", "Text" : "Clindamycin 450mg PO q6h ($)[H,O] <AND> Primaquine 26.3 mg PO QDay ($)[DI]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID ATOVAQUONE 750MG PO BID", "Text" : "Atovaquone 750mg PO BID for 21 days ($$)[DI]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID TRIMETH/SULFA 5/25 MG/KG IV Q8H", "Text" : "Trimethoprim 5mg/kg - sulfamethoxazole 25MG/KG IV q8h for 21 days", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 600 IV Q6H PRIMAQUINE 26.3MG QD", "Text" : "Clindamycin 600mg IV q6h ($$)[H,O] <AND> primaquine 26.3mg PO QD ($)[DI]", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSJZID PREDNISONE 40MG PO BID THEN 40 6DAYS THEN 20 10 DAYS", "Text" : "Prednisone 40mg PO twice daily for 5 days, then 40mg PO daily for 6 days,", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PNEUMOCYSTIS JIROVECII DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis and treatment are complex, consult Infectious Diseases in all cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pneumocystis jirovecii (formerly termed Pneumocystis carinii) in an ubiquitious",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "organism that causes disease in people with compromised cell-mediated immunity.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Disease is exceedingly rare in people with intact host defenses. Pneumonia is",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "the usual manifestation but P. jirovecii can infect extrapulmonary sites,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "especially in patients who have been receiving prophylaxis with aerosolized",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "pentanmidine. P. jirovecii disease occurs most commonly in people with AIDS and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "fewer than 200 CD4 T lymphocytes/microliter.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "The abbreviation PCP is often used for Pneumocystis pneumonia. It was derived",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "from the old species name, Pneumocystis carinii.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Trimethoprim-sulfamethoxazole (TMP-SMZ) is the treatment of choice for P.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "jirovecii disease, including disease that occurs despite TMP-SMZ prophylaxis.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Corticosteriods should be prescribed for patients with AIDS and P. jirovecii",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "pneumonia and an arterial oxygen tension <70 torr or an alveolar-arterial oxygen",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "gradient of >35 torr.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for mild to moderate disease or step-down treatment once",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "disease has stabilized",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "PO QDay ($)[DI] for 21 days",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "for 21 days",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for severe disease",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "($$)[R,DI]",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "for 21 days",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Requires ID Approval: Pentamidine 4mg/kg IV q24h ($$$)[DI]",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Prednisone for patient WITH AIDS",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "then 20 mg daily for 10 days.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Mandell Chapter Management of Opportunistic Infections",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Associated with Human Immunodeficiency Virus Infection",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: pneumocystis pneumonia, Adult",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of Pneumocystis infection in HIV-",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "infected patients",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Pneumocystis jirovecii", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED POSTOP", "Text" : "CIED Surgery Post-op Prophylaxis", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU SURG CV POSTOP", "Text" : "CV Surgery (Open Heart) Postoperative Prophylaxis", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SURG THORACIC POSTOP", "Text" : "Thoracic Surgery Postoperative Prophylaxis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU POSTSEPTAL CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM Q24H METRO 500GM Q8H VANCO 15MG/KG Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX AMOX-CLAV 875 PO Q12H TRIMETH-SULFA 2DS PO Q12", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND >", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX CEFDINIR 300MG PO Q12H TMP/SMX 2DS PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R] < AND > trimethoprim-sulfamethoxazole 2 DS PO", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "POSTSEPTAL CELLULITIS (ORBITAL CELLULITIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Postseptal cellulitis (orbital cellulitis) is often preceded by sinusitis and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "requires immediate consultation with otolaryngology and ophthalmology. Urgent",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "surgical drainage may be necessary. The most common pathogenic organisms in",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "adults are streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "aureus. Broad-spectrum empirical antimicrobials should be used until a pathogen",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "can be identified from the drainage fluid.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Orbital cellulitis should be treated until all signs of infection have resolved.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Uncomplicated orbital cellulitis should be treated for minimum of 2 weeks and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "complicated orbital cellulitis (severe ethmoid sinusitis and bony destruction of",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "sinus) should be treated for at least 4 weeks.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Empiric treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Step-down treatment after initial intravenous therapy. Base selection on cultur",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "results.Adjust duration based on criteria above.",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "trimethoprim-sulfamethoxazole 2 DS PO BID ($) [R,DI] for 7 days",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "q12h ($) [R,DI] for 7 days",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Periocular infections",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Orbital Cellulitis",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Orbital cellulitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PRESEPTAL CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX PIP/TAZ4.5GM(NE-EXTINF,CI-CEFEP/METRO) VANCO15MG/KG", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM Q24H METRO 500GM Q8H VANCO 15MG/KG Q12H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX AMOX-CLAV 875 PO Q12H TRIMETH-SULFA 2DS PO Q12", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND>", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX CEFDINIR 300MG PO Q12H TMP/SMX 2DS PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R] <AND> trimethoprim-sulfamethoxazole 2 DS PO", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PRESEPTAL CELLULITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Preseptal cellulitis involves soft tissues in front of the orbital septum and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the eyelids and is often preceded by sinusitis. Infection does not involve the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "orbital contents. The most common pathogenic organisms in adults are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat under the guidance of ophthalmology and/or otolaryngology. Intravenous",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobials are indicated initially for treatment of moderate to severe",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "disease. Switch to oral antimicrobials when the patient's symptoms improve and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "the patient can tolerate oral medications.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Moderate to severe infection or failure of oral antibiotics",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Transition to oral antibiotics can be considered if significant improvement",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "within 24-48 hours.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15 mg/kg IV q12h ($) [R] for 5 days",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment of mild disease or step-down treatment after initial intravenous",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "therapy. Treat for a total duration of 5 days.",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Trimethoprim-sulfamethoxazole 2 DS PO BID ($) [R,DI] for 5 days",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "BID ($) [R,DI] for 5 days",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Periocular infections",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Johns Hopkins website",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Preseptal cellulitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PREV INFECT BACT PROPHYL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "Text" : "Levofloxacin 500 mg PO q24h ($) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID CEFPODOXIME 100MG PO Q12H", "Text" : "Cefpodoxime 100 mg PO q12h ($$) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF BACTERIAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is often given to patients likely to have profound,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "prolonged neutropenia.Profound neutropenia is less than 100 neutrophils and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "bands per microliter, and such neutropenia is considered prolonged when it is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "expected to last more than 7 days.Most patients who should receive prophylaxis",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "have received stem cell transplants or are undergoing induction chemotherapy for",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "acute leukemia.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "If antibacterial prophylaxis is indicated",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration of therapy: During period of expected neutropenia",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell chapter:Prophylaxis and Empirical Therapy for Infection in Cancer",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Patients",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Related Infections. Version 1.2019. nccn.org", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PREV INFECT FUNGAL PROPHYL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 400MG PO Q24H", "Text" : "Fluconazole 400 mg po q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF FUNGAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antifungal chemoprophylaxis is often given to patients undergoing induction",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "chemotherapy for acute leukemia expected to have profound neutropenia (less than",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "100 neutrophils and bands per milliliter) for more than 10 days and for patients",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "receiving allogeneic stem cell transplantation.For most other patients the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "expected benefits do not outweigh the risks of adverse effects and selection of",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "resistant fungi.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antifungal is usually given until the absolute neutrophil concentration",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "increases to more than 500 cells/microliter in patients undergoing induction",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "chemotherapy for leukemia.Duration is 100 days for patients undergoing stem",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "cell transplantation.Some physicians continue prevention after 100 days if",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "corticosteroids are part of the immunosuppressive regimen.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Recommend posaconazole prophylaxis for patients with Acute Myeloid Leukemia.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Contact Hematology Oncology or Infectious Disease for more information.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Patients who have had invasive fungal infection in the recent past and who are",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "about to become neutropenic may require chemoprophylaxis.Contact Hematology-",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Oncology or Infectious Disease for more information.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "If antifungal prophylaxis is indicated:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Duration of therapy: during period of expected neutropenia",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "For patients being treated for AML:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Requires Infectious Disease approval:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Posaconazole 300mg Tablets twice daily on day 1, then 300mg once daily on",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "day 2 and thereafter. Continue for 7 days after the neutrophil count",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "rises above 500/mm3. ($$$$) [DI]",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Prophylaxis and empirical therapy for infection in cancer",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "patients",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Related Infections. Version 1.2019. nccn.org", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX ENDOCARDITIS PDF COMP INFO", "Text" : "<Link> AHA Prevention of Infective Endocarditis Guidelines", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID2 GMENU DRUG PT UNDERGO DENTAL PROC", "Text" : "Patients undergoing dental or oral mucosa procedures", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU SURG HEAD AND NECK SURG", "Text" : "Patients undergoing procedures on the respiratory tract that involve incision or", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID2 GMENU ABX PROCED FOR INFECTED SKIN, SKIN STRUCTURES", "Text" : "Patients undergoing procedures for infected skin, skin structures, or infected", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF BACTERIAL ENDOCARDITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Bacteremia occurs several times a day during daily activities like eating and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "brushing teeth and rarely results in endocarditis, even in people with abnormal",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "valves.While bacteremia might occur following dental or other procedures, most",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cases of endocarditis are from the millions more episodes of transient",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "bacteremia a person experiences per year from ordinary daily activities.There",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "is no evidence that antimicrobial prophylaxis prevents endocarditis after",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "procedures.The best available evidence suggests that prophylactic",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "antimicrobials confer more risks than benefits in most situations.A decision",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "about whether to administer antimicrobial prophylaxis should be based on both",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "the risk of endocarditis conferred by the patient's cardiac defect and the risk",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "of bacteremia from a planned dental or surgical procedure.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "For complete information follow this link:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Determine the need for prophylaxis through the 2-step process outlined",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "below.",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Step 1.Assess the risk of endocarditis for your patient",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Prophylaxis is recommended if a patient has any of the following conditions:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "oProsthetic cardiac valve or material including: Presence of cardiac",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "prosthetic valve, transcatheter implantation of prosthetic valves (e.g. TAVR",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "cardiac valve repair with devices (e.g. annuloplasty, rings, or clips), left",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "ventricular assist devices or implantable heart",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "oA history of infective endocarditis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "oCertain specific congenital heart conditions - refer to the full guidelines",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "(link above) or consult Cardiology for more detailed recommendations",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "oCardiac transplant that develops a problem in the heart valve",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Step 2.Assess the risk of bacteremia from the planned procedure",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Prophylaxis is indicated for these procedures:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "oAll dental procedures that involve manipulation of gingival tissue or the",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "periapical region of teeth or perforation of the oral mucosa.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "oProcedures on the respiratory tract that involve incision or biopsy of the",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "respiratory mucosa, such as tonsillectomy and adenoidectomy. Prophylaxis is",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "recommended for bronchoscopy when procedure involves incision of the respira",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "tract mucosa.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "oProcedures that involve incision through infected skin, skin structures, or",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "musculoskeletal tissue.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "oDermatologic procedures that breach the oral mucosa.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Prophylactic Antimicrobials select below:",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "biopsy of the respiratory mucosa",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "musculoskeletal tissues",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "endocarditis",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PREV OF PERTUSSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO ONCE THEN 250MG PO Q24H 4DAYS", "Text" : "Azithromycin 500mg PO once on day one then 250mg PO qday for 4 days ($) [M]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF PERTUSSIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Immunization",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Give a single dose of tetanus-diphtheria acellular pertussis vaccine (Tdap) in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "adults regardless of interval between most recent Td vaccine. One dose of Tdap",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "vaccine is given to pregnant women during each pregnancy.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Postexposure prophylaxis in adults",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Household contacts with symptomatic coughing should be treated as if they have",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "pertussis. Consult Infectious Diseases for all suspected cases of pertussis and",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "exposure to pertussis.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "CDC recommends postexposure prophylaxis in household contacts within 21 days",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "after exposure to pertussis regardless of immunization history. Non-household",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "contacts who are at high risk of severe illness or who have close contact with",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "high risk individuals should receive post exposure prophylaxis within 21 days of",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "exposure. Those at high risk of severe illness are infants less than one year of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "age, women in third trimester of pregnancy and those with preexisting health",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "conditions that may be exacerbated by pertussis (e.g. immunosuppressed and",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "asthmatic individuals). A single dose of Tdap should be administered in those",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "who are not up to date.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for macrolide intolerant or allergic patients",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "CDC:Pertussis https://www.cdc.gov/pertussis/outbreaks/pep.html",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Kim et al, Annals of internal medicine (2016) 184-194",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pertussis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bordetella species", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PREV PROS JOINT DENTAL", "Contents" : [
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF PROSTHETIC JOINT INFECTION BEFORE DENTAL PROCEDURES",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Dental procedures are not associated with an increased risk of prosthetic joint",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "infection. The routine use of antimicrobial prophylaxis before dental procedures",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "in patients with prosthetic joints is not recommended. Good dental health should",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "be maintained in patients with prosthetic joints and dental infections should be",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "treated promptly.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For more information contact Infectious Diseases.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Up-To-Date Article: Prevention of prosthetic joint and other types of orthopedic",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "hardware infection",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sollecito et al., J Am Dent Assoc, 2015, 146(1):11-16",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Rethman et al., J Am Acad Orthop Surg, 2013, 21:180-189", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PROPHYLAXIS M. AVIUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1200MG PO Q WEEK", "Text" : "Azithromycin 1200 mg PO q week ($) [M]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID CLARITHROMYCIN 500MG PO Q12H", "Text" : "Clarithromycin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROPHYLAXIS AGAINST MYCOBACTERIUM AVIUM DISEASE IN PERSONS WITH HIV/AIDS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases should be involved in all cases. Patients with CD4 count <",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "50 cells per microliter, after ruling out disseminated MC disease, should",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "receive prophylaxis until CD4 count is >100 for at least 3 months in response to",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antiretroviral therapy.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred prophylaxis",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Mycobacterium avium complex",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "patients", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PROPHYLAXIS OPTH SURG", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROPHYLAXIS FOR OPHTHALMIC SURGERY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "When indicated, ophthalmology will order antimicrobial prophylaxis before",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "procedures.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PROS B/J ENTEROCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJZID LINEZOLID 600MG PO Q12H", "Text" : "Linezolid 600 mg PO q12h ($) [DI,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTEROCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "followed by oral antibiotics. For severe infections, add an aminoglycoside for",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "synergy during the first weeks of therapy. Mild infections can be treated with",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "oral antibiotics only.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of Treatement",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "may follow treatment based on individual patient circumstances.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy or resistant organism",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Optional Addition to Above IV Treatment < ADD >",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy and Chronic",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Suppression",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Allergy to penicillin",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "For resistant isolates only",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PROS B/J GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem 1 gm IV q24h ($$) [R,DI,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875-125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS) INFECTIONS IN BONE OR JOINT",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "PROSTHESES",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antibiotics only.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of Treatement",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "may follow treatment based on individual patient circumstances.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin or cephalosporin allergy",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy and Chronic",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Suppression",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative Oral Treatment for Intolerance to Above Oral Antibiotics",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "For treatment of mild infections and continuation of therapy",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "For Chronic Suppression",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PROS B/J P. AERUGINOSA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "Text" : "Cefepime 2g IV q12h ($$) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID CIPROFLOX 400MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q8h ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG IV Q24H", "Text" : "Gentamicin 1 mg/kg IV q8h ($) [R,O]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PSEUDOMONAS AERUGINOSA INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antibiotics only.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Duration of Treatement",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "may follow treatment based on individual patient circumstances.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "For cephalosporin allergy",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Optional addition to above IV antibiotic < ADD >",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Oral Treatment For Mild Infections, For Continuation of Therapy",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Oral Treatment for Chronic Suppression",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PROS B/J STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($$) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJZID PENICILLIN V 500MG PO Q6H", "Text" : "Penicillin VK 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STREPTOCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antibiotics only.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases for specific management advice.",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration of Treatement",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 4-6 weeks. Chronic suppression with oral",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobials may follow treatment based on individual patient circumstances.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Allergy to penicillin or cephalosporin",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy or Chronic",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Suppression",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Allergy to penicillin or cephalosporin",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PROS BONE/JOINT S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSJZID RIFAMPIN 600MG PO Q24H", "Text" : "Rifampin 600 mg PO q24h ($) [DI,O]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "PSJZID RIFAMPIN 600MG PO Q24H", "Text" : "Rifampin 600 mg PO q24h ($) [DI,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STAPHYLOCOCCUS AUREUS INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment Following Debridement and Retention of Prosthesis",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 to 6 months of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "an oral antibiotic combined with rifampin (3 months in total hip, elbow,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "shoulder and ankle arthroplasty and 6 months in total knee arthroplasty).",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment Following 2-stage Exchange or Resection Arthroplasty Without Planned",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Staged Reimplantation of Prosthesis",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat with intravenous antibiotic for 6 weeks for all joint types.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment Following 1-Stage Exchange of Prosthesis",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 months of an",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "oral antibiotic combined with rifampin for all joint types.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Rifampin Synergy",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Rifampin is recommended for treatment with debridement and retention or one",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "stage exchange. When rifampin is combined with a beta-lactam or vancomycin in",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "vitro, bacterial killing is enhanced. Do not use rifampin alone, as bacterial",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "resistance develops rapidly. If patient does not tolerate rifampin it may be",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "omitted from treatment regimen. Contact Infectious Diseases for more",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Chronic Suppression",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Chronic suppression with oral antimicrobials may follow treatment based on",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "individual patient circumstances.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Oxacillin-susceptible:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "MRSA or allergy to penicillin and cephalosporins:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Rifampin Synergy for Debridement and Retention or One Stage Exchange",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "In addition to IV treatment above < ADD >",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Oral Treatment for Continuation of Therapy or Chronic Suppression",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "MRSA or allergy to penicillin or cephalosporin",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Rifampin Synergy for Debridement and Retention or One Stage Exchange (Not For",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Chronic Suppression)",  "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "In addition to PO treatment above < ADD >",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PROS JOINT BONE INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU PROS BONE/JOINT S. AUREUS", "Text" : "Staphylococcus aureus infections", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J STREPTOCOCCI", "Text" : "Streptococci infections", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J ENTEROCOCCI", "Text" : "Enterococci infections", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J GNB", "Text" : "Gram negative bacilli (other than Pseudomonas) infections", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU PROS B/J P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa infections", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV Q12H VANCO 15MG/KG Q12H", "Text" : "Cefepime 2g IV q12h ($$) [R] <AND> Vancomycin 15 mg/kg q12h ($)[R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Common important pathogens include coagulase-negative staphylococci,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus, streptococci, enterococci, and gram negative bacilli.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Obtain material for gram stain and culture and base antimicrobial therapy on",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "results of Gram stain. Blood, joint fluid, and affected tissue and/or bone are",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "ideal specimens to culture. Sinus tracts are often colonized and isolates from",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "drainage may not be pathogens. If Staphylococcus aureus is present,it is likely",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "to be a pathogen in the bone.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Pathogen-directed Treatment Regimens",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Acute infections can often be cured with debridement with joint retention",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "followed by antimicrobials. Infections with duration of symptoms greater then 3",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "weeks or infection within 4 weeks of implantation require one or two stage",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "remimplantation. Cases that are inoperable can be managed with long-term",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "suppressive antimicrobial therapy or joint removal without replacement depending",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "on patient's condition. Consult Infectious Diseases (inpatient) for more",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Infectious Disease and Orthopedics consultations are essential.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Empirical Therapy Before a Pathogen is Identified is Not Recommended.",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "If patient has sepsis or is otherwise unstable, empiric treatment before culture",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "results are obtained may be justified.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID PERMETHRIN 1% LOTION TO AFFECT AREA 10MIN", "Text" : "Permethrin 1% lotion. Apply to affected area for 10 minutes then comb out", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PUBIC LICE (PEDICULOSIS PUBIS)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "To make a diagnosis, use a nit comb, bright light, or lens to find a louse",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "living in pubic hair.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "The presence of nits on a hair shaft, especially when they are located more",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "than 6 mm from the skin, does NOT indicate active infestation.Nits may remain",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "present for months after successful treatment.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Household contacts and persons who may have come into contact with personal",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "belongings of an infested individual should be examined for evidence of lice",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "and discarded or cleaned if contaminated.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "A repeat application may be used if live lice are seen 7-10 days after",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "treatment.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "nits ($) [M]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: lice",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU PYOMYOSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15mg/kg IV q 12 hours ($) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV Q4H ($$) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PYOMYOSITIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Pyomyositis is the presence of pus in a muscle group.It occurs more often in",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "patients with HIV infection or diabetes, and is usually associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Early drainage of purulent material should be performed.Cultures",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "of blood and abscess material should be obtained to guide therapy.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antibiotics should be administered intravenously initially, but once",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "the patient is clinically improved, oral antibiotics are appropriate",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "for whom bacteremia cleared promptly and there is no evidence of endocarditis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "or metastatic abscess.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of treatment: 2 to 3 weeks",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Initial empirical therapy:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "ADD for immunocompromised patient or following open trauma to muscles:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "IF proven MSSA:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Myositis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU RECURRENT/PERSIST URETHRITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX METRONIDAZOLE 2GM PO X1 AZITHROMYCIN 1GM PO ONCE", "Text" : "Metronidazole 2 gm PO ONCE ($) [DI] Azithromycin 1 gm PO ONCE ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERSISTENT OR RECURRENT URETHRITIS OR CERVICITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Retreat with initial treatment regimen if patient was non-compliant with initial",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "treatment regimen or re-exposed to an untreated sex partner. If infection is not",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "due to non-compliance with treatment regimen or re-exposure to an untreated sex",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "partner, infection is most commonly caused by M. genitalium and less commonly T.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "vaginalis.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment for persistent or recurrent urethritis and failure of initial",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "doxycycline treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Failure of above treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases (inpatient)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urethritis",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and Cervicitis",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Urethritis, Recurrent/Persistent",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute cervicitis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Urethritis in men", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU RETINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV RETINITIS", "Text" : "Link to Treatment of CMV Retinitis and ARN", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 800MG PO 5X/D", "Text" : "Acyclovir 800 mg PO 5x/d for 5-7 days ($) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "Text" : "Acyclovir 10 mg/kg IV q8h for 7 days ($$) [R]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "Text" : "Valacyclovir 1 gm PO q8h for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJZID ACYCLOVIR 400MG Q8H", "Text" : "Acyclovir 400 mg PO q8h for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 5 MG/KG IV Q8H", "Text" : "Acyclovir 5 mg/kg IV q8h ($$) [R]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q12H", "Text" : "Valacyclovir 1 gm PO q12h for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "PSJIZID ACYCLOVIR 10 MG/KG IV Q8H", "Text" : "Acyclovir 10 mg/kg IV q8h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSJZID FOSCARNET 2.4MG INTRAVITREOUS INJECT ONCE", "Text" : "< Optional add-on therapy > Foscarnet 2.4mg/0.1 mL intravitreal injection STAT", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "PSJZID VALACYCLOVIR 1GM PO Q8H", "Text" : "Valacyclovir 1 gm PO q8h for 42 days ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "RETINITIS AND ACUTE RETINAL NECROSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Retinitis is a subset of uveitis, is rare in immunocompetent people: in these",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "individuals it is usually caused by varicella-zoster virus (VZV) or herpes",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "simplex virus (HSV). Retinitis is more common in immunocompromised patients and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus being the most common pathogen in these patients. Other",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "retinitis pathogens include Toxoplasma gondii, Bartonella henselae, Histoplasma",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "capsulatum, and Treponema pallidum. In most cases, patients have other",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "neurological symptoms or signs.Patients with candidemia may present with 1-3",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "mm white punctate retinal lesions called cotton-wool spots. These may only be",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "visible on fundus examination. Treatment of candidal retinitisis systemic",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "antifungal therapy. Consult Ophthalmology, Infectious Diseases, or Neurology for",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "help.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "VZV and HSV cause nearly all cases of acute retinal necrosis (ARN), with a small",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "number being caused by cytomegalovirus. ARN is a rapidly progressing retinitis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "that occurs primarily in immunocompetent people and can cause vision loss.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment with intravenous acyclovir or valacyclovir is essential to halt",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "progression of ARN.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Ophthalmology and Infectious Diseases consultation is essential",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment of Non-viral Retinitis or ARN",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Refer to specific pathogen treatment recommendations of the CDSS to treat",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "underlying infection",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment of Retinitis or ARN due to CMV:",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Treatment of VZV Retinitis",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Treatment of HSV Retinitis",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Treatment of VZV and HSV Acute Retinal Necrosis",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Ophthalmologist involvement is essential for treatment including",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "corticosteroids, vitrectomy, or laser therapy. Intravitreal foscarnet in",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "addition to a systemic antiviral may provide added therapeutic efficacy.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Duration",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Treat with intravenous therapy for a minimum of 7 days until disease has",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "stabilized then treat with or therapy for a minimum of 6 weeks",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "($$$$) [R,O]",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "< THEN >",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Lau et al, Ophthalmology. 2007, 114(4)756-762",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious causes of uveitis",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Schoenbergeret al., Ophthalmology. 2017, 124(3)382-392",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Acute Retinal Necrosis",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes Simplex",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Retinitis",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Varicella-zoster Virus (Chickenpox)", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU ROCKY MTN SPOT FEVER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID DOXYCYCLINE 100MG IV Q12H", "Text" : "Doxycycline 100 mg IV q12h ($$) [DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ROCKY MOUNTAIN SPOTTED FEVER",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Rocky Mountain Spotted Fever is a tick-borne, potentially life-threatening",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "rickettsial disease. The highest incidence in the United States is in the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Southeastern and South-central states. Clinical diagnosis include fever in an",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "endemic area, known or possible tick bite, with or without rash. Rash typically",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "spreads from the extremities to the trunk.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diagnosis is difficult, consult Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consider empirical therapy with doxycycline for a patient with an undiagnosed",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "febrile illness and relevant tick exposure.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treat for 7 days.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Rocky mountain spotted fever",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Masters EJ Arch Intern Med 2003, 163: 769", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SCABIES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID PERMETHRIN 5% CREAM APPLY FROM HEAD TO FEET", "Text" : "Permethrin 5% cream apply from head to feet, leave on for 8-14 hours, then", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "SCABIES",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Scabies is an infestation of the skin by the mite Sarcoptes scabiei.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "It is transmitted by skin to skin contact. Outbreaks occur in nursing",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "homes, day care centers, and residential institutions.Scabies is highly",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "contagious and meticulous infection control is needed.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment is a single application of permethrin cream.Some experts recommend a",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "second application 7-10 days after the first application if the patient is still",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "symptomatic or if live mites are found at that time.Contact Dermatology or",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat family members and other close contacts to prevent spread and recurrence.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Repeat application 7-10 days after the first application if patient is still",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "experiencing symptoms, or if lives mites are found.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "wash cream off with soap and water ($) [M]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Scabies",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPSIS AND SHOCK", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX SOFA ONLINE CALCULATOR", "Text" : "SOFA Online Calculator", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GMENU SEPSIS PROTOCOL MAIN INPT", "Text" : "ICU sepsis order set", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ GMENU SEPSIS WARD", "Text" : "Ward sepsis order set", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ GMENU UC/ED SEPSIS 2", "Text" : "ED sepsis order set", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS AND SEPTIC SHOCK",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Per the Sepsis-3 task force, sepsis is defined as life-threatening",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "organ dysfunction caused by dysregulated host response to infection.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "The Sequential Organ Failure Assessment (SOFA) score can be used to help",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "identify organ dysfunction. An acute increase of 2 or more points in a patient",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "with sepsis is associated with in-hospital mortality greater than 10%. Neither",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the SOFA nor the abbreviated qSOFA is sufficiently sensitive to be used as the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "sole method of identifying sepsis related organ dysfunction.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Septic shock is a subset of sepsis in which profound circulatory, cellular and",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "metabolic abnormalities occur. Septic shock is associated with in-hospital",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "mortality greater than 40%.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Early intervention is crucial to prevention of death from sepsis. Antimicrobials",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "active against likely pathogens and supportive treatment to maintain vascular",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "perfusion should be initiated immediately.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Reassess antimicrobial therapy daily to narrow therapeutic spectrum when culture",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "and susceptibility data are available.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment of Sepsis or Septic Shock",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Sepsis, Severe Sepsis and Septic Shock",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Rhodes et al., Intensive Care Medicine (2017), 45.3: 304-377",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Singer et al., JAMA (2016), 315(8) 801-810", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPSIS EMPIRIC THERAPY SITE UNK", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO 4.5GM IV Q6H VANCO 15MG/KG", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg IV q12H", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS AZTREO 2GM Q8H METRO 1GM Q12H VANCO 15MG/KG", "Text" : "Aztreonam 2 gm IV q8h ($$$$) [R] <AND> metronidazole 1 gm IV q12H ($) [DI] <AND>", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG Q24H SEPSIS", "Text" : "<ADD> Gentamicin 5 mg/kg IV x 1 dose", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "RAZ ABDOMINAL CT SEVERE SEPSIS PROTOCOL", "Text" : "Please Click Here To Order an Abdominal CT", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "For Severe Penicillin Allergy:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "vancomycin 15 mg/kg IV q12H ($) [R]",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "*Pharmacy to follow",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Consider abdominal CT",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH UNKNOWN INFECTIOUS SITE", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SEPSIS PNEUMONIA", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO 4.5GM IV Q6H VANCO 15MG/KG", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg IV q12H", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO VANCO 15MG/KG AZITH", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R] <AND> vancomycin 15 mg/kg IV q12H", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFEPIME 2GM IV Q8H VANCO 15MG/KG Q12H AZITH", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R] <AND>", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS LEVOFLOXACIN 750MG IV Q24H VANCO 15MG/KG", "Text" : "Levofloxacin 750 mg IV q24h ($) [R,DI] <AND> vancomycin 15 mg/kg IV q12H ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG Q24H SEPSIS", "Text" : "<ADD> Gentamicin 5 mg/kg IV x 1 dose", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Nosocomial pneumonia preferred treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Community acquired pneumonia preferred treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "($) [R] <AND> Azithromycin 500 mg IV once then 250mg IV q24H x 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Azithromycin 500 mg IV once then 250mg IV q24H x 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For severe penicillin allergy in nosocomial and community acquired pneumonia",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "*Pharmacy to follow",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED PNEUMONIA",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPSIS PROTOCOL ANTIMICROBIALS", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS EMPIRIC THERAPY SITE UNK", "Text" : "Unknown Infectious Site (see below for Intraabdominal infection)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS PNEUMONIA", "Text" : "Suspected Pneumonia", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSPECTED MENINGITIS", "Text" : "Suspected Meningitis, CNS Infection", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSP NATIVE VALVE ENDOCARD", "Text" : "Suspected Native Valve Endocarditis", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSP PROS VALVE ENDOCARD", "Text" : "Suspected Prosthetic Valve Endocarditis", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSPECTED SKIN SOFT TISSUE", "Text" : "Suspected Skin Soft Tissue Infection", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSPECTED URO SEPSIS", "Text" : "Suspected Urinary Tract Infection (AKA urospesis)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSPECTED INTRAABDOMINAL INFECTION", "Text" : "Suspected Intraabdominal Infection", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU SEPSIS SUSP C. DIFFICILE", "Text" : "Suspected Severe Clostridium Difficile Infection", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER CAND NOT ORAL THERA", "Text" : "Suspected Neutropenic Fever", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Initial Empiric Antibiotic Guidelines for Severe Sepsis:", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSP C. DIFFICILE", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "PSJZID VANCOMYCIN 125MG PO QID SEPSIS", "Text" : "Vancomycin 125MG PO QID", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS METRONI 500MG IV Q6H VANCO ENEMA 500MG Q6H", "Text" : "Metronidazole 500MG IV Q6H AND Vancomycin Enema 500MG PR Q6H", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "If No ileus:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "If ileus:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED SEVERE CLOSTRIDIUM DIFFICILE INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSP NATIVE VALVE ENDOCARD", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO GENT 1.5 MG/KG VANCO 15MG/KG IV", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS AZTREO 2GM GENT 1.5 MG/KG VANCO 15MG/KG", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "No Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Piperacillin/Tazobactam 4.5GM IV Q6H AND",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Gentamicin 2 MG/KG LOAD then 1.5 MG/KG IV Q8H AND",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "If Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Aztreonam 2GM IV Q8H AND",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Gentamicin 2 MG/KG LOAD then 1.5 MG/KG IV Q8H AND",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED NATIVE VALVE ENDOCARDITIS",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSP PROS VALVE ENDOCARD", "Contents" : [
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZ GENT 1.5 M/K VANC 15M/K RIFAMP 300MG", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS AZTREO GENT VANCO RIFAMPIN 300MG", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "No Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Piperacillin/Tazobactam 4.5GM IV Q6H AND",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Gentamicin 2 MG/KG LOAD THEN 1.5 MG/KG IV Q8H AND",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines) AND",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Rifampin 300MG IV Q8H",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Aztreonam 2GM IV Q8H AND",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Gentamicin 2 MG/KG LOAD THEN 1.5 MG/KG IV Q8H AND",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines) AND",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Rifampin 300MG IV Q8H",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED PROSTHETIC VALVE ENDOCARDITIS",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSPECTED INTRAABDOMINAL INFECTION", "Contents" : [
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID PIPERACILLIN/TAZOBACTAM 4.5GM IV Q6H SEPSIS", "Text" : "Piperacillin/tazobactam 4.5 gm IV q6H ($$) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFEPIME 2GM IV Q8H METRO 1GM Q12H", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND>metronidazole 1 gm IV q12h ($) [DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CIPRO 400MG IV Q12H METRO 1GM IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12H ($) [R,DI] <AND> metronidazole 1 gm IV q12h", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5 MG/KG Q24H SEPSIS", "Text" : "<ADD> Gentamicin 5 mg/kg IV x 1 dose", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "RAZ ABDOMINAL CT SEVERE SEPSIS PROTOCOL", "Text" : "Please Click Here To Order an Abdominal CT", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "For severe penicillin allergy",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "($) [DI]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "If patient is at risk of multi-drug resistant gram-negative rods:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "*If CrCl less than 50 ml/min: 2 mg/kg x 1 dose",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "*Pharmacy to follow",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Consider Abdominal CT",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED INTRAABDOMINAL INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSPECTED MENINGITIS", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFTRIAXONE 2GM IV VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CEFTRIAX 2GM VANCO 15MG/KG AMPICILLIN 2GM IV", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS TRIMETHO/SULFA 5 MG/KG VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "No Penicillin Allergy and Listeria is NOT a concern:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Ceftriaxone 2GM IV Q12H AND Vancomycin 15mg/kg IV Q12H",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "(Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "No Penicillin Allergy and Listeria IS a concern (Patient with age > 50",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "yrs, alcoholism, or impaired cellular immunity:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Ceftriaxone 2GM IV Q12H AND",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines) AND",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Ampicillin 2GM IV Q4H",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Definite, Severe Penicillin Allergy (Whether or not Listeria is a concern):",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Trimethoprim/Sulfamethoxazole 5mg/kg (TMP component) IV Q6H AND",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED MENINGITIS, CNS INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSPECTED SKIN SOFT TISSUE", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO, CLINDA 900, VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here to Order This Set.", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS MEROPENEM, CLINDA 900, VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here to Order This Set.", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CIPRO 400, CLINDA 900, VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here to Order This Set", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Aggressive surgical debridement is recommended.",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "No Pencillin Allergy:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Piperacillin/Tazobactam 4.5GM IV Q6H AND",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Clindamycin 900MG IV Q8HAND",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "If Penicillin Allergy= Non-type 1 allergy (e.g.rash, etc.)",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Meropenem 1 GM IV Q8H AND",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Clindamycin 900 MG IV Q8HAND",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "If Penicillin Allergy= Type 1 allergy (e.g. anaphylaxis, hives, angioedema,",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "hypotension, etc.)",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Ciprofloxacin 400 MG IV Q12HAND",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Clindamycin 900 MG IV Q8HAND",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED SKIN SOFT TISSUE INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPSIS SUSPECTED URO SEPSIS", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS PIP/TAZO, GENT 5M/KG, VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here To Order This Set.", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX SEPSIS CIPRO GENT 5M/KG VANCO 15MG/KG IV Q12H", "Text" : "Please Click Here to Order This Set", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Site:Unless the specific site or etiologic agent is known with a high",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "level of probability strong consideration should be given:1) To",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "empiric broad spectrum antibiotics for empiric first dose therapy in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "first 24 hours following presentation (Empirical Therapy Site Unknown)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and 2) Strongly consider ID consult.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "No Pencillin Allergy:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Piperacillin/Tazobactam 4.5GM IV Q6H AND",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Gentamicin 5 mg/kg IV Q24H (If CrCl less than 50 ml/min:2 mg/kg x1,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Pharmacy to follow) AND",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "If Penicillin Allergy:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Ciprofloxacin 400 mg IV q12H AND",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Gentamicin 5 mg/kg IV q day (if CrCl<50 ml/min: 2 mg/kg x1,",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Pharmacy to follow) AND",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV Q12H (Pharmacy to adjust dose per guidelines)",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(Add Vancomycin **IF** gram positive bacteria from urine gram stain.)",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Consider selecting alternative agents from separate drug class if",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "recently treated with any of the above antibiotics.",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS WITH SUSPECTED URINARY TRACT INFECTION",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH ENTEROCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 500MG PO Q8H", "Text" : "Amoxicillin 500 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX AMPICI 2GM IV Q4H GENT 1MG/KG IV Q8H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R] < AND > gentamicin 1 mg/kg IV q8h ($) [R,O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15MG/KG IV Q12 GENT 1MG/KG IV Q8H", "Text" : "Vancomycin 15mg/kg IV q12h ($) [R] < AND > gentamicin 1 mg/kg IV q8h ($) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH ENTEROCOCCI",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For severe enterococcal infections, add an aminoglycoside for synergy during the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "first 2-4 weeks of therapy.Consult Infectious Diseases for specific management",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "advice.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of treatment for 2-4 weeks, depending on response",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treatment, MILD-MODERATE infections",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy or resistant organism",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment, SEVERE infections",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy or resistant organism",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Inf Dis 2014, 59:e10-52", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]< OR >", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV Q24H", "Text" : "Levofloxacin 500 mg IV q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJZID AMOXICILLIN-CLAVULANATE 875-125 MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID LEVOFLOX 500MG PO Q24H", "Text" : "Levofloxacin 500 mg po q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH GRAM NEGATIVE BACILLI (OTHER THAN",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "PSEUDOMONAS)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Administer parenteral therapy initially for approximately 1-2 weeks",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "then can be converted to appropriate oral therapy.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Oral therapy to complete the course after intravenous therapy initially:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-to-date online",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Mathews CJ Lancet 2010, 375:846", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH N. GONORRHOEAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 1GM IV Q24H", "Text" : "Ceftriaxone 1 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO one-time dose ($) [M]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO q12h for 7 days ($) [DI] < OR >", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH NEISSERIA GONORRHOEAE",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treat presumptively also for Chlamydia trachomatis infection (asymptomatic",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "urethritis) and test for HIV.Infection control will report cases with N.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "gonorrhea isolated to the state department of health.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Susceptibility results are required to guide potential switch to an oral medicat",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "N. gonorrheae Treat for 1-2 weeks (Plus see below for Chlamydia treatment)",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative for severe penicillin allergy",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Disease for alternative",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Concomitant treatment for C. trachomatis",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Preferred treatment:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative treatment:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mathews CJ Lancet 2010, 375:846",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "MMWR Recommendations and Reports CDC 2015, 64:1-137", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH P. AERUGINOSA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 4.5 gm IV q6h ($$) [R] < OR >", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 750MG PO Q12H", "Text" : "Ciprofloxacin 750 mg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH PSEUDOMONAS AERUGINOSA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Up-to-date online",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mathews CJ Lancet 2010, 375:846", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]< OR >", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]< OR >", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO q6h ($) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] < OR >", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO q12h ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJZID MINOCYCLINE 100MG PO Q12H", "Text" : "Minocycline 100 mg PO q12h ($) [DI]< OR >", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH STAPHYLOCOCCUS AUREUS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Administer parenteral therapy initially for approximately two weeks",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "then can be converted to appropriate oral therapy.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Methicillin-SUSCEPTIBLE Staphylococcus aureus",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treat for 4-6 weeks depending on response",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Oral therapy to complete the course after intravenous therapy initially:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Methicillin-RESISTANT Staphylococcus aureus",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treat for 4-6 weeks depending on response",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Oral therapy to complete the course after intravenous therapy initially:",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-to-date online",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mathews CJ Lancet 2010, 375:846",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Coakley G Rheumatology (Oxford) 2006, 45:1039", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTH STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID PENICILLIN G 4 MILLION UNITS IV Q4H", "Text" : "Penicillin G 4 million units IV q4h ($) [R]", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID AMOXICILLIN 1000MG PO Q8H", "Text" : "Amoxicillin 1000 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 300MG PO Q6H", "Text" : "Clindamycin 300 mg PO q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH STREPTOCOCCI",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Duration: treat for 2-4 weeks",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy, or when beta-lactam resistance",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "is suspected or proved:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Oral step-down therapy to complete full course once sensitivities are known:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-to-date online",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mathews CJ Lancet 2010, 375:846", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU PROS JOINT BONE INFECT", "Text" : "Infections in bone or joint prostheses", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU BITE WOUNDS", "Text" : "Bite wounds", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX LYME DISEASE", "Text" : "Lyme disease", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15mg/kg IV q 12 hours ($) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSJIZID AMPICILLIN 2 GM IV Q4H", "Text" : "Ampicillin 2 gm IV q4h ($$) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM Q24H AZITHRO 1GM PO ONCE", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> Azithromycin 1 gm PO x1dose ($) [O]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID CEFTAZIDIME 2GM IV Q8H", "Text" : "Ceftazidime 2 gm IV q8h ($$) [R]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2 gm IV q8h ($$) [R] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH S. AUREUS", "Text" : "Staphylococcus aureus", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH STREPTOCOCCI", "Text" : "Streptococci", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH ENTEROCOCCI", "Text" : "Enterococci", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH GNB", "Text" : "Gram negative bacilli (other than Pseudomonas)", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU SEPTIC ARTH N. GONORRHOEAE", "Text" : "Neisseria gonorrhoeae", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : ">>For arthritis associated with a PROSTHETIC JOINT see",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : ">>For arthritis associated with a BITE WOUND see",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : ">>For arthritis associated with TICK EXPOSURE in an endemic area, consider",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Septic arthritis native joint:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Aspirate the joint for gram stain and culture.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Use the Gram stain of aspirated fluid to select initial therapy.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Use culture results to guide definitive therapy.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "In addition to antimicrobial treatment, successful management of acute",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "septic arthritis requires removal of intra-articular pus.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "**Synovial fluid Gram stain with organisms:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Gram positive cocci in clusters:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Gram positive cocci in chains (streptococci):",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Gram negative diplococci (Neisseria) or STD risk and Gram stain negative:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "(one dose of azithromycin for possible concomitant C. trachomatis)",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Gram negative rods:",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "**Synovial fluid without organisms on Gram stain:",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "*No MRSA risk factors:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "*MRSA risk factors, high risk of Gram negative infection (elderly,",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "nursing home, hospitalized, cutaneous ulcers)",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Pathogen-specific septic arthritis treatment regimens",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Duration of therapy based on pathogen and clinical response. (See pathogen)",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "If the patient has an underlying rheumatoid arthritis, 6 to 12 weeks of",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "antimicrobials may be needed, depending on clinical response.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Consult Rheumatology for more information",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Sharff KA Curr Rheumatol Rep 2013 15:332",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Coakley G Lancet 2010, 375:846", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEPTIC BURSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]< OR >", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV Q8h ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO BID($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "SEPTIC BURSITIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Aspiration for treatment and diagnostic confirmation should be performed in all",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "cases. Obtain synovial fluid for gram stain and culture to guide therapy. Most",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cases are associated with Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Intravenous therapy is recommended. Some clinicians treat mild cases in",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "otherwise healthy individuals with intravenous therapy for part of the course",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and then switch to oral therapy. Other clinicians treat mild cases with oral",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "therapy for the entire course. Drug selection should be based on microbiological",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "results. Close clinical follow-up is needed for all cases",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat for 2 to 3 weeks.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Mild cases in otherwise healthy adults",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bursitis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Baumbach SF, Arch Orthop Trauma Surg 2014, 134:359",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEVERE SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 10 days", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJZID CEFDINIR 300MG PO Q12H", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 10 days", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID DOXYCYCLINE 100MG PO Q12H", "Text" : "Doxycycline 100 mg PO BID($) [DI] for 10 days", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3gm IV q6h ($) [R] for 10 days", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] for 10 days", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "Text" : "Cefepime 2 gm IV q12h ($$) [R] for 10 days", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEVERE SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pneumoniae, Haemophilus influenza or Moraxella catarrhalis. Group A",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Streptococci, Staphylococcus aureus and anaerobes are isolated less frequently.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "For patients who present with severe symptoms (high fever (>/= 102 degrees",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Fahrenheit, >/= 39 degrees Celsius) and purulent nasal discharge for 3-4",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "consecutive days or facial pain lasting for at least 3-4 consecutive days at the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "beginning of illness), initiate empiric antimicrobials and obtain CT of sinuses",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "to determine the extent of infection. If the CT shows extension of sinusitis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "infection into surrounding structures (i.e. the cranium or orbit) consult ENT",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "immediately. Closely monitor all patients who present with severe signs and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "symptoms to ensure that signs and symptoms improve within 72 hours.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Outpatient Treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternatives:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment of hospitalized patient",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Treatment failure",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "If symptoms worsen or no improvement is seen after 3-5 days of treatment,",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "broaden coverage, switch to different antimicrobial class and treat 10 days. If",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "symptoms continue to worsen or there is no improvement after 3-5 more days of",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "treatment, obtain CT to investigate non-infectious or suppurative causes. ENT",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "consultation is recommended. If sinuses are aspirated, specimens should be",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "cultured.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "for 10 days",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Chronic",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "rhinosinusitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "Human Immunodeficiency Virus (HIV)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "Text" : "HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Sexually Transmitted Infections (STI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A diagnosis of a sexually transmitted infection can suggest sexual activity",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "that could result in HIV exposure. Recommendation is for the provider to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "HIV acquisition.If the patient is interested, the provider should place a",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "consult to MRTC clinic for further discussion and evaluation for PrEP.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Pre-exposure prophylaxis (or PrEP) is a way for people who do not have",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "HIV but who are at high risk of getting HIV to prevent HIV infection by",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "taking a pill every day. When someone is exposed to HIV through sex or",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "injection drug use, these medicines can work to keep the virus from",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "establishing a permanent infection.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Per CDC, when taken daily PrEP is highly effective for preventing HIV. Studies",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "have shown that PrEP reduces the risk of getting HIV from sex by about",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "99% when taken daily. PrEP is much less effective if not taken consistently.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "As PrEP only protects against HIV, condoms are important for the protection",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "against other STIs. Condoms are also an important prevention strategy",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "if PrEP is not taken consistently.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SPINAL EPIDURAL ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM Q12H AND VANCO 15MG/KG Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Cefepime 2gm IV Q8h ($$) [R]< AND > vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SPINAL EPIDURAL ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are associated with Staphylococcus aureus. Others are associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Gram-negative bacilli and streptococci. Beta-lactam antibiotics are more",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "effective than vancomycin against susceptible Staphylococci. If Staphylococcus",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "is isolated, once methicillin-resistance is ruled out, switch to an anti-",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen in",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "post-surgical patients or patients with known Pseudomonas colonization.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat for 4 to 8 weeks. Shorter durations may be used in patients who have",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "undergone surgical drainage and who have responded well to therapy.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred if Pseudomonas is not suspected:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Preferred if Pseudomonas is suspected:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment if methicillin-sensitive S. aureus is isolated",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Krishnamohan et al, Curr Infect Dis Rep, 2014, 16(11)1-6",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-To-Date Article: Spinal Epidural Abscess", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SPOROTRICHOSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJZID ITRACONAZOLE 200MG PO Q12H", "Text" : "Itraconazole 200 mg PO q12h continue for 2-4 weeks after all lesions", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "SPOROTRICHOSIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Sporotrichosis occurs most often in people who have had significant outdoor",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "exposure to soil.In immunocompetent people, disease is usually limited to the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "skin.In people with decreased host defenses (eg, HIV/AIDS, alcoholism,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "diabetes mellitus, or chronic obstructive pulmonary disease) sporotrichosis",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "often disseminates to bones, joints, or lungs.Consult Infectious Diseases or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Dermatology",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "____________________________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Cutaneous infection in a patient without HIV infection",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "____________________________________________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "resolved, usually for a total of 3-6 months ($) [DI]",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Consult Dermatology or Infectious Diseases.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "____________________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Extracutaneous infection or any infection in a patient with HIV/AIDS",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "____________________________________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Consult Dermatology or Infectious Diseases.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Kaufman CA Clin Infect Dis 2000, 30: 684",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU STAPH SCALDED SYNDROME", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "STAPHYLOCOCCAL SCALDED SKIN SYNDROME (RITTER'S DISEASE)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Staphylococcal scalded skin syndrome (SSSS) presents with severe skin",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "blistering and exfoliation resulting from toxins produced by Staphylococcus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "aureus.SSSS is usually found in children and rarely in older adults.Obtain",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "a skin biopsy to differentiate between SSSS and toxic epidermal necrolysis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Initiate anti-staphylococcal therapy and obtain cultures and susceptibilities.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empiric therapy active against both MRSA and MSSA until results available.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "If cultures reveal methicillin-susceptible Staphylococcus aureus (MSSA), change",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "to nafcillin or cefazolin for better antimicrobial activity.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Empirical treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment if MSSA is isolated",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staph. Scalded skin syndrome",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: The acutely ill patient with fever and rash",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Patel GK Am J Clin Dermatol 2003, 4:165", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU STAPH TOXIC SHOCK SYNDROME", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CDC CRITERIA FOR DIAGNOSIS OF STAPHYLOCOCCAL TOXIC SHOCK SYNDROME",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "These criteria were developed for epidemiological purposes.Treat cases when",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "fewer criteria are met if staphylococcal TSS seems likely.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Definite:All 6 of the following criteria are met.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Probable:Five of the 6 criteria are met.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Fever",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "T >38.9 degree Celsius (102.0 degree Fahrenheit)",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Hypotension",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Systolic blood pressure 90 mmHg, orthostatic drop in diastolic 15 mmHg,",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "orthostatic syncope or dizziness",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Rash",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Diffuse macular erythroderma",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Desquamation",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Occurs 1 to 2 weeks after onset of illness and usually involving palms and",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "soles",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Multisystem involvement (3 or more of the following organ systems)",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "GI",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Vomiting or diarrhea at onset of illness",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Muscular",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Severe myalgia or CPK elevation >2 times the normal upper limit",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mucous membranes",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Vaginal, oropharyngeal, or conjunctival hyperemia",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Renal",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "BUN or serum creatinine >2 times the normal upper limit, or pyuria (>5",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "WBC/hpf)",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Hepatic",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Bilirubin or transaminases >2 times the normal upper limit",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Hematologic",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Platelets <100,000/microLiter",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Central nervous system",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Disorientation or alterations in consciousness without focal neurologic",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "signs in the absence of fever and hypotension",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Negative results on the following tests, if obtained",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Blood, throat, or cerebrospinal fluid cultures for another pathogen (blood",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "cultures may be positive for S. aureus).",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Serologic tests for Rocky Mountain spotted fever, leptospirosis, or measles",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "MMWR 1990, 39(RR-13):1",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "DeVries AS PLoS One 2011, 6(8):e22997", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU STREP TOXIC SHOCK SYNDROME", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CRITERIA FOR DIAGNOSIS OF STREPTOCOCCAL TOXIC SHOCK SYNDROME",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "These criteria were developed for epidemiological purposes.Treat cases when",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "fewer criteria are met if streptococcal TSS seems likely.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "1.)Isolation of Group A Streptococcus from a normally sterile site (eg, blood",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "cerebrospinal, pleural, or peritoneal fluid, tissue biopsy, or surgical wound)",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "< AND >",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "2.)Hypotension (systolic blood pressure 90 mm Hg in adults",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< AND >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "3.)Two or more of the following:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Renal impairment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "(creatinine in adults, 2 mg/dL, in children, two-times upper limit of normal",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "for age, in patients with pre-existing renal disease two-fold elevation over",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "baseline)",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Coagulopathy",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(eg, thrombocytopenia, disseminated intravascular coagulation)",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Liver involvement",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "(eg, two-times upper limit of normal for age of transaminases or bilirubin, in",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "patients with pre-existing liver disease two-fold elevation over baseline)",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Adult respiratory distress syndrome",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Erythematous macular rash",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "may desquamate",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Soft tissue necrosis (eg, necrotizing fasciitis, myositis, or gangrene)",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Working Group on Severe Streptococcal Infections JAMA 1993, 269:390", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SUBDURAL EMPYEMA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAX 2GM IV Q12H METRO 15 MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 15 mg/kg IV q12h ($) [DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID MEROPENEM 2GM IV Q8H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM METRO 15MG/KG VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm q12h ($) [M] <AND> metronidazole 15 mg/kg IV q12h ($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] ] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SUBDURAL EMPYEMA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases (60-90%) result from extension of sinusitis or otitis media",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(contiguous sources). Surgical drainage is necessary. Obtain material for",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "culture. For patients with severe penicillin allergy consult Infectious",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consult Neurosurgery, Neurology, and Infectious Disease",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for 4-6 weeks",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment for Infection from Contiguous Source",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment for Unknown Source, History of MRSA Infection or Colonization",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "<AND> vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Intracranial Thrombophlebitis",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Subdural empyema", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SUPP INTRACRANIAL THROMBOPH", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CEFTR 2GM METRO 15MG/KG VANCO 15MG/KG IV Q12H", "Text" : "Ceftriaxone 2 gm IV q12h ($) [M] <AND> metronidazole 15 mg/kg IV q12h ($)", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFE2GMIVQ8H METRO15MG/KGIVQ12H VANCO15MG/KGIVQ12H", "Text" : "Cefepime 2gm IV q8h ($$) [R] <AND> metronidazole 15 mg/kg IV q12h ($)", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX MEROPENEM 2GM IV Q8H VANCO 15MG/KG IV Q12H", "Text" : "Meropenem 2 gm IV q8h ($$) [R,O] ] <AND> vancomycin 15mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin 2 gm IV q4h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin 2 gm IV q8h ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SUPPURATIVE INTRACRANIAL THROMBOPHLEBITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Adjust therapy from empirical regimens listed below after consultation with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Infectious Disease or Neurosurgery services. Beta-lactam antibiotics are more",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "effective than vancomycin against susceptible Staphylococci. If Staphylococcus",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "is isolated, once methicillin-resistance is ruled out, switch to an anti-",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "staphylococcal beta-lactam antibiotic. Pseudomonas is a potential pathogen in",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "post-surgical patients or patients with known pseudomonas colonization.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Disease and Neurosurgery.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat for 3 to 6 weeks.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Preferred if Pseudomonas is not suspected:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "[DI] <AND> vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Preferred if Pseudomonas is suspected:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "[DI] <AND> vancomycin 15mg/kg IV q12h ($) [R]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treatment if Methicillin-Sensitive S. Aureus is Isolated",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Kombogiorgas et al, British Journal of Neurosurgery, 2007, 21(6)603 - 609",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Subdural Empyema, Epidural Abscess, and Suppurative",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Intracranial Thrombophlebitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SUPP ODONTOGENIC INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJZID CLINDAMYCIN 450MG PO Q8H", "Text" : "Clindamycin 450 mg PO q8h for 7 days ($) [H,O]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3gm IV q6h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2GM IV Q24H METRON 500MG IV Q8H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> metronidazole 500 mg IV q8h ($) [DI] for", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 4.5GM IV Q6H(NE-EXTINF,CI-CEFEP/METRO)", "Text" : "", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX CEFEPIME 2 GM IV Q12H VANCO 15MG/KG Q12H", "Text" : "Cefepime 2 gm IV q12h ($$) [R] < AND > vancomycin 15 mg/kg IV q 12 hours ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TOOTH ABSCESS AND OTHER SUPPURATIVE ODONTOGENIC INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Surgical drainage, scaling and antimicrobial treatment are essential and tooth",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "extraction is required in most cases. All patients should be referred to the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "dental service for assessment and direction of treatment. Empirical coverage for",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "likely pathogens (streptococci, Peptostreptococcus, Finegoldia, Bacteriodes and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "other oral anaerobes is required. Immunocompromised patients need additional",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "coverage for Pseudomonas aeruginosa.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult Dental Service",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease in immunocompetent patients or step-down",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "therapy after initial intravenous therapy. Adjust duration for a total of 7 day",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of antimicrobial therapy.",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease in immunocompetent patients",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "7 days",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Treatment in immunocompromised patients",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "for 7 days",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "for 7 days",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Complications, diagnosis and treatment of odontogenic",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG 48HRS AFTER PROC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "GMRCTZ WOCN OSTOMY INPT", "Text" : "Wound care (ET) nurse consult", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX VANCO NEW START 15MG/KG Q12H + MRSA NARES SCREENING", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R] < OR >", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ SET ABX CIPROFL 400 MG IV Q12H CLINDA 600MG IV Q8H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> Clindamycin 600 mg IV", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX AMPI/SULB 3GM IV Q6H VANCO 15MG/KG IV Q12H", "Text" : "Ampicillin-sulbactam 3 gm IV q6h ($$) [R] <AND> vancomycin 15 mg/kg", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) <AND> vancomycin 15 mg/kg", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX CIPROFL, METRONI, VANCO", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] <AND> metronidazole 500 mg", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PATIENTS WITH SIGNS OF INFECTION MORE THAN 48 HOURS AFTER PROCEDURE",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most post-operative infections appear at least 4 days after the operation.If",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the wound appears normal to examination surgical site infection is unlikely.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Seek other source of fever.Consider opening wounds that show induration or",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "erythema.Obtain material for gram stain and culture whenever possible.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Determine whether the patient has signs of invasive or systemic infection like",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "erythema (diameter greater than 5 centimeters), temperature greater than 38.5",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "degrees Celsius (101.3 degrees Fahrenheit) or heart rate higher than 100 beats",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "per minute.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "If there are no signs of invasive or systemic infection systemic antimicrobials",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "are unnecessary.Dressing changes alone are indicated.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "For wounds that require complicated care",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "If there are signs of invasive or systemic infection obtain blood cultures and",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "wound Gram stain and cultures.Whenever possible select antimicrobial therapy",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "based on the Gram stain.When the Gram stain cannot provide guidance give",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "empirical therapy as indicated:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of INFECTED WOUNDS AFTER CLEAN SURGERY or wounds on the",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "trunk, head, neck, arms or legs",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Vancomycin should be included in the initial regimen due to the prevalence of",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "methicillin-resistant Staphylococcus aureus.However beta-lactam antibiotics",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "are more effective for susceptible bacteria than is vancomycin.If methicillin-",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "susceptible S. aureus is identified switch to an anti-staphylococcal beta-lactam",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "antibiotic.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Preferred empirical treatment for INFECTED WOUNDS AFTER CLEAN-CONTAMINATED or",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "CONTAMINATED SURGERY",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "q8h ($$) [H]",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Alternative if methicillin-resistant Staphylococcus aureus is suspected",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "IV q12h ($) [R] < OR >",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "IV q12h ($) [R] < OR >",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "IV q8h ($) [DI] <AND> vancomycin 15mg/kg IV q12 ($) [R]",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG ANTIBIOTIC RENAL REDOSING", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Recommended Redosing Interval",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Based on Normal and ESRD renal function",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Recommended redosing interval 2 times the half-life",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIAL",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Ampicillin",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Ampicillin sulbactam",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Aztreonam",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Cefazolin",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Cefuroxime",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Cefoxitin",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Cefotetan",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Ceftriaxone",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Ciprofloxacin",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Clindamycin",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Gentamicin",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Levofloxacin",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Metronidazole",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Piperacilln Tazobactam",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Vancomycin",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Am J Health-Syst Pharm. 2013, 70: 195-283",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Sanford Guide Online",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "REDOSING INTERVAL**",  "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "NORMAL RENAL FXN",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "2 hours",  "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "2 hours",  "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "4 hours",  "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "4 hours",  "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "4 hours",  "Header" : 1}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "2 hours",  "Header" : 1}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "6 hours",  "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "6 hours",  "Header" : 1}, 
{"Row" : 39, "Column" : 2, "Item" : null, "Text" : "2 hours",  "Header" : 1}, 
{"Row" : 45, "Column" : 2, "Item" : null, "Text" : "Doses based on Dosing Weight (DW)*",  "Header" : 1}, 
{"Row" : 46, "Column" : 2, "Item" : null, "Text" : "*Calculate Dosing Weight (DW)",  "Header" : 1}, 
{"Row" : 47, "Column" : 2, "Item" : null, "Text" : "DW = IBW + 0.4 (ABW - IBW)",  "Header" : 1}, 
{"Row" : 48, "Column" : 2, "Item" : null, "Text" : "IBW=Ideal Body WtABW=Actual Body Wt",  "Header" : 1}, 
{"Row" : 49, "Column" : 2, "Item" : null, "Text" : "Male IBW (kg)=50+2.3 * (Ht-60inches)",  "Header" : 1}, 
{"Row" : 50, "Column" : 2, "Item" : null, "Text" : "Female IBW (kg)=45.5+2.3 * (Ht-60inches)",  "Header" : 1}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Antimicrobial Surgical Prophylaxis",  "Header" : 1}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "REDOSING INTERVAL**",  "Header" : 1}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "END STAGE RENAL DISEASE",  "Header" : 1}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 21, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 23, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 25, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 27, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 31, "Column" : 3, "Item" : null, "Text" : "6 hours",  "Header" : 1}, 
{"Row" : 33, "Column" : 3, "Item" : null, "Text" : "Only give 3mg/kg preop ONCE*",  "Header" : 1}, 
{"Row" : 39, "Column" : 3, "Item" : null, "Text" : "6 hours",  "Header" : 1}, 
{"Row" : 41, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 44, "Column" : 3, "Item" : null, "Text" : "based on typical case length, for",  "Header" : 1}, 
{"Row" : 45, "Column" : 3, "Item" : null, "Text" : "unusually long procedures,",  "Header" : 1}, 
{"Row" : 46, "Column" : 3, "Item" : null, "Text" : "redosing may be needed.",  "Header" : 1}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "**For those marked N/A --",  "Header" : 1}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "based on typical case length,",  "Header" : 1}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "unusually long procedures,",  "Header" : 1}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "redosing may be needed.",  "Header" : 1}, 
{"Row" : 43, "Column" : 3, "Item" : null, "Text" : "**For those marked N/A --",  "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "Single dose only preop",  "Header" : 1}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "Do not redose",  "Header" : 1}, 
{"Row" : 29, "Column" : 3, "Item" : null, "Text" : "Do not redose",  "Header" : 1}, 
{"Row" : 41, "Column" : 2, "Item" : null, "Text" : "12 hours",  "Header" : 1}, 
{"Row" : 37, "Column" : 2, "Item" : null, "Text" : "12 hours",  "Header" : 1}, 
{"Row" : 37, "Column" : 3, "Item" : null, "Text" : "12 hours",  "Header" : 1}, 
{"Row" : 35, "Column" : 2, "Item" : null, "Text" : "Do not redose",  "Header" : 1}, 
{"Row" : 35, "Column" : 3, "Item" : null, "Text" : "Do not redose",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "John Hopkins Antibiotic Guide.Online.Oct2021.", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG CARDIAC SURG", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED PREOP", "Text" : "Click here to go to CIED Surgery Prophylaxis", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDS DELAYED PRE-OP ANTIBIOTICS CV SURGERY2", "Text" : "Click here to go to CV (open heart) Surgery Prophylaxis", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IVover 30 minutes, beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CARDIAC SURGERY",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is not indicated before cardiac catheterization",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "with or without stent placement or for transesophageal echocardiogram.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For patients undergoing cardiac procedures the recommended regimen is a",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "single pre-incision dose of antibiotic with additional doses",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "while incisions are open for long procedures.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Prophylaxis should not be continued beyond 24 hours",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "even if drains or intravenous catheters remain in place.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Cefazolin is preferred for prophylaxis, as it is more active than vancomycin",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "against methicillin-susceptible staphylococci.Vancomycin should",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "be used when methicillin-resistant Staphylococcus aureus infection is likely.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Consult Cardiothoracic Surgery or Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Prophylaxis",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "($) [R] < OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Letter 2012 Vol 10 pages 73-77",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Baddour LM, et al. Circulation 2010 Vol 121 pages 458-477", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG CIED POSTOP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2 GM IV Q8H X 2DOSES", "Text" : "Cefazolin 2 GM q8h for 2 doses post-op ($) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 3 GM POSTOP X2DOSES FOR WT GREATER THAN 120KG", "Text" : "Cefazolin 3 GM q8h for 2 doses post-op ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID VANCOM 15 MG/KG IV Q12H 2DOSES POSTOP", "Text" : "Vancomycin 15mg/kg for 2 doses post-op ($) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 2GM + VANCO 15MG/KG 2DOSES POSTOP", "Text" : "Cefazolin 2 GM q8h x 2 doses post-op ($) [R] < AND >", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 3GM + VANCOMYCIN 15MG/KG POSTOP X2DOSES", "Text" : "Cefazolin 3 GM q8h x 2 doses post-op ($) [R] < AND >", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO BID X3DAYS CIED POSTOP", "Text" : "Cephalexin 500MG PO bid for 3 days AFTER CIED PROCEDURE", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID X3DAYS CIED POSTOP", "Text" : "Clindamycin 300MG po qid for 3 days AFTER CIED PROCEDURE", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO BID X3DAYS CIED POSTOP", "Text" : "Doxycycline 100MG PO bid for 3 days AFTER CIED PROCEDURE", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Cardiac Implantable Electronic Device (CIED) Post-Op Prophylaxis Antibiotics",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Post-procedure CIED IV antibiotic prophylaxis:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Place post-op IV antimicrobial prophylaxis after admission.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If new CIED implant, then give same antibiotic(s) as preop for 2 doses post-op",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "If generator replacement only, then no additional doses recommended.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred POST-PROCEDURE prophylaxis:",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "For patients weight less than 120 kg:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For patients weight equal to or greater than 120kg:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative in patients with beta lactam allergy:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "MRSA Positive Patients Post-Procedure antibiotics:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For patients weight less than 120 kg:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV q12h x 2 doses post-op ($) [R]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For patients weight equal to or greater than 120 kg:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Vancomycin 15mg/kg IV q12h x 2 doses post-op ($) [R]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Post-procedure CIED ORAL TAKE HOME MEDICATIONS:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Preferred POST-PROCEDURE prophylaxis:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "MRSA Positive Patients Post-Procedure antibiotics:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG CIED PREOP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision($) [R]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 3 GM PREOP FOR WT GREATER THAN OR EQUAL 120KG", "Text" : "Cefazolin 3 GM IV over 30 minutes beginning 60 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID MUPIROCIN 2% OINT DECOLON TOPICAL BID 5D", "Text" : "Mupirocin Ointment applytopical to each nares bid for 5 days PRIOR TO", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 2GM + VANCOMYCIN 15MG/KG PREOP CIED", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 3 GM + VANCOMYCIN 15 MG/KG POSTOP CIED", "Text" : "Cefazolin 3 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Cardiac Implantable Electronic Device (CIED) Pre-Op Prophylaxis Antibiotics",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Pre-procedure IV prophylaxis antibiotic recommendations:",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Preferred prophylaxis:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "For patients weight less than 120 kg:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "For patients weight equal to or greater than 120kg:",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Alternative in patients with beta lactam allergy:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Recommended for MRSA Positive Patients: Decolonization AND Pre-op Antibiotics",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Decolonization for MRSA positive:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "PROCEDURE (ideally) ($) [M]",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred prophylaxis for MRSA positive:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "For patients weight less than 120 kg:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "($) [R] < AND > Vancomycin 15 MG/KG IV beginning 120 minutes before",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "incision ($) [R]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "For patients weight equal to or greater than 120 kg:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "($) [R] < AND > Vancomycin 15 MG/KG IV beginning 120 minutes before",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "incision ($) [R]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG COLON AND RECTAL SURG", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX METOCLOPRAMIDE 10MG PO ONCE GOLYTELY 4L ONCE", "Text" : "Metoclopramide 10 mg PO once then Golytely 4 L PO starting in the afternoon", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX OP METOCLOPRAMIDE 10MG GOLYTELY 4L PO", "Text" : "Metoclopramide 10 mg PO once then Golytely 4 L PO starting in the afternoon", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX CEFAZO 2GM IV 30MIN METRON 500MG IV X1", "Text" : "Cefazolin 2gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX GENTAM 5 MG/KG IV 30MIN METRO 500MG IV X1", "Text" : "Gentamicin 5 MG/KGIV over 30 minutes ($) [R,O] beginning 60 minutes", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG IV/LEVOFLOXACIN 500MG IV", "Text" : "Clindamycin 900mg IV over 30 minutes ($)[H,O] beginning 60 minutes", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Bowel/Colo-rectal Surgery",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Bowel preparation should be done for cases in which the colon should be cleansed",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "for surgical reasons.Evidence suggests that routine mechanical bowel does not",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "prevent infection and may increase anastomotic leakage and wound complications.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Systemic antimicrobials should provide coverage for aerobes and anaerobes.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "_____________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Mechanical bowel preparation (when needed for technical reasons)",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "_____________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "the day before the procedure--INPATIENT STATUS",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "the day before the procedure--OUTPATIENT STATUS",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_____________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Systemic antimicrobials",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Preferred prophylaxis",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "($) [R] <AND> metronidazole 500 mg IV over 30 minutes beginning 60",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "minutes before incision ($) [DI]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative in patient with beta lactam allergy",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "before incision <AND> metronidazole 500 mg IV ($) [DI] over 30 minutes",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "beginning 60 minutes before incision",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "before incision <AND> levofloxacin 500mg IV over 60 minutes ($)[R,DI]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "beginning 60 minutes before incision.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013, 70: 195-283",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Medical Letter 2012, 10: 73-77",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prophylaxis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG CV POSTOP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED POSTOP", "Text" : "CIED Surgery Postoperative Prophylaxis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX CEFUR 1.5G VANCO 15MG/KG POSTOP CARD", "Text" : "Cefuroxime 1.5 gm IV q8h x 1 dose post-op ($$) [R] <AND> vancomycin 15 mg/kg", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "Text" : "Vancomycin 15 mg/kg (pharmacy to dose) IV q12h x 1 dose post-op ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CV SURGERY (OPEN HEART) MVAHCS POSTOPERATIVE PROPHYLAXIS RECOMMENDATIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Place post-op IV antimicrobial prophylaxis orders after admission to ward.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial prophylaxis should not exceed 24 hours. Durations",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "longer than 24 hours have not been shown effective in preventing cardiothoracic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "surgical site infections. There is no benefit to continuing antimicrobial",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "prophylaxis until all indwelling drains and intravascular catheters are removed.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For CIED surgery postoperative antimicrobial prophylaxis click link below:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "CV Surgery (including CAB and TAVR) Postoperative Prophylaxis",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "(pharmacy to dose) IV q12h x 1 dose post-op ($) [R]",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with cephalosporin allergy",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Levofloxacin has a duration of action of 24 hours. If patient received a pre-op",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "dose of levofloxacin, a post-op dose is not required.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Bratzler DW et al, Clinical Practice Guidelines for Antimicrobial Prophylaxis in",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Surgery, Am J Health-Syst Pharm (2013) 70:195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG ERCP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU SURG ERCP INCOMP DRAINAGE", "Text" : "Antimicrobial prophylaxis after ERCP with incomplete drainage", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 2GM AND GENTAMICIN 5MG/KG PREOP", "Text" : "Ampicillin 2 gm IV over 20 minutes ($) [R] < AND > gentamicin 5mg/kg", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CIPROFL 400MG IV ONCE SURG PREOP", "Text" : "Ciprofloxacin 400 mg IV over 60 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15 MG/KG IV 60MIN GENT 5MG/KG IV ONCE", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are not indicated in the absence of obstruction or intervention.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "If obstruction is present or intervention is likely antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "is recommended.Use of gentamicin is optional.Contact Gastroenterology for",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "more information.If drainage is incomplete, prophylactic antimicrobials after",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "ERCP may be indicated.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred prophylaxis",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "over 20 minutes ($) [R,O] both beginning 60 minutes before incision",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "($) [R,DI]",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< AND > gentamicin 5mg/kg ($) [R,O] over 20 minutes beginning 60",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "minutes before incision",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford website: Surgical Prophylaxis Gastroduodenal, Biliary",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Prophylaxis in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Medical Letter 2012 vol 10 pages 73-77",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Endoscopy 2008 vol 67 pages 791-795", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG ERCP INCOMP DRAINAGE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJZID AMOX/CLAV 875-125MG PO Q12H", "Text" : "Amoxicillin-clavulante 875/125 mg PO q12h ($) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIAL PROPHYLAXIS AFTER ERCP WITH INCOMPLETE DRAINAGE",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The risk of symptomatic infection is increased when drainage of the common bile",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "duct is incomplete or if dye is trapped in the biliary tract.In such cases,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "give antimicrobials for 5 days.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Up to date website",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Guideline: Antibiotic prophylaxis for GI endoscopy, Gastrointestinal",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Endoscopy 2008, vol 67 pages 791-795", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG GASTRODUODENAL SURG", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IVPB GASTRIC PREOP", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GASTRODUODENAL SURGERY",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Prophylaxis is indicated in procedures involving entry into lumen of",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "gastrointestinal tract.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "For procedures without entry into gastrointestinal tract, prophylaxis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "is indicated only in patients with unusual risk for infection.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : ">>Patients with high gastric pH or acid-suppression therapy,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : ">>Patients with decreased gastroduodenal motility due to obstruction,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "hemorrhage, gastric ulcer, malignancy, or diabetic gastroparesis, or",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : ">>Obese patients",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Prophylaxis",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Medical Letter 2012 vol 10 pages 73-77",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG<AND> CIPROFLO 400 GASTRICPREOP", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "($) [H,O] < AND > Ciprofloxacin 400 mg IV over 60 minutes beginning 120 minutes",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "before incision ($) [R,O]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "For a patient with a history of anaphylactic shock or severe allergy to",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "penicillin OR beta-lactam antibiotic please order:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Less than 120kg:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Greater than or equal to 120kg:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 3GM IV ONCE GASTRIC PREOP", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG GENTAMICIN IV SPECIFIC DOSING", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 240 MG IVPB DOSE LESS 50KG PREOP", "Text" : "Gentamicin 240 mg IV beginning 60 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 300 MG IVPB DOSE 50-75KG PREOP", "Text" : "Gentamicin 300 mg IV beginning 60 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 400 MG IVPB DOSE 75-100KG PREOP", "Text" : "Gentamicin 400 mg beginning 60 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 500 MG IVPB DOSE 100-125KG PREOP", "Text" : "Gentamin 500 mg beginning 60 minues before incision ($) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 600 MG IVPB 100-125 KG PREOP", "Text" : "Gentamicin 600 mg IV beginning 60 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Recommended Gentamicin Doses based on patient weight:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Weight equal/less 50kg:",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Weight greater 50 kg and less 75 kg",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Weight equal 75 kg and less than 100kg:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Weight equal to 100 kg and less than 120kg:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Weight equal/greater 120 kg:", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG GYNECOL SURG", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG GENTAMICIN 5MG/KG PREOP", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GYNECOLOGICAL SURGERY",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Prophylaxis is indicated for abdominal or vaginal hysterectomy with either open",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "or laparoscopic approach.Antimicrobials are not indicated after incisions are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "closed.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred prophylaxis",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative in patients with beta lactam allergy",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "($) [H,O] <AND> gentamicin 5 mg/kg IV over 30 minutes beginning 60 minutes",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "before incision ($) [R,O]",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG HEAD AND NECK SURG", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes, beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID AMPICILLIN-SULBACTAM 3GM IV ONCE PREOP", "Text" : "Ampicillin-sulbactam 3 gm IV over 30 minutes beginning 60 minutes before", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX CEFAZO 2GM IV 30MIN METRON 500MG IV X1", "Text" : "Cefazolin 2gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "HEAD AND NECK SURGERY",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Clean procedures include thyroidectomy and lymph node excisions.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Clean-contaminated procedures include all procedures involving an incision",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "through the oral or pharyngeal mucosa. Clean-contaminated procedures include",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "esophagectomy.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Clean procedures, no prosthesis:No antimicrobial prophylaxis recommended.",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Clean, prosthesis inserted:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Post-op doses are not indicated.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Post-op doses are not indicated.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Clean-contaminated procedures** including cancer surgery:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "incision. ($) [R]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendations includes q6h for 3 doses post-op.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Please place post-op antimicrobial prophylaxis order after admission.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "($) [R] <AND> metronidazole 500 mg IV over 30 minutes beginning 60",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "minutes before incision ($) [DI]",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendations includes BOTH MEDICATIONS q8h for 2 doses post-op.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Please place post-op antimicrobial prophylaxis orders after admission.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order after admission.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "**Prophylaxis not indicated for tonsillectomy or functional endoscopic sinus",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "procedures.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG HERNIA REPAIR", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 mg/kg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 mg/kg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HERNIA REPAIR SURGERY",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Surgical prophylaxis is recommended for hernioplasty and herniorrhaphy.For",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "patients known to be colonized with MRSA, add a single dose of vancomycin",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to the preferred agent (cefazolin).",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are not indicated after incisions are closed.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred prophylaxis",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "($) [R}",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For patients colonized with MRSA ADD Vancomycin in addition to cefazolin:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta lactam allergy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "($) [H,O]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG NEUROSURGERY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "NEUROSURGERY",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Risk factors for postoperative infections following neurologic procedures",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "include diabetes, procedure duration longer than two to four hours, placement",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "of a foreign body, repeat surgery, emergency surgery, cerebrospinal fluid",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(CSF) leak, postoperative intracranial pressure monitoring or presence of a",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "ventricular drain for more than five days postoperatively, and concurrent or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "prior infection of an incision or shunt.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "In spinal surgery, the infection rate after conventional lumbar discectomy is",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "low, but due to the severe consequences of postoperative infection at this site",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "antimicrobial prophylaxis is recommended. Infection rates are higher after",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "prolonged spinal surgery or spinal procedures involving fusion or insertion of",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "foreign material, and antimicrobial prophylaxis is also recommended.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is warranted for patients undergoing clean craniotomy",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "CSF shunt procedures, or intrathecal pump placement.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "For all other neurosurgical procedures, antimicrobial prophylaxis is not",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "indicated.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Cefazolin is preferred for most patients as it penetrates into the cerebrospinal",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "fluid and is more active than vancomycin against susceptible staphylococci.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Vancomycin should be used when the patient is colonized or has been recently",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "infected with methicillin-resistant Staphylococcus aureus.Consult Neurosurgery",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "or Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Letter 2012 Vol 10 pages 73-77", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG OPHTHALMIC SURG", "Contents" : [
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID MOXIFLOXACIN (VIGAMOX) 0.5% EYE DROPS CATARACT SURGERY", "Text" : "Moxifloxacin 0.5% Eye Drops INTRACAMERAL for Cataract Surgery (0.5mg/0.1ml)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OPHTHALMIC SURGERY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "When indicated, ophthalmology will order antimicrobial prophylaxis before",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "procedures.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Cataract Surgery",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Intracameral moxifloxacin is recommended for use to reduce the risk of",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "post-operative endophthalmitis after cataract surgery only in those patients",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "at highest risk of infection, including the following:",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "* Patients with prior intravitreal injections",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "* Immunosuppressed patients",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "* Patients with significant ocular surface eyelid disease",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "* Complication occurs during surgery (i.e. capusle rupture, vitreous loss)",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "* Other possible high risk situations as they arise but not listed above",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Arshinoff S., J Cataract Refract Surg, (2016) 42:1730-1741",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG ORTHO ALBC HIP AND KNEE JOINT INFECTIONS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX VANCO + CEFUROXIME ALBC SPACER ORTHO", "Text" : "Cefuroxime and vancomycin ALBC order set", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX VANCO + AZTREONAM ALBC SPACER ORTHO", "Text" : "Aztreonam and vancomycin ALBC order set", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ GTX ABX ALBC ORTHOPEDIC HYPERLINK", "Text" : "Select here for full protocol", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MVAHCS Protocol for Antibiotic Loaded Bone Cement (ALBC) for",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Treatment of Periprosthetic Hip and Knee Joint Infections",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Patient Classification:",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "No beta-lactam allergy: gram-positive and/or non-pseudomonas",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "gram-negative infection",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Patient Classification:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Beta-lactam allergy, any infecting organism OR No beta-lactam allergy,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "but with documented pseudomonas infection",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "MVAHCS Protocol for Use of Antibiotic Loaded Cement (ALBC) for Treatment of",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Periprosthetic Hip and Knee Joint Infections at The Minneapolis VA",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Medical Center, July 2017", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG ORTHO SURG JOINT ARTHRO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 102, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 110, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 117, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 123, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 129, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ORTHOPAEDIC SURGERY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is not recommended for most clean procedures,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "including knee, hand or foot procedures, arthroscopy, or other procedures",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "without implantation of foreign materials.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Prophylaxis is indicated for joint replacement, internal fixation, or hip",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "fracture repair.Open fractures should be treated as infected.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Cefazolin is preferred for prophylaxis, as it is more active than vancomycin",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "against susceptible staphylococci, the most common surgical pathogens.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Vancomycin should be used when methicillin-resistant Staphylococcus aureus",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "infection, in patients who are colonized or were recently infected with",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "methicillin-resistant Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Prophylaxis beyond 24 hours is not supported by current data and guidelines.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Longer durations provide no additional benefit and are associated with",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "side effects, increased costs, and bacterial resistance.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Also, there is no evidence of benefit of antimicrobial administration until",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "all drains or catheters are removed.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Clean operations involving hand, knee, or foot and NOT involving implantation",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "of foreign materials: (Select below)",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Total Joint Replacement",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Known MRSA colonization:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Hip Fracture Repair:",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]< OR >",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Known MRSA colonization:",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Implantation of Internal Fixation Devices (e.g. nails, screws,",  "Header" : 1}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "plates, wires):",  "Header" : 1}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]< OR >",  "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place",  "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 101, "Column" : 1, "Item" : null, "Text" : "Known MRSA colonization:",  "Header" : 0}, 
{"Row" : 103, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place",  "Header" : 0}, 
{"Row" : 104, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 105, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 107, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Orthopedic Spinal Procedures with and without instrumentation",  "Header" : 1}, 
{"Row" : 108, "Column" : 1, "Item" : null, "Text" : "(e.g. rods, plates):",  "Header" : 1}, 
{"Row" : 109, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 111, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 112, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 113, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 114, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 116, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 0}, 
{"Row" : 118, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]< OR >",  "Header" : 0}, 
{"Row" : 119, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 120, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 121, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 124, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place",  "Header" : 0}, 
{"Row" : 125, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 126, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 128, "Column" : 1, "Item" : null, "Text" : "Known MRSA colonization:",  "Header" : 0}, 
{"Row" : 130, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place",  "Header" : 0}, 
{"Row" : 131, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order from orthopedic standing post-op orders",  "Header" : 0}, 
{"Row" : 132, "Column" : 1, "Item" : null, "Text" : "AFTER patient is admitted.",  "Header" : 0}, 
{"Row" : 134, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 135, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 136, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013, vol 70 pages 195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG OTHER PROCEDURES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OTHER PROCEDURES",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In view of the small number of wound infections that would be prevented by",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "systemic antimicrobial prophylaxis the risks outweigh benefits for patients who",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "will have cardiac catheterization, varicose vein surgery, most dermatologic and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "plastic surgery, arterial puncture, thoracentesis, paracentesis, repair of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "simple lacerations, outpatient treatment of burns, dental extractions, or root",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "canal therapy.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG PLASTIC SURGERY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PLASTIC SURGERY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is not recommended for most clean procedures in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "patients without additional postoperative infection risk factors.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Risk factors that increase the risk of postoperative infectious complications",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "for plastic surgery procedures include implants, skin irradiation before the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "procedure, and procedures below the waist.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is recommended for clean-contaminated procedures,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "breast cancer procedures, and clean procedures with risk factors. A single",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "preoperative dose is recommended.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Clean with risk factors or clean-contaminated:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Preferred Prophylaxis:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Letter 2012 Vol 10 pages 73-77", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG PODIATRY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "[Select here] No antimicrobial prophylaxis recommended for procedure/surgery", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Letter 2012 Vol 10 pages 73-77",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Podiatry Surgery",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Known MRSA colonization:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For patients weight < 120kg:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "For patients weight >/= 120kg:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 3GM IVPB ONCE PREOP", "Text" : "", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZID2 GMENU SURG WND CLASS PROPHYL REC", "Text" : "[Select here] Surgical wound classification and prophlaxis recommendations", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE PODIATRY ORDER", "Text" : "[Select here] No antimicrobial prophylaxis, already on concurrent antimicrobials", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select appropriate order below:", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG POST-OP WND INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU SURG W/I 48HRS PROCEDURE", "Text" : "Patients with signs of infection WITHIN 48 HOURS of procedure", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU SURG 48HRS AFTER PROC", "Text" : "Patients with signs of infection 48 HOURS OR MORE after procedure", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "POST-OPERATIVE WOUND INFECTION",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Surgical site infections are categorized by the extent of tissues involved.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Superficial incisional infections involve only the subcutaneous space and occur",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "within 30 days of operation.Deep incisional infections involve deep layers of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "soft tissue, such as fascia and muscle, and occur within 30 days of operation,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "or within 1 year of operation if prosthetic material was inserted.Organ/space",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "infections involve anatomical areas other than the incisional wound that were",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "opened or manipulated during operation.Organ/space infections should be",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "treated as infections of the relevant area of the anatomy.Return to the main",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "page and choose the pertinent organ system for advice on management of these",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "infections.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Post-operative wound infections usually occur between 2 and 30 days after the",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "operation.Infections within 48 hours of the surgery are uncommon, but are",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "serious when they do occur.Symptoms commonly begin to appear no sooner than 5",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "days after the operation and may take up to 2 weeks to appear.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG PROPHYL GENRL INFO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SURGICAL PROPHYLAXIS COMMON PRINCIPLES",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Potential pathogens are introduced into normally sterile areas of the body",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "during most surgical procedures.The purpose of antimicrobial prophylaxis is to",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "reduce the intraoperative microbial burden so that local host defenses can",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "eliminate microorganisms and prevent disease.Prophylaxis cannot be expected to",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "sterilize tissues.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antimicrobial agent for surgical prophylaxis should be:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "1. active against the pathogens most likely to contaminate the surgical site",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "2. given in an appropriate dosage and at a time that ensures adequate serum",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "and tissue concentrations during the period of potential contamination",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "3. safe, and",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "4. administered for the shortest effective period to minimize adverse",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "effects, the development of resistance, and costs.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Medical Letter 2012 Vol 10 pages 73-77", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG PROPHYLAXIS DOSES AND REDOSING", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Recommended Doses and Redosing Interval",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Existing renal or hepatic dysfunction:",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "for single dose, no modification usually necessary.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIAL",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Ampicillin",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Ampicillin sulbactam",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Aztreonam",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Cefazolin",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Cefuroxime",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Cefoxitin",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Cefotetan",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Ceftriaxone",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Ciprofloxacin",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Clindamycin",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Gentamicin",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Levofloxacin",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Metronidazole",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Piperacilln Tazobactam",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Vancomycin",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Am J Health-Syst Pharm. 2013, 70: 195-283",  "Header" : 1}, 
{"Row" : 33, "Column" : 2, "Item" : "ORZID2 GMENU SURG GENTAMICIN IV SPECIFIC DOSING", "Text" : "Select for Gentamicin doses", "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Select for Vancomycin doses", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "RECOMMENDED DOSE",  "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "2 grams",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "3 grams",  "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "2 grams",  "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "2 grams",  "Header" : 1}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "Recommend 3gm dose patients >=120kg",  "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "1.5 grams",  "Header" : 1}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "2 grams",  "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "2 grams",  "Header" : 1}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "2 grams",  "Header" : 1}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "400 mg",  "Header" : 1}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "900 mg",  "Header" : 1}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : "5mg/kg based on dosing wt*",  "Header" : 1}, 
{"Row" : 35, "Column" : 2, "Item" : null, "Text" : "500 mg",  "Header" : 1}, 
{"Row" : 37, "Column" : 2, "Item" : null, "Text" : "500 mg",  "Header" : 1}, 
{"Row" : 39, "Column" : 2, "Item" : null, "Text" : "3.375 grams",  "Header" : 1}, 
{"Row" : 41, "Column" : 2, "Item" : null, "Text" : "15mg/kg based on dosing wt",  "Header" : 1}, 
{"Row" : 45, "Column" : 2, "Item" : null, "Text" : "Doses based on Dosing Weight (DW)*",  "Header" : 1}, 
{"Row" : 46, "Column" : 2, "Item" : null, "Text" : "*Calculate Dosing Weight (DW)",  "Header" : 1}, 
{"Row" : 47, "Column" : 2, "Item" : null, "Text" : "DW = IBW + 0.4 (ABW - IBW)",  "Header" : 1}, 
{"Row" : 48, "Column" : 2, "Item" : null, "Text" : "IBW=Ideal Body WtABW=Actual Body Wt",  "Header" : 1}, 
{"Row" : 49, "Column" : 2, "Item" : null, "Text" : "Male IBW (kg)=50+2.3 * (Ht-60inches)",  "Header" : 1}, 
{"Row" : 50, "Column" : 2, "Item" : null, "Text" : "Female IBW (kg)=45.5+2.3 * (Ht-60inches)",  "Header" : 1}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Antimicrobial Surgical Prophylaxis",  "Header" : 1}, 
{"Row" : 9, "Column" : 3, "Item" : null, "Text" : "REDOSING INTERVAL**",  "Header" : 1}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "(from initiation of preop dose)",  "Header" : 1}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "2 hours",  "Header" : 1}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "2 hours",  "Header" : 1}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "4 hours",  "Header" : 1}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "4 hours",  "Header" : 1}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "4 hours",  "Header" : 1}, 
{"Row" : 22, "Column" : 3, "Item" : null, "Text" : "2 hours",  "Header" : 1}, 
{"Row" : 24, "Column" : 3, "Item" : null, "Text" : "6 hours",  "Header" : 1}, 
{"Row" : 26, "Column" : 3, "Item" : null, "Text" : "N/A",  "Header" : 1}, 
{"Row" : 28, "Column" : 3, "Item" : null, "Text" : "Do not redose",  "Header" : 1}, 
{"Row" : 30, "Column" : 3, "Item" : null, "Text" : "6 hours",  "Header" : 1}, 
{"Row" : 35, "Column" : 3, "Item" : null, "Text" : "Do not redose",  "Header" : 1}, 
{"Row" : 37, "Column" : 3, "Item" : null, "Text" : "12 hours",  "Header" : 1}, 
{"Row" : 39, "Column" : 3, "Item" : null, "Text" : "2 hours",  "Header" : 1}, 
{"Row" : 41, "Column" : 3, "Item" : null, "Text" : "12 hours",  "Header" : 1}, 
{"Row" : 43, "Column" : 3, "Item" : null, "Text" : "**For those marked N/A--",  "Header" : 1}, 
{"Row" : 44, "Column" : 3, "Item" : null, "Text" : "based on typical case length, for",  "Header" : 1}, 
{"Row" : 45, "Column" : 3, "Item" : null, "Text" : "unusually long procedures,",  "Header" : 1}, 
{"Row" : 46, "Column" : 3, "Item" : null, "Text" : "redosing may be needed.",  "Header" : 1}, 
{"Row" : 32, "Column" : 3, "Item" : null, "Text" : "Do not redose",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "**For those marked N/A -",  "Header" : 1}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "based on typical case length, for",  "Header" : 1}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "unusually long procedures,",  "Header" : 1}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "redosing may be needed.",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "John Hopkins Antibiotic Guide Online Oct2021", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG SPINAL CORD STIMULATOR TRIAL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV ONCE PRE-PROCEDURE PAIN CLINIC", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred Prophylaxis:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta lactam allergy:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Medical Letter 2012 vol 10 pages 73-77",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For patients weight < 120 kg:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For patients weight >/= 120 kg:",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Pain Clinic Antimicrobial Prophylaxis Pre-procedure Orders",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Spinal Cord Stimulator Trial",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 3GM IV ONCE PRE-PROCEDURE PAIN CLINIC", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJIZID CLINDAMYCIN 900MG IV ONCE PRE-PROCEDURE PAIN CLINIC", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG SURGICAL SITE INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU SURG POST-OP WND INFECT", "Text" : "Post-operative wound infection", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX MEDIASTINITIS", "Text" : "Mediastinitis", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatologic Infections", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++SURGICAL SITE INFECTION++",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "++SURGICAL PROPHYLAXIS FOR DERMATOLGY/POST-OP SKIN INFECTION++", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG THORACIC POSTOP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU SURG CIED POSTOP", "Text" : "CIED Surgery Postoperative Prophylaxis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU SURG CV POSTOP", "Text" : "CV Surgery Postoperative Prophylaxis", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 2GM METRONIDAZOLE 500MG 2 DOSES POST OP", "Text" : "Cefazolin 2 gm IV q8h x 2 doses post-op ($) [R] <AND> metronidazole 500 mg IV", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CLINDAM 900MG IV Q8H X2DOSES POSTOP", "Text" : "Clindamycin 900 mg IV q8h x 2 doses post-op ($$)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 15MG/KG POSTOPERATIVE Q12H ONCE", "Text" : "Vancomycin 15 mg/kg IV (pharmacy to dose) q12h x 1 dose post-op ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "THORACIC SURGERY POST-OPERATIVE ANTIMICROBIAL PROPHYLAXIS RECOMMENDATIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Place post-op IV antimicrobial prophylaxis orders after admission to ward.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial prophylaxis should not exceed 24 hours. Durations",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "longer than 24 hours have not been shown effective in preventing cardiothoracic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "surgical site infections. There is no benefit to continuing antimicrobial",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "prophylaxis until all indwelling drains and intravascular catheters are removed.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For CIED surgery postoperative antimicrobial prophylaxis click link below:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "For CV surgery (Open Heart) postoperative prophylaxis click link below:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Esophageal Surgical Procedures Postoperative Prophylaxis",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "q8h x 2 doses post-op ($) [R]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with cephalosporin allergy",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative for patient colonized or recently infected with MRSA",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Non-Esophageal Thoracic Procedures Postoperative Prophylaxis",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Includes video-assisted thoracoscopic surgery (VATS) and non-cardiac procedures",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "including lobectomy, pneumonectomy, lung resection and thoracotomy.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "No postoperative antibiotic prophylaxis is recommended",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Bratzler DW et al, Clinical Practice Guidelines for Antimicrobial Prophylaxis in",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Surgery, Am J Health-Syst Pharm (2013) 70:195-283", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG THORACIC SURGERY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZ SET ABX CEFAZO 2GM IV 30MIN METRON 500MG IV X1", "Text" : "Cefazolin 2gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 20 minutes, beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "THORACIC SURGERY (INCLUDES SECTION ON ESOPHAGEAL PROCEDURES)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Esophageal Surgical Procedures:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Prophylaxis:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "($) [R] <AND> metronidazole 500 mg IV over 30 minutes beginning 60",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "minutes before incision ($) [DI]",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendations includes BOTH MEDICATIONS q8h for 2 doses post-op.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Please place post-op antimicrobial prophylaxis orders after admission.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta-lactam allergy:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "($) [H,O]",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Please place post-op antimicrobial prophylaxis order after admission.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "___________________________________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Thoracic surgery (except for esophageal procedures):",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Includes video-assisted thoracoscopic surgery (VATS) and non-cardiac procedures,",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "including lobectomy, pneumonectomy, lung resection and thoracotomy.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "No post-operative doses are recommended.",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Prophylaxis",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta-lactam allergy:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "($) [H,O]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative for patient colonized or recently infected with MRSA",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The Medical",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Letter 2012 Vol 10 pages 73-77", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG TIMING DOSING PROPHYL ABX", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU SURG PROPHYLAXIS DOSES AND REDOSING", "Text" : "Doses and Redosing Recommendations for Common Antimicrobials", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TIMING AND DOSING (INCLUDING RE-DOSING) OF PROPHYLACTIC ANTIMICROBIALS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For optimal prevention, antimicrobial concentrations should be above the minimal",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "inhibitory concentration (MIC) of potential pathogens from initial incision",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "until closure.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "There is no advantage to giving post-operative doses. Despite a lack of",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "demonstrated benefit, post-operative doses are sometimes given in clinical",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "practice.If post-operative doses are given, they should be discontinued by 24",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "hours after closure of the incision.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "When prophylaxis consists of a single dose as should be the case in the majority",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "of procedures, adjustment for renal or hepatic dysfunction is not necessary.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "The optimal time for administration of preoperative doses is 30 to",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "60 minutes before surgical incision for most antimicrobials.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Infusions of drugs like fluoroquinolones and vancomycin that require longer",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "infusion times should begin 60 to 120 minutes before first incision.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "During procedures that last so long that concentrations might fall below the",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "MICs of potential pathogens, repeated doses of antimicrobials should be given.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Re-dosing may also be warranted if prolonged or excessive bleeding",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "occurs.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Medical Letter 2012 Vol 10 pages 73-77", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG UROLOGICAL PROCED", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX AUA SURGERY PROPHYL", "Text" : "<Hyperlink> AUA Surgical Prophylaxis Guidelines", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJZID NITROFURANTOIN SA 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 MG po Q12H ($) [R,O]-INPATIENT ORDER", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]-OUTPATIENT ORDER", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJZID CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin 500 mg PO q6h ($) [R]-INPATIENT ORDER", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 3DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]-OUTPATIENT ORDER", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSJZID CIPROFL 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]-INPATIENT ORDER", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]-OUTPATIENT ORDER**ADJUST QUANTITY**", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZID2 GMENU ABX CANDIDA UTI", "Text" : "Candida urinary tract infection- INPATIENT", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "Text" : "Candida urinary tract infection- OUTPATIENT", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU PROPHYLAXIS PROSTATE BIOPSY", "Text" : "Link to prophylaxis for TRUSP procedure", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID2 GMENU SURG UROLOGY SURGERY (OPEN,ROBOTIC,LAP)", "Text" : "Link to Urology Surgery Antimicrobial Prophylaxis (OPEN,ROBOTIC,LAP)", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "ORZID2 GMENU SURG GENTAMICIN IV SPECIFIC DOSING", "Text" : "Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : "ORZID2 GMENU SURG GENTAMICIN IV SPECIFIC DOSING", "Text" : "Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : "ORZID2 GMENU SURG GENTAMICIN IV SPECIFIC DOSING", "Text" : "Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 102, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 108, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 111, "Column" : 1, "Item" : "ORZID2 GMENU SURG GENTAMICIN IV SPECIFIC DOSING", "Text" : "Gentamicin 5mg/kg IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 117, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 120, "Column" : 1, "Item" : "ORZ SET ABX CLINDAMYCIN 900MG GENTAMICIN 5MG/KG PREOP", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "UROLOGICAL PROCEDURES",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Though uncommon, most post-operative infections after urological surgery occur",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "when 1) a procedure is done in a person with significant bacteriuria and the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "urinary mucosa is cut, 2) fecal flora enter tissues when the colon or rectal",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "mucosa is cut, or 3) skin flora enter tissues when the skin is cut.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is given to prevent symptomatic infection after",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "procedures with these characteristics.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Patient-related factors affecting host response to surgical infections",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "In situations when the risk benefit ratio supporting antimicrobial",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "prophylaxis is not clear, certain risk factors may tip the balance in favor",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "of prophylaxis. These risk factors include:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Advanced age: Anatomic anomalies of the urinary tract:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Smoking: Chronic corticosteroid use: Immunodeficiency:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Externalized catheters: Colonized endogenous - exogenous material:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Distant coexistent infection: Prolonged hospitalization",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "When surgical prophylaxis is recommended, a single dose of the appropriate",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "antibiotic should be administered prior to the urological procedure",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "UNLESS otherwise noted.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "The recommended antimicrobial prophylaxis is based on the incision site.An",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "antimicrobial active against pathogens likely to be present at the site and",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "to cause post-operative wound infection is needed.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Recommendations are based on AUA guidelines",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Obtain urine culture for invasive or complex urological procedures:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "For invasive or complex urological procedures, whenever possible,",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "please obtain an urine culture a few days before the procedure.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "If bacteriuria or fungiuria is present, select an antimicrobial that will be",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "be effective against organisms that have been isolated.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "If prosthetic material is to be placed, test of cure recommended.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment of bacteriuria before procedures in which urinary mucosa will be cut",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treat for 3 to 7 days.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "If known susceptibility to a fluoroquinolone:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Treatment of funguria before procedures in which urinary mucosa will be cut",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Prevention of Prosthetic Joint Infection Before Genitourinary Procedures",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Recommended prophylaxis TRUSP (transrectal ultrasound biopsy prostate)",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Recommended antimicrobial prophylaxis for Urology Surgery (Open,Robotic,Lap)",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Recommended antimicrobial prophylaxis for Lower Tract Instrumentation",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Procedure: Removal of external urinary catheter",  "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Prophylaxis indicated for patients with higher risk of developing urinary",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "retention, such as BPH, or neurogenic bladder.",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Also could be considered if risk factors.",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "($) [R,O]",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Procedure: Cystography, urodynamic study, or simple cystourethrosocpy",  "Header" : 1}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Prophylaxis not usually indicated, could consider if risk factors.",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta lactam allergy:",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "($) [R,O]",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "Procedure: Cystourethroscopy with manipulation OR Ureteroscopy",  "Header" : 1}, 
{"Row" : 88, "Column" : 1, "Item" : null, "Text" : "Prophylaxis indicated for all procedures.",  "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : null, "Text" : "($) [R,O]",  "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : null, "Text" : "Procedure: Prostate brachytherapy or cyrotherapy",  "Header" : 1}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "Prophylaxis indicated uncertain, assess individual case.",  "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 100, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 101, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 103, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 105, "Column" : 1, "Item" : null, "Text" : "Procedure: Shock-wave lithotripsy",  "Header" : 1}, 
{"Row" : 106, "Column" : 1, "Item" : null, "Text" : "Prophylaxis indicated IF risk factors.",  "Header" : 0}, 
{"Row" : 107, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 109, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 110, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 112, "Column" : 1, "Item" : null, "Text" : "($) [R,O]",  "Header" : 0}, 
{"Row" : 114, "Column" : 1, "Item" : null, "Text" : "Procedure: Percutaneous renal surgery",  "Header" : 1}, 
{"Row" : 115, "Column" : 1, "Item" : null, "Text" : "Prophylaxis indicated for all procedures.",  "Header" : 0}, 
{"Row" : 116, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 118, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 119, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 121, "Column" : 1, "Item" : null, "Text" : "($) [H,O] <AND> Gentamicin 5 mg/kg IV over 30 minutes beginning 60",  "Header" : 0}, 
{"Row" : 122, "Column" : 1, "Item" : null, "Text" : "minutes before incision ($) [R,O]",  "Header" : 0}, 
{"Row" : 124, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 125, "Column" : 1, "Item" : null, "Text" : "Lightner DJ, et al. Best Practice Statement on Urologic Procedures",  "Header" : 0}, 
{"Row" : 126, "Column" : 1, "Item" : null, "Text" : "and Antimicrobial Prophylaxis, The Journal of Urology (2019)",  "Header" : 0}, 
{"Row" : 128, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 129, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG UROLOGY SURGERY (OPEN,ROBOTIC,LAP)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophlaxis recommended", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes beginning 60 minutes before procedure", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 2 GM GENTAMICIN 5MG/KG PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes ($) [R] < AND > gentamicin 5mg/kg", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15 MG/KG IV 60MIN GENT 5MG/KG IV ONCE", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX GENTAMICIN 60MG RIFAMPIN 600MG PENILE IMPLANT SOAK", "Text" : "Penile Implant Soak (Gentamicin 60MG and Rifampin 600MG) prior to implantation", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU SURG COLON AND RECTAL SURG", "Text" : "Link to Bowel Surgery", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Urology Surgery Open, Robotic or Laparoscopic",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Surgery through skin without opening urinary tract",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Prophylaxis indicated IF risk factors.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Vaginal surgery includes urethral sling procedures",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Prophylaxis indicated for all surgeries.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "($$) [H,O]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Surgery involving implanted prosthesis including penile prosthesis",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Prophylaxis indicated for all surgeries.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "over 30 minutes ($) [R,O] both beginning 60 minutes before incision < OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta-lactam allergy or history of MRSA:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< AND > gentamicin 5mg/kg ($) [R,O] over 30 minutes beginning 60",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "minutes before incision",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Soak Solution for Penile Implant prior to implantation in OR",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Urologic surgery with entry into bowel/intestines",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "(Note: updated antibiotics 8/2021 per Dr. J. Bodie, Urologist)",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Reference: Lokeshwar SD, et al. Current Urology Reports (2019) 20:11", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 1000 MG IVPB DOSE LESS 70KG PREOP", "Text" : "Vancomycin 1000 mg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 1500 MG IVPB DOSE 70-100KG PREOP", "Text" : "Vancomycin 1500 mg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 2000MG IVPB DOSE GREATER 100KG PREOP", "Text" : "Vancomycin 2000 mg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Recommended Vancomycin Doses based on patient weight:",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Weight less than 70 kg:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Weight equal/greater 70 kg and equal/less than 100 kg:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Weight greater than 100 kg:", "Header" : 1}
]},
{"Name" : "ORZID2 GMENU SURG VANCOMYCIN POST-OP SPECIFIC DOSING", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Recommended Vancomycin Doses based on patient weight:",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Weight less than 70 kg:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Weight equal/greater 70 kg and equal/less than 100 kg:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Weight greater than 100 kg:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 1000MG POSTOP DOSE LESS 70KG", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID VANCOMCYIN 1500 MG POSTOP DOSE 70-100KG", "Text" : "", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "POSTOP DOSE",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID VANCOMYCIN 2000 MG POSTOP DOSE GREATER 100KG", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG VASCULAR SURG", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes, beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID CLINDAMY 900MG IV ONCE '30MIN'", "Text" : "Clindamycin 900 mg IV over 30 minutes, beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSJIZID CEFAZO 2GM IV ONCE '30MIN' PREOP", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU SURG VANCOMYCIN DOSING SPECIFIC", "Text" : "Vancomycin 15 MG/KG IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSJIZID RIFAMPIN 600 MG VIAL FOR VASCULAR SURGERY", "Text" : "Rifampin Vascular Graft Soak (600mg)", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSJIZID CEFAZOLIN 2GM IV ONCE", "Text" : "Cefazolin 2 gm IV over 30 minutes beginning 60 minutes before incision", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX VANCOM 15 MG/KG IV 60MIN GENT 5MG/KG IV ONCE", "Text" : "Vancomycin 15mg/kg IV beginning 120 minutes before incision ($) [R]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "VASCULAR SURGERY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is not recommended for some procedures, including",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "brachiocephalic procedures (e.g., carotid endarterectomy, brachial artery",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "repair) without implantation of prosthetic material.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is recommended in vascular procedures that involve",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "implantation of prosthetic material and procedures for which there is greater",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "risk of infection, such as aneurysm repair, thromboendarterectomy and vein",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "bypass. Longer duration of antimicrobial prophylaxis therapy is warranted for",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "graft placement.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for vascular procedures OTHER THAN graft placement* and procedures",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "involving the groin** (SEE BELOW FOR * AND **):",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta-lactam allergy:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "($$) [R]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "*Prophylaxis for graft placement procedures:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q8h for 2 doses post-op. Please place",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis orders.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Alternative for beta lactam allergy or MRSA concern:",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendation includes q12h for 1 dose post-op. Please place",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "post-op antimicrobial prophylaxis order.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Rifampin vascular graft soak for INFECTED graft",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "**Prophylaxis for procedures that involve the abdominal aorta or groin incision",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "due to the potential for gastrointestinal flora:",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "($) [R]",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Alternative for beta lactam allergy or MRSA concern:",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "<AND> gentamicin 5 mg/kg IV over 30 minutes ($) [R,O] beginning 60",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "minutes before incision",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial prophylaxis",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 vol 70 pages 195-283",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Medical Letter 2012 vol 10 pages 73-77", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG W/I 48HRS PROCEDURE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU NECROTIZING INFECTIONS", "Text" : "Necrotizing infections", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PATIENTS WITH SIGNS OF INFECTION WITHIN 48 HOURS OF PROCEDURE",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Fever within 48 hours of procedure is usually due to anesthesia or other non-",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infectious factors but Clostridium species and Streptococcus pyogenes can cause",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "early infections.Examine the wound of any patient with systemic signs of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "infection, like fever, within 48 hours of surgery.If there are signs of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "infection consider opening the wound.Obtain a STAT Gram stain and culture of",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "any drainage. If the Gram stain shows evidence of streptococci or clostridia",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "refer to the section on necrotizing infections.If signs of wound infection are",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "absent seek an alternative source of the fever.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU SURG WND CLASS PROPHYL REC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SURGICAL WOUND CLASSIFICATION AND ANTIMICROBIAL PROPHYLAXIS RECOMMENDATIONS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : ">>Clean<<",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "A wound resulting from a procedure in which no inflammation or infection was",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "encountered and the respiratory, alimentary, genital, or uninfected urinary",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "tract was not entered.Clean wounds are closed at the end of surgery and if",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "drainage is necessary wounds are closed with drains in place.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is usually not indicated.Exceptions are procedures",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "in which prosthetic material will be inserted or for operations in which a",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "surgical site infection would be catastrophic.These exceptions include most",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "cardiac operations, joint replacement, revascularization procedures in legs, and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "most neurosurgical operations.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : ">>Clean contaminated<<",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Clean-contaminated wounds are those in which the respiratory, alimentary,",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "genital, or urinary tracts are entered but there is no evidence of infection and",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "there is no major break in technique.These include operations on the biliary",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "tract, appendix, vagina, and oropharynx.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is indicated for most of these procedures.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : ">>Contaminated<<",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Contaminated wounds include an open, fresh, accidental wound, or operations with",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "major breaks in sterile technique, gross spillage from the gastrointestinal",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "tract, or incisions in which acute, non-purulent inflammation is encountered.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are therapeutic and not prophylactic.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : ">>Dirty-Infected<<",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Dirty-infected wounds are old traumatic wounds with devitalized tissue and those",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "that involve existing infection or perforated viscera.The organisms usually",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "have been present in the operative field since before the operation.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are therapeutic and not prophylactic.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Bratzler DW, et al.Clinical practice guidelines for antimicrobial",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "in surgery, Am J Health-Syst Pharm. 2013 Vol 70 page 195-283",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Prophylaxis for Surgery, Treatment Guidelines from The",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Medical Letter 2012 Vol 10 pages 73-77", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU TINEA CAPITIS (RINGWORM)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJZID TERBINAFINE 250MG PO QDAY", "Text" : "Terbinafine 250 mg PO QDAY ($) [R,H,DI,O]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "TINEA CAPITIS (RINGWORM)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Tinea capitis is a common fungal infection of the scalp and hair. It is",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "characterized by itchy, red, raised, scaly patches often sharply defined. The",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "redder margins than centers create impression of ring. Tinea capitis primarily",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "affects prepubescent children, but can affect people of any age.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tinea", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CLOTRIMAZOLE 1% CREAM TOPICAL BID", "Text" : "Clotrimazole 1% cream apply to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID TERBINAFINE 1% CREAM TOP BID", "Text" : "Terbinafine 1% cream apply to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 150MG PO QWEEK", "Text" : "Fluconazole 150mg q week x 2-6 weeks ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJZID TERBINAFINE 250MG PO QDAY", "Text" : "Terbinafine 250 mg PO QDAY x 2 weeks ($) [R,H,DI,O]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Dermatophyte (tinea) Infections",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TINEA PEDIS (ATHLETE'S FOOT), TINEA CORPORIS, TINEA MANUUM, OR TINEA CRURIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Dermatophyte fungal infections are common worldwide. Dermatophytes",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "metabolize and subsist upon keratin in the skin, hair, and nails.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Most tinea infections can often be cured with topical therapy alone.Systemic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "therapy is reserved for severe or refractory infection, recurrent infection, or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "in immunocompromised patients.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Systemic treatment",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tinea", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSJZID TERBINAFINE 250MG PO QDAY", "Text" : "Terbinafine 250 mg PO QDAY ($) [R,H,DI,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TINEA UNGUIUM (ONYCHOMYCOSIS)",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Treat fingernail infections for 6 weeks",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tinea",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Gupta AK, et al. Br J Dermatol 2020 182(2): 287-299",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Up-to-date website: Onychomycosis Management",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Obtain baseline labs prior to starting: CBC, liver enzymes, and serum creatinine",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treat toenail infections for 12 weeks",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Alternative oral therapy:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Preferred Terbinafine first-line oral:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Treat fingernail infections for 3 months",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Treat toenail infections for 6 months",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 300MG PO QWEEK FOR NAIL INFECTION", "Text" : "", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Topical Treatment:",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Ciclopirox is a topical first-line treatment for both fingernails and toenails",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Complete resolution occurs in approximately 7 percent of patients treated",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "daily for 48 weeks.Ciclopirox is a well-tolerated treatment. Potential side",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "effects include temporary nail changes and local skin irritation.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "See accompanying medication pamphlet for specific instructions.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Treatment is continued until nail clearance or up to 48 weeks.",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSJZID CICLOPIROX 8% NAIL LACQUER QDAY REMOVE Q7DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Remove with rubbing alcohol every 7 days. ($) [M]",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Onychomycosis is a fungal infection of the nail that presents with yellow,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "thick, or crumbling nails. Obtain a fungal stain of nail sample prior to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "initiating treatment. Using large nail clippers, remove as much of the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "unattached dystrophic nail as possible. Place the piece of clipped nail plate",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "in formalin jar and send to pathology for fungal stain (PAS). Treatment should",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "only be initiated if stain is positive for fungal elements. Fungal culture is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "NOT recommended.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Cure is unlikely if the entire nail is involved, or if a portion of the lunula",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "is involved. Sometimes after treatment the fungus is cured, but the nail",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "still does not appear normal because once nail dystrophy occurs, that",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "is not reversible.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Systemic therapy is most likely to achieve a cure, especially with more nail",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "involvement. If <25% involvement topical therapy may be considered. If",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : ">50-75% involvement systemic therapy should be considered.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Terbinafine works about 70% of the time to cure the fungus, and reinfection",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "is common, so many patients will need to do more than one course",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "of treatment.Fluconazole pulse dosing response rate is approximately 50%.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "May consider retreatment with oral therapy after one year.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Recommend Dermatology Consult for retreatment after failure of 2 courses of",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "terbinafine or fluconazole.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Oral Treatment:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Toenails take 12-18 months to grow out completely, so improvement should not",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "be expected to be observed for at least 6-9 months.Continued improvement can",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "be experienced following treatment completion.", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU TINEA VERSICOLOR", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJZID KETOCONAZOLE 2% CREAM TOP QDAY", "Text" : "Ketoconazole 2% cream to affected area QDAY for 14 days ($) [M]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJZID TERBINAFINE 1% CRM TOP QDAY", "Text" : "Terbinafine 1% cream apply to affected area QDAY for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJZID SELENIUM SULFIDE LOT 2.5% 10MIN", "Text" : "Selenium sulfide lotion 2.5% apply to affected area, leave on for 10", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJZID FLUCONAZOLE 300MG PO WEEKLY X2 WEEKS", "Text" : "Fluconazole 300 MG PO weekly for 2 weeks ($) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "TINEA VERSICOLOR",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Pityriasis or tinea versicolor is a common superficial fungal infection.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients often present with erythematous, hypo- or hyperpigmented patches,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "usually on the trunk or extremities.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Topical antifungals can be used for limited disease.For disease that involves",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "nails or does not respond to topical therapy, use oral antifungals.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Oily skin products or exposure to hot environments often lead to recurrences.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Return of normal skin color often takes several weeks after the treatment",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "course is finished.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment limited disease:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "minutes, then rinse/shower thoroughly QDAY for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment extensive disease:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tinea",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "AK Gupta AK, J Cutan Med Surg. 2014, 18:79", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU TOXIC SHOCK SYNDROME", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU STREP TOXIC SHOCK SYNDROME", "Text" : "Link to Diagnosis of Streptococcal toxic shock syndrome", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU STAPH TOXIC SHOCK SYNDROME", "Text" : "Link to Diagnosis of Staphylococcal toxic shock syndrome", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX PENICI 4MU IV Q4H CLINDA 900MG IV Q8H", "Text" : "Penicillin 4 million units IV q4h ($) [R] <AND> clindamycin 900 mg", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG AND CLINDA 900MG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> Clindamycin 900 mg IV", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15MG/KG AND CLINDA 900MG IV Q8H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX NAFCIL 2GM IV Q4H CLINDA 900MG Q8H", "Text" : "Nafcillin 2 gm IV q4h ($$) [H,O]) [R] <AND> Clindamycin 900 mg IV q8h ($$", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX CEFAZOLIN 2GM Q8H AND CLINDA 900MG Q8H IV", "Text" : "Cefazolin 2 gm IV q8h ($) [R] <AND> Clindamycin 900 mg IV q8h ($$) [H,O]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "TOXIC SHOCK SYNDROME",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Toxic shock syndrome (TSS) can be associated with either staphylococci or",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "streptococci.Antimicrobial treatment and supportive care is urgent.Click one",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "of the links below for diagnostic criteria.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "_________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment of Streptococcal Toxic Shock Syndrome",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "_________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "IV q8h ($$) [H,O]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "q8h ($$) [H,O]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "_________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment of Staphylococcal Toxic Shock Syndrome",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Use vancomycin initially in case methicillin-resistant Staphylococcus aureus is",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "present.If cultures reveal methicillin-susceptible Staphylococcus aureus",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "(MSSA), change to nafcillin or cefazolin for better antimicrobial activity.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Empirical treatment",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Treatment if MSSA is isolated",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "MMWR 1990, 39(RR-13):1",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford: Staphylococcal toxic shock",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Lappin E, Lancet Infect Dis 2009, 9:281",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU TOXOPLASMA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX PYRIM200MGTHEN50MGQ24H SULFDIAZ1GMQ6H LEUCO10MGQ24H", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 50 mg PO q24h ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX PYRIM200MGTHEN75MGQ24H SULFAD1.5GMQ6H LEUCO10MGQ24H", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 75 mg PO q24h ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX PYRIM200MGTHEN50MGQ24H CLINDA600MGQ6H LEUCO10MGQ24H", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 50 mg PO q24h ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX PYRIM200MGTHEN75MGQ24H CLINDA600MGQ6H LEUCO10MGQ24H", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 75 mg PO q24h ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID TRIMETHOPRIM/SULFAMETH 5/25 MG/KG IV Q12H", "Text" : "Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg IV q12h ($$) [R,DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 5/25 MG/KG PO Q12H", "Text" : "Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX PYRIM 50MG Q24H SULFADIAZ 0.5GM Q6H LEUCO 10MG Q24H", "Text" : "Pyrimethamine 50 mg PO q24h ($$) [DI,O] <AND> sulfadiazine 0.5-1 gm PO q6h", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX PYRIM 50MG Q24H CLINDA 600MG Q8H LEUCO 10MG Q24H", "Text" : "Pyrimethamine 50 mg PO q24h ($$) [DI,O] <AND> clindamycin 600 mg PO q8h ($)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZ SET ABX PYRIME 25MG Q24H ATOVA 750MG Q12H LEUCO 10MG Q24H", "Text" : "Pyrimethamine 25 mg PO q24h ($$) [DI,O] <AND> atovaquone 750-1500 mg PO", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "PSJZID TRIMETH/SULFA 1 DS TABLET PO Q24H", "Text" : "Trimethoprim sulfamethoxazole 1DS tablet PO q24h ($) [R,DI]", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "PSJZID ATOVAQUONE 750MG PO Q12H", "Text" : "Atovaquone 750-1500 mg PO q12h ($) [M]", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "ORZ SET ABX PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY", "Text" : "Pyrimethamine 50 mg q12h for 2 days, then 50 mg PO q24h ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TOXOPLASMA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If patient is immunocompetent and not pregnant, treatment is usually not needed",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "as disease is usually self-limited. Patients who are immunocompromised, pregnant",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "or have severe disease should be treated. Consult Infectious Diseases in all",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Non-pregnant patients",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat immunocompetent patients for 2-4 weeks. Treat immunocompromised patients",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "for 6 weeks or longer if radiologic disease is extensive or response is",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "incomplete at 6 weeks.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Patients weighing <60 kg",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "sulfadiazine 1 gm PO q6h ($$) [DI,O] <AND> leucovorin 10-25 mg PO q24h($) [M]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Patients weighing >60kg",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "sulfadiazine 1.5 gm PO q6h ($$) [DI,O] <AND> leucovorin 10-25 mg PO q24h($) [M]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Preferred alternative for sulfa allergy",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Patients weighing <60 kg",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "clindamycin 600 mg PO q6h ($) [H,O] <AND> leucovorin 10-25 mg PO q24h ($) [M]",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Patients weighing >60 kg",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "clindamycin 600 mg PO q6h ($) [H,O] <AND> leucovorin 10-25 mg PO q24h ($) [M]",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Secondary alternatives",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Chronic Maintenance therapy for immunocompromised patients",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Discontinue maintenance therapy if patient has remained asymptomatic and CD4 >",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "200 cells per microliter.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Maintenance therapy",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "($$) <AND> leucovorin 10-25 mg PO q24h ($) [M]",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Preferred alternative for sulfa allergy",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "[H,O] <AND> leucovorin 10-25 mg PO q24h ($) [M]",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Secondary alternatives",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "q12h ($) [M] <AND> leucovorin 10-25 mg PO q24h ($) [M]",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Pregnant patients",  "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Patient diagnosed <16-18 weeks of gestation",  "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "*Contact Infectious Diseases, non-formulary consult is required for spiramycin",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Spiramycin 1 gm po q8h until week 18 of gestation",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Patient diagnosed >16-18 weeks of gestation",  "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "sulfadiazine 75mg/kg once, then 50mg/kg q12h ($$) [DI,O] <AND> leucovorin 10-25",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "mg PO q24h ($) [M] for 4 weeks or duration of pregnancy if ultrasound evidence",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "of fetal distress",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Toxoplasma gondii",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Toxoplasmosis",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Toxoplasmosis in immunocompetent hosts", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU TRANSPLANTATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TRANSPLANTATION",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Organ transplantation is associated with many host defense defects.Early on,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "surgical wounds may become infected.Preparation for transplantation and anti-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "rejection drugs can induce neutropenia.Later, CMI defects predominate.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Patients become infected with exogenous pathogens and also endogenous pathogens",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "like cytomegalovirus that might have been present in latent or subclinical form.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Cell-mediated immune defects caused by anti-rejection drugs cause patients to be",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "especially susceptible to infections with organisms that infrequently cause",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "disease in healthy people.They include: Pneumocystis jirovecii (formerly",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Pneumocystis carinii), mycobacteria, salmonella, candida, aspergillus,",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Toxoplasma gondii, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus,",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "and cryptosporidia.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "The approach to fever or other signs or symptoms suggesting the possibility of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "an infectious disease depends on the specific defects present in the patient,",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "the nature of the presenting signs and symptoms and a bedside assessment of the",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "severity of illness.Empirical antimicrobials are usually not indicated for",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "fever alone unless the patient has a host defense defect that predisposes to",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "rapid progression of illness like severe neutropenia or splenectomy.Contact",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU TRAVELERS DIARRHEA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO one time dose ($) [M]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJZID AZITHROMYCIN 500MG PO Q24H", "Text" : "Azithromycin 500 mg PO q24h for 3 days ($) [M]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h for 3 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJZID RIFAXAMIN 200MG PO Q8H FOR 3 DAYS", "Text" : "Rifaximin 200 mg q8h for 3 days ($$) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TRAVELER'S DIARRHEA",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Acute non-bloody diarrhea (< 14 days of symptoms)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Most cases are mild and self-limited. Reserve antimicrobial therapy for",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "patients who have severe traveler's diarrhea: pus, or mucus in stool, fever, or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "diarrhea that is incapacitating.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "For more information on when an antimicrobial is indicated or if the patient has",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Empiric antimicrobial treatment for non-bloody severe acute diarrhea",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Subacute diarrhea (>/= 14 days of symptoms)",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Primary treatment is hydration and electrolyte replacement. Empirical",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy is not indicated. Attempt to make a diagnosis with, for",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "example, enteric pathogen PCR testing, Clostridium difficile testing in those",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "who used a PPI or were treated with antimicrobials in the last 8-12 weeks, and",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "endoscopy. If bloody diarrhea, fever, or abdominal pain/tenderness is present",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "the case should be evaluated by Gastroenterology and/or Infectious Diseases.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Travelers Diarrhea",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Travelers' diarrhea: Clinical manifestations, diagnosis, and",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "treatment", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU UROSEPSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX SOFA ONLINE CALCULATOR", "Text" : "Link to sepsis screening tool (SOFA online calculator)", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ GMENU SEPSIS PROTOCOL MAIN INPT", "Text" : "Link to sepsis and septic shock bundle", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX AMPICILLIN 1GM IV Q6H AND GENT 5MG/KG IV Q24H", "Text" : "Ampicillin 1-2 gm IV q6h ($$) [R] <AND> gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 2GM IV Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSJIZID CEFEPIME 2 GM IV Q12H", "Text" : "Cefepime 2 gm IV q12h ($$) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSJIZID PIP/TAZ 3.375 GM IV Q6H (NE-EXTINF,CI-CEFEP/METRO)", "Text" : "Piperacillin-tazobactam 3.375 gm IV q6h ($$) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX CIPRO 400 IV Q12H GENT 5MG/KG IV Q24H", "Text" : "Ciprofloxacin 400 mg IV q12h ($) [R,DI] < AND > gentamicin 5 mg/kg IV q24h", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTEREMIA OR SEPSIS WITH URINARY TRACT SOURCE (AKA UROSEPSIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Early intervention is crucial to prevention of death from sepsis. Patients with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "signs and symptoms of sepsis, like hypotension or end-organ dysfunction, should",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "be treated as outlined in the sepsis pathway. Patients with bacteremia but",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "without signs and symptoms of severe sepsis should be treated with",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antimicrobials for severe urinary tract infection and monitored closely for",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "signs and symptoms of sepsis.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment for patients with signs and/or symptoms of sepsis",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment for patients without signs and/or symptoms of sepsis",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for patient allergic to penicillins and cephalosporins:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "($) [R,O]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Calandra T, Crit Care Med 2005, 33: 1538",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU UVEITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Inpt)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU RETINITIS", "Text" : "VZV or HSV retinitis and ARN", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX CMV RETINITIS", "Text" : "CMV retinitis and ARN", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "UVEITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are non-infectious. Most infectious cases are associated with a",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pathogen causing systemic or central nervous system infection. Diagnosis of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "uveitis usually must be made presumptively due to the technical difficulty of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "sampling the uvea. Cases have been associated with fungi, bacteria, viruses, and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "protozoa like Toxoplasma gondii.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For treatment of posterior uveitis (retinitis) or acute retinal necrosis (ARN)",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "due to Varicella-zoster virus (VZV) or herpes simplex virus (HSV) or",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Cytomegalovirus (CMV)",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment of uveitis involves treating the underlying infection and is usually",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "systemic. Refer to specific pathogen recommendations for treatment of underlyin",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "infection. Contact Ophthalmology and/or Infectious Diseases for assistance.",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious causes of uveitis", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU VERTEBRAL (DISKITIS) OSTEOM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX VANCO 15 MG/KG IV Q12H CEFTRIAX 2GM IV Q24H", "Text" : "Vancomycin 15 mg/kg IV q12h ($) [R] <AND> Ceftriaxone 2GM IV", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX VAN 15 mg/kg IV Q12H CIPRO 400 MG IV Q12H", "Text" : "Vancomycin 15mg/kg IV q12h ($) [R] <AND> Ciprofloxacin 400mg IV q12h ($) [R,DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DISKITIS AND VERTEBRAL OSTEOMYELITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "About half of cases of diskitis are culture negative, and many of those appear",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to be uninfected.Infectious cases often result from a surgical procedure near",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "the disk or back trauma.Vertebral osteomyelitis usually results from",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "hematogenous seeding or directly from nearby organs.Patients usually present",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with subacute or chronic pain which is often attributed initially to other",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "conditions including osteoarthritis, trauma, and malignancy.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "When possible obtain diagnostic cultures before starting empiric therapy.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Obtain blood cultures and image guided aspirates or surgical bone biopsy.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Definitive therapy based on culture and susceptibility test results.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "The most common causes of vertebral osteomyelitis are staphylococci,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "streptococci, and gram-negative bacilli. Anaerobes are uncommon pathogens.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "If cultures are negative but infection is suspected, direct empirical",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "therapy against the most common pathogens.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Surgical intervention and spinal stabilization may be required.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Surgery and Infectious Diseases consultations are essential.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Recommended duration of therapy:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treat for 6 to 8 weeks for low risk infections.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treat for at least 8 weeks of pathogen-directed IV/PO therapy for high risk",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "including MRSA infection, ESRD, or undrained abscess or device implantation.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Once culture and susceptibility testing is available switch to",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "pathogen directed therapy.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Empiric therapy:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Recommended:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "q24h ($) [M]",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Alternative for allergy to penicillin:",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date online",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Park KH Clin Infect Dis 2016, 62:1262",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26", "Header" : 0}
]},
{"Name" : "ORZID2 GMENU YERSINIA ENTEROCOLITICA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSJZID CIPROFLOXACIN 500MG PO Q12H", "Text" : "Ciprofloxacin 500 mg PO q12h for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSJZID TMP/SMX DS PO Q12H", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet q12h for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX CEFTRIAXONE 2G Q24H GENT 5MG/KG Q24H", "Text" : "Ceftriaxone 2 gm IV q24h ($) [M] <AND> gentamicin 5 mg/kg IV q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "YERSINIA ENTEROCOLITICA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are indicated only for patients with severe disease or immune",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "compromise.For patients with extra-intestinal disease, consult Infectious",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Diseases or Gastroenterology for more information.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Primary treatment of gastroenteritis",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of severe gastroenteritis or immunocompromised patient",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative for fluoroquinolone intolerant patients",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of extra-intestinal infection",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "for 2-3 weeks",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastroenteritis, Yersinia enterocolitica",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of Yersinia enterocolitica and",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Yersinia pseudotuberculosis infection", "Header" : 0}
]},
{"Name" : "ORZID2 TEST PEP OCCUPATIONAL 2", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "01 Exposure to potentially infectious substance?",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "|",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "NO",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "YES",  "Header" : 1}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "|",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "|",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "NO PEP",  "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "|",  "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "02 Percutaneous exposure or exposure on non-intact",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "skin or mucous membrane?",  "Header" : 1}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "| |",  "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "NOYES",  "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "| |",  "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "NO PEP03HIV positive or suspect source?",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "HIV, PEP Algorithm (Post Exposure Prophylaxis Algorithm)",  "Header" : 1}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "| |",  "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "NO PEPPEP",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Select the question at the decision point to display information",  "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "04 Select to Order PEP Medication",  "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "|",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "**Recommended to contact Infectious Disease on-call for all cases:",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Select for link to on-call calendar", "Header" : 0}
]},
{"Name" : "ORZID2 TESTING COST $", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "This is a test of automacro and its functionality",  "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Test line 2",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Test Line 3",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Test Line4", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABSCESSES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU CUTANEOUS ABSCESS", "Text" : "Cutaneous abscess", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perirectal abscess", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Furuncles and carbuncles", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU PYOMYOSITIS", "Text" : "Pyomyositis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ABSCESSES: CUTANEOUS ABSCESS, FURUNCLE, AND CARBUNCLE",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "This section describes management of skin and soft tissue infections.For",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "information on abscesses in other areas, please return to the main CDSS menu and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "choose the appropriate organ system.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX APPROACH TO UTI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPROACH TO URINARY TRACT INFECTION (UTI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In most infants, children, and young adults, urine typically has few or no",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "detectable bacteria. When bacteriuria (>= 10,000 bacteria/ml urine) occurs in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "these groups, it often results from a recognizable risk factor like congenital",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "or acquired structural abnormalities in children or young adults or sexual",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "intercourse in young women. As men and women progress through middle age and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "beyond, bacteriuria is increasingly prevalent because of laxity of the urinary",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "sphincter and urethra or supporting pelvic structures and prostatic",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "hypertrophy. Asymptomatic bacteriuria is present in the majority of elderly",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "people with chronic illness. Asymptomatic bacteriuria is not harmful and should",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "not be treated with antimicrobials except in pregnant women or just before and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "during urological surgery.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "When patients present with urinary tract infection (UTI) symptoms, obtain",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "urinalysis with microscopic examination. Depending on symptoms and signs,",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "clinicians should also order semi-quantitative urine culture, blood cultures,",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "renal ultrasound, or cystoscopy.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Cystitis refers to infection of the urinary bladder, but inflammation often",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "extends into the urethra. Typical symptoms and signs include dysuria, increased",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "urinary frequency, urgency, and/or suprapubic tenderness.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Pyelonephritis refers to infection of the kidney, renal pelvis or ureter.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Typical symptoms and signs include flank pain or tenderness, chills and/or",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "fever. The urinalysis may have white cell casts. Signs or symptoms of cystitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "are often present also.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Complicated or uncomplicated?",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Treatment and follow-up plans depend on whether an infection is considered",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "complicated or uncomplicated. Infection is considered complicated when one",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "or more of the following is present:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "> Most men with cystitis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "> Pregnant women",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "> Structural abnormalities (e.g. presence of obstruction, catheter or",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "nephrostomy tubes, neurogenic bladder)",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "> Metabolic abnormalities that reduce local host defenses (e.g. diabetes,",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "pregnancy, neutropenia, pelvic irradiation)",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "> Unusual or resistant pathogen",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "> Treatment failure or relapse or recurrence of infection",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Prevention of urinary tract infections in patients who are incontinent of urine",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Use indwelling (Foley) catheters only when needed for careful fluid management",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "or in cases where diapers or intermittent straight-catheterization are not",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "possible. Indwelling catheters substantially increase the risk of symptomatic",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "urinary tract infection and subsequent septicemia and death. Treatment of",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "recurrent infections in people with indwelling catheters selects for resistant",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "organisms, which are difficult to treat. These resistant organisms represent a",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "threat to the catheterized patients and others in the environment.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Individuals who cannot drain their bladders are best managed with intermittent",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "straight catheterization. The bladder should be drained 5 or 6 times daily to",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "simulate normal bladder function and effectively prevent cystitis. Individuals",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "who are incontinent from structural, physiological, or mental dysfunction should",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "wear diapers. This keeps the bladder and urethra free of foreign bodies, allows",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "them to drain, and reduces the incidence of urinary tract infection to",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "background levels. Modern, disposable diapers are convenient, non-obtrusive,",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "and inexpensive.",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary Tract Infection",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nosocomial Urinary Tract Infection",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Hooten et al, Clinical Infectious Diseases (2010) 50.625-663", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX BEBTELOVIMAB EUA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help page (instructions, microbiology, drug properties, etc.)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "Text" : "[Click here] PROVIDER/PHARMACIST to complete EUA prior to ordering/administering", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PATIENT EUA FACT SHEET", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Bebtelovimab", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Bebtelovimab", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ GTX ABX URL BEBTELOVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Bebtelovimab (EUA)",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-Bebtelovimab is available via FDA Emergency Use Authorization (EUA)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "for treating patients that meet specific criteria. bebtelovimab is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "not FDA approved drug.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "-Bebtelovimab EUA does NOT include post-exposure prophylaxis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Bebtelovimab Emergency Use Authorization (EUA)",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "**Treatment:**",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "ID available to discuss if needed.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Inclusion Criteria",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "ALL of the following criteria must be met for a patient to receive:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "1) Patient has a laboratory-confirmed diagnosis of mild to moderate COVID-19.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "2) Patient is not hospitalized due to COVID-19.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Note: patient may be hospitalized for some other reason.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "increase in baseline oxygen flow rate due to COVID-19.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "4) Administration will begin within 7 days of symptom onset.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "5) Patient does not have known hypersensitivity to bebtelovimab or components.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "6) Patient has at least one risk factor for progression to severe disease",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "including hospitalization or death.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "See link below for complete list:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "The provider has communicated with the patient/caregiver regarding",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "unapproved drug that is authorized for use under an EUA, given information",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Exclusion Criteria",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "If patient recieved tixagevimab plus cilgavimab previously, discuss with ID.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "If patient agreeable and meets criteria, please contact Minneapolis VA Emergency",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Department charge nurse at 31-6736 to arrange for treatment if available. Click",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "*Patients treated with this drug should continue to self-isolate and use",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "infection control measures (wear mask, isolate, social distance, avoid",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "frequent handwashing) according to CDC guidelines.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "text order below to complete order form for ED administration.",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Note: order does not contain medication order. ED provider will order.",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : "GMRCTZ COVID-19 BEBTELOVIMAB INFO", "Text" : "ED text order for administration of INV-Bebtelovimab 175 mg IV Push ONCE", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX CANDIDA UTI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 400MG PO QDAY", "Text" : "Fluconazole 400 mg (6 mg/kg) PO QDAY for 3 days before and 3 days after", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 200MG QDAY 14 DAYS", "Text" : "Fluconazole 200 mg (3 mg/kg) PO QDAY for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 200MG QDAY 14 DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 400MG PO QDAY", "Text" : "Fluconazole 400 mg (6 mg/kg) PO QDAY for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA URINARY TRACT INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A positive urine culture for candida usually reflects colonization. Treat",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cystitis only if the patient has symptoms of urinary tract infection (e.g.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "dysuria, frequency, urgency, and/or suprapubic tenderness) or if the patient",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "will undergo invasive urological manipulation",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Asymptomatic candiduria in a patient with a urinary catheter should not be",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "treated without an additional indication. Removal of catheter is strongly",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "recommended. Contact Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Neutropenic patients with asymptomatic candiduria should be assessed for",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "candidemia because they are at risk of dissemintation. Obtain blood cultures and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "assess potential sources of candidemia such as central venous catheters. Refer",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "to fungemia page in the Inpatient Antimicrobialc CDSS for treatment",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "recommendations.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment of patient undergoing invasive urological manipulation",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "procedure ($) [R,DI]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment of symptomatic candida cystitis:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment of pyelonephritis",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Alternative for resistant candida",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "IDSA Guidelines: Pappas et al, Clin Infect Dis (2016) 62.409",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary Tract Infections",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Candida Infections of the Bladder and Kidneys",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-To Date article: Epidemiology and pathogenesis of candidemia in adults",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Urinary Tract Infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX CARD SURGERY DECOLON", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZ SET ABX CHLORHEX MUPIRO DECOLON CARDIOTHOR", "Text" : "Chlorhexidine 4% liquid topically Q24h ($) [M] < AND > Mupirocin 2%", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX INPT CHLORHEX MUPIRO DECOLON CARDIOTHOR", "Text" : "Chlorhexidine 4% liquid topically Q24h ($) [M] nursing text order", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Cardiac Surgery MRSA/MSSA Decolonization Protocol Pre-Op",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Outpatient",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "ointment topically Q12h ($) [M]",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Inpatient",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "If patient is discharged prior to surgery, place outpatient orders as well",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "< AND > Mupirocin 2% ointment topically Q12h ($) [M]",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "adults: Prevention and control", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX CMV MAIN PAGE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU CMV COLITIS/ESOPHAGITIS", "Text" : "Colitis or esophagitis", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU CMV ENCEPHALITIS", "Text" : "Encephalitis", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU CMV POLYRADICULOPATHY", "Text" : "Polyradiculopathy", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU CMV RETINITIS", "Text" : "Retinitis", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU CMV PNEUMONIA", "Text" : "Pneumonia", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CYTOMEGALOVIRUS (CMV)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antiviral toxicity information",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "The major toxicities of both ganciclovir and valganciclovir are neutropenia.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Nephrotoxicity is the major toxicity associated with foscarnet, which may be",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "reduced by concomitant saline administration (generally 0.5-1L).",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patient",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Infection is rare and usually associated with minimal or no symptoms.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Mononucleosis can be associated with CMV, but is more commonly associated with",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Epstein Barr virus. Antiviral treatment is not usually necessary as most",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "patients recover without intervention.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patient",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Patients in whom the risk for CMV disease is increased include solid organ and",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "bone marrow transplant recipients, persons receiving prolonged immunosuppressive",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "chemotherapy, and persons with advanced HIV disease indicated by a CD4 count of",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "less than 50 cells/microliter.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "CMV treatment recommendations",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR OP", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COLONIZED RESPIRATORY TRACT IN A PATIENT ON A VENTILATOR",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The respiratory tracts of persons who are intubated, have a",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "tracheostomy, or have other abnormalities of the larynx or trachea are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "usually colonized with bacteria and often fungi. The bacteria can be of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "relatively low virulence (e.g. coagulase negative staphylococci, streptococci,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "candida) or of potentially greater virulence (Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "enterobacteriaceae, pseudomonas). Candida and enterococci are common",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "respiratory tract colonizers and they almost never cause pneumonia. There is",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "no benefit from treatment of patients with systemic antimicrobials simply",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "because the respiratory tract is colonized with a potential pathogen and there",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "is no evidence of an infiltrate. Systemic antimicrobial therapy will select for",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "resistant organisms and may lead to other adverse effects.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for ventilator-associated pneumonia",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "treatment recommendations in patients with a new or progressive infiltrate and",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "at least one of the following: fever greater than 100.4F, leukocytosis,",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "leukopenia or purulent bronchial secretions.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Kalil et al. Clin Infect Dis, 2016, 63(5): e61-e111.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX COLONIZED WOUNDS OP", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU DECUBITIS ULCERS", "Text" : "Decubitus ulcers", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "Text" : "Diabetic foot ulcers", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COLONIZED WOUNDS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Open wounds are usually colonized with bacteria and often fungi. This is true of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "ulcers (see below), post-operative wounds, traumatic wounds, and others. Then",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "bacteria can be of relatively low virulence (eg, coagulase negative",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "staphylococci, diphtheroids) or of potentially greater virulence (Staphylococcus",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "aureus, enterobacteriaceae, pseudomonas). Candida is commonly present on wounds",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "that are moist or covered. There is no need to treat patients with systemic",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobials simply because a wound culture is positive for a potential",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "pathogen. Topical antimicrobials are not effective in nearly all circumstances",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "and can select for resistant organisms or lead to other adverse effects.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Systemic antimicrobial therapy may be indicated if there are signs of infection.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Lipsky et al, Clin Infect Dis, 2012, 54(12): e132-e173",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clinical assessment of chronic wounds", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX COVID-19 MPLS PHARMACOLOGIC GUIDELINES OPT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZ GTX ABX URL MINNEAPOLIS COVID SHAREPOINT SITE", "Text" : "Minneapolis VAHCS COVID-19 SharePoint Site", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "Minneapolis On-Call Schedule - Infectious Disease", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 MONOCLONAL ANTIBODY SOP", "Text" : "Minneapolis VAHCS COVID Monocolonal Antibody and Antiviral Allocation SOP", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA", "Text" : "Paxlovid (EUA)", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ABX MOLNUPIRAVIR EUA", "Text" : "Molnupiravir (EUA)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OUTPATIENT COVID-19 PHARMACOLOGIC TREATMENT GUIDELINES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Minneapolis VAHCS COVID-19 SharePoint site for additional info.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "***COVID-19 therapy is a rapidly evolving field, including the widespread",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "dissemination of therapies with little or no evidence for benefit. Therapies an",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "dosages not specifically listed here or on the NIH clinical guidelines should b",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "discussed with the infectious diseases service. ***",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "OUTPATIENT TREATMENT OF COVID-19",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If you have any questions on the selection of therapy, please contact Infectious",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Disease.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "DECIDE ON APPROPRIATE TREATMENT PLAN BY REFERRING TO ALLOCATION SOP BELOW",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "ORAL COVID-19 ANTIVIRALS (Paxlovid or Molnupiravir):",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Please contact Pharmacy to determine supply and availability.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Outpatient Pharmacy - Mon-Fri 0800-2130 and Weekend/Holidays 0900-1700: 31-3144",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Inpatient Pharmacy - Off-Tours: 31-3128",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "*Please be ready to spend time on the phone with the pharmacist to complete EUA",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "documentation, address medication questions and determine the best method of",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "delivery.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "MONOCLONAL ANTIBODY:",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX BEBTELOVIMAB EUA", "Text" : "Bebtelovimab (EUA)", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ GTX ABX URL COVID-19 MED INTERACTION CHECKER", "Text" : "Interaction checker for COVID-19 medications website link", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX DERM IE JI PROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INFECTED SKIN SURGICAL SITE PROSTHETIC JOINT INFECTION PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Hematogenous prosthetic joint infection high risk conditions:",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "1. First two years following joint replacement",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "2. Previous prosthetic joint infection",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "3. Immunocompromised",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "4. Insulin dependent diabetes",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "5. HIV infection",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "6. Malignancy",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "7. Malnutrition",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "8. Hemophilia",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Nishimura et al, J Am Coll Cardiol (2014) 63, e57-185",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "infection in adults",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for the prevention of bacterial",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "endocarditis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Wilson et al, Circulation (2007) 116, 1736-1754",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is indicated in procedures involving infected skin",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If patient has one or more of the above conditions, antimicrobial prophylaxis is",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "indicated. Use the following link for antimicrobial prophylaxis recommendations.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX PROCED FOR INFECTED SKIN OUTPATIENT", "Text" : "Antimicrobial Prophylaxis in Patients with Prosthetic Joints", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "skin structures, or infected musculoskeletal tissue when the patient is at",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "high risk of hematogenous prosthetic joint infection.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX ENTERIC FEVER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 7-10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 AZITHRO 1000MG ONCE THEN 500MG PO QDAY 5DS", "Text" : "Azithromycin 1 gm PO once then 500 mg PO QDAY for 5 to 7 days ($) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 AZITHRO 1000MG ONCE THEN 500MG PO QDAY 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTERIC FEVER (INCLUDING TYPHOID AND PARATYPHOID FEVER)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Enteric fever is a systemic febrile illness caused by Salmonella enterica",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "serotypes Typhi and Paratyphi A, B, or C. It is characterized by dramatic fever",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "and abdominal pain. Enteric fever typically occurs in patients who have traveled",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "to impoverished areas where the organisms are endemic, but can also be acquired",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "within the United States. Treatment is based on location of acquisition due to",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "increasing rates of fluoroquinolone resistance in Asia.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for infection NOT acquired in Asia",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for infection acquired in Asia",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Typhoid Fever, Enteric Fever",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of enteric (typhoid and",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "paratyphoid) fever", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX ESOPHAGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "Text" : "Candidiasis", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU CMV COLITIS/ESOPHAGITIS", "Text" : "CMV Esophagitis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "Text" : "Herpes Simplex Esophagitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ESOPHAGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Esophagitis is usually associated with non-infectious diseases like",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "gastroesophageal reflux disease, mucositis and pill-induced esophagitis.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Esophageal infection occurs primarily in immunosuppressed individuals (e.g.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "chemotherapy, transplantation, HIV) and rarely in healthy individuals. The",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "majority of infectious esophagitis is caused by Candida albicans,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus (CMV) and herpes simplex virus. Aphthous ulceration of the",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "esophagus is common in HIV infection. HIV screening is recommneded.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Esophagitis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Candidiasis",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Cytomegalovirus, Gastrointestinal Disease",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Herpes simplex virus infection of the esophagus", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help and Additional Information Menu", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZ GMENU CONSULTS MAIN OP", "Text" : "Consult Menu - place consults to specialty service", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Antibiogram", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU NEED AN ALT ABX MAIN", "Text" : "Alternative Antimicrobials to CDSS Recommendations - select here", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU ABX ADDITIONAL ASSISTANCE", "Text" : "Contact Information", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "Antimicrobial Information", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "Text" : "Important Drug Properties", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "Text" : "Antimicrobial Cost Information", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "GENERAL INFORMATION",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "LEGEND ________________________________________________________________________",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "[DI] = Important interactions between antimicrobial and other drugs",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "[H] = Hepatic excretion of antimicrobial",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "[M] = Minimal risk posed by antimicrobial",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "[O] = Other important antimicrobial property",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "[R] = Renal excretion of antimicrobial",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "($) = <10 dollars per day",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "($$) = 10-50 dollars per day",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "($$$) = 51-100 dollars per day",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "($$$$) = 101-400 dollars per day",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "($$$$$) = >400 dollars per day",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "Text" : "Infectious Diseases Consult", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Beta-lactam Reaction Assessment", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: IM",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient HepA orders:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "HEPATITIS A VACCINE INJ,SUSP",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Havrix",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Hepatitis A",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "(HepA)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2021,",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "174(3)374-384.",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*All adults who want to be",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "protected from hepatitis A",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "virus (HAV) infection.",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "*People who travel or work",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "anywhere EXCEPT the U.S.,",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "most, but not all of",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "Western Europe, New",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Zealand, Australia,",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "Canada, and Japan.",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "*People with chronic liver",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "disease, injecting and",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "non-injecting drug users,",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "people who have HIV",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "infection, men who have",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "sex with men, people who",  "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "are homeless or live in",  "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "temporary housing (e.g., a",  "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "shelter), people who work",  "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "with HAV in lab settings.",  "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "*People who anticipate",  "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "close personal contact",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "with an international",  "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "adoptee from",  "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "a country of high or",  "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "intermediate endemicity",  "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : "during the first 60d",  "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "following the adoptee's",  "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : "arrival in the U.S.",  "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : null, "Text" : "*Postexposure: adults with",  "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : null, "Text" : "recent (within 2wks)",  "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : null, "Text" : "exposure to HAV, give",  "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : null, "Text" : "HepA. Vaccine may be used",  "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : null, "Text" : "in conjunction with IG at",  "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : null, "Text" : "the provider's discretion",  "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : null, "Text" : "in adults older than age",  "Header" : 0}, 
{"Row" : 43, "Column" : 2, "Item" : null, "Text" : "40 or immunocompromised",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Give 2 doses, spaced 6-",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "12 months apart.",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "*If dose2 is delayed, do",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "not repeat dose1. Just",  "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : null, "Text" : "give dose2.",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "History of severe allergic",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "Precautions:",  "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "Moderate or severe acute",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "illness with or",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "without fever.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "3 dose series", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES", "Text" : "4 dose series", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: IM",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient HepA/B orders:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Rapid schedule:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "HEPATITIS A/HEPATITIS B",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "VACCINE INJ,SUSP",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Twinrix",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Hepatitis A/B Recombinant",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "(HepA/HepB)",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2022,",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "175(3)432-443",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*All adults who want to be",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "protected from hepatitis A",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "and hepatitis B virus",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "infection.",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "HepA Specific:",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "*People who travel or work",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "anywhere EXCEPT the U.S.,",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "most, but not all of",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "Western Europe, New",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "Zealand, Australia,",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "Canada, and Japan.",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "*People with chronic liver",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "disease, injecting and",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "non-injecting drug users,",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "people who have HIV",  "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "infection, men who have",  "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "sex with men, people who",  "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "are homeless or live in",  "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "temporary housing (e.g., a",  "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "shelter), people who work",  "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "with HAV in lab settings.",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "*People who anticipate",  "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "close personal contact",  "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "with an international",  "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "adoptee from",  "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : "a country of high or",  "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "intermediate endemicity",  "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : "during the first 60d",  "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : null, "Text" : "following the adoptee's",  "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : null, "Text" : "arrival in the U.S.",  "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : null, "Text" : "*Postexposure: adults with",  "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : null, "Text" : "recent (within 2wks)",  "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : null, "Text" : "exposure to HAV, give",  "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : null, "Text" : "HepA. Vaccine may be used",  "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : null, "Text" : "in conjunction with IG at",  "Header" : 0}, 
{"Row" : 43, "Column" : 2, "Item" : null, "Text" : "the provider's discretion",  "Header" : 0}, 
{"Row" : 44, "Column" : 2, "Item" : null, "Text" : "in adults older than age",  "Header" : 0}, 
{"Row" : 45, "Column" : 2, "Item" : null, "Text" : "40 or immunocompromised",  "Header" : 0}, 
{"Row" : 47, "Column" : 2, "Item" : null, "Text" : "HepB Specific",  "Header" : 1}, 
{"Row" : 48, "Column" : 2, "Item" : null, "Text" : "*People age 19-59yrs",  "Header" : 0}, 
{"Row" : 50, "Column" : 2, "Item" : null, "Text" : "*People age 60yrs and older",  "Header" : 0}, 
{"Row" : 51, "Column" : 2, "Item" : null, "Text" : "who want to be protected",  "Header" : 0}, 
{"Row" : 52, "Column" : 2, "Item" : null, "Text" : "from hepatitis B virus",  "Header" : 0}, 
{"Row" : 53, "Column" : 2, "Item" : null, "Text" : "infection and those who are",  "Header" : 0}, 
{"Row" : 54, "Column" : 2, "Item" : null, "Text" : "at risk for hepatitis B",  "Header" : 0}, 
{"Row" : 55, "Column" : 2, "Item" : null, "Text" : "virus infection:",  "Header" : 0}, 
{"Row" : 56, "Column" : 2, "Item" : null, "Text" : "o Chronic liver disease",  "Header" : 0}, 
{"Row" : 57, "Column" : 2, "Item" : null, "Text" : "(e.g., persons with",  "Header" : 0}, 
{"Row" : 58, "Column" : 2, "Item" : null, "Text" : "hepatitis C, cirrhosis,",  "Header" : 0}, 
{"Row" : 59, "Column" : 2, "Item" : null, "Text" : "fatty liver disease,",  "Header" : 0}, 
{"Row" : 60, "Column" : 2, "Item" : null, "Text" : "alcoholic liver disease,",  "Header" : 0}, 
{"Row" : 61, "Column" : 2, "Item" : null, "Text" : "autoimmune hepatitis,",  "Header" : 0}, 
{"Row" : 62, "Column" : 2, "Item" : null, "Text" : "alanine aminotransferase",  "Header" : 0}, 
{"Row" : 63, "Column" : 2, "Item" : null, "Text" : "[ALT] or aspartate",  "Header" : 0}, 
{"Row" : 64, "Column" : 2, "Item" : null, "Text" : "aminotransferase [AST]",  "Header" : 0}, 
{"Row" : 65, "Column" : 2, "Item" : null, "Text" : "level greater than twice",  "Header" : 0}, 
{"Row" : 66, "Column" : 2, "Item" : null, "Text" : "upper limit of normal)",  "Header" : 0}, 
{"Row" : 67, "Column" : 2, "Item" : null, "Text" : "o HIV infection",  "Header" : 0}, 
{"Row" : 68, "Column" : 2, "Item" : null, "Text" : "o Sexual exposure risk",  "Header" : 0}, 
{"Row" : 69, "Column" : 2, "Item" : null, "Text" : "(e.g., sex partners of",  "Header" : 0}, 
{"Row" : 70, "Column" : 2, "Item" : null, "Text" : "hepatitis B surface",  "Header" : 0}, 
{"Row" : 71, "Column" : 2, "Item" : null, "Text" : "antigen [HBsAg]-positive",  "Header" : 0}, 
{"Row" : 72, "Column" : 2, "Item" : null, "Text" : "persons: sexually active",  "Header" : 0}, 
{"Row" : 73, "Column" : 2, "Item" : null, "Text" : "persons not in mutually",  "Header" : 0}, 
{"Row" : 74, "Column" : 2, "Item" : null, "Text" : "monogamous relationships:",  "Header" : 0}, 
{"Row" : 75, "Column" : 2, "Item" : null, "Text" : "persons seeking evaluation",  "Header" : 0}, 
{"Row" : 76, "Column" : 2, "Item" : null, "Text" : "or treatment for a",  "Header" : 0}, 
{"Row" : 77, "Column" : 2, "Item" : null, "Text" : "sexually transmitted",  "Header" : 0}, 
{"Row" : 78, "Column" : 2, "Item" : null, "Text" : "infection: men who have",  "Header" : 0}, 
{"Row" : 79, "Column" : 2, "Item" : null, "Text" : "sex with men)",  "Header" : 0}, 
{"Row" : 80, "Column" : 2, "Item" : null, "Text" : "o Current or recent",  "Header" : 0}, 
{"Row" : 81, "Column" : 2, "Item" : null, "Text" : "injection drug use",  "Header" : 0}, 
{"Row" : 82, "Column" : 2, "Item" : null, "Text" : "o Percutaneous or mucosal",  "Header" : 0}, 
{"Row" : 83, "Column" : 2, "Item" : null, "Text" : "risk for exposure to blood",  "Header" : 0}, 
{"Row" : 84, "Column" : 2, "Item" : null, "Text" : "(e.g., household contacts",  "Header" : 0}, 
{"Row" : 85, "Column" : 2, "Item" : null, "Text" : "of HBsAg-positive persons:",  "Header" : 0}, 
{"Row" : 86, "Column" : 2, "Item" : null, "Text" : "residents and staff of",  "Header" : 0}, 
{"Row" : 87, "Column" : 2, "Item" : null, "Text" : "facilities for",  "Header" : 0}, 
{"Row" : 88, "Column" : 2, "Item" : null, "Text" : "developmentally disabled",  "Header" : 0}, 
{"Row" : 89, "Column" : 2, "Item" : null, "Text" : "persons: health care and",  "Header" : 0}, 
{"Row" : 90, "Column" : 2, "Item" : null, "Text" : "public safety personnel",  "Header" : 0}, 
{"Row" : 91, "Column" : 2, "Item" : null, "Text" : "with reasonably",  "Header" : 0}, 
{"Row" : 92, "Column" : 2, "Item" : null, "Text" : "anticipated risk for",  "Header" : 0}, 
{"Row" : 93, "Column" : 2, "Item" : null, "Text" : "exposure to blood or",  "Header" : 0}, 
{"Row" : 94, "Column" : 2, "Item" : null, "Text" : "blood-contaminated body",  "Header" : 0}, 
{"Row" : 95, "Column" : 2, "Item" : null, "Text" : "fluids: hemodialysis,",  "Header" : 0}, 
{"Row" : 96, "Column" : 2, "Item" : null, "Text" : "peritoneal dialysis, home",  "Header" : 0}, 
{"Row" : 97, "Column" : 2, "Item" : null, "Text" : "dialysis, and predialysis",  "Header" : 0}, 
{"Row" : 98, "Column" : 2, "Item" : null, "Text" : "patients: patients with",  "Header" : 0}, 
{"Row" : 99, "Column" : 2, "Item" : null, "Text" : "diabetes)",  "Header" : 0}, 
{"Row" : 100, "Column" : 2, "Item" : null, "Text" : "o Incarcerated persons",  "Header" : 0}, 
{"Row" : 101, "Column" : 2, "Item" : null, "Text" : "o Travel in countries with",  "Header" : 0}, 
{"Row" : 102, "Column" : 2, "Item" : null, "Text" : "high or intermediate",  "Header" : 0}, 
{"Row" : 103, "Column" : 2, "Item" : null, "Text" : "endemic hepatitis B",  "Header" : 0}, 
{"Row" : 104, "Column" : 2, "Item" : null, "Text" : "patient is chronically",  "Header" : 0}, 
{"Row" : 105, "Column" : 2, "Item" : null, "Text" : "infected, assure",  "Header" : 0}, 
{"Row" : 106, "Column" : 2, "Item" : null, "Text" : "appropriate disease",  "Header" : 0}, 
{"Row" : 107, "Column" : 2, "Item" : null, "Text" : "management. For sex",  "Header" : 0}, 
{"Row" : 108, "Column" : 2, "Item" : null, "Text" : "partners and household",  "Header" : 0}, 
{"Row" : 109, "Column" : 2, "Item" : null, "Text" : "contacts of HBsAg-positive",  "Header" : 0}, 
{"Row" : 110, "Column" : 2, "Item" : null, "Text" : "people, provide serologic",  "Header" : 0}, 
{"Row" : 111, "Column" : 2, "Item" : null, "Text" : "screening and administer",  "Header" : 0}, 
{"Row" : 112, "Column" : 2, "Item" : null, "Text" : "initial dose of HepB",  "Header" : 0}, 
{"Row" : 113, "Column" : 2, "Item" : null, "Text" : "vaccine at same visit.",  "Header" : 0}, 
{"Row" : 115, "Column" : 2, "Item" : null, "Text" : "*Serologic testing is",  "Header" : 0}, 
{"Row" : 116, "Column" : 2, "Item" : null, "Text" : "recommended 1 to 2 months",  "Header" : 0}, 
{"Row" : 117, "Column" : 2, "Item" : null, "Text" : "after the final dose of",  "Header" : 0}, 
{"Row" : 118, "Column" : 2, "Item" : null, "Text" : "the primary vaccine series",  "Header" : 0}, 
{"Row" : 119, "Column" : 2, "Item" : null, "Text" : "and annually to determine",  "Header" : 0}, 
{"Row" : 120, "Column" : 2, "Item" : null, "Text" : "the need for booster",  "Header" : 0}, 
{"Row" : 121, "Column" : 2, "Item" : null, "Text" : "doses. Persons with anti-",  "Header" : 0}, 
{"Row" : 122, "Column" : 2, "Item" : null, "Text" : "HBs concentrations of <10",  "Header" : 0}, 
{"Row" : 123, "Column" : 2, "Item" : null, "Text" : "milliunits/mL should",  "Header" : 0}, 
{"Row" : 124, "Column" : 2, "Item" : null, "Text" : "receive a booster dose",  "Header" : 0}, 
{"Row" : 126, "Column" : 2, "Item" : null, "Text" : "NOTE: Provide serologic",  "Header" : 0}, 
{"Row" : 127, "Column" : 2, "Item" : null, "Text" : "screening for immigrants",  "Header" : 0}, 
{"Row" : 128, "Column" : 2, "Item" : null, "Text" : "from endemic areas. If",  "Header" : 0}, 
{"Row" : 129, "Column" : 2, "Item" : null, "Text" : "patient is chronically",  "Header" : 0}, 
{"Row" : 130, "Column" : 2, "Item" : null, "Text" : "infected, assure",  "Header" : 0}, 
{"Row" : 131, "Column" : 2, "Item" : null, "Text" : "appropriate disease",  "Header" : 0}, 
{"Row" : 132, "Column" : 2, "Item" : null, "Text" : "management. For sex",  "Header" : 0}, 
{"Row" : 133, "Column" : 2, "Item" : null, "Text" : "partners and household",  "Header" : 0}, 
{"Row" : 134, "Column" : 2, "Item" : null, "Text" : "contacts of HBsAg-positive",  "Header" : 0}, 
{"Row" : 135, "Column" : 2, "Item" : null, "Text" : "people, provide serologic",  "Header" : 0}, 
{"Row" : 136, "Column" : 2, "Item" : null, "Text" : "screening and administer",  "Header" : 0}, 
{"Row" : 137, "Column" : 2, "Item" : null, "Text" : "initial dose of HepB",  "Header" : 0}, 
{"Row" : 138, "Column" : 2, "Item" : null, "Text" : "vaccine at same visit.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Standard Schedule: Give 3",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "doses on a 0, 1, 6-month",  "Header" : 0}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "schedule.",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "*Rapid Schedule: Give 4",  "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : null, "Text" : "doses on a 0, 1wk, 3wks,",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "and 1yr schedule. Must",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "receive all dose for long",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "term protection.",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "History of severe allergic",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "Precautions:",  "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "Moderate or severe acute",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "illness with or",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "without fever.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HEPATITIS A", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "HEPATITIS A",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Disease Management",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Most acute disease is self-limited, and the virus does not cause chronic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "disease. No specific antiviral therapy is available.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Patients who appear to be developing fulminant hepatitis, including those with",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "mental status changes should receive supportive treatment. Fulminant hepatitis",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "is suggested by increased prothrombin time, cholestasis, ascites, decreased",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "liver size, or decreasing serum albumin. Supportive treatment includes",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "maintenance of fluid and electrolyte balance, monitoring and possible correction",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "of coagulation defects, treatment of hepatic encephalopathy, and good nutrition",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "with a low-protein diet.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Prevention for persons with continuing high risk of disease",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Vaccine should be offered to persons at high risk of hepatitis A infection: men",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "who have sex with men, travelers to endemic areas likely to be exposed, illegal",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "drug users, persons at occupational risk of disease, persons with chronic liver",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "disease or clotting factor disorders.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Prevention for persons with a specific, defined exposure",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Post-exposure prophylaxis should be offered to persons with substantial exposure",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "to hepatitis A. Specifically, persons exposed to acute hepatitis through",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "household or sexual contact, persons who attend or work in a day care center",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "with a recent case, or employee or patron of a restaurant with a food handler",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "with hepatitis. Post exposure prophylaxis must be given within 2 weeks of",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "exposure. Vaccine can be given at the same time as immune-globulin.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Immune globulin 0.02 ml/kg IM x 1 <AND>",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Give Hepatitis A vaccine 1 ml IM x 2, separated by 6 to 12 months",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute viral hepatitis",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Hepatitis A, Acute, Treatment",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Hepatitis A virus infections: Treatment and prevention", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HEPATITIS B", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "Text" : "Hepatitis B Evaluation", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HEPATITIS B",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute disease management",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Most acute hepatitis B disease is mild and self-limited. Patients who appear to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "be developing fulminant hepatitis, including those with mental status changes",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "should receive supportive treatment. Fulminant hepatitis is suggested by",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "increased prothrombin time, cholestasis, ascites, decreased liver size, or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "decreasing serum albumin. Supportive treatment includes maintenance of fluid",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "and electrolyte balance, monitoring and possible correction of coagulation",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "defects, treatment of hepatic encephalopathy, and good nutrition with a low-",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "protein diet. Antiviral therapy is not indicated. Gastroenterology consult",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "encouraged.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Chronic disease management",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Antiviral therapy for chronic hepatitis B is a complicated, highly specialized",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "task. Consult with gastroenterology and infectious diseases.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Prevention",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Vaccinate persons at high risk of disease including men who have sex with men,",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "illegal drug users, and health care workers with substantial exposure to blood",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "or body fluids.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Give Hepatitis B vaccine 1 dose IM in deltoid at 0, then 1 or 2 months, and",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "again at 4 to 6 months.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Select below for Hepatitis B evaluation for patients receiving Anti-CD20",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Antibody Treatment",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute viral hepatitis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Chronic viral hepatitis",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Hepatitis B virus: Overview of management", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HEPATITIS C", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HEPATITIS C",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment of acute disease",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Most acute disease is asymptomatic or mild. Patients with acute hepatitis C",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "should be referred to the Hepatitis C clinic. Treatment may be indicated for",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "disease that persists beyond 2 months",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Chronic disease treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antiviral therapy for chronic hepatitis C is a complicated, highly specialized",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "task",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute viral hepatitis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Chronic viral hepatitis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Overview of the management of chronic hepatitis C virus",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "3 dose series", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "4 dose series", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: IM",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient HepB orders:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "*Hemodialysis pts only:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "HEPATITIS B INJ",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Engerix-B",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Hepatitis B",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "(HepB)",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2022,",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "175(3)432-443",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*People age 19-59yrs",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "*People age 60yrs and older",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "who want to be protected",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "from hepatitis B virus",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "infection and those who are",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "at risk for hepatitis B",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "virus infection:",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "o Chronic liver disease",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "(e.g., persons with",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "hepatitis C, cirrhosis,",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "fatty liver disease,",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "alcoholic liver disease,",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "autoimmune hepatitis,",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "alanine aminotransferase",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "[ALT] or aspartate",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "aminotransferase [AST]",  "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "level greater than twice",  "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "upper limit of normal)",  "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "o HIV infection",  "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "o Sexual exposure risk",  "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "(e.g., sex partners of",  "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "hepatitis B surface",  "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "antigen [HBsAg]-positive",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "persons: sexually active",  "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "persons not in mutually",  "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "monogamous relationships:",  "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "persons seeking evaluation",  "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : "or treatment for a",  "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "sexually transmitted",  "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : "infection: men who have",  "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : null, "Text" : "sex with men)",  "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : null, "Text" : "o Current or recent",  "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : null, "Text" : "injection drug use",  "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : null, "Text" : "o Percutaneous or mucosal",  "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : null, "Text" : "risk for exposure to blood",  "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : null, "Text" : "(e.g., household contacts",  "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : null, "Text" : "of HBsAg-positive persons:",  "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : null, "Text" : "residents and staff of",  "Header" : 0}, 
{"Row" : 43, "Column" : 2, "Item" : null, "Text" : "facilities for",  "Header" : 0}, 
{"Row" : 44, "Column" : 2, "Item" : null, "Text" : "developmentally disabled",  "Header" : 0}, 
{"Row" : 45, "Column" : 2, "Item" : null, "Text" : "persons: health care and",  "Header" : 0}, 
{"Row" : 46, "Column" : 2, "Item" : null, "Text" : "public safety personnel",  "Header" : 0}, 
{"Row" : 47, "Column" : 2, "Item" : null, "Text" : "with reasonably",  "Header" : 0}, 
{"Row" : 48, "Column" : 2, "Item" : null, "Text" : "anticipated risk for",  "Header" : 0}, 
{"Row" : 49, "Column" : 2, "Item" : null, "Text" : "exposure to blood or",  "Header" : 0}, 
{"Row" : 50, "Column" : 2, "Item" : null, "Text" : "blood-contaminated body",  "Header" : 0}, 
{"Row" : 51, "Column" : 2, "Item" : null, "Text" : "fluids: hemodialysis,",  "Header" : 0}, 
{"Row" : 52, "Column" : 2, "Item" : null, "Text" : "peritoneal dialysis, home",  "Header" : 0}, 
{"Row" : 53, "Column" : 2, "Item" : null, "Text" : "dialysis, and predialysis",  "Header" : 0}, 
{"Row" : 54, "Column" : 2, "Item" : null, "Text" : "patients: patients with",  "Header" : 0}, 
{"Row" : 55, "Column" : 2, "Item" : null, "Text" : "diabetes)",  "Header" : 0}, 
{"Row" : 56, "Column" : 2, "Item" : null, "Text" : "o Incarcerated persons",  "Header" : 0}, 
{"Row" : 57, "Column" : 2, "Item" : null, "Text" : "o Travel in countries with",  "Header" : 0}, 
{"Row" : 58, "Column" : 2, "Item" : null, "Text" : "high or intermediate",  "Header" : 0}, 
{"Row" : 59, "Column" : 2, "Item" : null, "Text" : "endemic hepatitis B",  "Header" : 0}, 
{"Row" : 60, "Column" : 2, "Item" : null, "Text" : "patient is chronically",  "Header" : 0}, 
{"Row" : 61, "Column" : 2, "Item" : null, "Text" : "infected, assure",  "Header" : 0}, 
{"Row" : 62, "Column" : 2, "Item" : null, "Text" : "appropriate disease",  "Header" : 0}, 
{"Row" : 63, "Column" : 2, "Item" : null, "Text" : "management. For sex",  "Header" : 0}, 
{"Row" : 64, "Column" : 2, "Item" : null, "Text" : "partners and household",  "Header" : 0}, 
{"Row" : 65, "Column" : 2, "Item" : null, "Text" : "contacts of HBsAg-positive",  "Header" : 0}, 
{"Row" : 66, "Column" : 2, "Item" : null, "Text" : "people, provide serologic",  "Header" : 0}, 
{"Row" : 67, "Column" : 2, "Item" : null, "Text" : "screening and administer",  "Header" : 0}, 
{"Row" : 68, "Column" : 2, "Item" : null, "Text" : "initial dose of HepB",  "Header" : 0}, 
{"Row" : 69, "Column" : 2, "Item" : null, "Text" : "vaccine at same visit.",  "Header" : 0}, 
{"Row" : 71, "Column" : 2, "Item" : null, "Text" : "*Serologic testing is",  "Header" : 0}, 
{"Row" : 72, "Column" : 2, "Item" : null, "Text" : "recommended 1 to 2 months",  "Header" : 0}, 
{"Row" : 73, "Column" : 2, "Item" : null, "Text" : "after the final dose of",  "Header" : 0}, 
{"Row" : 74, "Column" : 2, "Item" : null, "Text" : "the primary vaccine series",  "Header" : 0}, 
{"Row" : 75, "Column" : 2, "Item" : null, "Text" : "and annually to determine",  "Header" : 0}, 
{"Row" : 76, "Column" : 2, "Item" : null, "Text" : "the need for booster",  "Header" : 0}, 
{"Row" : 77, "Column" : 2, "Item" : null, "Text" : "doses. Persons with anti-",  "Header" : 0}, 
{"Row" : 78, "Column" : 2, "Item" : null, "Text" : "HBs concentrations of <10",  "Header" : 0}, 
{"Row" : 79, "Column" : 2, "Item" : null, "Text" : "milliunits/mL should",  "Header" : 0}, 
{"Row" : 80, "Column" : 2, "Item" : null, "Text" : "receive a booster dose",  "Header" : 0}, 
{"Row" : 82, "Column" : 2, "Item" : null, "Text" : "NOTE: Provide serologic",  "Header" : 0}, 
{"Row" : 83, "Column" : 2, "Item" : null, "Text" : "screening for immigrants",  "Header" : 0}, 
{"Row" : 84, "Column" : 2, "Item" : null, "Text" : "from endemic areas. If",  "Header" : 0}, 
{"Row" : 85, "Column" : 2, "Item" : null, "Text" : "patient is chronically",  "Header" : 0}, 
{"Row" : 86, "Column" : 2, "Item" : null, "Text" : "infected, assure",  "Header" : 0}, 
{"Row" : 87, "Column" : 2, "Item" : null, "Text" : "appropriate disease",  "Header" : 0}, 
{"Row" : 88, "Column" : 2, "Item" : null, "Text" : "management. For sex",  "Header" : 0}, 
{"Row" : 89, "Column" : 2, "Item" : null, "Text" : "partners and household",  "Header" : 0}, 
{"Row" : 90, "Column" : 2, "Item" : null, "Text" : "contacts of HBsAg-positive",  "Header" : 0}, 
{"Row" : 91, "Column" : 2, "Item" : null, "Text" : "people, provide serologic",  "Header" : 0}, 
{"Row" : 92, "Column" : 2, "Item" : null, "Text" : "screening and administer",  "Header" : 0}, 
{"Row" : 93, "Column" : 2, "Item" : null, "Text" : "initial dose of HepB",  "Header" : 0}, 
{"Row" : 94, "Column" : 2, "Item" : null, "Text" : "vaccine at same visit.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Give 3 doses on a 0, 1, 6-",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "month schedule.",  "Header" : 0}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "There must be at least",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "4wks between doses1 and",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "2, and at least 8wks",  "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : null, "Text" : "between doses2 and3.",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "Overall, there must be at",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "least 16wks between doses",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "1 and3.",  "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "[Alternative timing",  "Header" : 0}, 
{"Row" : 14, "Column" : 3, "Item" : null, "Text" : "Options for vaccination",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "include:",  "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : null, "Text" : "1) 0, 2, 4 months",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "2) 0, 1, 4 months",  "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : null, "Text" : "3) 0, 1, 2, 12 months]",  "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "*For adults on",  "Header" : 0}, 
{"Row" : 21, "Column" : 3, "Item" : null, "Text" : "hemodialysis or with other",  "Header" : 0}, 
{"Row" : 22, "Column" : 3, "Item" : null, "Text" : "conditions, give 2 doses",  "Header" : 0}, 
{"Row" : 23, "Column" : 3, "Item" : null, "Text" : "of 20 micrograms/mL",  "Header" : 0}, 
{"Row" : 24, "Column" : 3, "Item" : null, "Text" : "simultaneously at 0, 1, 2,",  "Header" : 0}, 
{"Row" : 25, "Column" : 3, "Item" : null, "Text" : "6 months",  "Header" : 0}, 
{"Row" : 27, "Column" : 3, "Item" : null, "Text" : "*Schedule for those who",  "Header" : 0}, 
{"Row" : 28, "Column" : 3, "Item" : null, "Text" : "have fallen behind: If the",  "Header" : 0}, 
{"Row" : 29, "Column" : 3, "Item" : null, "Text" : "series is delayed between",  "Header" : 0}, 
{"Row" : 30, "Column" : 3, "Item" : null, "Text" : "doses, DO NOT start the",  "Header" : 0}, 
{"Row" : 31, "Column" : 3, "Item" : null, "Text" : "series over. Continue from",  "Header" : 0}, 
{"Row" : 32, "Column" : 3, "Item" : null, "Text" : "where the schedule was",  "Header" : 0}, 
{"Row" : 33, "Column" : 3, "Item" : null, "Text" : "interrupted.",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "History of severe allergic",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "Precautions:",  "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "Moderate or severe acute",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "illness with or",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "without fever.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HERPES KERATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 7DAYS 400MG PO TID", "Text" : "Acyclovir 400 mg PO TID for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 7DAYS 400MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 500MG BID 7D", "Text" : "Valacyclovir 500 mg PO BID for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 500MG BID 7D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 800MG 5X/DAY 14D", "Text" : "Acyclovir 800 mg PO 5x/day for 14-21 days ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 800MG 5X/DAY 14D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1GM TID 14D", "Text" : "Valacyclovir 1 gm PO TID for 14-21 days ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1GM TID 14D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 400MG BID 1YR", "Text" : "Acyclovir 400 mg PO BID for 12 months ($) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 400MG BID 1YR", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "Text" : "Valacyclovir 500 mg PO QDay for 12 months ($) [R]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HERPES KERATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Ocular herpes infection can be caused by either HSV-1 or HSV-2. The majority of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cases are caused by HSV-1. The recurrence rate of ocular herpes is 40% over a 5",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "year period, less than that of oral or genital herpes. Ocular herpes is a",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "major cause of blindness and typically presents as infection of the epithelium",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "of the cornea but can also rarely involve the stroma and endothelium.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Ophthalmology consultation is recommended.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Involvement of the stroma or endothelium requires treatment with topical",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "steroid and close monitoring. For these cases, start oral antiviral and consult",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "ophthalmology for management.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Antiviral prophylaxis is recommended for patients with multiple recurrences,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "recurrent episodes with ulceration, recurrent inflammation with",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "scar/vascularization approaching visual axis, patients who have had keratoplasty",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "for HSV-related scarring/astigmatism, and patients who have had HSV keratitis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "while on immunosuppressive therapy. Post-surgical prophylaxis is not discussed",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "here. Please consult ophthalmology for more information.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treatment of acute infection",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Without epithelial ulceration",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Ulceration of epithelium (Geographic ulcer)",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Infection prophylaxis for prevention of recurrence",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Reassess need for prophylaxis every 12 months",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Baratz, Arch Ophthalmology, (2012) 130.1: 108-110",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Guess et al, The Ocular Surface, (2007) 5.3:240-250",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Wilhelmus, Cochrane Database of Systematic Reviews, (2015), 1:CD002898",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Miserocchi et al, Efficacy of Valacyclovir vs Acyclovir for the Prevention of",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Recurrent Herpes Simplex",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Virus Eye Disease: A Pilot Study, American Journal of Ophthalmology, 2007",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "144:547-551",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "White et al, Ocular Microbiology and Immunology Group and American Academy of",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Ophthalmology, (2014)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID ACYCLOVIR 400MG PO 5X/DAY 7D", "Text" : "Acyclovir 400 mg PO 5x/day for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID ACYCLOVIR 400MG PO 5X/DAY 7D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1GM PO BID", "Text" : "Valacyclovir 1 gm PO BID for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1GM PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 14DS 400MG PO 5X/D", "Text" : "Acyclovir 400 mg PO 5x/day for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 14DS 400MG PO 5X/D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID VALCYCLOVIR 1GM PO BID 14D", "Text" : "Valacyclovir 1 gm PO BID for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSHZID VALCYCLOVIR 1GM PO BID 14D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HERPES SIMPLEX ESOPHAGITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "HSV infection of the esophagus usually occurs in patients who are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "immunocompromised, typically solid organ and bone marrow transplant",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "recipients. In healthy patients HSV esophagitis occurs occasionally,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "usually in men under the age of 40.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Patients usually present with odynophagia and dysphagia. Fever",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "epigastric pain, nausea, vomiting, and heartburn are less frequent.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Some patients may have coexistent herpes labialis or oropharyngeal",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "ulcers. Diagnosis is usually established with an upper endoscopy.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Suggestive findings may also be seen during a barium swallow.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Spontaneous resolution usually occurs in immunocompetent patients after",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "one to two weeks. Patients may respond more quickly if treated with a",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "short course of oral acyclovir.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treat for 7-10 days",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Treat for 14-21 days",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "John Hopkin's Guides keyword: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes simplex",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Herpes simplex virus infection of the esophagitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSOZID HAEMOPHILUS B VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID HAEMOPHILUS B VACCINE 3 DOSE SERIES", "Text" : "3 dose series", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: IM",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient Hib orders:",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "HSCT Pts only:",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "HAEMOPHILUS B VACCINE",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "INJ,LYPHL",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Hiberix",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Haemophilus influenzae",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "type b",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "(Hib)",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2021,",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "174(3)374-384.",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*Not routinely recommended",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "for healthy adults.",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "*Those adults at highest",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "risk of serious Hib",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "disease include people who",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "1) have anatomic or",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "functional asplenia,",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "2) are undergoing an",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "elective splenectomy, or",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "3) are recipients of",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "hematopoietic stem cell",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "transplant (HSCT).",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Give 1 dose to adults in",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "categories 1 or 2 (see 2nd",  "Header" : 0}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "bullet in column to left)",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "if no history of previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "Hib vaccine.",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "*For HSCT patients,",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "regardless of Hib vacci-",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "nation history, give 3",  "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "doses, at least 4wks",  "Header" : 0}, 
{"Row" : 14, "Column" : 3, "Item" : null, "Text" : "apart, beginning 6-12",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "months after transplant.",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "History of severe allergic",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "Precautions:",  "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "Moderate or severe acute",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "illness with or",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "without fever.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HIV-AIDS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "Text" : "ID consult", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "GMRCTZ MRTC - OUTPT", "Text" : "MRTC consult", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HIV",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "HIV infection and AIDS are associated with several host defense defects. Cell-",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "mediated immune defects render a patient more susceptible to opportunistic",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "infections with pathogens like Pneumocystis jirovecii (formerly Pneumocystis",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "carinii), Toxoplasma gondii, cytomegalovirus, mycobacterium-avium intracellulare",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "complex, and Candida spp.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Contact ID or HIV (MRTC) service for assistance.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds. Clinical Immunology",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Roitt l, et al, eds. Immunology", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "3 dose series", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: IM",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient HPV orders:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "PAPILLOMAVIRUS HUMAN",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "VACCINE INJ,SUSP",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Gardasil 9",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Human papillomavirus",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(HPV)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2021,",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "174(3)374-384.",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*For unvaccinated or",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "partially vaccinated",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "adults through age 26yrs:",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "Complete a 3-dose series",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "of HPV.",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "*Unvaccinated adults age",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "27 through 45yrs may be",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "vaccinated based on",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "shared clinical decision-",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "making.",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "*Other guidance: Pregnancy",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "is neither a",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "contraindication nor a",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "precaution",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "to HPV vaccine.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Give 3 doses on a 0, 1-2,",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "6-month schedule.",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "*There must be at least",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "4wks between doses1 and",  "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : null, "Text" : "2 and at least 12wks",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "between doses2 and3.",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "Overall, there must be at",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "least 5 months between",  "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "doses1 and3",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "*If the type of HPV",  "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : null, "Text" : "vaccine previously given",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "is not known or not",  "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : null, "Text" : "available, any available",  "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "HPV vaccine should be used",  "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "to complete the series.",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "History of severe allergic",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "Precautions:",  "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "Moderate or severe acute",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "illness with or",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "without fever.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION 65 YEARS OR GREATER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series.", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series for 19 to 23yrs, and for those w/additional risk", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal information page", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series for those w/additional risk factor or another.", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS AGE 65 YEARS OR GREATER",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients age 65 years or greater:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "risk factor or another indication.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Human papillomavirus: not indicated.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Measles, mumps, and rubella: not indicated",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION AGE 19-26 YEARS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series.", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series for 19 to 23yrs, and for those w/additional risk", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS AGE 19-26 YEARS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients age 19-26 years:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "risk factor or another indication.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Herpes zoster: not indicated.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "or another indication.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "specific immunization recommendations for patients with these indications or",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "refer to the Pneumococcal vaccine information menus below.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Varicella: not indicated.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION AGE 27-49 YEARS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series for age 27-45yrs based on shared clinical", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series for those born 1980 or later.", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS AGE 27-49 YEARS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients age 27-49 years:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "risk factor or another indication.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Herpes zoster: not indicated.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "decision making.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "or another indication.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "indication.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "specific immunization recommendations for patients with these indications or",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "refer to the Pneumococcal vaccine information menus below.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION AGE 50-64 YEARS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series for those w/additional risk factor or another.", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS AGE 50-64 YEARS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients age 50-64 years:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "risk factor or another indication.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Human papillomavirus: not indicated.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "nor another indication.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "indication.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "specific immunization recommendations for patients with these indications or",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "refer to the Pneumococcal vaccine information menus below.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION HEART, LUNG DISEASE, ALCOHOLISM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal information page", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS WITH HEART/LUNG DISEASE OR ALCOHOLISM",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients with heart/lung disease or alcoholism:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "risk factor or another indication.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "based on shared clinical decision making.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "or another indication.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "indication.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series.", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series.", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal information page", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS WITH CHRONIC LIVER DISEASE",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See specific immunization information pages located at the bottom of this page",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "for other indications, contraindications, and one-time dose orders to listed",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "vaccines.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients with chronic liver disease:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "based on shared clinical decision making.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "or another indication.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "indication.",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN DIABETES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal information page", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS WITH DIABETES",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients with diabetes:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "risk factor or another indication.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "based on shared clinical decision making.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "or another indication.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "indication.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN HEALTH CARE PERSONNEL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS WHO ARE HEALTH CARE PERSONNEL",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients who are health care personnel:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "risk factor or another indication.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "based on shared clinical decision making.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "or another indication.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "indication.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "specific immunization recommendations for patients with these indications or",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "refer to the Pneumococcal vaccine information menus below.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series.", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series.", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella *CONTRAINDICATED IF CD4<200 cells/mm3: 2 dose", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACCINE 2 DOSE SERIES", "Text" : "Meningococcal A, C, W and Y: 2 dose primary series, booster every 5yrs.", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal information page", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: *CONTRAINDICATED IF CD4<200 cells/mm3: 2 dose series.", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS WITH HIV",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See specific immunization information pages located at the bottom of this page",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "for other indications, contraindications, and one-time dose orders to listed",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "vaccines.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients with HIV:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "based on shared clinical decision making.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "series.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "indication.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series.", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal information page", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PATIENTS WITH END STAGE RENAL DISEASE OR ON HEMODIALYSIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for patients with end stage renal disease or on",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "hemodialysis:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Hepatitis A/B: refer to hepatitis A vaccine series above and high dose hepatitis",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "vaccine series below.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Hepatitis B: give high dose series below.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "based on shared clinical decision making.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "or another indication.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "indication.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION IN MEN WHO HAVE SEX WITH MEN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs.", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs and for age 27-45yrs", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, mumps, and rubella: one dose.", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, mumps, and rubella: 2 dose series, for those w/additional risk factor", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs.", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "Varicella: 2 dose series.", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF MEN WHO HAVE SEX WITH MEN",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for men who have sex with men:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "based on shared clinical decision making.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "or another indication.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "indication.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "specific immunization recommendations for patients with these indications or",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "refer to the Pneumococcal vaccine information menus below.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: 2 dose series, for those who want protection, or w/additional risk", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: 3 dose series, for those who want protection, or w/additional", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster: 2 dose series in those age >/= 50yrs", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID HUMAN PAPILLOMAVIRUS VACCINE 3 DOSE SERIES", "Text" : "Human papillomavirus: 3 dose series through age </= 26yrs", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B: 2 dose series, for those w/additional risk factor or another", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal information page", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: 3 dose primary series, booster every 10yrs", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF IMMUNOCOMPROMISED PATIENTS (EXCLUDING HIV and HSCT)",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See specific immunization information pages located at the bottom of this page",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "for other indications, contraindications, and one-time dose orders to listed",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "vaccines.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for immunocompromised patients:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "factor or another indication.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "risk factor or another indication.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Measles, mumps, and rubella *CONTRAINDICATED*",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "indication",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Varicella: *CONTRAINDICATED*",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX IMMUNIZATIONS SPECIALTY CLINICS", "Contents" : [
{"Row" : 22, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A 2 Dose Series", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B 3 Dose Series", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B 4 Dose High Dose Series (for immunocompromised patients)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B (Twinrix) 3 Dose Series", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES", "Text" : "Hepatitis A/B (Twinrix) Accelerated 4 Dose Series", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster (Shingrix) 2 dose series", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE ONE DOSE", "Text" : "Herpes zoster (Shingrix) one-time dose", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B Vaccine 2 Dose Series", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACCINE ONE DOSE", "Text" : "Meningococcal Conjugate (MenACWY) Vaccine ONCE", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID PNEUMOCOCCAL 13-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 13-valent vaccine ONCE", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 23-valent vaccine ONCE", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID TETANUS/DIPHTHERIA VACCINE ONE DOSE", "Text" : "Tetanus Diptheria Vaccine ONCE", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE", "Text" : "Tetanus/Diphteria/Pertussis (TDAP) Vaccine ONCE", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Vaccines - Administered in Clinic (select vaccine to place order)",  "Header" : 1}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Recommended Immunization Schedules and Outpatient Vaccine Orders",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "Text" : "[Click Here] Main CDSS Recommended Immunizations Page", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Patient Vaccine History:",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "[Click Here] for vaccination history including link to Joint Legacy Viewer", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Below are links to immunization information and outpatient vaccine orders:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "[Click Here] for links to PDFs of CDC Adult Immunization Schedules", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Please note:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "*A vaccine series does not need to be restarted, regardless of the time",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "that has elapsed between doses.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "*For the purpose of calculating intervals between doses, 4 weeks = 28 days.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Intervals of 4 months or greater are determined by calendar months.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "*Any vaccine can be given with another unless otherwise noted on the",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "specific vaccine page. (See link above for Main CDSS Immunization page)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "*Mild illness is not a contraindication to receiving any vaccine.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX INDEX OUTPATIENT", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Abscess, brain", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Abscess, cranial epidural", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU CUTANEOUS ABSCESS", "Text" : "Abscess, cutaneous", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Abscess, liver", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU LUNG ABSCESS", "Text" : "Abscess, lung", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Abscess, perianal/anorectal", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABSCESSES", "Text" : "Abscess, skin and soft tissue", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Abscess, spinal epidural", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG A. BAUMANNI", "Text" : "Acinetobacter baumannii, general", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Acinetobacter baumannii, nosocomial pneumonia", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "Acquired immunodeficiency syndrome (AIDS)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS ACTINOMYCES SPP.", "Text" : "Actinomyces infections, general", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Adenovirus diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "Text" : "Aerobic bottle, large uniform bacilli", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "Text" : "Aerobic bottle, small pleomorphic bacilli", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA AEROMONAS", "Text" : "Aeromonas diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Aggregatibacter native valve endocarditis", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Aggregatibacter prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "Text" : "Allergy information", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA", "Text" : "Altered microbial flora", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ABX LIVER AMEBIC ABSCESS", "Text" : "Amebic liver abscess", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "Text" : "Anaerobic bottle, large uniform bacilli", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "Text" : "Anaerobic bottle, small pleomorphic bacilli", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "Text" : "Anaerobic gram-positive cocci", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU PATH A. PHAGOCYTOPHILUM", "Text" : "Anaplasma phagocytophilum (human granulocytotropic anaplasmosis)", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Anorectal abscess", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "Text" : "Antibacterial prophylaxis in malignancy", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Antibiogram", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "Text" : "Antifungal prophylaxis in malignancy", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Antimicrobial interactions with warfarin", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Antimicrobial shortages updates", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Antimicrobial susceptibilities", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Antiviral prophylaxis in malignancy", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU APPENDICITIS W/ PERFORATION", "Text" : "Appendicitis with perforation", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU APPENDICITIS W/O PERFORATION", "Text" : "Appendicitis without perforation", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU LYME ARTHRITIS ASSOC", "Text" : "Arthritis associated with Lyme disease", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI ASPERGILLUS SPP.", "Text" : "Aspergillus infections, general", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "Text" : "Aspiration pneumonia", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Asplenia [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Astrovirus diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "Text" : "Asymptomatic bacteriuria", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "Text" : "Asymptomatic candiduria", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "Text" : "Asymptomatic pyuria", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU PARASITE BABESIA SPP.", "Text" : "Babesia infections, general", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "Text" : "Bacillary dysentery", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "Text" : "Bacilli, large uniform, aerobic bottle", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "Text" : "Bacilli, large uniform, anaerobic bottle", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "Text" : "Bacilli, small pleomorphic, aerobic bottle", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "Text" : "Bacilli, small pleomorphic, anaerobic bottle", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS BACILLI SPP.", "Text" : "Bacillus infections, general", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Bacteremia", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU GRAM NEGATIVE BACTERIA", "Text" : "Bacteria, Gram-Negative section", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU GRAM POSITIVE BACTERIA", "Text" : "Bacteria, Gram-Positive section", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "Text" : "Bacteriuria", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "Text" : "Bacteroides infections, general", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU BED BUGS (HEMIPTERA)", "Text" : "Bed bugs", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU BELL PALSY", "Text" : "Bell's palsy", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU BITE WOUNDS", "Text" : "Bite wounds", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI BLASTOMYCES DERM", "Text" : "Blastomycosis infections, general", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Text" : "Body lice", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "Text" : "Bone and Joint section", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "ORZ GMENU BONE MARROW MAIN", "Text" : "Bone marrow transplant immunizations", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J ENTEROCOCCI", "Text" : "Bone prosthesis infection", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG BORDETELLA SPP.", "Text" : "Bordetella infections, general", "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Brain abscess from contiguous or hematogenous spread", "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Brain abscess with Nocardia spp.", "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Brain abscess with Pseudomonas spp.", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Brain abscess with Toxoplasma gondii", "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Brain abscess, post-surgical or post-traumatic", "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "Text" : "Bronchitis", "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "Text" : "Bronchitis in otherwise healthy patient", "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG BRUCELLA SPP.", "Text" : "Brucella infections, general", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG BRUCELLA SPP.", "Text" : "Brucella spp.", "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC BURSITIS", "Text" : "Bursitis, septic", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA CAMPYLOBACTER", "Text" : "Campylobacter diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG CAMPYLOBACTER SPP.", "Text" : "Campylobacter, general", "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM MALIGNANCY", "Text" : "Cancer [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "Text" : "Candida albicans infections, general", "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. GLABRATA", "Text" : "Candida glabrata infections, general", "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Candida intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. KRUSEI", "Text" : "Candida krusei infections, general", "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : "ORZID3 GMENU RETINITIS", "Text" : "Candida retinitis", "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "Text" : "Candida urinary tract infection", "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "Text" : "Candida vulvo-vaginitis", "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Candidemia", "Header" : 0}, 
{"Row" : 100, "Column" : 1, "Item" : "ORZID3 GMENU CUTANEOUS CANDIDIASIS", "Text" : "Candidiasis", "Header" : 0}, 
{"Row" : 101, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "Text" : "Candiduria", "Header" : 0}, 
{"Row" : 102, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Carbuncles", "Header" : 0}, 
{"Row" : 103, "Column" : 1, "Item" : "ORZID3 GMENU LYME CARDIAC DISEASE", "Text" : "Cardiac disease associated with Lyme disease", "Header" : 0}, 
{"Row" : 104, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Cardiobacterium native valve endocarditis", "Header" : 0}, 
{"Row" : 105, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Cardiobacterium prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 106, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Cardiovascular device infections (excluding valves)", "Header" : 0}, 
{"Row" : 108, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Catheter-associated infection, intravascular", "Header" : 0}, 
{"Row" : 109, "Column" : 1, "Item" : "ORZID3 GMENU CAT-SCRATCH DISEASE", "Text" : "Cat-scratch disease", "Header" : 0}, 
{"Row" : 110, "Column" : 1, "Item" : "ORZID2 GMENU CMI DEFECTS", "Text" : "Cell-mediated immunity (CMI) defects", "Header" : 0}, 
{"Row" : 111, "Column" : 1, "Item" : "ORZID3 GMENU CELLULITIS", "Text" : "Cellulitis", "Header" : 0}, 
{"Row" : 112, "Column" : 1, "Item" : "ORZID3 GMENU HERPES WHITLOW", "Text" : "Cellulitis, herpes whitlow", "Header" : 0}, 
{"Row" : 113, "Column" : 1, "Item" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "Text" : "Cellulitis, postseptal (orbital)", "Header" : 0}, 
{"Row" : 114, "Column" : 1, "Item" : "ORZID3 GMENU PRESEPTAL CELLULITIS", "Text" : "Cellulitis, preseptal", "Header" : 0}, 
{"Row" : 115, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Central Nervous System section", "Header" : 0}, 
{"Row" : 116, "Column" : 1, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "Text" : "Cervicitis associated with sexually transmitted diseases", "Header" : 0}, 
{"Row" : 117, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Chickenpox vaccination", "Header" : 0}, 
{"Row" : 118, "Column" : 1, "Item" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "Text" : "Chickenpox, primary infection", "Header" : 0}, 
{"Row" : 119, "Column" : 1, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "Text" : "Chickenpox, reactivation of primary infection", "Header" : 0}, 
{"Row" : 120, "Column" : 1, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "Text" : "Chlamydia urethritis", "Header" : 0}, 
{"Row" : 121, "Column" : 1, "Item" : "ORZID3 GMENU CHOLANGITIS", "Text" : "Cholangitis", "Header" : 0}, 
{"Row" : 122, "Column" : 1, "Item" : "ORZID3 GMENU CHOLECYSTITIS", "Text" : "Cholecystitis", "Header" : 0}, 
{"Row" : 123, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG CITROBACTER SPP.", "Text" : "Citrobacter infections, general", "Header" : 0}, 
{"Row" : 124, "Column" : 1, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Clostridium difficile suspected, sepsis", "Header" : 0}, 
{"Row" : 125, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "Text" : "Clostridium difficile, mild to moderate disease", "Header" : 0}, 
{"Row" : 126, "Column" : 1, "Item" : "ORZID3 GMENU ILEUS/TOXI MEGACOLON", "Text" : "Clostridium difficile, severe/life-threatening disease", "Header" : 0}, 
{"Row" : 127, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS CLOSTRIDIUM SPP.", "Text" : "Clostridium infections, general", "Header" : 0}, 
{"Row" : 128, "Column" : 1, "Item" : "ORZID3 GMENU ABX POSITIVE BLOOD CULTURE OP COAG NEG STAPH", "Text" : "Coagulase negative staphylococci, single blood culture positive", "Header" : 0}, 
{"Row" : 129, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Coagulase-negative Staphylococci (CNS) bacteremia", "Header" : 0}, 
{"Row" : 130, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS COAG NEG STAPH", "Text" : "Coagulase-negative staphylococci, general", "Header" : 0}, 
{"Row" : 131, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Coagulase-negative staphylococci, intravascular catheter-associated infectio", "Header" : 0}, 
{"Row" : 132, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI COCCIDIOIDOMYCES", "Text" : "Coccidioides infections, general", "Header" : 0}, 
{"Row" : 133, "Column" : 1, "Item" : "ORZID3 GMENU CMV COLITIS/ESOPHAGITIS", "Text" : "Colitis, cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 134, "Column" : 1, "Item" : "ORZID3 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR OP", "Text" : "Colonized respiratory tract patient on a ventilator", "Header" : 0}, 
{"Row" : 135, "Column" : 1, "Item" : "ORZID3 GMENU ABX COLONIZED WOUNDS OP", "Text" : "Colonized wound", "Header" : 0}, 
{"Row" : 136, "Column" : 1, "Item" : "ORZID3 GMENU COM ACQ DIARRHEA/NO TRAVEL", "Text" : "Community-acquired diarrhea", "Header" : 0}, 
{"Row" : 137, "Column" : 1, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "Text" : "Community-acquired pneumonia (CAP)", "Header" : 0}, 
{"Row" : 138, "Column" : 1, "Item" : "ORZID2 GMENU ABX COM-ACQ PNEUMONIA", "Text" : "Community-acquired pneumonia (CAP), inpatient treatment setting", "Header" : 0}, 
{"Row" : 139, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM COMP DEFICIENCY", "Text" : "Complement deficiency", "Header" : 0}, 
{"Row" : 140, "Column" : 1, "Item" : "ORZID3 GMENU COMPLICATED CYSTITIS", "Text" : "Complicated cystitis", "Header" : 0}, 
{"Row" : 141, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT REQUIRED MAIN OP", "Text" : "Conditions not benefitted by antimicrobials", "Header" : 0}, 
{"Row" : 142, "Column" : 1, "Item" : "ORZID3 GMENU CONJUNCTIVITIS", "Text" : "Conjunctivitis", "Header" : 0}, 
{"Row" : 143, "Column" : 1, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Contact CDSS staff", "Header" : 0}, 
{"Row" : 144, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Contiguous or hematogenous spread brain abscess", "Header" : 0}, 
{"Row" : 145, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "Text" : "COPD exacerbation", "Header" : 0}, 
{"Row" : 146, "Column" : 1, "Item" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD", "Text" : "COPD, prevention of exacerbations", "Header" : 0}, 
{"Row" : 147, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS CORYNEBACTERIUM SPP.", "Text" : "Corynebacterium spp.", "Header" : 0}, 
{"Row" : 148, "Column" : 1, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Crabs", "Header" : 0}, 
{"Row" : 149, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Cranial epidural abscess", "Header" : 0}, 
{"Row" : 150, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "Text" : "Cryptococcus neoformans", "Header" : 0}, 
{"Row" : 151, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA C. PARVUM", "Text" : "Cryptosporidium parvum diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 152, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA C. CAYETANENSIS", "Text" : "Cyclospora cayetanensis diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 153, "Column" : 1, "Item" : "ORZID3 GMENU COMPLICATED CYSTITIS", "Text" : "Cystitis, complicated", "Header" : 0}, 
{"Row" : 154, "Column" : 1, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "Text" : "Cystitis, uncomplicated", "Header" : 0}, 
{"Row" : 155, "Column" : 1, "Item" : "ORZID3 GMENU ABX CMV MAIN PAGE", "Text" : "Cytomegalovirus (CMV) [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 160, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Decolonization of Staphylococcus aureus", "Header" : 0}, 
{"Row" : 161, "Column" : 1, "Item" : "ORZID3 GMENU DECUBITIS ULCERS", "Text" : "Decubitus ulcers", "Header" : 0}, 
{"Row" : 162, "Column" : 1, "Item" : "ORZID3 GMENU DEEP OROPHARYN INFECT", "Text" : "Deep oropharyngeal infections", "Header" : 0}, 
{"Row" : 163, "Column" : 1, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Dental infections", "Header" : 0}, 
{"Row" : 164, "Column" : 1, "Item" : "ORZID3 GMENU ABX STASIS DERMATITIS OP", "Text" : "Dermatitis, stasis", "Header" : 0}, 
{"Row" : 165, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatological surgery guidelines", "Header" : 0}, 
{"Row" : 166, "Column" : 1, "Item" : "ORZID3 GMENU DERMATOLOGY OUTPT MAIN", "Text" : "Dermatological Infections section", "Header" : 0}, 
{"Row" : 167, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatology post-op infection", "Header" : 0}, 
{"Row" : 168, "Column" : 1, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "Text" : "Desensitization protocol, penicillin", "Header" : 0}, 
{"Row" : 169, "Column" : 1, "Item" : "ORZID3 GMENU DEVICE-RELATED INFECT", "Text" : "Device-related infections", "Header" : 0}, 
{"Row" : 170, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS", "Text" : "Diabetes Mellitus", "Header" : 0}, 
{"Row" : 171, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "Text" : "Diabetic foot ulcer", "Header" : 0}, 
{"Row" : 172, "Column" : 1, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "Text" : "Diarrhea, infectious/gastroenteritis", "Header" : 0}, 
{"Row" : 173, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Diphtheria vaccination", "Header" : 0}, 
{"Row" : 174, "Column" : 1, "Item" : "ORZID2 GMENU ABX EXCLUSIONS", "Text" : "Diseases and Syndromes not covered", "Header" : 0}, 
{"Row" : 175, "Column" : 1, "Item" : "ORZID3 GMENU DISKITIS", "Text" : "Diskitis and vertebral osteomyelitis", "Header" : 0}, 
{"Row" : 176, "Column" : 1, "Item" : "ORZID3 GMENU PATH DISS M. AVIUM DISEASE", "Text" : "Disseminated Mycobacterium avium", "Header" : 0}, 
{"Row" : 177, "Column" : 1, "Item" : "ORZID3 GMENU DIVERTICULITIS", "Text" : "Diverticulitis", "Header" : 0}, 
{"Row" : 178, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "Text" : "Drug allergy information", "Header" : 0}, 
{"Row" : 179, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "Drug Information", "Header" : 0}, 
{"Row" : 180, "Column" : 1, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "Text" : "Drug properties, important", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "OUTPATIENT ANTIMICROIBAL CDSS INDEX",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "A______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "antimicrobial prophylaxis, management of fever,",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "patient initiated antibiotics, vaccines",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "B______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "C______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "antimicrobial prophylaxis, neutropenic fever",  "Header" : 0}, 
{"Row" : 156, "Column" : 1, "Item" : null, "Text" : "colitis, esophagitis, encephalitis, polyradiculopathy",  "Header" : 0}, 
{"Row" : 157, "Column" : 1, "Item" : null, "Text" : "retinitis, and pneumonia",  "Header" : 0}, 
{"Row" : 159, "Column" : 1, "Item" : null, "Text" : "D______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 183, "Column" : 1, "Item" : "ORZID3 GMENU HEAD AND NECK/ENT OUTPT MAIN", "Text" : "Ear, nose, throat (ENT)/Head and Neck section", "Header" : 0}, 
{"Row" : 184, "Column" : 1, "Item" : "ORZID3 GMENU ECTHYMA GANGRENOSUM", "Text" : "Ecthyma gangrenosum", "Header" : 0}, 
{"Row" : 185, "Column" : 1, "Item" : "ORZID3 GMENU PATH E. CHAFFEENSIS", "Text" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Header" : 0}, 
{"Row" : 186, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS EIKENELLA CORRODENS", "Text" : "Eikenella corrodens, bite wound", "Header" : 0}, 
{"Row" : 187, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Eikenella native valve endocarditis", "Header" : 0}, 
{"Row" : 188, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Eikenella prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 189, "Column" : 1, "Item" : "ORZID3 GMENU EMPYEMA", "Text" : "Empyema", "Header" : 0}, 
{"Row" : 190, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Empyema, subdural", "Header" : 0}, 
{"Row" : 191, "Column" : 1, "Item" : "ORZID3 GMENU HSV ENCEPHALITIS", "Text" : "Encephalitis", "Header" : 0}, 
{"Row" : 192, "Column" : 1, "Item" : "ORZID3 GMENU CMV ENCEPHALITIS", "Text" : "Encephalitis, Cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 193, "Column" : 1, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Endocarditis with sepsis", "Header" : 0}, 
{"Row" : 194, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Endocarditis, approach to", "Header" : 0}, 
{"Row" : 195, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Endocarditis, diagnosis of", "Header" : 0}, 
{"Row" : 196, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Endocarditis, native valve [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 200, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Endocarditis, native valve empirical therapy", "Header" : 0}, 
{"Row" : 201, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Endocarditis, prosthetic valve [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 205, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Endocarditis, prosthetic valve empirical therapy", "Header" : 0}, 
{"Row" : 206, "Column" : 1, "Item" : "ORZID3 GMENU ENDOPHTHALMITIS", "Text" : "Endophthalmitis", "Header" : 0}, 
{"Row" : 207, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA E. HISTOLYTICA", "Text" : "Entamoeba histolytica diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 208, "Column" : 1, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "Text" : "Enteric fever", "Header" : 0}, 
{"Row" : 209, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG ENTEROBACTER SPP.", "Text" : "Enterobacter species, general", "Header" : 0}, 
{"Row" : 210, "Column" : 1, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Enterobacteriaceae (ESBL+) nosocomial pneumonia", "Header" : 0}, 
{"Row" : 211, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS ENTEROCOCCI", "Text" : "Enterococcal infections, general", "Header" : 0}, 
{"Row" : 212, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Enterococcal intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 213, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH ENTEROCOCCI", "Text" : "Enterococcal native joint infection", "Header" : 0}, 
{"Row" : 214, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Enterococcal native valve endocarditis", "Header" : 0}, 
{"Row" : 215, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J ENTEROCOCCI", "Text" : "Enterococcal prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 216, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Enterococcal prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 217, "Column" : 1, "Item" : "ORZID3 GMENU PYELONEPHRITIS SPECIFIC PATHOGEN", "Text" : "Enterococcal pyelonephritis", "Header" : 0}, 
{"Row" : 218, "Column" : 1, "Item" : "ORZID3 GMENU EPIDIDYMITIS", "Text" : "Epididymitis", "Header" : 0}, 
{"Row" : 219, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Epidural abscess, cranial", "Header" : 0}, 
{"Row" : 220, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Epidural abscess, spinal", "Header" : 0}, 
{"Row" : 221, "Column" : 1, "Item" : "ORZID3 GMENU EPIGLOTTITIS", "Text" : "Epiglottitis", "Header" : 0}, 
{"Row" : 222, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELAS", "Text" : "Erysipelas", "Header" : 0}, 
{"Row" : 223, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELOID", "Text" : "Erysipeloid", "Header" : 0}, 
{"Row" : 224, "Column" : 1, "Item" : "ORZID3 GMENU LYME ERYTHEMA MIGRANS", "Text" : "Erythema migrans, Lyme disease", "Header" : 0}, 
{"Row" : 225, "Column" : 1, "Item" : "ORZID3 GMENU ERYTHRASMA", "Text" : "Erythrasma", "Header" : 0}, 
{"Row" : 226, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA ENTEROHEM E. COLI", "Text" : "Escherichia coli diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 227, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-NEG E. COLI", "Text" : "Escherichia coli infections, general", "Header" : 0}, 
{"Row" : 228, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Escherichia coli meningitis", "Header" : 0}, 
{"Row" : 229, "Column" : 1, "Item" : "ORZID3 GMENU ABX ESOPHAGITIS", "Text" : "Esophagitis", "Header" : 0}, 
{"Row" : 230, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "Text" : "Exacerbation of COPD", "Header" : 0}, 
{"Row" : 231, "Column" : 1, "Item" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD", "Text" : "Exacerbations of COPD, prevention of", "Header" : 0}, 
{"Row" : 234, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA 2021-2022 OUTPATIENT", "Text" : "Flu", "Header" : 0}, 
{"Row" : 235, "Column" : 1, "Item" : "ORZID3 GMENU FOLLICULITIS", "Text" : "Folliculitis", "Header" : 0}, 
{"Row" : 236, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "Text" : "Foot ulcer in patient with diabetes", "Header" : 0}, 
{"Row" : 237, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Fungal native valve endocarditis", "Header" : 0}, 
{"Row" : 238, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Fungal prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 239, "Column" : 1, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "Text" : "Fungal sinusitis", "Header" : 0}, 
{"Row" : 240, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Fungemia associated with Candida spp.", "Header" : 0}, 
{"Row" : 241, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI", "Text" : "Fungi section", "Header" : 0}, 
{"Row" : 242, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Furuncles", "Header" : 0}, 
{"Row" : 182, "Column" : 1, "Item" : null, "Text" : "E______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 197, "Column" : 1, "Item" : null, "Text" : "culture negative, enterococci, fungi,",  "Header" : 0}, 
{"Row" : 198, "Column" : 1, "Item" : null, "Text" : "gram-negative bacilli, streptococci, staphylococci,",  "Header" : 0}, 
{"Row" : 199, "Column" : 1, "Item" : null, "Text" : "and HACEK bacteria",  "Header" : 0}, 
{"Row" : 202, "Column" : 1, "Item" : null, "Text" : "culture negative, enterococci, fungi,",  "Header" : 0}, 
{"Row" : 203, "Column" : 1, "Item" : null, "Text" : "gram-negative bacilli, Streptococcus bovis,",  "Header" : 0}, 
{"Row" : 204, "Column" : 1, "Item" : null, "Text" : "staphylococci, HACEK bacteria, and Viridans group streptococci",  "Header" : 0}, 
{"Row" : 233, "Column" : 1, "Item" : null, "Text" : "F______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 1, "Column" : 2, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Contact CDSS staff", "Header" : 0}, 
{"Row" : 2, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "Text" : "Gastroenteritis/infectious diarrhea", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID3 GMENU GASTROINT OUTPT MAIN", "Text" : "Gastrointestinal and Intraabdominal section", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID3 GMENU GENITAL HERPES", "Text" : "Genital herpes", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU GENITOURINARY", "Text" : "Genitourinary section", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA G. LAMBLIA", "Text" : "Giardia lamblia diarrhea", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA G. LAMBLIA", "Text" : "Giardia lamblia infections, general", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "Text" : "Gonococcal urethritis", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Gram-negative bacilli bacteremia", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID3 GMENU INT RS GRAM-NEG BACILLI", "Text" : "Gram-negative bacilli interim culture results", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Gram-negative bacilli intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Gram-negative bacilli meningitis", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Gram-negative bacilli, non-HACEK, native valve endocarditis", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Gram-negative bacilli, non-HACEK, prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU OSTEOM GNB", "Text" : "Gram-negative bacilli, non-pseudomonas, osteomyelitis", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID3 GMENU PROS B/J GNB", "Text" : "Gram-negative bacilli, non-pseudomonas, prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTH GNB", "Text" : "Gram-negative bacilli, non-pseudomonas, native joint infection", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU GRAM NEGATIVE BACTERIA", "Text" : "Gram-Negative Bacteria section", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Gram-negative cocci bacteremia", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU INT RS GRAM-NEG COCCI", "Text" : "Gram-negative cocci interim culture results", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Gram-negative diplococci meningitis", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Gram-positive bacilli bacteremia", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Gram-positive bacilli meningitis", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU INT RS GRAM-POS BACILLI", "Text" : "Gram-positive bacilli, interim culture results", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU GRAM POSITIVE BACTERIA", "Text" : "Gram-positive bacteria, section", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Gram-positive cocci in pairs and chains bacteremia", "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Gram-positive cocci in pairs and clusters bacteremia", "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Gram-positive cocci in pairs bacteremia", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "ORZID3 GMENU INT RS GRAM-POS COCCI PAIRS", "Text" : "Gram-positive cocci in pairs interim culture results", "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "Text" : "Gram-positive cocci, anaerobic", "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Gram-positive coccobacilli meningitis", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Gram-positive diplococci meningitis", "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. PYOGENES", "Text" : "Group A streptococci", "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. AGALACTIAE", "Text" : "Group B Streptococci", "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. BOVIS", "Text" : "Group D Streptococci", "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS GROUPS C, F, G", "Text" : "Groups C, F, G Streptococci", "Header" : 0}, 
{"Row" : 44, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "HACEK bacteria native valve endocarditis", "Header" : 0}, 
{"Row" : 45, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "HACEK bacteria prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 46, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG HAEMOPHILUS SPP.", "Text" : "Haemophilus infections, general", "Header" : 0}, 
{"Row" : 47, "Column" : 2, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae B vaccination", "Header" : 0}, 
{"Row" : 48, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Haemophilus native valve endocarditis", "Header" : 0}, 
{"Row" : 49, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Haemophilus prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 50, "Column" : 2, "Item" : "ORZID3 GMENU HEAD AND NECK/ENT OUTPT MAIN", "Text" : "Head and Neck/ENT section", "Header" : 0}, 
{"Row" : 51, "Column" : 2, "Item" : "ORZID3 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "Text" : "Head lice", "Header" : 0}, 
{"Row" : 52, "Column" : 2, "Item" : "ORZID3 GMENU H. PYLORI INFECT", "Text" : "Helicobacter pylori", "Header" : 0}, 
{"Row" : 53, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help", "Header" : 0}, 
{"Row" : 54, "Column" : 2, "Item" : "ORZID3 GMENU BED BUGS (HEMIPTERA)", "Text" : "Hemiptera", "Header" : 0}, 
{"Row" : 55, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Hemodialysis immunizations", "Header" : 0}, 
{"Row" : 56, "Column" : 2, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Hepatic abscess", "Header" : 0}, 
{"Row" : 57, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "Text" : "Hepatic disease immunizations", "Header" : 0}, 
{"Row" : 58, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPATITIS A", "Text" : "Hepatitis A", "Header" : 0}, 
{"Row" : 59, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A vaccination", "Header" : 0}, 
{"Row" : 60, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A/Hepatitis B vaccination", "Header" : 0}, 
{"Row" : 61, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPATITIS B", "Text" : "Hepatitis B", "Header" : 0}, 
{"Row" : 62, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B vaccination", "Header" : 0}, 
{"Row" : 63, "Column" : 2, "Item" : "ORZID3 GMENU ABX HEPATITIS C", "Text" : "Hepatitis C", "Header" : 0}, 
{"Row" : 64, "Column" : 2, "Item" : "ORZID3 GMENU ABX HERPES SIMPLEX ESOPHAGITIS", "Text" : "Herpes esophagitis", "Header" : 0}, 
{"Row" : 65, "Column" : 2, "Item" : "ORZID3 GMENU ABX HERPES KERATITIS", "Text" : "Herpes keratitis", "Header" : 0}, 
{"Row" : 66, "Column" : 2, "Item" : "ORZID3 GMENU RETINITIS", "Text" : "Herpes retinitis", "Header" : 0}, 
{"Row" : 67, "Column" : 2, "Item" : "ORZID3 GMENU HERPES WHITLOW", "Text" : "Herpes whitlow (digit or hand cellulitis)", "Header" : 0}, 
{"Row" : 68, "Column" : 2, "Item" : "ORZID3 GMENU GENITAL HERPES", "Text" : "Herpes, genital", "Header" : 0}, 
{"Row" : 69, "Column" : 2, "Item" : "ORZID3 GMENU OROLABIAL HERPES", "Text" : "Herpes, orolabial", "Header" : 0}, 
{"Row" : 70, "Column" : 2, "Item" : "ORZID3 GMENU HIDRADENITIS SUPPURATIVA", "Text" : "Hidradenitis suppurativa", "Header" : 0}, 
{"Row" : 71, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI H. CAPSULATUM", "Text" : "Histoplasma capsulatum", "Header" : 0}, 
{"Row" : 72, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "Text" : "HIV patient immunization", "Header" : 0}, 
{"Row" : 73, "Column" : 2, "Item" : "ORZID3 GMENU ABX HIV-AIDS", "Text" : "HIV infection, general", "Header" : 0}, 
{"Row" : 74, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "Text" : "Home IV therapy at MVAMC", "Header" : 0}, 
{"Row" : 75, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Hospital-acquired pneumonia (HAP)", "Header" : 0}, 
{"Row" : 76, "Column" : 2, "Item" : "ORZ GMENU BONE MARROW MAIN", "Text" : "HSCT immunizations", "Header" : 0}, 
{"Row" : 77, "Column" : 2, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papilloma virus vaccination", "Header" : 0}, 
{"Row" : 78, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA", "Text" : "Hypochlorhydria", "Header" : 0}, 
{"Row" : 81, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "Text" : "Immunization of immunocompromised patients (except HIV)", "Header" : 0}, 
{"Row" : 82, "Column" : 2, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "Text" : "Immunization of patients at high-risk of rabies exposure", "Header" : 0}, 
{"Row" : 83, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Immunization of patients in kidney failure/HD", "Header" : 0}, 
{"Row" : 84, "Column" : 2, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Immunization of patients with asplenia", "Header" : 0}, 
{"Row" : 85, "Column" : 2, "Item" : "ORZ GMENU BONE MARROW MAIN", "Text" : "Immunization of patients with bone marrow transplant", "Header" : 0}, 
{"Row" : 86, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "Text" : "Immunization of patients with chronic liver disease", "Header" : 0}, 
{"Row" : 87, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "Text" : "Immunization of patients with HIV", "Header" : 0}, 
{"Row" : 88, "Column" : 2, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Immunization of patients with pregnancy", "Header" : 0}, 
{"Row" : 89, "Column" : 2, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "Text" : "Immunization, adult [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 94, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS", "Text" : "Immunocompromised patients basic concepts", "Header" : 0}, 
{"Row" : 95, "Column" : 2, "Item" : "ORZID3 GMENU IMMUNOCOMPROMISED PT", "Text" : "Immunocompromised Patients section", "Header" : 0}, 
{"Row" : 96, "Column" : 2, "Item" : "ORZID3 GMENU IG DEFICIENCY HIS", "Text" : "Immunoglobulin (Humoral immune system) deficiency", "Header" : 0}, 
{"Row" : 97, "Column" : 2, "Item" : "ORZID3 GMENU IMPETIGO", "Text" : "Impetigo", "Header" : 0}, 
{"Row" : 98, "Column" : 2, "Item" : "ORZID2 GMENU ABX IMPORTANT DRUG PROPERTIES", "Text" : "Important drug properties", "Header" : 0}, 
{"Row" : 99, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "Text" : "Infection control department information", "Header" : 0}, 
{"Row" : 100, "Column" : 2, "Item" : "ORZID3 GMENU PREVENTION OF INFECT", "Text" : "Infection Prevention section", "Header" : 0}, 
{"Row" : 101, "Column" : 2, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "Text" : "Infectious diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 102, "Column" : 2, "Item" : "ORZID3 GMENU INFLUENZA 2021-2022 OUTPATIENT", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 103, "Column" : 2, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 104, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOME IV AT MPLS", "Text" : "Intravenous therapy at home, MVAMC", "Header" : 0}, 
{"Row" : 105, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA ISOSPORA BELLI", "Text" : "Isospora diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 108, "Column" : 2, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "Text" : "Joint and Bone section", "Header" : 0}, 
{"Row" : 109, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Text" : "Joint infection, native [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 113, "Column" : 2, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "Text" : "Joint infection, prosthetic [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 119, "Column" : 2, "Item" : "ORZID3 GMENU KERATITIS", "Text" : "Keratitis", "Header" : 0}, 
{"Row" : 120, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Kidney failure immunizations", "Header" : 0}, 
{"Row" : 121, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Kingella native valve endocarditis", "Header" : 0}, 
{"Row" : 122, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Kingella prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 123, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG KLEBSIELLA SPP.", "Text" : "Klebsiella infections, general", "Header" : 0}, 
{"Row" : 126, "Column" : 2, "Item" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "Text" : "Large uniform bacilli, aerobic bottle", "Header" : 0}, 
{"Row" : 127, "Column" : 2, "Item" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "Text" : "Large uniform bacilli, anaerobic bottle", "Header" : 0}, 
{"Row" : 128, "Column" : 2, "Item" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP", "Text" : "Laryngitis", "Header" : 0}, 
{"Row" : 129, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG LEGIONELLA SPP.", "Text" : "Legionella infections, general", "Header" : 0}, 
{"Row" : 130, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Legionella pneumophila nosocomial pneumonia", "Header" : 0}, 
{"Row" : 131, "Column" : 2, "Item" : "ORZID3 GMENU LEISHMANIASIS", "Text" : "Leishmaniasis", "Header" : 0}, 
{"Row" : 132, "Column" : 2, "Item" : "ORZID2 GMENU LEUKOCYTOSIS", "Text" : "Leukocytosis", "Header" : 0}, 
{"Row" : 133, "Column" : 2, "Item" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Text" : "Lice, body", "Header" : 0}, 
{"Row" : 134, "Column" : 2, "Item" : "ORZID3 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "Text" : "Lice, head", "Header" : 0}, 
{"Row" : 135, "Column" : 2, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Lice, pubic", "Header" : 0}, 
{"Row" : 136, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS LISTERIA SPP.", "Text" : "Listeria infections, general", "Header" : 0}, 
{"Row" : 137, "Column" : 2, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Listeria monocytogenes bacteremia", "Header" : 0}, 
{"Row" : 138, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Listeria monocytogenes meningitis", "Header" : 0}, 
{"Row" : 139, "Column" : 2, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Liver abscess", "Header" : 0}, 
{"Row" : 140, "Column" : 2, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "Text" : "Liver disease immunizations", "Header" : 0}, 
{"Row" : 141, "Column" : 2, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "Text" : "Liver disease, prevention of spontaneous bacterial peritonitis", "Header" : 0}, 
{"Row" : 142, "Column" : 2, "Item" : "ORZID3 GMENU LUNG ABSCESS", "Text" : "Lung abscess", "Header" : 0}, 
{"Row" : 143, "Column" : 2, "Item" : "ORZID3 GMENU LUNGS AND MEDIASTINUM", "Text" : "Lungs and Mediastinum section", "Header" : 0}, 
{"Row" : 144, "Column" : 2, "Item" : "ORZID3 GMENU LYME DISEASE", "Text" : "Lyme disease [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 149, "Column" : 2, "Item" : "ORZID3 GMENU IMMUNOCOM MALIGNANCY", "Text" : "Malignancy [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 151, "Column" : 2, "Item" : "ORZID3 GMENU MALIGN OTITIS EXTERNA", "Text" : "Malignant otitis externa", "Header" : 0}, 
{"Row" : 152, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION", "Text" : "Malnutrition", "Header" : 0}, 
{"Row" : 153, "Column" : 2, "Item" : "ORZID3 GMENU MASTOIDITIS", "Text" : "Mastoiditis", "Header" : 0}, 
{"Row" : 154, "Column" : 2, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles vaccination", "Header" : 0}, 
{"Row" : 155, "Column" : 2, "Item" : "ORZID3 GMENU MEDIASTINITIS", "Text" : "Mediastinitis", "Header" : 0}, 
{"Row" : 156, "Column" : 2, "Item" : "ORZID3 GMENU LUNGS AND MEDIASTINUM", "Text" : "Mediastinum and Lung section", "Header" : 0}, 
{"Row" : 157, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis associated with trauma or nosocomial infection", "Header" : 0}, 
{"Row" : 158, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with E. coli, Pseudomonas or other organism", "Header" : 0}, 
{"Row" : 159, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with Escherichia coli", "Header" : 0}, 
{"Row" : 160, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with gram-negative bacilli", "Header" : 0}, 
{"Row" : 161, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with gram-negative diplococci", "Header" : 0}, 
{"Row" : 162, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with gram-positive bacilli/coccobacilli", "Header" : 0}, 
{"Row" : 163, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with gram-positive diplococci", "Header" : 0}, 
{"Row" : 164, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with Listeria monocytogenes", "Header" : 0}, 
{"Row" : 165, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with Neisseria meningitidis", "Header" : 0}, 
{"Row" : 166, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with pseudomonas", "Header" : 0}, 
{"Row" : 167, "Column" : 2, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Meningitis with sepsis", "Header" : 0}, 
{"Row" : 168, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis with Streptococcus pneumoniae", "Header" : 0}, 
{"Row" : 169, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis without gram stain results", "Header" : 0}, 
{"Row" : 170, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Meningitis, other organism", "Header" : 0}, 
{"Row" : 171, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal conjugate (MENACWY) vaccination", "Header" : 0}, 
{"Row" : 172, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MENB) vaccination", "Header" : 0}, 
{"Row" : 173, "Column" : 2, "Item" : "ORZID3 GMENU BITE WNDS METH RES S. AUREUS", "Text" : "Methicillin-resistant Staphylococcus aureus bite wounds", "Header" : 0}, 
{"Row" : 174, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA MICROSPORIDIA", "Text" : "Microsporidia diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 175, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG M. CATARRHALIS", "Text" : "Moraxella catarrhalis infections, general", "Header" : 0}, 
{"Row" : 176, "Column" : 2, "Item" : "ORZID3 GMENU BITE WNDS METH RES S. AUREUS", "Text" : "MRSA bite wounds", "Header" : 0}, 
{"Row" : 177, "Column" : 2, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "MRSA risk factors", "Header" : 0}, 
{"Row" : 178, "Column" : 2, "Item" : "ORZID3 GMENU BITE WNDS METH SUSC S. AUREUS", "Text" : "MSSA bite wounds", "Header" : 0}, 
{"Row" : 179, "Column" : 2, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Mumps vaccination", "Header" : 0}, 
{"Row" : 180, "Column" : 2, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "Text" : "Muscle and Soft Tissue section", "Header" : 0}, 
{"Row" : 181, "Column" : 2, "Item" : "ORZID3 GMENU PATH M. AVIUM INTRACELL", "Text" : "Mycobacterium avium intracellular complex (MAI or MAC)", "Header" : 0}, 
{"Row" : 182, "Column" : 2, "Item" : "ORZID3 GMENU PATH M. AVIUM PNEUMONIA", "Text" : "Mycobacterium avium pneumonia", "Header" : 0}, 
{"Row" : 183, "Column" : 2, "Item" : "ORZID3 GMENU PATH PRO M. AVIUM W/ HIV", "Text" : "Mycobacterium avium prophylaxis", "Header" : 0}, 
{"Row" : 184, "Column" : 2, "Item" : "ORZID3 GMENU PATH DISS M. AVIUM DISEASE", "Text" : "Mycobacterium avium, disseminated", "Header" : 0}, 
{"Row" : 185, "Column" : 2, "Item" : "ORZID3 GMENU PATHO M. TUBERCULOSIS", "Text" : "Mycobacterium tuberculosis", "Header" : 0}, 
{"Row" : 186, "Column" : 2, "Item" : "ORZID3 GMENU PATH MYCOPLASMA PNEUMO", "Text" : "Mycoplasma pneumonia infections, general", "Header" : 0}, 
{"Row" : 187, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Myocarditis", "Header" : 0}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "G through Pn",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "G______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 43, "Column" : 2, "Item" : null, "Text" : "H______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 80, "Column" : 2, "Item" : null, "Text" : "I______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 90, "Column" : 2, "Item" : null, "Text" : "diphtheria, Haemophilus influenza B, Hepatitis A and B,",  "Header" : 0}, 
{"Row" : 91, "Column" : 2, "Item" : null, "Text" : "human papilloma virus, influenza, measles, mumps,",  "Header" : 0}, 
{"Row" : 92, "Column" : 2, "Item" : null, "Text" : "meningococcal, pneumococcal, pertussis, rubella,",  "Header" : 0}, 
{"Row" : 93, "Column" : 2, "Item" : null, "Text" : "tetanus, varicella, zoster",  "Header" : 0}, 
{"Row" : 107, "Column" : 2, "Item" : null, "Text" : "J______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 110, "Column" : 2, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 111, "Column" : 2, "Item" : null, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,",  "Header" : 0}, 
{"Row" : 112, "Column" : 2, "Item" : null, "Text" : "Staphylococcus aureus, streptococcus",  "Header" : 0}, 
{"Row" : 114, "Column" : 2, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 115, "Column" : 2, "Item" : null, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 116, "Column" : 2, "Item" : null, "Text" : "and streptococcus",  "Header" : 0}, 
{"Row" : 118, "Column" : 2, "Item" : null, "Text" : "K______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 125, "Column" : 2, "Item" : null, "Text" : "L______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 145, "Column" : 2, "Item" : null, "Text" : "arthritis, carditis, erythema migrans,",  "Header" : 0}, 
{"Row" : 146, "Column" : 2, "Item" : null, "Text" : "neurological complications, prophylaxis",  "Header" : 0}, 
{"Row" : 148, "Column" : 2, "Item" : null, "Text" : "M______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 150, "Column" : 2, "Item" : null, "Text" : "antimicrobial prophylaxis, neutropenic fever",  "Header" : 0}, 
{"Row" : 190, "Column" : 2, "Item" : "ORZID3 GMENU NASAL PACKING", "Text" : "Nasal packing", "Header" : 0}, 
{"Row" : 191, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Text" : "Native joint infection [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 195, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Native valve endocarditis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 199, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Native valve endocarditis empirical therapy", "Header" : 0}, 
{"Row" : 200, "Column" : 2, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Native valve endocarditis with sepsis", "Header" : 0}, 
{"Row" : 201, "Column" : 2, "Item" : "ORZID3 GMENU NECROTIZING INFECTIONS", "Text" : "Necrotizing infections", "Header" : 0}, 
{"Row" : 202, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG N. GONORRHOEAE", "Text" : "Neisseria gonorrhoeae infections, general", "Header" : 0}, 
{"Row" : 203, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTH N. GONORRHOEAE", "Text" : "Neisseria gonorrhoeae native joint infection", "Header" : 0}, 
{"Row" : 204, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG N. MENINGITIDIS", "Text" : "Neisseria meningitidis infections, general", "Header" : 0}, 
{"Row" : 205, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Neisseria meningitidis meningitis", "Header" : 0}, 
{"Row" : 206, "Column" : 2, "Item" : "ORZID3 GMENU LYME ACUTE NEURO DISEASE", "Text" : "Neurological disease associated with Lyme disease", "Header" : 0}, 
{"Row" : 207, "Column" : 2, "Item" : "ORZID3 GMENU IMMUNOCOM NEUROL DYSFUNCT", "Text" : "Neurological dysfunction", "Header" : 0}, 
{"Row" : 208, "Column" : 2, "Item" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA", "Text" : "Neutropenia", "Header" : 0}, 
{"Row" : 209, "Column" : 2, "Item" : "ORZID3 GMENU TYPHLITIS", "Text" : "Neutropenic enterocolitis", "Header" : 0}, 
{"Row" : 210, "Column" : 2, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "Text" : "Neutropenic fever", "Header" : 0}, 
{"Row" : 211, "Column" : 2, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Neutropenic fever with sepsis", "Header" : 0}, 
{"Row" : 212, "Column" : 2, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Nocardia spp. brain abscess", "Header" : 0}, 
{"Row" : 213, "Column" : 2, "Item" : "ORZID3 GMENU APPENDICITIS W/O PERFORATION", "Text" : "Non-perforated appendicitis", "Header" : 0}, 
{"Row" : 214, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "Text" : "Non-streptococcal pharyngitis", "Header" : 0}, 
{"Row" : 215, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Nosocomial pneumonia", "Header" : 0}, 
{"Row" : 216, "Column" : 2, "Item" : "ORZID3 GMENU NOSO SINUSITIS", "Text" : "Nosocomial sinusitis", "Header" : 0}, 
{"Row" : 219, "Column" : 2, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "Occupational post-exposure prophylaxis", "Header" : 0}, 
{"Row" : 220, "Column" : 2, "Item" : "ORZID3 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "Text" : "Onychomycosis", "Header" : 0}, 
{"Row" : 221, "Column" : 2, "Item" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "Text" : "Orbital cellulitis", "Header" : 0}, 
{"Row" : 222, "Column" : 2, "Item" : "ORZID3 GMENU OROLABIAL HERPES", "Text" : "Orolabial herpes", "Header" : 0}, 
{"Row" : 223, "Column" : 2, "Item" : "ORZID3 GMENU DEEP OROPHARYN INFECT", "Text" : "Oropharyngeal infections, deep", "Header" : 0}, 
{"Row" : 224, "Column" : 2, "Item" : "ORZID3 GMENU OSTEOMYELITIS", "Text" : "Osteomyelitis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 227, "Column" : 2, "Item" : "ORZID3 GMENU OTHER PATHOGENS", "Text" : "Other Pathogens section", "Header" : 0}, 
{"Row" : 228, "Column" : 2, "Item" : "ORZID3 GMENU OTITIS EXTERNA", "Text" : "Otitis externa", "Header" : 0}, 
{"Row" : 229, "Column" : 2, "Item" : "ORZID3 GMENU MALIGN OTITIS EXTERNA", "Text" : "Otitis externa, malignant", "Header" : 0}, 
{"Row" : 230, "Column" : 2, "Item" : "ORZID3 GMENU OTITIS MEDIA", "Text" : "Otitis media", "Header" : 0}, 
{"Row" : 233, "Column" : 2, "Item" : "ORZID3 GMENU PANCREATITIS", "Text" : "Pancreatitis", "Header" : 0}, 
{"Row" : 234, "Column" : 2, "Item" : "ORZID3 GMENU ABX PARAINFLUENZA", "Text" : "Parainfluenza", "Header" : 0}, 
{"Row" : 235, "Column" : 2, "Item" : "ORZID3 GMENU PARASITES MAIN", "Text" : "Parasites", "Header" : 0}, 
{"Row" : 236, "Column" : 2, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "Text" : "Paratyphoid fever", "Header" : 0}, 
{"Row" : 237, "Column" : 2, "Item" : "ORZID3 GMENU PARONYCHIA", "Text" : "Paronychia", "Header" : 0}, 
{"Row" : 238, "Column" : 2, "Item" : "ORZID3 GMENU ABX PAROTITIS", "Text" : "Parotitis", "Header" : 0}, 
{"Row" : 239, "Column" : 2, "Item" : "ORZID3 GMENU BITE WNDS P. MULTOCIDA", "Text" : "Pasteurella multocida bite wounds", "Header" : 0}, 
{"Row" : 240, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG P. MULTOCIDA", "Text" : "Pasteurella multocida infections, general", "Header" : 0}, 
{"Row" : 241, "Column" : 2, "Item" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Text" : "Pediculosis corporis", "Header" : 0}, 
{"Row" : 242, "Column" : 2, "Item" : "ORZID3 GMENU PELVIC INFLAM DISEASE", "Text" : "Pelvic inflammatory disease (PID)", "Header" : 0}, 
{"Row" : 243, "Column" : 2, "Item" : "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN", "Text" : "Pelvic pain syndrome/prostatitis, chronic", "Header" : 0}, 
{"Row" : 244, "Column" : 2, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "Text" : "Penicillin desensitization protocol", "Header" : 0}, 
{"Row" : 245, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "Text" : "Peptostreptococcus infections, general", "Header" : 0}, 
{"Row" : 246, "Column" : 2, "Item" : "ORZID3 GMENU APPENDICITIS W/ PERFORATION", "Text" : "Perforated appendicitis", "Header" : 0}, 
{"Row" : 247, "Column" : 2, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal abscess", "Header" : 0}, 
{"Row" : 248, "Column" : 2, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Pericarditis", "Header" : 0}, 
{"Row" : 249, "Column" : 2, "Item" : "ORZID2 GMENU PERIOCULAR INFECTIONS", "Text" : "Periocular infections", "Header" : 0}, 
{"Row" : 250, "Column" : 2, "Item" : "ORZID3 GMENU PERIODENTAL DISEASE", "Text" : "Periodontal disease", "Header" : 0}, 
{"Row" : 251, "Column" : 2, "Item" : "ORZID3 GMENU PERI ASSOC CAPD", "Text" : "Peritoneal dialysis peritonitis", "Header" : 0}, 
{"Row" : 252, "Column" : 2, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "Text" : "Peritonitis, acute spontaneous bacterial", "Header" : 0}, 
{"Row" : 253, "Column" : 2, "Item" : "ORZID3 GMENU PERI ASSOC CAPD", "Text" : "Peritonitis, peritoneal dialysis associated", "Header" : 0}, 
{"Row" : 254, "Column" : 2, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "Text" : "Peritonitis, secondary", "Header" : 0}, 
{"Row" : 255, "Column" : 2, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "Text" : "Persistent or recurrent urethritis", "Header" : 0}, 
{"Row" : 256, "Column" : 2, "Item" : "ORZID3 GMENU PERTUSSIS", "Text" : "Pertussis", "Header" : 0}, 
{"Row" : 257, "Column" : 2, "Item" : "ORZID3 GMENU PREVENTION PERTUSSIS", "Text" : "Pertussis post-exposure prophylaxis", "Header" : 0}, 
{"Row" : 258, "Column" : 2, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Pertussis vaccination", "Header" : 0}, 
{"Row" : 259, "Column" : 2, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "Text" : "Pharyngitis, non-streptococcal", "Header" : 0}, 
{"Row" : 260, "Column" : 2, "Item" : "ORZID3 GMENU PHARYNGITIS", "Text" : "Pharyngitis, streptococcal", "Header" : 0}, 
{"Row" : 261, "Column" : 2, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal vaccination", "Header" : 0}, 
{"Row" : 262, "Column" : 2, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "Text" : "Pneumocystis", "Header" : 0}, 
{"Row" : 263, "Column" : 2, "Item" : "ORZID3 GMENU SURG PNEUMOCYSTIS JIROVECII", "Text" : "Pneumocystis prophylaxis", "Header" : 0}, 
{"Row" : 264, "Column" : 2, "Item" : "ORZID3 GMENU COMM INFECT PNEUMO", "Text" : "Pneumonia", "Header" : 0}, 
{"Row" : 265, "Column" : 2, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Pneumonia with sepsis", "Header" : 0}, 
{"Row" : 266, "Column" : 2, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "Text" : "Pneumonia, aspiration", "Header" : 0}, 
{"Row" : 267, "Column" : 2, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "Text" : "Pneumonia, community-acquired (CAP)", "Header" : 0}, 
{"Row" : 268, "Column" : 2, "Item" : "ORZID3 GMENU CMV PNEUMONIA", "Text" : "Pneumonia, Cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 269, "Column" : 2, "Item" : "ORZID3 GMENU PATH M. AVIUM PNEUMONIA", "Text" : "Pneumonia, Mycobacterium avium", "Header" : 0}, 
{"Row" : 270, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Pneumonia, nosocomial [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 189, "Column" : 2, "Item" : null, "Text" : "N______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 192, "Column" : 2, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 193, "Column" : 2, "Item" : null, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,",  "Header" : 0}, 
{"Row" : 194, "Column" : 2, "Item" : null, "Text" : "Staphylococcus aureus, streptococcus",  "Header" : 0}, 
{"Row" : 196, "Column" : 2, "Item" : null, "Text" : "culture negative, enterococci, fungi,",  "Header" : 0}, 
{"Row" : 197, "Column" : 2, "Item" : null, "Text" : "gram-negative bacilli, streptococci, staphylococci,",  "Header" : 0}, 
{"Row" : 198, "Column" : 2, "Item" : null, "Text" : "and HACEK bacteria",  "Header" : 0}, 
{"Row" : 218, "Column" : 2, "Item" : null, "Text" : "O______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 225, "Column" : 2, "Item" : null, "Text" : "empirical therapy, gram-negative bacilli, Pseudomonas aeruginosa,",  "Header" : 0}, 
{"Row" : 226, "Column" : 2, "Item" : null, "Text" : "Staphylococcus aureus, and streptococci",  "Header" : 0}, 
{"Row" : 232, "Column" : 2, "Item" : null, "Text" : "Pa-Pn__________________________________________________________________________",  "Header" : 1}, 
{"Row" : 271, "Column" : 2, "Item" : null, "Text" : "72 hour re-evaluation, Acinetobacter baumannii,",  "Header" : 0}, 
{"Row" : 272, "Column" : 2, "Item" : null, "Text" : "empirical therapy, Enterobacteriaceae, HAP, Legionella pneumophila,",  "Header" : 0}, 
{"Row" : 273, "Column" : 2, "Item" : null, "Text" : "Pseudomonas aeruginosa, Staphylococcus aeruginosa, and VAP",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "Drug Information", "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : "ORZID3 GMENU CMV POLYRADICULOPATHY", "Text" : "Polyradiculopathy, Cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "Text" : "Porphyromonas infections, general", "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "Post-exposure prophylaxis, occupational", "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : "ORZID3 GMENU PREVENTION PERTUSSIS", "Text" : "Post-exposure prophylaxis, pertussis", "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "Text" : "Post-operative antimicrobial prophylaxis", "Header" : 0}, 
{"Row" : 14, "Column" : 3, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Post-operative dermatology infection", "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : "ORZID3 GMENU SURG SITE INFECT", "Text" : "Post-operative wound infection", "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "Text" : "Postseptal cellulitis", "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Post-surgical or post-traumatic brain abscess", "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Pregnancy immunizations", "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "Text" : "Pregnancy risk factors for antimicrobials", "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "Text" : "Pre-operative antimicrobial prophylaxis", "Header" : 0}, 
{"Row" : 21, "Column" : 3, "Item" : "ORZID3 GMENU PRESEPTAL CELLULITIS", "Text" : "Preseptal cellulitis", "Header" : 0}, 
{"Row" : 22, "Column" : 3, "Item" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD", "Text" : "Prevention of COPD exacerbations", "Header" : 0}, 
{"Row" : 23, "Column" : 3, "Item" : "ORZID3 GMENU PREVENTION OF INFECT", "Text" : "Prevention of Infection section", "Header" : 0}, 
{"Row" : 24, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "Text" : "Prevotella infections, general", "Header" : 0}, 
{"Row" : 25, "Column" : 3, "Item" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "Text" : "Prophylactic antibiotics in malignancy", "Header" : 0}, 
{"Row" : 26, "Column" : 3, "Item" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "Text" : "Prophylactic antifungals in malignancy", "Header" : 0}, 
{"Row" : 27, "Column" : 3, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Prophylactic antimicrobials for asplenia", "Header" : 0}, 
{"Row" : 28, "Column" : 3, "Item" : "ORZID3 GMENU LYME DISEASE PROPHYLAXIS", "Text" : "Prophylactic antimicrobials for Lyme disease", "Header" : 0}, 
{"Row" : 29, "Column" : 3, "Item" : "ORZID3 GMENU PATH PRO M. AVIUM W/ HIV", "Text" : "Prophylactic antimicrobials for Mycobacterium avium", "Header" : 0}, 
{"Row" : 30, "Column" : 3, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "Prophylactic antimicrobials for occupational post-exposure", "Header" : 0}, 
{"Row" : 31, "Column" : 3, "Item" : "ORZID3 GMENU SURG PNEUMOCYSTIS JIROVECII", "Text" : "Prophylactic antimicrobials for Pneumocystis", "Header" : 0}, 
{"Row" : 32, "Column" : 3, "Item" : "ORZID3 GMENU PREVENTION PERTUSSIS", "Text" : "Prophylactic antimicrobials for post-exposure pertussis", "Header" : 0}, 
{"Row" : 33, "Column" : 3, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "Text" : "Prophylactic antimicrobials for spontaneous bacterial peritonitis", "Header" : 0}, 
{"Row" : 34, "Column" : 3, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "Text" : "Prophylactic antimicrobials, post-operative", "Header" : 0}, 
{"Row" : 35, "Column" : 3, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "Text" : "Prophylactic antimicrobials, pre-operative", "Header" : 0}, 
{"Row" : 36, "Column" : 3, "Item" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Prophylactic antivirals in malignancy", "Header" : 0}, 
{"Row" : 39, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS PROPIONIBACT SPP.", "Text" : "Propionibacterium infections, general", "Header" : 0}, 
{"Row" : 40, "Column" : 3, "Item" : "ORZID3 GMENU ACUTE BACT PROSTATITIS", "Text" : "Prostatitis, acute", "Header" : 0}, 
{"Row" : 41, "Column" : 3, "Item" : "ORZID3 GMENU CHRONIC BACT PROSTATITIS", "Text" : "Prostatitis, chronic", "Header" : 0}, 
{"Row" : 42, "Column" : 3, "Item" : "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN", "Text" : "Prostatitis/pelvic pain syndrome, chronic", "Header" : 0}, 
{"Row" : 43, "Column" : 3, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "Text" : "Prosthetic bone/joint infection [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 47, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Prosthetic valve endocarditis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 51, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Prosthetic valve endocarditis empirical therapy", "Header" : 0}, 
{"Row" : 52, "Column" : 3, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Prosthetic valve endocarditis with sepsis", "Header" : 0}, 
{"Row" : 53, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG PROTEUS SPP.", "Text" : "Proteus infections, general", "Header" : 0}, 
{"Row" : 54, "Column" : 3, "Item" : "ORZID2 GMENU ABX PENICILLIN DESENS PROTOCOL", "Text" : "Protocol for Penicillin Desensitization", "Header" : 0}, 
{"Row" : 55, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC ARTH P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa native joint infection", "Header" : 0}, 
{"Row" : 56, "Column" : 3, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Pseudomonas aeruginosa nosocomial pneumonia", "Header" : 0}, 
{"Row" : 57, "Column" : 3, "Item" : "ORZID3 GMENU OSTEOM PSEUDOMONAS AERUGINOSA", "Text" : "Pseudomonas aeruginosa osteomyelitis", "Header" : 0}, 
{"Row" : 58, "Column" : 3, "Item" : "ORZID3 GMENU PROS B/J P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 59, "Column" : 3, "Item" : "ORZID3 GMENU PYELONEPHRITIS SPECIFIC PATHOGEN", "Text" : "Pseudomonas aeruginosa pyelonephritis", "Header" : 0}, 
{"Row" : 60, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG PSEUDOMONAS SPP.", "Text" : "Pseudomonas infections, general", "Header" : 0}, 
{"Row" : 61, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Pseudomonas meningitis", "Header" : 0}, 
{"Row" : 62, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Pseudomonas spp. brain abscess", "Header" : 0}, 
{"Row" : 63, "Column" : 3, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Pubic lice", "Header" : 0}, 
{"Row" : 64, "Column" : 3, "Item" : "ORZID3 GMENU PYELONEPHRITIS", "Text" : "Pyelonephritis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 66, "Column" : 3, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Pyogenic liver abscess", "Header" : 0}, 
{"Row" : 67, "Column" : 3, "Item" : "ORZID3 GMENU PYOMYOSITIS", "Text" : "Pyomyositis", "Header" : 0}, 
{"Row" : 68, "Column" : 3, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "Text" : "Pyuria", "Header" : 0}, 
{"Row" : 75, "Column" : 3, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "Text" : "Rabies vaccination", "Header" : 0}, 
{"Row" : 76, "Column" : 3, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "Text" : "Recurrent or persistent urethritis", "Header" : 0}, 
{"Row" : 77, "Column" : 3, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Renal failure immunizations", "Header" : 0}, 
{"Row" : 78, "Column" : 3, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "Resistant bacteria, more about", "Header" : 0}, 
{"Row" : 79, "Column" : 3, "Item" : "ORZID3 GMENU ABX RSV", "Text" : "Respiratory syncytial virus (RSV)", "Header" : 0}, 
{"Row" : 80, "Column" : 3, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "Text" : "Restrictions on antimicrobials", "Header" : 0}, 
{"Row" : 81, "Column" : 3, "Item" : "ORZID3 GMENU RETINITIS", "Text" : "Retinitis [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 83, "Column" : 3, "Item" : "ORZID3 GMENU TINEA CAPITIS (RINGWORM)", "Text" : "Ringworm", "Header" : 0}, 
{"Row" : 84, "Column" : 3, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "Risk factors for MRSA", "Header" : 0}, 
{"Row" : 85, "Column" : 3, "Item" : "ORZID3 GMENU ROCK MTN SPOTTED FEVER", "Text" : "Rocky mountain spotted fever", "Header" : 0}, 
{"Row" : 86, "Column" : 3, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Rubella vaccination", "Header" : 0}, 
{"Row" : 89, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA SALMONELLA", "Text" : "Salmonella diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 90, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG SALMONELLA SPP.", "Text" : "Salmonella infections, general", "Header" : 0}, 
{"Row" : 91, "Column" : 3, "Item" : "ORZID3 GMENU SCABIES", "Text" : "Scabies", "Header" : 0}, 
{"Row" : 92, "Column" : 3, "Item" : "ORZID3 GMENU STAPH SCALDED SKIN SYNDROME", "Text" : "Scalded skin syndrome", "Header" : 0}, 
{"Row" : 93, "Column" : 3, "Item" : "ORZID3 GMENU INFLUENZA 2021-2022 OUTPATIENT", "Text" : "Seasonal influenza", "Header" : 0}, 
{"Row" : 94, "Column" : 3, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "Text" : "Secondary peritonitis", "Header" : 0}, 
{"Row" : 95, "Column" : 3, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Sepsis and septic shock", "Header" : 0}, 
{"Row" : 96, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Text" : "Septic arthritis, native joint [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 100, "Column" : 3, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "Text" : "Septic arthritis, prosthetic joint [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 104, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC BURSITIS", "Text" : "Septic bursitis", "Header" : 0}, 
{"Row" : 105, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG SERRATIA SPP.", "Text" : "Serratia infections, general", "Header" : 0}, 
{"Row" : 106, "Column" : 3, "Item" : "ORZID3 GMENU BACTERIAL VAGINOSIS", "Text" : "Sexually transmitted infection, bacterial vaginitis", "Header" : 0}, 
{"Row" : 107, "Column" : 3, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "Text" : "Sexually transmitted infection, cervicitis", "Header" : 0}, 
{"Row" : 108, "Column" : 3, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "Text" : "Sexually transmitted infection, chlamydia cervicitis", "Header" : 0}, 
{"Row" : 109, "Column" : 3, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "Text" : "Sexually transmitted infection, chlamydia urethritis", "Header" : 0}, 
{"Row" : 110, "Column" : 3, "Item" : "ORZID3 GMENU GENITAL HERPES", "Text" : "Sexually transmitted infection, genital warts", "Header" : 0}, 
{"Row" : 111, "Column" : 3, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "Text" : "Sexually transmitted infection, gonorrhea cervicitis", "Header" : 0}, 
{"Row" : 112, "Column" : 3, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "Text" : "Sexually transmitted infection, gonorrhea urethritis", "Header" : 0}, 
{"Row" : 113, "Column" : 3, "Item" : "ORZID3 GMENU PELVIC INFLAM DISEASE", "Text" : "Sexually transmitted infection, pelvic inflammatory disease", "Header" : 0}, 
{"Row" : 114, "Column" : 3, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Sexually transmitted infection, pubic lice (crabs)", "Header" : 0}, 
{"Row" : 115, "Column" : 3, "Item" : "ORZID3 GMENU ABX SYPHILIS", "Text" : "Sexually transmitted infection, syphilis", "Header" : 0}, 
{"Row" : 116, "Column" : 3, "Item" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "Text" : "Sexually transmitted infection, trichomoniasis", "Header" : 0}, 
{"Row" : 117, "Column" : 3, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "Text" : "Sexually transmitted infection, urethritis", "Header" : 0}, 
{"Row" : 118, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "Text" : "Shigella diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 119, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-NEG SHIGELLA SPP.", "Text" : "Shigella infections, general", "Header" : 0}, 
{"Row" : 120, "Column" : 3, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "Text" : "Shingles", "Header" : 0}, 
{"Row" : 121, "Column" : 3, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Shingles vaccination", "Header" : 0}, 
{"Row" : 122, "Column" : 3, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Shortages of antimicrobials updates", "Header" : 0}, 
{"Row" : 123, "Column" : 3, "Item" : "ORZID3 GMENU ACUTE SINUSITIS (OPT)", "Text" : "Sinusitis, acute", "Header" : 0}, 
{"Row" : 124, "Column" : 3, "Item" : "ORZID3 GMENU CHRONIC SINUSITIS", "Text" : "Sinusitis, chronic", "Header" : 0}, 
{"Row" : 125, "Column" : 3, "Item" : "ORZID2 GMENU FUNGAL SINUSITIS", "Text" : "Sinusitis, fungal", "Header" : 0}, 
{"Row" : 126, "Column" : 3, "Item" : "ORZID3 GMENU NOSO SINUSITIS", "Text" : "Sinusitis, nosocomial", "Header" : 0}, 
{"Row" : 127, "Column" : 3, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Skin and soft tissue infection with sepsis", "Header" : 0}, 
{"Row" : 128, "Column" : 3, "Item" : "ORZID3 GMENU DERMATOLOGY OUTPT MAIN", "Text" : "Skin Infections section", "Header" : 0}, 
{"Row" : 129, "Column" : 3, "Item" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "Text" : "Small pleomorphic bacilli, aerobic bottle", "Header" : 0}, 
{"Row" : 130, "Column" : 3, "Item" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "Text" : "Small pleomorphic bacilli, anaerobic bottle", "Header" : 0}, 
{"Row" : 131, "Column" : 3, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "Text" : "Soft Tissue and Muscle section", "Header" : 0}, 
{"Row" : 132, "Column" : 3, "Item" : "ORZID2 GMENU INTRO SPEC PATHOGEN", "Text" : "Specific pathogen introduction", "Header" : 0}, 
{"Row" : 133, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Spinal epidural abscess", "Header" : 0}, 
{"Row" : 134, "Column" : 3, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Spleen absent or dysfunctional [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 137, "Column" : 3, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "Text" : "Spontaneous bacterial peritonitis prevention", "Header" : 0}, 
{"Row" : 138, "Column" : 3, "Item" : "ORZID3 GMENU SPOROTRICHOSIS", "Text" : "Sporotrichosis infections, general", "Header" : 0}, 
{"Row" : 139, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS STAPHYLOCOCCI", "Text" : "Staphylococcal infections, general", "Header" : 0}, 
{"Row" : 140, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Staphylococcal native valve endocarditis", "Header" : 0}, 
{"Row" : 141, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Staphylococcal prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 142, "Column" : 3, "Item" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "Text" : "Staphylococcal toxic shock syndrome", "Header" : 0}, 
{"Row" : 143, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS COAG NEG STAPH", "Text" : "Staphylococci, coagulase-negative", "Header" : 0}, 
{"Row" : 144, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS TREAT S. AUREUS", "Text" : "Staphylococcus aureus infections, general", "Header" : 0}, 
{"Row" : 145, "Column" : 3, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Staphylococcus aureus nosocomial pneumonia", "Header" : 0}, 
{"Row" : 146, "Column" : 3, "Item" : "ORZID3 GMENU OSTEOM STAPHYLOCOCCUS AUREUS", "Text" : "Staphylococcus aureus osteomyelitis", "Header" : 0}, 
{"Row" : 147, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Staphylococcus aureus bacteremia", "Header" : 0}, 
{"Row" : 148, "Column" : 3, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Staphylococcus aureus decolonization", "Header" : 0}, 
{"Row" : 149, "Column" : 3, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Staphylococcus aureus intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 150, "Column" : 3, "Item" : "ORZID3 GMENU PROS B/J S. AUREUS", "Text" : "Staphylococcus aureus prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 151, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC ARTH S. AUREUS", "Text" : "Staphylococcus aureus, native joint infection", "Header" : 0}, 
{"Row" : 152, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Staphylococcus lugdunensis bacteremia", "Header" : 0}, 
{"Row" : 153, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS STAPH LUGDUNENSIS", "Text" : "Staphylococcus lugdunensis infections, general", "Header" : 0}, 
{"Row" : 154, "Column" : 3, "Item" : "ORZID3 GMENU ABX STASIS DERMATITIS OP", "Text" : "Stasis dermatitis", "Header" : 0}, 
{"Row" : 155, "Column" : 3, "Item" : "ORZID3 GMENU BITE WNDS STREPTOCOCCI", "Text" : "Streptococcal bite wounds", "Header" : 0}, 
{"Row" : 156, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Streptococcal native valve endocarditis (highly resistant isolate)", "Header" : 0}, 
{"Row" : 157, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Streptococcal native valve endocarditis (sensitive isolate)", "Header" : 0}, 
{"Row" : 158, "Column" : 3, "Item" : "ORZID3 GMENU OSTEOM STREPTOCOCCI", "Text" : "Streptococcal osteomyelitis", "Header" : 0}, 
{"Row" : 159, "Column" : 3, "Item" : "ORZID3 GMENU PHARYNGITIS", "Text" : "Streptococcal pharyngitis", "Header" : 0}, 
{"Row" : 160, "Column" : 3, "Item" : "ORZID3 GMENU PROS B/J STREPTOCOCCI", "Text" : "Streptococcal prosthetic bone/joint infection", "Header" : 0}, 
{"Row" : 161, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Streptococcal prosthetic valve endocarditis", "Header" : 0}, 
{"Row" : 162, "Column" : 3, "Item" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "Text" : "Streptococcal toxic shock syndrome", "Header" : 0}, 
{"Row" : 163, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS GROUPS C, F, G", "Text" : "Streptococci Groups C, F, G infections, general", "Header" : 0}, 
{"Row" : 164, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS VIRIDANS STREPTO", "Text" : "Streptococci viridans infections, general [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 166, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. AGALACTIAE", "Text" : "Streptococcus agalactiae (Group B)", "Header" : 0}, 
{"Row" : 167, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. ANGINOSUS", "Text" : "Streptococcus anginosus (formerly S. milleri)", "Header" : 0}, 
{"Row" : 168, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. BOVIS", "Text" : "Streptococcus bovis (Group D)", "Header" : 0}, 
{"Row" : 169, "Column" : 3, "Item" : "ORZID3 GMENU SEPTIC ARTH STREPTOCOCCI", "Text" : "Streptococcus native joint infection", "Header" : 0}, 
{"Row" : 170, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. PNEUMONIAE", "Text" : "Streptococcus pneumoniae infections, general", "Header" : 0}, 
{"Row" : 171, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Streptococcus pneumoniae meningitis", "Header" : 0}, 
{"Row" : 172, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS S. PYOGENES", "Text" : "Streptococcus pyogenes (Group A) infections, general", "Header" : 0}, 
{"Row" : 173, "Column" : 3, "Item" : "ORZID2 GMENU IMMUNOCOM STRESS", "Text" : "Stress", "Header" : 0}, 
{"Row" : 174, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Subdural empyema", "Header" : 0}, 
{"Row" : 175, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Suppurative intracranial thrombophlebitis", "Header" : 0}, 
{"Row" : 176, "Column" : 3, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Suppurative odontic infections", "Header" : 0}, 
{"Row" : 177, "Column" : 3, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Suppurative thrombophlebitis", "Header" : 0}, 
{"Row" : 178, "Column" : 3, "Item" : "ORZID3 GMENU SURG SITE INFECT", "Text" : "Surgical site infection", "Header" : 0}, 
{"Row" : 179, "Column" : 3, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Susceptibilities, antimicrobial", "Header" : 0}, 
{"Row" : 180, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Suspected bacteremia, blood cultures not yet positive", "Header" : 0}, 
{"Row" : 181, "Column" : 3, "Item" : "ORZID3 GMENU ABX SYPHILIS", "Text" : "Syphilis", "Header" : 0}, 
{"Row" : 182, "Column" : 3, "Item" : "ORZID3 GMENU SYSTEMIC INFECT DIS", "Text" : "Systemic Infections section", "Header" : 0}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "Po through Z",  "Header" : 1}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "Po-Py__________________________________________________________________________",  "Header" : 1}, 
{"Row" : 44, "Column" : 3, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 45, "Column" : 3, "Item" : null, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 46, "Column" : 3, "Item" : null, "Text" : "and streptococcus",  "Header" : 0}, 
{"Row" : 48, "Column" : 3, "Item" : null, "Text" : "culture negative, enterococci, fungi,",  "Header" : 0}, 
{"Row" : 49, "Column" : 3, "Item" : null, "Text" : "gram-negative bacilli, Streptococcus bovis,",  "Header" : 0}, 
{"Row" : 50, "Column" : 3, "Item" : null, "Text" : "staphylococci, HACEK bacteria, and Viridans group streptococci",  "Header" : 0}, 
{"Row" : 65, "Column" : 3, "Item" : null, "Text" : "empiric therapy, enterococcus, pseudomonas",  "Header" : 0}, 
{"Row" : 70, "Column" : 3, "Item" : null, "Text" : "Q______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 72, "Column" : 3, "Item" : null, "Text" : "R______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 82, "Column" : 3, "Item" : null, "Text" : "candida, Cytomegalovirus, herpes, zoster, and others",  "Header" : 0}, 
{"Row" : 88, "Column" : 3, "Item" : null, "Text" : "S______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 97, "Column" : 3, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 98, "Column" : 3, "Item" : null, "Text" : "Neisseria gonorrhoeae, Pseudomonas aeruginosa,",  "Header" : 0}, 
{"Row" : 99, "Column" : 3, "Item" : null, "Text" : "Staphylococcus aureus, streptococcus",  "Header" : 0}, 
{"Row" : 101, "Column" : 3, "Item" : null, "Text" : "empirical therapy, enterococci, gram-negative bacilli,",  "Header" : 0}, 
{"Row" : 102, "Column" : 3, "Item" : null, "Text" : "Pseudomonas aeruginosa, Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 103, "Column" : 3, "Item" : null, "Text" : "and streptococcus",  "Header" : 0}, 
{"Row" : 135, "Column" : 3, "Item" : null, "Text" : "antimicrobial prophylaxis, management of fever,",  "Header" : 0}, 
{"Row" : 136, "Column" : 3, "Item" : null, "Text" : "patient initiated antibiotics, vaccines",  "Header" : 0}, 
{"Row" : 165, "Column" : 3, "Item" : null, "Text" : "S. mutans, S. mitis, S. sanguis",  "Header" : 0}, 
{"Row" : 185, "Column" : 3, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus vaccination", "Header" : 0}, 
{"Row" : 186, "Column" : 3, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "Text" : "Thrush", "Header" : 0}, 
{"Row" : 188, "Column" : 3, "Item" : "ORZID3 GMENU TINEA CAPITIS (RINGWORM)", "Text" : "Tinea capitis", "Header" : 0}, 
{"Row" : 189, "Column" : 3, "Item" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Text" : "Tinea corporis", "Header" : 0}, 
{"Row" : 190, "Column" : 3, "Item" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Text" : "Tinea cruris", "Header" : 0}, 
{"Row" : 191, "Column" : 3, "Item" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Text" : "Tinea pedis", "Header" : 0}, 
{"Row" : 192, "Column" : 3, "Item" : "ORZID3 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "Text" : "Tinea unguium", "Header" : 0}, 
{"Row" : 193, "Column" : 3, "Item" : "ORZID3 GMENU TINEA VERSICOLOR", "Text" : "Tinea versicolor", "Header" : 0}, 
{"Row" : 194, "Column" : 3, "Item" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE", "Text" : "Tobacco smoke", "Header" : 0}, 
{"Row" : 195, "Column" : 3, "Item" : "ORZID3 GMENU PHARYNGITIS", "Text" : "Tonsillitis", "Header" : 0}, 
{"Row" : 196, "Column" : 3, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Tooth abscess and other suppurative odontic infections", "Header" : 0}, 
{"Row" : 197, "Column" : 3, "Item" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "Text" : "Toxic shock syndrome", "Header" : 0}, 
{"Row" : 198, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Toxoplasma gondii brain abscess", "Header" : 0}, 
{"Row" : 199, "Column" : 3, "Item" : "ORZID3 GMENU PARASITE TOXOPLASMA SPP.", "Text" : "Toxoplasma infections, general", "Header" : 0}, 
{"Row" : 200, "Column" : 3, "Item" : "ORZID2 GMENU TRANSPLANTATION", "Text" : "Transplantation", "Header" : 0}, 
{"Row" : 201, "Column" : 3, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Trauma or nosocomial infection associated meningitis", "Header" : 0}, 
{"Row" : 202, "Column" : 3, "Item" : "ORZID3 GMENU TRAVELER DIARRHEA", "Text" : "Traveler's diarrhea", "Header" : 0}, 
{"Row" : 203, "Column" : 3, "Item" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "Text" : "Trichomonas vaginitis", "Header" : 0}, 
{"Row" : 204, "Column" : 3, "Item" : "ORZID3 GMENU TUBERCULOSIS", "Text" : "Tuberculosis", "Header" : 0}, 
{"Row" : 205, "Column" : 3, "Item" : "ORZID3 GMENU TYPHLITIS", "Text" : "Typhlitis", "Header" : 0}, 
{"Row" : 206, "Column" : 3, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "Text" : "Typhoid fever", "Header" : 0}, 
{"Row" : 209, "Column" : 3, "Item" : "ORZID3 GMENU DECUBITIS ULCERS", "Text" : "Ulcer, decubitus", "Header" : 0}, 
{"Row" : 210, "Column" : 3, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "Text" : "Ulcer, diabetic foot", "Header" : 0}, 
{"Row" : 211, "Column" : 3, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "Text" : "Uncomplicated cystitis", "Header" : 0}, 
{"Row" : 212, "Column" : 3, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Updates on antimicrobial shortages", "Header" : 0}, 
{"Row" : 213, "Column" : 3, "Item" : "ORZID3 GMENU ABX UPPER RESPIRATORY INFECTIONS OP (URI)", "Text" : "Upper respiratory infections (URI)", "Header" : 0}, 
{"Row" : 214, "Column" : 3, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "Text" : "Urethritis associated with STIs [CLICK HERE], includes:", "Header" : 0}, 
{"Row" : 216, "Column" : 3, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "Text" : "Urethritis, recurrent or persistent", "Header" : 0}, 
{"Row" : 217, "Column" : 3, "Item" : "ORZID3 GMENU URINARY TRACT INFECTION", "Text" : "Urinary tract infection (UTI), bacterial", "Header" : 0}, 
{"Row" : 218, "Column" : 3, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "Text" : "Urinary tract infection (UTI), candida", "Header" : 0}, 
{"Row" : 219, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Urinary tract infection with sepsis", "Header" : 0}, 
{"Row" : 220, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Urosepsis", "Header" : 0}, 
{"Row" : 221, "Column" : 3, "Item" : "ORZID2 GMENU UVEITIS", "Text" : "Uveitis", "Header" : 0}, 
{"Row" : 225, "Column" : 3, "Item" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "Text" : "Vaginitis, Candida", "Header" : 0}, 
{"Row" : 226, "Column" : 3, "Item" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "Text" : "Vaginitis, Trichomonas", "Header" : 0}, 
{"Row" : 227, "Column" : 3, "Item" : "ORZID3 GMENU BACTERIAL VAGINOSIS", "Text" : "Vaginosis, bacterial", "Header" : 0}, 
{"Row" : 228, "Column" : 3, "Item" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "Text" : "Varicella", "Header" : 0}, 
{"Row" : 229, "Column" : 3, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella vaccination", "Header" : 0}, 
{"Row" : 230, "Column" : 3, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Ventilator-associated pneumonia (VAP)", "Header" : 0}, 
{"Row" : 231, "Column" : 3, "Item" : "ORZID3 GMENU DISKITIS", "Text" : "Vertebral osteomyelitis and diskitis", "Header" : 0}, 
{"Row" : 232, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA VIBRIO CHOLERA", "Text" : "Vibrio cholerae diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 233, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA VIBRIO NON CHOLERA", "Text" : "Vibrio non-cholerae, diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 234, "Column" : 3, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Viral diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 235, "Column" : 3, "Item" : "ORZID3 GMENU GRAM-POS VIRIDANS STREPTO", "Text" : "Viridans streptococci", "Header" : 0}, 
{"Row" : 236, "Column" : 3, "Item" : "ORZID3 GMENU VIRUSES OUTPT MAIN", "Text" : "Viruses section", "Header" : 0}, 
{"Row" : 237, "Column" : 3, "Item" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "Text" : "Vulvo-vaginitis, candida", "Header" : 0}, 
{"Row" : 240, "Column" : 3, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "Warfarin interactions with antimicrobials", "Header" : 0}, 
{"Row" : 241, "Column" : 3, "Item" : "ORZID3 GMENU SURG SITE INFECT", "Text" : "Wound infection, post-op", "Header" : 0}, 
{"Row" : 242, "Column" : 3, "Item" : "ORZID3 GMENU BITE WOUNDS", "Text" : "Wound, bite", "Header" : 0}, 
{"Row" : 243, "Column" : 3, "Item" : "ORZID2 GMENU ABX COLONIZED WOUNDS", "Text" : "Wound, colonized", "Header" : 0}, 
{"Row" : 248, "Column" : 3, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Yeast bacteremia", "Header" : 0}, 
{"Row" : 249, "Column" : 3, "Item" : "ORZID3 GMENU DIARRHEA Y. ENTEROCOLITICA", "Text" : "Yersinia enterocolitica diarrhea/gastroenteritis", "Header" : 0}, 
{"Row" : 252, "Column" : 3, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "Text" : "Zoster", "Header" : 0}, 
{"Row" : 253, "Column" : 3, "Item" : "ORZID3 GMENU RETINITIS", "Text" : "Zoster retinitis", "Header" : 0}, 
{"Row" : 254, "Column" : 3, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Zoster vaccination", "Header" : 0}, 
{"Row" : 184, "Column" : 3, "Item" : null, "Text" : "T______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 208, "Column" : 3, "Item" : null, "Text" : "U______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 215, "Column" : 3, "Item" : null, "Text" : "chlamydia and gonococcal",  "Header" : 0}, 
{"Row" : 223, "Column" : 3, "Item" : null, "Text" : "V______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 224, "Column" : 3, "Item" : null, "Text" : "Vaccination: see immunization, specific organism or condition",  "Header" : 0}, 
{"Row" : 239, "Column" : 3, "Item" : null, "Text" : "W______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 245, "Column" : 3, "Item" : null, "Text" : "X______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 247, "Column" : 3, "Item" : null, "Text" : "Y______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 251, "Column" : 3, "Item" : null, "Text" : "Z______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "A through F",  "Header" : 1}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "Post-exposure prophylaxis, Rabies - see Emergency",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "Department CDSS or contact ID for more information",  "Header" : 0}, 
{"Row" : 37, "Column" : 3, "Item" : null, "Text" : "Prophylaxis for post-exposure, Rabies - see Emergency",  "Header" : 0}, 
{"Row" : 38, "Column" : 3, "Item" : null, "Text" : "Department CDSS or contact ID for more information",  "Header" : 0}, 
{"Row" : 73, "Column" : 3, "Item" : null, "Text" : "Rabies post-exposure prophylaxis - see Emergency",  "Header" : 0}, 
{"Row" : 74, "Column" : 3, "Item" : null, "Text" : "Department CDSS or contact ID for more information",  "Header" : 0}, 
{"Row" : 107, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Cardiovascular Section", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "Text" : "Bite, Tick", "Header" : 0}, 
{"Row" : 187, "Column" : 3, "Item" : "ORZID3 GMENU LYME DISEASE", "Text" : "Tick bite", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX LARYNGITIS AND CROUP", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LARYNGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cases are almost always viral (e.g. rhinovirus, influenza, adenovirus,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "coronavirus). Treatment is based on symptomatic therapy alone.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Acute laryngitis",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Hoarseness in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX LIVER AMEBIC ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP METRO 750MG TID PAROMOMYCIN 25-35MG/KG/DAY TID", "Text" : "Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "AMEBIC LIVER ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Serological testing for amoebiasis should be obtained in all patients with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "suspected amebic liver abscess. Multiple sets of anaerobic and aerobic blood",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures should also be obtained prior to starting antibiotics to exclude",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "pyogenic liver abscess, which is a much more common cause of liver abscess.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Serologic testing can be negative in a small number of patients with acute",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "presentation (symptoms <2 weeks). Repeat serology is usually positive. If repeat",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "serological testing is negative for amoebiasis or patient does not respond to",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "treatment of amebic liver abscess, patient should have further diagnostic",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "testing completed to exclude pyogenic liver abscess.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Drainage of amebic liver abscess should be considered in patients with large",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "lesions at risk of rupture.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Due to complicated treatment and follow up, Infectious Diseases consultation",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "is recommended in all patients with liver abscess.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment of patients with confirmed or suspected amebic liver abscess (obtain",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "blood cultures prior to starting in suspected cases)",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Paromomycin is nonformulary and must be ordered by Infectious Diseases.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "25-35 mg/kg/day PO TID for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Liver and Biliary System",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Amoebiasis, Entamoeba histolytica",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Extraintestinal Entamoeba histolytica amoebiasis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: IM",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient MenACWY orders:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "MENINGOCOCCAL",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "OLIGOSACCHARIDE",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "CONJ. VACC INJ,SUSP",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Menveo",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Meningococcal conjugate",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "(MenACWY)",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2021,",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "174(3)374-384.",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*People with anatomic or",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "functional asplenia, HIV",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "infection, or persistent",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "complement component",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "deficiency, or complement",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "inhibitor use.",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "*People who travel to or",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "reside in countries in",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "which meningococcal",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "disease is hyperendemic or",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "epidemic (e.g., the",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "meningitis belt of Sub-",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "Saharan Africa).",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "*Microbiologists routinely",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "exposed to isolates of N.",  "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "meningitidis.",  "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "*For first year college",  "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "students living in a",  "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "residence hall, regardless",  "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "of age,",  "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : ">> if unvaccinated, give 1",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "dose.",  "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : ">> if history of 1 dose",  "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "given when younger than",  "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "age 16, give dose2.",  "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : ">> if most recent dose",  "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "given after 16th birthday",  "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : "and more than 5 years",  "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : null, "Text" : "have elapsed, give 1 dose.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Give 2 initial doses of",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "MenACWY separated by 2m to",  "Header" : 0}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "adults with risk factors",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "listed in 1st bullet in",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "column to left.",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "*Give 1 initial dose of",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "MenACWY to all other",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "adults with risk factors",  "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "(see 2nd-4th bullets in",  "Header" : 0}, 
{"Row" : 14, "Column" : 3, "Item" : null, "Text" : "column to left).",  "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : null, "Text" : "*Give booster doses of",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "MenACWY every 5yrs to",  "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : null, "Text" : "adults with continuing",  "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "risk (see the 1st-3rd",  "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "bullets in column to",  "Header" : 0}, 
{"Row" : 21, "Column" : 3, "Item" : null, "Text" : "left).",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "History of severe allergic",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "Precautions:",  "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "Moderate or severe acute",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "illness with or",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "without fever.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: IM",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient MenB orders:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "MENINGOCOCCAL B VACCINE",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "INJ,SUSP",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Bexsero",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Meningococcal serogroup B",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(MenB)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2021,",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "174(3)374-384.",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*People with anatomic or",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "functional asplenia or",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "persistent complement",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "component deficiency.",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "*Microbiologists routinely",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "exposed to isolates of N.",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "meningitidis.",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "*People identified as at",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "a serogroup B",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "meningococcal disease",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "outbreak.",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "*Young adults through age",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "23yrs may be vaccinated",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "routinely.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Give 2 doses spaced 1",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "month apart",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "*For people with continuing",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "risk (see 1st-3rd bullets",  "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : null, "Text" : "in column to left), give a",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "booster 1 year after",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "completing the primary",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "series, followed by a",  "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "booster every 2-3 years as",  "Header" : 0}, 
{"Row" : 14, "Column" : 3, "Item" : null, "Text" : "long as risk continues.",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "Booster doses must be same",  "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : null, "Text" : "brand as primary series.",  "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : null, "Text" : "*MenB vaccine may be given",  "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "concomitantly with MenACWY",  "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "vaccine",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "History of severe allergic",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "Precautions:",  "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "*Moderate or severe acute",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "illness with or",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "without fever.",  "Header" : 0}, 
{"Row" : 16, "Column" : 4, "Item" : null, "Text" : "*Pregnancy", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: Subcutaneous",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient MMR orders:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "MEASLES/MUMPS/RUBELLA",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "VIRUS VACCINE INJ",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "M-M-R II",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Measles, mumps, rubella",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(MMR)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2021,",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "174(3)374-384.",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*People born in 1957 or",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "later (especially those",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "born outside the U.S.)",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "should receive at least 1",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "dose of MMR if they have",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "no laboratory evidence of",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "immunity to each of the 3",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "diseases or documentation",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "of a dose given on or",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "after the first birthday.",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "*People in high-risk",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "groups, such as healthcare",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "personnel (paid, unpaid,",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "or volunteer), students",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "entering college and other",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "post-high school",  "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "educational institutions,",  "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "and international",  "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "travelers, should receive",  "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "a total of 2 doses.",  "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "*HIV infection with CD4",  "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "count >/=200 cells/mm3 for",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "at least 6 months and no",  "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "evidence of immunity to",  "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "measles, mumps, or rubella",  "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "should receive a total of",  "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : "2 doses. MMR",  "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "contraindicated for HIV",  "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : "infection with CD4 count",  "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : null, "Text" : "<200 cells/mm3",  "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : null, "Text" : "*People born before 1957",  "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : null, "Text" : "are usually considered",  "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : null, "Text" : "immune, but evidence of",  "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : null, "Text" : "immunity (serology or",  "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : null, "Text" : "documented history of 2",  "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : null, "Text" : "doses of MMR) should be",  "Header" : 0}, 
{"Row" : 43, "Column" : 2, "Item" : null, "Text" : "considered for healthcare",  "Header" : 0}, 
{"Row" : 44, "Column" : 2, "Item" : null, "Text" : "personnel.",  "Header" : 0}, 
{"Row" : 46, "Column" : 2, "Item" : null, "Text" : "*Women of childbearing age",  "Header" : 0}, 
{"Row" : 47, "Column" : 2, "Item" : null, "Text" : "who do not have acceptable",  "Header" : 0}, 
{"Row" : 48, "Column" : 2, "Item" : null, "Text" : "evidence of rubella",  "Header" : 0}, 
{"Row" : 49, "Column" : 2, "Item" : null, "Text" : "immunity or vaccination.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Give 1 or 2 doses (see",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "criteria in 1st and 2nd",  "Header" : 0}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "bullets in box to left).",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "*If dose2 is",  "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : null, "Text" : "recommended, give it no",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "sooner than 4wks after",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "dose1.",  "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "*If woman of childbearing-",  "Header" : 0}, 
{"Row" : 14, "Column" : 3, "Item" : null, "Text" : "age is found to be rubella",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "susceptible and is not",  "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : null, "Text" : "pregnant, give 1 dose of",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "MMR. If she is pregnant,",  "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : null, "Text" : "the dose should be given",  "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "postpartum. This includes",  "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "women who have already",  "Header" : 0}, 
{"Row" : 21, "Column" : 3, "Item" : null, "Text" : "received 1 or 2 doses of",  "Header" : 0}, 
{"Row" : 22, "Column" : 3, "Item" : null, "Text" : "rubella-containing",  "Header" : 0}, 
{"Row" : 23, "Column" : 3, "Item" : null, "Text" : "vaccine.",  "Header" : 0}, 
{"Row" : 25, "Column" : 3, "Item" : null, "Text" : "*If 2 or more of the",  "Header" : 0}, 
{"Row" : 26, "Column" : 3, "Item" : null, "Text" : "following live virus",  "Header" : 0}, 
{"Row" : 27, "Column" : 3, "Item" : null, "Text" : "vaccines are to be given -",  "Header" : 0}, 
{"Row" : 28, "Column" : 3, "Item" : null, "Text" : "MMR, LAIV, Var, ZVL,",  "Header" : 0}, 
{"Row" : 29, "Column" : 3, "Item" : null, "Text" : "and/or yellow fever - they",  "Header" : 0}, 
{"Row" : 30, "Column" : 3, "Item" : null, "Text" : "should be given on the",  "Header" : 0}, 
{"Row" : 31, "Column" : 3, "Item" : null, "Text" : "same day. If they are not",  "Header" : 0}, 
{"Row" : 32, "Column" : 3, "Item" : null, "Text" : "given on the same day,",  "Header" : 0}, 
{"Row" : 33, "Column" : 3, "Item" : null, "Text" : "space them by at least 28d",  "Header" : 0}, 
{"Row" : 34, "Column" : 3, "Item" : null, "Text" : "(30d for yellow fever).",  "Header" : 0}, 
{"Row" : 35, "Column" : 3, "Item" : null, "Text" : "May use as post-exposure",  "Header" : 0}, 
{"Row" : 36, "Column" : 3, "Item" : null, "Text" : "prophylaxis if given",  "Header" : 0}, 
{"Row" : 37, "Column" : 3, "Item" : null, "Text" : "within 3d of exposure.",  "Header" : 0}, 
{"Row" : 35, "Column" : 4, "Item" : "ORZ GTX ABX URL ACIP BEST PRACTICES GUIDANCE", "Text" : "Best Practices Guidance", "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "*History of severe allergic",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "*Pregnancy or possibility",  "Header" : 0}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "of pregnancy within 4wks.",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "*Severe immunodeficiency",  "Header" : 0}, 
{"Row" : 15, "Column" : 4, "Item" : null, "Text" : "(e.g., hematologic and",  "Header" : 0}, 
{"Row" : 16, "Column" : 4, "Item" : null, "Text" : "solid tumors, receiving",  "Header" : 0}, 
{"Row" : 17, "Column" : 4, "Item" : null, "Text" : "chemotherapy, congenital",  "Header" : 0}, 
{"Row" : 18, "Column" : 4, "Item" : null, "Text" : "immunodeficiency, long-",  "Header" : 0}, 
{"Row" : 19, "Column" : 4, "Item" : null, "Text" : "term immunosuppressive",  "Header" : 0}, 
{"Row" : 20, "Column" : 4, "Item" : null, "Text" : "therapy, people with human",  "Header" : 0}, 
{"Row" : 21, "Column" : 4, "Item" : null, "Text" : "immunodeficiency virus",  "Header" : 0}, 
{"Row" : 22, "Column" : 4, "Item" : null, "Text" : "(HIV) infection who are",  "Header" : 0}, 
{"Row" : 23, "Column" : 4, "Item" : null, "Text" : "severely",  "Header" : 0}, 
{"Row" : 24, "Column" : 4, "Item" : null, "Text" : "immunocompromised (CD4",  "Header" : 0}, 
{"Row" : 25, "Column" : 4, "Item" : null, "Text" : "count <200 cells/mm3).)",  "Header" : 0}, 
{"Row" : 27, "Column" : 4, "Item" : null, "Text" : "Precautions",  "Header" : 1}, 
{"Row" : 28, "Column" : 4, "Item" : null, "Text" : "*Moderate or severe acute",  "Header" : 0}, 
{"Row" : 29, "Column" : 4, "Item" : null, "Text" : "illness with or without",  "Header" : 0}, 
{"Row" : 30, "Column" : 4, "Item" : null, "Text" : "fever.",  "Header" : 0}, 
{"Row" : 32, "Column" : 4, "Item" : null, "Text" : "*If blood, plasma, and/or",  "Header" : 0}, 
{"Row" : 33, "Column" : 4, "Item" : null, "Text" : "immune globulin were given",  "Header" : 0}, 
{"Row" : 34, "Column" : 4, "Item" : null, "Text" : "in past 11m, see ACIP's",  "Header" : 0}, 
{"Row" : 36, "Column" : 4, "Item" : null, "Text" : "regarding time to wait",  "Header" : 0}, 
{"Row" : 37, "Column" : 4, "Item" : null, "Text" : "before vaccinating.",  "Header" : 0}, 
{"Row" : 39, "Column" : 4, "Item" : null, "Text" : "*History of",  "Header" : 0}, 
{"Row" : 40, "Column" : 4, "Item" : null, "Text" : "thrombocytopenia or",  "Header" : 0}, 
{"Row" : 41, "Column" : 4, "Item" : null, "Text" : "thrombocytopenic purpura.",  "Header" : 0}, 
{"Row" : 43, "Column" : 4, "Item" : null, "Text" : "*Need for tuberculin skin",  "Header" : 0}, 
{"Row" : 44, "Column" : 4, "Item" : null, "Text" : "testing (TST) or",  "Header" : 0}, 
{"Row" : 45, "Column" : 4, "Item" : null, "Text" : "interferon-gamma release",  "Header" : 0}, 
{"Row" : 46, "Column" : 4, "Item" : null, "Text" : "assay (IGRA) testing.",  "Header" : 0}, 
{"Row" : 47, "Column" : 4, "Item" : null, "Text" : "note: If TST or IGRA and",  "Header" : 0}, 
{"Row" : 48, "Column" : 4, "Item" : null, "Text" : "MMR are both needed but",  "Header" : 0}, 
{"Row" : 49, "Column" : 4, "Item" : null, "Text" : "not given on same day,",  "Header" : 0}, 
{"Row" : 50, "Column" : 4, "Item" : null, "Text" : "delay TST or IGRA for at",  "Header" : 0}, 
{"Row" : 51, "Column" : 4, "Item" : null, "Text" : "least 4wks after MMR.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX MOLNUPIRAVIR EUA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX URL MOLNUPIRAVIR PATIENT EUA FACT SHEET", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Molnupiravir", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL MOLNUPIRAVIR PROVIDER FACT SHEET EUA", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Molnupiravir", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MOLNUPIRAVIR (EUA)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Molnupiravir is available via FDA Emergency Use Authorization (EUA) for treating",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "patients that meet specific criteria. Molnupiravir is not an FDA approved drug.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "**Treatment:**",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "ID available to discuss if needed.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Inclusion Criteria, ALL the following criteria must be met for a patient to",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "receive:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "1) Patient has tested positive for COVID-19.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "2) Patient is not hospitalized due to COVID-19. Note: patient may be",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "hospitalized for some other reason.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "4) Administration will begin within 5 days of symptom onset.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "5) Patient does not have known hypersensitivity to Molnupiravir or components.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Contraindications: None",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Warnings and Precautions:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "1) Embryo-Fetal Toxicity: Molnupiravir is not recommended for use during",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "pregnancy.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "2) Bone and Cartilage Toxicity: Molnupiravir is not authorized for use in",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "patients less than 18 years of age because it may affect bone and cartilage",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "growth.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "If above requirements are met, place medication order:",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "*Patients treated with this drug should continue to self-isolate and use",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "infection control measures (wear mask, isolate, social distance, avoid sharing",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "personal items, clean and disinfect \"high touch\" surfaces, and frequent",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "handwashing) according to CDC guidelines.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX MOLNUPIRAVIR PHARMACY INFO", "Text" : "INV-Molnupiravir 800 mg PO BID for 5 days", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX NIRMATRELVIR RITONAVIR (PAXLOVID) EUA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL PAXLOVID PATIENT EUA FACT SHEET", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Paxlovid", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX URL PAXLOVID PROVIDER FACT SHEET EUA", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Paxlovid", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX PAXLOVID PHARMACY INFO", "Text" : "INV-Nirmatrelvir 300 mg and ritonavir 100 mg (Paxlovid) PO BID for 5 days", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PAXLOVID (EUA)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Paxlovid (nirmatrelvir-ritonavir) is available via FDA Emergency Use",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Authorization (EUA) for treating patients that meet specific criteria. Paxlovid",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "is not an FDA approved drug.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "**Treatment:**",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "ID available to discuss if needed.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Inclusion Criteria, ALL the following criteria must be met for a patient to",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "receive:",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "1) Patient has tested positive for COVID-19 with a lab-confirmed test",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "2) Patient is not hospitalized due to COVID-19. Note: patient may be",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "hospitalized for some other reason.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "4) Administration will begin within 5 days of symptom onset.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "5) Patient does not have known hypersensitivity to Paxlovid or components.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Contraindications, NONE of the following must be met for patient to receive:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "1) Severe renal impairment (eGFR <30 mL/min).",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "2) Severe hepatic impairment (Child-Pugh Class C).",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "3) History of clinically significant hypersensitivity reactions to the active",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "ingredients (nirmatrelvir or ritonavir) or any other components.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "4) Co-administration with drugs highly dependent on CYP3A for clearance and for",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "which elevated concentrations are associated with serious and/or",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "life-threatening reactions.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "5) Co-administration with potent CYP3A inducers where significantly reduced",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "nirmatrelvir or ritonavir plasma concentrations may be associated with the",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "potential for loss of virologic response and possible resistance.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Warnings and Precautions:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "1) The concomitant use of PAXLOVID and certain other drugs may result in",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "potentially significant drug interactions. Consult the full prescribing",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "information prior to and during treatment for potential drug interactions.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "2) Hepatotoxicity: Hepatic transaminase elevations, clinical hepatitis, and",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "jaundice have occurred in patients receiving ritonavir.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "3) HIV-1 Drug Resistance: PAXLOVID use may lead to a risk of HIV-1 developing",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "resistance to HIV protease inhibitors in individuals with uncontrolled or",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "undiagnosed HIV-1 infection.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "If all above criteria above are met and there are no contraindications, place",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "medication order:",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "*Patients treated with this drug should continue to self-isolate and use",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "infection control measures (wear mask, isolate, social distance, avoid sharing",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "personal items, clean and disinfect \"high touch\" surfaces, and frequent",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "handwashing) according to CDC guidelines.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "6) Patient must be able to take PO and swallow tablets whole",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX PAXLOVID RENAL DOSING PHARMACY INFO", "Text" : "INV-Nirmatrelvir 150 mg and ritonavir 100 mg (Paxlovid) PO BID for 5 days", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Dose reduction for moderate renal impairment (eGFR =30 to <60 mL/min):", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX NON-VA ORDER INFORMATION", "Contents" : [
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Non-VA orders are available below each prescription order for CBOC use", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "Contents" : [
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ASYMP BACTERIURIA", "Text" : "Treatment of Asymptomatic Bacteriuria", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "Text" : "Treatment of Candida Urinary Tract Infections", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIURIA, CANDIDURIA, AND PYURIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Asymptomatic bacteriuria (>= 100,000 bacteria per ml of urine) is common in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "middle aged and older people, especially those who have chronic medical",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "conditions. Pyuria is common in persons with bacteriuria and individuals with",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "indwelling catheters in place. By itself, the presence of pyuria is not",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "sufficient to diagnose bacteriuria, and the presence or absence of pyuria does",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "not differentiate symptomatic from asymptomatic urinary infection. Candiduria is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "less common than bacteriuria, but the implications of candiduria are similar to",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "those of bacteriuria.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Many studies, including randomized clinical trials have shown that",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treatment of asymptomatic bacteriuria and candiduria, with or without pyuria is",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of no benefit, except in certain well-defined circumstances. Antimicrobial",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "therapy is always accompanied by risk of harms, including drug reactions,",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Clostridium difficile colitis, anaphylaxis and death. Except in circumstances",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "specified below, it is best to not order urinalysis or urine culture in",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "asymptomatic persons. If bacteriuria, candiduria or pyuria is discovered in an",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "asymptomatic person for some reason, antimicrobial therapy should not be given",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "except as specified below.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Pregnant women or patients undergoing urological procedures with bacteriuria",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Patients undergoing urological procedures or neutropenic patients with",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "candiduria",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Pappas et al, Clin Infect Dis, 2016, 62.409",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Nicolle et al, Clin Infect Dis, 2005, 40:643", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX NOT REQUIRED MAIN OP", "Contents" : [
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU ABX UPPER RESPIRATORY INFECTIONS OP (URI)", "Text" : "Upper Respiratory Infections (URI)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU ABX COLONIZED RESPIRATORY TRACT VENTILATOR OP", "Text" : "Colonized Respiratory Tract in a Patient on a Ventilator", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX STASIS DERMATITIS OP", "Text" : "Stasis Dermatitis", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU ABX COLONIZED WOUNDS OP", "Text" : "Colonized Wounds", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX NOT BENEFITTED BACTERIURIA OP", "Text" : "Asymptomatic Bacteriuria, cadiduria and pyuria", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU ABX POSITIVE BLOOD CULTURE OP COAG NEG STAPH", "Text" : "Blood culture positive for coagulase negative staphylococci", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CONDITIONS NOT BENEFITTED BY ANTIMICROBIAL THERAPY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Several common conditions associated with inflammation or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "microorganisms do not benefit from antibiotic therapy in most or all cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Yet, antimicrobials are frequently prescribed for these conditions leading to",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "unnecessary toxicity and costs, rare deaths, and the relentless increase in",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antimicrobial resistance. Please review these conditions and do not give",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobials for these conditions unless there are extraordinary",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "circumstances that make your situation different. If you have any questions,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "please contact the infectious disease physician on call.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Lungs and Mediastinum",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Skin and Soft Tissue",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Genitourinary",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Miscellaneous",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "`Last reviewed 9-2018",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "Text" : "Bronchitis in and Otherwise Healthy Patient", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX NOT BENEFITED PHARYNGITIS", "Text" : "Pharyngitis, non-streptococcal", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX OUTPT MAIN", "Contents" : [
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ABX INDEX OUTPATIENT", "Text" : "[CLICK HERE]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "Text" : "By Organism/Vaccine", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU CNS OUTPT", "Text" : "Central Nervous System (CNS)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU HEAD AND NECK/ENT OUTPT MAIN", "Text" : "Head and Neck", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU LUNGS AND MEDIASTINUM", "Text" : "Lungs & Mediastinum", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA 2021-2022 OUTPATIENT", "Text" : "[a] Influenza Seasonal 2021-2022", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU COMM INFECT PNEUMO", "Text" : "[b] Pneumonia", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "Text" : "[c] Acute Respiratory Infection (ARI) Symptomatic Therapy", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Cardiovascular", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU GASTROINT OUTPT MAIN", "Text" : "GI & Intraabdominal", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "Text" : "[a] C. difficile colitis Mild/Moderate", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU GENITOURINARY", "Text" : "Urogenital", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "[a] Sexually Transmitted Infections (STI)", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "Text" : "Soft Tissue, Bone and Joint Infections", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU DERMATOLOGY OUTPT MAIN", "Text" : "Skin", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU SYSTEMIC INFECT DIS", "Text" : "Systemic Infections", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "[a] Bacteremia", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "[b] Sepsis and Septic Shock", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID2 GMENU INTRO SPEC PATHOGEN", "Text" : "Introduction to Specific Pathogen", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZID3 GMENU GRAM NEGATIVE BACTERIA", "Text" : "Gram-negative Bacteria", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU GRAM POSITIVE BACTERIA", "Text" : "Gram-positive Bacteria", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU VIRUSES OUTPT MAIN", "Text" : "Viruses", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI", "Text" : "Fungi", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU PARASITES MAIN", "Text" : "Parasites", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU OTHER PATHOGENS", "Text" : "Other Pathogens", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "*******************************************************",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "* ANTIMICROBIAL DECISION SUPPORT*",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "* >>>>>>>>OUTPATIENT<<<<<<<<< *",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "*******************************************************",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Welcome.Please click on the",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "diagnosis or syndrome you wish to treat.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "**********************",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Index of Antimicrobial CDSS content",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Immunization Information and Vaccine Orders",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Syndromes and diseases, by body systems",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Specific organisms",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Medicine is an inexact and rapidly",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "changing discipline.The developers of",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "this system have made every effort to",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "provide current, accurate information.",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "However, in view of the possibility of",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "human error or changes in medical",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "service, readers are encouraged to",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "confirm the information contained",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "herein with other sources.In",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "particular, readers are encouraged to",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "check the product information for",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "antimicrobials to be certain that",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "information in this system is accurate",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "and current, especially for new or",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "infrequently used drugs.",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "SELECT below for TESTING Menu",  "Header" : 1}, 
{"Row" : 5, "Column" : 2, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "Contact CDSS Staff", "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help page...", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZ GTX ABX CDSS FAQ", "Text" : "Frequently Asked Questions (FAQ)", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU CONTACT CDSS STAFF", "Text" : "Comments or Suggestions about this CDSS", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU ABX SUSCEPTIBILITIES (ANTIBIOGRAM)", "Text" : "Antibiogram (Susceptibilities)", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZ GTX ABX ANTIMICROBIAL FORMULARY", "Text" : "Antimicrobial Formulary (Restricted)", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID2 GMENU ABX ABX RESTRICTION POLICY", "Text" : "Restrictions on Antimicrobials", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID2 GMENU ABX ADJ EXIST ABX THERAPY", "Text" : "Adjust Existing Antimicrobial Therapy", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID2 GMENU ABX HOW TO FIND ALT ABX", "Text" : "How to Find Alternative Antimicrobials", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "Clinical On-Call Schedule (Infectious Disease)", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZ GTX ABX UP TO DATE", "Text" : "UpToDate Online (Clinical Resource)", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX INFECTION CTRL", "Text" : "Infection Control/Prevention Information", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatologic Guidelines", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU DEVICE-RELATED INFECT", "Text" : "Device-Related Infections", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU PREVENTION OF INFECT", "Text" : "Prevention of Infection", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "HIV-AIDS", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU IMMUNOCOMPROMISED PT", "Text" : "Immunocompromised Patients", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "OCCUPATIONAL Post-Exposure Prophylaxis Blood or Body Fluids", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "Text" : "NON-OCCUPATIONAL Post-Exposure Prophylaxis Blood or Body Fluids", "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : "ORZID2 GMENU MEDS DELAYED PRE-OP ANTIBIOTICS", "Text" : "Antimicrobial Prophylaxis Pre-op", "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : "ORZID2 GMENU POST-OP ANTIMICROBIAL PROPHYLAXIS", "Text" : "Antimicrobial Prophylaxis Post-op", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "ORZID3 GMENU SURG SITE INFECT", "Text" : "Surgical Site Infections", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "Important Drug (Abx) Properties", "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : "ORZ GTX ABX LEXICOMP ONLINE", "Text" : "Lexicomp Online Drug Information", "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : "ORZ GTX ABX RESOURCE QTC", "Text" : "QTc Prolongation Drug Resource", "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Text" : "DDI Warfarin and Antimicrobials", "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : "ORZID3 GMENU PREGNANCY RISK INFO", "Text" : "Pregnancy Risk Factors for Antibiotics", "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : "ORZID2 GMENU ABX ANTIMICROBIAL SHORTAGES", "Text" : "Shortages of Antimicrobials", "Header" : 0}, 
{"Row" : 45, "Column" : 2, "Item" : "ORZID3 GMENU ABX NOT REQUIRED MAIN OP", "Text" : "Conditions NOT benefitted by antibiotics", "Header" : 0}, 
{"Row" : 46, "Column" : 2, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "ESBLs, Amp-C beta-lactamases, and Carbapenemases", "Header" : 0}, 
{"Row" : 47, "Column" : 2, "Item" : "ORZ GTX ABX MEASLES OUTBREAK INFO", "Text" : "Measles Outbreak Information", "Header" : 0}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "HELP",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "Important Antimicrobial Information",  "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "General",  "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "Post-Exposure Prophylaxis (PEP)",  "Header" : 1}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "Surgical infections",  "Header" : 1}, 
{"Row" : 36, "Column" : 2, "Item" : null, "Text" : "Drug Information Links",  "Header" : 1}, 
{"Row" : 44, "Column" : 2, "Item" : null, "Text" : "Miscellaneous/Emerging Topics",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "CDSS-MicroGuide Web and Mobile App",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX MICROGUIDE MOBILE APP INSTRUCTIONS", "Text" : "[CLICK HERE]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX COVID-19 INFORMATION", "Text" : "MPLS SharePoint Site", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Text version", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Beta-lactam Allergy Assessment *Updated",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX BETA-LACTAM ALLERGIES PDF", "Text" : "PDF version *Preferred", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID3 GMENU URINARY TRACT INFECTION", "Text" : "[b] Urinary Tract Infections", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Call Ext 313144 to expedite URGENT medications only",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "(List starts at top and goes down body systems)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "COVID-19",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU ABX COVID-19 MPLS PHARMACOLOGIC GUIDELINES OPT", "Text" : "Pharmacologic Treatment Guidelines", "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : "ORZID3 GMENU ABX COVID-19 MPLS PHARMACOLOGIC GUIDELINES OPT", "Text" : "Outpatient COVID-19 Pharmacologic Guidelines Update", "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : "ORZ SET ABX TIX-CIL INV MED + NURSING INSTRUCTIONS", "Text" : "Tix-Cil med orders (DO NOT Remove)", "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : "ORZID2 GMENU ABX BEBTELOVIMAB EUA", "Text" : "Bebtelovimab EUA Inpt/ED", "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : "ORZ SET ABX BEBTELIVOMAB ED INFO", "Text" : "Bebtelovimab EUA OutPt", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : "PSCZID INV-BEBTELOVIMAB 175 MG IV ONCE", "Text" : "Bebtelovimab Clinic Order", "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : "ORZ SET ABX SECOND DOSE EVUSHELD 150/150", "Text" : "Second dose Evusheld", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY AGE", "Text" : "By Age", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY INDICATION", "Text" : "By Indication", "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : "ORZ SET ABX HEPATITIS B VACCINE 3 DOSE SERIES START TODAY", "Text" : "Hepatitis B Vaccine 3 Dose Series Start Today", "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : "PSCZID TICK-BORNE ENCEPHALITIS VACCINE ONCE", "Text" : "Tick-Borne Encephalitis Vaccine Once", "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : "PSCZID TICK-BORNE ENCEPHALITIS VACCINE 3 DOSE SERIES", "Text" : "Tick-Borne Encephalitis Vaccine 3 Dose Series", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : "ORZ SET ABX HEPATITIS B VACCINE 3 DOSE SERIES START FUTURE", "Text" : "Hepatitis B Vaccine 3 Dose Series Start at a Future Date", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PARAINFLUENZA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PARAINFLUENZA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "No specific antimicrobial therapy is indicated. Contact Infectious Diseases for",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "more information on management of this disease.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Parainfluenza virus", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PAROTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX PAROTITIS MORE INFORMATION", "Text" : "More information on Parotitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PAROTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection of salivary tissue is a relatively common disease. It is usually",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "caused by a stone in the parotid duct, dehydration, or a viral infection.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Sialolithiasis in elderly patients often leads to ductal obstruction and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "secondary infection. Other predisposing factors for ductal occlusion include",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "dehydration, anticholinergic medications such as tricyclics and diphenhydramine,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "general disability and trauma. Once culture results are available adjust",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy based on specific etiologic organism.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "For more information click on the link below",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Suppurative Parotitis or Chronic Bacterial Parotitis Exacerbation Empiric",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Viral Parotitis",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Suspect mumps parotitis if there is fever, malaise, earache and bilateral tender",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "swelling of the parotid glands. For mumps parotitis treat with warm compresses",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "and analgesics and maintain good hydration to prevent secondary bacterial",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "infection. Other viral causes of parotitis include influenza and enteroviruses.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Am Fam Physician. 2014, 89(11)882-888",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Parotitis",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-To-Datearticle: Suppurative parotitis in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PAROTITIS MORE INFORMATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MORE ABOUT PAROTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Suppurative Parotitis. Acute bacterial parotitis affects primarily elderly,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "malnourished, dehydrated or post-operative patients. Symptoms include fever,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "toxicity, and tender swelling along the mandible with purulent drainage from the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "parotid duct. Suppurative parotitis is usually unilateral whereas viral",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "parotitis is usually bilateral. Pain is intense and aggressive, analgesic",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "therapy is required. Progression of infection may lead to massive swelling of",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the neck, respiratory obstruction, septicemia and osteomyelitis of adjacent",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "facial bones. Empiric antibiotics are required for coverage of Staphylococcus",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "aureus if bacterial, and surgical drainage is usually necessary.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Chronic Parotitis. Parotitis is recurrent with intermittent acute exacerbations.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Chronic, low-grade bacterial infection results in functional destruction of the",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "salivary gland. It may be confused with Sjogren's syndrome, a noninfectious",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "illness. Therapy includes systemic antibiotics. Parotidectomy may eventually be",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "required for patients with long-standing infection.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Viral Parotitis. Mumps parotitis is characterized by the rapid, painful swelling",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "of one or both parotid glands within 2 to 3 weeks after exposure to the mumps",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "virus. Mumps usually involves both parotid glands whereas bacterial parotitis is",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "unilateral. Other viral causes of parotitis include influenza and enteroviruses.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mumps parotitis usually resolves spontaneously in 5 to 10 days. Provide",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "symptomatic relief of pain and fever and maintain hydration to prevent secondary",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "bacterial infection.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Am Fam Physician. 2014, 89(11)882-888",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell chapter:Principles and Practice of Infectious Diseases",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Parotitis",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-To-Datearticle: Suppurative parotitis in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZ GTX ABX POST EXPOSURE PROPHYLAXIS NON-OCCUP HYPERLINK", "Text" : "< SELECT HERE > Post-Exposure Prophylaxis Non-occup Protocol", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NONOCCUP RISK TABLE BY EXPOSURE ACT", "Text" : "< SELECT HERE > FOR TABLE", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL LABORATORY ORDERS", "Text" : "< SELECT HERE > INITIAL LABORATORY ORDERS", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL DRUG TX", "Text" : "< SELECT HERE > ANTIRETROVIRAL RECOMMENDATIONS for nPEP", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX OP LABS 4WEEK FOLLOW-UP FOR PEP NON-OCCUP", "Text" : "< SELECT HERE > ORDER FOLLOW-UP FOR BOTH LABS AND RTC ID PHARMACY", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "GMRCTZ MRTC - OUTPT", "Text" : "< SELECT HERE> Consult MRTC", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Non-occupational:",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Post-Exposure Prophylaxis (nPEP) for Exposure to Blood or Body Fluids",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "for HIV (sexual, injection drug use, or other substantial non-occupational",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "HIV exposure)",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Please review and follow the Post-Exposure Prophylaxis (nPEP) Protocol:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Assessment for nPEP:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "A case-by-case determination about nPEP is recommended when the HIV",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "status of the source of the body fluids is unknown and the reported",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "exposure presents a substantial risk for transmission if the source did",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "have HIV infection.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Eligibility for nPEP requires BOTH:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "1.Less than 72 hours since exposure < AND >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "2.High risk for acquisition (all three factors below)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Assess for three key risk factors, all three must be present for an",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "exposure to qualify as high risk:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "1.High-risk anatomic site of exposure < AND >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "a. Vagina",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "b. Rectum",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "c. Eye",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "d. Mouth or other mucous membrane",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "e. Nonintact skin",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "f. Percutaneous inoculation",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "2.High-risk type of fluid < AND >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "a. Blood",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "b. Semen",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "c. Vaginal secretions",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "d. Rectal secretions",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "e. Breast milk",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "f. Any body fluid visibly contaminated with blood",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "3.Known (or strongly suspected) HIV-positive source",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Estimated per-act risk for acquiring HIV from infected source, by exposure act:",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "****** Complete/assess all four items below for nPEP: ******",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "For initial laboratory orders for assessment:",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "For nPEP drug treatment recommendations:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "For Follow-up Laboratory Orders and Schedule Return to Clinic Appointment:",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "IF risk factors for HIV persist place MRTC consult:",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "If risk factors for HIV persist, place a consult to MRTC clinic for",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "consideration of PreP prior to the 28 days of nPEP ending.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "CDC Guidelines 2016",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL DRUG TX", "Contents" : [
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP PEP NON-OCCUP DOLUTEGRAVIR+TRUVADA CRCL >/=50", "Text" : "Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q day ($$)[R,O] < AND >", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Dolutegravir 50MG Tab 1 po qday ($$)[O] for 28 days",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Post-Exposure Prophylaxis (nPEP) for Exposure to Blood or Body Fluids",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "For non-pregnant individuals with creatinine clearance >/= 50 ml/min:",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "For pregnant females or females who may become pregnant while on PEP:",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "(Due to risk of neural tube defects associated with Dolutegravir at",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "conception, Dolutegravir is not recommended to be used.)",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "For non-pregnant individuals with creatinine clearance 30-49 ml/min:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "For non-pregnant individuals with creatinine clearance 15-29 ml/min:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX OP PEP NON-OCCUP DOLUTEGRAVIR+TRUVADA CRCL30-49", "Text" : "Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q OTHER day ($$)[R,O] < AND >", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Dolutegravir 50MG Tab 1 po qday ($$)[O] for 28 days",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX OP PEP NON-OCCUP RALTEGRAVIR + TRUVADA CRCL >/=50", "Text" : "Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q day ($$)[R,O] < AND >", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Raltegravir 400MG po bid ($$) [O] for 28 days",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "For pregnant females with creatinine clearance >/= 50 ml/min:",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "For pregnant females with creatinine clearance 30-49 ml/min:",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX OP PEP NON-OCCUP RALTEGRAVIR + TRUVADA CRCL 30-49", "Text" : "Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q OTHER day ($$)[R,O] < AND >", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Raltegravir 400MG po bid ($$) [O] for 28 days",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Non-Occupational:",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "All persons offered nPEP should be prescribed a 28-day course of a 3-drug",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antiretroviral regimen.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "* These medications may be taken with or without food",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "* Side effects of these medications are infrequent but may include:",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "nausea, vomiting, diarrha, rash, fever, headaches, insomnia, arthralgias,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "fatigue, abdominal pain, hepatitis, renal dysfunction, rare lactic acidosis",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "* IMPORTANT- First dose should be given as soon as possible after exposure",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment recommendations:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Select appropriate treatment below based on renal function:",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "For women of reproductive capacity who have had genital exposure to semen",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "and a negative pregnancy test when evaluated for possible nPEP, current",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "contraception use should be assessed, and if a risk for pregnancy exists,",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "emergency contraception should be discussed with the patient.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Online",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "CDC Guidelines 2016",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "For pregnant females with creatinine clearance 15-29 ml/min:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "For non-pregnant individuals with creatinine clearance <15 ml/min or dialysis:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Patient should receive all three drugs (Emtricitabine/Tenofovir/Dolutegravir)",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Consult drug information for appropriate dosing for each individual drug",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "based on renal function. Dispense supply for 28 days.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "For pregnant females with creatinine clearance <15 ml/min or dialysis:",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Patient should receive all three drugs (Emtricitabine/Tenofovir/Raltegravir))",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Consult drug information for appropriate dosing for each individual drug",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "based on renal function. Dispense supply for 28 days.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP PEP NON-OCCUP DOLUTEGRAVIR + TRUVADA CRCL 15-29", "Text" : "Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q72hours ($$)[R,O] < AND >", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Dolutegravir 50MG Tab 1 po qday ($$)[O] for 28 days",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX OP PEP NON-OCCUP TRUVADA RALTEGRAVIR 15-29", "Text" : "Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q72hours ($$)[R,O] < AND >", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Raltegravir 400MG po bid ($$) [O] for 28 days",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PEP NON-OCCUPATIONAL LABORATORY ORDERS", "Contents" : [
{"Row" : 10, "Column" : 1, "Item" : "LRTZHIV (RAPID) QUALITATIVE", "Text" : "Labs: HIV Rapid Test (results in ~60 minutes)", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "PAGE the INPATIENT ID Attending for HIV Positive Patients", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Order HIV Rapid Test to assess status for all persons:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "C) Hepatitis B and Hepatitis C labs to assess status:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : "GMRCTZ GASTROENTEROLOGY LIVER OUTPT", "Text" : "Consult Gastroenterology Liver Outpatient for Hep B or Hep C Positive patients", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZ SET ABX LRTZ COMPREHENSIVE METABOLIC AND CBC WITH DIFF", "Text" : "Labs: Comprehensive Metabolic AND CBC with Diff", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "A) Baseline labs:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "D) For females of child-bearing years:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : "LRTZ PREGNANCY TEST", "Text" : "Labs: Pregnancy Screen", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "E) For all persons considered for or prescribed nPEP for sexual exposure:",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Recommended laboratory assessments of exposed persons prior to providing nPEP:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "CDC Guidelines 2016",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX OP LABS CHLAMYDIA+GONORRHEA AND SYPHILIS", "Text" : "Labs: Chlamydia, Gonorrhea, and Syphilis", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX OP LAB HEP B SEROLOGY + HEP C ANTIBODY", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "LRTZ HIV AG/AB", "Text" : "Labs: HIV Ag/Ab confirmatory test (results ~4hours)", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "LRTZ CHLAMYDIA WITH GONORRHEA THROAT", "Text" : "Lab: Throatswab for Chlamydia with Gonorrhea (submit only ONE swab in media)", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "LRTZ CHLAMYDIA WITH GONORRHEA RECTAL", "Text" : "Lab: Rectalswab for Chlamydia with Gonorrhea (submit only ONE swab in media)", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "For women of reproductive capacity who have had genital exposure to semen",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "and a negative pregnancy test when evaluated for possible nPEP, current",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "contraception use should be assessed, and if a risk for pregnancy exists,",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "emergency contraception should be discussed with the patient.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "IF Rapid HIV Test is NEGATIVE, continue with assessment for nPEP.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "IF Rapid HIV Test is POSITIVE, order a confirmatory HIV test.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Patients with baseline rapid tests indicating existing HIV infection",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "should NOT be started on nPEP.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Next steps in assessment depends on if Rapid HIV test is positive or negative.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Next steps in assessment depends on if Confirmatory HIV test is positive",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "or negative.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "IF Confirmatory HIV Test is NEGATIVE, continue with assessment for nPEP.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "IF Confirmatory HIV Test is POSITIVE, consult ID. Do not start nPEP.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "NEGATIVE Rapid HIV Test:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "POSITIVE Rapid HIV Test:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "NEGATIVE Confirmatory HIV Test:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "POSITIVE Confirmatory HIV Test:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "___________________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "B) HIV Testing",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "**ADD Labs** below for relevant exposure:",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : "LRTZ CHLAMYDIA WITH GONORRHOEAE VAGINAL", "Text" : "Lab: Vaginal swab for Chlamydia with Gonorrhea (submit only ONE swab in media)", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Call Lab x2400 for APTIMA Unisex Swab Specimen Collection Kit", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PEP NONOCCUP RISK TABLE BY EXPOSURE ACT", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Parenteral",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "Parenteral",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Blood Transfusion",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "9,250",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Needle sharing during injection drug use",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "63",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Percutaneous (needlestick)",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "EXPOSURE TYPE",  "Header" : 1}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Rate for HIV acquisition",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "per 10,000 exposures",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Sexual",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "Sexual",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Receptive anal intercourse",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "138",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "23",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Receptive penile-vaginal intercourse",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "8",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Insertive anal intercourse",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "11",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Insertive penile-vaginal intercourse",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "4",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "Low",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Receptive oral intercourse",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Insertive oral intercourse",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "Low",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "OTHER:",  "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "OTHER:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Biting",  "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "Negligible",  "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "Negligible",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Spitting",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Throwing body fluids (including semen or saliva)",  "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "Negligible",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sharing sex toys",  "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "Negligible",  "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Estimated per-act risk for qcquiring HIV",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "from an infected source, by exposure act", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZ GTX ABX POST EXPOSURE PROPHYLAXIS OCCUP HYPERLINK", "Text" : "Post-Exposure Prophylaxis Protocol", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZ GMENU OCC HEALTH BBP LABS MAIN", "Text" : "Blood Borne Pathogen Labs", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ GMENU LAB ED PEP CBC LFT BASIC METABOLIC", "Text" : "Select to place order for labs [CBC, LFTs, Basic Metabolic(SMA-7)]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX OP PEP OCCUP (DOLUTEGRAVIR EMTRICITABINE TENOFIR)", "Text" : "Emtricitabine 200MG/Tenofovir 300MG Tab 1 po q day($$)[R,DI,O] < AND >", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Post-Exposure Prophylaxis (PEP) for Exposure to Blood or Body Fluids",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "A.Please review and follow the Post-Exposure Prophylaxis Protocol:",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "B.Order the following laboratory tests for the source patient and employee:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "C.Evaluate employee for post-exposure prophylaxis antiviral medications:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "If the source patient is known or suspected of having HIV infection, you are",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "strongly encouraged to call the infectious diseases staff physician",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "on call for advice any time, day or night.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "If there has been a significant known or potential exposure to blood or",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "body fluids from a patient with HIV infection, the employee must be seen",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "in Occupational Health by the end of the next business day.Post-exposure",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "prophylaxis (PEP) medications should be recommended to the employee.If",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "acceptable to the employee, medications should be started within two hours of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "of exposure and should be taken for up to 28 days.To get the medications",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "started, order a 5-day supply of antiviral medications here (see link below).",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Additional medications can only be ordered by Occupational Health personnel",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "after the employee is seen.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If the employee accepts PEP, employee baseline labs CBC, LFTs,",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Basic Metabolic(SMA-7) should be drawn:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Select below to order 5 day emergency supply of PEP antiviral medications:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Dolutegravir 50MG Tab 1 po qday ($$)[O]", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX DERM IE JI PROPHYLAXIS", "Text" : "High risk of hematogenous prosthetic joint infection", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "Link to MRSA Risk Factors menu", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZ SET ABX OP TMP/SMX 1DS TAB BID METRON 1GM BID PO 5DAYS", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZ SET ABX NV TMP/SMX 1DS TAB BID METRON 1GM BID PO 5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "Text" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 500MG PO BID METRON 1GM PO BID 5DS", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO BID", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 500MG PO BID METRON 1GM PO BID 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERIANAL/ANORECTAL ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Primary therapy: abscess drainage",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Prompt surgical drainage is important. Antibiotics have a limited role in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "treatment of uncomplicated anorectal abscess. In general, the addition of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antibiotics to routine incision and drainage of uncomplicated anorectal abscess",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "does not improve healing time or reduce recurrences. Antibiotics may be",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "considered in patients with significant cellulitis, underlying",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "immunosuppression, concomitant systemic illness, or failure to improve with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "drainage alone.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Antibiotic prophylaxis for prevention of infective endocarditis or hematogenous",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "prosthetic joint infection is recommended for procedures involving infected skin",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "or skin structures in patient with underlying cardiac or high-risk prosthetic",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "joint conditions. Click on link below for list of conditions and",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "recommendations.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Although culture of abscess fluid in patients who undergo drainage is rarely",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "helpful, it may be considered in patients who will be treated with adjunctive",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "antibiotic treatment, recurrent infection or nonhealing wounds, substantial host",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "defense deficiency, and patients with MRSA risk factors. Click on the link below",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "for list of MRSA risk factors.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Duration of adjunctive antimicrobial therapy",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "After adequate drainage, 5-14 days of antibiotic coverage is indicated for those",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "who receive adjunctive antimicrobial therapy, with duration in part based on",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "resolution of fever and leukocytosis, severity of infection, and additional",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "indicators of clinical response.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Adjunctive antibiotic treatment for drained perirectal abscess in patients with",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "significant cellulitis, underlying immunosuppression, concomitant systemic",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "illness, or failure to improve with drainage alone",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Mild disease",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "metronidazole 1000 mg PO BID ($) [DI] for 5 days",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "($) [DI] for 5 days",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Moderate to severe disease",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Perirectal abscess",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Steele et al, Dis Colon Rectum 54(12):1465-74, 2011",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Wilson et al, Circulation 116:1736, 2007",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Perianal and perirectal abscess",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Cellulitis and skin abscess in adults: Treatment",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU PREV OF BACT ENDOCARDITIS", "Text" : "High risk of infective endocarditis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PNEUMOCOCCAL PNEUMO HIGH RISK", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX PCV-13 FOLLOWED BY PCV-23 IN 8 WEEKS", "Text" : "1 dose PCV13 followed by 1 dose PPSV23 at least 8 weeks later. At age 65", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX PCV-13 FOLLOWED BY PCV-23 IN 8 WEEKS", "Text" : "1 dose PCV13 followed by 1 dose PPSV23 at least 8 weeks later, then another", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "Text" : "PPSV23 second dose, 5 years after first dose above", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSOZID PNEUMOCOCCAL 13-VALENT VACCINE ONE DOSE", "Text" : "PCV13 one dose", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSOZID PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "Text" : "PPSV23 one dose, one year after PCV13 (if patient has previously received", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "PATIENTS AT HIGH RISK OF PNEUMOCOCCAL INFECTION",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Patients at high risk of serious pneumococcal infection include those that:",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "1) Cerebrospinal fluid leak",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "2) Cochlear implant",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "years or older, administer another dose PPSV23 at least 5 years after PPSV23",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "(note: only 1 dose PPSV23 recommended at age 65 years or older).",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Patients at highest risk of serious pneumococcal infection include those that:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "1) Have anatomic or functional asplenia, including sickle cell disease.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "2) Have an immunocompromising condition, including HIV infection, leukemia,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "renal failure, or nephrotic syndrome.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "3) Are receiving immunosuppressive chemotherapy (including high-dose",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "corticosteroids).",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "4) Have received an organ or bone marrow transplant.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "dose PPSV23 at least 5 years after previous PPSV23 (must be ordered separately",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "below when due). At age 65 years or older, administer 1 dose PPSV23 at least 5",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "years after most recent PPSV23 (note: only 1 dose PPSV23 recommended at age 65",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "years or older)",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Considerations for shared clinical decision-making regarding use of PCV13 in",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "those with increased risk of pneumococcal infection and aged >/= to 65:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "1) Persons residing in nursing homes or other long-term care facilities",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "2) Persons residing in settings with low pediatric PCV13 uptake 3) Persons",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "traveling to settings with no pediatric PCV13 program",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "4) Incidence of PCV13-type invasive pneumococcal disease and pneumonia increases",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "with increasing age and is higher among persons with chronic heart, lung, or",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "liver disease, diabetes, or alcoholism, and those who smoke cigarettes or who",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "have more than one chronic medical condition.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Vaccinate patients with PCV13 and PPSV23:",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "PPSV23, give second dose of PPSV23 at least 5 years after first dose)",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of internal medicine, 2021, 174(3)374-384.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 14, "Column" : 1, "Item" : "PSOZID PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "Text" : "PPSV23 one dose", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route:",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "IM (PCV20 and PPSV23)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Subcutaneous (PPSV23 only)",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Outpatient orders:",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "PCV20 one dose (quick order",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "will be added once available)",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "*for those who received",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "prior dose of PCV13:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "CPRS names:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "PNEUMOCOCCAL 20-VALENT",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "CONJUGATE VACCINE INJ",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(PCV20)",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "PNEUMOCOCCAL 23-VALENT",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "CONJUGATE VACCINE INJ",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "(PPSV23)",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Stocked brand names:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Prevnar 20 (PCV20)",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Pneumovax 23 (PPSV23)",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Pneumococcal conjugate",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "(PCV20)",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Pneumococcal",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "polysaccharide",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "(PPSV23)",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2022,",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "175(3)432-443",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*People age 65yrs or older.",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "*People younger than age",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "65yrs with certain",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "underlying medical",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "conditions:",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "alcoholism, chronic",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "heart/liver/lung disease,",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "chronic renal failure,",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "cigarette smoking,",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "cochlear implant,",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "congenital or acquired",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "asplenia, CSF leak,",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "diabetes mellitus,",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "generalized malignancy,",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "HIV, Hodgkin disease,",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "immunodeficiency,",  "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "iatrogenic",  "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "immunosuppression,",  "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "leukemia, lymphoma,",  "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "multiple myeloma,",  "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "nephrotic syndrome, solid",  "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "organ transplants, or",  "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "sickle cell disease or",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "other hemoglobinopathies.",  "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "public health authorities",  "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "if increased risk exists",  "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "in their community.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*When recommended (see",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "column 2), give PCV20 if",  "Header" : 0}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "unvaccinated or if",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "previous vaccination",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "history is unknown.",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "*Give another dose of",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "PCV20 to people who are",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "age 65yrs and older.",  "Header" : 0}, 
{"Row" : 14, "Column" : 3, "Item" : null, "Text" : "*If patient received PCV13",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "previously, give one dose",  "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : null, "Text" : "of PPSV23 at least 1 year",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "after PSV13. A minimum",  "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : null, "Text" : "of 8 weeks may be",  "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "considered in patients",  "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "with immunocompromising",  "Header" : 0}, 
{"Row" : 21, "Column" : 3, "Item" : null, "Text" : "conditions:",  "Header" : 0}, 
{"Row" : 22, "Column" : 3, "Item" : null, "Text" : "Chronic renal failure,",  "Header" : 0}, 
{"Row" : 23, "Column" : 3, "Item" : null, "Text" : "nephrotic syndrome,",  "Header" : 0}, 
{"Row" : 24, "Column" : 3, "Item" : null, "Text" : "immunodeficiency,",  "Header" : 0}, 
{"Row" : 25, "Column" : 3, "Item" : null, "Text" : "iatrogenic",  "Header" : 0}, 
{"Row" : 26, "Column" : 3, "Item" : null, "Text" : "immunosuppression,",  "Header" : 0}, 
{"Row" : 27, "Column" : 3, "Item" : null, "Text" : "generalized malignancy,",  "Header" : 0}, 
{"Row" : 28, "Column" : 3, "Item" : null, "Text" : "human immunodeficiency",  "Header" : 0}, 
{"Row" : 29, "Column" : 3, "Item" : null, "Text" : "virus, Hodgkin disease,",  "Header" : 0}, 
{"Row" : 30, "Column" : 3, "Item" : null, "Text" : "leukemia, lymphoma,",  "Header" : 0}, 
{"Row" : 31, "Column" : 3, "Item" : null, "Text" : "multiple myeloma, solid",  "Header" : 0}, 
{"Row" : 32, "Column" : 3, "Item" : null, "Text" : "organ transplants,",  "Header" : 0}, 
{"Row" : 33, "Column" : 3, "Item" : null, "Text" : "congenital or acquired",  "Header" : 0}, 
{"Row" : 34, "Column" : 3, "Item" : null, "Text" : "asplenia, sickle cell",  "Header" : 0}, 
{"Row" : 35, "Column" : 3, "Item" : null, "Text" : "disease, or other",  "Header" : 0}, 
{"Row" : 36, "Column" : 3, "Item" : null, "Text" : "hemoglobinopathies.",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 0}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications:",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "History of severe allergic",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component including (for",  "Header" : 0}, 
{"Row" : 10, "Column" : 4, "Item" : null, "Text" : "PCV13) to any diphtheria",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "toxoid containing vaccine,",  "Header" : 0}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "or to any of its",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "components, including",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "yeast.",  "Header" : 0}, 
{"Row" : 16, "Column" : 4, "Item" : null, "Text" : "Precautions:",  "Header" : 1}, 
{"Row" : 17, "Column" : 4, "Item" : null, "Text" : "Moderate or severe acute",  "Header" : 0}, 
{"Row" : 18, "Column" : 4, "Item" : null, "Text" : "illness with or",  "Header" : 0}, 
{"Row" : 19, "Column" : 4, "Item" : null, "Text" : "without fever.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX POSITIVE BLOOD CULTURE OP COAG NEG STAPH", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BLOOD CULTURE POSITIVE FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "CNS are the most common contaminants isolated from blood cultures. When CNS",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "isolated from blood cultures represent true bacteremia, the blood is usually",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "obtained from a patient with plastic or metal in the body. The most common",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "source of coagulase negative staphylococcal bacteremia is an infected",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "intravascular catheter.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "When CNS are isolated from blood, the physician should carefully assess the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "patient to decide whether the isolation represents disease or colonization.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Colonization is more likely if a single bottle is positive or both bottles from",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "a single blood draw are positive. If multiple bottles are positive from separate",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "blood draws, it is more likely that the isolates reflect disease or colonization",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of an intravascular device. Isolates from contaminated bottles often take",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "several days to become positive. If the patient has risk factors for true",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "coagulase negative staphylococcal bacteremia, catheter-related blood stream",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "infection and/or the patient is severely ill, antimicrobials should be given. If",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "there is a plastic or metal prosthesis in the body, the physician should",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "evaluate the site for possible infection. If the isolates are likely to",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "represent contamination and the patient does not seem ill with CNS,",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy would not be helpful and should not be given.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for treatment CNS bacteremia and infected",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "intravascular catheters treatment recommendations",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus epidermis and Other Coagulase-Negative",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Staphylococci",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mermel et al, Clin Infect Dis, 2009, 49", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX PROCED FOR INFECTED SKIN OUTPATIENT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID DICLOXACILLIN 500MG PO ONCE", "Text" : "Dicloxacillin 500 mg PO 1 hour before procedure ($)[DI]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 2000MG PO ONCE", "Text" : "Cephalexin 2 gm PO 1 hour before procedure ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TAB PO ONCE PREOP", "Text" : "Trimethoprim/Sulfamethoxazole 1 DS table PO 1 hour before incision", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO ONCE", "Text" : "Minocycline 100 mg PO 1 hour before incision ($) [DI]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIALS FOR PATIENTS UNDERGOING PROCEDURES THAT INVOLVE INFECTED SKIN,",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "SKIN STRUCTURES, OR INFECTED MUSCULOSKELETAL TISSUE TO PREVENT ENDOCARDITIS OR",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "PROSTHETIC JOINT INFECTION",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pathogen unknown or possibly MSSA or beta-hemolytic streptococcus",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Patients unable to take oral medications",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for parenteral prophylaxis",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Suspected MRSA",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "($) [R,DI]",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for parenteral prophylaxis",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Bratzler et al, Am J Health-Syst Pharm (2013) 70, 195-283",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Curr Derm Rep (2012) 1, 55-63",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Rosengren et al, Am J Clin Dermatol (2010) 11.1, 35-44",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Antimicrobial prophylaxis for prevention of surgical site",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "infection in adults",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Skin surgery: Prevention and treatment of complications",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Wright et al, J Am Acad Dermatol (2008) 59, 464-73",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RABIES HIGH RISK GROUPS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "RABIES HIGH RISK GROUPS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Occupational",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "1. Veterinarians and their staff (e.g. students and technicians)",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "2. Laboratory workers working with rabies virus or specimens that may contain",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "rabies virus",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "3. Other people with occupations or activities that bring them in to contact",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "with animal species at risk for rabies (e.g. animal control officers and cavers)",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Travel",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "1. Travelers who will be working with or around potentially rabid animals",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "2. People who will be in areas where dog-rabies is common and who won't be in an",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "area where safe and effective biologics are readily available within a few days",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "after exposure",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "9", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX MDH ANIMAL BITES AND RABIES RISK", "Text" : "Minnesota Department of Health Guide on Animal Bites and Rabies Risk", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ GTX ABX ON-CALL SCHEDULE", "Text" : "Infectious Diseases On-Call Schedule", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSCZID POVIDINE-IODINE SOLN WOUND CLEANSE ONE TIME DOSE", "Text" : "Povidine-iodine irrigation solution", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES IGG AND VACCINE SERIES", "Text" : "Rabies immune globulin STAT < AND > rabies vaccine STAT", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES STAT AND VACCINE SERIES", "Text" : "Rabies vaccine STAT", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSCZID TETANUS/DIPTHERIA VACCINE ONE DOSE STAT", "Text" : "Tetanus and Diphtheria (Td) vaccine one dose", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID3 GMENU BITE WOUNDS", "Text" : "Bite wounds recommendations (outpatient)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "RABIES POST-EXPOSURE PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Patients are given post-exposure prophylaxis based upon their risk including",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "type of exposure, epidemiology of rabies in the area where contact occurred,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "circumstances of the exposure incident, species and the availability of animal",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "involved. The Minnesota Department of Health has staff available 24/7 to consult",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "health care providers on risk-status of individuals. They can be contacted by",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "phone at 651-201-5414. Refer to link below for more information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Discussion with Infectious Diseases inpatient attending by phone is highly",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "recommended. Use the link below to obtain the pager number for on-call staff.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Wound cleansing",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "All post-exposure prophylaxis should begin with immediate thorough cleansing of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "all wounds with soap and water. After cleansing, use povidine-iodine solution to",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "irrigate the wounds.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Patients without history of rabies vaccination",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "After wound cleansing, administer rabies immune globulin and first dose of",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "rabies vaccine series immediately.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Administer second, third and fourth doses of rabies vaccine series on days 3, 7,",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "and 14. An additional dose is given on day 28 for immunocompromised patients.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Patients with history of rabies vaccination",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Patients with a history of complete pre-exposure vaccination regimen and a",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "documented antibody response to the rabies virus, do not require rabies immune",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "globulin administration. If the patient does not meet these criteria, treat as a",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "patient without history of rabies vaccination above. If patient does meet these",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "criteria, after wound cleansing, administer first dose of rabies vaccine series.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Administer second dose of rabies vaccine series on day 3.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Tetanus Prophylaxis",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "In bite wounds that break the skin, tetanus vaccine is indicated if patient has",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "received <3 doses of tetanus vaccine or immunization history is unknown. Tetanus",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "immune globulin is also indicated in these patients if they have a tetanus prone",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "wound. For patients with 3 or more documented tetanus vaccine doses, tetanus",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "vaccine is indicated if >5 years since last booster in tetanus prone wounds and",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "indicated if >10 years since last booster in non-tetanus-prone wounds.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Treatment of infection",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1.",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "9", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE VACCINATED PATIENTS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSCZID RABIES POST EXPOSURE VACCINE 2 DOSE SERIES", "Text" : "[CLICK HERE] to place clinic order for second dose", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX CBOC INFO", "Text" : "[CLICK HERE] for CBOC open hours and contact information", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID RABIES VACCINE POST EXPOSURE DOSE CBOC 2 SERIES", "Text" : "[CLICK HERE] to place outpatient prescription for second dose", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "ORDER RABIES POST-EXPOSURE PROPHYLAXIS SUBSEQUENT VACCINE DOSES",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "A second dose of the rabies vaccine is required on day 3 for patients with a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "history of documented rabies vaccination. To order the second dose of the rabies",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "vaccination, follow these two steps:",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "1) Select vaccine series below based on administration location",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "2) Click the [Next] button at the top right of this window when finished",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "If second dose will be administered at MVAMC ED",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If second dose will be administered at a CBOC",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Complete the following 4 steps:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "1) Call pharmacy at extension 3128 to ensure vaccine dose is mailed over night",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "to the CBOC for administration.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "2) Complete rabies vaccination plan in the EMERGENCY DEPARTMENT STAFF NOTE and",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "attach patient's primary care provider for follow up.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "3) Ensure the CBOC is open on day 3.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "4) Order vaccine dose",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "9", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE VACCINE NAIVE PATIENTS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSCZID RABIES POST EXPOSURE VACCINE MVAMC 2-4 SERIES", "Text" : "[CLICK HERE] for immunocompetent patients", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSCZID RABIES POST EXPOSURE VACCINE MVAMC 2-5 SERIES", "Text" : "[CLICK HERE] for immunocompromised patients", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ GTX ABX CBOC INFO", "Text" : "[CLICK HERE] for CBOC open hours and contact information", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID RABIES VACCINE POST EXPOSURE DOSE CBOC 2-4 SERIES", "Text" : "[CLICK HERE] for immunocompetent patients", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID RABIES VACCINE POST EXPOSURE DOSE CBOC 2-5 SERIES", "Text" : "[CLICK HERE] for immunocompromised patients", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES VACCINE MVAMC/CBOC 4 DOSE SERIES", "Text" : "[CLICK HERE] for immunocompetent patients", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX OP RABIES VACCINE MVAMC/CBOC 5 DOSE SERIES", "Text" : "[CLICK HERE] for immunocompromised patients", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "ORDER RABIES POST-EXPOSURE PROPHYLAXIS SUBSEQUENT VACCINE DOSES",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "In patients without documented rabies vaccination, subsequent doses of the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "rabies vaccine are required on days 3, 7, and 14. An additional dose is given on",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "day 28 for immunocompromised patients. To order subsequent rabies vaccinations,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "follow these two steps:",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "1) Select vaccine series below based on administration location and immune",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "status",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "2) Click the [Next] button at the top right of this window when finished",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "If all subsequent rabies vaccine doses will be administered at the MVAMC ED",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "If at least one subsequent rabies vaccine dose will be administered at a CBOC",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Complete the following 4 steps:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "1) Call pharmacy at extension 3128 to ensure vaccine doses are mailed over night",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "to the CBOC for administration.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "2) Complete rabies vaccination plan in the EMERGENCY DEPARTMENT STAFF NOTE and",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "attach patient's primary care provider for follow up.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "3) Ensure CBOC is open on days when vaccine is scheduled to be given there. The",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "rabies vaccine is given on a 3, 7, 14-day schedule, an additional dose is given",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "on day 28 for immunocompromised patients",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "4) Order vaccine doses based on location of administration",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "*If all subsequent rabies vaccine doses will be administered at a CBOC:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "*If subsequent rabies vaccine doses will be administered at the MVAMC ED and at",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "a CBOC:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "The following order sets contain a clinic order and an outpatient prescription.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "The first order is the clinic order. Complete it by selecting the doses to be",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "administered at the MVAMC ED. The second order is the outpatient prescription.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Complete it by selecting the doses to be administered at the CBOC. Finish the",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "outpatient prescription by selecting the quantity of vaccine doses to be mailed",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "to the CBOC.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "9", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "Text" : "Rabies Post-Exposure Prophylaxis", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES HIGH RISK GROUPS", "Text" : "Rabies high risk groups", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID RABIES VACCINE 3 DOSE SERIES", "Text" : "Rabies vaccine, 3 dose series", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES RISK CATEGORIES", "Text" : "Rabies risk categories", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "LRTZID RABIES VIRUS RAPID FLUORESCENT INHIBITION TEST", "Text" : "Rabies virus rapid fluorescent focus inhibition test", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID RABIES BOOSTER VACCINE ONE DOSE", "Text" : "Rabies booster vaccine", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "RABIES PRE-EXPOSURE PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "For patients exposed to a rabid animal, refer to the Rabies-Post Exposure",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Prophylaxis recommendations in the emergency department CDSS.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Rabies Vaccination",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "People who are in high-risk groups should be vaccinated against rabies.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Rabies Booster",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "People with continuous risk of rabies exposure should be tested for rabies virus",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "neutralizing antibody every six months. Those with frequent risk of rabies",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "exposure should be tested every two years.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "A booster vaccination should be administered if the serum titer falls to",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "maintain a value of at least complete virus neutralization at a 1:5 serum",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "dilution by the rapid fluorescent focus inhibition test.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "9", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RABIES RISK CATEGORIES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "RABIES RISK CATEGORIES",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Continuous",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Rabies research laboratory workers, rabies biologics production workers",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Frequent",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Rabies diagnostic laboratory workers, cavers, veterinarians and staff and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "animal-control and wildlife workers in areas where rabies is enzootic. All",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "persons who frequently handle bats.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Infrequent",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Veterinarians and animal-control staff working with terrestrial animals in areas",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "where rabies is uncommon to rare. Veterinary students. Travelers visiting areas",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "where rabies is enzootic and immediate access to appropriate medical care",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "including biologics is limited.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Rare",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "U.S. population at large, including persons in areas where rabies is epizootic.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention-United",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "States, 2008: recommendations of the Advisory Committee on Immunization",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Practices. MMWR Recomm Rep 2008, 57:1.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Rupprecht, Charles E., et al. Use of a reduced (4-dose) vaccine schedule for",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "postexposure prophylaxis to prevent human rabies: recommendations of the",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "advisory committee on immunization practices. MMWR Recomm Rep 59.RR-2 (2010): 1-",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "9", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "[Click Here] for vaccination history including link to Joint Legacy Viewer", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "[Click Here] for link to PDF of CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Chickenpox (Varivax, VAR)", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX COVID-19 VACCINE RECOMMENDATIONS", "Text" : "COVID-19 *Inpatient orders only* (Comirnaty, Spikevax, Janssen)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Diphtheria (Tenivac, Td / Boostrix, Tdap)", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Flu (seasonal influenza)", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hiberix, Hib)", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (Havrix, HepA)", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (Engerix-B, HepB)", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (Twinrix, HepA/B)", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (Shingrix, RZV)", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (Gardasil 9, HPV)", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza (seasonal influenza)", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles (M-M-R II, MMR)", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (Menveo, MenACWY)", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (Bexsero, MenB)", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Mumps (M-M-R II, MMR)", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Pertussis (Boostrix, Tdap)", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcus (PCV20, Prevnar20 / PPSV23, Pneumovax 23)", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "Text" : "Rabies (Imovax) - for post-exposure prophylaxis, refer to ED Antimicrobial CDSS", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Rubella (M-M-R II, MMR)", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Shingles (Shingrix, RZV)", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus (Tenivac, Td / Boostrix, Tdap)", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Whooping cough (Boostrix, Tdap)", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Zoster (Shingrix, RZV)", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 19-26 YEARS", "Text" : "19-26 years", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 27-49 YEARS", "Text" : "27-49 years", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 50-64 YEARS", "Text" : "50-64 years", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION 65 YEARS OR GREATER", "Text" : ">/= 65 years", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZ GMENU BONE MARROW MAIN", "Text" : "Bone Marrow Transplant, hematopoietic stem cell transplant (HSCT)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "Text" : "Chronic Liver Disease", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN DIABETES", "Text" : "Diabetes", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Functional or Anatomical Asplenia - Outpatient Orders", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Functional or Anatomical Asplenia - Inpatient Orders", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HEALTH CARE PERSONNEL", "Text" : "Health Care Personnel", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION HEART, LUNG DISEASE, ALCOHOLISM", "Text" : "Heart/Lung Disease or Alcoholism", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "Text" : "HIV", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "Text" : "Immunocompromised (not including HIV and HSCT)", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Kidney Failure or on Hemodialysis", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN MEN WHO HAVE SEX WITH MEN", "Text" : "Men who Have Sex with Men", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Pregnancy", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "RECOMMENDED IMMUNIZATION SCHEDULES AND OUTPATIENT VACCINE ORDERS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patient Vaccine History:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "CDC Recommended Adult Immunization Schedule",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Please note:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "*A vaccine series does not need to be restarted, regardless of the time that has",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "elapsed between doses.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "*For calculating intervals between doses, 4 weeks = 28 days. Intervals of 4",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "months or greater are determined by calendar months.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "*Any vaccine can be given with another unless otherwise noted on the specific",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "vaccine page.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "*Mild illness is not a contraindication to receiving any vaccine.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Vaccine information and orders - listed alphabetically below by organism name",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "*see below for immunization based on age or indication",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Cholera (Vaxchora) - refer to Travel Clinic",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Japanese encephalitis (Ixiaro) - refer to Travel Clinic",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Poliovirus (IPOL) - refer to Travel Clinic",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Tick-Borne Encephalitis (Ticovac) - refer to Travel Clinic",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Typhoid (Typhim Vi) - refer to Travel Clinic",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Varicella-zoster: refer to chickenpox for prevention of primary infection or",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "herpes zoster/shingles/zoster for prevention of viral reactivation",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Yellow fever (YF-VAX) - refer to Travel Clinic",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "By Age",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "By Indication",  "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY AGE", "Contents" : [
{"Row" : 4, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 19-26 YEARS", "Text" : "19-26 years", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 27-49 YEARS", "Text" : "27-49 years", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION AGE 50-64 YEARS", "Text" : "50-64 years", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION 65 YEARS OR GREATER", "Text" : ">/= 65 years", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "RECOMMENDED IMMUNIZATION SCHEDULES AND OUTPATIENT VACCINE ORDERS BY AGE", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX RECOMMENDED IMMUNIZATIONS BY INDICATION", "Contents" : [
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "RECOMMENDED IMMUNIZATION SCHEDULES AND OUTPATIENT VACCINE ORDERS BY INDICATION",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZ GMENU BONE MARROW MAIN", "Text" : "Bone Marrow Transplant, hematopoietic stem cell transplant (HSCT)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN CHRONIC LIVER DISEASE", "Text" : "Chronic Liver Disease", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN DIABETES", "Text" : "Diabetes", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Functional or Anatomical Asplenia - Outpatient Orders", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU ABX SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Functional or Anatomical Asplenia - Inpatient Orders", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HEALTH CARE PERSONNEL", "Text" : "Health Care Personnel", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION HEART, LUNG DISEASE, ALCOHOLISM", "Text" : "Heart/Lung Disease or Alcoholism", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN HIV PTS", "Text" : "HIV", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION OF IMMUNOCOMPROMISED PTS", "Text" : "Immunocompromised (not including HIV and HSCT)", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN KIDNEY FAILURE/HD", "Text" : "Kidney Failure or on Hemodialysis", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX IMMUNIZATION IN MEN WHO HAVE SEX WITH MEN", "Text" : "Men who Have Sex with Men", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU PREGNANCY VACCINE", "Text" : "Pregnancy", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RESPIRATORY PAPILLOMATOSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSJIZID CIDOFOVIR 5MG/ML INJECTION", "Text" : "Cidofovir 5 mg/ml for mucosal injection ($525/75mg Vial) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "RESPIRATORY PAPILLOMATOSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Respiratory papillomas are usually associated with human papillomavirus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infection. The papillomas are found in the pharynx, usually in the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "larynx.They can be surgically removed, but they often recur.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Cidofovir is injected into the respiratory mucosa after papillomas are",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "removed to prevent recurrences.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Elina Kiverniti o Nick Sevdalis oAnastasia Rachmanidou-Doran:A",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "systematic review on recurrent respiratory papillomatosis:clinical",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "effect and duration of benefit of different treatment modalities, Oncol",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Rev (2010) 4:35-42", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX RSV", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "RESPIRATORY SYNCYTIAL VIRUS (RSV)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "No specific antimicrobial therapy is indicated. Contact Infectious Diseases for",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "more information on management of this disease.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Respiratory Syncytial Virus", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "Text" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX NV CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX OP CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "Text" : "Mupirocin 2% ointment topically BID ($) [M] <AND> chlorhexidine 4% liquid", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX NV CHLORHEXIDINE MUPIROCIN DECOLONIZATION", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STAPHYLOCOCCUS AUREUS DECOLONIZATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "From 10% to 40% of adults are colonized with Staphylococcus aureus, and the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "anterior nares is the most common site of colonization. The great majority of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "people never have disease with S. aureus, but a tiny fraction of people develop",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "clinical infections with the S. aureus that has colonized their skin or anterior",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "nares. Steps to decolonize the skin and anterior nares can transiently diminish",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "or eradicate S. aureus colonization and can prevent post-operative wound",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "infection in certain high-risk circumstances. For people who have other forms",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "of recurrent S. aureus disease, not associated with an operation, results with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "decolonization have been disappointing, and decolonization is not routinely",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "recommended. Colonization typically reappears in most patients within a few",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "days or weeks after decolonization has been attempted. Clinicians occasionlly",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "wish to attempt decolonization for patients with frequent, troublesome",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "recurrences. The procedure here is one of several that have been studied, but",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "none have been particularly effective over the long run.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Consultation with Infectious Diseases is recommended.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Inpatient Decolonization Order Set:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "topically QDAY nursing text order ($) [M] for 5 days",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Outpatient Decolonization Order Set:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Order if patient is being discharged within 5 days",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "topically QDAY ($) [M] for 5 days",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Instructions",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "* Patient must wear clean clothes after bathing to prevent recontaminat",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "* Bedding and linens must be changed/cleaned daily until the end of the",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "decolonization protocol.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Bradley S Clin Infect Dis 2007, 44: 186",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Lonneke G NEJM 2010, 362: 9",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Schweizer et al, JAMA 2015, 313.212:162-2171",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Methicillin-resistant Staphylococcus aureus (MRSA) in",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "adults: Prevention and control", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX SOTROVIMAB EUA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "If patient agreeable and meets criteria, please contact Minneapolis VA Emergency",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "infection control measures (wear mask, isolate, social distance, avoid",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "sharing personal items, clean and disinfect \"high touch\" surfaces, and",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "frequent handwashing) according to CDC guidelines.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Inclusion Criteria",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "ALL of the following criteria must be met for a patient to receive:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "2) Patient is not hospitalized due to COVID-19.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "3) Patient does NOT require oxygen therapy for COVID-19.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "For patients on chronic oxygen therapy: patient does NOT require an",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "increase in baseline oxygen flow rate due to COVID-19.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "4) Administration will begin within 7 days of symptom onset.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "5) Patient does not have known hypersensitivity to sotrovimab or components.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "The provider has communicated with the patient/caregiver regarding",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "information contained in the \"Fact Sheet for Patients\". The patient/",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "caregiver has been given the Fact sheet, informed that the drug is an",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "unapproved drug that is authorized for use under an EUA, given information",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "on alternatives and their risks and benefits, and the patient/caregiver",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "has the right to refuse or accept. (See top of page for Fact Sheet)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "1) Patient has a laboratory-confirmed diagnosis of mild to moderate COVID-19.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "7) Counseling is provided and documented in the electronic health record per EUA",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Note: See below for inclusion criteria. Does not require ID approval.",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "ID available to discuss if needed.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "including hospitalization or death.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "6) Patient has at least one risk factor for progression to severe disease",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "See link below for complete list:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "**Treatment:**",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Note: patient may be hospitalized for some other reason.",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Sotrovimab (EUA) Information",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-Sotrovimab is available via FDA Emergency Use Authorization (EUA)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "for treating patients that meet specific criteria. Sotrovimab is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "not FDA approved drug.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "-Sotrovimab EUA does NOT include post-exposure prophylaxis.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "*Patients treated with this drug should continue to self-isolate and use",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PATIENT EUA FACT SHEET", "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Sotrovimab", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Sotrovimab", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ GTX ABX URL SOTROVIMAB PROVIDER FACT SHEET EUA", "Text" : "[Click Here] Fact Sheet for HCP - Medical Conditions or Other Factors", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Exclusion Criteria",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "If patient recieved tixagevimab plus cilgavimab previously, discuss with ID.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Department charge nurse at 31-6736 to arrange for treatment if available.", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ABX STASIS DERMATITIS OP", "Contents" : [
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU CELLULITIS", "Text" : "Bacterial Cellulitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STASIS DERMATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Stasis dermatitis is a common condition that is often confused with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "bacterial cellulitis. Stasis dermatitis does not benefit from antimicrobial",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "therapy. It is important to distinguish between the two. The provider",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "should be mindful of the fact that bacterial cellulitis can occur on skin",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with underlying stasis dermatitis. (See link below for bacterial cellulitis)",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Common risk factors for venous stasis include advancing age, family",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "history of venous disease, increased body mass index, smoking, a history of",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "trauma, prior venous thrombosis and pregnancy. Chronic venous disease and",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "arterial vascular disease have some common risk factors (eg, smoking,",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "obesity) and pathophysiological processes. The most common symptoms reported",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "by patients with chronic venous disease are limb discomfort (tired, heavy",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "legs), pain, and limb swelling. Swelling is often worse with prolonged",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "standing and improves with leg elevation and walking. The skin of the",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "anterior surfaces of the lower legs often has brown or blue-grey",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "hyperpigmentation.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "People with venous stasis are prone to develop stasis dermatitis which",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "is one of the most common and earliest dermatologic signs of chronic venous",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "insufficiency. Stasis dermatitis is an inflammatory process that presents as",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "an eczematous rash characterized by itching, erythema, scaling, weeping,",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "erosions, and crusting. Longstanding cases may develop lipodermatosclerosis",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "a fibrosing panniculitis of the subcutaneous tissue. Lipodermatosclerosis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "typically starts with a firm area of induration at the medial ankle. As the",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "process progresses, the entire leg lower leg can become involved with",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "extension up to the mid leg in more advanced cases. The skin overlying the",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "panniculitis is typically heavily pigmented and bound down to the",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "subcutaneous tissues. Brawny edema above the fibrotic area and on the foot",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "below is seen in advanced cases. Leukocytosis and fever are common in people",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "with stasis dermatitis.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Chronic venous disease is the most common cause of leg ulcers. They",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "are usually found low on the medial ankle over a perforating vein, or along",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "the course of the great or small saphenous veins. They occur more proximally",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "if precipitated by trauma. Venous ulcers are not found on the forefoot or",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "above the level of the knee. Venous ulcers can be multiple or single, and",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "can be exquisitely tender, shallow, exudative and have a granulation base.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "The ulcer borders are usually irregular but not undermined. They can extend",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "circumferentially around the leg if left untreated.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Arterial ulcers are typically painful, and punched out or stellate. The",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "surrounding skin is red and taut. Some arterial ulcers are pale - others have",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "a black or yellow eschar. They are often associated with trauma and commonly",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "occur on the foot over pressure points. There may be other signs of arterial",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "insufficiency on the lower limb including thin atrophic or hairless skin,",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "poor pedal pulses, diminished capillary refill, or hypertrophic deformed",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "nails.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Patients with stasis or lipodermatosclerosis are prone to bouts of",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "bacterial cellulitis, usually caused by Staphylococcus aureus or encapsulated",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "streptococci. Typically, stasis dermatitis develops slowly, over a week or",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "more. It is often bilateral. The onset of bacterial cellulitis is usually",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "abrupt, typically developing over 1 or 2 days. Bacterial cellulitis often",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "starts in one area and spreads to adjacent areas. Bacterial cellulitis is",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "unilateral. Both can present with fever and leukocytosis.",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "In a patient with stasis and cellulitis and the physician is uncertain",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "about whether bacterial cellulitis is present, the physician should consider",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "a trial of bed rest, leg elevation, and if there is fluid overload, diuresis",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "If the cellulitis improves in 24-48 hours, antibacterial therapy and the",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "attendant adverse reactions can be avoided. If it is clear that bacterial",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "cellulitis has occurred, antimicrobial therapy should be given.",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Stevens et al, Clin Infect Dis, 2014, 59(2): e10-52",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Stasis dermatitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX SYPHILIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "LRTZ SYPHILIS AB W/REFLEX TO RPR W/TITER", "Text" : "Syphilis antibody test with reflex to rapid plasma reagin (RPR)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "LRTZ FTA-ABS", "Text" : "Fluorescent treponemal antibody absorbed (FTA-ABS)", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSCZID BENZATHINE PENICILLIN 2.4MU IM ONCE", "Text" : "Benzathine Penicillin 2.4 million units IM once ($$$) [M]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Beta-lactam Reaction Assessment", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 14 days", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSCZID2 BENZATHINE PENICILLIN 2.4MU IM QWEEK X3 SYPHILIS", "Text" : "Benzathine Penicillin 2.4 million units IM qweek ($$$) [M] x3 doses", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Beta-lactam Reaction Assessment", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 28DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 28 days", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 28DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SYPHILIS",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases. Evaluation and management are complex.",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Syphilis is a sexually transmitted disease caused by the spirochete Treponema",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "pallidum that can manifest as a variety of signs or symptoms. Primary syphilis",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "typically consists of painless ulcers or chancre at the site of infection with",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "regional adenopathy. Secondary syphilis often includes a skin rash (disseminated",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "and/or including the palms and soles), fever, malaise, mucocutaneous lesions and",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "lymphadenopathy. Tertiary syphilis includes those with cardiovascular or",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "gummatous disease.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Latent syphilis is a period of disease when a patient does not have symptoms but",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "is found to be infected through serologic testing. Early latent syphilis refers",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "to latent syphilis acquired within the preceding year and late latent syphilis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "refers to all other cases of latent syphilis. Neurosyphilis, Ocular syphilis or",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Otosyphilis, can occur at any stage of syphilis with early manifestations (e.g.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "meningitis, stroke, vision or hearing loss) occurring within the first months to",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "years of infection and late manifestations (e.g. dementia, tabes dorsalis)",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "occurring after 10-30 years.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "A presumptive diagnosis is made through use of a nontreponemal or serologic test",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "(i.e. rapid plasma reagin [RPR]) and a treponemal test (i.e. fluorescent",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "treponemal antibody absorbed [FTA-ABS]). Direct methods through darkfield",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "microscopy and direct fluorescent antibody (DFA) must be used for definitive",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "diagnosis since T. pallidum cannot be cultured.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Management of sex partners",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Persons with sexual contact with a person with primary, secondary or early",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "latent syphilis within the last 90 days should be presumptively treated even if",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "serologic test is negative.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Primary, Secondary and Early Latent Syphilis",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Secondary treatment for patients who are not pregnant",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Tertiary and Late Latent Syphilis",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "*Outpatient treatment requires a follow up appointment on day 7 and day 14 to",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "administer 2nd and 3rd dose respectfully. Ensure these appointments are made",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "when ordering this treatment regimen.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Secondary treatment for patients who are not pregnant",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Neurosyphilis, Ocular syphilis or Otosyphilis",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Disease for treatment",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines MMWR (2021) 70.4",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Syphilis (Treponema pallidum)",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Syphilis",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Syphilis: Screening and diagnostic testing",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Syphilis: Treatment and monitoring", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Td/Tdap 3 dose series", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID TETANUS/DIPHTHERIA VACCINE ONE DOSE", "Text" : "Td one dose", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE", "Text" : "Tdap one dose", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: IM (Td and Tdap)",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient orders:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "CPRS names:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "TETANUS/DIPHTERIA VACCINE",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "INJ (Td)",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "DIPHTHERIA/TETANUS/",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "PERTUSSIS VACCINE INJ,SUSP",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "(Tdap)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Tenivac (Td)",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Boostrix (Tdap)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Tetanus, diphtheria and",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "acellular pertussis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "(Td, Tdap)",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2021,",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "174(3)374-384.",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*All people who lack",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "written documentation of a",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "primary series consisting",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "of at least 3 doses of",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "tetanus- and diphtheria-",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "toxoid-containing vaccine.",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "*A booster dose of Td or",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Tdap may be needed for",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "wound management, so",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "consult ACIP",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "recommendations.",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "*Adults who have not",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "received Td or Tdap in the",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "past 10 years or whose",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "Tdap history is not known.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*For people who are",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "unvaccinated or behind,",  "Header" : 0}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "complete a 3-dose series",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "with Tdap as the first",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "dose, followed by Td or",  "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : null, "Text" : "Tdap (observe intervals of",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "1-2m between dose1 and",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "2, and an interval of 6-",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "12m between dose2 and",  "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "3).",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "*Give Tdap to pregnant",  "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : null, "Text" : "women during each",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "pregnancy (preferred",  "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : null, "Text" : "during the early part of",  "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "gestational weeks 27",  "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "through 36), regardless of",  "Header" : 0}, 
{"Row" : 21, "Column" : 3, "Item" : null, "Text" : "the interval since prior",  "Header" : 0}, 
{"Row" : 22, "Column" : 3, "Item" : null, "Text" : "Td or Tdap.",  "Header" : 0}, 
{"Row" : 24, "Column" : 3, "Item" : null, "Text" : "*Give Td or Tdap booster",  "Header" : 0}, 
{"Row" : 25, "Column" : 3, "Item" : null, "Text" : "every 10yrs after the",  "Header" : 0}, 
{"Row" : 26, "Column" : 3, "Item" : null, "Text" : "primary series has been",  "Header" : 0}, 
{"Row" : 27, "Column" : 3, "Item" : null, "Text" : "completed.",  "Header" : 0}, 
{"Row" : 29, "Column" : 3, "Item" : null, "Text" : "*If Tdap is indicated,",  "Header" : 0}, 
{"Row" : 30, "Column" : 3, "Item" : null, "Text" : "Tdap should be given",  "Header" : 0}, 
{"Row" : 31, "Column" : 3, "Item" : null, "Text" : "regardless of interval",  "Header" : 0}, 
{"Row" : 32, "Column" : 3, "Item" : null, "Text" : "since previous Td.",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "*History of severe",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "allergic reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or to a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "*For Tdap only, history of",  "Header" : 0}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "encephalopathy not",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "attributable to an",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "identifiable cause, within",  "Header" : 0}, 
{"Row" : 15, "Column" : 4, "Item" : null, "Text" : "7d following DTP/DTaP, or",  "Header" : 0}, 
{"Row" : 16, "Column" : 4, "Item" : null, "Text" : "Tdap.",  "Header" : 0}, 
{"Row" : 18, "Column" : 4, "Item" : null, "Text" : "Precautions",  "Header" : 1}, 
{"Row" : 19, "Column" : 4, "Item" : null, "Text" : "*Moderate or severe acute",  "Header" : 0}, 
{"Row" : 20, "Column" : 4, "Item" : null, "Text" : "illness with or without",  "Header" : 0}, 
{"Row" : 21, "Column" : 4, "Item" : null, "Text" : "fever.",  "Header" : 0}, 
{"Row" : 23, "Column" : 4, "Item" : null, "Text" : "*History of Guillain-Barr",  "Header" : 0}, 
{"Row" : 24, "Column" : 4, "Item" : null, "Text" : "syndrome within 6wks",  "Header" : 0}, 
{"Row" : 25, "Column" : 4, "Item" : null, "Text" : "following previous dose of",  "Header" : 0}, 
{"Row" : 26, "Column" : 4, "Item" : null, "Text" : "tetanus-toxoid containing",  "Header" : 0}, 
{"Row" : 27, "Column" : 4, "Item" : null, "Text" : "vaccine.",  "Header" : 0}, 
{"Row" : 29, "Column" : 4, "Item" : null, "Text" : "*History of Arthus-type",  "Header" : 0}, 
{"Row" : 30, "Column" : 4, "Item" : null, "Text" : "reaction following a prior",  "Header" : 0}, 
{"Row" : 31, "Column" : 4, "Item" : null, "Text" : "dose of tetanus or",  "Header" : 0}, 
{"Row" : 32, "Column" : 4, "Item" : null, "Text" : "diphtheria-toxoid",  "Header" : 0}, 
{"Row" : 33, "Column" : 4, "Item" : null, "Text" : "containing vaccine",  "Header" : 0}, 
{"Row" : 34, "Column" : 4, "Item" : null, "Text" : "(including MenACWY): defer",  "Header" : 0}, 
{"Row" : 35, "Column" : 4, "Item" : null, "Text" : "vaccination until at least",  "Header" : 0}, 
{"Row" : 36, "Column" : 4, "Item" : null, "Text" : "10yrs have elapsed since",  "Header" : 0}, 
{"Row" : 37, "Column" : 4, "Item" : null, "Text" : "the last tetanus toxoid-",  "Header" : 0}, 
{"Row" : 38, "Column" : 4, "Item" : null, "Text" : "containing vaccine.",  "Header" : 0}, 
{"Row" : 40, "Column" : 4, "Item" : null, "Text" : "*For pertussis-containing",  "Header" : 0}, 
{"Row" : 41, "Column" : 4, "Item" : null, "Text" : "vaccines only, progressive",  "Header" : 0}, 
{"Row" : 42, "Column" : 4, "Item" : null, "Text" : "or unstable neurologic",  "Header" : 0}, 
{"Row" : 43, "Column" : 4, "Item" : null, "Text" : "disorder, uncontrolled",  "Header" : 0}, 
{"Row" : 44, "Column" : 4, "Item" : null, "Text" : "seizures, or progressive",  "Header" : 0}, 
{"Row" : 45, "Column" : 4, "Item" : null, "Text" : "encephalopathy until a",  "Header" : 0}, 
{"Row" : 46, "Column" : 4, "Item" : null, "Text" : "treatment regimen has been",  "Header" : 0}, 
{"Row" : 47, "Column" : 4, "Item" : null, "Text" : "established and the",  "Header" : 0}, 
{"Row" : 48, "Column" : 4, "Item" : null, "Text" : "condition has stabilized.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX UPPER RESPIRATORY INFECTIONS OP (URI)", "Contents" : [
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "Text" : "Bronchitis", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS (OPT)", "Text" : "Sinusitis", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PHARYNGITIS", "Text" : "Pharyngitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "UPPER RESPIRATORY INFECTION (URI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Upper respiratory infections include several common syndromes including",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the common cold, bronchitis (see below), pharyngitis (see below) and sinusitis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(see below). Most are caused by viruses and there is no benefit from",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy. If a patient presents with a URI, consider specific",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "infections that do respond to antimicrobial therapy like herpes simplex",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "stomatitis, pertussis or thrush. If no condition that benefits from",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy is present, antimicrobials will almost certainly not help",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "but will likely select for antimicrobial resistance and may lead to other",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "adverse effects.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Kogawa et al, General medicine, 2009, 10:7-15", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 7, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID VARICELLA VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: Subcutaneous",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient VAR orders:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "VARICELLA VIRUS VACCINE",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "INJ",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Varivax",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Varicella",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(Chickenpox, VAR)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2021,",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "174(3)374-384.",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*All adults without",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "evidence of immunity.",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : "NOTE: Evidence of immunity",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "is defined as written",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "documentation",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "of 2 doses of varicella",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "vaccine, a history of",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "varicella disease or",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "herpes zoster (shingles)",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "based on healthcare-",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "provider diagnosis,",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "laboratory evidence of",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "immunity or confirmation",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "of disease, and/or birth",  "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : null, "Text" : "in the U.S. before 1980,",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "with the exceptions that",  "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "follow:",  "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : ">>Healthcare personnel",  "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "(HCP) born in the U.S.",  "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "before 1980 who do not",  "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "meet any of the criteria",  "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "above should be tested or",  "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "given the 2-dose vaccine",  "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "series. If testing",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "indicates they are not",  "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "immune, give the 1st dose",  "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "of varicella vaccine",  "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "immediately. Give the 2nd",  "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : "dose 4-8 wks later.",  "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : ">>Pregnant women born in",  "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : "the U.S. before 1980 who",  "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : null, "Text" : "do not meet any of the",  "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : null, "Text" : "criteria above should",  "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : null, "Text" : "either 1) be tested for",  "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : null, "Text" : "susceptibility during",  "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : null, "Text" : "pregnancy and if found",  "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : null, "Text" : "susceptible, given the 1st",  "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : null, "Text" : "dose of varicella vaccine",  "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : null, "Text" : "postpartum before hospital",  "Header" : 0}, 
{"Row" : 43, "Column" : 2, "Item" : null, "Text" : "discharge, or 2) not be",  "Header" : 0}, 
{"Row" : 44, "Column" : 2, "Item" : null, "Text" : "tested for susceptibility",  "Header" : 0}, 
{"Row" : 45, "Column" : 2, "Item" : null, "Text" : "and given the 1st dose of",  "Header" : 0}, 
{"Row" : 46, "Column" : 2, "Item" : null, "Text" : "varicella vaccine post-",  "Header" : 0}, 
{"Row" : 47, "Column" : 2, "Item" : null, "Text" : "partum before hospital",  "Header" : 0}, 
{"Row" : 48, "Column" : 2, "Item" : null, "Text" : "discharge. Give the 2nd",  "Header" : 0}, 
{"Row" : 49, "Column" : 2, "Item" : null, "Text" : "dose 4-8wks later.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Give 2 doses.",  "Header" : 0}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "*Dose2 is given 4-8wks",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "after dose1.",  "Header" : 0}, 
{"Row" : 9, "Column" : 3, "Item" : null, "Text" : "*If dose2 is delayed, do",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "not start over. Just give",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "dose2.",  "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "*If 2 or more of the",  "Header" : 0}, 
{"Row" : 14, "Column" : 3, "Item" : null, "Text" : "following live virus",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "vaccines are to be given -",  "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : null, "Text" : "MMR, LAIV, Var, ZVL,",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "and/or yellow fever - they",  "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : null, "Text" : "should be given on the",  "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "same day. If they are not",  "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "given on the same day,",  "Header" : 0}, 
{"Row" : 21, "Column" : 3, "Item" : null, "Text" : "space them by at least 28d",  "Header" : 0}, 
{"Row" : 22, "Column" : 3, "Item" : null, "Text" : "(30d for yellow fever).",  "Header" : 0}, 
{"Row" : 24, "Column" : 3, "Item" : null, "Text" : "*May use as post exposure",  "Header" : 0}, 
{"Row" : 25, "Column" : 3, "Item" : null, "Text" : "prophylaxis if given",  "Header" : 0}, 
{"Row" : 26, "Column" : 3, "Item" : null, "Text" : "within 5d of exposure.",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "*History of severe",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "allergic reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or to a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "*Pregnancy or possibility",  "Header" : 0}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "of pregnancy within 4wks.",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "*People on long-term",  "Header" : 0}, 
{"Row" : 15, "Column" : 4, "Item" : null, "Text" : "immunosuppressive therapy",  "Header" : 0}, 
{"Row" : 16, "Column" : 4, "Item" : null, "Text" : "or who are",  "Header" : 0}, 
{"Row" : 17, "Column" : 4, "Item" : null, "Text" : "immunocompromised",  "Header" : 0}, 
{"Row" : 18, "Column" : 4, "Item" : null, "Text" : "because of malignancy and",  "Header" : 0}, 
{"Row" : 19, "Column" : 4, "Item" : null, "Text" : "primary or acquired",  "Header" : 0}, 
{"Row" : 20, "Column" : 4, "Item" : null, "Text" : "immunodeficiency,",  "Header" : 0}, 
{"Row" : 21, "Column" : 4, "Item" : null, "Text" : "including HIV/AIDS",  "Header" : 0}, 
{"Row" : 22, "Column" : 4, "Item" : null, "Text" : "(although vaccination",  "Header" : 0}, 
{"Row" : 23, "Column" : 4, "Item" : null, "Text" : "may be considered if CD4+",  "Header" : 0}, 
{"Row" : 24, "Column" : 4, "Item" : null, "Text" : "T-lymphocyte counts are",  "Header" : 0}, 
{"Row" : 25, "Column" : 4, "Item" : null, "Text" : "greater than or equal to",  "Header" : 0}, 
{"Row" : 26, "Column" : 4, "Item" : null, "Text" : "200 cells/mm3)",  "Header" : 0}, 
{"Row" : 28, "Column" : 4, "Item" : null, "Text" : "*People with isolated B-",  "Header" : 0}, 
{"Row" : 29, "Column" : 4, "Item" : null, "Text" : "lymphocyte deficiency may",  "Header" : 0}, 
{"Row" : 30, "Column" : 4, "Item" : null, "Text" : "receive varicella vaccine.",  "Header" : 0}, 
{"Row" : 32, "Column" : 4, "Item" : null, "Text" : "Precautions:",  "Header" : 1}, 
{"Row" : 33, "Column" : 4, "Item" : null, "Text" : "*Moderate or severe acute",  "Header" : 0}, 
{"Row" : 34, "Column" : 4, "Item" : null, "Text" : "illness with or without",  "Header" : 0}, 
{"Row" : 35, "Column" : 4, "Item" : null, "Text" : "fever.",  "Header" : 0}, 
{"Row" : 37, "Column" : 4, "Item" : null, "Text" : "*If blood, plasma, and/or",  "Header" : 0}, 
{"Row" : 38, "Column" : 4, "Item" : null, "Text" : "immune globulin (IG or",  "Header" : 0}, 
{"Row" : 39, "Column" : 4, "Item" : null, "Text" : "VZIG) were given in past",  "Header" : 0}, 
{"Row" : 40, "Column" : 4, "Item" : null, "Text" : "11m, see ACIP's Best",  "Header" : 0}, 
{"Row" : 41, "Column" : 4, "Item" : null, "Text" : "Practices Guidance",  "Header" : 0}, 
{"Row" : 42, "Column" : 4, "Item" : null, "Text" : "regarding time to wait",  "Header" : 0}, 
{"Row" : 43, "Column" : 4, "Item" : null, "Text" : "before vaccinating.",  "Header" : 0}, 
{"Row" : 45, "Column" : 4, "Item" : null, "Text" : "*Receipt of specific",  "Header" : 0}, 
{"Row" : 46, "Column" : 4, "Item" : null, "Text" : "antivirals (i.e.,",  "Header" : 0}, 
{"Row" : 47, "Column" : 4, "Item" : null, "Text" : "acyclovir, famciclovir, or",  "Header" : 0}, 
{"Row" : 48, "Column" : 4, "Item" : null, "Text" : "valacyclovir) 24hrs before",  "Header" : 0}, 
{"Row" : 49, "Column" : 4, "Item" : null, "Text" : "vaccination, if possible.",  "Header" : 0}, 
{"Row" : 50, "Column" : 4, "Item" : null, "Text" : "Delay resumption of these",  "Header" : 0}, 
{"Row" : 51, "Column" : 4, "Item" : null, "Text" : "antiviral drugs for 14d",  "Header" : 0}, 
{"Row" : 52, "Column" : 4, "Item" : null, "Text" : "after vaccination.",  "Header" : 0}, 
{"Row" : 54, "Column" : 4, "Item" : null, "Text" : "*Use of aspirin or",  "Header" : 0}, 
{"Row" : 55, "Column" : 4, "Item" : null, "Text" : "aspirin-containing",  "Header" : 0}, 
{"Row" : 56, "Column" : 4, "Item" : null, "Text" : "products.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "2 dose series", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE ONE DOSE", "Text" : "One dose", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Vaccine route, orders, names",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Route: IM",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Outpatient RZV (Shingrix)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Orders:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "CPRS name:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "ZOSTER VACCINE INJ,LYPHL",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Stocked brand name:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Shingrix",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Other names:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Zoster, Shingles",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(RZV)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Immunization Action",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Coalition,",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Summary of Adult",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Immunizations, 2021, P2011",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Freedman et al., Annals of",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "internal medicine, 2021,",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "174(3)374-384.",  "Header" : 0}, 
{"Row" : 1, "Column" : 2, "Item" : null, "Text" : "Recommended populations",  "Header" : 1}, 
{"Row" : 2, "Column" : 2, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : null, "Text" : "*People age 50yrs and",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "older",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : null, "Text" : ">>NOTE: Do not test people",  "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "age 50yrs or older for",  "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "varicella immunity prior",  "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : null, "Text" : "to zoster vaccination.",  "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "Persons born in the U.S.",  "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "prior to 1980 can be",  "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "presumed to be immune to",  "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "varicella for the purpose",  "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "of zoster vaccination,",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "regardless of their",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "recollection of having had",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "chickenpox.",  "Header" : 0}, 
{"Row" : 1, "Column" : 3, "Item" : null, "Text" : "Administration Schedule",  "Header" : 1}, 
{"Row" : 2, "Column" : 3, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 3, "Item" : null, "Text" : "*Give 2 doses of RZV,",  "Header" : 0}, 
{"Row" : 5, "Column" : 3, "Item" : null, "Text" : "separated by 2-6m,",  "Header" : 0}, 
{"Row" : 6, "Column" : 3, "Item" : null, "Text" : "regardless of previous",  "Header" : 0}, 
{"Row" : 7, "Column" : 3, "Item" : null, "Text" : "history of herpes zoster",  "Header" : 0}, 
{"Row" : 8, "Column" : 3, "Item" : null, "Text" : "(shingles) or chickenpox.",  "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "*If previously vaccinated",  "Header" : 0}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "with ZVL (Zostavax), give",  "Header" : 0}, 
{"Row" : 12, "Column" : 3, "Item" : null, "Text" : "2 doses of RZV at least 2m",  "Header" : 0}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "after ZVL.",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : null, "Text" : "*A 1-time dose of ZVL may",  "Header" : 0}, 
{"Row" : 16, "Column" : 3, "Item" : null, "Text" : "be given to previously",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "unvaccinated",  "Header" : 0}, 
{"Row" : 18, "Column" : 3, "Item" : null, "Text" : "immunocompetent adults age",  "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : null, "Text" : "60y and older: however,",  "Header" : 0}, 
{"Row" : 20, "Column" : 3, "Item" : null, "Text" : "RZV is preferred.",  "Header" : 0}, 
{"Row" : 22, "Column" : 3, "Item" : null, "Text" : "*If 2 or more of the",  "Header" : 0}, 
{"Row" : 23, "Column" : 3, "Item" : null, "Text" : "following live virus",  "Header" : 0}, 
{"Row" : 24, "Column" : 3, "Item" : null, "Text" : "vaccines are to be given -",  "Header" : 0}, 
{"Row" : 25, "Column" : 3, "Item" : null, "Text" : "LAIV, MMR, Var, ZVL,",  "Header" : 0}, 
{"Row" : 26, "Column" : 3, "Item" : null, "Text" : "and/or yellow fever - they",  "Header" : 0}, 
{"Row" : 27, "Column" : 3, "Item" : null, "Text" : "should be given on the",  "Header" : 0}, 
{"Row" : 28, "Column" : 3, "Item" : null, "Text" : "same day. If they are not,",  "Header" : 0}, 
{"Row" : 29, "Column" : 3, "Item" : null, "Text" : "space them by at least 28d",  "Header" : 0}, 
{"Row" : 30, "Column" : 3, "Item" : null, "Text" : "(30d for yellow fever).",  "Header" : 0}, 
{"Row" : 1, "Column" : 4, "Item" : null, "Text" : "Contraindications/Precautions",  "Header" : 1}, 
{"Row" : 2, "Column" : 4, "Item" : null, "Text" : "__________________________",  "Header" : 1}, 
{"Row" : 4, "Column" : 4, "Item" : null, "Text" : "Contraindications",  "Header" : 1}, 
{"Row" : 5, "Column" : 4, "Item" : null, "Text" : "*History of severe",  "Header" : 0}, 
{"Row" : 6, "Column" : 4, "Item" : null, "Text" : "allergic reaction (e.g.,",  "Header" : 0}, 
{"Row" : 7, "Column" : 4, "Item" : null, "Text" : "anaphylaxis) to a previous",  "Header" : 0}, 
{"Row" : 8, "Column" : 4, "Item" : null, "Text" : "dose or to a vaccine",  "Header" : 0}, 
{"Row" : 9, "Column" : 4, "Item" : null, "Text" : "component.",  "Header" : 0}, 
{"Row" : 11, "Column" : 4, "Item" : null, "Text" : "Precautions",  "Header" : 1}, 
{"Row" : 12, "Column" : 4, "Item" : null, "Text" : "*Moderate or severe acute",  "Header" : 0}, 
{"Row" : 13, "Column" : 4, "Item" : null, "Text" : "illness with or without",  "Header" : 0}, 
{"Row" : 14, "Column" : 4, "Item" : null, "Text" : "fever.",  "Header" : 0}, 
{"Row" : 16, "Column" : 4, "Item" : null, "Text" : "*Consider delaying",  "Header" : 0}, 
{"Row" : 17, "Column" : 4, "Item" : null, "Text" : "vaccination in pregnant",  "Header" : 0}, 
{"Row" : 18, "Column" : 4, "Item" : null, "Text" : "or lactating women", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ACUTE BACT PROSTATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 10DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 10DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACUTE BACTERIAL PROSTATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute bacterial prostatitis typically presents with dysuria and fever. The",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "prostate gland is tense, boggy, and extremely tender. The urinalysis reveals",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pyuria, and the urine culture is positive. Most cases are associated with",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "aerobic Gram-negative rods. Men with dysuria and fever but without pyuria",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and/or bacteriuria should be seen by a urologist. If there is any suspicion of",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "abscess, especially in men older than 40 years, the patient should be seen by a",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "urologist and transurethral prostate resection for drainage should be",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "considered.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Hydration, bed rest and analgesics are recommended along with these",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "antimicrobials.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat for 10-14 days",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prostatitis",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute Bacterial Prostatitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ACUTE SINUSITIS (OPT)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS MILD TO MOD", "Text" : "[CLICK HERE] for treatment of mild to moderate bacterial sinusitis", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS SEVERE", "Text" : "[CLICK HERE] for treatment of severe bacterial sinusitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACUTE SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases of acute sinusitis are viral and resolve within 10 days. Symptoms",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(nasal congestion, purulent nasal discharge, and tooth or facial pain) can be",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "treated with decongestants, analgesics, and nasal saline. Diagnosis of acute",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "sinusitis is based on the presence of at least 2 major or 1 major and at least 2",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "minor symptoms.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Major Symptoms",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "1. Purulent anterior nasal discharge",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "2. Purulent or discolored posterior nasal discharge",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "3. Nasal congestion or fullness",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "4. Facial pain or pressure",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "5. Hyposmia or anosmia",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "6. Fever",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Minor Symptoms",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "1. Headache",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "2. Ear pain, pressure or fullness",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "3. Halitosis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "4. Dental pain",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "5. Cough",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "6. Fatigue",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "If patient meets criteria above for acute sinusitis, treat with antimicrobials",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "according to the following criteria for mild to moderate or severe bacterial",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "sinusitis.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mild to moderate bacterial sinusitis",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "1. Symptoms persisting beyond 10 days",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "2. Double-sickening - Symptoms typical of viral upper respiratory infection",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "initially improving for 5-6 days then worsening with new development of fever,",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "headache or increased nasal discharge.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Severe bacterial sinusitis",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Severe signs or symptoms of high fever (>/= 102 degrees Fahrenheit, >/= 39",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "degrees Celsius) and purulent nasal discharge for 3-4 consecutive days or facial",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "pain lasting for at least 3-4 consecutive days at the beginning of illness.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ACUTE SINUSITIS MILD TO MOD", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "Text" : "[CLICK HERE] to go to acute respiratory infection symptomatic treatment menu", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 5 days", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 5DAYS", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 5 days", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 5 days", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 7DS 500MG PO QDAY", "Text" : "Levofloxacin 750 mg PO q24h ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 7DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MILD TO MODERATE SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pneumoniae, Haemophilus influenzae or Moraxella catarrhalis. Streptococci,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus and anaerobes are isolated less frequently.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment for first 10 days of illness",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat with decongestants, analgesics, and nasal saline spray.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment of cases that have not improved in 10 days despite",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treatment with decongestants, analgesics, and nasal saline.",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternatives:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment Failure",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "If symptoms worsen despite 72 hours orfail to improve after 3-5 days of",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "initial empirical antimicrobial therapy, broaden coverage, switch to different",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "antimicrobial class and treat 7-10 days. If symptoms continue to worsen or there",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "is no improvement after 3-5 more days of treatment, obtain CT to investigate",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "non-infectious or suppurative causes. ENT consultation is recommended. If",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "sinuses are aspirated, specimens should be cultured.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ACUTE SINUSITIS SEVERE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h ($) [R] for 10 days", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 5DAYS", "Text" : "Cefdinir 300 mg PO q12h ($) [R] for 10 days", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID($) [DI] for 10 days", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEVERE SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Community-acquired bacterial sinusitis is most often due to Streptococcus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pneumoniae, Haemophilus influenza or Moraxella catarrhalis. Group A",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Streptococci, Staphylococcus aureus and anaerobes are isolated less frequently.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "For patients who present with severe symptoms (high fever (>/= 102 degrees",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Fahrenheit, >/= 39 degrees Celsius) and purulent nasal discharge for 3-4",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "consecutive days or facial pain lasting for at least 3-4 consecutive days at the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "beginning of illness), initiate empiric antimicrobials and obtain CT of sinuses",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "to determine the extent of infection. If the CT shows extension of sinusitis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "infection into surrounding structures (i.e. the cranium or orbit) consult ENT",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "immediately. Closely monitor all patients who present with severe signs and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "symptoms to ensure that signs and symptoms improve within 72 hours.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Outpatient Treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternatives:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Treatment of hospitalized patient",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Treatment failure",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "If symptoms worsen or no improvement is seen after 3-5 days of treatment,",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "broaden coverage, switch to different antimicrobial class and treat 10 days. If",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "symptoms continue to worsen or there is no improvement after 3-5 more days of",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "treatment, obtain CT to investigate non-infectious or suppurative causes. ENT",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "consultation is recommended. If sinuses are aspirated, specimens should be",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "cultured.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Acute, Empiric Therapy",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute sinusitis and rhinosinusitis in adults: Clinical",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Chronic",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "rhinosinusitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 90DAYS 1DS TAB PO QDAY", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO QDAY ($) [R,DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 90DAYS 1DS TAB PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "Text" : "Ciprofloxacin 500 mg PO QDAY ($) [R,DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 500MG PO QDAY PROPHYLAXIS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SPONTANEOUS BACTERIAL PERITONITIS (SBP)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "SBP is infection of the peritoneal cavity in the absence of apparent trauma or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "other obvious cause. SBP occurs primarily in people with end-stage liver disease",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "and ascites. The diagnosis is made when a peritoneal fluid sample has >/= 250",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "polymorphonuclear leukocyte cells per microliter, or when bacterial pathogens",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "are isolated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Long-term SBP prophylaxis is indicated for patients who experience a first",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "episode of SBP. Short-term SBP prophylaxis is indicated for patients with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "variceal bleeding, or for patients who have low-protein refractory ascites (<1",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "gm albumin/dl ascitic fluid). Some give long-term antimicrobials to patients",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "with low-protein refractory ascites. Consult Gastroenterology for more",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Acute SBP",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Prophylaxis in a patient with a previous SBP episode",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Prophylaxis in a patient with cirrhosis and variceal hemorrhage",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for hospitalized patients with refractory low-protein ascites",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "(less than 1 gm/dL peritoneal fluid)",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Peritonitis, Primary: Spontaneous, Bacterial",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Spontaneous bacterial peritonitis in adults: Treatment and",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "prophylaxis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL IMMUNOSUPPRESIVE MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID ACYCLOVIR 800 MG PO BID", "Text" : "Acyclovir 800 MG PO BID ($0.40/day) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID ACYCLOVIR 800 MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID ACYCLOVIR 800 MG PO BID", "Text" : "Acyclovir 800 MG PO BID ($0.40/day) [R]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID ACYCLOVIR 800 MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Severly Immunosuppressive Chemo-immunotherapy",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Purine Analogues",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Chemotherapy with purine analogues such as fludarabine, cladribine, or",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "pentostatin results in major cellular-immunodeficiency that may outlast the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "exposure by months and enhances the risk for viral infections.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Recommend antiviral prophylaxis for patients treated with purine analogues",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "if at least one of the following risk factors is present:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "a) Second-line chemotherapy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "b) Treatment with corticosteroids",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "c) CD4 cell count <50/ul",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "d) Age >65 years",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "e) Prolonged Mild or Moderate Neutropenia: Mild<1000 Neutrophils /",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "L (Grade III neutropenia) OR Moderate: <500 Neutrophils/L",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(Grade IV neutropenia)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Recommendations:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Duration: Antiviral prophylaxis should be initiated in the first week of",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "therapy and continued until 2 months after completion of therapy.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alemtuzumab Therapy:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alemtuzumab is a potent reactivator of latent intracellular pathogens,",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "including CMV. Chemotherapy with alemtuzumab results in major cellular-",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "immunodeficiency that may outlast the exposure by months and enhances the",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "risk for viral infections. The risk of viral disease increases with the",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "intensity and duration of functional T-cell suppression experienced with",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "recipients of alemtuzumab.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Duration: Initiate antiviral prophylaxis with alemtuzumab therapy and",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "continue therapy for at least 2 months after last dose or until CD4 counts",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "are greater than or equal to 200 cells/ul, whichever is later.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Cancer Patients",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date (accessed 6-10-12)",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL IMMUNOSUPPRESIVE MALIGNANCY", "Text" : "Select for recommendations for antiviral prophylaxis", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA 2021-2022 OUTPATIENT", "Text" : "Seasonal Influenza", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "Text" : "Consult Infectious Disease", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (INPT)", "Text" : "Consult Infectious Disease", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Influenza and Other Respiratory Viruses",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Patients with active malignant disease are at higher risk for upper",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "respiratory infections due to influenza, parainfluenza or respiratory",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "syncytial virus (RSV). Although response to vaccination with the attenuate",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "influenza vaccine in patients on chemotherapy is variable, ranging",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "from 24-75%, immnunoprophylaxis with the influenza vaccine is recommended",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "patients with active malignant disease or chemotherapy, lymphoproliferative",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "disease, or multiple myeloma. In areas and seasons where influenza is",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "endemic, chemoprophylaxis can be considered in addition to vaccination in",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "exposed patients with a high risk of influenza complications.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Recommendations:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Cytomegalovirus (CMV)",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Prophylaxis and monitoring for CMV reactivation is not recommended unless",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "patient has received an allogeneic HSCT. Usually the recommendations for",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "surveillance and prophylaxis of CMV infections from the institution",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "performing the HSCT will be followed.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Recommendations:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Chronic Hepatitis B",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Reactivation of chronic hepatitis B in patients undergoing immunosuppressive",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "or antineoplastic treatment is a severe complication. Patients with positive",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "HBsAg, chronic hepatitis B infection, or a previous episode of HBV",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "reactivation who will receive immunosuppressive therapy should receive",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "prophylaxis.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Recommend routine testing for Hepatitis B prior to initiating Rituximab",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "therapy in patients.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Recommendations:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Cancer Patients",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sandherr, M et al, Annals of Oncology 17: 1051-1059, 2006", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL TYPE OF MALIGNANCY", "Text" : "Solid Tumors, Acute Leukemia, or Lymphoma", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL IMMUNOSUPPRESIVE MALIGNANCY", "Text" : "Purine analogues or Alemtuzumab", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Text" : "Stem cell transplant recipients (autologous or allogeneic)", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Text" : "Rituximab Therapy", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Herpes Simplex Virus (HSV) or Varicella Zoster Virus (VZV)", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Influenza and Other Respiratory Viruses", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Cytomegalovirus (CMV)", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Hepatitis B", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Viral infections reactivate in a small percentage of people with malignancy",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Most viral infections in patients with hematologic malignancies or solid",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "tumors result from reactivation of asymptomatic latent infections,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "predominantly of herpes viruses, including herpes simplex virus (HSV),",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "varicella zoster virus (VZV) and cytomegalovirus (CMV). Exogenous",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "respiratory tract infections caused by influenza, parainfluenza",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "or respiratory syncytial virus (RSV) are less common.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "The main risk factor for clinically relevant reactivation is profound",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "disruption of cellular immune response, usually due to chemotherapy.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "The duration and severity of neutropenia are of lesser importance.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "The risk of viral disease increases with the intensity and duration",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "of functional T-cell suppression. Patients receiving conventionally",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "dosed chemotherapy regimens for solid tumors experience no major",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "T-cell suppression and do not have a higher incidence of",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "invasive viral infections.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "This section is organized mainly by type of malignancy.",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "There are separate sections for purine analogues (fludarabine,",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "cladribine, pentostatin), alemtuzumab and rituximab.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Select below for recommended antiviral prophylaxis:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "This section is organized by virus.",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Select below for recommended antiviral prophylaxis:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Cancer Patients",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL STEM CELL MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL INFECTION MALIGNANCY", "Text" : "Select for Hepatitis B recommendations", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Stem cell transplant recipients (autologous or allogeneic)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Usually the standard prophylaxis and monitoring strategies recommended",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "by the institution performing the stem cell transplant will be",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "followed.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Consult Hematology-Oncology or Infectious Disease for recommendations.",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Rituximab Therapy",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Recommend routine testing for Hepatitis B prior to initiating treatment",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "with Rituximab.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Vega, J et al, J Clin Oncol 26: 2008 (May 20 suppl, abstract 8558)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL TREATMENT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSOZID2 OSELTAMIVIR 75MG PO BID 5 DAYS TREAT", "Text" : "Oseltamivir 75 mg po bid for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSHZID3 OSELTAMIVIR 75MG PO BID 5 DAYS TREAT", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Antiviral Therapy Recommendations:",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Who to Treat:",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "The decision to treat should be based on clinical symptoms and/or presence of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "a high risk condition, and should NOT be delayed until laboratory test",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "results are available.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "It is important to use antiviral drugs early to treat influenza in people who",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "are very sick with influenza (for example hospitalized people) and people who",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "are sick with influenza and have a greater chance of getting severe",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "complications. If a patient is not in a high-risk group or is not hospitalized,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "healthcare providers should use clinical judgment to guide treatment decisions.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "People who have a greater chance of serious influenza complications include:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "*Persons who have chronic pulmonary (including asthma) or cardiovascular",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "(except isolated hypertension), renal, hepatic, hematologic, metabolic",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "disorders (including diabetes mellitus), neurologic and",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "*Persons who are immunocompromised due to any cause (including immunosuppresion",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "caused by medications or by HIV infection)",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "*Women who are or will be pregnant during the influenza season",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "*Persons younger than 19 years of age who are receiving long-term aspirin-",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "or salicylate-containing medications and who might be at risk for experiencing",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Reye syndrome after influenza virus infection",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "*Residents of nursing homes and other long-term care facilities",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "*American Indians/Alaska Natives",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "*Persons who are extremely obese (BMI greater than or equal to 40)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Antiviral Treatment:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "If indicated, antivirals should be started as soon as possible.Maximal",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "benefit occurs when started within 48 hours of symptom onset.However,",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "antivirals should not be withheld if symptoms began more than 48 hours prior",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "and the patient meets criteria for treatment and remains severely ill.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "CDC is recommending for this influenza season.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "The adamantanes (amantadine and rimantadine) are not recommended for",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "treatment or chemoprophylaxis this influenza season.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Treatment Dosing:",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Zanamivir is not recommended for patients with chronic respiratory disease such",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "as asthma or chronic obstructive pulmonary disease. These patients may have",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "bronchospasm with zanamivir. If zanamivir must be used, and patients are using",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "an inhaled bronchodilator, zanamivir should be taken just after the",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "bronchodilator.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Recommended:",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Requires Infectious Disease Approval",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Zanamivir 2 inhalations (2 x 5 mg) BID for 5 days ($) [O]",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Centers for Disease Control (CDC) (Accessed 9/8/21)",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Up-to-date online: Treatment of influenza in adults",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Yoo JW, J Med Virol. (2015) 87(10):1649-1655",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "*Adults aged 65 years and older",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "neuro-developmental disorders",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "(https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm)",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Baloxavir 80 mg PO x1 dose patients wt 80kg or greater, 40mg PO x1dose for",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "patients wt <80kg ($$$) [O]",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "The neuraminidase inhibitors (oral oseltamivir, inhalded zanamivir, and",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "intravenous peramivir) and oral baloxavir are the antiviral medications the",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to tolerate or absorb oral oseltamvir:",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Peramivir 600 mg IV once ($$$$$) [R]",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Requires Infectious Disease Approval",  "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Uyeki TM, Clin Infect Dis. (2019) 68(6):895-902",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Extending the duration of treatment for oseltamivir or peramivir may be",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "needed for those patients with prolonged illness or who are immunosuppressed.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ANTIVIRAL TYPE OF MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF ANTIVIRAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Solid Tumors",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "No Antiviral Prophylaxis Recommended",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Solid tumors do not significantly compromise the cellular immune system.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Therefore, patients are at low risk for opportunistic viral infections.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Documented invasive viral infections are very rare. Coincidental",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "mucocutaneous infections by herpes simplex are easily treated and do not",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "result in life-threatening invasive infections. Reactivation of",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) is rarely observed.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Acute Leukemia",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "No Antiviral Prophylaxis Recommended",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "In patients with acute leukemia, treatment is highly aggressive and consists",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of a combination of various cytotoxic agents administered in sequential",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "cycles as induction, consolidation and maintenance therapy. Persistent, i.e.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : ">10 days and profound neutropenia (<500 neutrophils) regularly occurs and",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "correlates with the risk of developing fever and infections. Almost all viral",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "infections during neutropenia constitute reactivations of herpes viruses.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "None of the available studies demonstrated an effect of antiviral prophylaxis",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "on the initiation of antibiotic treatment, number of febrile days, duration",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "of antibiotic treatment, and onset of opportunistic infections. Therefore,",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "recommendation for antiviral prophylaxis in patients with acute leukemia can",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "be given.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Lymphoma",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "No Antiviral Prophylaxis Recommended",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Rituximab is a monoclonal anti-CD-20 antibody used for treatment of",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "lymphomas. It leads to a profound depletion of circulating B-cells. B-cell",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "recover usually within 3-6 months after treatment. Prolonged administration",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "of rituximab (e.g., maintenance treatment >12 months) may result in a",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "significant decrease of levels of immunoglobulin M. Parvovirus B19 and JC-",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "papovavirus infections have been reported with maintenance rituximab therapy",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "but drugs that would prevent these infections are not available. There is",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "substantial increase in risk of reactivation of herpes viruses (including",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "HSV, VZV, and CMV).",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Recommend routine testing for Hepatitis B prior to initiating Rituximab",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "therapy in patients.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Prophylaxis and Empirical Therapy of Infection in",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Cancer Patients",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date (accessed 6-10-11)",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Sandherr,M et al, Annals of Oncology 17: 1051-1059, 2006", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU APPENDICITIS W/ PERFORATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPENDICITIS WITH PERFORATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU APPENDICITIS W/O PERFORATION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "APPENDICITIS WITHOUT PERFORATION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Acute Respiratory Infection (ARI) Symptomatic Therapy",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Per CDC: Antibiotics Aren't Always the Answer. Be Antibiotics Aware.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antibiotics do not work on viruses, such as colds and flu, or runny noses,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "even if the mucus is thick, yellow or green. Antibiotics also won't help",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "some common bacterial infections including most cases of bronchitis, many",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "sinus infections, and some ear infections. When antibiotics aren't needed,",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Antitussive Therapy:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID GUAIFENESIN DM 10ML Q4H PRN COUGH", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID GUAIFENESIN W/CODEINE 10ML Q4HPRN COUGH", "Text" : "", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Wheezing:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID ALBUTEROL ORAL INHL I2P Q6H PRN", "Text" : "", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Pain and/or Fever:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID ACETAMINOPHEN 650MG PO Q6H PRN", "Text" : "", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID IBUPROFEN 400 MG PO Q6H PRN", "Text" : "", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Throat Pain:",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Nasal Congestion:",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : "PSOZID PSEUDOEPHEDRINE 60MG PO Q6H PRN NASAL CONG", "Text" : "", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Rhinorrhea and Sneezing:",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : "PSOZID IPRATROPIUM BR 0.06% NASAL 2 SPRAYS EN QID", "Text" : "", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Rhinorrhea:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID OXYMETAZOLINE 0.5% NASAL 2 SPRAYS EN BID FOR 3DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSOZID SALINE NASAL SPRAY 2 SPRAYS EN Q1H PRN", "Text" : "", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID THROAT LOZENGE Q1H PRN", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "they won't help you, and the side effects could still hurt you. Reactions",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "ARI: Symptom-based therapy represents the mainstay of treatment.",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : "PSOZID CETIRIZINE 10MG PO QDAY POSTNASAL DRIP", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID BENZONATATE 100MG PO TID PRN 10DS", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "from antibiotics cause 1 out of 5 medication-related visits to ED.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Please select only one item from each symptom category patient experencing.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX URL CDC ANTIBIOTICS AREN'T THE ANSWER", "Text" : "<Link> CDC Print Pamphlet-Antibiotics aren't always the answer", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Select links below to print educational material for patient:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX URL RX PRESCRIPTION FOR VIRUSES", "Text" : "<Link> CDC Print Pamphlet-Symptomatic RX for Acute Respiratory Infections", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "Contact Antimicrobial Stewardship/CDSS Team", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID GUAIFENESIN DM 10ML Q4H PRN COUGH", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID GUAIFENESIN W/CODEINE 10ML Q4HPRN COUGH", "Text" : "Non-VA for above (*Controlled Substance: Requires written prescription*)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID BENZONATATE 100MG PO TID PRN 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID ALBUTEROL ORAL INHL I2P Q6H PRN", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSHZID ACETAMINOPHEN 650MG PO Q6H PRN", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSHZID IBUPROFEN 400 MG PO Q6H PRN", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSHZID THROAT LOZENGE Q1H PRN", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSHZID SALINE NASAL SPRAY 2 SPRAYS EN Q1H PRN", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSHZID CETIRIZINE 10MG PO QDAY POSTNASAL DRIP", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSHZID PSEUDOEPHEDRINE 60MG PO Q6H PRN NASAL CONGESTION", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSHZID IPRATROPIUM BR 0.06% NASAL 2 SPRAYS EN QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSHZID OXYMETAZOLINE 0.5% NASAL 2 SPRAYS EN BID FOR 3DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "___________________________________________________________________", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "Text" : "Community acquired pneumonia (CAP)< OR >", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU LUNG ABSCESS", "Text" : "Lung abscess", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ASPIRATION PNEUMONIA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Aspiration of oropharyngeal or gastric contents induces inflammation and is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "often accompanied by fever and/or an infiltrate.Bacterial pneumonia occurs in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "a minority of patients who aspirate, typically about 3 days later.The patient",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "usually improves for the first 2 days and then worsens as bacterial pneumonia",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "develops with increased fever, new or progressive infiltrates, leukocytosis, and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "newly purulent sputum.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antimicrobials have no role for treatment of aspiration and their use entails",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "risk of side effects and selection of resistant organisms.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Antimicrobials used for community-acquired pneumonia are appropriate for cases",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "that develop after an episode of aspiration.For more information, consult",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pulmonary or Infectious Diseases.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for patients with pneumonitis but WITHOUT LUNG ABSCESS or putrid",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "sputum",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Therapy directed towards anaerobic pathogens is usually unnecessary.If",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "pneumonia is confirmed, treat as",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Refer to Nosocomial Pneumonia in the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treament for patients WITH LUNG ABSCESS",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Chastre J JAMA 2003, 290:2588",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Dennesen PJ Am J Respir Crit Care Med 2001, 163: 1371",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Kalil AC et al Clin Infect Dis 2016, 63:1",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Luna CMCrit Care Med 2003, 31: 676",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious Diseases",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell LA Clin Infect Dis 2003,37:1405",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Roig JJ Antimicrob Chemother 2003, 51: 1119", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ASYMP BACTERIURIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU SURG UROLOGICAL PROCED", "Text" : "Antimicrobial prophylaxis for urological procedures", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID for 7 days ($) [R,O] CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 3DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO TID for 3 days ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 3DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 3DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID for 3 days ($) [R]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 3DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 250MG PO ONCE POST-COITUS 30DS", "Text" : "Cephalexin 250 mg PO x 1 dose post-coitus ($) [R]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 250MG PO ONCE POST-COITUS 30DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 100MG PO ONCE POST-COITUS 30DS 1RF", "Text" : "Nitrofurantoin SA 100 mg PO x 1 dose post-coitus ($) [R,O]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 NITROFURANTOIN SA 100MG PO ONCE POST-COITUS 30DS 1RF", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 250MG PO QHS 30DS 1RF", "Text" : "Cephalexin 250 mg PO at bedtime ($) [R]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 250MG PO QHS 30DS 1RF", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 30DS 100MG PO QHS 1RF", "Text" : "Nitrofurantoin SA 100 mg PO at bedtime ($) [R,O] CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "PSHZID2 NITROFURANTOIN SA 30DS 100MG PO QHS 1RF", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ASYMPTOMATIC BACTERIURIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Asymptomatic bacteriuria is common and harmless in most people. Asymptomatic",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "bacteriuria is common in middle-aged and older people, especially in people with",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "chronic medical problems. Patients with no symptoms of cystitis (i.e., no",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "dysuria, pain, urgency) should not be treated. The presence of pyuria (>7",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "wbc/hpf) or positive leukocyte esterase, urine nitrate, or urine bacteria s not",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "a sufficient indication for antibiotic treatment. Treatment is indicated for",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "pregnant women, patients who will have urological procedures and post-renal",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "transplant patients. If a Foley catheter is in place and can be removed safely,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "it should be done. The bacteriuria may clear.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Patients having urological procedures",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Pregnant women",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Bacteriuria in pregnant women is associated with pyelonephritis, premature",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "delivery, and lower birth weight. Screening for bacteriuria is recommended at",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "least x 1 dose early in pregnancy. If bacteriuria is not found upon initial",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "testing, further screening cultures are not needed. If bacteriuria (>10,000",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "CFU/mL) is present, the patient should be treated. Testing should be repeated",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "throughout the pregnancy to detect recurrences. Suppressive therapy (see below)",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "is used for patients with 2 or more recurrences of bacteriuria during a",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "pregnancy.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Initial treatment of pregnant women with bacteriuria",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Avoid nitrofurantoin in 3rd trimester due to risk of hemolytic anemia in newborn",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treat for 5 to 7 days",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Treat for 3 to 7 days.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Suppressive therapy treatment of pregnant women with bacteriuria",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Suppressive therapy is indicated for pregnant women with more than 2 or more",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "episodes of bacteriuria.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Use post-coital dosing if infection is associated with intercourse",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "If infection is not associated with intercourse",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary Tract Infections",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Nicolle LE Clin Infect Dis 2005, 40: 643",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bacteriuria, Asymptomatic",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Urinary tract infections and asymptomatic bacteriuria in",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "pregnancy",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Approach to the adult with asymptomatic bacteriuria",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "US Preventive Services Task Force (USPSTF): Final recommendation statement on",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "asymptomatic bacteriuria in adults - Screening (2008)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ GTX ABX RESOURCE QTC", "Text" : "Please Click Here for Resource for Drugs that Cause QTc Prolongation", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ GMENU COPD OUTPATIENT ORDERS", "Text" : "COPD OUTPATIENT GUIDELINES", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSOZIDAZITHROMYCIN LONGTERM COPD PULM", "Text" : "Azithromycin 250 mg po daily for COPD prophylaxis ($/day) [DI]", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN LONGTERM COPD PULM", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Azithromycin for Prevention of Exacerbations in Advanced COPD",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Daily azithromycin prevents chronic obstructive pulmonary disease (COPD)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "exacerbations in people with advanced COPD (Albert et al, see below).",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Of note, in the study there was no benefit in the most severely ill",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "subgroup that was on the most pulmonary medications.People",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "with frequent exacerbations have more doctor visits and hospitalizations then",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "people with fewer or no exacerbations.Frequent exacerbations are associated",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with rapid decline in lung function and quality of life and increased risk",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "death.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "To receive daily azithromycin, patients must meet the following criteria and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "receive approval from pulmonary service.The evidence that benefits of daily",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "azithromycin outweigh risks is limited to people who meet the following",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "criteria.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Eligibility Criteria:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "*Age >40 years",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "*Clinical diagnosis of COPD (>= 10 pack-years cigarette smoking, a ratio of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "postbronchodilator forced expiratory volume in 1 second [FEV1] to forced",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "vital capacity of <70%, and a postbronchodilator FEV1 of <80% of the",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "predicted value), *AND*",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "*Were either using continuous supplemental oxygen or had received systemic",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "glucocorticoids within the previous year, *OR*",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "*Had gone to an emergency room or had been hospitalized for an acute",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "exacerbation of COPD.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Exclusion criteria:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "*Asthma",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "*People with hearing impairments",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "*Congestive Heart Failure",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "*Resting heart rate > 100 beats per minute",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "*Use of medications that are associated with torsades de pointes (with the",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "exception of amiodarone)",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "*Prolonged QTc interval (>450 msec)",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "*Use of medications that prolong the QTc interval",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "If, after trying all of the standard treatments, patients are still having",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "acute exacerbations of COPD, long-term antibiotic treatment with Azithromycin",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "may be considered.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Note: Guidelines for COPD can be found on the CPRS Tools Menu.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Select below for Outpatient COPD order sets for comprehensive management:",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "If the patient meets the criteria and is willing to have audiometric testing",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "and an electrocardiogram, please place a Pulmonary Consult for long-term",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Azithromycin therapy for the prevention of exacerbations of COPD.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Pulmonary is the only approved provider for ordering long-term",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Azithromycin therapy for COPD.",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Albert, RK, et al, Azithromycin for Prevention of Exacerbations of COPD.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "England Journal of Medicine 2011, 365:689-698",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Ray, WA, et al, Azithromycin and the Risk of Cardiovascular Death.New",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "England Journal of Medicine 2012: 366:1881-1890", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BACTEREMIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTEREMIA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BACTERIAL VAGINOSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 METRONI 7DS 500MG PO BID", "Text" : "Metronidazole 500 mg PO BID for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 METRONI 7DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 METRONIDAZOLE 0.75% VAG GEL 1 APPL INTRAVAG QHS 5DS", "Text" : "Metronidazole topical gel, contents of 1 applicator intravaginally at", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 METRONIDAZOLE 0.75% VAG GEL 1 APPL INTRAVAG QHS 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 7DS 300MG PO BID", "Text" : "Clindamycin 300 mg PO BID for 7 days ($) [H,O]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 7DS 300MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN PHOSPHATE VAG 2% CRM 5GM QHS 7DS", "Text" : "Clindamycin phosphate vaginal cream 5 gram (contents of 1 applicator)", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN PHOSPHATE VAG 2% CRM 5GM QHS 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTERIAL VAGINOSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Vaginitis usually presents with discharge, itching, irritation, odor, or pain.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Bacterial vaginosis is the most common form of vaginitis. The vaginal flora is",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disrupted by one or more of the following common pathogens: Gardnerella",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "vaginalis, Mycobacterium hominis, or Gram-negative anaerobes. Vaginal pH should",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "be measured and the specimen should be examined under the microscope.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "The vaginal pH is greater than 4.5, the discharge is homogenous and gray-white,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "and the specimen has a positive amine or whiff test characterized by a fishy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "odor before or after addition of 10% KOH.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "bedtime for 5 days ($)[DI]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternatives",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "intravaginally at bedtime for 7 days ($) [H,O]",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bacterial Vaginosis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Bacterial Vaginosis Treatment", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BED BUGS (HEMIPTERA)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSOZID2 TRIAMCINOLONE 0.1% CRM TOP BID PRN 10DAYS", "Text" : "Triamcinolone 0.1% cream apply to affected area BID PRN for itching ($)[M]", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSHZID2 TRIAMCINOLONE 0.1% CRM TOP BID PRN 10DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 HYDROXYZINE PAMOATE 25MG PO TID THEN 25 TID PRN", "Text" : "Hydroxyzine pamoate 25 mg PO TID until symptoms resolve, then take 25 mg PO", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 HYDROXYZINE PAMOATE 25MG PO TID THEN 25 TID PRN", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BED BUGS (HEMIPTERA)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment is not indicated.Treat itching with topical",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "corticosteroids or systemic antihistamines.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "TID PRN for itching ($) [H]",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BELL PALSY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "Text" : "Lyme Disease", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP PRED 60MG QID PO 7D VALACYC 1000MG PO Q8H 7D", "Text" : "Prednisone 60 mg q24h PO for 7 days <AND> valacyclovir 1000 mg PO q8h ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX NV PRED 60MG QID PO 7D VALACYC 1000MG PO Q8H 7D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP PRED 60MG QID PO 7D ACYCL 400MG PO Q6H 10D", "Text" : "Prednisone 60 mg q24h PO for 7 days <AND> acyclovir 400 mg PO q6h ($) [R] for 10", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX NV PRED 60MG QID PO 7D ACYCL 400MG PO Q6H 10D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BELL'S PALSY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Herpes simplex and varicella-zoster are possible causes of Bell's palsy. Others",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "include Borrelia burgdorferi trauma. Some cases are idiopathic. Risk factors for",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Bell's Palsy include pregnancy, diabetes, obesity, hypertension, and upper",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "respiratory infections. Neurology consult is encouraged.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "If Lyme disease is suspected, refer to the Lyme disease treatment page:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment with prednisone and an antiviral within 72 hours of symptoms onset",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "improves the chances of a complete recovery.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "for 7 days",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "days",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Baugh et al., Otolaryngology-Head and Neck Surgery, 2013, 149(3S)S1-S27",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Eviston et al., J Neurol Neurosurg Psychiatry, 2015, 56.1356-1361",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Jalali et al., Laryngoscope, 2021, 131.1615-1625",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Antivirals against Herpes Viruses",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes Simplex, Bell's Palsy",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Schwartz et al., Otolaryngology-Head and Neck Surgery, 2014, 150(5)709-711",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Bell's palsy: Treatment and prognosis in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BITE WNDS EIKENELLA CORRODENS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH EIKENELLA CORRODENS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BITE WNDS METH RES S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 10DS 100MG PO BID", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 14DS 100MG PO BID", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BITE WNDS METH SUSC S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 10DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]< OR >", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 10DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 10DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 10DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]< OR >", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 14DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]< OR >", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 14DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 DICLOX 14DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 DICLOX 14DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH METHICILLIN-SUSCEPTIBLE STAPHYLOCOCCUS AUREUS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treat for 14-21 days.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BITE WNDS P. MULTOCIDA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Doxycycline 100mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH PASTEURELLA MULTOCIDA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BITE WNDS STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 10DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]< OR >", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 10DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 10DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($0.48/day) [DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 10DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 10DS 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID for 10 days ($) [H,O]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 10DS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 14DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]< OR >", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 14DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 DICLOX 14DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 DICLOX 14DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 14DS 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID for 14 days ($) [H,O]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 14DS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS WITH STREPTOCOCCI",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection but no arthritis - 10 days joint involved - 14-21 days",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment for infection without joint involvement",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment for infection with joint involvement",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "__________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BITE WOUNDS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, Diphtheria and Acellular Pertussis Vaccine Information Page", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "Text" : "Moxifloxacin 400 mg PO QDAY for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 5DS 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 10DS 400MG PO QDAY", "Text" : "Moxifloxacin 400 MG PO qday for 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 10DS 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS P. MULTOCIDA", "Text" : "Pasteurella multocida", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS EIKENELLA CORRODENS", "Text" : "Eikenella corrodens", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS METH SUSC S. AUREUS", "Text" : "Methicillin-susceptible Staphylococcus aureus", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS METH RES S. AUREUS", "Text" : "Methicillin-resistant Staphylococcus aureus", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU BITE WNDS STREPTOCOCCI", "Text" : "Streptococci", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BITE WOUNDS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Bite wounds are prone to infection because of the pathogenic oral flora carried",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "into tissuesby teeth.Common pathogens include Eikenella corrodens, usually",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "from human bites, and Pasteurella multocida, often from dog or cat bites",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "streptococci and staphylococci.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Clean wounds with soap and water as soon as possible, add local antiseptic",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and debride non-viable tissue.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Consult Orthopedic surgery for all bite wounds involving the hand.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Antibiotic Prophylaxis Indications:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Severe injury less than 8 hours, Crush injury, Bone or joint penetration,",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Wound of the face or hands or genitals, Immunocompromised host, Asplenia,",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Advanced liver disease",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "*Routine use of prophylactic antibiotics for non-immunocompromised patients",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "with superficial wounds with no puncture that do not involve the face/",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "genitals/hands is not recommended.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Treatment:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Empiric treatment for suspected or established infection following bite wound",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "In these cases, therapy should be directed against pathogen indentified",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "by Gram stain and culture whenever possible.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Rabies Prophylaxis:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Consider rabies post-exposure prophylaxis for all animal bite cases.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Contact Infectious diseases for assistance.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Consider tetanus immunization status:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "If immunization is up to date, nothing more needs to be done to prevent tetanus.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "If immunization is lacking, and:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "wound IS NOT tetanus prone, bring immunization up to date with Td",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "wound IS tetanus prone, bring immunization up to date with Td< AND >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Human Tetanus Immune Globulin Inject 250 units deeply into muscle (deep IM)",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Select below for Tetanus vaccination information page:",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Treat deep wounds for the first 3-5 days after a bite to prevent infection.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "For wounds that later develop evidence of infection but without arthritis, treat",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "with antimicrobials for 7-14.For wounds that develop infection of a joint,",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "treat 14 to 21 days.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Prophylaxis:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Duration 3 to 5 days:",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with penicillin allergy:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Empiric treatment for suspected or estabished infection:",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Duration 7 to 14 days:",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with penicllin allergy:",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Pathogen-directed bite wound therapy",  "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Bites",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Abrahamian FM New Engl Journ Med 1999, 340:85", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "Text" : "Permethrin 1% lotion Apply to affected area for 10 minutes then comb out", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BODY LICE (PEDICULOSIS CORPORIS)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Body lice proliferate in places where crowding of persons with poor hygiene",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "common, especially homeless persons.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Infested clothing and bed linen should be heat washed or discarded.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Itching is the most common symptom, but some patients present only with",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "excoriations and inflammation on the neck and trunk.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "A repeat application may be used if live lice are seen 7-10 days after",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "treatment.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "nits ($) [M]",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: lice",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU BRONCHITIS NEW", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU PERTUSSIS", "Text" : "Pertussis", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX BRONCHITIS NOT BENEFIT", "Text" : "Bronchitis-antibiotics not a benefit in otherwise healthy patient", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 5DS 100MG PO BID BRONCHITIS", "Text" : "Doxcycline 100 mg PO BID for 5 days ($) [DI]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 5DS 100MG PO BID BRONCHITIS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2 TMP/SMX 5DAYS 1DS TAB BID BRONCHITIS", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSHZID2 TMP/SMX 5DAYS 1DS TAB BID BRONCHITIS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO once on day one then 250 mg PO qday for 4 days ($) [M]", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Amoxicillin-clavulanate 875-125 mg PO BID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 5DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BRONCHITIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis should not be treated with antimicrobials except in specific",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "circumstances. If pneumonia is suspected, order a chest x-ray.If an",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infiltrate is not present, the patient does not have bacterial pneumonia and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "need not be treated for it.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis in an otherwise HEALTHY PATIENT",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Antimicrobials provide no benefit.If bronchitis persists beyond 2 weeks,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "additional diagnostic workup is needed to find a cause.If a patient has",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "persistent cough with inspiratory whoop, consider a diagnosis of pertussis.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "For symptomatic treatment dextromethorphan and benzonatate combined with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "guaifenesin has shown some benefit. Benzonatate and guaifenesin",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "alone did not show benefit. Also, allergy medicines and codeine",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "do not appear to help the symptoms.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Acute bronchitis in patients with COPD",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Symptoms of COPD exacerbation include dyspnea with increased sputum purulence",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "and volume, together with increased cough and wheeze. Co-morbidities are",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "common in COPD patients, thus exacerbations must be differentiated clinically",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "from other events such as acute coronary syndrome, worsening heart failure,",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "pulmonary embolism and pneumonia.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Cornerstones of therapy include oxygen, bronchodilators, and in some cases",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "corticosteroids. Recommend antibiotics for moderately or severely ill patients",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "with COPD exacerbation who have increased sputum purulence and volume.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Treatment for MILD DISEASE:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "No antibiotics recommended",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Treatment for MODERATE DISEASE",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treat for 5 to 7 days.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Treatment for SEVERE DISEASE",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "NOTE: Fluoroquinolones are not listed as a choice because the risk of serious",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "side effects outweigh the benefits.",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Access: http://www.goldcopd.org",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Wenzel WP et al NEJM 2006, 355: 2125",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bronchitis",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bronchitis",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Murphy TF Chest 2000, 118: 204",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Masterton RG Int J Antimicrob Agents 2001, 18: 503", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 150MG PO ONCE", "Text" : "Fluconazole 150 mg PO x 1 dose ($) [R,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 150MG PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 CLOTRIMAZOLE VAG 1% CRM 1 APP QHS 7DS", "Text" : "Clotrimazole vaginal 1% cream 1 applicator full at bedtime for 7 to 14 days", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 CLOTRIMAZOLE VAG 1% CRM 1 APP QHS 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 TERCONAZOLE 0.4% VAG CRM QHS 7DS", "Text" : "Terconazole 0.4% vaginal cream 1 applicator full at bedtime for 7 days ($)", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 TERCONAZOLE 0.4% VAG CRM QHS 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 150 MG PO Q72H 7DS", "Text" : "Fluconazole 150 mg PO every 3 days for 7 days (3 doses) ($) [R,DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 150 MG PO Q72H 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID2 CLOTRIMAZOLE VAG 1% CRM 1 APP QHS 10DS", "Text" : "Clotrimazole vaginal 1% cream 1 applicator full at bedtime for 10-14 days", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSHZID2 CLOTRIMAZOLE VAG 1% CRM 1 APP QHS 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID2 TERCONAZOLE 0.4% VAG CRM QHS 10DS", "Text" : "Terconazole 0.4% vaginal cream 1 applicator full at bedtime for 10-14 days", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSHZID2 TERCONAZOLE 0.4% VAG CRM QHS 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 150MG PO QWEEK 6MO", "Text" : "Fluconazole 150 mg PO QWEEK for 6 months ($) [R,DI]", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 150MG PO QWEEK 6MO", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA VULVOVAGINITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "The vaginal pH is 3.5 to 3.8. The discharge is typically thick and curdy.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Diagnosis is confirmed by identifying fungus or yeast with KOH prep.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Recurrent candida vulvovaginitis is treated as complicated candida",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "vulvovaginitis for induction treatment, followed by maintenance regimen for 6",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "months.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Most non-C. albicans species respond to fluconazole treatment except C. krusei",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "and C. glabrata. C. krusei can be treated with topical agents as for complicated",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "candida vulvovaginitis below. C. glabrata treatment is complicated and azole",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "therapy is frequently unsuccessful. Consult Infectious Diseases (outpatient) in",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "patients with C. glabrata vulvovaginitis.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for uncomplicated candida vulvovaginitis",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "($) [M]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "[M]",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Treatment for complicated candida vulvovaginitis (immunocompromised, severe",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "disease) or recurrent infection induction treatment",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "($) [M]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "($) [M]",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Recurrent candida vulvovaginitis maintenance regimen following induction",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "treatment above",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Treatment for C. glabrate vulvovaginitis",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Failure of azole therapy is common, alternative topical treatments below require",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "compounding by a pharmacist. Please call pharmacy (x3128) to order.",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Topical flucytosine cream (17%) QDAY for 14 days",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Topical boric acid capsule 600 mg intravaginal QDAY for 14 days",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "IDSA Guidelines: Pappas et al, Clin Infect Dis (2016) 62.409",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Vulvovaginitis",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Candida Vulvovaginitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CAP TREATED IN OUTPT SETTING", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 PNA DOXYCYCLINE 100MG PO BID 5DAYS", "Text" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 PNA DOXYCYCLINE 100MG PO BID 5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 PNA AMOXICILLIN 1000MG PO TID X5DAYS", "Text" : "Amoxicillin 1000 mg PO TID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 PNA AMOXICILLIN 1000MG PO TID X5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP PNA AMOX-CLAV 875/125 BID AZITH 500 THEN 250", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX NV PNA AMOX-CLAV 875/125 BID AZITH 500 THEN 250", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZ SET ABX OP PNA CEFDINIR 300MG PO BID AZITH 500 THEN 250", "Text" : "Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Azithromycin", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZ SET ABX NV PNA CEFDINIR 300MG PO BID AZITH 500 THEN 250", "Text" : "NON-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP PNA AMOX-CLAV 875/125 BID DOXY 100MG BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 5 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX NV PNA AMOX-CLAV 875/125 BID DOXY 100MG BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX OP PNA CEFDINIR 300MG BID DOXY 100MG BID", "Text" : "Cefdinir 300 mg PO BID for 5 days ($) [R] <AND> Doxycycline", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX NV PNA CEFDINIR 300MG BID DOXY 100MG BID", "Text" : "Non-VA for above", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "[Link] Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2 PNA LEVOFLOXACIN 5DS 750MG PO QDAY", "Text" : "Levofloxacin 750 mg PO QDAY for 5 days($)[R,DI]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSHZID2 PNA LEVOFLOXACIN 5DS 750MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP) TREATED IN AN OUTPATIENT SETTING",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Preferred outpatient treatment for PREVIOUSLY HEALTHY PATIENT:",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "(WITHOUT chronic obstructive pulmonary disease, diabetes, renal failure,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "conditions, or use of immunosuppressing drugs)",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Outpatient and UNcomplicated:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred outpatient treatment for PATIENTS WITH COMORBIDITIES:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "(WITH chronic obstructive pulmonary disease, diabetes, renal failure,",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "congestive heart failure, malignancy, alcoholism, asplenia, immunosuppressing",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "conditions, or use of immunosuppressing drugs)",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Outpatient and comorbidity:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Azithromycin 500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "500 mg po once on day 1, then 250mg PO QDAY for 4 days ($) [M]",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Doxycycline 100 mg PO BID for 5 days ($) [DI]",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "100 mg PO BID for 5 days ($) [DI]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Metlay JP, Am J Respir Crit Care Med. 2019, 200(7):e45",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Sanford: Community Acquired Pneumonia",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CARDIOVASCULAR",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Section last reviewed9/2020", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU CAT-SCRATCH DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO x 1on day 1, then 250 mg PO QDAY for 4 days ($) [M]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CAT-SCRATCH DISEASE",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Cat-scratch disease occurs when a cat infected with Bartonella henselae",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "scratches or bites a person or licks a person's open wound.A local pustule",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "develops followed by lymphadenopathy, typically on the same side of the body as",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "the scratch or bite.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Infections associated with other pathogens such as Francisella tularemia,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Coxiella burnetiid and other slow-growing bacteria may present with similar",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "symptoms.Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "About 10% of cases of cat-scratch disease present atypically with symptoms",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "involving the eye, nervous system, or lungs.Consult Infectious Diseases in",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "these cases.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bartonella, including cat-scratch disease",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: cat-scratch disease",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CDIFFICILE COLITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU INI EPISODE ABX ASSOC COLITIS", "Text" : "Initial Episode", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU FIRST RECURRENCE ABX ASSOCIATED COLITIS", "Text" : "First Recurrence", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU SECOND RECURRENCE CDIFF COLITIS", "Text" : "Second Recurrence", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CLOSTRIDIUM DIFFICILE INFECTION [CDI]",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Discontinue implicated antibiotic and avoid high risk antibiotic if antibiotic",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "therapy is still needed. Discontinue laxatives. Reassess need for tube feeds. C.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "difficile PCR testing should be completed to confirm diagnosis of C. difficile",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "infection.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Antibiotic risk (rank order):",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "High: clindamycin, fluoroquinolones, 2nd/3rd/4th generation cephalosporins,",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Medium: carbapenems, penicillins, 1st generation cephalosporins, macrolides,",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "vancomycin, metronidazole",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Low: tetracyclines, aminoglycosides, trimethoprim/sulfamethoxazole, rifampi",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Very low: sulfonamides, nitrofurantoin, fosfomycin, methenamine",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Avoid antiperistaltic agents (narcotics, loperamide, etc.). Increasing evidence",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "suggests that antacid therapy, especially with PPIs and H2 blockers, increases",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "the risk for C. difficile disease and recurrences. Avoid antacid therapy",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "without clear indication, especially in patients at risk for primary recurrent C",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "difficile disease.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "The preferred route of antimicrobial therapy for C. difficile infection is by",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "mouth. Intravenous metronidazole should be used only when oral therapy cannot",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "be used to deliver drug to the colon. Intravenous vancomycin does not get into",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "colonic contents and is not effective.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "C. difficile infection usually responds to antimicrobial therapy, especially if",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "other antimicrobial therapy has been stopped. Relapse is usually due to failure",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "of normal colonic flora to re-establish itself, rather than antimicrobial",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "treatment failure. If symptoms do not respond to appropriate antimicrobial",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "therapy, re-consider the diagnosis. Relapse occurs in 6% to 25% of people after",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "their first episode of C. difficile infection.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Third Recurrence: Consult Gastroenterology and/or Infectious Disease",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Clostridium difficile infection",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium difficile",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "CDI: Patient with clinical symptom onset (e.g., 3 or more unformed stools in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "24 hours after discontinuation of laxatives) and laboratory confirmation of CDI.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "CDI Recurrence: Typically defined as a repeated symptomatic, laboratory",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "case of CDI within 12 weeks after a prior episode.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU MORE ABOUT CELLULITIS", "Text" : "More about cellulitis...", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 500MG PO QID 5DS", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 500MG PO QID 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 500MG PO QID 5DS", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 500MG PO QID 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "BACTERIAL CELLULITIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Cellulitis refers to inflammation of the skin and subcutaneous tissue and is",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "often associated with bacterial pathogens.The most common pathogens are group",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "A streptococci and Staphylococcus aureus.Group B streptococci are associated",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "with cellulitis in elderly people, in those with diabetes mellitus, and on feet",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "and legs of patients with athlete's foot (tinea pedis).",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Mild cases can be treated with oral antimicrobials.Moderate to severe cases",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "should be treated initially with intravenous antimicrobials.Switch to oral",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "drugs after clinical improvement.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consider MRSA coverage for cellulitis associated with penetrating trauma,",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "history of MRSA infection, injection drug use, or infections not responding",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "to first line beta-lactams.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Duration: Treat for 5 days. Re-evaluate the patient and extend/modify treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "if not improved in this time.",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mild: Cellulitis without systemic signs of infection",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for MILD cellulitis",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Alternative for Penicillin Allergy or MRSA suspected",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "MRSA Suspected Mild Cellulitis",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Empirical treatment for MODERATE to SEVERE cellulitis",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CERVICITIS ASSOC STD", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC PCR TEST", "Text" : "Chlamydia & GC PCR/LCR test", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "Text" : "Treatment of recurrent or persistent cervicitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CERVICITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "The main diagnostic signs that characterize cervicitis are 1)women who present",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "with purulent or mucopurulent exudate in the endocervical canal or on an",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "endocervical swab specimen and 2)sustained endocervical bleeding induced by",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "gentle passage of cotton swab through the cervical os. One or both signs may be",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "present.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Neisseria gonorrhoeae and Chlamydia trachomatis are the two most common sexually",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "transmitted cervicitis pathogens. Nucleic acid amplification tests for these",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "pathogens are more sensitive than culture and should be used for patients at",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "risk for sexually transmitted cervicitis.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For patients who have recently been treated for cervicitis",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "When diagnosed with sexually transmitted cervicitis, the patient's sexual",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "transmitted infection. If diagnostic tests for the cause of cervicitis are not",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "feasible, therapy for both N. gonorrhoeae and C. trachomatis should be given to",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "partners.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Initial treatment of patients and sex partners",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Patients and partners are often infected with both N. gonorrhoeae and C.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "trachomatis.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urethritis",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute cervicitis",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "Text" : "Treatment for Gonococcal and Chlamydial trachomatis co-infections", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CHLAMYDIA URETHRITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1 gm PO x 1 dose ($) [M]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHLAMYDIAL OR NON-GONOCOCCAL URETHRITIS OR CERVICITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment for chlamydial or non-gonococcal urethritis or cervicitis",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urethritis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and Cervicitis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Urethritis, cervicitis: chlamydial",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute cervicitis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Urethritis in men",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "< OR >", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CHOLANGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "Text" : "Moxifloxacin 400 mg PO qday ($) [R,DI]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP LEVOFLOXACIN 500MG QDAY METRONID 1GM BID 7DAYS", "Text" : "Levofloxacin 500mg PO qday ($)[R,DI] <AND> metronidazole 1000mg PO bid ($) [DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX NV LEVOFLOXACIN 500MG QDAY METRONID 1GM BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CHOLANGITIS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for initial IV treatment",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are due to common bile duct obstruction. Obstruction (if present)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "must be relieved with an endoscopical, transcutaneous, or surgical procedure.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Step down treatment for completion of antimicrobial course after initial",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "intravenous treatment in patients who can tolerate oral therapy. Base selection",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "on culture results.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Duration of treatment for total of 7 to 10 days.",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Liver and Biliary System (Liver Abscess",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Cholangitis, Cholecystitis)",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gallbladder Infections",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Acute cholangitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CHOLECYSTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHOLECYSTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 IBUPROFEN 14DS 400MG PO TID", "Text" : "Ibuprofen 200-800 mg PO TID", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 IBUPROFEN 14DS 400MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHRONIC PROSTATITIS / CHRONIC PELVIC PAIN SYNDROME",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "This syndrome presents with intermittent perineal and/or low back pain,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "obstructive voiding symptoms, relatively normal examination, and negative urine",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cultures. Suggest urology consult.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For pain control, try for symptomatic relief. Treat for 2 to 3 weeks.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prostatitis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Chronic prostatitis/chronic pelvic pain syndrome", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CHRONIC BACT PROSTATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 28DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 28DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 30DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 30DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHRONIC BACTERIAL PROSTATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Chronic bacterial prostatitis usually presents as recurrent urinary tract",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infections with the same strain. Pain, tenderness, and fever may accompany",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "intermittent episodes of cystitis, but men are usually asymptomatic between",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "episodes and the prostate examination may be normal. Non-steroidal anti-",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "inflammatory drugs (NSAIDs) often relieve pain. If the diagnosis is uncertain",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "or if the patient's symptoms do not respond to therapy, consult urology. The",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "presence of hematuria may be a sign of carcinoma, especially in older men, and",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "a urology consult should be requested.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treat for 1 to 3 months.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Prostatitis, Epididymitis and Orchitis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prostatitis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Chronic bacterial prostatitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CHRONIC SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SINUSITIS SEVERE", "Text" : "Severe Sinusitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CHRONIC SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis of chronic sinusitis is based on presence of at least 2 of the 4",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cardinal signs/symptoms lasting >/= 12 weeks. In addition, diagnosis requires",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "objective evidence of mucosal inflammation using nasal endoscopy and/or CT",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "imaging. The initial therapy for chronic sinusitis is treatment with intranasal",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "corticosteroids and saline. For patients with severe nasal blockage by polyps,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "treat with a short course of oral glucocorticoids. Reassess patient after 1 to 3",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "months of intranasal therapy or after completion of glucocorticoid therapy. If",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "signs/symptoms have not improved, consult surgery, ENT and Infectious Diseases",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "as treatment is complex.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Acute exacerbations of chronic sinusitis can be caused by discontinuing medical",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "therapy, viral infections, allergens, noxious inhalants and bacterial or fungal",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "infections. Bacterial infections should be suspected when the patient has",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "increased signs/symptoms persisting for more than 10 days. Refer to Severe",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sinusitis recommendations for choice of antimicrobial therapy in these patients.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Repeated use of the same agent should be avoided to prevent promotion of drug",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "resistant bacteria or increased fungal colonization.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Cardinal Signs/Symptoms of Chronic Sinusitis",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "1. Anterior and/or posterior nasal mucopurulent drainage",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "2. Nasal obstruction/nasal blockage/congestion",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "3. Facial pain, pressure, and/or fullness",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "4. Reduction or loss of sense of smell",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Objective Evidence mucosal inflammation",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "1. Purulent (not clear) mucus or edema in the middle meatus or ethmoid regions",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "2. Polyps in the nasal cavity or the middle meatus",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "3. Radiographic imaging demonstrating mucosal thickening or partial or complete",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "opacification of the paranasal sinuses",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Rudmik et al., JAMA. 2015, 314(9) 926-939",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Chronic",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Chronic rhinosinusitis: Clinical manifestations,",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "pathophysiology, and diagnosis",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Microbiology and antibiotic management of chronic",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "rhinosinusitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CMV COLITIS/ESOPHAGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 VALGANCICLOVIR 21DS 900MG PO BID", "Text" : "Valganciclovir 900 mg PO BID ($$$) [R,O]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 VALGANCICLOVIR 21DS 900MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV COLITIS OR ESOPHAGITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection in immunocompetent patients is rare and usually associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and requires Infectious Diseases consultation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for 3-6 weeks. Patients may be converted to oral therapy after initial",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "intravenous therapy and after clinical improvement of severe disease.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease or following clinical improvement of",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "severe disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CMV ENCEPHALITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV ENCEPHALITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CMV PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV PNEUMONIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CMV POLYRADICULOPATHY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID VALGANCICLOVIR 900MG PO BID", "Text" : "Valganciclovir 900 mg PO BID ($$$) [R,O]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID VALGANCICLOVIR 900MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV POLYRADICULOPATHY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection in immunocompetent patients is rare and usually associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and requires Infectious Diseases consultation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration is likely to be prolonged and is individualized based on response.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Patients may be converted to oral therapy after initial intravenous therapy and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "after clinical improvement of severe disease.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease or following clinical improvement of",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "severe disease",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CMV RETINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 VALGANCICLOVIR 14DS 900MG PO BID", "Text" : "Valganciclovir 900 mg PO q12h ($$$) [R,O]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 VALGANCICLOVIR 14DS 900MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID VALGANCICLOVIR 900MG PO QDAY MAINTENANCE", "Text" : "Valganciclovir 900 mg PO q24h ($$$) [R,O]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID VALGANCICLOVIR 900MG PO QDAY MAINTENANCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CMV RETINITIS AND ACUTE RETINAL NECROSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infection in immunocompetent patients is rare and usually associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "minimal or no symptoms. Patients in whom the risk for CMV disease is increased",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "include solid organ and bone marrow transplant recipients, persons receiving",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "prolonged immunosuppressive chemotherapy, and persons with advanced HIV disease",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "indicated by a CD4 count of less than 50 cells/microliter. Treatment is complex",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and requires Infectious Diseases consultation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For sight threatening lesions (lesions within 1500 microns of the fovea)",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "intravitreal infections of ganciclovir or foscarnet are recommended in addition",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "to systemic treatment. Contact Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat retinitis for 14 to 21 days. Patients may be converted to oral therapy",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "after initial intravenous therapy and after clinical improvement of severe",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "disease. Treat acute retinal necrosis with IV therapy for at least 7 days and",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "until disease stabilizes then oral therapy for a minimum of 6 weeks. Maintenance",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "therapy after completion of treatment is indicated when CD4 count <100.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Discontinue maintenance therapy when CD4 count is >100 for 6 months.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment acute retinal necrosis or severe disease",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate retinitis or after clinical improvement of severe",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "retinitis/acute retinal necrosis",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Maintenance therapy",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cytomegalovirus",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Epidemiology, clinical manifestations, and treatment of",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus infection in immunocompetent adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CNS OUTPT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU BELL PALSY", "Text" : "Bell's Palsy", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "Text" : "Lyme Disease", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU SURG NEUROSURGERY", "Text" : "Neurosurgery prophylaxis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CENTRAL NERVOUS SYSTEM",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for Other Central Nervous System Infectio",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "(e.g. meningitis, brain abscess, HSV encephalitis,cranial/spinal epidural",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "abscess, subdural empyema, and suppurative intracranial thrombophilia).", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU COM ACQ DIARRHEA/NO TRAVEL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "Text" : "Clostridium difficile", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 3DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 3-5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 3DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "Text" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMMUNITY ACQUIRED DIARRHEA (NO RECENT TRAVEL)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Acute diarrhea (< 14 days of symptoms)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobials should be given only in cases of severe acute disease",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "or high-risk conditions: fever, >/= 6 stools in 24 hours, volume depletion",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "requiring hospitalization, severe abdominal pain, immune compromise, cardiac",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "disease, >/= 70 years old.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "If in the preceding two months the patient has taken a PPI or has been",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "hospitalized for three or more days, consider Clostridium difficile infection.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "For more information on when an antimicrobial is indicated or if the patient has",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Empiric antimicrobial treatment for non-bloody severe acute diarrhea",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Subacute or chronic (>/= 14 days of symptoms)",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Primary treatment is hydration and electrolyte replacement. Empiric",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy is not indicated. Investigate for the cause of diarrhea.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Gastroenterology and/or Infectious Diseases involvement is encouraged.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "settings", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ GTX ABX CAP PSI", "Text" : "CAP Pneumonia Severity Index (PSI) Calculator", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU CAP TREATED IN OUTPT SETTING", "Text" : "CAP treated in an outpatient setting", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMMUNITY-ACQUIRED PNEUMONIA (CAP)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Empirical regimens listed here cover the usual pathogens associated with CAP,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "including atypical pathogens.Specific therapy should be guided by culture",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "results.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "CAP Pneumonia Severity Index (PSI) or PORT Score",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "The CAP pneumonia severity index is useful for estimation of mortality risk for",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "a patient with pneumonia.Pre-estimated risk can then be used to determine how",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "aggressively to treat the patient's pneumonia and whether the patient can be",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treated safely outside of the hospital.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "The Community-Acquired Pneumonia Severity Index (PSI) is a guide and",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "should be used to augment clinical judgment. If social circumstances",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "or cognitive dysfunction would interfere with success of outpatient",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "treatment, the patient should be hospitalized.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Empirical treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "If a patient has taken an antimicrobial in the previous 3 months, it is prudent",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "to avoid giving the same or a similar drug for the current episode of pneumonia.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "(SEE INPATIENT CDSS for CAP treated in an Inpatient Setting)",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Fine MJ, et al. N Engl J Med. (1997) 336: 243-250", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU COMM INFECT PNEUMO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "Text" : "Aspiration pneumonia", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "Text" : "Community-acquired pneumonia (CAP)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Nosocomial pneumonia (including HAP or VAP) SEE INPATIENT CDSS", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++PNEUMONIA - OUTPATIENT++",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Note: Healthcare-associated pneumonia (HCAP), no longer used in the 2019",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "ATS/IDSA CAP Guideline. Instead, prior history or risks for MRSA",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and/or P. aeruginosa are use to guide whether to start",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "appropriate coverage empirically. (See CAP above)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "VIRAL GASTROENTERITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infectious diarrhea caused by viral pathogens such as Adenovirus, Astrovirus,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Norovirus, Rotavirus, and Sapovirus is usually self-limited. Treatment includes",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "supportive measures such as oral rehydration and unrestricted nutrition.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antiviral therapy is not recommended and for most viruses is unavailable.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Antimotility agents may be used for one or two days in patients with mild to",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "moderate volume depletion. Antiemetic agents may be used for one or two days in",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "patients with vomiting.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute viral gastroenteritis in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU COMPLICATED CYSTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet BID ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] for 7 days, CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 7DAYS", "Text" : "Cefdinir 300 mg PO BID ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO", "Text" : "Select for updated Ciprofloxacin Info Page", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 500MG TID 7DAYS", "Text" : "Amoxicillin 500 mg PO TID ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 500MG TID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSOZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO every other day ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] for 7 days, CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 7DS 100 MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMPLICATED CYSTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cystitis is considered complicated when one or more of the following is present:",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "> Most men with cystitis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "> Pregnant women",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "> Structural abnormalities (e.g. presence of obstruction, catheter or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "nephrostomy tubes, neurogenic bladder)",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "> Metabolic abnormalities that reduce local host defenses (e.g. diabetes,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "pregnancy, neutropenia, pelvic irradiation)",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "> Unusual or resistant pathogen",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "> Treatment failure or relapse or recurrence of infection",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Empirical treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative (weigh risk for potential serious side effects vs benefit)",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Treatment for SEVERE DISEASE or if patient cannot take oral therapy",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Treatment for specific pathogens",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Treatment if enterococcus identified",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Unable to use amoxicillin",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Treatment if Pseudomonas identified",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Drekonja, Dimitri M., et al. JAMA 326.4 (2021): 324-331",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Gupta K. et. al. IDSA Clinical Practice Guidelines (2011) 52.1",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cystitis",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CONJUNCTIVITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID TRIMETHOPRIM/POLYMIXIN B OPHTH 1 DROP Q3H 7D", "Text" : "Trimethoprim/polymixin B ophthalmic solution 1 drop in affected eye(s)", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID TRIMETHOPRIM/POLYMIXIN B OPHTH 1 DROP Q3H 7D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 OFLOXACIN OPTH 2 DRPS Q2H X2D THEN QID 5D", "Text" : "Ofloxacin 0.3% ophthalmic solution 2 drops in affected eye q2h while awake for 2", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 OFLOXACIN OPTH 2 DRPS Q2H X2D THEN QID 5D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CONJUNCTIVITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Conjunctivitis is associated with viral or bacterial pathogens. Viral",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "conjunctivitis presents with watery discharge. Bacterial infections are more",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "likely to present with thick exudate and conjunctival injection. Allergic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "conjunctivitis typically presents with stringy mucus. If there is pus",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "(hypopion), corneal involvement, possible bacterial conjunctivitis, or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "keratitis, consult ophthalmology.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Viral conjunctivitis is most commonly caused by adenovirus. It is self-limited",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "and antivirals provide no benefit. Symptomatic treatment with ophthalmic",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "antihistamine/decongestants and warm or cool compresses may relieve symptoms.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Bacterial conjunctivitis is most commonly associated with Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Streptococcus pneumoniae, Haemophilus spp., Moraxella catarrhalis,",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Corynebacterium diphtheriae, Neisseria spp. or enteric gram-negative rods. It is",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "generally self-limited, but topical antimicrobials reduce duration of symptoms",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "and limit person-to-person spread of infection. If symptoms do not improve after",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "2 days of antimicrobial therapy, the patient should be seen by an",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "ophthalmologist.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment for acute bacterial conjunctivitis",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "q3h for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment for severe cases of bacterial conjunctivitis involving suppuration or",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "contact lens wearers",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Consult ophthalmology and begin topical antimicrobials.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "days then 2 drops QID for 5 days ($) [M]",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Azari eta al, JAMA (2013) 1721-1730",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Microbial conjunctivitis",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Conjunctivitis",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Conjunctivitis, Bacterial", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CONTACT CDSS PROJECT STAFF", "Contents" : [
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Plans call for a direct e-mail link once the Minneapolis VAMC intranet website",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "is in place.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Thank you.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The CDSS Project Team can be contacted in Outlook using the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "612-467-1781",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "group Email: VISN23AntimicrobialCDSS@va.gov", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CUTANEOUS ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX MRSA RISK FACTORS", "Text" : "[CLICK HERE] for list of MRSA risk factors", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS PO BID 7DS", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100 mg PO bid for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 CLINDAM 7DS 300MG PO QID", "Text" : "Clindamycin 300 mg po qid for 7 days ($) [H]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 CLINDAM 7DS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO qid for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 7DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO qid for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal/Anorectal Abscess", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CUTANEOUS ABSCESS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Incise and drain and cover the site with a dry dressing.For small abscesses,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "systemic antimicrobial therapy is rarely necessary.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "If the patient is neutropenic, has multiple lesions, or has fever or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "leukocytosis, antimicrobial treatment may be necessary.Contact Infectious",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diseases for assistance.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For the few CUTANEOUS ABSCESSES away from the rectal area that need a systemic",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "antimicrobial",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration: Treat for 5 to 7 days",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mild to Moderate Cases:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Moderate or high suspicion of MRSA",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Low suspicion of MRSA",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "For SEVERE cases empiric coverage with MRSA agent",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "See Inpatient CDSS for intravenous therapy",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "For Perirectal/Anorectal Abscess Select Below",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword:Skin infections",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU CUTANEOUS CANDIDIASIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 CLOTRIM 1% CRM TOP BID 28DAYS", "Text" : "Clotrimazole 1% cream apply to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 CLOTRIM 1% CRM TOP BID 28DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID NYSTATIN CREAM APPLY BID", "Text" : "Nystatin Cream to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID NYSTATIN CREAM APPLY BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CUTANEOUS CANDIDIASIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Cutaneous candidiasis is a superficial fungal infection of the epidermis.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Presents with red, erythematous patches, often in areas where skin contact",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "skin, including axillae, groin, and abdominal folds.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Keep affected areas dry and clean.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Up-to-date",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Sanford: Cutaneous Candidiasis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DECUBITIS ULCERS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R] < OR >", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 7DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI] < OR >", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 CLINDAM 7DS 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 CLINDAM 7DS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perianal/Anorectal Abscess", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID3 GMENU CELLULITIS", "Text" : "Cellulitis", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOMYELITIS", "Text" : "Osteomyelitis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DECUBITUS ULCERS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Relieve pressure and friction, provide good nutrition, and debride the ulcer.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Decubitus ulcers are colonized with bacteria.Antimicrobial therapy is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "unnecessary unless the patient has infection of surrounding tissues signified by",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "erythema, warmth, local tenderness, or purulent discharge.Rectal or groin",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "decubitus ulcers with surrounding infection need broad spectrum antimicrobials.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Ulcers located in other sites are usually treated with antimicrobials for",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "staphylococci and streptococci.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration of therapy usually 7-14 days, but adjust to clinical response",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For deep abscesses away from the rectal area, obtain material for Gram stain and",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "culture and treat with:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treatment for Mild to Moderate Infections:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment for severe infection:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient CDSS",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "For PERIRECTAL ABSCESSES that need a systemic antimicrobial:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "If there are signs and/or symptoms of cellulitis or osteomyelitis, refer to the",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "advice page for the appropriate syndrome.Contact the ET nurse, Infectious",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Diseases, Dietician, or Vascular surgery for more information.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Parish LC Dermatol Clin 2004, 22: 87",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DEEP OROPHARYN INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DEEP OROPHARYNGEAL INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Deep oropharyngeal infections may threaten life and must be treated immediately.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Assess the risk of airway compromise and monitor the airway if it is threatened.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "These infections are more common in people with diabetes mellitus and are caused",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "by mixed organisms including streptococcus sp., Staphylococcus aureus and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "anaerobes . Perform CT scan to diagnose abscess. ENT and Infectious Diseases",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "consults are essential.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "If the patient's condition worsens or does not improve during the first 48 hours",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "of antimicrobial therapy, surgical drainage is indicated. If surgical drainage",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "is done, antimicrobials are usually continued for 48 hours after the procedure.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "If surgical drainage is not done, 2 weeks of antimicrobial therapy until",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "clinical improvement is observed (e.g. resolution of fever and leukocytosis) is",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "appropriate.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Empiric Treatment",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Step-down treatment after initial intravenous therapy. Adjust duration based on",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "criteria above.",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Submandibular space infections (Ludwig's angina)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DERMATOLOGY OUTPT MAIN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU IMPETIGO", "Text" : "Impetigo", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU FOLLICULITIS", "Text" : "Folliculitis", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELAS", "Text" : "Erysipelas", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Furuncles and carbuncles", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU CELLULITIS", "Text" : "Cellulitis", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU NECROTIZING INFECTIONS", "Text" : "Necrotizing infections", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ECTHYMA GANGRENOSUM", "Text" : "Ecthyma gangrenosum", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU STAPH SCALDED SKIN SYNDROME", "Text" : "Scalded Skin Syndrome", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU HIDRADENITIS SUPPURATIVA", "Text" : "Hidradenitis Suppurativa", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "Text" : "Toxic Shock Syndrome", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU ERYTHRASMA", "Text" : "Erythrasma", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELOID", "Text" : "Erysipeloid", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU CAT-SCRATCH DISEASE", "Text" : "Cat-scratch disease", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU LEISHMANIASIS", "Text" : "Leishmaniasis", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ROCK MTN SPOTTED FEVER", "Text" : "Rocky Mountain Spotted Fever", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX DERMATOLOGIC SURGERY GUIDELINES", "Text" : "Dermatology Post-Op Infection", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++DERMATOLOGICAL INFECTIONS - OUTPATIENT++",  "Header" : 1}, 
{"Row" : 5, "Column" : 2, "Item" : "ORZID3 GMENU CUTANEOUS CANDIDIASIS", "Text" : "Candidiasis", "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID3 GMENU PARONYCHIA", "Text" : "Paronychia", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID3 GMENU BED BUGS (HEMIPTERA)", "Text" : "Bed bugs (hemiptera)", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID3 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "Text" : "Head lice (pediculosis capitis)", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID3 GMENU BODY LICE (PEDICULOSIS CORPORIS)", "Text" : "Body lice (pediculosis corporis)", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Text" : "Pubic lice (pediculosis pubis)", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID3 GMENU SCABIES", "Text" : "Scabies", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU LYME DISEASE", "Text" : "Lyme disease", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI BLASTOMYCES DERM", "Text" : "Blastomycosis", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID3 GMENU SPOROTRICHOSIS", "Text" : "Sporotrichosis", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU GENITAL HERPES", "Text" : "Genital herpes (Outpatient)", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID3 GMENU HERPES WHITLOW", "Text" : "Herpes whitlow (Digit or Hand Cellulitis) - Outpatient", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU OROLABIAL HERPES", "Text" : "Oral lesions: Mouth, Lips (Cold sores)", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU TINEA CAPITIS (RINGWORM)", "Text" : "Tinea capitis (ringworm)", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "Text" : "Tinea unguium (onychomycosis)", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Text" : "Tinea pedis, Tinea corporis, Tinea cruris", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZID3 GMENU TINEA VERSICOLOR", "Text" : "Tinea versicolor", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "Text" : "Varicella/Chickenpox (primary infection)", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "Text" : "Zoster/Shingles (reactivation)", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "Herpes simplex virus infections",  "Header" : 1}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "Tinea fungal infections",  "Header" : 1}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "Varicella-Zoster virus infections", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU DEVICE-RELATED INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Intravascular catheter-related infection", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Prosthetic-valve endocarditis - Empirical Therapy", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Prosthetic valve endocarditis - Selected pathogens", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU CARDIOVASCULAR OUTPATIENT", "Text" : "Infections involving cardiovascular devices (except valves)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "Text" : "Infections in bone or joint prostheses", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "++ DEVICE-RELATED INFECTIONS ++",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "If the desired syndrome is not listed below, return to the main menu and refer",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "to the pertinent organ-system.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Last reviewed 11/17", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU DIARRHEA AEROMONAS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "Text" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 3DAYS 1DS TABLET BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 3 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 3DAYS 1DS TABLET BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH AEROMONAS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8(94)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Aeromonas sp.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Aeromonas infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA C. CAYETANENSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID for 7 to 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CYCLOSPORA CAYETANENSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for patients with allergy to sulfonamides.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for patients without HIV/AIDS",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for patients with HIV/AIDS",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for patients with HIV/AIDS.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cyclosporiasis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Cyclospora infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA C. PARVUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 NITAZOXANIDE 3DS 500MG PO BID", "Text" : "Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CRYPTOSPORIDIUM PARVUM",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antibiotic therapy is usually used only for persons with severe disease or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "immunocompromised persons.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for patients without HIV/AIDS",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for patients with HIV/AIDS",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for patients with HIV/AIDS.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cryptosporidiosis",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of cryptosporidiosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA CAMPYLOBACTER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "Text" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 5DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 5DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CAMPYLOBACTER",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Fluoroquinolone resistance is increasing worldwide. Macrolide resistance is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "rare.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Campylobacter",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Campylobacter infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA E. HISTOLYTICA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP METRO 750MG TID PAROMOMYCIN 25-35MG/KG/DAY TID", "Text" : "Metronidazole 750 mg PO TID for 10 days ($) [DI] <FOLLOWED BY> paromomycin", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTAMOEBA HISTOLYTICA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Primary treatment for gastroenteritis",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment for gastroenteritis or extraintestinal disease",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases. Paromomycin is nonformulary and must",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "be order by Infectious Diseases.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "25-35 mg/kg/day PO TID for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Amoebiasis, Entamoeba histolytica",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Intestinal Entamoeba histolytica amoebiasis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA ENTEROHEM E. COLI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "Text" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID RIFAXAMIN 3DS 200MG TID", "Text" : "Rifaximin 200 mg TID for 3 days ($$) [M]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID RIFAXAMIN 3DS 200MG TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "Text" : "Link to Shigella/Enteroinvasive E. coli menu", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH ESCHERICHIA COLI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Enteroaggretive E. coli (EAEC), Enteropathogenic E. coli (EPEC), and",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Enterotoxigenic E. coli (ETEC)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "EAEC infection can cause watery diarrhea with mucus that is occasionally bloody.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "It is more common in patients with HIV and those who have traveled to developing",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "regions. EPEC infection is associated with severe acute watery diarrhea that is",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "occasionally bloody. ETEC infection causes acute watery diarrhea that is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "occasionally severe. It is most common in travelers to tropical regions who are",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "exposed to contaminated food and water.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antibiotic therapy is not required for mild to moderate disease caused by these",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "organisms because diarrhea often resolves on its own. Do not use antimotility",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "agents in patients with bloody stool.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of severe diarrhea",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment in patients with AIDS",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Enterohemorrhagic E. coli (EHEC) and Shiga Toxin-producing E. coli (STEC)",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "EHEC and STEC disease often presents as bloody diarrhea. It is more common in",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "people who have consumed undercooked meats or poultry, fruits or unpasteurized",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "fruit juices, vegetables, leafy greens or seed sprouts. Exposure risks include",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "swimming in or drinking untreated fresh water and visiting a farm, petting zoo,",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "healthcare facility, prison or childcare facility.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treatment includes supportive measures such as volume repletion and",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "administering appropriate nutrition. Do not use antimotility or antimicrobial",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "agents as they can increase shiga-toxin release and increase the risk of",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "hemolytic uremia syndrome (HUS).",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Enteroinvasive E. coli (EIEC)",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "EIEC disease typically presents as watery diarrhea, sometimes progressing to",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "bloody diarrhea. Refer to Shigella/Enteroinvasive E. coli menu for",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "recommendations.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Brunette, Gary W. CDC Yellow Book 2018: Oxford University Press, 2017",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterohemorrhagic E. coli / Shiga toxin-producing E. coli",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Pathogenic Escherichia coli",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treatment is complex, consult Infectious Diseases", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA G. LAMBLIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 NITAZOXANIDE 3DS 500MG PO BID", "Text" : "Nitazoxanide 500 mg PO BID for 3 days ($$$) [M]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 METRONIDAZOLE 5DS 250MG PO TID", "Text" : "Metronidazole 250 mg PO TID for 5 to 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 METRONIDAZOLE 5DS 250MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH GIARDIA DUODENALIS (ALSO KNOWN AS G. LAMBLIA AND G.INTESTINALIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Illness with Giardia is typically subacute but varies widely in its time course.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment is necessary when the patient has symptomatic disease. Diarrhea,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "abdominal pain, bloating, belching, flatus, nausea, and vomiting are present",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "acutely and after several days give way to flatus, loose stools, belching, and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "weight loss.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Asymptomatic carriage of Giardia is common in household contacts of people who",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "are infected with Giardia. Treatment of asymptomatic patients can be considered",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "if they have contact with immunocompromised or pregnant people or live or work",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "in settings where there is risk of spreading infection to others (e.g., food",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "handlers, daycare, nursing home).",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Minetti et al, BMJ, 2016, 355.i5369",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Giardia duodenalis (G. intestinalis, G. lamblia)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Giardiasis: Treatment and prevention", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA ISOSPORA BELLI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO BID for 7 to 10 days ($)", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 75MG PO 21DS LEUCOV PO 25MG QDAY 21DS", "Text" : "Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 75MG PO 21DS LEUCOV PO 25MG QDAY 21DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO QID", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS QID for 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 75MG PO 21DS LEUCOV PO 25MG QDAY 21DS", "Text" : "Pyrimethamine 75 mg PO QDAY ($$) [DI,O] <AND> leucovorin 25 mg PO QDAY ($)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 75MG PO 21DS LEUCOV PO 25MG QDAY 21DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID TMP/SMX 1DS TAB PO 3X/WEEK", "Text" : "Trimethoprim-sulfamethoxazole 1 tablet DS PO 3X/week ($) [R,DI]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSHZID TMP/SMX 1DS TAB PO 3X/WEEK", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 25MG PO QDAY LEUCOV PO 10MG QDAY PPX", "Text" : "Pyrimethamine 25 mg PO QDAY ($$) [DI,O] <AND> leucovorin 10 mg PO QDAY ($)", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 25MG PO QDAY LEUCOV PO 10MG QDAY PPX", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CYSTOISOSPORA BELLI (FORMALLY ISOSPORA BELLI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "C. belli is associated with diarrhea in persons with HIV/AIDS and only rarely in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "immunocompetent persons.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of persons without HIV/AIDS",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "[R,DI]",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "for 21-28 days",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of persons with HIV/AIDS",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases involvement is essential. Initial treatment of acute",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "infection is followed by secondary prophylaxis until CD4 count is >200 for >6",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "months in response to ART without evidence of active C. belli.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Initial treatment",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "for 21 to 28 days",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Secondary prophylaxis",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Alternative for trimethoprim or sulfamethoxazole allergy",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cystoisospora belli",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Management of Cystoisospora (Isospora) infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA MICROSPORIDIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 ALBENDAZOLE 7DS 400MG PO BID", "Text" : "Albendazole 400 mg PO BID for 7 to 14 days ($$) [O]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 ALBENDAZOLE 7DS 400MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID ALBENDAZOLE 400MG PO BID", "Text" : "Albendazole 400 mg PO BID ($$) [O]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID ALBENDAZOLE 400MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH MICROSPORIDIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In patients without HIV/AIDs, symptoms may resolve without antimicrobial",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "therapy. In persons with AIDS, highly active anti-retroviral therapy (HAART) is",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "beneficial because recovery of host defenses helps to control microsporidial",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "disease. Infectious Diseases involvement is essential in patients with HIV/AIDS.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of persons without HIV/AIDS",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of persons with HIV/AIDS",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Continue treatment until CD4 count is >200 for >6 months after",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "initiation of ART.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Microsporidiosis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Microsporidiosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA SALMONELLA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "Text" : "Link to Enteric Fever Menu", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 7DS 500MG PO QDAY", "Text" : "Azithromycin 500 mg PO QDAY for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 7DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 14DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 14DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 14DS 500MG PO QDAY", "Text" : "Azithromycin 500 mg PO QDAY for 14 days ($) [M]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 14DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH SALMONELLA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For systemic febrile illness or typhoidal Salmonella, refer to Enteric Fever",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Menu:",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment is not recommended for mild or moderately severe disease in otherwise",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "healthy individuals <50 years old, because the disease is self-limiting and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobials can prolong the carrier state and increase the risk of relapse.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "By contrast, treatment should be considered for severe disease, and if the",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "patient is > 50 years old, is immunocompromised, or has another debilitating",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "underlying disease.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of immunocompetent patients",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "If infection acquired in Asia or patient is intolerant to fluoroquinolones",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of immunocompromised patients",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "If infection acquired in Asia or patient is intolerant to fluoroquinolones",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastroenteritis, Salmonella: Non-typhi",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Nontyphoidal Salmonella: Gastrointestinal infection and",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "carriage", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA SHIGELLA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "Text" : "Ciprofloxacin 750 mg PO QDAY for 3 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO QDAY 3DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "Text" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH SHIGELLA (BACILLARY DYSENTERY) OR ENTEROINVASIVE E. COLI (EIEC)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Shigellosis is generally a self-limited infection lasting 5-7 days.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Antimicrobial resistance is common and continues to rise for all recommended",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antimicrobials. Treatment should be reserved for patients who are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "immunocompromised, or who develop severe illness (e.g., requiring",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "hospitalization, invasive, or with complications) or live or work in settings",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "where there is risk of spreading infection to others (e.g., food handlers,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "daycare, nursing home).",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "CDC advisory: https://emergency.cdc.gov/han/han00401.asp",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastroenteritis, Shigella",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Shigella infection: Treatment and prevention in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA VIBRIO CHOLERA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 300MG PO ONCE", "Text" : "Doxycycline 300 mg PO once ($) [DI]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 300MG PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 1000MG PO ONCE", "Text" : "Ciprofloxacin 1000 mg PO once ($) [R,DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 1000MG PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIARRHEA WITH CHOLERA (VIBRIO CHOLERAE)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Primary Treatment",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Aggressive hydration and electrolyte replacement are essential",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Tetracycline intolerant patient",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastroenteritis, Vibrio cholerae",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Cholera: Clinical features, diagnosis, treatment, and",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "prevention", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA VIBRIO NON CHOLERA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 3DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 3-5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 3DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 3DS 100MG PO BID", "Text" : "Doxycycline 100 mg BID for 3-5 days ($) [DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 3DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NON-CHOLERA VIBRIO",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Non-cholera vibrio is associated with gastroenteritis, septicemia, and wound",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infections. Vibrio vulnificans infections are acquired from contact with",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "seawater or seafood, especially raw oysters. V. vulnificans cases are more",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "severe than cases with other species. V. parahaemolyticus causes",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "gastroenteritis and milder wound infections.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Antimicrobials do not shorten the course of disease in immunocompetent patients",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "with mild gastroenteritis.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Primary treatment for gastroenteritis",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of minor wound infection, severe gastroenteritis or",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "immunocompromised patient with gastroenteritis",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for patient intolerant of fluoroquinolones",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of severe wound infection or septicemia",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Vibrio parahaemolyticus",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Vibrio vulnificus: Cellulitis, Sepsis",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Vibrio parahaemolyticus infections",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Vibrio vulnificus infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIARRHEA Y. ENTEROCOLITICA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 5DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 5DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet BID for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "YERSINIA ENTEROCOLITICA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are indicated only for patients with severe disease or immune",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "compromise. For patients with extra-intestinal disease, consult Infectious",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Diseases or Gastroenterology for more information.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Primary treatment of gastroenteritis",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of severe gastroenteritis or immunocompromised patient",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative for fluoroquinolone intolerant patients",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment of extra-intestinal infection",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastroenteritis, Yersinia enterocolitica",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of Yersinia enterocolitica and",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Yersinia pseudotuberculosis infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DISKITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DISKITIS AND VERTEBRAL OSTEOMYELITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU DIVERTICULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 to 10 days ($) [R]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP TRIMETH/SULFA 1DS BID METRO 1GM PO BID 7 DAYS", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] <AND>", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX NV TRIMETH/SULFA 1DS BID METRO 1GM PO BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "Text" : "Moxifloxacin 400 mg PO QDAY for 7 to 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 400MG PO QDAY 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 7DS 500 BID METRO 7DS 1G BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> metronidazole 1000 mg PO", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 7DS 500 BID METRO 7DS 1G BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DIVERTICULITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diverticulitis involves inflammation of an intestinal diverticulum, usually in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the colon, causing pain and disturbed bowel function.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Mild disease",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "metronidazole 1000 mg PO BID ($) [DI] for 7 to 10 days",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "BID ($) [DI] for 7 to 10 days",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Moderate to severe disease",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Diverticulitis and Typhlitis",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Diverticulitis",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Acute colonic diverticulitis: Medical management", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ECTHYMA GANGRENOSUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ECTHYMA GANGRENOSUM",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Ecthyma gangrenosum lesions commonly begin as painless red macules which",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "rapidly evolve into areas of induration that develop into pustules and-or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "bullae. Ultimately, these become gangrenous ulcers. Ecthyma lesions",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "typically progress rapidly within 12 to 18 hours. They are often associate",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "with Pseudomonas aeruginosa bacteremia, especially in neutropenic patients.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Recommend blood cultures and culture of skin exudates.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Pseudomonas aeruginosa",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU EMPYEMA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMPYEMA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ENDOPHTHALMITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENDOPHTHALMITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Endophthalmitis is a medical emergency and presents with eye pain and visual",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "loss. It may be associated with gram positive or gram-negative bacteria,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "including Staphylococcus aureus and Pseudomonas aeruginosa, or with fungi.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Consult ophthalmology immediately. The ophthalmologist will obtain an aqueous or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "vitreous fluid sample for gram stain and culture and begin intravitreal",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobials.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment with intravitreal antimicrobials",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Fungal endophthalmitis",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Fungal endophthalmitis is rarely diagnosed in temperate climates and treatment",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "is complicated. Ophthalmology and Infectious Diseases involvement is essential.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endophthalmitis",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Endophthalmitis, Hematogenous or Endogenous",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Tranos et al., Advances in therapy. 2016, 33(5)727-746",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Bacterial endophthalmitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU EPIDIDYMITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "Text" : "Levofloxacin 500mg PO QDAY for 10 days ($) [R, DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID CIPROFLOXAC 500MG PO BID X10DAYS", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSHZID CIPROFLOXAC 500MG PO BID X10DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 10DAYS", "Text" : "Cefdinir 300 mg PO BID for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 10DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EPIDIDYMITIS",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Most cases in men under age 35 are associated with N. gonorrhoeae and C.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "trachomatis. Most cases in older men are associated with enteric Gram-negative",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "rods. Resistant organisms are more likely if the patient has been in the",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "hospital for more than 48 hours or received a course of antibiotics. There is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "increasing resistance in urinary pathogens to ciprofloxacin.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Patients with bacterial epididymitis treated with antibiotics should improve",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "within two or three days. If no improvement is noted, other causes of scrotal",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "increasing resistance in urinary pathogens to ciprofloxacin.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Management should include bed rest, analgesics, and scrotal elevation. Older",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "men should have their residual urinary volume checked. If the residual volume",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "is elevated, the patient should be seen by a urologist as epididymitis is",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "unlikely to respond if the prostate is blocking the vas deferens.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment in men < 35 years who do not practice insertive anal intercourse",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment in men >/= 35 years who do not practice insertive anal intercourse",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treatment in men who practice insertive anal intercourse",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "If previous cultures indicate that the urinary pathogen is susceptible and oral",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "therapy is appropriate:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Prostatitis, Epididymitis and Orchitis",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Epididymo-orchitis",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Evaluation of acute scrotal pain in adults",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "Text" : "Gonococcal infections with/without Chlamydial infections", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTR 500MG IM X1 LEVOFLOX 500MG QDAY 10DAYS", "Text" : "Ceftriaxone 500 mg IM once ($) [M] < AND > levofloxacin 500 mg PO QDAY", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "Text" : "Non-VA order for above Levofloxacin", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "for 10 days ($) [R,DI]", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU EPIGLOTTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EPIGLOTTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Maintaining the airway is the key to management. Call ENT service and ask them",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to see the patient immediately. Blood cultures and epiglottal cultures (in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "intubated patients) should be used to direct antimicrobial therapy. Empirical",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "therapy should be initiated prior to results of cultures as infection is life",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "threatening and cover for likely pathogens (Moraxella catarrhalis, penicillin",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "resistant S. pneumonia, beta-hemolytic streptococci and possibly Staph. aureus)",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Epiglottitis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Rafei et al., Pediatric Clinics 2006, 53.2, 215-242",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Epiglottitis, Supraglottis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Epiglottis (supraglottis): Management", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ERYSIPELAS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 PENICILLIN VK 10DS 250MG PO QID", "Text" : "Penicillin VK 250 - 500 mg PO QID for 10 days($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 PENICILLIN VK 10DS 250MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 ERYTHROMYCIN 10DS 250MG PO QID", "Text" : "Erythromycin 250-500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 ERYTHROMYCIN 10DS 250MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ERYSIPELAS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "In contrast to cellulitis, erysipelas has sharply demarcated borders and a",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "characteristic raised, orange-peel appearance.Most cases are associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "streptococcus.In a minority of cases, especially those involving the face,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is also a potential pathogen.In severe cases,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "methicillin-resistant Staphylococcus aureus (MRSA) coverage must be provided",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "until microbiology results are available.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treat for 5 to 10days, longer if patient is bacteremic.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Facial",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sudden onset of rapidly spreading red edematous tender plaque-like skin on",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "face in an otherwise healthy host.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If erysipelas-like on the face treat as if MRSA is present:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Non-facial",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "MILD TO MODERATE disease",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "SEVERE disease",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Erysipelas",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ERYSIPELOID", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 PENICILLIN V 7DS 500MG PO QID", "Text" : "Penicillin V 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 PENICILLIN V 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 ERYTHROMYCIN 7DS 500MG PO QID", "Text" : "Erythromycin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 ERYTHROMYCIN 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ERYSIPELOID (ERYSIPELOTHRIX RHUSOPATHIAE INFECTION)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Erysipeloid is a localized cutaneous infection with Erysipelothrix rhusopathiae",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "It is a zoonotic infection of fisherman, fish handlers, and butchers acquired by",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "direct animal contact, most commonly with fish, but also with other animals",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(e.g., swine). It usually affects the hand or fingers and is characterized",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "throbbing pain and a red rash with a purple center and an elevated border.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Localized infections can be treated with oral antimicrobials.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Severe, diffuse cutaneous infections or systemic infections with E.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "rhusopathiae occur rarely after ingestion of undercooked pork or contaminated",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "seafood in immunosuppressed individuals.These infections are treated",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "initially with intravenous antimicrobials.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment of localized infection (erysipeloid)",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "_____________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "___________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment of systemic or severe diffuse cutaneous infection with E.",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "rhusopathiae",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "___________________________________________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Erysipelothrix",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ERYTHRASMA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CLINDAM 1% TOP SOLN BID 14DAYS", "Text" : "Clindamycin 1% topical solution apply twice daily ($) [M]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CLINDAM 1% TOP SOLN BID 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID CLARITHROMYCIN 500 MG PO BID 14DAYS", "Text" : "Clarithromycin 500 mg PO bid ($) [DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID CLARITHROMYCIN 500 MG PO BID 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ERYTHRASMA",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Erythrasma presents as brownish-red, well circumscribed, irregularly shaped",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "patches in or near skin folds.Patches in the groin often itch.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Most cases respond to topical therapy.Systemic antibiotics are used for more",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "severe cases or those that do not respond to topical therapy.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: erythrasma",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Holdiness MR Drugs 2002, 62:1131", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FEVER OF UNKNOWN ORIGIN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "Text" : "NEUTROPENIC FEVER", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FEVER OF UNKNOWN ORIGIN",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Fever of unknown origin (FUO) is the occurrence of several episodes of fever",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "greater than 101 degrees Fahrenheit over a time period of at least 3 weeks",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "despite 1 week of hospital evaluation. Cases with FUO are often classified in",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "four categories: (1) classical, (2) neutropenic, (3) nosocomial, and (4) fever",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "in persons with HIV/AIDS. Empirical antimicrobial therapy is rarely indicated",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "in patients with FUO.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Note that FUO in neutropenic patients refers to persistent fever that has",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "remained undiagnosed after extensive diagnostic work and empirical antimicrobial",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "therapy. New fever in patients with profound neutropenia is a different",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "syndrome and does require empirical antimicrobial therapy. Infectious Diseases",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "should be involved in any case where empirical treatment for fever of unknown",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "origin is being considered.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Fever of Unknown Origin", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FIRST RECURRENCE ABX ASSOCIATED COLITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 VANCOMYCIN TAPER AND PULSE DOSING", "Text" : "Vancomycin Extended Pulse-Taper Regimen ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FIRST RECCURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION (CDI)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Discontinue implicated antibiotic and avoid high-risk antibiotic if",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "First Recurrence CDI: *The REGIMEN should be different from initial treatment*",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Clostridium difficile infection",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium difficile",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Treatment and",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "prevention",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "CDI Recurrence: Typically defined as a repeated symptomatic, laboratory",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "confirmed case of CDI within 12 weeks after a prior episode.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200 MG EXTENDED-PULSE REGIMEN", "Text" : "Fidaxomicin Extended-Pulse Regimen ($$) [M]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG EXTENDED PULSE REGIMEN", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200MG PO Q12H 10DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG PO BID 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID VANCOMYCIN 125MG CAP QID 10DS", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID VANCOMYCIN 125MG CAP QID 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 VANCOMYCIN TAPER AND PULSE DOSING", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "125 mg po twice daily for seven days, then 125mg po qday for 7 days, then",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "125mg every other day for 6 weeks)",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Fulminant CDI:", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU FOLLICULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 MUPIROCIN 2% OINT TOP TO AFFECT AREA TID 7DS", "Text" : "Mupirocin 2% ointment topical to affected area TID for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 MUPIROCIN 2% OINT TOP TO AFFECT AREA TID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 CLOTRIMAZOLE 1% CRM TOP TID 7DS", "Text" : "Clotrimazole cream to affected area TID for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 CLOTRIMAZOLE 1% CRM TOP TID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "FOLLICULITIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Folliculitis is an infection of the hair follicle with purulent exudate in the",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "epidermis. It is usually associated with Staphylococcus aureus.In patients",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "exposed to swimming pools or hot tubs, folliculitis may be associated with",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pseudomonas aeruginosa. Candida albicans can cause folliculitis in patients",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "receiving antimicrobials and/or corticosteroids. For folliculitis in patients",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "with severe acne, consult Dermatology.For extensive folliculitis or in",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "patients with HIV, consult Infectious Diseases.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Usually self-limiting. For most cases, treat with daily saline compresses until",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "symptoms resolve.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For moderate to severe cases associated with Staphylococcus aureus:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "For cases associated with Candida albicans",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Folliculitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCERS W/O INFECT SURR TISS", "Text" : "Foot ulcers WITHOUT infection of surrounding tissues", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCERS W/ INFECT SURR TISSUES", "Text" : "Foot ulcers WITH infection of surrounding tissues", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOOT ULCER IN PATIENT WITH DIABETES MELLITUS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Foot ulcers in patients with diabetes mellitus are colonized with bacteria.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Antimicrobials should not be used to treat colonization.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Cases with infection of surrounding tissues signified by erythema, warmth, local",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "tenderness, or purulent discharge should be treated with antimicrobials. Pain",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "may not be present in patients with neuropathy.In patients with substantial",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "vascular disease, erythema and warmth may not be present and instead the tissues",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "will be dusky, mottled, or cool.Capillary refill may be impaired.Patients",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "with diabetes and ulcers are at risk for gangrenous infections.If there is any",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "suggestion of gangrene, consult surgery immediately.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FOOT ULCERS W/ INFECT SURR TISSUES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CEPHALEX 7DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOOT ULCERS WITH INFECTION OF SURROUNDING TISSUES",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Duration of therapy:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antibiotics may be stopped 24-48 hours following curative amputation.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Otherwise, continue antibiotics until signs of infection have resolved.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Typically, 1-2 weeks for mild, 1-3 weeks for moderate and 2-4 weeks for severe.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "___________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Mild: ulcer with superficial inflammation",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Duration: treat until resolution of symptoms usually 1-2 weeks",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Oral therapy, no MRSA coverage:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Oral therapy, MRSA coverage:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "________________________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Moderate: Ulcer with inflammation, extension into fascia",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Duration: treat to resolution of symptoms usually 1-3 weeks",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "For patients started on parenteral therapy, a switch to an oral regimen",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "is reasonable following clinical improvement.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Oral therapy with MRSA coverage:",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Regimens for MODERATE intravenous therapy or SEVERE infections:",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID CEFADROXIL 500MG PO BID 7DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID CEFADROXIL 500MG PO BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX-CLAV 875 BID + TMP/SULFA 14DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX CLAV 875 + DOXY 14DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R] <AND> Doxycycline", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "100 mg PO BID for 14 days ($) [DI]",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 14 days ($) [R,DI]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Obtain cultures of inflamed ulcer or wound to permit targeted antimicrobial",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "therapy, de-escalate/modify regimen based on culture and susceptibility data.",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875/125 BID 14D+DOXY 100MG BID 14D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875/125 BID + TRIMETH SULF BID 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU APPRO FOOT ULCER W/ INFECT", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FOOT ULCERS W/O INFECT SURR TISS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOOT ULCERS WITHOUT INFECTION OF SURROUNDING TISSUES",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Clinically uninfected wounds do not need antibiotic treatment.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Topical antimicrobials are not helpful, are associated with allergic reactions,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "and select for resistant organisms.In general, local treatment should consist",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "of dressings with frequent changes, soaks, and debridement. Patients with",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "edema or impaired venous return should keep the limb elevated.Wound care and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "improved control of diabetes can improve outcomes of infection and prevent",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "future complications.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59:147",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:e132", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FUNGAL SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FUNGAL SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Fungal sinusitis mainly affects immunocompromised patients, but occasionally it",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "occurs in immunocompetent hosts. Drainage is essential. Consult ENT and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Infectious Disease.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Aspergillosis, Allergic Fungal Sinusitis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Fungal rhinosinusitis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FUNGI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI ASPERGILLUS SPP.", "Text" : "Aspergillus and other moulds", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI BLASTOMYCES DERM", "Text" : "Blastomyces dermatitidis", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "Text" : "Candida albicans", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. GLABRATA", "Text" : "Candida glabrata", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI C. KRUSEI", "Text" : "Candida krusei", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI COCCIDIOIDOMYCES", "Text" : "Coccidioidomyces", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "Text" : "Cryptococcus neoformans", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI H. CAPSULATUM", "Text" : "Histoplasma capsulatum", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "Text" : "Pneumocystis (considered a fungus)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ FUNGI ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "into site, and whether organism is pathogen, colonizer, or contaminant. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Last reviewed 8/18", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU FUNGI ASPERGILLUS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ASPERGILLUS SPECIES",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mild/moderate disease:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Alternative treatment:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "Text" : "Voriconazole 400 mg PO BID for 2 doses, then 200 mg PO BID ($$) [R,H,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Preferred treatment:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Disease for alternative.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Patterson TF, et al. Clin Infect Dis. (2016) 63(4):433-442",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-Aspergillus species are ubiquitous, but invasive aspergillosis occurs primarily",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "in immunocompromised hosts. Neutropenia and glucocorticoid use are the most",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "common predisposing factors. Optimal management involves early diagnosis and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "early initiation of antifungal treatment.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "UpToDate: Treatment and prevention of invasive aspergillosis",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "-The most common clinical manifestation of invasive aspergillosis is pulmonary",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "disease, but other manifestations include central nervous system infection,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "rhinosinusitis, endocarditis, gastrointestinal disease, annd others.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration of therapy should be a minimum of 6 to 12 weeks, although duration",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "is highly dependent on degree/duration of immunosuppression, disease site, and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "and evidence of disease improvement. Consult Infectious Disease.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Severe disease:",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient CDSS for treatment.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FUNGI BLASTOMYCES DERM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID ITRACONAZOLE 200 PO TIDX3DAYS THEN 200BID", "Text" : "Itraconazole 200 mg PO TID for 3 days then BID ($) [DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID ITRACONAZOLE 200 PO TIDX3DAYS THEN 200BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BLASTOMYCES DERMATITIDIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Diseases in all cases. Lifelong suppressive therapy may be",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "required in immunosuppressed patients if immunosuppression cannot be reversed.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Disease outside of the central nervous system",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat for 6-12 months. It is recommended that immunocompromised patients be",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treated with at least 1-2 weeks of intravenous treatment and a total treatment",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "duration of 12 months.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Central nervous system infection",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Stanley et al. Clinical Infectious Diseases. 2008, (46)1801-12",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Blastomycosis",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of blastomycosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FUNGI C. ALBICANS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID CLOTRIMAZOLE TROCHE 10MG PO 5X/D 7D", "Text" : "Clotrimazole troche 10 mg PO 5X/day for 7-14 days ($) [M]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID CLOTRIMAZOLE TROCHE 10MG PO 5X/D 7D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 200MG PO QDAY 7DS", "Text" : "Fluconazole 200 mg PO QDay for 7-14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 200MG PO QDAY 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 400MG QDAY 14 DAYS", "Text" : "Fluconazole 400 mg PO QDay for 14-21 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 FLUCONAZOLE 400MG QDAY 14 DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 800MG PO ONCE THEN 400MG PO QDAY", "Text" : "Fluconazole 800 mg PO once then 400 mg PO QDay ($) [R,DI]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 800MG PO ONCE THEN 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA ALBICANS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Avoid using fluconazole empirically to treat candidal infections in patients who",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "have received an imidazole in the previous year.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment of thrush or oropharyngeal candidiasis",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Oropharyngeal candidal disease may present in different patterns, like white",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "plaques in the oropharyngeal area, erythematous macules (often in patients with",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "dentures), or as pseudomembranes.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Thrush infection often recurs, especially in patients with AIDS. Consult MRTC",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "clinic or Infectious Diseases (MRTC may also be consulted in the MVAHCS) for",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "more information on treatment of recurrent infection.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mild disease",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Moderate to severe disease",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Esophageal candidiasis",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Esophageal infection requires systemic therapy.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative for patient who cannot swallow tablets",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Systemic candidal infection",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Fluconazole is preferred empirical therapy in most cases. Amphotericin B should",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "be used empirically in patients who have received an azole antifungal drug",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "recently, or in patients who are critically ill.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location, severity of infection,",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Recent azole antifungal treatment",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 NYSTATIN SWISH/SWALLOW 5ML QID 7D", "Text" : "Nystatin swish and swallow QID for 7-14 days ($) [M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 NYSTATIN SWISH/SWALLOW 5ML QID 7D", "Text" : "Non-VA order for above", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FUNGI C. GLABRATA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "Text" : "Voriconazole 400 mg PO BID for 2 doses, then 200 mg PO BID ($$) [R,H,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA GLABRATA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "C. glabrata is often resistant to fluconazole and occasionally has some degree",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "of resistance to amphotericin. Higher doses of amphotericin are recommended due",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "to delayed killing effects against Candida glabrata.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location and severity of infection,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative for susceptible isolates",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FUNGI C. KRUSEI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "Text" : "Voriconazole 400 mg PO BID for 2 doses, then 200 mg PO BID ($$) [R,H,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID VORICONAZOLE 400MG PO BID 1DAY THEN 200MG BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CANDIDA KRUSEI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "C. krusei is resistant to fluconazole, and often has some degree of resistance",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to amphotericin. Higher doses of amphotericin are recommended for treatment of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "C. krusei due to decreased susceptibility.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location and severity of infection,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Candidemia or Disseminated",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of candidemia and invasive candidiasis in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FUNGI COCCIDIOIDOMYCES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID ITRACONAZOLE 200MG PO BID", "Text" : "Itraconazole 200 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID ITRACONAZOLE 200MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 400MG PO QDAY", "Text" : "Fluconazole 400 mg PO QDay ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COCCIDIOIDOMYCES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pulmonary and Infectious Diseases consultations are essential for diagnosis and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "treatment.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location and severity of infection,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Mild to moderate disease",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Observation alone is indicated for some cases. Consult Infectious Diseases for",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "more information. If antifungal treatment is indicated:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Severe disease (diffuse pneumonia, rapid progression or central nervous system",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "infection)",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Galgiani et al. Clinical Infectious Diseases. 2016, 63(6) e112-46",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Coccidioidomycosis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford guide keyword: Coccidioidomycosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FUNGI CRYPTOCOCCUS NEOFORMANS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 400MG PO QDAY", "Text" : "Fluconazole 400 mg PO QDay ($) [R,DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID ITRACONAZOLE 200MG PO BID", "Text" : "Itraconazole 200 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID ITRACONAZOLE 200MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CRYPTOCOCCUS NEOFORMANS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Duration of therapy is dependent upon location and severity of infection,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and response to therapy. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate infection outside of the central nervous system",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "or step-down treatment once disease has stabilized",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment of central nervous system infection or severe infection outside",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "central nervous system",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cryptococcosis (Cryptococcus neoformans and Cryptococcus",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "gattii)",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Perfect et al. Clinical Infectious Diseases 2010, (50) 291-322",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cryptococcus", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FUNGI H. CAPSULATUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HISTOPLASMA CAPSULATUM",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Select here for Staphylococcus aureus Decolonization", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Doxycycline 100 mg po BID ($) [DI]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Doxycycline 100 mg po BID ($) [DI]", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 5DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FURUNCLES AND CARBUNCLES",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Localized purulent infections include furuncles, carbuncles and cutaneous",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "abscesses. Nearly all are caused by Staphylococcus aureus. A furuncle is a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "inflamed nodule that usually develops as a complication of folliculitis. A",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "carbuncle is a more extensive lesion that extends further into the subcutaneous",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "tissue.Contact a wound care nurse for more information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Incision and drainage is the mainstay of therapy for carbuncles, cutaneous",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "abscesses, and large furuncles.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "The decision to administer antibiotics directed against S. aureus as an adjunct",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "to incision and drainage should be made based on the presence of systemic",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "inflammatory response syndrome (SIRS) or in patients with markedly impaired",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "host defenses.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For recurrent skin abscesses in addition to culture and antibiotic therapy",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "recommended consider a decolonization regimen.",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mild infection: Purulent infection without systemic signs of infection",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Recommend incision and drainage. No antibiotic indicated.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Moderate Infection: Purulent infection with signs of systemic infection.",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Recommend incision and drainage. Culture material and use results to guide",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "therapy.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treat for 5 days and extend/modify treatment if not improved in this time.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Alternatives",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "If methicillin-RESISTANT Staphylococcus aureus (MRSA) is suspected or proved",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Severe Infections:",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Patients who have failed incision and drainage along with oral antibiotics",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "or those with SIRS or for infections in those with neutropenia or diminished",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "neutrophil function.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "See Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Furuncle, carbuncle",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 CEFADROXIL 1000MG PO BID X5DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "PSOZID2 LINEZOLID 600MG PO BID 5DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSHZID2 LINEZOLID 600 MG PO BID 5DAYS", "Text" : "Non-VA order for above", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GASTROINT OUTPT MAIN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU GI LIVER ABSCESS", "Text" : "Hepatic abscess", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "Text" : "Intraabdominal abscess", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "Text" : "Intraperitoneal abscess", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU ABX PERIANAL/ANORECTAL ABSCESS", "Text" : "Perirectal/Anorectal abscess", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU APPENDICITIS W/O PERFORATION", "Text" : "Appendicitis without perforation", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU APPENDICITIS W/ PERFORATION", "Text" : "Appendicitis with perforation", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU CHOLECYSTITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU CHOLANGITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "Text" : "Mild to moderate disease", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ILEUS/TOXI MEGACOLON", "Text" : "Severe/life-threatening disease", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU DIVERTICULITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ GASTROINTESTINAL ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Abscess",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Appendicitis",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Cholecystitis",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Cholangitis",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Clostridium difficile disease",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "(shock, ileus and megacolon)",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Diarrhea, infectious",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Diverticulitis",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "SECTION LAST REVIEWED MAY 2018",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID3 GMENU ABX ENTERIC FEVER", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU H. PYLORI INFECT", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS A", "Text" : "Hepatitis A", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS B", "Text" : "Hepatitis B", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID2 GMENU ABX HEPATITIS C", "Text" : "Hepatitis C", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU TYPHLITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU PANCREATITIS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "Text" : "Acute Spontaneous Bacterial Peritonitis (SBP)", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU PERI ASSOC CAPD", "Text" : "Peritonitis associated with", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "ORZID3 GMENU SECONDARY PERITONITIS", "Text" : "Secondary peritonitis", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Helicobacter pylori infection",  "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "Hepatitis",  "Header" : 1}, 
{"Row" : 20, "Column" : 2, "Item" : null, "Text" : "Neutropenic enterocolitis",  "Header" : 1}, 
{"Row" : 21, "Column" : 2, "Item" : null, "Text" : "(Typhlitis)",  "Header" : 1}, 
{"Row" : 24, "Column" : 2, "Item" : null, "Text" : "Pancreatitis",  "Header" : 1}, 
{"Row" : 27, "Column" : 2, "Item" : null, "Text" : "Peritonitis",  "Header" : 1}, 
{"Row" : 30, "Column" : 2, "Item" : null, "Text" : "peritoneal dialysis",  "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : null, "Text" : "Thrush",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Asplenia (Vaccines/Abx Prophylaxsis)",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "Esophagitis",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU ABX ESOPHAGITIS", "Text" : "Other", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "Text" : "Candidal", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Enteric fever", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU GENITAL HERPES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 7DAYS 400MG PO TID", "Text" : "Acyclovir 400 mg PO TID for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 7DAYS 400MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1GM PO BID", "Text" : "Valacyclovir 1 gm PO BID for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1GM PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 400MG PO TID", "Text" : "Acyclovir 400 mg PO TID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 5DS 400MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 2DS 800MG PO TID", "Text" : "Acyclovir 800 mg PO TID for 2 days ($) [R]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 2DS 800MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID VALACYCLOVIR 3DS 500MG PO BID", "Text" : "Valacyclovir 500 mg PO BID for 3 days ($) [R]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSHZID VALACYCLOVIR 3DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 10DS 400MG PO TID", "Text" : "Acyclovir 400 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 10DS 400MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 10DS 1GM PO BID", "Text" : "Valacyclovir 1 gm PO BID ($) [R]", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 10DS 1GM PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 1YR 400MG PO BID", "Text" : "Acyclovir 400 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 1YR 400MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "Text" : "Valacyclovir 500 mg PO QDay ($) [R]", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1YR 1000MG PO QDAY", "Text" : "Valacyclovir 1000 mg PO QDay ($) [R]", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1YR 1000MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GENITAL HERPES",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment of the initial episode decreases the duration of pain, lesions, and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "viral shedding by 1 to 2 days. Treatment of the initial episode does not",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "decrease likelihood of recurrent episodes.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Episodic therapy for relapses",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment of recurrent episodes must be started within 24 hours of symptom",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "onset. Treatment decreases the duration of pain and lesions, and viral shedding",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "by 1 to 2 days. Consider suppressive treatment for patients with more than 6",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "episodes per year.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients in whom genital herpes simplex disease is often",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "severe include: patients with HIV infection, organ transplants, malnourishment,",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "eczema or severe burns, and in patients receiving immunosuppressive",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "chemotherapy.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Treat mild to moderate disease for 10 days. In severe disease, treat with",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "intravenous acyclovir for 2 to 7 days based on clinical response, then treat",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "with an oral antiviral for a total duration of 10 days.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease or after clinical improvement of severe",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "disease",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases consult encouraged.",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Chronic suppressive therapy",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Suppressive therapy is indicated in patients with more than 6 episodes per year.",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Suppressive therapy is optional, and some patients may find episodic treatment",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "more convenient. The frequency of recurrences usually decreases after 1 to 5",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "years, and suppressive therapy should be stopped every few years to see if it is",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "still needed.",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "For a patient with more than 9 episodes per year",  "Header" : 1}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : null, "Text" : "Center for Disease Control. MMWR 55(RR 11) 1-94",  "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes simplex",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GENITOURINARY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU URINARY TRACT INFECTION", "Text" : "Urinary Tract Infection (UTI)", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU ASYMP BACTERIURIA", "Text" : "Asymptomatic bacteriuria", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU COMPLICATED CYSTITIS", "Text" : "Complicated cystitis", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "Text" : "Uncomplicated cystitis", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU PYELONEPHRITIS", "Text" : "Pyelonephritis", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX CANDIDA UTI", "Text" : "Candida Urinary Tract Infection", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE BACT PROSTATITIS", "Text" : "Acute bacterial prostatitis", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU CHRONIC BACT PROSTATITIS", "Text" : "Chronic bacterial prostatitis", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU CHRON PROS/CHRON PELVIC PAIN SYN", "Text" : "Chronic prostatitis/Chronic pelvic pain syndrome", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU EPIDIDYMITIS", "Text" : "Epididymitis", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU BACTERIAL VAGINOSIS", "Text" : "Bacterial vaginosis", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU CANDIDA VULVO-VAGINITIS", "Text" : "Candida vulvo-vaginitis", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Trichomonas vaginitis", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Pelvic Inflammatory Disease (PID)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ GENITOURINARY ++",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Urinary tract infections, Bacterial",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Urosepsis (See Inpatient CDSS)",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Urinary tract infections, fungal",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Prostatitis/Epididymitis",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Vaginitis, vaginosis",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Pelvic Inflammatory Disease (PID)",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Last updated Dec 2017",  "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Sexually Transmitted Infections", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Cervicitis associated with sexually transmitted infection", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Epididymitis", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Genital Herpes", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Pelvic Inflammatory Disease (PID)", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Syphilis", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Urethritis associated with sexually transmitted infections", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Vaginitis Trichomonas", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZID3 GMENU NECROTIZING INFECTIONS", "Text" : "Necrotizing Infection", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU PREVENTION OF INFECT", "Text" : "Prevention of infection", "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : "ORZID3 GMENU SURG SITE INFECT", "Text" : "Surgical site infection", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Sexually Transmitted Infections (STI)",  "Header" : 1}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "Chlamydia (See Cervicitis or Urethritis",  "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "Gonorrhea (See Cervicitis or Urethritis)",  "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : null, "Text" : "Necrotizing Infection (including Fournier gangrene)",  "Header" : 1}, 
{"Row" : 29, "Column" : 2, "Item" : null, "Text" : "Prevention of Infection",  "Header" : 1}, 
{"Row" : 32, "Column" : 2, "Item" : null, "Text" : "Surgical Site Infection", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU GI LIVER ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU ABX LIVER AMEBIC ABSCESS", "Text" : "Link to Amebic Liver Abscess menu", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LIVER ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Liver abscess should be suspected in all patients with fever, leukocytosis, and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "a space-occupying liver lesion. Liver abscesses fall broadly into two",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "categories: pyogenic and amebic. In the United States, pyogenic liver abscess is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "much more common. Amebic liver abscess occurs almost exclusively in travelers",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "and immigrants. If amebic liver abscess is suspected, select the link below.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment of pyogenic liver abscess",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Liver and Biliary System",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Hepatic Abscess",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Solomkin et al, Clin Infect Dis, 2010, 50:133-64",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Pyogenic liver abscess", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GONOCOCCAL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID2 GMENU ABX GENERAL INFORMATION INPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Uncomplicated gonococcal infections of the pharynx, cervix, urethra, or rectum:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "chlamydia.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Patients weighing less than 300lbs:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Patients weighing 300lbs or greater:",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "No reliable alternative treatments are available for pharyngeal gonorrhea.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "of the reaction is recommended. For persons with an anaphylactic or other",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "severe reaction to ceftriaxone, consult Infectious Disease for alternative",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "treatment recommendation.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTRIAXONE 1GM IM X1 + DOXY 100MG PO BID X7DAYS", "Text" : "Ceftriaxone 1 GM IM Once ($) [M] <AND> Doxycycline 100mg PO bid x7days($) [DI]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "-If chlamydial infection has not been excluded, recommend to treat for",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTRIAXONE 500MG IM X1 + DOXY 100MG BID X7D", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "-A test-of-cure is unnecessary for uncomplicated urogenital or rectal",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "gonorrhea for patients treated with the recommended or alternative regimen.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "For persons with a history of a beta-lactam allergy, a thorough assessment",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "of the reaction is recommended.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZ SET ABX OP GENTAMICIN 240MG IMX1 +AZITH 2000MG X1 GONOC", "Text" : "", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Alternative treatment for beta-lactam allergy for pharynx:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Alternative treatment for beta-lactam allergy for cervix, urethra, or rectum:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "-A test-of-cure is recommended for patients with pharyngeal gonorrhea.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Obtain nucleic acid amplification test (NAAT) 7 to 14 days after initial",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "treatment, regardless of regimen used for pharyngeal gonorrhea.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for patients and no chlamydial co-infection:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Preferred treatment with chlamydial co-infection or chlamydial infection has",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "not been excluded:",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Patients weighing less than 300lbs:",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Patients weighing 300lbs or greater:",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 500MG IM X1 GONOCOCCAL", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 1GM IM X1 GONOCOCCAL", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU CHLAMYDIA URETHRITIS", "Text" : "[Click here] Chlamydial infection and no co-infection", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Chlamydial infection and no co-infection:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC PCR TEST", "Text" : "[Click here] Place order for gonorrhea/chlamydia lab NAAT test", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Lab test:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-When diagnosed with sexually transmitted disease, the patient's sexual",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "partner(s) during the previous 60 days should be evaluated for sexually",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "transmitted infection.",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Gonococcal Infections:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for Doxycycline above", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for Doxycycline above", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM NEGATIVE BACTERIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU INT RS GRAM-NEG BACILLI", "Text" : "Gram-negative bacilli", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU INT RS GRAM-NEG COCCI", "Text" : "Gram-negative cocci", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ GRAM-NEGATIVE BACTERIA ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "site of infection, penetration of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "drug(s)into site, and whether",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "organism is pathogen, colonizer, or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "contaminant. See disease/syndrome",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "section for more information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Interim culture results",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "++ MULTIDRUG RESTANT ORGANISMS ++",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "ESBLS, Amp-C beta-lactamases, and",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Carbapenemases",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Gram-negative bacilli carrying",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "extended-spectrum beta-lactamases",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(ESBLs), AmpC beta-lactamases, or",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "carbapenemases.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "lactamases, and carbapenemases.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Last Reviewed December 2017",  "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG A. BAUMANNI", "Text" : "Acinetobacter baumanni", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG CITROBACTER SPP.", "Text" : "Citrobacter spp.", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG ENTEROBACTER SPP.", "Text" : "Enterobacter spp.", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG E. COLI", "Text" : "Escherichia coli", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG KLEBSIELLA SPP.", "Text" : "Klebsiella spp.", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG PROTEUS SPP.", "Text" : "Proteus spp.", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG SERRATIA SPP.", "Text" : "Serratia spp.", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG BORDETELLA SPP.", "Text" : "Bordetella spp.", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG BRUCELLA SPP.", "Text" : "Brucella spp.", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG CAMPYLOBACTER SPP.", "Text" : "Campylobacter spp.", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG HAEMOPHILUS SPP.", "Text" : "Haemophilus spp.", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU H. PYLORI INFECT", "Text" : "Helicobacter pylori", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG LEGIONELLA SPP.", "Text" : "Legionella spp.", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG P. MULTOCIDA", "Text" : "Pasteurella multocida", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG PSEUDOMONAS SPP.", "Text" : "Pseudomonas spp.", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG SALMONELLA SPP.", "Text" : "Salmonella spp.", "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "Text" : "Shigella spp (bacillary dysentery)", "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG N. MENINGITIDIS", "Text" : "Neisseria meningitidis", "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG N. GONORRHOEAE", "Text" : "Neisseria gonorrhoeae", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG M. CATARRHALIS", "Text" : "Moraxella catarrhalis", "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "Text" : "Bacteroides, Porphyromonas,", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Final culture results",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : ">> Gram-negative bacilli <<",  "Header" : 1}, 
{"Row" : 34, "Column" : 2, "Item" : null, "Text" : ">> Gram-negative cocci <<",  "Header" : 1}, 
{"Row" : 36, "Column" : 2, "Item" : null, "Text" : "Prevotella", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM POSITIVE BACTERIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU INT RS GRAM-POS COCCI PAIRS", "Text" : "Gram-positive cocci", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU INT RS GRAM-POS BACILLI", "Text" : "Gram-positive bacilli", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ GRAM-POSTITIVE BACTERIA ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "site of infection, penetration of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "drug(s) into site, and whether",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "organism is pathogen, colonizer, or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "contaminant. See disease/syndrome",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "section for more information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Interim culture results",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Last Reviewed December 2017",  "Header" : 1}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS STAPHYLOCOCCI", "Text" : "Staphylococci", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. PYOGENES", "Text" : "Group A (S. pyogenes)", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. AGALACTIAE", "Text" : "Group B (S. agalactiae)", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS GROUPS C, F, G", "Text" : "Groups C, F, G", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. BOVIS", "Text" : "Group D (S. bovis)", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS VIRIDANS STREPTO", "Text" : "Viridans streptococci (including", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. PNEUMONIAE", "Text" : "Streptococcus pneumoniae", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS S. ANGINOSUS", "Text" : "Streptococcus anginosus (formerly", "Header" : 0}, 
{"Row" : 30, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "Text" : "Anaerobic Gram-positive cocci", "Header" : 0}, 
{"Row" : 33, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ENTEROCOCCI", "Text" : "Enterococci", "Header" : 0}, 
{"Row" : 36, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS BACILLI SPP.", "Text" : "Bacillus spp.", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS CLOSTRIDIUM SPP.", "Text" : "Clostridium spp.", "Header" : 0}, 
{"Row" : 38, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS CORYNEBACTERIUM SPP.", "Text" : "Corynebacteriium spp.", "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS PROPIONIBACT SPP.", "Text" : "Cutibacterium (formerly", "Header" : 0}, 
{"Row" : 41, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS ACTINOMYCES SPP.", "Text" : "Actinomyces spp.", "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : "ORZID3 GMENU GRAM-POS LISTERIA SPP.", "Text" : "Listeria spp.", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Final culture results",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "____________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : ">> Gram-positive cocci <<",  "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "Streptococci",  "Header" : 1}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "S. mutans, S. mitis, S. sanguis)",  "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : null, "Text" : "S. milleri)",  "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : null, "Text" : "(including Peptostreptococcus)",  "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : null, "Text" : ">> Gram-positive bacilli <<",  "Header" : 1}, 
{"Row" : 40, "Column" : 2, "Item" : null, "Text" : "Propionibacterium) spp.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG A. BAUMANNI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases.", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACINETOBACTER BAUMANNII",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Isolation of Acinetobacter baumannii from a culture often represents",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "contamination or colonization and not disease. For questions about whether a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "patient should be treated, contact Infectious Diseases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Many isolates are resistant to multiple antimicrobials. If susceptibilities are",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "not known, start therapy with imipenem or amikacin.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "If susceptibities are known, use appropriate antimicrobial.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Acinetobacter carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Acinetobacter baumannii",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acinetobacter infection: Treatment and prevention", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG BACTEROIDES SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID METRONIDAZOLE 1 GM PO BID", "Text" : "Metronidazole 1000 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID METRONIDAZOLE 1 GM PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACTEROIDES SPP. (INCLUDING PREVOTELLA, PORPHYROMONAS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "These bacteria are strict anaerobes and will only grow in anaerobic media.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bacteriodes sp., Overview",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Anaerobic bacterial infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG BORDETELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BORDETELLA SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bordetella pertussis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG BRUCELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP DOXY 100MG PO BID RIFAMP 600MG PO QD", "Text" : "Doxycycline 100 mg PO BID ($) [DI] < AND > rifampin 600 mg PO QDAY ($)", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX NV DOXY 100MG PO BID RIFAMP 600MG PO QD", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BRUCELLA SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment for non-localizing disease only. Consult Infectious Diseases for",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "specifc clinical syndrome since regimens vary (e.g. arthritis, neurobrucellosis,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "endocarditis, etc.)",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treat with both drugs for 45 days.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "[DI,O]",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Brucellosis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "brucellosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG CAMPYLOBACTER SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 500MG PO QDAY", "Text" : "Azithromycin 500 mg PO QDAY ($) [O]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CAMPYLOBACTER SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal Optimal therapy depends on both the disease or syndrome and the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pathogen. See diagnosis/syndrome section for more information. Drugs",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "recommended below are best for most cases. If susceptibility results or other",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "factors make these inappropriate for this case, click need an alternative",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For information on gastroenteritis (usually involving C. jejuni), refer to the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Gastrointestinal and Intraabdominal infection section.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment of extraintestinal infectious not involving the central nervous",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "system infections",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment of central nervous system infections",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Campylobacter jejuni, Campylobacter coli",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Campylobacter infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG CITROBACTER SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CITROBACTER SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Citrobacter sp.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG E. COLI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "Text" : "Fosfomycin 3 gm sachet PO ($$) [M] x 1 dose", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSOZID FOSFOMYCIN 3GM PO QOTHERDAY FOR 3DOSES", "Text" : "Fosfomycin 3 gm sachet PO QOD ($$) [M] x 3 doses", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ESCHERICHIA COLI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "infections section.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "E. coli carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections including cystitis",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "E. coli carrying ESBL:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "E. coli carrying carbapenemase:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Escherichia coli",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG ENTEROBACTER SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTEROBACTER SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterobacter sp.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG HAEMOPHILUS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HAEMOPHILUS SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Haemophilus influenzae",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG KLEBSIELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID CEFPODOXIME 100MG PO BID", "Text" : "Cefpodoxime 100 mg PO BID ($$) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID CEFPODOXIME 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "Text" : "Fosfomycin 3 gm sachet PO ($$) [M] x 1 dose", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "KLEBSIELLA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "klebsiella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections including cystitis",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Klebsiella sp.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG LEGIONELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 500MG PO QDAY", "Text" : "Azithromycin 500 mg PO QDAY ($) [O]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "Text" : "Levofloxacin 500 mg PO QDAY ($) [R,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 10DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LEGIONELLA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Consider treating for up to 21 days in immunosuppressed patients who are",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "severely ill upon presentation.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative for patients intolerant to macrolides",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Legionella sp.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment and prevention of Legionella infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG M. CATARRHALIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MORAXELLA CATARRHALIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For intravenous options, please refer to the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Moraxella catarrhalis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Moracella catarrhalis infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG N. GONORRHOEAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEISSERIA GONORRHOEAE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "See diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Disseminated gonococcal infection",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "See Inpatient CDSS for disseminated gonococcal infection",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG N. MENINGITIDIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEISSERIA MENINGITIDIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Central nervous system infections require higher doses of antimicrobials.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neisseria meningitidis",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment and prevention of meningococcal infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG P. MULTOCIDA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID DOXYCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PASTEURELLA MULTOCIDA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pasteurella multocida",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Pasteurella infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG PROTEUS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID CEFPODOXIME 100MG PO BID", "Text" : "Cefpodoxime 100 mg PO BID ($$) [R]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID CEFPODOXIME 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROTEUS SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "proteus carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections including cystitis",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Allergy to penicillin",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Proteus sp.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Extended-spectrum beta-lactamases", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG PSEUDOMONAS SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 750MG PO BID", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 750MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PSEUDOMONAS SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "In severe cases, addition of an aminoglycoside to a beta",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "lactam may be beneficial. Aminoglycoside monotherapy is effective only in",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "treatment of UTI. Refer to genitourinary section for treatment of UTI due to",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "pseudomonas. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Oral treatment for mild infections",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for severe infections",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pseudomonas aeruginosa",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Principles of antimicrobial therapy of Pseudomonas",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "aeruginosa infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG SALMONELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX ESBL KPC ETC", "Text" : "More about ESBLs, Amp-C beta-lactamases, and carbapenemases", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SALMONELLA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For gastroenteritis antimicrobials are not usually indicated. Please refer to",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the Gastrointestinal and Intra-abdominal infections section for more",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consider whether patient is at risk for or has evidence of infection with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "salmonella carrying extended spectrum beta-lactamase (ESBL), Amp-C beta-",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "lactamase, or carbapenemase.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "For localized or systemic extraintestinal infections",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Salmonella sp.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG SERRATIA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID CEFPODOXIME 100MG PO BID", "Text" : "Cefpodoxime 100 mg PO BID ($$) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID CEFPODOXIME 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SERRATIA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Serratia marcescens",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Infections due to Serratia species", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-NEG SHIGELLA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 500MG PO QDAY", "Text" : "Azithromycin 500 mg PO QDAY ($) [O]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SHIGELLA SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information. Drugs recommended below are",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "best for most cases. If susceptibility results or other factors make these",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "inappropriate for this case, click need an alternative antimicrobial.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For gastroenteritis, please refer to the Gastrointestinal and Intra-abdominal",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "infections section for more information. antibiotic resistance is increasing,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "especially among men who have sex with men. Drug selection should be based on",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "antimicrobial susceptibility tests.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for systemic infections",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "MMWR (2015) 64.318",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Shigella Sp.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Shigella infection: Treatment and prevention in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS ACTINOMYCES SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID DOXYCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACTINOMYCES SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with beta-lactam allergy",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Actinomycosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS ANAEROBIC GPC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANAEROBIC GRAM-POSITIVE COCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Anaerobic Gram-positive cocci, including peptostreptococci, are often involved",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "in mixed aerobic/anaerobic infections. Beta-lactams (like ampicillin and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "penicillin) and clindamycin are the drugs of choice against anaerobic gram-",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "positive cocci. Beta-lactam/beta-lactamase inhibitors are active against",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "peptostreptococci, so no additional anaerobic antimicrobials are needed",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "specifically to cover peptostreptococcus when drugs such as ampicillin-sulbactam",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "or piperacillin-tazobactam are used.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Anaerobic Cocci and Anaerobic Gram-Positive Nonsporulating",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Bacilli",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Peptostreptococcus sp.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS BACILLI SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BACILLUS SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "B. cereus",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease/syndrome sections for more information.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "For intravenous options, please refer to the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "If isolate is clindamycin-susceptable",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "B. anthracis",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Start combination therapy and contact Infectious Diseases immediately.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Hendricks et al., Emerg Infect Dis 2014, 20.2",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS CLOSTRIDIUM SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "Text" : "Clostridium difficile disease", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID DOXYCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CLOSTRIDIUM SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For Clostridium difficile disease refer to",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections may be treated with oral antimicrobials. For",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "neutropenic enterocolitis, gas gangrene, or other necrotizing infection,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "intravenous therapy is indicated. Combination therapy may be preferred. Refer",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "to the appropriate section of the CDSS or contact Infectious Diseases for more",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "C. perfringens food poisoning is treated with supportive care. Diarrhea resolves",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "within 24 hours.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "For severe infection with Clostridium spp. other than perfringens, septicum or",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "sordellii, call Infectious Diseases.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Preferred empirical treatment for mild to moderate infections",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "For intravenous options, please refer to the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for beta-lactam allergic patients",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Preferred empirical therapy for severe infections",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford Table 2: Recommended antimicrobial agents",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS COAG NEG STAPH", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS STAPH LUGDUNENSIS", "Text" : "Treatment for Staphylococcus lugdunensis", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID DICLOXACILLIN 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID DICLOXACILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TREATMENT FOR COAGULASE NEGATIVE STAPHYLOCOCCI (CNS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Commonly isolated CNS are S. epidermidis, S. haemolyticus, S. lugdunensis and S.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "saprophyticus. Less commonly isolated CNS are S. auricularis, S capitis, S.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "caprae, S. carnosus, S. cohnii, S. hominis, S. pasteuri, S. petrasii, S.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "pettenkoferi, S. pulvereri, S. saccharolyticus, S. schleiferi, S. simulans, S.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "warneri and S. xylosus",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Unlike other CNS, S. lugdunensis can cause severe disease like S. aureus. Refer",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "to S. lugdunensis page for treatment.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Isolation of coagulase-negative staphylococci from a culture often represents",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "contamination or colonization and not disease. For questions about whether a",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "patient should be treated, contact Infectious Diseases.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "If susceptibility results are known, use them to select one of the following",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "drugs.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "If not, use vancomycin empirically until final culture and susceptibilities are",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "available.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for urinary tract infection associated with S. saprophyticu",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Alternative for resistant organisms",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to take vancomycin",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "promotes bacterial resistance. It should only be used in cases where other",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "options are not feasible. Contact Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Staphylococci",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus sp., Coagulase-negative",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus epidermidis",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Infection due to coagulase-negative staphylococci: Treatment", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS CORYNEBACTERIUM SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID ERYTHROMYCIN 500MG PO TID", "Text" : "Erythromycin 500 mg PO TID ($$) [DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID ERYTHROMYCIN 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID PENICILLIN VK 250MG PO QID", "Text" : "Penicillin VK 250 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID PENICILLIN VK 250MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CORYNEBACTERIUM SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Corynebacterium jeikeium",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease/syndrome sections for more information.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Corynebacterium diphtheriae",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Diphtheria is usually severe and often fatal. Antitoxin is the most important",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "treatment. Contact Infectious Diseases immediately.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "For intravenous options, please refer to the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative for patients intolerant of erythromycin",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Corynebacterium diptheriae",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Corynebacterium jeikeium",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "diptheria", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS ENTEROCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS TREAT ENTEROCOCCI", "Text" : "Treatment for enterococcal infections", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTEROCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The important human pathogens are Enterococcus faecium and Enterococcus",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "faecalis. The antimicrobial susceptibilities that are reported for enterococci",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "depend on the site of the sample. For all enterococci the microbiology",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "laboratory reports susceptibility for ampicillin and vancomycin. Additionally",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "the lab reports fluoroquinolone susceptibility for urinary isolates and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "susceptibility to gentamicin synergy for bloodstream isolates. For more",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "information on culture and susceptibilities, contact the microbiology laboratory",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Ampicillin is the drug of choice for enterococcal infections. Piperacillin is",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "also active against enterococcus. Cephalosporins are ineffective as single",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "agents for enterococcal infections. For patients who are allergic to penicillin",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "or infected with penicillin-resistant enterococcus, vancomycin is the preferred",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "drug. Nitrofurantoin is effective in urinary tract infections only. Linezolid",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "must be reserved for cases where no other drug can be used as it has many side",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "effects and drug interactions, is expensive, is bacteriostatic rather than",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "bactericidal, and its use promotes resistance.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Combination regimens include a primary anti-enterococcal agent (ampicillin or",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "vancomycin) plus gentamicin or streptomycin are synergistic in vitro and are",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "needed for severe infections like endocarditis or prosthetic joint infections.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "See relevant disease/syndrome sections for more information. Milder diseases",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "like cystitis or wound infection can usually be treated with a single drug. For",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "more information on treatment of enterococcal infections, contact Infectious",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Enterococcus Species, Streptococcus gallolyticus Group, and",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Leuconostoc Species",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococcus faecalis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococcus faecium",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment of enterococcal infection",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococcus faecium",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment of enterococcal infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS GROUPS C, F, G", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STREPTOCOCCI GROUPS C, F, G",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If isolate is clindamycin-susceptable",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Groups C and G Streptococci, and Other Related Organisms",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Strep",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Group C and group G streptococcal infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS LISTERIA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LISTERIA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "For meningitis, please refer to the meningitis section for treatment advice.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Listeria monocytogenes",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment, prognosis, and prevention of Listeria",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "monocytogenes infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS PROPIONIBACT SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CUTIBACTERIUM (FORMERLY PROPIONIBACTERIUM) SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Isolation of Propionibacterium species from a culture often represents",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "contamination or colonization and not disease. For questions about whether a",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "patient should be treated, contact Infectious Diseases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "disease/syndrome sections for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Propionibacterium acnes",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Invasive Cutibacterium (formerly Propionibacterium)",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. AGALACTIAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GROUP B STREPTOCOCCI (S. AGALACTIAE)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Group B streptococci (Streptococcus agalactiae) are associated most commonly",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "with bacteremia and meningitis in infants and bacteremia and urinary tract",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "infections in elderly people and people with diabetes mellitus.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "If isolate is clindamycin-susceptable",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Severe infections",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Streptococcus agalactiae (Group B Streptococcus)",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus agalactiae, Group B Strep",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Group B streptococcal infections in nonpregnant adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. ANGINOSUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STREPTOCOCCUS ANGINOSUS (FORMERLY S. MILLERI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Ceftriaxone or penicillin are preferred for central nervous system infection.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Cefazolin or penicillin are preferred for infection outside of the central",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "nervous system.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Streptococcus anginosus group",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus anginosus group",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Infections due to the Streptococcus anginosus (Streptococcus",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "milleri) group", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. BOVIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GROUP D STREPTOCOCCI (S. BOVIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Bacteremia with Streptococcus bovis is associated with malignancy of the colon.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Resistance to penicillin is uncommon. Vancomycin should only be used in a",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "patient with beta-lactam allergy, or if beta-lactam resistance is strongly",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "suspected.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Clinical manifestations, diagnosis, and treatment of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "infections due to group D streptococci (Streptococcus bovis/Streptococcus",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "equinus complex)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. PNEUMONIAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 1000MG PO TID", "Text" : "Amoxicillin 1000 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 1000MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID LEVOFLOXACIN 750MG PO Q24H", "Text" : "Levofloxacin 750 mg PO QDAY ($) [R,DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID LEVOFLOXACIN 750MG PO Q24H", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STREPTOCOCCUS PNEUMONIAE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Refer to Central Nervous System section of the Inpatient Antimicrobial CDSS for",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "treatment of meningitis.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for infections outside of the central nervous system",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with beta-lactam allergy, or when beta-lactam resistance",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "is suspected or proved",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Streptococcus pneumoniae",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus pneumoniae",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Invasive pneumococcal (Streptococcus pneumoniae) infections",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "and bacteremia", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS S. PYOGENES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO x 1 ($) [O] on day 1, then 250 mg PO QDAY ($) [O]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GROUP A STREPTOCOCCI (S. PYOGENES)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Group A streptococcus (Streptococcus pyogenes) is the most virulent",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "streptococcal species. Important syndromes include pharyngitis, cellulitis,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "streptococcal toxic shock syndrome, necrotizing fasciitis, erysipelas, rheumatic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "fever, and post-streptococcal glomerulonephritis. Optimal therapy depends on",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "both the disease or syndrome and the pathogen. See diagnosis/syndrome section",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Mild to moderate infections (non-necrotizing)",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "for 4 days",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Bacteremia, toxic shock syndrome and necrotizing infections",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Streptococcus pyogenes",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcus pyogenes, Beta hemolytic, Group A, B, C, F, G",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Strep",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Group A streptococcal (Streptococcus pyogenes) bacteremia in",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS STAPH LUGDUNENSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID DICLOXACILLIN 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID DICLOXACILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TREATMENT FOR STAPHYLOCOCCUS LUGDUNENSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Severity of S. lugdenensis infections vary from moderate to severe.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Approximately 25% of isolates are resistant to penicillin, but methicillin",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "resistance is uncommon, less than 5% of isolates.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "If susceptibility results are known, use them to select one of the following",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "drugs. If not, use vancomycin empirically until final culture and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "susceptibilities are available.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative for resistant organisms",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to take vancomycin",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "promotes bacterial resistance. It should only be used in cases where other",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "options are not feasible. Contact Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus epidermidis and Other Coagulase-Negative",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Staphylococci",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus lugdunensis",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Staphylococcus lugdunensis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS STAPHYLOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS TREAT S. AUREUS", "Text" : "for Staphylococcus aureus", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZID3 GMENU GRAM-POS COAG NEG STAPH", "Text" : "for coagulase-negative staphylococci", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Click Here", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STAPHYLOCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is a virulent pathogen, and staphylococcal disease tends",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "to relapse. Optimal therapy often involves intravenous therapy for defined",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "durations. See sections on specific syndromes (e.g., bacteremia or",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "endocarditis) for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Coagulase-negative staphylococci, including Staphylococcus epidermidis and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "several less common species, are less virulent than S. aureus and are most",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "commonly pathogenic when they colonize plastic or metal devices in a patient",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "(e.g., intravenous catheters, prosthetic joints or heart valves). S.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "lugdunensis is an uncommon but virulent coagulase-negative staphylococcus",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "species. S. saprophyticus is associated with urinary tract infections in women.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Beta-lactam antimicrobials are the most active drugs against beta-lactam",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "susceptible staphylococci. Penicillin is superior for penicillin-susceptible",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "staphylococci, but most strains are resistant. Nafcillin and oxacillin are",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "nearly as active as penicillin. Cefazolin or ceftriaxone (also beta-lactams are",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "next best. Vancomycin, a glycopeptide, is less active than the beta-lactams.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Trimethoprim-sulfamethoxazole, minocycline, and clindamycin are less effective",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "than beta-lactams for treatment of methicillin-susceptible staphylococcal",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "infections, but may be useful in patients with severe penicillin allergy. For",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "methicillin-resistant staphylococcal infections, trimethoprim-sulfamethoxazole,",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "minocycline, and clindamycin are useful alternatives to to vancomycin, as they",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "are inexpensive and available in both intravenous and oral formulations. They",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "are preferred over linezolid in most circumstances because linezolid is",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "expensive, toxic with long-term use, and needed for treatment of highly",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "resistant bacteria like vancomycin-resistant enterococci.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Combination regimens include a primary anti-staphylococcal agent (beta-lactam or",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "vancomycin) plus one or more supplemental drugs (e.g. gentamicin and/or",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "rifampin) often synergistic against staphylococci in vitro, but there is no",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "evidence that combination therapy improves outcomes in staphylococcal infections",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "in humans. Combination therapy has become the community standard for treatment",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "of prosthetic-valve staphylococcal endocarditis based on experimental models and",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "limited clinical data that combination therapy is superior (see endocarditis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "section for details).",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Decolonization",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Baddour, et al. Circulation 2015, 132.15",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Endocarditis and Intravascular Infections",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus aureus", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS TREAT ENTEROCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID NITROFURANTOIN SA 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TREATMENT FOR ENTEROCOCCAL INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Isolation of enterococci in wounds often represents colonization rather than",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "infection. When colonization is suspected, enterococci need not be treated.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment for urinary tract infections",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment for systemic infections",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to take vancomycin or vancomycin resistant",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "enterococci",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "promotes bacterial resistance. It should only be used in cases where other",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "options are not feasible. Contact Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Enterococcus Species, Streptococcus gallolyticus Group, and",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Leuconostoc Species",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococcus faecalis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Enterococcus faecium",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment of enterococcal infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS TREAT S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID DICLOXACILLIN 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID DICLOXACILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TREATMENT FOR STAPHYLOCOCCUS AUREUS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If susceptibility results are known, use them to select one of the following",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "drugs.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "If not, use vancomycin empirically until final culture and susceptibilities are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "available.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative for resistant organisms",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Alternative for patients unable to take vancomycin",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Linezolid has many drug interactions and adverse effects, is expensive, and",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "promotes bacterial resistance. It should only be used in cases where other",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "options are not feasible. Contact Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Staphylococcus aureus",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staphylococcus aureus", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU GRAM-POS VIRIDANS STREPTO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "VIRIDANS STREPTOCOCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Viridans streptococci are a heterogeneous group defined by their production of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "green pigment on blood agar. Clinically important members of this group include",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "S. mutans, S. mitis, and S. sanguis. S. anginosus (formerly S. milleri) and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Streptococcus bovis are described separately. Viridans streptococci are",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "important, common pathogens in endocarditis and can also be contaminants in",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "cultures of blood and other specimens. Consult Infectious Diseases for more",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Refer to the Cardiovascular Section of the Inpatient Antimicrobialc CDSS for",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "diagnosis and treatment of endocarditis",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred treatment is penicillin or cefazolin. Vancomycin should be used only",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "in patients with beta-lactam allergy, or if beta-lactam resistance is strongly",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "suspected. For serious disease, consider addition of gentamicin for synergy.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Intravenous antimicrobials are indicated. Refer to Inpatient Animicrobial CDSS.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Viridans Streptococci, Nutritionally Variant Streptococci,",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Groups C and G Streptococci, and Other Related Organisms",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococci, viridans group", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU H. PYLORI INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP CLAR500MGBID AMOX1GMBID METRO500MGBID OMEP20MG", "Text" : "Clarithromycin 500 mg PO BID ($)[R,DI] <AND> Amoxicillin 1000 mg PO BID", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX NV CLAR500MGBID AMOX1GMBID METRO500MGBID OMEP20MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX OP BIS524MGQID DOXY100MGBID METRO500MGBID OMEP20MG", "Text" : "Bismuth subsalicylate 524 mg PO QID <AND> doxycycline 100 mg BID ($)", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX NV BIS524MGQID DOXY100MGBID METRO500MGBID OMEP20MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HELICOBACTER PYLORI INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "H. pylori infection is associated with peptic ulcers, gastritis, gastric",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "adenocarcinoma, and gastric lymphoma. Antimicrobials should be given to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "patients with confirmed H. pylori infection. Antisecretory therapy should be",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "given concurrently. Contact Gastroenterology for more information.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "($)[R] <AND> metronidazole 500 mg PO BID ($) [DI] <AND> omeprazole 20",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "mg PO BID for 14 days",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "[DI]<AND> metronidazole 500 mg PO BID ($) [DI] <AND> omeprazole 20 mg PO BID",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "for 14 days",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Fallone et al, Gastroenterology, 2016,151:61-69",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Helicobacter pylori and Other Gastric Helicobacter Species",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gastric/Duodenal Ulcer, Helicobacter pylori",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment regimens for Helicobacter pylori", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU HEAD AND NECK/ENT OUTPT MAIN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU MALIGN OTITIS EXTERNA", "Text" : "Malignant Otitis Externa", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU MASTOIDITIS", "Text" : "Mastoiditis", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU OTITIS EXTERNA", "Text" : "Otitis Externa", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU OTITIS MEDIA", "Text" : "Otitis Media", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU CONJUNCTIVITIS", "Text" : "Conjunctivitis", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ENDOPHTHALMITIS", "Text" : "Endophthalmitis", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU KERATITIS", "Text" : "Keratitis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU PERIOCULAR INFECTIONS", "Text" : "Periocular Infections", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU PROPHYLAXIS OPTH SURG", "Text" : "Prophylaxis for Ophthalmic Surgery", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU RETINITIS", "Text" : "Retinitis", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU UVEITIS", "Text" : "Uveitis", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU BELL PALSY", "Text" : "Bell's Palsy", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU PRESEPTAL CELLULITIS", "Text" : "Pre-septal Cellulitis", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "Text" : "Post-septal Cellulitis (Orbital Cellulitis)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++HEAD AND NECK++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Ear/Otologic",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Eye/Ophthalmologic",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Facial",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Section last reviewed June 2021",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID3 GMENU ACUTE SINUSITIS (OPT)", "Text" : "Acute Sinusitis", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID3 GMENU CHRONIC SINUSITIS", "Text" : "Chronic Sinusitis", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID3 GMENU FUNGAL SINUSITIS", "Text" : "Fungal Sinusitis", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID3 GMENU NASAL PACKING", "Text" : "Nasal Packing (to prevent infection)", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU NOSO SINUSITIS", "Text" : "Nosocomial Sinusitis", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU DEEP OROPHARYN INFECT", "Text" : "Deep Oropharyngeal Infections", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Dental Infections", "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID3 GMENU EPIGLOTTITIS", "Text" : "Epiglottitis", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "ORZID3 GMENU ABX ESOPHAGITIS", "Text" : "Esophagitis", "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID2 GMENU ABX LARYNGITIS AND CROUP", "Text" : "Laryngitis", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "ORZID3 GMENU ABX PAROTITIS", "Text" : "Parotitis", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "ORZID3 GMENU PERIODENTAL DISEASE", "Text" : "Periodontal Disease", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU PERTUSSIS", "Text" : "Pertussis", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "ORZID3 GMENU PHARYNGITIS", "Text" : "Pharyngitis", "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : "ORZID3 GMENU FUNGI C. ALBICANS", "Text" : "Thrush", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU PHARYNGITIS", "Text" : "Tonsillitis", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "Text" : "Tooth Abscess and other Suppurative Odonotogenic Infections", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Nasal/Sinus",  "Header" : 1}, 
{"Row" : 12, "Column" : 2, "Item" : null, "Text" : "Throat/Oropharyngeal", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU HEAD LICE (PEDICULOSIS CAPITIS)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX TREAT HEAD LICE URL", "Text" : "http://www.cdc.gov/ncidod/dpd/parasites/lice/2004_PDF_Treating_head_lice.pdf", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "Text" : "Permethrin 1% lotion Apply to affected area for 10 minutes then comb out", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "HEAD LICE (PEDICULOSIS CAPITIS)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "To make a diagnosis, use a nit comb, bright light, or lens to find a louse",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "living on the scalp.Dead nits may remain for months after successful",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "treatment.Dead nits are usually located more than 6 mm from the scalp.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Lice are often transmitted by infected clothing and bedclothes but not by",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "ordinary furniture that is not typically in contact with hair or scalp.Refer",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "to the following for advice on household cleaning for lice infestations:",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Repeat if live lice are seen 7-10 days after treatment.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "nits ($) [M]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: lice",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU HEPATITIS B EVALUATION ANTI-CD20 ANTIBODY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX HEPATITIS B ONCOLOGY SHAREPOINT", "Text" : "Hepatitis B Oncology SharePoint", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "LRTZ HEPATITIS B SEROLOGY PANEL", "Text" : "HEPATITIS B SEROLOGY PANEL", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "GMRCTZ GASTROENTEROLOGY LIVER OUTPT", "Text" : "GASTROENTEROLOGY LIVER OUTPATIENT CONSULT", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "LRTZHIV (RAPID) QUALITATIVE", "Text" : "HIV RAPID TEST (results in 1-2 hours)", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "Text" : "CONSULT ID FOR HIV POSITIVE PATIENTS", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX LRTZ COMPREHENSIVE METABOLIC + MG + PHOSPHORUS", "Text" : "ORDER LABS: COMPREHENSIVE METABOLIC + PHOSPHORUS", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "LRTZ Hepatitis B DNA level (viral load)", "Text" : "HEPATITIS B DNA LEVEL (VIRAL LOAD)", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "GMRCTZ GASTROENTEROLOGY LIVER OUTPT", "Text" : "GASTROENTEROLOGY LIVER OUTPATIENT CONSULT", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "LRTZ Hepatitis B DNA level (viral load)", "Text" : "Hepatitis B DNA level (viral load)", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSOZID ENTECAVIR 0.5MG PO QDAY HEPATITIS B (ANTI-CD20 AB)", "Text" : "Entecavir 0.5 mg po daily (throughout anti-CD20 antibody therapy", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSOZID ENTECAVIR 1MG PO QDAY HEPATITIS B (ANTI-CD20 AB)", "Text" : "Entecavir 1 mg po daily (througout anti-CD20 antibody therapy", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "PSOZID TENOFOVIR 300MG PO QDAY ANTI-CD20 THERAPY", "Text" : "Tenofovir 300 mg PO daily (throughout anti-CD20 antibody therapy", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Hepatitis B evaluation for patients receiving Anti-CD20 Antibody Treatment",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NOTE: OUTPATIENT ORDERS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Before initiating anti-CD20 antibody treatment (rituximab, obinutuzumab,",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "ofatumumab) test all patients for Hepatitis B. Testing should be completed",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "within the last 6 months prior to the start of the initial infusion (same day",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "is acceptable, but not preferred). Annual Hepatitis B screening is not",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "necessary unless there are risk factors.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "More information at VHA Oncology SharePoint site for hepatitis B reactivation:",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Order Hepatitis B Serology Panel for all patients:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Includes hepatitis B surface antigen (HBsAg), anti-hepatitis B core antibody",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "(total anti-HBcAb),and anti-hepatitis B surface antibody (anti-HBsAb).",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "IF HBsAg or anti-HBcAb is positive, Consult GI for all services except",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Oncology:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "(Includes Rheumatology, Renal, Neurology, and Dermatology)",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "IF HBsAg or anti-HBcAB is positive for an ONCOLOGY patient initial orders:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "a) Assess HIV status. To avoid potential HIV resistance-",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "refer HIV positive patients to ID for management.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "b) Obtain Labs: Comprehensive Metabolic AND Phosphorus",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "c) Obtain HBV DNA level (viral load) initially",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "d) Schedule GI Clinic Consult for co-management to order",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "liver imaging and follow-up as indicated.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "e) Start hepatitis B antiviral treatment (see below)",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Recommended Antiviral Treatment:",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Continue antivirals throughout anti-CD20 Ab therapy and for an additional",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "12 months to prevent hepatitis B reactivation, hepatitis, liver failure,",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "and death.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Obtain HBV DNA level (viral load) every 3 months",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "IF PATIENT IS CURRENTLY ON HEPATITIS B ANTIVIRAL THERAPY:",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "(lamivudine, adefovir, or telbivudine)",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Consult the provider who ordered the antiviral and inform the",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "provider the patient is being initiated on Anti-CD20 antibody therapy.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "IF PATIENT IS NOT ON HEPATITIS B ANTIVIRAL THERAPY:",  "Header" : 1}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Lamivudine-naive patients:",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "and for an additional 12 months after therapy completed). (Cost $$) [R,O]",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Lamivudine-experienced patients:",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Preferred Treatment:",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "and for an additional 12 months after therapy completed). (Cost $$) [R,O]",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Alternative Treatment:",  "Header" : 1}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "IF creatinine clearance equal to or greater than 50 ml per minute",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "and for an additional 12 months after therapy completed). (Cost $$) [R,O]",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Terrault NA, Hepatology 2016, 63:261",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Perrillo RP, Gastroenterology 2015, 148:221",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Hwang JP, Journal of Clinical Oncology 2015, 33:2212",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Up-to-Date", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU HERPES WHITLOW", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 10DS 400MG PO TID", "Text" : "Acyclovir 400 mg PO TID for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 10DS 400MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 10DS 1GM PO BID", "Text" : "Valacyclovir 1 gm PO BID for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 10DS 1GM PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HERPES WHITLOW (DIGIT OR HAND CELLULITIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Alternative for easier compliance schedule",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Whitlow, herpetic", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU HIDRADENITIS SUPPURATIVA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID CHLORHEXIDINE GLUCONATE WASH Q24H", "Text" : "Chlorhexidine gluconate 4% liquid topically wash affected area q24h ($) [M]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSHZID CHLORHEXIDINE GLUCONATE WASH Q24H", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID BENZOYL PEROXIDE 10% WASH TOPICALLY Q24H", "Text" : "Benzoyl peroxide 10% soap topically wash affected area q24h ($) [M]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSHZID BENZOYL PEROXIDE 10% WASH TOPICALLY Q24H", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 1% CRM TOP BID PRN", "Text" : "Clindamycin 1% solution topically to affected areas q12h prn for flares ($) [M]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 1% CRM TOP BID PRN", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO Q12H 12WEEKS", "Text" : "Doxycycline 100 mg PO q12h ($) [DI] for 12 weeks", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO Q12H 12WEEKS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 100MG PO Q12H 12WEEKS", "Text" : "Minocycline 100 mg PO q12h ($) [DI] for 12 weeks", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 100MG PO Q12H 12WEEKS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 300MG PO Q12H 12WEEKS", "Text" : "Clindamycin 300 mg PO q12h for 12 weeks ($) [H,O]", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 300MG PO Q12H 12WEEKS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZ SET ABX OP MOXI400POQ12H RIFAM300POQ12H 12W METRO500Q8H6W", "Text" : "Moxifloxacin 400 mg PO q24h ($)[R,DI] for 12 weeks <AND> metronidazole 500", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZ SET ABX NV MOXI400POQ12H RIFAM300POQ12H 12W METRO500Q8H6W", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HIDRADENITIS SUPPURATIVA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A chronic inflammatory condition that typically involves occlusion, rupture,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "abscess formation and infection of hair follicles as well as secondary infection",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "of apocrine glands/surrounding tissues. Lesions most often occur in the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "intertriginous areas (axillae, inguinal and anogenital) in is associated with",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "smoking and obesity. There is a 40% genetic predisposition for hidradenitis",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "suppurativa (HS) and is often accompanied by pain, malodor, and drainage.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Cultures are negative 50% of the time and often are polymicrobial with S.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "epidermidis and S. aureus most isolated. The Hurley Staging System is often used",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "to determine severity of HS.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Therapy generally consists of treatment of comorbidities that can exacerbate HS,",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "avoidance of triggers, pain management, wound care, and topical/oral",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "antimicrobials. Hormonal agents, steroids, retinoids, and surgery can also be",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "used to treat certain patients. Biologics may be considered in Stage II-III HS.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Consult Dermatology in all cases",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Hurley Staging System:",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Stage I: recurrent nodules and abscesses with minimal scarring",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Stage II: limited number of sinuses and/or scarring within a body region",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Stage III: multiple or extensive sinuses and/or scarring",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Duration of Therapy:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Treatment is typically for 12 weeks but may require longer durations in certain",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "cases. Metronidazole should only be used for a maximum of 6 weeks to avoid",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "neurologic toxicity.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Interventions for All Patients:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Smoking cessation, weight loss, avoidance of triggers, and pain management",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "should be part of all treatment plans. Consult Dermatology for use of hormonal",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "agents, steroids, retinoids, and surgery.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Optional Topical Treatment, May be Used in Addition to Oral Therapies Below:",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "< ADD ON THERAPY FOR FLARES - MUST USE IN ADDITION TO ONE OF THE AGENTS ABOVE>",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Stage I-II Initial Treatment:",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Stage III Initial Treatment and Stage I-II Failure of Oral Doxycycline:",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Stage II-III Failure of Oral Clindamycin:",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "mg q8h ($) [DI] for 6 weeks <AND> rifampin 300 mg PO q12h ($) [DI,O] for 12",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "weeks",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Alikhan, Ali, et al. Journal of the American Academy of Dermatology 81.1 (2019):",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "76-90",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "John Hopkins ABX Guide Keyword: Hidradenitis Suppurativa",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Hidradenitis suppurativa: Management",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Hidradenitis suppurativa: Pathogenesis, clinical features,",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "and diagnosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU HSV ENCEPHALITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "HERPES SIMPLEX VIRUS ENCEPHALITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU IG DEFICIENCY HIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "IMMUNOGLOBULIN DEFICIENCY (HUMORAL IMMUNE SYSTEM)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antibody deficiency typically leads to recurrent, severe respiratory tract",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infections associated with encapsulated bacteria, especially Streptococcus",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pneumoniae and Haemophilus influenzae, and to a lesser extent, Staphylococcus",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "aureus. Recurrent otitis media, sinusitis, and pneumonia are common syndromes.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Gastrointestinal disease associated with Salmonella, Shigella, Campylobacter, or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "rotavirus is also common in some patients.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Preferred empirical treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ILEUS/TOXI MEGACOLON", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEVERE/LIFE-THREATENING CLOSTRIDIUM DIFFICILE INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU IMMUNOCOM COMP DEFICIENCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "COMPLEMENT DEFICIENCY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Complement deficiency can be inherited or acquired complement deficiency.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Acquired defects are usually a consequence of other diseases like systemic lupus",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "erythematosus.Complement deficiency leads to increased rates of infections,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "usually of the upper respiratory tract, but also occasionally with bacteremia or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "meningitis.Pathogens are usually Streptococcus pneumoniae, Neisseria",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "meningitidis, and Neisseria gonorrhea.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Patients presenting with fever or other symptoms suggesting systemic bacterial",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "infection should be treated immediately with antimicrobials active against these",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "pathogens.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred empirical treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Rich RR et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Roitt I et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU IMMUNOCOM MALIGNANCY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "Text" : "Neutropenic fever", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "Text" : "Prevention of bacterial infections in a patient with malignancy", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "Text" : "Prevention of fungal infections in a patient with malignancy", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Prevention of antiviral infections in a patient with malignancy", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MALIGNANCY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Malignancies affect host defenses in many ways.Hematogenous malignancies can",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diminish the effectiveness of neutrophils and other cells involved in host",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "defense.Tumors often disrupt mucous membranes or blood vessels and allow",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "contaminating organisms into hollow cavities or the bloodstream.Chemotherapy",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "used to treat these malignancies often impairs mucus membranes and suppresses",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "neutrophil production and function.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobials are not indicated for patients with malignancy and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "fever unless they have neutropenia or a specific infectious disease, except in",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "specific circumstances.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU IMMUNOCOM NEUROL DYSFUNCT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "Text" : "Aspiration pneumonia", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUROLOGICAL DYSFUNCTION",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Several types of neurological dysfunction predispose patients to infectious",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diseases.Comatose patients are unable to keep weight off dependent tissues,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "predisposing them to decubitus ulcers and pressure necrosis.Atelectasis is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "common in obtunded patients who cannot cough or breathe deeply.When patients",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "require artificial ventilation, intubation compounds the risk of respiratory",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "infection.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Neurological dysfunction of the bladder can interfere with normal bladder",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "emptying and predisposes patients to bacteriuria.The risk of bacteruria",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "increases if patients are catheterized.Antimicrobial treatment is not",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "indicated for asymptomatic bacteriuria.It provides no benefit and increases",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "risk of colonization with resistant organisms.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Neurological dysfunction of the gastrointestinal or pulmonary systems",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "predisposes patients to aspiration of oropharyngeal or gastric contents.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Aspiration causes fever, inflammation, and/or pulmonary infiltrate, but does not",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "require antimicrobial treatment. Bacterial pneumonia occurs in a minority of",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "patients who experience significant aspiration, typically about 3 days later.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "The patient usually improves for the first 2 days and then worsens as bacterial",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "pneumonia develops with increased fever, new or progressive infiltrates,",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "leukocytosis, and newly purulent sputum.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Rich RR, et al, eds.Clinical Immunology",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Roitt I, et al, eds.Immunology", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU IMMUNOCOMPROMISED PT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM BASIC CONCEPTS", "Text" : "Basic concepts", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM ALTERED MICRO FLORA", "Text" : "Altered microbial flora", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM COMP DEFICIENCY", "Text" : "Complement deficiency", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM DIABETES MELLITUS", "Text" : "Diabetes Mellitus", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM HYPOCHLORHYDRIA", "Text" : "Hypochlorhydria", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM MALIGNANCY", "Text" : "Malignancy", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM MALNUTRITION", "Text" : "Malnutrition", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU IMMUNOCOM NEUROL DYSFUNCT", "Text" : "Neurological dysfunction", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM NEUTROPENIA", "Text" : "Neutropenia", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "Text" : "Neutropenic fever", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "Text" : "Spleen absent or dysfunctional", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM STRESS", "Text" : "Stress", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID2 GMENU IMMUNOCOM TOBACCO SMOKE", "Text" : "Tobacco smoke", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "Text" : "Pneumocystis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ INFECTIONS IN IMMUNOCOMPROMISED PATIENTS - OUTPATIENT ++",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Innate defects",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Last reviewed February 2012",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID2 GMENU ABX HIV-AIDS", "Text" : "HIV", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID2 GMENU CMI DEFECTS", "Text" : "Cell-mediated immunity (CMI) defects", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : "ORZID3 GMENU IG DEFICIENCY HIS", "Text" : "Immunoglobulin deficiency (humoral immune system)", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "ORZID2 GMENU TRANSPLANTATION", "Text" : "Transplantation", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : null, "Text" : "Immune defects", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU IMPETIGO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID MUPIROCIN 2% OINT TID FOR 5 DAYS", "Text" : "Mupirocin ointment to affected area TID for 5 days ($) [M]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID MUPIROCIN 2% OINT TID FOR 5 DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 10DS 250MG PO QID", "Text" : "Cephalexin 250 mg PO QID ($) [R] < OR >", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 CEPHALEXIN 10DS 250MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 DICLOXACILLIN 10DS 250MG PO QID", "Text" : "Dicloxacillin 250 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 DICLOXACILLIN 10DS 250MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100MG PO bid ($) [DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS PO BID 7DS", "Text" : "Trimethoprim sulfamethoxazole 1 DS tablet PO bid ($) [R,DI]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100MG PO bid ($) [DI]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Impetigo and Ecthyma",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Impetigo is a superficial skin infection that rarely causes systemic",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "symptoms. Ecthyma is a skin infection characterized by crusted sores",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "beneath which ulcers form. It is a deep form of impetigo, as the same",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "bacteria causing the infection are involved. Ecthyma causes deeper",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "erosions of the skin into the dermis.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Gram stain and culture of the pus or exudates from skin lesions of",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "impetigo and ecthyma are recommended to help identify whether",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus and/or beta-hemolytic Streptococcus is the cause.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Bullous and non-bullous impetigo can be treated with oral or topical",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobials, but oral therapy is recommended for patients with",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "numerous lesions or in outbreaks affecting several people to help",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "decrease transmission of infection. Treatment for ecthyma should be an",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "oral antimicrobial.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment for impetigo with few lesions",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment for ecthyma and for impetigo with numerous lesions or",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "whose symptoms have not responded to topical treatment",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treat orally for 7 days",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "IF MRSA confirmed or suspected:",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014 59: 147",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Montravers P Curr Opin Infect Dis 2016, 29:131", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU COM ACQ DIARRHEA/NO TRAVEL", "Text" : "Community acquired diarrhea (no recent travel)", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID3 GMENU TRAVELER DIARRHEA", "Text" : "Traveler's diarrhea", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA AEROMONAS", "Text" : "Aeromonas", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Adenovirus", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Astrovirus", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA CAMPYLOBACTER", "Text" : "Campylobacter", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "ORZID3 GMENU CDIFFICILE COLITIS", "Text" : "[CLICK HERE] for mild to moderate disease", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "ORZID3 GMENU ILEUS/TOXI MEGACOLON", "Text" : "[CLICK HERE] for severe/life-threatening disease (shock, ileus and megacolon)", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA ISOSPORA BELLI", "Text" : "Cystoisospora belli", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA C. PARVUM", "Text" : "Cryptosporidium parvum", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA C. CAYETANENSIS", "Text" : "Cyclospora cayetanensis", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA E. HISTOLYTICA", "Text" : "Entamoeba histolytica", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA ENTEROHEM E. COLI", "Text" : "Escherichia coli [CLICK HERE], including varieties listed below:", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA G. LAMBLIA", "Text" : "Giardia duodenalis", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA MICROSPORIDIA", "Text" : "Microsporidia", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Norovirus", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Rotavirus", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU COMM VIRAL GASTROENTERITIS", "Text" : "Sapovirus", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA SALMONELLA", "Text" : "Salmonella", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA SHIGELLA", "Text" : "Shigella", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA VIBRIO CHOLERA", "Text" : "Vibrio cholerae", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA VIBRIO NON CHOLERA", "Text" : "Vibrio non-cholerae", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "ORZID3 GMENU DIARRHEA Y. ENTEROCOLITICA", "Text" : "Yersinia enterocolitica", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INFECTIOUS DIARRHEA / GASTROENTERITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most episodes of acute diarrhea are self limited and do not need to be evaluated",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "or treated. In most mild to moderate cases, antimicrobial therapy does not",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "provide benefit and may prolong symptoms or shedding. Antimicrobial therapy is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "detrimental in cases involving enterohemorrhagic Escherichia coli.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "The decision for whether to test stool depends on illness severity and duration,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "the likelihood of specific infectious agents and the severity of any underlying",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "diseases. Send stool sample for enteric pathogen PCR testing if the patient has",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "volume depletion warranting hospitalization, bloody stool, >/= 6 stools in 24",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "hours, temperature >38.4?C, or severe abdominal pain or signs of sepsis, or is",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : ">/= 70 years old or substantially immunocompromised. Replace fluid losses and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "correct electrolyte imbalances. Patients with diarrhea who were potentially",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "exposed during a community outbreak of infectious diarrhea should be tested for",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "the suspected bacterial, viral, and parasitic agents regardless of symptom",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "severity.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Obtain blood cultures if patients have signs of septicemia, suspected enteric",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "fever (e.g., fever plus recent travel to an endemic area or contact with someone",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "who has enteric fever), other systemic symptoms, immune compromise, or other",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "high-risk conditions.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm.",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "For more information on when an antimicrobial is indicated or if the patient has",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobial treatment of diarrhea",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Treatment of diarrhea caused by specific bacteria, parasites, and viruses",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Clostridium difficile:",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Enteroaggretive E. coli (EAEC), Enterotoxigenic E. coli (ETEC),",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Enterohemorrhagic E. coli (EHEC), Shiga Toxin-producing E. coli (STEC),",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Enteropathogenic E. coli (EPEC), Enteroinvasive E. Coli (EIEC)",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Sanford guide keyword: Gastroenteritis, Diarrhea: Overview",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Approach to the adult with acute diarrhea in resource-rich",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "settings", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU INFLUENZA 2021-2022 OUTPATIENT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza Vaccination Recommendations", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL TREATMENT", "Text" : "Antiviral Treatment Recommendations", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA CHEMOPROPHYLAXIS", "Text" : "Chemoprophylaxis Recommendations", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ GMENU LAB NASOPHARYNGEAL TESTING MAIN", "Text" : "Lab Influenza Testing Menu", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Seasonal Influenza",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Last reviewed September 2021", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU INFLUENZA CHEMOPROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Early treatment as alternative to chemoprophylaxis:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "In most cases, if a person is suspected of having been exposed to influenza,",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "early treatment should signs or symptoms develop is preferred rather than",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "chemoprophylaxis.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "The provider should explain the early signs and symptoms of influenza to the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "patient and advise the patient to immediately contact a health care provider",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "for evaluation and possible early treatment if these symptoms or signs",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "develop. Influenza-like symptoms or signs include fever, cough, sore throat,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "runny or stuffy nose, body aches, headache, chills, fatigue, vomiting, and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "diarrhea. Influenza can present without fever.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Health care providers should use clinical judgment regarding situations where",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "early recognition of illness and treatment might be an appropriate",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "alternative to chemoprophylaxis.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Early treatment alternative or chemoprophylaxis may be considered:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "*Persons who are part of a high-risk group and are household or close",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "contacts of someone with influenza-like illness",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "*Health care personnel who have occupational exposures",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Chemoprophylaxis recommended:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Chemoprophylaxis considered:",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "*Atypical situations (such as case clusters). Contact state health department",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "for consultation.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Antiviral Prophylaxis Recommendations:",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Zanamivir is not recommended for patients with chronic respiratory disease such",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "as asthma or chronic obstructive pulmonary disease. These patients may have",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "bronchospasm with zanamivir. If zanamivir must be used, and patients are using",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "an inhaled bronchodilator, zanamivir should be taken just after the",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "bronchodilator.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Zanamivir 2 inhalations (2 x 5 mg) daily for 14 days ($) [O] Duration based on",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Centers for Disease Control (CDC) (Accessed 9/8/21)",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "(https://www.cdc.gov/flu/index.htm)",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Up-to-date: Prevention of seasonal influenza with antiviral drugs in adults",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Chemoprophylaxis duration: 7 days after last known exposure",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "*For control of outbreaks in institutional settings (long-term care",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "facilities and hospitals)",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Chemoprophylaxis duration: minimum of 2 weeks and continuing up to 1 week",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "after the last known case identified",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Note: Antiviral chemoprophylaxis is recommended for all residents, including",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "those who have received influenza vaccination.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Preferred treatment:",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 OSELTAMIVIR 75 MG PO QDAY PROPHY 14 DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSHZID3 OSELTAMIVIR 75 MG PO QDAY 14D PROPHY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Alternative treatment:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Requires Infectious Disease Approval",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "last exposure",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Baloxavir 80 mg PO x1 dose patients wt 80kg or greater, 40mg PO x1dose for",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "patients wt <80kg ($$$) [O]", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID2 GMENU ABX INFLUENZA EGG ALLERGY ACIP", "Text" : "ACIP Information on Influenza Vaccination and Egg Allergies", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "MVAHCS Vaccination Recommendations for Outpatients:",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Annual influenza vaccination is recommended for all persons aged 6",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "months and older without a specific contraindication. The Quadrivalent",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "influenza vaccine is made up of the four flu strains most likely to",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cause the flu during the upcoming season (H1N1, H3N2, and two",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "group B viruses).",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Quadrivalent influenza vaccine will be administered at MVAHCS",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "for seasonal influenza 2021-2022.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "The Advisory Committee on Immunization Practices (ACIP) does not express a",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "preference for use of any particular product over another, for persons for",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "whom more than one type of influenza vaccine is appropriate.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Flu shot information:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "The influenza vaccine dispensed at MVAHCS is latex and preservative free.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Recommended administration to pregnant women during any trimester per CDC.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "All Veterans should receive flu vaccine regardless of egg allergyor",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "present illness.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "History of Guillain Barre Syndrome or previous flu shot reaction more severe",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "than mild-modrate arm pain, swelling, fatigue, or low grade fever, is",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "a contraindication to future receipt of the vaccine.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Recommend observing all patients for 15 minutes after receipt of any",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "influenza vaccine. A previous severe allergic reaction to influenza vaccine,",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "regardless of the component suspected of being responsible for the reaction,",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "is a contraindication to future receipt of ANY influenza vaccine.",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Recommended for all patients (including patients with egg allergies):",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "** Influenza vaccine is a Standing Order, thus does not need an order placed **",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Administer: Standard Dose Quadrivalent Vaccine Once",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Additional information regarding influenza vaccine for patients with",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "egg allergies.",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "It was once believed that patients with egg allergies were at risk of allergic",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "reaction to traditional starting influenza vaccines.However, in 2016-2017",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "the ACIP changed the recommendation for persons with egg allergies to state",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "that they can receive any formulation of age-appropriate flu vaccine",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "regardless of severity of egg allergy. To read more about reason for this",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "change select below.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Minneapolis VAHCS Influenza Commitee 2021-2022",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Up-to-date online: Influenza vaccination in individuals with egg allergy",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Grohskopf LA, MMWR Recommendations and Reports 2021, 70(5):1-28", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU INI EPISODE ABX ASSOC COLITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID VANCOMYCIN 125MG CAP QID 10DS", "Text" : "Vancomycin 125 mg PO QID for 10 days ($) [M]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID VANCOMYCIN 125MG CAP QID 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INITIAL EPISODE OF CLOSTRIDIUM DIFFICILE INFECTION (CDI)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Discontinue implicated antibiotic and avoid high-risk antibiotic if antibiotic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "therapy is still needed. Discontinue antacid therapy if possible.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Initial Episode Preferred Treatment:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Clostridium difficile infection",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium difficile",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Clinical",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "manifestations and diagnosis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "(e.g., age >65 years old, concomitant antibiotic use during CDI treatment,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "and/or immunosuppression)",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Patient at increased risk of CDI recurrence:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200MG PO Q12H 10DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Patient not meeting criteria above for increased risk of CDI recurrence:",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Patient with clinical symptom onset (e.g., 3 or more unformed stools in 24 hours",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "after discontinuation of laxatives) and laboratory confirmation of CDI.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG PO BID 10DS", "Text" : "Non-VA order for above", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU INT RS GRAM-NEG BACILLI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM RESULTS: GRAM-NEGATIVE BACILLI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pseudomonas, Bordetella, and Brucella spp. usually grow aerobically (but can",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "show up in an anaerobic bottle). Bacteroides, Fusobacterium, Porphyromonas, and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Prevotella spp. usually grow anaerobically (but can show up in an aerobic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "bottle). Most other gram-negative bacilli are facultative, i.e. they can grow",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "in aerobic or anaerobic culture conditions.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Some antimicrobial combinations are synergistic in vitro against some Gram-",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "negative bacilli. Combination therapy has not been shown to improve outcomes",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "in most circumstances. Single drug therapy is used in most cases. Contact",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Use susceptibility information to select an antimicrobial when a pathogen is",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "identified.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Antibacterial Activity Spectra",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford Keyword: Pseudomonas aeruginosa",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Principles of antimicrobial therapy of Pseudomonas",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "aeruginosa infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU INT RS GRAM-NEG COCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM RESULTS: GRAM-NEGATIVE COCCI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Gram-negative cocci may represent meningococci, gonococci, or Moraxella.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neisseria meningitidis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Neisseia gonorrhoeae",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Moraxella catarrhalis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU INT RS GRAM-POS BACILLI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "Text" : "LARGE UNIFORM BACILLI in an AEROBIC bottle", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "Text" : "LARGE UNIFORM BACILLI in an ANAEROBIC bottle", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "Text" : "SMALL PLEOMORPHIC BACILLI in ANAEROBIC bottle", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "Text" : "SMALL PLEOMORPHIC BACILLI in AEROBIC bottle", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTERIM REPORT OF GRAM-POSITIVE BACILLI",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "There are three typical morphologies (1)large and regular, (2)medium sized and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "variable, and (3)small and pleomorphic. The large, uniformly rod-shaped Gram-",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "positive bacilli are usually Bacillus spp. (aerobic) or Clostridium species",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "(anaerobic). Bacillus spp. include Bacillus subtilis (usually a contaminant),",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Bacillus cereus, and Bacillus anthracis. Medium-sized Gram-positive bacilli are",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "usually Lactobacilli (anaerobic). Small and pleomorphic bacilli are usually",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Listeria (aerobic), diphtheroids (aerobic), Propionibacteria (anaerobic), and",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Corynebacteria (aerobic)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU INT RS GRAM-POS COCCI PAIRS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Help, additional information:",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help page (instructions, restrictions, microbiology, etc.)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "Text" : "Consult Infectious Diseases", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "INTERIM REPORT OF GRAM-POSITIVE COCCI IN PAIRS",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "A preliminary report of gram-positive cocci in pairs suggests staphylococci,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "streptococci, or enterococci.If the patient is severely ill, is likely",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "colonized with resistant organisms, or if staphylococci or enterococci are",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "likely, treat with vancomycin until susceptibility results are known.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Cephalosporins are not active against enterococci or methicillin-resistant",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "staphylococcus aureus.If encapsulated streptococci are likely, treat with",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Gilbert DN, Moellering RC, Eliopoulos GM, Sande MA.The Sanford Guide to",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Therapy.35th ed.Hyde Park, VT: Antimicrobial Therapy Inc,",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "2005.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell GL, Bennett JE, Dolin R, eds.Principles and Practice of Infectious",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Diseases.6th ed.Philadelphia, PA: Churchill-Livingston, 2005.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Medical Letter Treatment Guidelines 2007, 5:57",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "penicillin or cefazolin.If pneumococci are likely, treat with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "penicillin or ceftriaxone.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "For intravenous treatment options, please refer to Inpatient Antimicrobiala", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INTRAVASCULAR CATHETER-ASSOCIATED INFECTION",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU KERATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU ABX HERPES KERATITIS", "Text" : "Herpes keratitis", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID2 MOXIFLOXACIN 0.5% OPH 1 DROP Q1H 14DAYS", "Text" : "Moxifloxacin 0.5% ophthalmic drops: 1-2 drops in affected eye(s) q1h ($) [M]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID2 MOXIFLOXACIN 0.5% OPH 1 DROP Q1H 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX OP CEFAZ 5% OPH GENT 15MG/ML OPH Q1H 14DAYS", "Text" : "Cefazolin 50 mg/ml ophthalmic drops: 1-2 drops q1h <AND> gentamicin 15 mg/ml", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX NV CEFAZ 5% OPH GENT 15MG/ML OPH Q1H 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "KERATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Keratitis is an emergency requiring prompt treatment to prevent vision loss.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Contact Ophthalmology immediately.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Keratitis is associated with viral or bacterial infection, trauma, foreign",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "bodies, or allergies. About half of cases of infectious keratitis are caused by",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "bacterial pathogens, most commonly Staphylococcus spp., Streptococcus spp., and",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "gram-negative bacilli. Viruses are the second leading cause. Fungi and parasites",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "have also been associated with corneal infection. Obtain corneal scrapings for",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "gram stain and bacterial and viral cultures and start empirical therapy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "immediately.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Link to herpes keratitis page",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "If bacterial keratitis is likely, contact ophthalmology to obtain a corneal",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "scraping and give empirical antibacterial drops immediately. Modify therapy",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "based on Ophthalmology and/or Infectious Diseases recommendations. Ophthalmic",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "corticosteroids are contraindicated in patients with keratitis.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Duration of therapy",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment should be continued until ulcer and other signs of infectious",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "keratitis have resolved. A minimum of two weeks and in rare cases, up to a month",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "of therapy may be required.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mild to moderate bacterial keratitis empirical treatment",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Severe (vision-threatening) bacterial keratitis empirical treatment",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "ophthalmic drops: 1-2 drops q1h ($) [M] in affected eye(s)",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Suspected MRSA",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Patient may require vancomycin 50mg/mL eye drops q1h in addition to gentamicin",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "eye drops. Vancomycin eye drops must be specially compounded and managed by",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Ophthalmology.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Lin et al., Ophthalmology. 2019,126(1):1-55",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Microbial keratitis",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Keratitis",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article:Complications of contact lenses", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LEISHMANIASIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LEISHMANIASIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis and treatment are complex.Consult Infectious Diseases and/or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Dermatology in all cases.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LRG UNIF BAC AEROBIC BOT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LARGE UNIFORM BACILLI IN AN AEROBIC BOTTLE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Large uniform bacilli in an aerobic bottle usually suggest Bacillus species.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Bacillus subtilis is usually a contaminant, Bacillus cereus is uncommon but",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "usually pathogenic. If Bacillus anthracis is suspected or isolated contact",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases immediately.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected non-anthracis Bacillus spp. associated with",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "disease",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of suspected Bacillus anthracis",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Hendricks et al., Emerg Infect Dis 2014, 20.2",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Bacillus cereus and other non-anthracis Bacillus species", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LRG UNIF BAC ANAEROBIC BOT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LARGE UNIFORM BACILLI IN AN ANAEROBIC BOTTLE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Large uniform bacilli in an anaerobic bottle usually suggest clostridium, a",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "potentially severe pathogen. Combination therapy is recommended for necrotizing",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "infections as clindamycin has the theoretical benefit of inhibiting toxin",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "production.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of mild to moderate infection",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of severe or necrotizing infection",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium perfingens",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Stevens et al., Clinical Infectious Diseases 2014 59.2", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LUNG ABSCESS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 6WKS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 6WKS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 6WKS 300MG PO QID", "Text" : "Clindamycin 300 mg po q6h ($) [H,O]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 6WKS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LUNG ABSCESS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pulmonary and/or Infectious Diseases consultations are strongly encouraged for",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "all cases.Obtain samples for gram stain and culture from fine needle",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "aspiration whenever possible.Sputum culture is less helpful because it will be",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "contaminated with upper respiratory flora.Classically, lung abscess is a",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "complication of mixed anaerobic and aerobic pulmonary infection. The initial",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "infection may or may not be clinically apparent.Malaise, weight loss, fever,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "chills, and malodorous sputum typically develop over a period of weeks.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Cavitation and/or abscess can occur in cases of pneumonia from a single",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "pathogen, commonly Staphylococcus aureus or Pseudomonas aeruginosa.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment should be directed against the specific pathogen.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat for 6 to 8 weeks and adjust treatment based on clinical response.Oral",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "medications should be used in patients who can take them.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Preferred oral treatment:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative for patient with severe penicillin allergy:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Bartlett JG Anaerobe 2012, 18:234",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter:Principles and Practice of Infectious Diseases",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Harrison's chapter: Infections due to mixed organisms",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Sanford keyword lung abscess",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LUNGS AND MEDIASTINUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU ARI SYMPTOMATIC THERAPY", "Text" : "Acute Respiratory Infection (ARI) Symptomatic Therapy", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "Text" : "Bronchitis", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU EMPYEMA", "Text" : "Empyema", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU BRONCHITIS NEW", "Text" : "Exacerbation of chronic obstructive pulmonary disease (COPD)", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA 2021-2022 OUTPATIENT", "Text" : "Influenza Seasonal", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU LUNG ABSCESS", "Text" : "Lung abscess", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU MEDIASTINITIS", "Text" : "Mediastinitis", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU PERTUSSIS", "Text" : "Pertussis", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU TUBERCULOSIS", "Text" : "Tuberculosis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU AZITHROMYCIN PREVENTION OF COPD", "Text" : "Azithromycin for prevention of COPD exacerbations", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++LUNGS AND MEDIASTINUM - OUTPATIENT++",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Last reviewed July 2019",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID3 GMENU ASPIRATION PNEUMONIA", "Text" : "Aspiration pneumonia", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID3 GMENU COMM ACQ PNEUMONIA", "Text" : "Community-acquired pneumonia (CAP)", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Text" : "Nosocomial pneumonia (including HAP, VAP, and HCAP)", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Pneumonia", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU LYME ACUTE NEURO DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ACUTE NEUROLOGICAL DISEASE ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treat isolated facial palsy (Bell palsy) with oral antimicrobials. Treat more",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "extensive neurological disease with intravenous antimicrobials.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment of isolated facial paresthesia (Bell palsy)",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment of neurological disease other than Bell palsy",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Halperin et. al., Neurology (2007) 69.91-102",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LYME ARTHRITIS ASSOC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 28DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID for 28 days ($) [DI]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 28DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 28DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO TID for 28 days ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 28DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ARTHRITIS ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases respond to a 28 day course of oral antimicrobials. If symptoms",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "persist or recur, Consult Infectious Diseases or Rheumatology.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LYME CARDIAC DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID for 14 days ($) [DI]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "CARDIAC DISEASE ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treat for 14 to 21 days. Cardiology consult recommended.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment of first degree or second degree heart block",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment of third degree heart block or other manifestation",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Refer to inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LYME DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE PROPHYLAXIS", "Text" : "Lyme Disease Prophylaxis", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU LYME ERYTHEMA MIGRANS", "Text" : "Erythema migrans associated with Lyme disease (outpatient)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU LYME ACUTE NEURO DISEASE", "Text" : "Acute neurological disease associated with Lyme disease (outpatient)", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU LYME ARTHRITIS ASSOC", "Text" : "Arthritis associated with Lyme disease (outpatient)", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU LYME CARDIAC DISEASE", "Text" : "Cardiac disease associated with Lyme disease (outpatient)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Lyme disease results from the transmission of Borrelia burgdorferi from an",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Ixodes spp. tick bite. Patients who display signs of illness or fever within 30",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "days of removing an attached tick should be evaluated for tick-borne illness.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "In the upper Midwest these are Lyme disease, human anaplasmosis, babesiosis, and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Powassan virus disease. Patients who have been bitten by an Ixodes spp. tick",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "(deer tick) but who do not display signs or symptoms of infection should not",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "be treated with antimicrobials.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Prophylactic antimicrobial treatment may be beneficial in certain patients who",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "have been bitten while in endemic areas.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Except for erythema migrans, Lyme disease is a complicated, difficult disease to",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "diagnose and treat. Infectious Diseases consultation is strongly encouraged.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LYME DISEASE PROPHYLAXIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ GTX ABX TICK IDENTIFICATION LINK", "Text" : "Ixodes scapularis identification", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ GTX ABX MN TICKBORNE RISK MAP", "Text" : "Tickborne Disease Risk in Minnesota", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 200MG PO ONCE", "Text" : "Doxyclycline PO 200mg once ($) [DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID DOXYCYCLINE 200MG PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "LYME DISEASE PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients who have been bitten while in endemic areas of New England, Mid-",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Atlantic States, Minnesota and Wisconsin where local rate of Ixodes scapularis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "tick infection rate with Borrelia burgdorferi is equal to or greater than 20%",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "may be treated with prophylactic antibiotics for prevention of Lyme disease.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Using a wait and see method by monitoring for signs and symptoms of Lyme disease",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "is also an acceptable approach in patients who have been bitten by an Ixodes",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "scapularis tick.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "All following criteria must be met to be considered for prophylactic treatment:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "1. Doxyclycline is not contraindicated (i.e. allergy, pregnant, lactating)",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "2. Attached tick is reliably identified as an adult or nymphal Ixodes",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "scalpularis. Follow link below for identification guide:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "3. Tick is attached for greater than or equal to 36 hours based on degree of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "tick engorgement with blood or likely time of exposure to tick infested area.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "4. Prophylaxis must be started within 72 hours after time tick was removed.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "5. Patient was exposed to tick bite in endemic areas where rate of Ixodes",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "scapularis infection with Borrelia burgdorferi is greater than 20%. Minnesota",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "counties where there is high risk of tickborne disease are shown in the",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "following link:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Providers can call the Minnesota Department of Health (651-201-5414) or the",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Wisconsin Department of Health Services (608-266-1865) for specific rates of B.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "burdorferi infection of ixodes ticks in area where a patient was exposed.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Disease if patient was exposed to an Ixodes scapularis tick",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "bite in New England or Mid-Atlantic States.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Prophylactic treatment if all above criteria are met",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Wormser GP Clin Infect Dis (2006), 43: 1089",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health, Disease Control Newsletter (2006), 34.2:9-24",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Minnesota Department of Health, Lyme Disease Basics (2017)",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "http://www.health.state.mn.us/divs/idepc/diseases/lyme/basics.html",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Wisconsin Department of Health Services, Tickborne Illness in Wisconsin (2010)",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "bitehttps://www.dhs.wisconsin.gov/tickborne/lyme-training-071210.pdf",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Wisconsin Department of Health Services, Lyme Disease Trends in Wisconsin (2016)",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "https://www.dhs.wisconsin.gov/publications/p01295.pdf", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU LYME ERYTHEMA MIGRANS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO TID for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ERYTHEMA MIGRANS ASSOCIATED WITH LYME DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Erythema migrans is the first manifestation of Lyme disease in 70-80% of cases.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "It is typically an erythematous circular rash, 5cm or larger in diameter, with",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "induration and central clearing (although other patterns occur). It usually",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "develops at the site of the bite and/or in one or more distant locations. The",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "rash occurs 3 to 30 days after the bite. Rashes with onset less than 3 days",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "after a tick bite are not from Lyme disease.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For pregnant patients or patients with doxycycline allergy",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Lyme Disease (Lyme Borreliosis) Due to Borrelia burgdorferi",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanchez et al., JAMA (2016) 315.16",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Wormser et al., Clin Infect Dis (2006) 43.1089-134", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU MALIGN OTITIS EXTERNA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO BID 28DS", "Text" : "Ciprofloxacin 750 mg PO q12h for 6 weeks ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO BID 28DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MALIGNANT OTITIS EXTERNA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Those who are elderly, diabetic, immunocompromised and debilitated are at",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "highest risk. Most cases are associated with Pseudomonas aeruginosa, but other",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pathogens can be involved. Obtain culture to identify etiologic agent and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "susceptibilities. Obtain a CT scan to determine whether osteomyelitis is",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "present. ENT and Infectious Disease consultations are recommended.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment of uncomplicated disease",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment of advanced disease, immunocompromised patients, or for coverage of",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "fluoroquinolone resistant Pseudomonas aeruginosa, in addition to above therapy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Treatment of early infection or step-down treatment after initial intravenous",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy. Adjust for a total duration of 6 weeks of antimicrobial",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "therapy.",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Evans, Journal of Laryngology and Otology. 2011, 125(12)1212-1217Mandell",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "chapter: Otitis Externa, Otitis Media, and Mastoiditis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mahdyoun et al., Otol Neurotol. 2013, 34(4)620-629",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Otitis Externa",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Malignant (necrotizing) external otitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU MASTOIDITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 CEFUROXIME 500MG PO BID 7DS", "Text" : "Cefuroxime 500 mg PO q12h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 CEFUROXIME 500MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100 mg PO q12h for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 28 DAYS", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 4 weeks ($)", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 28 DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSOZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 28 DAYS", "Text" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID for 4", "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : "PSHZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 28 DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MASTOIDITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute Mastoiditis",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Acute mastoiditis most commonly occurs as a suppurative complication of acute",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "otitis media. Diagnosis is supported by CT or MRI imaging and culture of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "drainage. Antibiotics and drainage of middle ear are sufficient treatment in",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "most cases. Mastoidectomy is necessary if abscess has formed in the mastoid",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "bone. If complication of first episode of acute otitis media, etiologies",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "typically include Streptococcus pneumonia (most common), Streptococcus pyogenes,",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "or Staphylococcus aureus. If secondary to chronic otitis media, etiologies",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "typically include Staphylococcus aureus or Pseudomonas aeruginosa. Patients",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "usually too ill for outpatient therapy. ENT consultation recommended. Obtain",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "cultures of auditory canal or middle ear fluid (preferred).",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Empirical treatment of uncomplicated disease",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment of complicated disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Step down treatment after initial intravenous antibiotic treatment in patients",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "who can tolerate oral therapy. Base selection on culture results. Adjust for a",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "total duration of 3 weeks of antimicrobial therapy.",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Chronic Mastoiditis",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Chronic mastoiditis is usually the result of chronic otitis media with",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "perforation of the tympanic membrane. There is often associated formation of a",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "cholesteatoma (keratoma). Diagnosis is supported by CT or MRI imaging and",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "culture of drainage. Long term treatment with topical antimicrobials is first",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "line therapy. Infection is often polymicrobial, including Staphylococcus aureus,",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Pseudomonas aeruginosa and anaerobes. Treatment should be managed in",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "collaboration with otolaryngology and includes topical antimicrobials, care of",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "external auditory canal, and is some cases mastoidectomy. If possible, withhold",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "therapy until a pathogen is identified by culture of drainage to direct therapy.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Specific drug choice dictated by culture results.",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Empirical Treatment",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "[M]",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "weeks ($) [M]",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Loh et. al., The Journal of Laryngology & Otology. 2018, 132(2)96-104.",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mastoiditis",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Chronic otitis media, cholesteatoma, and mastoiditis in",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU MEDIASTINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MEDIASTINITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU MORE ABOUT CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU ERYSIPELAS", "Text" : "Erysipelas", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "Text" : "Foot ulcer in patient with diabetes mellitus", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "THE APPROACH TO CELLULITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In addition to antimicrobial therapy, several non-pharmacological treatments",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "improve the outcome of cellulitis. Elevation and immobilization of the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "affected limb reduces swelling.Heat reduces discomfort.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Prevent tinea pedis infection by keeping feet clean and dry.In patients with",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "peripheral edema, good skin hygiene and support stockings reduce the incidence",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "of recurrent infection.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "In many cases of cellulitis, the affected area is usually not well-",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "differentiated from unaffected areas of the skin. Erysipelas is a special case",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "with typically a well-defined border and raised, orange-peel appearance.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Use broad-spectrum therapy for cellulitis arising in feet of patients with",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "advanced diabetes.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Schwartz MN New Eng J Med 2004, 350: 904",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cellulitis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Cellulitis and subcutaneous tissue infections",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU MORE ABOUT PHARYNGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MORE ABOUT PHARYNGITIS/ TONSILLITIS AND THE MODIFIED CENTOR SCORE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "As most cases are of viral origin, antimicrobials are not indicated in these",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "cases. Warm saltwater gargle rinses and throat lozenges provide temporary relief",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "of throat pain. Five to 10% of cases are caused by group A Streptococcus.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Antimicrobial treatment reduces symptoms by one day, prevents suppurative",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "complications and prevents acute rheumatic fever, an uncommon disease in US",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "adults.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Streptococcal pharyngitis or tonsillitis should be suspected when patients have",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "fever and exudate on the pharyngeal wall or tonsils without symptoms like cough,",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "nasal congestion, or runny nose that suggest viral infection or common cold. If",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "streptococcal pharyngitis is suspected in adults, perform PCR testing for group",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "A streptococci and treat only if positive.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Neisseria gonorrhoeae is a rare cause of pharyngitis. N. gonorrhoeae should be",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "considered for patients with risk factors for sexually transmitted diseases. N.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "gonorrhoeae infections must be reported to the state health department and this",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "will be done by Infection Control if the culture is positive.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "The Modified Centor score",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Used to estimate the likelihood that a patient with sore throat has",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "streptococcal pharyngitis and whether rapid PCR testing should be performed.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "1) Absence of cough = 1 point",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "2) Swollen and tender anterior cervical nodes = 1 point",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "3) Temperature greater than 100.4 degrees Fahrenheit (38 degrees Centigrade) = 1",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "point",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "4) Tonsillar exudates or swelling = 1 point",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "5) Age: 3-14 years = 1 point",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "15-44 years = 0 points",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "45 years and older = -1 point",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Patients with a score of 0 or 1 are at very low risk. PCR testing and antibiotic",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "treatment are not indicated. Patients with a score of 2 to 4 are at moderate to",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "high risk. PCR testing should be obtained in these patients to determine if GAS",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "is present. In patients with a score of 4 or greater, consider empiric",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "antibiotic treatment.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "CDC STD 2015 Guidelines MMWR. 2015, 64(3)1-7",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Pharyngitis",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcal Pharyngitis",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU NASAL PACKING", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF INFECTION IN PATIENTS WITH NASAL PACKING",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis to prevent infection and toxic shock syndrome in",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "patients with nasal packing is not recommended. Antibiotics increase the risk of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "adverse events in patients with nasal packing with no proven effectiveness in",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "preventing infection.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Cohn, Annals of emergency medicine 2015, 1.65, 109-111",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Kucik et al, Am Fam Physician 2005, 71.2, 305-311",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Approach to the adult with epistaxis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU NECROTIZING INFECTIONS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NECROTIZING INFECTIONS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU NEED AN ALT ABX MAIN", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX OP PT ALLERGIC TO RECOM DRUGS", "Text" : "Allergic to recommended drug(s)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX OP DECREASED RENAL CLR", "Text" : "Decreased renal clearance", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP LIVER SEC METAB IMPAIR", "Text" : "Liver secretory or metabolic impairment", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP DRUG INTERACTION", "Text" : "Drug interaction", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP PT HAS MULT INFECT REQ ABX", "Text" : "Patient has multiple infections requiring antimicrobials", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX OP ADJ THERA BASED ON ABX SUSP", "Text" : "Adjust therapy based on antimicrobial susceptibility", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP OTHER ADVERSE DRUG AFFECT", "Text" : "Other adverse drug effect", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX OP ALTERNATIVE OTHER REASON", "Text" : "Other reason", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "Please Click Here to Send comments to the CDSS team", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG ALLERGIES", "Text" : "Information about drug allergies", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEED AN ALERNATIVE ANTIMICROBIAL?",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If you cannot use the recommended antimicrobials or you believe another one",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "would be better for your patient, you can order another drug. Please indicate",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "the reason you need an alternative drug below.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Note: Alternative antimicrobial selections will be reviewed and we may contact",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "prescribers to learn more about situations that need alternatives, improve the",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "CDSS, and in some cases offer suggestions.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Clarification/Comments:", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU NEUT CAND ORAL THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 500 BID AMOX-CLAV 875/125 BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] <AND> amoxicillin-clavulanate", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 500 BID AMOX-CLAV 875/125 BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP CIPRO 500 BID CLINDAMYCIN 300 QID X7DAYS", "Text" : "Ciprofloxacin 500mg po bid ($) [R,DI] <AND> Clindamycin 300mg po qid ($) [H,O]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZ SET ABX NV CIPRO 500 BID CLINDAMYCIN 300 QID X7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC FEVER--PATIENT IS A CANDIDATE FOR ORAL THERAPY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Can the patient be treated with oral therapy?",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "875/125 mg PO BID ($) [R]",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Freifeld AG Clinical Infectious Disease 2011, 52: 427-431",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Taplitz RA, J Clin Oncol 2018, 36: 1443-1453",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Sanford: Neutropenia, Febrile, Low-Risk",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Related Infections. Version 1.2019. nccn.org", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU NEUT NOT CAND ORAL THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC FEVER--PATIENT IS NOT A CANDIDATE FOR ORAL THERAPY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU NEUTROPENIC FEVER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU NEUT CAND ORAL THERAPY", "Text" : "If patient IS a candidate for oral therapy", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU NEUT NOT CAND ORAL THERAPY", "Text" : "If patient is NOT a candidate for oral therapy", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID2 GMENU NEUT FEVER SCORING TOOL", "Text" : "Link to a scoring tool that identifies low risk patients for oral therapy", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC FEVER",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The risk of severe, rapidly progressive infections increases when the absolute",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "neutrophil count (ANC, segmented neutrophils plus bands) is less than 500",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "cells/microliter.The risk increases dramatically when the ANC is <100",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cells/microliter.Because of these risks, patients with fever and neutropenia",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "to this degree should receive empirical antimicrobial therapy immediately.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empirical therapy should also be given to patients with fever and ANC 500-1000",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "cells/microliter when the concentration is expected to be <500 cells/microliter",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "within the next 48 hours.For this purpose, fever is defined as a single",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "temperature greater than 38.3 degrees Celsius.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Initial therapy",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Since infection can be rapidly progressive and severe, broad-spectrum",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "antimicrobials are given urgently to patients with neutropenic fever as defined",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "above.Vancomycin should only be given when there are clear indications for its",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "use.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Candidates for empirical treatment with oral antimicrobials include those who",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "are febrile but who have no evidence of focal infection or signs or symptoms of",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "severe disease, like hypotension.Outpatient antimicrobials for neutropenic",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "fever must be ordered only in consultation with Hematology-Oncology or",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Modifcation to therapy",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Hughes WT Clin Infect Dis 2002, 34: 730",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Rolston KVI Clin Infect Dis 2004, 39: S44",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sipsas NV Cancer 2005, 103: 1103", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU NOSO SINUSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL SINUSITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Nasogastric tubes increase the risk of bacterial sinus infection associated with",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus, streptococcus, and gram-negative bacilli, including",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pseudomonas aeruginosa. Aspirate sinuses for gram stain and culture to direct",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy. Adequate sinus drainage is vital to treatment.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobial treatment",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Chow et al, Clinical Infectious Diseases. 2012, 54(8) e72-e112",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Sinusitis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Meltzer et al, J Allergy Clin Immunol. 2004, 114(6) S155-S212.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al, Otolaryngology - Head and Neck Surgery. 2015, 152(4) 598-609",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Sinusitis, Intubation Associated",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Complications of the endotracheal tube following initial",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "placement: Prevention and management in adult intensive care unit patients", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU NOSOCOMIAL PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NOSOCOMIAL PNEUMONIA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OROLABIAL HERPES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 400MG PO TID", "Text" : "Acyclovir 400 mg PO TID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 400MG PO 5X/D 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1DAY 2GM PO BID", "Text" : "Valacyclovir 2 gm BID for 1 day ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1DAY 2GM PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 7DAYS 400MG PO TID", "Text" : "Acyclovir 400 mg PO TID for 7-14 days($) [R]", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 400MG PO 5X/DAY 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1GM PO BID", "Text" : "Valacyclovir 1 gm BID for 7-14 days ($) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1GM PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 1YR 400MG PO BID", "Text" : "Acyclovir 400 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 1YR 400MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "Text" : "Valacyclovir 500 mg PO QDay ($) [R]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 1YR 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OROLABIAL HERPES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Antiviral therapy is not beneficial after formation of vesicles. However, when",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "started as soon as prodromal symptoms of burning or tingling occur, antivirals",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "reduce duration of pain and lesions.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients in whom herpes simplex infections can be more severe",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "include: patients with HIV infection, organ transplant recipients, patients",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "undergoing chemotherapy, malnourished patients, and those with compromised skin",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "integrity.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Chronic suppressive therapy",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Indicated for patients with greater than 6 recurrences or severe recurrences,",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "immunocompromised patients or as adjunct to prevent transmission. Suppressive",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "therapy is optional, and some patients may find episodic treatment more",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "convenient. Patients should be reassessed every few years to evaluate if chronic",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "suppressive therapy is still necessary.",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Herpes simplex virus",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes simplex",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment of herpes simplex virus type 1 infection in",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "immunocompetent patients", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OSTEOM EMP THERAPY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 28DS 500MG PO QDAY", "Text" : "Levofloxacin 500 mg PO qday ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 28DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EMPIRICAL THERAPY FOR OSTEOMYELITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Therapy should be modified when culture results and patient response to therapy",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "are known.If cultures cannot be obtained, the oral regimens listed below can",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "be used for empirical therapy or to complete a treatment course after the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "patient's disease has improved. Consult Infectious Diseases for more",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Duration of treatment 4 to 6 weeks.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "ORAL treatment for MILD disease or for completion of treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "course",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "INTRAVENOUS treatment for MODERATE to SEVERE disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Osteomyelitis",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Calhoun JH Infect Dis Clin North AM 2005, 19:765",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Dis 2012, 54:393", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OSTEOM GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 28DS 875/125 MG PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < OR >", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 28DS 875/125 MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 28DS 500MG PO QDAY", "Text" : "Levofloxacin 500 mg PO qday ($) [R,DI]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 28DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS WITH GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Osteomyelitis",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Lew DP Lancet 2004, 364: 369",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OSTEOM PSEUDOMONAS AERUGINOSA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 750MG PO BID 28DS", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 750MG PO BID 28DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS WITH PSEUDOMONAS AERUGINOSA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Osteomyelitis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Lew DP Lancet 2004, 364: 369",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OSTEOM STAPHYLOCOCCUS AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 CEPHALEX 28DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R] < OR >", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 CEPHALEX 28DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 DICLOX 28DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 DICLOX 28DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 28DS 100MG PO BID", "Text" : "Minocycline 100 mg PO BID ($) [DI] < OR >", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 28DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS WITH STAPHYLOCOCCUS AUREUS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Methicillin-SUSCEPTIBLE S. aureus",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Methicillin-RESISTANT S. aureus",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Osteomyelitis",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Spellberg B Clin Infect Dis 2012, 54:393",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Berbari EF Clin Infect Dis 2015, 61:e26",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Calhoun JH Infect Dis Clin North Am 2005, 19:765", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OSTEOM STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] < OR >", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID2 CEPHALEX 28DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]< OR >", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSHZID2 CEPHALEX 28DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 DICLOX 28DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 DICLOX 28DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS WITH STREPTOCOCCI",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Osteomyelitis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Lew DP Lancet 2004, 364: 369",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Cunha BA Clin Infect Dis 2002, 35: 287", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OSTEOMYELITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM EMP THERAPY", "Text" : "Empirical therapy for osteomyelitis", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM STAPHYLOCOCCUS AUREUS", "Text" : "Osteomyelitis with Staphylococcus aureus", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM STREPTOCOCCI", "Text" : "Osteomyelitis with Streptococci", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM GNB", "Text" : "Osteomyelitis with Gram negative bacilli (other than Pseudomonas)", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU OSTEOM PSEUDOMONAS AERUGINOSA", "Text" : "Osteomyelitis with Pseudomonas aeruginosa", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "Text" : "Infections in bone or joint prostheses", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OSTEOMYELITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "In acute osteomyelitis, symptoms have been present for several days to weeks.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Chronic osteomyelitis is characterized by a longer duration of symptoms,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "sometimes months or years, and often dead, necrotic bone is present.There is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "considerable overlap between the syndromes of acute and chronic osteomyelitis.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Symptom duration may be unreliable in a patient with neuropathy.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Obtain material for gram stain and culture before initiating antimicrobials.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Blood and bone cultures are ideal.Sinus tracts are often colonized with",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "multiple species and usually only one or two are pathogens in bone.If",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus is present, it is likely to be a pathogen in bone.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Empirical antimicrobial therapy is the same for acute and chronic osteomyelitis,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "but necrotic bone must often be removed for cure of chronic osteomyelitis.If",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "complete debridement is not possible, long-term suppressive antimicrobials may",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "be needed.Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "The most important pathogens are S. aureus and streptococci.Gram negative",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "bacilli are common pathogens in osteomyelitis associated with diabetic foot",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "infection.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Empirical treatment regimens",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Pathogen-directed treatment regimens",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Recommend Orthopedic, Neurosurgery (for spine or skull osteomyelitis), Podiatry",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "(for foot infections), and Infectious Diseases consults.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Treat for 4 to 6 weeks.Do not place a long-term intravascular access device",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "(e.g. a PICC line) until it is clear the patient will need long-term intravenous",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "therapy.Consult Infectious Diseases or Orthopedic Surgery for more",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : ">>For patients with infections associated with prosthetic materials see",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : ">>For patients with sternal infection associated with chest surgery, refer to",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "mediastinitis, under Lungs and Mediastinum, in the Inpatient Antimicrobial",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "CDSS.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Osteomyelitis",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Lipsky BA Clin Infect Disease 2012, 54:393", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OTHER PATHOGENS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU PATH E. CHAFFEENSIS", "Text" : "Ehrlichia chaffeensis (Human Monocytotropic Ehrlichiosis)", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU PATH A. PHAGOCYTOPHILUM", "Text" : "Anaplasma phagocytophilum (Human Granulocytotropic Anaplasmosis)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "Text" : "Lyme disease", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PATHO M. TUBERCULOSIS", "Text" : "Mycobacterium tuberculosis", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PATH M. AVIUM INTRACELL", "Text" : "Mycobacterium avium intracellulare complex (a.k.a. MAI or MAC)", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZID3 GMENU PATH MYCOPLASMA PNEUMO", "Text" : "Mycoplasma pneumonia", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "Text" : "Pneumocystis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ OTHER PATHOGENS ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "into site, and whether organism is pathogen, colonizer, or",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "contaminant. See disease/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Coxiella and Ehrlichia",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Lyme Disease",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mycobacteria",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Mycoplasma",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Pneumocystis infection",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Last reviewed 8/2018", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU OTITIS EXTERNA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU FURUNCLES AND CARBUNCLES", "Text" : "Furuncles and Carbuncles", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 7DAYS", "Text" : "Neomycin-polymyxin-hydrocortisone ear drops 4 drops in affected ear(s) QID", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 NEOMYCIN/POLYMYXIN/HYDROC EAR 4 DRPS QID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 7DAYS", "Text" : "Ciprofloxacin-Dexamethasone otic 4 drops in affected ear(s) BID for 7 days ($)", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN-DEXAMETHASONE OTIC BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "< ADD > ciprofloxacin 500 mg PO q12h for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OTITIS EXTERNA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Acute Localized Disease",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Often due to furunculosis and usually associated with Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treat mild cases with moist local heat. For cases with cellulitis or deep",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "invasion, incision and drainage as well as systemic antibiotics may be needed.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Refer to the Furuncles and Carbuncles page for antibiotic recommendations.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Acute diffuse and chronic otitis externa",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Most commonly associated with Pseudomonas aeruginosa, Staphylococcus aureus and",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Staphylococcus epidermidis. Irrigate to remove cerumen, desquamated skin and",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "purulent material which can improve effectiveness of topical antibiotics. Avoid",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "products that contain neomycin if the tympanic membrane is perforated.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred treatment if tympanic membrane is intact",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Alternative if tympanic membrane is perforated or allergy to preferred treatmen",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "[M]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Complicated Cases",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "For cases resistant to topical therapy alone, patients with poorly controlled",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "diabetes mellitus, immunocompromised patients, cases where infection has spread",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "beyond ear canal and in those where topical therapy cannot be delivered",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "effectively. Culture secretions to guide therapy.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "In addition to topical therapy above",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Rosenfeld et al., Otolaryngology-Head and Neck Surgery. 2014, 150(2)161-168",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Otitis Externa",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: External otitis: Treatment", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OTITIS MEDIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 10DS PO TID", "Text" : "Amoxicillin 1000 mg PO q8h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 10DS PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Amoxicillin/clavulanate 875-125 mg PO q12h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 10DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 10DAYS", "Text" : "Cefdinir 300 mg PO q12h for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 10DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 CEFPODOXIME 200MG PO BID 10DS", "Text" : "Cefpodoxime 200 mg PO BID for 10 days ($$) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 CEFPODOXIME 200MG PO BID 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "OTITIS MEDIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the most common bacteria to cause otitis media.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Patient has NOT received antibiotics in the prior month",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Patient has received antibiotics in the prior month",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Alternatives",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Harmes et al, American Family Physician. 2013, 88(7)435-440",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Otitis Externa, Otitis Media, and Mastoiditis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Otitis media",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Online: Acute otitis media in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU OUTPATIENT GENRL ALT LIST", "Contents" : [
{"Row" : 4, "Column" : 1, "Item" : "PSJIZID ALT ACYCLOVIR 500MG IV BID", "Text" : "Acyclovir IV", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSOZID ALT ACYCLOVIR 800MG PO TID", "Text" : "Acyclovir PO", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSHZID ALT ACYCLOVIR 800MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSJIZID ALT AMIKACIN 250MG IV QDAY", "Text" : "Amikacin IV", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID ALT AMOXICILLIN 500MG PO TID", "Text" : "Amoxicillin PO", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID ALT AMOXICILLIN 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID ALT AMOXICILLIN-CLAVULANATE 875MG PO BID", "Text" : "Amoxicillin-clavulanate PO", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID ALT AMOXICILLIN-CLAVULANATE 875MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID ALT AMPHO B LIPOSOMAL 5MG/KG IV Q24H", "Text" : "Amphotericin B IV", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSJIZID ALT AMPICILLIN 2GM IV Q6H", "Text" : "Ampicillin IV", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSJIZID ALT AMPICILLIN-SULBACTAM 3GM IV Q6H", "Text" : "Ampicillin-sulbactam IV", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID ALT ATOVAQUONE SUSP 750MG PO BID", "Text" : "Atovaquone PO", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID ALT ATOVAQUONE SUSP 750MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSJIZID ALT AZITHROMYCIN 500MG ONCE THEN 250MG QD 4DS", "Text" : "Azithromycin IV", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 ALT AZITHROMYCIN 500MG ONCE THEN 250 QDAY 4DS", "Text" : "Azithromycin PO", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 ALT AZITHROMYCIN 500MG ONCE THEN 250 QDAY 4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSJIZID ALT AZTREONAM 2GM IV Q8H", "Text" : "Aztreonam IV", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSCZID ALT BENZATHINE PENICLLIN 1.2", "Text" : "Benzathine penicillin IM", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID ALT CEFADROXIL 500MG PO BID", "Text" : "Cefadroxil PO", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSHZID ALT CEFADROXIL 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSJIZID ALT CEFAZOLIN 2GM IV Q8H", "Text" : "Cefazolin IV", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID ALT CEFDINIR 300MG PO BID", "Text" : "Cefdinir PO", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSHZID ALT CEFDINIR 300MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSJIZID ALT CEFEPIME 2GM IV Q8H", "Text" : "Cefepime IV", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSJIZID ALT CEFOTETAN IV 2GM Q12H", "Text" : "Cefotetan IV", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSJIZID ALT CEFOXITIN 2GM IV Q6H", "Text" : "Cefoxitin IV", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSOZID ALT CEFPODOXIME 200 MG PO BID", "Text" : "Cefpodoxime PO", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSHZID ALT CEFPODOXIME 200 MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSJIZID ALT CEFTAZIDIME 2GM IV Q8H", "Text" : "Ceftazidime IV", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSJIZID ALT CEFTRIAXONE 500MG IM ONCE", "Text" : "Ceftriaxone IM", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSJIZID ALT CEFTRIAXONE 2GM IV QDAY", "Text" : "Ceftriaxone IV", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "PSOZID ALT CEFUROXIME 500MG PO BID", "Text" : "Cefuroxime PO", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSHZID ALT CEFUROXIME 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "PSOZID ALT CEPHALEXIN 500MG PO Q6H", "Text" : "Cephalexin PO", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "PSHZID ALT CEPHALEXIN 500MG PO Q6H", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "PSJIZID ALT CIPROFLOXACIN 400MG IV Q12H", "Text" : "Ciprofloxacin IV", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "PSOZID ALT CIPROFLOXACIN 500MG PO BID", "Text" : "Ciprofloxacin PO", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "PSHZID ALT CIPROFLOXACIN 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "PSOZID ALT CLARITHROMYCIN 500MG PO BID", "Text" : "Clarithromycin PO", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "PSHZID ALT CLARITHROMYCIN 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "PSJIZID ALT CLINDAMYCIN 600MG IV Q8H", "Text" : "Clindamycin IV", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : "PSOZID ALT CLINDAMYCIN 300MG PO QID", "Text" : "Clindamycin PO", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "PSHZID ALT CLINDAMYCIN 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : "PSOZID2 ALT CLINDAMYCIN 2% CRM VAG 1 APPLFUL QHS 30DS", "Text" : "Clindamycin Vaginal", "Header" : 0}, 
{"Row" : 78, "Column" : 1, "Item" : "PSHZID2 ALT CLINDAMYCIN 2% CRM VAG 1 APPLFUL QHS 30DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : "PSOZID2 ALT CLOTRIMAZOLE 1% CRM TOP AFFECT AREA QID", "Text" : "Clotrimazole Topical", "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : "PSHZID2 ALT CLOTRIMAZOLE 1% CRM TOP AFFECT AREA QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : "PSOZID2 ALT CLOTRIM 1% CRM VAG 1 APPLFUL QHS 30DS", "Text" : "Clotrimazole Vaginal", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : "PSHZID2 ALT CLOTRIM 1% CRM VAG 1 APPLFUL QHS 30DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : "PSOZID ALT DICLOXACILLIN 500MG PO Q6H", "Text" : "Dicloxacillin PO", "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : "PSHZID ALT DICLOXACILLIN 500MG PO Q6H", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : "PSJIZID ALT DOXYCYCLINE 100MG IV Q12H", "Text" : "Doxycycline IV", "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : "PSOZID ALT DOXYCYCLINE 100MG PO BID", "Text" : "Doxycycline PO", "Header" : 0}, 
{"Row" : 92, "Column" : 1, "Item" : "PSHZID ALT DOXYCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : "PSJIZID ALT ERTAPENEM 1GM IV Q24H", "Text" : "Ertapenem IV", "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : "PSJIZID ALT ERYTHROMYCIN 500MG IV Q6H", "Text" : "Erythromycin IV", "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : "PSOZID ALT ERYTHROMYCIN 0.5% OINT OPH AFFECT EYE QID", "Text" : "Erythromycin OPTH", "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : "PSHZID ALT ERYTHROMYCIN 0.5% OINT OPH AFFECT EYE QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 101, "Column" : 1, "Item" : "PSOZID ALT ERYTHROMYCIN 500MG PO FQID", "Text" : "Erythromycin PO", "Header" : 0}, 
{"Row" : 102, "Column" : 1, "Item" : "PSHZID ALT ERYTHROMYCIN 500MG PO FQID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "ALTERNATIVE ANTIMICROBIALS",  "Header" : 1}, 
{"Row" : 4, "Column" : 2, "Item" : "PSJIZID ALT FLUCONAZOLE 400MG IV Q24H", "Text" : "Fluconazole IV", "Header" : 0}, 
{"Row" : 6, "Column" : 2, "Item" : "PSOZID ALT FLUCONAZOLE 400MG PO QDAY", "Text" : "Fluconazole PO", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "PSHZID ALT FLUCONAZOLE 400MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "PSJIZID ALT GANCICLOVIR 500MG IV Q12H", "Text" : "Gancicilovir IV", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : "PSJIZID ALT GENTAMICIN 5MG/KG IV Q24H", "Text" : "Gentamicin IV", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "PSOZID ALT ITRACONAZOLE 200MG PO QDAY", "Text" : "Itraconazole PO", "Header" : 0}, 
{"Row" : 14, "Column" : 2, "Item" : "PSHZID ALT ITRACONAZOLE 200MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 2, "Item" : "PSJIZID ALT LEVOFLOXACIN 500MG IV Q24H", "Text" : "Levofloxacin IV", "Header" : 0}, 
{"Row" : 18, "Column" : 2, "Item" : "PSOZID ALT LEVOFLOXACIN 500MG PO Q24H", "Text" : "Levofloxacin PO", "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : "PSHZID ALT LEVOFLOXACIN 500MG PO Q24H", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 2, "Item" : "PSJIZID ALT MEROPENEM 1GM IV Q8H", "Text" : "Meropenem IV", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "PSJIZID ALT METRONIDAZOLE 500MG IV Q6H", "Text" : "Metronidazole IV", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "PSOZID ALT METRONIDAZOLE 500MG PO TID", "Text" : "Metronidazole PO", "Header" : 0}, 
{"Row" : 26, "Column" : 2, "Item" : "PSHZID ALT METRONIDAZOLE 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 2, "Item" : "PSOZID2 ALT METRONIDAZOLE 0.75% GEL VAG 1 APPLFUL QHS", "Text" : "Metronidazole Vaginal", "Header" : 0}, 
{"Row" : 29, "Column" : 2, "Item" : "PSHZID2 ALT METRONIDAZOLE 0.75% GEL VAG 1 APPLFUL QHS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 2, "Item" : "PSOZID ALT MINOCYCLINE 100MG PO BID", "Text" : "Minocycline PO", "Header" : 0}, 
{"Row" : 32, "Column" : 2, "Item" : "PSHZID ALT MINOCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 34, "Column" : 2, "Item" : "PSOZID2 ALT MOXIFLOXACIN SOLN OPH 1DRP TID 7DAYS", "Text" : "Moxifloxacin OPTH", "Header" : 0}, 
{"Row" : 35, "Column" : 2, "Item" : "PSHZID2 ALT MOXIFLOXACIN SOLN OPH 1DRP TID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 37, "Column" : 2, "Item" : "PSJIZID ALT NAFCILLIN 2GM IV Q4H", "Text" : "Nafcillin IV", "Header" : 0}, 
{"Row" : 39, "Column" : 2, "Item" : "PSOZID ALT NEOMYCIN 1000MG PO TID", "Text" : "Neomycin PO", "Header" : 0}, 
{"Row" : 40, "Column" : 2, "Item" : "PSHZID ALT NEOMYCIN 1000MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 42, "Column" : 2, "Item" : "PSOZID ALT NITROFURANTOIN 100MG PO BID", "Text" : "Nitrofurantoin PO", "Header" : 0}, 
{"Row" : 43, "Column" : 2, "Item" : "PSHZID ALT NITROFURANTOIN 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 47, "Column" : 2, "Item" : "PSOZID ALT PENICILLIN 500MG PO QID", "Text" : "Penicillin PO", "Header" : 0}, 
{"Row" : 48, "Column" : 2, "Item" : "PSHZID ALT PENICILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 50, "Column" : 2, "Item" : "PSJIZID ALT PENICILLIN 4MU IV Q4H", "Text" : "Penicillin IV", "Header" : 0}, 
{"Row" : 52, "Column" : 2, "Item" : "PSJIZID ALT PIP/TAZO 3.375 GM IV Q6H", "Text" : "Piperacillin/tazobactam IV", "Header" : 0}, 
{"Row" : 54, "Column" : 2, "Item" : "PSOZID ALT PYRIMETHAMINE 75MG PO QDAY", "Text" : "Pyrimethamine PO", "Header" : 0}, 
{"Row" : 55, "Column" : 2, "Item" : "PSHZID ALT PYRIMETHAMINE 75MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 57, "Column" : 2, "Item" : "PSJIZID ALT RIFAMPIN 300MG IV Q12H", "Text" : "Rifampin IV", "Header" : 0}, 
{"Row" : 59, "Column" : 2, "Item" : "PSOZID ALT RIFAMPIN 300MG PO BID", "Text" : "Rifampin PO", "Header" : 0}, 
{"Row" : 60, "Column" : 2, "Item" : "PSHZID ALT RIFAMPIN 300MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 62, "Column" : 2, "Item" : "PSOZID2 ALT SULFACETAMIDE 10% SOLN OPH 1DRP QID 7DAYS", "Text" : "Sulfacetamide OPTH", "Header" : 0}, 
{"Row" : 63, "Column" : 2, "Item" : "PSHZID2 ALT SULFACETAMIDE 10% SOLN OPH 1DRP QID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 65, "Column" : 2, "Item" : "PSOZID ALT SULFADIAZINE 1000MG PO QID", "Text" : "Sulfadiazine PO", "Header" : 0}, 
{"Row" : 66, "Column" : 2, "Item" : "PSHZID ALT SULFADIAZINE 1000MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 68, "Column" : 2, "Item" : "PSOZID ALT TERBINAFINE 250 MG PO QDAY", "Text" : "Terbinabine PO", "Header" : 0}, 
{"Row" : 69, "Column" : 2, "Item" : "PSHZID ALT TERBINAFINE 250 MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 71, "Column" : 2, "Item" : "PSOZID2 ALT TERCONAZOLE 0.4% CRM VAG 1 APPLFUL QHS 30DS", "Text" : "Terconazole 0.4% Vaginal", "Header" : 0}, 
{"Row" : 72, "Column" : 2, "Item" : "PSHZID2 ALT TERCONAZOLE 0.4% CRM VAG 1 APPLFUL QHS 30DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 74, "Column" : 2, "Item" : "PSJIZID ALT TOBRAMYCIN 5 MG/KG IV Q24H", "Text" : "Tobramycin IV", "Header" : 0}, 
{"Row" : 76, "Column" : 2, "Item" : "PSOZID ALT TRIMETHOPRIM PO QD", "Text" : "Trimethoprim PO", "Header" : 0}, 
{"Row" : 77, "Column" : 2, "Item" : "PSHZID ALT TRIMETHOPRIM PO QD", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 79, "Column" : 2, "Item" : "PSJIZID ALT TRIMETH/SULFA 5MG/KG IV Q12H", "Text" : "Trimethoprim-sulfamethoxazole IV", "Header" : 0}, 
{"Row" : 81, "Column" : 2, "Item" : "PSOZID ALT TRIMETHOPRIM-SULFAMETHOXAZOLE 1DS TAB PO BID", "Text" : "Trimethoprim-sulfamethoxazole PO", "Header" : 0}, 
{"Row" : 82, "Column" : 2, "Item" : "PSHZID ALT TRIMETHOPRIM-SULFAMETHOXAZOLE 1DS TAB PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 84, "Column" : 2, "Item" : "PSOZID ALT VALACYCLOVIR 1000MG PO BID", "Text" : "Valacyclovir PO", "Header" : 0}, 
{"Row" : 85, "Column" : 2, "Item" : "PSHZID ALT VALACYCLOVIR 1000MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 87, "Column" : 2, "Item" : "PSJIZID ALT VANCOMYCIN 1000MG IV Q12H", "Text" : "Vancomycin IV", "Header" : 0}, 
{"Row" : 89, "Column" : 2, "Item" : "PSOZID ALT VANCOMYCIN 125MG PO QID", "Text" : "Vancomycin PO", "Header" : 0}, 
{"Row" : 90, "Column" : 2, "Item" : "PSHZID ALT VANCOMYCIN 125MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 45, "Column" : 2, "Item" : null, "Text" : "Oseltamivir (see Influenza Menu)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PANCREATITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PANCREATITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PARASITE BABESIA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP AZITH 500 THEN 250 X6DS ATOVA 750MG Q12H 7DS", "Text" : "Azithromycin 500 mg PO once ($) on day 1, then 250 mg PO QDay ($) [M] for 6", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX NV AZITH 500 THEN 250 X6DS ATOVA 750MG Q12H 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "BABESIA SPECIES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treat for 7-10 days. If patient has persistent relapsing disease, treat for 6",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "weeks including 2 weeks after babesia are no longer detected in blood smear.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "days <AND> atovaquone 750 mg PO BID ($) [M] for 7 days",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "*Consult Infectious Diseases, requires NF consult for quinine.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Clindamycin 600 mg PO TID <AND> quinine 650mg PO TID",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Babesia Species",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Babesiosis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Babesiosis: Treatment and prevention",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Vannier et al. N Engl J Med. 2012 (366)2397-407", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PARASITE TOXOPLASMA SPP.", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 200 THEN 50 SULFADIA 1GM LEUCORV 10MG", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 50 mg PO QDay ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 200 THEN 50 SULFADIA 1GM LEUCORV 10MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 200MG THEN 75MG SULFADIA 1.5GM LEUC 25MG", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 75 mg PO QDay ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 200MG THEN 75MG SULFADIA 1.5GM LEUC 25MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETH 200 THEN 50 CLINDA 600 LEUCOV 10MG", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 50 mg PO QDay ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETH 200 THEN 50 CLINDA 600 LEUCOV 10MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 200MG THEN 75MG CLINDA 600MG LEUC 25MG", "Text" : "Pyrimethamine 200 mg PO once ($$$), then 75 mg PO QDay ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 200MG THEN 75MG CLINDA 600MG LEUC 25MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID TRIMETH 5MG/KG-SULFA 25MG/KG PO BID", "Text" : "Trimethoprim 5 mg/kg-sulfamethoxazole 25 mg/kg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSHZID TRIMETH 5MG/KG-SULFA 25MG/KG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 50MG SULFADIAZ 500MG LEUCO 10MG", "Text" : "Pyrimethamine 50 mg PO QDay ($$) [DI,O] <AND> sulfadiazine 0.5-1 gm PO QID", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 50MG SULFADIAZ 500MG LEUCO 10MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 50MG CLINDA 600MG LEUCO 10MG", "Text" : "Pyrimethamine 50 mg PO QDay ($$) [DI,O] <AND> clindamycin 600 mg PO TID ($)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 50MG CLINDA 600MG LEUCO 10MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIM 25MG ATOVA 750MG LEUCO 10MG", "Text" : "Pyrimethamine 25 mg PO QDay ($$) [DI,O] <AND> atovaquone 750-1500 mg PO", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIM 25MG ATOVA 750MG LEUCO 10MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "PSOZID TRIEMTH/SULFA 1 DS TABLET PO QDAY", "Text" : "Trimethoprim sulfamethoxazole 1DS tablet PO QDay ($) [R,DI]", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "PSHZID TRIEMTH/SULFA 1 DS TABLET PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "PSOZID ATOVAQUONE SUSP 750MG PO BID", "Text" : "Atovaquone 750-1500 mg PO BID ($) [M]", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : "PSHZID ATOVAQUONE SUSP 750MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : "ORZ SET ABX OP PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY", "Text" : "Pyrimethamine 50 mg BID for 2 days, then 50 mg PO QDay ($$) [DI,O] <AND>", "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : "ORZ SET ABX NV PYRIMETHAMINE SULFADIAZINE LEUCOVORIN PREGNANCY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TOXOPLASMA SPP.",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "If patient is immunocompetent and not pregnant, treatment is usually not needed",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "as disease is usually self-limited. Patients who are immunocompromised, pregnant",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "or have severe disease should be treated. Consult Infectious Diseases in all",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Non-pregnant patients",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat immunocompetent patients for 2-4 weeks. Treat immunocompromised patients",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "for 6 weeks or longer if radiologic disease is extensive or response is",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "incomplete at 6 weeks.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Patients weighing <60 kg",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "sulfadiazine 1 gm PO QID ($$) [DI,O] <AND> leucovorin 10-25 mg PO QDay($) [M]",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Patients weighing >60kg",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "sulfadiazine 1.5 gm PO QID ($$) [DI,O] <AND> leucovorin 10-25 mg PO QDay($) [M]",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Preferred alternative for sulfa allergy",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Patients weighing <60 kg",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "clindamycin 600 mg PO QID ($) [H,O] <AND> leucovorin 10-25 mg PO QDay ($) [M]",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Patients weighing >60 kg",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "clindamycin 600 mg PO QID ($) [H,O] <AND> leucovorin 10-25 mg PO QDay ($) [M]",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Secondary alternatives",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Chronic Maintenance therapy for immunocompromised patients",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Discontinue maintenance therapy if patient has remained asymptomatic and CD4 >",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "200 cells per microliter.",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Maintenance therapy",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "($$) <AND> leucovorin 10-25 mg PO QDay ($) [M]",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Preferred alternative for sulfa allergy",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "[H,O] <AND> leucovorin 10-25 mg PO QDay ($) [M]",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Secondary alternatives",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "BID ($) [M] <AND> leucovorin 10-25 mg PO QDay ($) [M]",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "Pregnant patients",  "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Patient diagnosed <16-18 weeks of gestation",  "Header" : 1}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "*Contact Infectious Diseases, non-formulary consult is required for spiramycin",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "Spiramycin 1 gm po TID until week 18 of gestation",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "Patient diagnosed >16-18 weeks of gestation",  "Header" : 1}, 
{"Row" : 86, "Column" : 1, "Item" : null, "Text" : "sulfadiazine 75mg/kg once, then 50mg/kg BID ($$) [DI,O] <AND> leucovorin 10-25",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "mg PO QDay ($) [M] for 4 weeks or duration of pregnancy if ultrasound evidence",  "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : null, "Text" : "of fetal distress",  "Header" : 0}, 
{"Row" : 91, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 94, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Toxoplasma gondii",  "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Toxoplasmosis",  "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Toxoplasmosis in immunocompetent hosts", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PARASITES MAIN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU PARASITE BABESIA SPP.", "Text" : "Babesia spp.", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "Text" : "Diarrhea, parasitic", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "Text" : "Pneumocystis", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU PARASITE TOXOPLASMA SPP.", "Text" : "Toxoplasma", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ PARASITES ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Always consider disease or syndrome, site of infection, penetration of drug(s)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "into site, and whether organism is pathogen, colonizer, or contaminant. See",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "disease/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Last reviewed 2/2018", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PARONYCHIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 CLOTRIM 1% CRM TOP QDAY 14DAYS", "Text" : "Clotrimazole 1% apply to affected area once daily ($) [M]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 CLOTRIM 1% CRM TOP QDAY 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID NYSTATIN CREAM APPLY BID", "Text" : "Nystatin Cream to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID NYSTATIN CREAM APPLY BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 10DAYS 1DS TAB PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZID3 GMENU HERPES WHITLOW", "Text" : "Link to Herpes whitlow", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PARONYCHIA",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Cutaneous infection of the hand, cuticle or fingers usually occurring near",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "around the nail.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treatment depends on etiology.Candida spp. are commonly involved when the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "patient has extensive exposure to water (e.g. dishwashers).Staphylococcus",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "aureus is more commonly after manicures or nail biting.Herpes simplex",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "(whitlow) usually follows exposure to oral mucosa (e.g. wrestlers, dentists, or",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "anesthetists).",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment for paronychia associated with Candida",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment for paronychia associated with Staphylococcus",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treat for 10 days.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Treatment for paronychia associated with Herpes whitlow",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: paronychia", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PATH A. PHAGOCYTOPHILUM", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID for 10 days ($) [DI]", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 10DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANAPLASMA PHAGOCYTOPHILUM (HUMAN GRANULOCYTOTROPIC ANAPLASMOSIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "MMWR RR. 2016, 65 (2) 1-44",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Ehrlichia sp., Anaplasma sp.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Human ehrlichiosis and anaplasmosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PATH DISS M. AVIUM DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ SET ABX OP CLARITHRO 500MG ETHAMBU 15 MG/KG", "Text" : "Clarithromycin 500 mg PO BID ($) [R,DI] <AND> ethambutol 15 mg/kg PO QDay", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX NV CLARITHRO 500MG ETHAMBU 15 MG/KG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP AZITHRO 250 MG ETHAMBUTOL 15 MG/KG", "Text" : "Azithromycin 250 mg PO QDay ($) [M] <AND> ethambutol 15 mg/kg PO QDay [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX NV AZITHRO 250 MG ETHAMBUTOL 15 MG/KG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX OP CLARITH 500 ETHAMB 15 RIFABUTIN 300", "Text" : "Clarithromycin 500 mg PO BID($) [R,DI] <AND> ethambutol 15 mg/kg PO QDay", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZ SET ABX NV CLARITH 500 ETHAMB 15 RIFABUTIN 300", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX OP AZITH 250 ETHAMB 15 RIFABUTIN 300", "Text" : "Azithromycin 250 mg PO QDay ($) M <AND> ethambutol 15 mg/kg PO QDay [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ SET ABX NV AZITH 250 ETHAMB 15 RIFABUTIN 300", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DISSEMINATED MYCOBACTERIUM AVIUM DISEASE TREATMENT",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Many of these patients have HIV/AIDS. Management is complex. Consult",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Rifabutin is optional for disseminated disease. Rifabutin can improve cure",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "rates, but may decrease blood concentrations of many drugs. Consult Infectious",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diseases or Pharmacy for more information.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment is continued for 12 months and until CD4 count is >100 cells per",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "microliter for at least 6 months.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Two-drug treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "($$) [R]",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Three-drug treatment",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "($$) [R] <AND> rifabutin 300 mg PO QDay ($$) [R,DI]",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "<AND> rifabutin 300 mg QDay ($$) [R,DI]",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Mycobacterium avium complex",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "patients", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PATH E. CHAFFEENSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 5DS", "Text" : "Doxycycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "EHRLICHIA CHAFFEENSIS (HUMAN MONOCYTOTROPIC EHRLICHIOSIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Treat for at least 5 to 7 days, up to 10 days may be required for more severe or",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "complicated cases",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for IV options",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Rickettsioses, Ehrlichioses, and Anaplasmosis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "MMWR RR. 2016, 65 (2) 1-44",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Ehrlichiosis: Human monocytic ehrlichiosis (HME)",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Human ehrlichiosis and anaplasmosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PATH M. AVIUM INTRACELL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU PATH M. AVIUM PNEUMONIA", "Text" : "Treatment for pneumonia", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PATH DISS M. AVIUM DISEASE", "Text" : "Treatment for disseminated disease", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PATH PRO M. AVIUM W/ HIV", "Text" : "Prophylaxis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MYCOBACTERIUM AVIUM INTRACELLULARE (MAI OR MAC)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "MAI colonization in patients with chronic lung disease is common. These",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "patients should not be treated with antimicrobials.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Occasionally, MAI causes pulmonary disease in patients who are not",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "immunosuppressed. Diagnosis and management are complex. Consult Infectious",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diseases and/or Pulmonary.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "MAI causes systemic disease commonly in patients with HIV/AIDS. Most of these",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "cases do not involve the lungs. After treatment, long-term prophylaxis is",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "usually given. Consult Infectious Diseases in all cases.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PATH M. AVIUM PNEUMONIA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP CLARITH 500 ETHAMB 15 RIFABUTIN 300", "Text" : "Clarithromycin 500 mg PO BID ($) [R,DI] <AND> ethambutol 15 mg/kg PO QDay", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX NV CLARITH 500 ETHAMB 15 RIFABUTIN 300", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP AZITH 250 ETHAMB 15 RIFABUTIN 300", "Text" : "Azithromycin 250 mg PO QDay ($) M <AND> ethambutol 15 mg/kg PO QDay [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZ SET ABX NV AZITH 250 ETHAMB 15 RIFABUTIN 300", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MYCOBACTERIUM AVIUM PNEUMONIA",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis and treatment are complex. Regimens containing 3 or 4 drugs are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "usually recommended, but two drug regimens may be sufficient in some cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases and/or Pulmonary in all cases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Duration of antimicrobial therapy",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treatment is continued until sputum cultures are consecutively negative for 12",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "months.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Three-drug regimens",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "($$) [R] <AND> rifabutin 300 mg PO QDay ($$) [R,DI]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "<AND> rifabutin 300 mg QDay ($$) [R,DI]",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Four-drug regimens may be recommended for advanced (severe) or previously",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "treated disease-Consult Infectious Diseases",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Mycobacterium avium Complex",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment of Mycobacterium avium complex lung infection in",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PATH MYCOPLASMA PNEUMO", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100 mg PO BID for 7 to 14 days ($) [DI]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO x 1 ($) on day 1, then 250 mg PO QD ($) for 4 days", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 5DS 500MG PO QDAY", "Text" : "Levofloxacin 500 mg PO QDay for 5 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 5DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MYCOPLASMA PNEUMONIAE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Optimal therapy depends on both the disease or syndrome and the pathogen. See",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "diagnosis/syndrome section for more information.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Preferred treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Intolerance to doxycycline and azithromycin",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell Chapter: Mycoplasma pneumoniae and Atypical Pneumonia",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mycoplasma pneumoniae",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Mycoplasma pneumoniae infection in adults", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PATH PRO M. AVIUM W/ HIV", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 1200MG PO Q WEEK", "Text" : "Azithromycin 1200 mg PO q week ($) [M]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID AZITHROMYCIN 1200MG PO Q WEEK", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID CLARITHROMYCIN 500MG PO BID", "Text" : "Clarithromycin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID CLARITHROMYCIN 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROPHYLAXIS AGAINST MYCOBACTERIUM AVIUM DISEASE IN PERSONS WITH HIV/AIDS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases should be involved in all cases. Patients with CD4 count <",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "50 cells per microliter, after ruling out disseminated MC disease, should",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "receive prophylaxis until CD4 count is >100 for at least 3 months in response to",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antiretroviral therapy.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Preferred prophylaxis",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Mycobacterium avium complex",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Mycobacterium avium-intracellulare",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Mycobacterium avium complex (MAC) infections in HIV-infected",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "patients", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PATHO M. TUBERCULOSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "MYCOBACTERIUM TUBERCULOSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Management of tuberculosis is complex. Contact Infectious Diseases and/or",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Pulmonary service for more information.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PBE DENTAL ORAL RESP PROC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 2GM PO ONCE 'C'", "Text" : "Amoxicillin 2 gm PO 1 hour before procedure ($) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of beta-lactam reaction", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CEPHALEXIN 2GM PO ONCE 'C'", "Text" : "Cephalexin 2 gm PO 1 hour before procedure ($) [R]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 500MG PO ONCE 'C'", "Text" : "Azithromycin 500mg PO 1 hour before procedure ($) [M]", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ANTIMICROBIALS FOR PATIENTS UNDERGOING DENTAL OR ORAL MUCOSA TO PREVENT",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "BACTERIAL ENDOCARDITIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral prophylaxis",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Primary Alternative",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral prophylaxis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Secondary Alternative, after assessment of beta-lactam reaction above",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "endocarditis",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG ONCE DAILY", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "PSOZID PD CEFAZOLIN 1GM QDAY", "Text" : "Cefazolin 1 gm PD once daily", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID PD CEFAZOLIN 2GM QDAY", "Text" : "Cefazolin 2 gm PD once daily", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CEFAZOLIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Choose dose based on patient's actual body weight (ABW)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "ABW < 100 kg:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "ABW >/= 100kg", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG ONCE DAILY AND SUPPLIES", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFAZOLIN 1GM QDAY", "Text" : "Cefazolin 1 gm PD once daily", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFAZOLIN 2GM QDAY", "Text" : "Cefazolin 2 gm PD once daily", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CEFAZOLIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Choose dose based on patient's actual body weight (ABW)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "ABW < 100 kg:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "ABW >/= 100kg", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG Q24H GENTAMICIN 0.6MG/KG Q24H", "Contents" : [
{"Row" : 8, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFAZ 1GM QDAY GENT QDAY", "Text" : "Cefazolin 1 gm PD once daily", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFAZ 2GM QDAY GENT QDAY", "Text" : "Cefazolin 2 gm PD once daily", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "CEFAZOLIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Choose dose based on patient's actual body weight (ABW)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "ABW < 100 kg:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "ABW >/= 100kg", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "PSOZID PD GENTAMICIN 40MG QDAY", "Text" : "Gentamicin 40 mg PD once daily", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID PD GENTAMICIN 60MG QDAY", "Text" : "Gentamicin 60 mg PD once daily", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID PD GENTAMICIN 80MG QDAY", "Text" : "Gentamicin 80 mg PD once daily", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "GENTAMICIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(see below for AJBW calculation)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "AJBW < 80 kg:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 80kg and <120 kg:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 120 kg:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Calculations:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "IBW:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY WITH SUPPLIES", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX OP PD GENTAMICIN 40MG QDAY", "Text" : "Gentamicin 40 mg PD once daily", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP PD GENTAMICIN 60MG QDAY", "Text" : "Gentamicin 60 mg PD once daily", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP PD GENTAMICIN 80MG QDAY", "Text" : "Gentamicin 80 mg PD once daily", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "GENTAMICIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(see below for AJBW calculation)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "AJBW < 80 kg:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 80kg and <120 kg:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 120 kg:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Calculations:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "IBW:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PD VANCO 30MG/KG LD CEFEPIME 1GM Q24H", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 1000MG LD REDOSE Q3-7D CEFEPIME QD", "Text" : "Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 2000MG LD REDOSE Q3-7D CEFEPIME QD", "Text" : "Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 3000MG LD REDOSE Q3-7D CEFEPIME QD", "Text" : "Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "VANCOMYCIN",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(see below for AJBW calculation)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "AJBW < 50 kg:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 50kg and <85 kg:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 85 kg:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Calculations:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "IBW:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU PD VANCO 30MG/KG LD GENTAMICIN 0.6MG/KG Q24H", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 1000MG LD REDOSE Q3-7D GENT QD", "Text" : "Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 2000MG LD REDOSE Q3-7D GENT QD", "Text" : "Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 3000MG LD REDOSE Q3-7D GENT QD", "Text" : "Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "VANCOMYCIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(see below for AJBW calculation)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "AJBW < 50 kg:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 50kg and <85 kg:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 85 kg:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Calculations:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "IBW:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PD VANCO 30MG/KG LOADING DOSE", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "PSOZID PD VANCOMYCIN 1000MG LOADING DOSE REDOSE Q3-7D", "Text" : "Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID PD VANCOMYCIN 2000MG LOADING DOSE REDOSE Q3-7D", "Text" : "Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID PD VANCOMYCIN 3000MG LOADING DOSE REDOSE Q3-7D", "Text" : "Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "VANCOMYCIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(see below for AJBW calculation)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "AJBW < 50 kg:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 50kg and <85 kg:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 85 kg:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Calculations:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "IBW:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PD VANCO 30MG/KG LOADING DOSE AND SUPPLIES", "Contents" : [
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCOMYCIN 1000MG LOADING DOSE REDOSE Q3-7D", "Text" : "Vancomycin 1000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCOMYCIN 2000MG LOADING DOSE REDOSE Q3-7D", "Text" : "Vancomycin 2000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCOMYCIN 3000MG LOADING DOSE REDOSE Q3-7D", "Text" : "Vancomycin 3000 mg PD loading dose, pharmacy to redose in in 3-7 days", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "VANCOMYCIN",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "FOR PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Choose loading dose based on patient's adjusted body weight (AJBW)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "(see below for AJBW calculation)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "AJBW < 50 kg:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 50kg and <85 kg:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "AJBW >/= 85 kg:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pharmacy may be contacted at pager number 612-818-0841 for dosing information.",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Calculations:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "AJBW = Ideal Body Weight (IBW) + 0.4 (Actual Body Weight - IBW)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "IBW:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Males: IBW = 50 kg + 2.3 kg for each inch over 5 feet",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Females: IBW = 45.5 kg + 2.3 kg for each inch over 5 feet", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PELVIC INFLAM DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX OP CEFT IM DOXY 14DS 100MG METRO 14DS 500MG", "Text" : "Ceftriaxone 500 mg IM x 1 dose ($) [M] < AND > doxycycline 100 mg BID for 14", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX NV CEFT IM DOXY 14DS 100MG METRO 14DS 500MG", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTR 500MG IM X1 DOXYC 7DS 100 PO BID", "Text" : "Ceftriaxone 500 mg IM x 1 dose ($) [M] < AND > doxycycline 100 mg PO BID for", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV CEFTR 250MG IM X1 DOXYC 7DS 100 PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZ SET ABX OP CEFT 500MG IM ONCE AZITH 1GM PO ONCE", "Text" : "Ceftriaxone 500 mg IM x 1 dose ($) [M] < AND > azithromycin 1 gm PO x 1 dose", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PELVIC INFLAMMATORY DISEASE (PID)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pelvic inflammatory disease (PID) refers to bacterial infection of the upper",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "female reproductive tract. Likely bacterial pathogens include Neisseria",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "gonorrhoeae, Chlamydia trachomatis, anaerobes, enteric Gram-negative rods, and",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Streptococcus agalactiae. PID should be considered in sexually active women",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "with pelvic tenderness and signs of lower genital tract inflammation. Signs and",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "symptoms may be mild or non-specific, and providers should have a low threshold",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "to initiate treatment. All women who are diagnosed with acute PID should be",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "tested for N. gonorrohoeae, C. trachomatis, and HIV. Male sex partners of",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "patients with PID should be examined and treated (see below) if they had sexual",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "contact within the 60 days before onset of the patient's symptoms.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Judge severity of infection based on clinical signs and symptoms, including",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "blood pressure, pulse, mental status, and degree of fever.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "days ($) [DI] < OPTIONAL > metronidazole 500 mg PO BID ($) [DI]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "For patients who cannot take ceftriaxone and doxycycline, call ID",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Treatment of sex partner who is a veteran",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Treat for both Chlamydia and Gonorrhea",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "7 days ($) [DI]",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "($) [M]",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Neisseria gonorrheoeae (Gonorrhea)",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pelvic inflammatory disease",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Pelvic inflammatory disease: Treatment",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PENTAMADINE MENU", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZ SET ABX PENTAMIDINE HOME PROSTHETIC AND CLINIC", "Text" : ">>Click here to order this set", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX PENTAMIDINE NEB HOME", "Text" : ">>Click here to order this set", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Pentamidine Home Administration",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pentamidine may be administered at home for patients who find it difficult",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "going to monthly clinic visits and are capable of performing home",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "administration. Patients who decide to take pentamidine at home require",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "a LPN clinic visit for education and a nebulizer with their first",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "prescription.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Initial Pentamidine Prescription orders (90 day supply)",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "3V LPN clinic visit",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Pentamidine Neb Air Compressor prosthetic consult",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : ">>Equipment Requested: Pentamidine Neb Air Compressor",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Medical Condition: Pneumocystosis prevention",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Choose provisional diagnosis (e.g. lymphocytopenia)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pentamidine 300mg Inhalation QMONTH (Cost $) [DI,O]",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Albuterol inhaler",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Syringes (10mL)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Needles (22 gauge, 1.5 inch)",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Sterile Water vials (10mL)",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Iso-Neb Filtered Nebulizer System",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Subsequent Pentamidine Prescription orders (90 day supply)",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Pentamidine 300mg Inhalation QMONTH (Cost $) [DI,O]",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Albuterol inhaler",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Syringes (10mL)",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Needles (22 gauge, 1.5 inch)",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sterile Water vials (10mL)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Iso-Neb Filtered Nebulizer System", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PERI ASSOC CAPD", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 200MG PO QOD", "Text" : "Fluconazole 200 mg PO every other day ($) [R,DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 200MG PO QOD", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 100MG PO QDAY", "Text" : "Fluconazole 100 mg PO QDay ($) [R,DI]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 100MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "ORZ SET ABX OP PD HEPARIN SYRINGE/NEEDLE", "Text" : "Heparin 1000 units PD q24h", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFEP 1GM Q24H SNPW", "Text" : "Cefepime 1 gm PD q24h ($$) [R]", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG Q24H GENTAMICIN 0.6MG/KG Q24H", "Text" : "Cefazolin 15 mg/kg ($) [R] <AND> gentamicin 0.6 mg/kg ($) [R,O] PD q24h", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZ SET ABX OP PD VANCO 30MG/KG LD CEFEP 0.6MG/KG SNPW", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU PD VANCO 30MG/KG LD GENTAMICIN 0.6MG/KG Q24H", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R] <AND>", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG ONCE DAILY AND SUPPLIES", "Text" : "Cefazolin 15 mg/kg PD q24h ($) [R]", "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : "ORZID3 GMENU PD VANCO 30MG/KG LOADING DOSE AND SUPPLIES", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]", "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFEP 1GM Q24H SNPW", "Text" : "Cefepime 1 gm PD q24h ($$) [R]", "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY WITH SUPPLIES", "Text" : "Gentamicin 0.6 mg/kg PD q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : "ORZID3 GMENU PD CEFAZOLIN 15MG/KG ONCE DAILY AND SUPPLIES", "Text" : "Cefazolin 15 mg/kg PD q24h ($) [R]", "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFTAZ 1GM Q24H SNPW", "Text" : "Ceftazidime 1 gm PD q24h ($) [R]", "Header" : 0}, 
{"Row" : 86, "Column" : 1, "Item" : "ORZ SET ABX OP PD CEFTRI 1GM Q24H SNPW", "Text" : "Ceftriaxone 1 gm PD q24h ($) [M]", "Header" : 0}, 
{"Row" : 88, "Column" : 1, "Item" : "ORZID3 GMENU PD GENTAMICIN 0.6MG/KG ONCE DAILY WITH SUPPLIES", "Text" : "Gentamicin 0.6 mg/kg PD q24h ($) [R,O]", "Header" : 0}, 
{"Row" : 90, "Column" : 1, "Item" : "ORZID3 GMENU PD VANCO 30MG/KG LOADING DOSE AND SUPPLIES", "Text" : "Vancomycin 30 mg/kg PD LD then 15 mg/kg PD every 3 to 7 days ($) [R]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PERITONITIS ASSOCIATED WITH PERITONEAL DIALYSIS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Peritonitis associated with peritoneal dialysis usually presents with abdominal",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "pain, fever, nausea or vomiting, and cloudy effluent. The leukocyte",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "concentration is greater than 100 cells/microliter of dialysate, with more than",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "50% neutrophils.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Obtain Gram stain, culture, and cell count with differential of dialysate before",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antimicrobials are given. Nephrology consultation is essential. If cultures",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "show Gram-negative or mixed bacterial infection, a gastrointestinal tract",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "infectious source is more likely. Gram-positive organisms like staphylococci",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "usually result from external contamination. Fungal peritonitis is rare and",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "requires immediate catheter removal.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "**Antimicrobial recommendations are for empirical therapy only. Regimens should",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "be tailored according to patient response and microbiology results in",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "consultation with Nephrology and/or Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "To prevent catheter occlusion by turbid dialysate, add 1,000 units of heparin",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "per dialysis bag each day until one day after the dialysate is clear.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "If vancomycin is used, trough serum concentrations should be kept above 15",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "mcg/ml to ensure adequate intraperitoneal levels. Usually vancomycin must be",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "given every 3 to 7 days. Contact Nephrology and/or Pharmacy for more",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "**Fungal prophylaxis:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Antifungal prophylaxis may be used for the duration of antimicrobial therapy to",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "possibly reduce the risk of fungal peritonitis.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "**Heparin add on therapy",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "If heparin PD therapy is needed in addition to antimicrobial therapy, click on",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "the heparin order below.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Antimicrobial therapy",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Duration",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Duration of therapy depends on the pathogen identified. Treat staphylococcal and",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "streptococcal infections for 2 weeks and all other gram-positive infections for",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "3 weeks. In patients who have Staphylococcus isolated and had a previous",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "staphylococcal infection, treat for 3 weeks.",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "All antimicrobials below are administered via peritoneal dialysate bag over 6",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "hours",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Empirical treatment while waiting for results of gram stain",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "MRSA risk factors",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "cefepime 1 gm PD q24h ($) [R]",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Alternative for severe penicillin or cephalosporin allergy",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "gentamicin 0.6 mg/kg PD q24h ($) [R,O]",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Gram positive organism",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "Gram negative organism",  "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "Alternative for severe penicillin allergy",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "Alternative treatments for narrowing coverage based on isolate susceptibilities",  "Header" : 1}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 87, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 89, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 93, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 95, "Column" : 1, "Item" : null, "Text" : "De Vin et al, Peritoneal Dialysis International, 2009, Vol. 39, pp. 5-15",  "Header" : 0}, 
{"Row" : 96, "Column" : 1, "Item" : null, "Text" : "Li et al, Peritoneal Dialysis International, 2016, Vol. 36, pp. 481-508",  "Header" : 0}, 
{"Row" : 97, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Peritonitis and Intraperitoneal Abscesses",  "Header" : 0}, 
{"Row" : 98, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Peritonitis, Dialysis (CAPD) Associated",  "Header" : 0}, 
{"Row" : 99, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Microbiology and therapy of peritonitis in peritoneal",  "Header" : 0}, 
{"Row" : 100, "Column" : 1, "Item" : null, "Text" : "dialysis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PERIOCULAR INFECTIONS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERIOCULAR INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Eyelid infections",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Patients with moderate or severe eyelid infections should be referred to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "ophthalmology.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Blepharitis",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Wash margins with baby shampoo daily and use warm compresses daily.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antimicrobials have no benefit.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Hordeolum (stye)",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For external disease (involving the gland of Zeis), daily hot pack massage",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "encourages drainage and relieves symptoms. For internal disease (involving",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Meibomian glands) ophthalmology consult is encouraged, as the infection seldom",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "drains without intervention.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Lacrimal infections",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Refer cases of lacrimal infection to ophthalmology, including infections of the",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "lacrimal gland (dacryoadenitis), lacrimal sac (dacrocystitis), or tear ducts",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "(canaliculitis).",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Periocular infections",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Blepharitis",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Eyelid lesions",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Blepharitis",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Hordeolum, Stye", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PERIODENTAL DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 CHLORHEXIDINE 0.12% ORAL SWISH BID 7DAYS", "Text" : "Chlorhexidine 0.12% oral rinse swish for 30 seconds, then spit 15 ml twice", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 CHLORHEXIDINE 0.12% ORAL SWISH BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERIODONTAL DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Periodontal disease, including gingivitis and periodontitis, may progress into",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "more severe disease or cause hematogenous spreading of bacteria if left",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "untreated. All patients with periodontal disease should be referred to the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "dental service for assessment and direction of treatment. In the presence of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "gingivitis, the most commonly isolated subgingival flora includes Prevotella",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "intermedia, Capnocytophaga spp, Finegoldia magna and Peptostreptococcus. In the",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "presence of periodontitis, flora increases in complexity to most commonly",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "include Porphyromonas gingivalis, P. intermedia, Aggregatibacter",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "actinomycetemcomitans, Tanneralla forsythensis and Treponema denticola.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Consult Dental Service",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Non-severe periodontitis or acute simple gingivitis treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "daily for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Severe periodontitis or acute complicated gingivitis (ulceration, rapidly",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "advancing disease, severe pain, patients with immunocompromising conditions)",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "treatment",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Consult Dental Service",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Mandel Chapter: Infections of the Oral Cavity, Neck and Head",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Complications, diagnosis, and treatment of odontogenic",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "infections",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Overview of gingivitis and periodontitis in adults",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Vincent's Angina",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Slots et al., Periodontology. 2002, 28(1)106-176",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Tonetti et al., Journal of Periodontology, 2018, 89 S159-S172.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PERTUSSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID2 GMENU DIAGNOSIS PERTUSSIS", "Text" : "Diagnosis of pertussis", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU PREVENTION PERTUSSIS", "Text" : "Prevention of pertussis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500mg PO once on day one then 250mg PO QD for 4 days ($) [M]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERTUSSIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Pertussis is associated with persistent cough in adolescents and adults.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Immunity conferred by pertussis vaccine wanes after about 10 years. The first 1",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "to 2 weeks of disease resembles viral upper respiratory infection. After this,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "the characteristic cough with whoop is present for 1 to 6 weeks, followed by a",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "2 to 3 week period of gradual resolution.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative for macrolide intolerant or allergic patients",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Kline et al, Am Fam Physician (2013) 88.8, 507-514",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Langley et al, Pediatrics (2004), e96-e101",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pertussis",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bordetella pertussis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PHARYNGITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "Text" : "Treatment of Gonorrheal Infections", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "LRTZHIV (RAPID) QUALITATIVE", "Text" : "HIV Rapid Test", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU MORE ABOUT PHARYNGITIS", "Text" : "More About Pharyngitis/Tonsillitis and Modified Centor score", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "LRTZ STREP A PCR", "Text" : "Rapid Strep A throat PCR testing lab order", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 PENICILLIN V 500MG PO BID 10DS", "Text" : "Penicillin V 500 mg PO BID for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 PENICILLIN V 500MG PO BID 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 BENZATHINE PENICILLIN 1.2MU IM ONCE", "Text" : "Benzathine penicillin 1.2 million units IM x 1 ($$$) [M]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 BENZATHINE PENICILLIN 1.2MU IM ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO BID 10D", "Text" : "Cephalexin 500 mg PO BID for 10 days ($) [R]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO BID 10D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500 mg PO once on day one then 250mg PO qday for 4 days ($)", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PHARYNGITIS AND TONSILLITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are viral, primarily due to adenovirus. Aside from streptococcal and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "gonococcal pharyngitis, antimicrobials are not indicated. For gonococcal",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "pharyngitis, use link below for recommendations.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consider HIV screening for patients with pharyngitis",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Streptococcal Pharyngitis and Tonsillitis",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Diagnosis of group A streptococcal (GAS) infection is made through detection by",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "rapid PCR and should be reserved for patients who have a moderate to high risk",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of GAS infection according to the Modified Centor Score. Use link below for",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Modified Centor score criteria and for more details.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "PCR Negative, Viral and Other Non-GAS Causes of Pharyngitis Treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Antimicrobials are not indicated",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "GAS Pharyngitis and Tonsillitis Treatment",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Preferred",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Primary alternative:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Secondary alternative, after assessment of beta-lactam reaction above:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "[M]",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Choby, Am Fam Physician. 2009 79(5) 383-390",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Pharyngitis",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Streptococcal Pharyngitis",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Stanford et al, Clinical Infectious Diseases. 2012, cis629",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Evaluation of acute pharyngitis in adults",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article:Treatment and prevention of streptococcal pharyngitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PNEUMOCYSTIS JIROVECII DISEASE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU SURG PNEUMOCYSTIS JIROVECII", "Text" : "[CLICK HERE]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 TMP/SMX 2DS TABLETS PO Q8H 21DAYS", "Text" : "Trimethoprim-sulfamethoxazole 2 DS tablets PO TID for 21 days ($)[R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 TMP/SMX 2DS TABLETS PO Q8H 21DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP TMP 5MG/KG QD DAPSONE 100MG PO QD", "Text" : "Trimethoprim-sulfamethoxazole 5mg/kg PO TID ($)[R,DI] <AND> dapsone 100mg", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV TMP 5MG/KG QD DAPSONE 100MG PO QD", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX OP CLINDAM 450MG Q6H PRIMAQUINE 26.3MG QD", "Text" : "Clindamycin 450mg PO QID ($)[H,O] <AND> Primaquine 26.3 mg PO QDay ($)[DI]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "ORZ SET ABX NV CLINDAM 450MG Q6H PRIMAQUINE 26.3MG QD", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2 ATOVAQUONE 750MG PO BID 21DAYS", "Text" : "Atovaquone 750mg PO BID for 21 days ($)[M]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSHZID2 ATOVAQUONE 750MG PO BID 21DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 PREDNISONE 40MG BID 5DS THEN 40 QD 6DS THEN 20 QD", "Text" : "Prednisone 40mg PO twice daily for 5 days, then 40mg PO daily for 6 days,", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 PREDNISONE 40MG BID 5DS THEN 40 QD 6DS THEN 20 QD", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PNEUMOCYSTIS JIROVECII DISEASE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Diagnosis and treatment are complex, consult Infectious Diseases in all cases.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Pneumocystis jirovecii (formerly termed Pneumocystis carinii) in an ubiquitious",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "organism that causes disease in people with compromised cell-mediated immunity.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Disease is exceedingly rare in people with intact host defenses. Pneumonia is",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "the usual manifestation but P. jirovecii can infect extrapulmonary sites,",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "especially in patients who have been receiving prophylaxis with aerosolized",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "pentanmidine. P. jirovecii disease occurs most commonly in people with AIDS and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "fewer than 200 CD4 T lymphocytes/microliter.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "The abbreviation PCP is often used for Pneumocystis pneumonia. It was derived",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "from the old species name, Pneumocystis carinii.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Trimethoprim-sulfamethoxazole (TMP-SMZ) is the treatment of choice for P.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "jirovecii disease, including disease that occurs despite TMP-SMZ prophylaxis.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Corticosteriods should be prescribed for patients with AIDS and P. jirovecii",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "pneumonia and an arterial oxygen tension <70 torr or an alveolar-arterial oxygen",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "gradient of >35 torr.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for mild to moderate disease or step-down treatment once",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "disease has stabilized",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "PO QDay ($)[DI] for 21 days",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "for 21 days",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Preferred treatment for severe disease",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Prednisone for patient WITH AIDS",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "then 20 mg daily for 10 days.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2015) 1-282",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Mandell Chapter Management of Opportunistic Infections",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Associated with Human Immunodeficiency Virus Infection",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: pneumocystis pneumonia, Adult",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of Pneumocystis infection in HIV-",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "infected patients",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Prophylaxis for Pneumocystis jirovecii", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU POSTSEPTAL CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX-CLAV 875 BID + TMP/SULFA 2DS 7DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND >", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875 BID + TMP/SULFA 2DS 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZ SET ABX OP CEFDINIR 300MG BID TMP/SMX 2DS BID 7DAYS", "Text" : "Cefdinir 300 mg PO q12h ($) [R] < AND > trimethoprim-sulfamethoxazole 2 DS PO", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX NV CEFDINIR 300MG BID TMP/SMX 2DS BID 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "POSTSEPTAL CELLULITIS (ORBITAL CELLULITIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Postseptal cellulitis (orbital cellulitis) is often preceded by sinusitis and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "requires immediate consultation with otolaryngology and ophthalmology. Urgent",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "surgical drainage may be necessary. The most common pathogenic organisms in",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "adults are streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "aureus.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Contact otolaryngology or ophthalmology immediately for urgent surgical",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "drainage. Broad-spectrum empirical antimicrobials should be used until a",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "pathogen can be identified from the drainage fluid.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Duration of treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Orbital cellulitis should be treated until all signs of infection have resolved.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Uncomplicated orbital cellulitis should be treated for minimum of 2 weeks and",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "complicated orbital cellulitis (severe ethmoid sinusitis and bony destruction of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "sinus) should be treated for at least 4 weeks.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Empiric treatment",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Step-down treatment after initial intravenous therapy. Base selection on cultur",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "results.Adjust duration based on criteria above.",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "trimethoprim-sulfamethoxazole 2 DS PO BID ($) [R,DI] for 7 days",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "q12h ($) [R,DI] for 7 days",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Periocular infections",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Orbital Cellulitis",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Orbital cellulitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PREGNANCY RISK INFO", "Contents" : [
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX SANFORD PREGNANCY", "Text" : "Sanford Guide Pregnancy Risk & Lactation Safety Table", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "RISK FACTORS FOR ANTIMICROBIALS DURING PREGNANCY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "The FDA amended its rules in 2015 concerning the Pregnancy, Labor and delivery,",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "and Nursing mothers subsections of the Use in Specific Populations section of",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "product labeling. Pregnancy categories A, B, C, D, and X have been removed.",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Drugs approved after June 30 will use the new format immediately, while drugs",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "approved after June 30, 2001 will be phased in gradually.",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "See Sanford Guide for comprehensive antimicrobial pregnancy risk and lactation",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "safety information",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Risk Factors (A,B,C,D,X) were assigned to all drugs, based on the",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "level of risk the drug poses to the fetus. Risk Factors were designed to",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "help the clinician quickly classify a drug for use during pregnancy. They",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "do not refer to breastfeeding risk. The definitions of the Risk Factors",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "are those used by the FDA.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Category Description",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "A Controlled studies show no risk",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Adequate, well-controlled studies in pregnant women",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "have failed to demonstrate risk to the fetus.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "B No evidence of risk in humans",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Either animal findings show risk (but human",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "findings do not) or, if no adequate human studies",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "have been done, animal findings are negative.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "C Risk cannot be ruled out",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Human studies are lacking and animal studies",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "are either positive for fetal risk or lacking",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "as well. However, potential benefits may",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "justify the potential risk.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "D Positive evidence of risk",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Investigational or postmarketing data show risk",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "to fetus. Nevertheless, potential benefits may",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "outweigh the risk.",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "X Contraindicated in pregnancy",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Studies in animals or humans, or investigational",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "or postmarketing reports have shown fetal risk",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "which clearly outweighs any possible benefit to",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "the patient.",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Up-to-Date website",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Sanford website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PREGNANCY VACCINE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZ GTX ABX JOINT LEGACY VIEWER", "Text" : "Patient vaccine history", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ GTX ABX CDC ADULT IMMUNIZATION SCHEDULE", "Text" : "CDC Recommended Adult Immunization Schedule", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenza type b: indicated in asplenia, those undergoing", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A: if at risk for infection or severe outcome from infection during", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B: if at risk for infection or severe outcome from infection during", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B: 3 dose series.", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B high dose: 4 dose series, for those on hemodyalisis.", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Zoster (shingles) Information Page", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza: one dose annually.", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal A, C, W and Y: indicated in asplenia, HIV, complement deficiency", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal B: Delay until after pregnancy unless at increased risk and", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal: for those w/additional risk factor or another indication. Refer to", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZ SET ABX TD/TDAP VACCINE 3 DOSE SERIES", "Text" : "Tetanus, diphtheria and pertussis: Tdap booster dose during each pregnancy.", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus influenzae type b (Hib)", "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPA VACCINE INFORMATION PAGE", "Text" : "Hepatitis A (HepA)", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis B (HepB)", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPAHEPB VACCINE INFORMATION PAGE", "Text" : "Hepatitis A and Hepatitis B (HepA/B)", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "ORZID3 GMENU ABX ZOSTER VACCINE INFORMATION PAGE", "Text" : "Herpes zoster (RZV)", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "ORZID3 GMENU ABX HPV VACCINATION INFORMATION PAGE", "Text" : "Human papillomavirus (HPV)", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "ORZID3 GMENU INFLUENZA VACCINATION 2021-2022", "Text" : "Influenza", "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : "ORZID3 GMENU ABX MMR VACCINE INFORMATION PAGE", "Text" : "Measles, mumps, and rubella vaccine (MMR)", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroups A, C, W and Y (MenACWY)", "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal serogroup B (MenB)", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal 20-valent (PCV20)", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "ORZID3 GMENU ABX TDAP VACCINE INFORMATION PAGE", "Text" : "Tetanus, diphtheria, pertussis (Td/Tdap)", "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : "ORZID3 GMENU ABX VAR VACCINE INFORMATION PAGE", "Text" : "Varicella (VAR)", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "IMMUNIZATION OF PREGNANT PATIENTS",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Pregnant women should receive the tetanus, diphtheria, and acellular pertussis",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "vaccine (Tdap) during pregnancy and the influenza vaccine during or before",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "pregnancy. Live vaccines are contraindicated (e.g. MMR and Varicella). See",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "immunization information pages located at the bottom of this page for other",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "indications, contraindications, and one-time dose orders to listed vaccines.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Specific vaccine orders for pregnant patients:",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "splenectomy and HSCT patients. Refer to specific immunization recommendations",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "for patients with these indications or refer to the Haemophilus influenza type b",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "vaccine information menu below.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "pregnancy.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "pregnancy.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Herpes zoster: delay until after pregnancy unless at increased risk and",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "information menu below.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Human papillomavirus: *CONTRAINDICATED*.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Measles, mumps, and rubella *CONTRAINDICATED*.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "or inhibitor use, travel to endemic countries, microbiologists, and college",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "students. Refer to specific immunization recommendations for asplenia and HIV or",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "refer to the Meningococcal A, C, W and Y vaccine information menu below.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "vaccination benefits outweigh potential risks. Refer to Meningococcal B vaccine",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "information menu below.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "specific immunization recommendations for patients with these indications or",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "refer to the Pneumococcal vaccine information menus below.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Varicella: *CONTRAINDICATED*.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Specific vaccine information pages:",  "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "Murthy et al. Annals internal medicine, 2022, 175(3)432-443", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PRESEPTAL CELLULITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZ SET ABX OP AMOX-CLAV 875 BID + TMP/SULFA 2DS 5DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R] < AND>", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX NV AMOX-CLAV 875 BID + TMP/SULFA 2DS 5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZ SET ABX OP CEFDINIR 300MG BID TMP/SMX 2DS BID 5DAYS", "Text" : "Cefdinir 300 mg PO q12h ($) [R] <AND> trimethoprim-sulfamethoxazole 1 DS PO", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX NV CEFDINIR 300MG BID TMP/SMX 2DS BID 5DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PRESEPTAL CELLULITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Preseptal cellulitis involves soft tissues in front of the orbital septum and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "the eyelids and is often preceded by sinusitis. Infection does not involve the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "orbital contents. The most common pathogenic organisms in adults are",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "streptococci, Haemophilus influenzae, anaerobes, and Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treatunder the guidance of ophthalmology and/or otolaryngology. Intravenous",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "antimicrobials are indicated initially for treatment of moderate to severe",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "disease. Switch to oral antimicrobials when the patient's symptoms improve and",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "the patient can tolerate oral medications.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Trimethoprim-sulfamethoxazole 1 DS PO BID ($) [R,DI] for 5 days",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "BID ($) [R,DI] for 5 days",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Carlisle et al., American Family Physician. 2015, 92(2)106-112",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Periocular infections",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Johns Hopkins website",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Preseptal cellulitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 7DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 7DS 500MG PO QDAY", "Text" : "Levofloxacin 500 mg PO QDAY for 7days ($) [R,DI]", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 7DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID CEFPODOXIME 100MG PO BID X7DAYS", "Text" : "Cefpodofor ime 100 mg PO BID x7days ($$) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID CEFPODOXIME 100MG PO BID X7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF BACTERIAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antimicrobial prophylaxis is often given to patients likely to have profound,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "prolonged neutropenia.Profound neutropenia is less than 100 neutrophils and",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "bands per microliter, and such neutropenia is considered prolonged when it is",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "expected to last more than 7 days.Most patients who should receive prophylaxis",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "have received stem cell transplants or are undergoing induction chemotherapy for",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "acute leukemia.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "If antibacterial prophylaxis is indicated",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration of therapy: During period of expected neutropenia",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter:Prophylaxis and Empirical Therapy for Infection in Cancer-",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Patients",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Related Infections. Version 1.2019. nccn.org", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 400MG PO QDAY X10DAYS", "Text" : "Fluconazole 400 mg po qday for 10 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 400MG PO QDAY X10DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF FUNGAL INFECTIONS IN A PATIENT WITH MALIGNANCY",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Antifungal chemoprophylaxis is often given to patients undergoing induction",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "chemotherapy for acute leukemia expected to have profound neutropenia (less than",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "100 neutrophils and bands per milliliter) for more than 10 days and for patients",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "receiving allogeneic stem cell transplantation.For most other patients the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "expected benefits do not outweigh the risks of adverse effects and selection of",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "resistant fungi.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Antifungal is usually given until the absolute neutrophil concentration",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "increases to more than 500 cells/microliter in patients undergoing induction",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "chemotherapy for leukemia.Duration is 100 days for patients undergoing stem",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "cell transplantation.Some physicians continue prevention after 100 days if",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "corticosteroids are part of the immunosuppressive regimen.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Recommend posaconazole prophylaxis for patients with Acute Myeloid Leukemia.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Contact Hematology Oncology or Infectious Disease for more information.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Patients who have had invasive fungal infection in the recent past and who are",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "about to become neutropenic may require chemoprophylaxis.Contact Hematology-",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Oncology or Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "If antifungal prophylaxis is indicated",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Duration of therapy: during period of expected neutropenia",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "For patients being treated for AML:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Requires Infectious Disease approval:",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Posaconazole 300mg Tablets twice daily on day 1, then 300mg once daily on",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "day 2 and thereafter. Continue for 7 days after the neutrophil count",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "rises above 500/mm3. ($$$$) [DI]",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Taplitz RA Journal of Clinical Oncology, 2018, 36:3043",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "NCCN Clinical Practice Guidelines, Prevention and Treatment of Cancer-",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Related Infections. Version 1.2019. nccn.org",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Prophylaxis and empirical therapy for infection in cancer",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "patients", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZ GTX ABX ENDOCARDITIS PDF COMP INFO", "Text" : "<Link> AHA Prevention of Infective Endocarditis Guidelines", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU PBE DENTAL ORAL RESP PROC", "Text" : "Patients undergoing dental or oral mucosa procedures", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "ORZID2 GMENU SURG HEAD AND NECK SURG", "Text" : "Patients undergoing procedures on the respiratory tract that involve incision or", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZID3 GMENU ABX PROCED FOR INFECTED SKIN OUTPATIENT", "Text" : "Patients undergoing procedures for infected skin, skin structures, or infected", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF BACTERIAL ENDOCARDITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Bacteremia occurs several times a day during daily activities like eating and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "brushing teeth and rarely results in endocarditis, even in people with abnormal",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "valves.While bacteremia might occur following dental or other procedures, most",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cases of endocarditis are from the millions more episodes of transient",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "bacteremia a person experiences per year from ordinary daily activities.There",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "is no evidence that antimicrobial prophylaxis prevents endocarditis after",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "procedures.The best available evidence suggests that prophylactic",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "antimicrobials confer more risks than benefits in most situations.A decision",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "about whether to administer antimicrobial prophylaxis should be based on both",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "the risk of endocarditis conferred by the patient's cardiac defect and the risk",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "of bacteremia from a planned dental or surgical procedure.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "For complete information follow this link:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Determine the need for prophylaxis through the 2-step process outlined",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "below.",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Step 1.Assess the risk of endocarditis for your patient",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Prophylaxis is recommended if a patient has any of the following conditions:",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "oProsthetic cardiac valve or material including: Presence of cardiac",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "prosthetic valve, transcatheter implantation of prosthetic valves (e.g. TAVR",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "cardiac valve repair with devices (e.g. annuloplasty, rings, or clips), left",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "ventricular assist devices or implantable heart",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "oA history of infective endocarditis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "oCertain specific congenital heart conditions - refer to the full guidelines",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "(link above) or consult Cardiology for more detailed recommendations",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "oCardiac transplant that develops a problem in the heart valve",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Step 2.Assess the risk of bacteremia from the planned procedure",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Prophylaxis is indicated for these procedures:",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "oAll dental procedures that involve manipulation of gingival tissue or the",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "periapical region of teeth or perforation of the oral mucosa.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "oProcedures on the respiratory tract that involve incision or biopsy of the",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "respiratory mucosa, such as tonsillectomy and adenoidectomy. Prophylaxis is",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "recommended for bronchoscopy when procedure involves incision of the respira",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "tract mucosa.",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "oProcedures that involve incision through infected skin, skin structures, or",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "musculoskeletal tissue.",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "oDermatologic procedures that breach the oral mucosa.",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Prophylactic Antimicrobials select below:",  "Header" : 1}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "biopsy of the respiratory mucosa",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "musculoskeletal tissues",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Up-To-Date Article: Antimicrobial prophylaxis for the prevention of bacterial",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "endocarditis",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Wilson et al., Circulation, 2021, 143(20)e963-e978", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PREVENTION OF INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU PREV OF BACT ENDOCARDITIS OUTPATIENT", "Text" : "Prevention of bacterial endocarditis", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID2 GMENU PREV PROS JOINT DENTAL", "Text" : "Before dental procedures", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT ANTIBACT PROPHYL", "Text" : "Antibacterial prophylaxis", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU PREV INFECT FUNGAL PROPHYL", "Text" : "Antifungal prophylaxis", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU ANTIVIRAL PROPHYLAXIS MALIGNANCY", "Text" : "Antiviral prophylaxis", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ACUTE SPON BACT PERITONITIS", "Text" : "Spontaneous bacterial peritonitis", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU SURG PNEUMOCYSTIS JIROVECII", "Text" : "Pneumocystis jirovecii prophylaxis", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX SA DECOLONIZATION", "Text" : "Click Here", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++PREVENTION OF INFECTION - OUTPATIENT++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Prevention of bacterial endocarditis",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Prevention of prosthetic joint infection",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Prevention of infection in patient with malignancy",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Prevention of infection in patients with liver disease",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Prevention of Pneumocystis infection",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Prevention of recurrent Staphylococcus aureus skin infection",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Last reviewed January 2012",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU ABX DERM IE JI PROPHYLAXIS", "Text" : "Before procedures that involve infected skin, skin structures or musculoskeletal", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "tissue", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PREVENTION PERTUSSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Azithromycin 500mg PO once on day one then 250mg PO QD for 4 days ($) [M]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 AZITH 500MG PO ONCE THEN 250MG PO QDAY X4DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PREVENTION OF PERTUSSIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Immunization",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Give a single dose of tetanus-diphtheria acellular pertussis vaccine (Tdap) in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "adults regardless of interval between most recent Td vaccine. One dose of Tdap",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "vaccine is given to pregnant women during each pregnancy.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Postexposure prophylaxis in adults",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Household contacts with symptomatic coughing should be treated as if they have",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "pertussis. Consult Infectious Diseases (outpatient) for all suspected cases of",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "pertussis and exposure to pertussis.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "CDC recommends postexposure prophylaxis in household contacts within 21 days",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "after exposure to pertussis regardless of immunization history. Non-household",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "contacts who are at high risk of severe illness or who have close contact with",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "high risk individuals should receive post exposure prophylaxis within 21 days of",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "exposure. Those at high risk of severe illness are infants less than one year of",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "age, women in third trimester of pregnancy and those with preexisting health",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "conditions that may be exacerbated by pertussis (e.g. immunosuppressed and",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "asthmatic individuals). A single dose of Tdap should be administered in those",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "who are not up to date.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Prophylaxis:",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative for macrolide intolerant or allergic patients",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "CDC:https://www.cdc.gov/pertussis/outbreaks/pep.html (Accessed 3-17-17)",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Kim et al, Annals of internal medicine (2016) 184-194",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pertussis",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Bordetella species", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 800MG PO 5X/D", "Text" : "Acyclovir 800 mg PO 5x/day for 5-7 days ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 5DS 800MG PO 5X/D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 5DS 1GM PO TID", "Text" : "Valacyclovir 1 gm PO TID for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 5DS 1GM PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 800MG PO 5X/DAY 7DS", "Text" : "Acyclovir 800 mg PO 5x/day for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 800MG PO 5X/DAY 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1000MG PO TID", "Text" : "Valacyclovir 1000 mg PO TID for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1000MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PRIMARY INFECTION (CHICKENPOX)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Prevention",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Vaccinate all adults without evidence of immunity except for pregnant women.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Test antibody first in adults who have uncertain history of chickenpox or",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "vaccination.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Give Varicella vaccine x 2, 2nd dose 4-8 weeks after 1st dose",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Therapy must be started within 24 hrs onset of rash.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Therapy must be started within 24 hrs onset of rash.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Prevention",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients without prior immunity to varicella who are at risk",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "for disease include: patients with malignancy, current immunosuppressive",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "therapy, or HIV infection. Vaccination is not recommended while patients are",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "immunocompromised.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Contact Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease, or if mild to moderate disease doesn't improve on",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "above therapy",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Kim et al. Annals Intern Med. 2018, 168(3):210-220",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Varicella-Zoster Virus",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PROPHYLAXIS OPTH SURG", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PROPHYLAXIS FOR OPHTHALMIC SURGERY",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "When indicated, ophthalmology will order antimicrobial prophylaxis before",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "procedures.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PROPHYLAXIS PROSTATE BIOPSY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ SET ABX CIPRO CEFUROXIME MAIL PO", "Text" : "Ciprofloxacin 500 mg po once ($) [R,DI] < AND >", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZ SET ABX CIPRO CEFUROXIME PO WINDOW", "Text" : "Ciprofloxacin 500 mg po once ($) [R,DI] < AND >", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Antibiotic Prophylaxis Transrectal Ultrasound Prostate Biopsy Procedures (TRUSP)",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "The recommendations for prophylaxis for TRUSP procedures have been updated based",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Outpatient Prescriptions for Mailing:",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Cefuroxime 1000 mg po once ($) [M], BOTH 2 to 3 hours before",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "scheduled prostate biopsy.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Outpatient Prescriptions for Window Pick-up:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Cefuroxime 1000 mg po once ($) [M], BOTH 2 to 3 hours before",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "scheduled prostate biopsy.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with anaphylactic or other serious beta-lactam allergy",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Administer in clinic on the day of procedure.",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Becopoulos T et alJ Chemother 1990 2:244-246",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Charalabopoolos et al Chemotherapy 2003 49:269-279",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Nam R et al J Urol 2010 183:963-969",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "based on emergence of resistant E-coli bacteria strains.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Alternative for patients who have not taken the oral medications:",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZ SET ABX OP CEFTRIAXONE 250 IM AND CIPRO 500 PO X1", "Text" : "Ciprofloxacin 500 mg po once ($) [R,DI] < AND > Ceftriaxone 250 mg", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Administer in clinic on the day of procedure.",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Intramuscularly once ($) [M] BOTH given 1 hour before the procedure.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "_________________________________________________________________",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZ SET ABX OP AZTREONAM 1GM + CIPRO 500 ONCE PROPHYLAXIS TRUSP", "Text" : "Ciprofloxacin 500 mg po once ($) [R,DI] < AND > Aztreonam 1 gm intramuscularly", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "once ($$$$) [R] BOTH given 1 hour before the procedure.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PROS B/J ENTEROCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "Text" : "Minocycline 100mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "Text" : "Linezolid 600 mg PO BID ($) [DI,O]", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "ENTEROCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "followed by oral antibiotics. For severe infections, add an aminoglycoside for",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "synergy during the first weeks of therapy. Mild infections can be treated with",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "oral antibiotics only.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of Treatement",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "may follow treatment based on individual patient circumstances.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy and Chronic",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Suppression",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Allergy to penicillin",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "For resistant isolates only",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PROS B/J GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID AMOX-CLAV 875/125MG PO BID", "Text" : "Amoxicillin-clavulanate 875-125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID AMOX-CLAV 875/125MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 750MG PO BID", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 750MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "GRAM NEGATIVE BACILLI (OTHER THAN PSEUDOMONAS) INFECTIONS IN BONE OR JOINT",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "PROSTHESES",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "antibiotics only.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Duration of Treatment",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "may follow treatment based on individual patient circumstances.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy and Chronic",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Suppression",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Alternative Oral Treatment for Intolerance to Above Oral Antibiotics",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "For treatment of mild infections and continuation of therapy",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "For Chronic Suppression",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PROS B/J P. AERUGINOSA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 750MG PO BID", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID CIPROFLOXACIN 750MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID CIPROFL 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID CIPROFL 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PSEUDOMONAS AERUGINOSA INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antibiotics only.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Duration of Treatment",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 4-6 weeks. Chronic oral antimicrobial suppression",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "may follow treatment based on individual patient circumstances.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Oral Treatment For Mild Infections, For Continuation of Therapy",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Oral Treatment for Chronic Suppression",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PROS B/J S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSHZID CEPHALEXIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSOZID DICLOXACILLIN 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSHZID DICLOXACILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSOZID MINOCYCLINE 100MG PO BID", "Text" : "Minocycline 100mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "PSHZID MINOCYCLINE 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSOZID RIFAMPIN 600MG PO QDAY", "Text" : "Rifampin 600 mg PO QDay ($) [DI,O]", "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : "PSHZID RIFAMPIN 600MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STAPHYLOCOCCUS AUREUS INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment Following Debridement and Retention of Prosthesis",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 to 6 months of",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "an oral antibiotic combined with rifampin (3 months in total hip, elbow,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "shoulder and ankle arthroplasty and 6 months in total knee arthroplasty).",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment Following 2-stage Exchange or Resection Arthroplasty Without Planned",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Staged Reimplantation of Prosthesis",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat with intravenous antibiotic for 6 weeks for all joint types.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment Following 1-Stage Exchange of Prosthesis",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treat with intravenous antibiotic for 2 to 6 weeks followed by 3 months of an",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "oral antibiotic combined with rifampin for all joint types.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Rifampin Synergy",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Rifampin is recommended for treatment with debridement and retention or one",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "stage exchange. When rifampin is combined with a beta-lactam or vancomycin in",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "vitro, bacterial killing is enhanced. Do not use rifampin alone, as bacterial",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "resistance develops rapidly. If patient does not tolerate rifampin it may be",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "omitted from treatment regimen. Contact Infectious Diseases for more",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "information.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Chronic Suppression",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Chronic suppression with oral antimicrobials may follow treatment based on",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "individual patient circumstances.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Oral Treatment for Continuation of Therapy or Chronic Suppression",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "MRSA or allergy to penicillin or cephalosporin",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Rifampin Synergy for Debridement and Retention or One Stage Exchange (Not For",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Chronic Suppression)",  "Header" : 1}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "In addition to PO treatment above < ADD >",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PROS B/J STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500 MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID AMOXICILLIN 500 MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID PENICILLIN 500MG PO QID", "Text" : "Penicillin VK 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID PENICILLIN 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 300MG PO QID", "Text" : "Clindamycin 300 mg PO QID ($) [H,O]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STREPTOCOCCAL INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For acute, moderate or severe infections, treat with intravenous antibiotics",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "followed by oral antibiotics. Mild infections can be treated with oral",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antibiotics only.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases for specific management advice.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases in all cases for specific management advice.",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Duration of Treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat for a total duration of 4-6 weeks. Chronic suppression with oral",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobials may follow treatment based on individual patient circumstances.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Intravenous Treatment",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Oral Treatment For Mild Infections, Continuation of Therapy or Chronic",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Suppression",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Allergy to penicillin or cephalosporin",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J S. AUREUS", "Text" : "Staphylococcus aureus infections", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J STREPTOCOCCI", "Text" : "Streptococci infections", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J ENTEROCOCCI", "Text" : "Enterococci infections", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J GNB", "Text" : "Gram negative bacilli (other than Pseudomonas) infections", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU PROS B/J P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa infections", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "INFECTIONS IN BONE OR JOINT PROSTHESES",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Common important pathogens include coagulase-negative staphylococci,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Staphylococcus aureus, streptococci, enterococci, and gram negative bacilli.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Obtain material for gram stain and culture and base antimicrobial therapy on",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "results of Gram stain. Blood, joint fluid, and affected tissue and/or bone are",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "ideal specimens to culture. Sinus tracts are often colonized and isolates from",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "drainage may not be pathogens. If Staphylococcus aureus is present,it is likely",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "to be a pathogen in the bone.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Pathogen-directed Treatment Regimens",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Acute infections can often be cured with debridement with joint retention",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "followed by antimicrobials. Infections with duration of symptoms greater then 3",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "weeks or infection within 4 weeks of implantation require one or two stage",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "remimplantation. Cases that are inoperable can be managed with long-term",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "suppressive antimicrobial therapy or joint removal without replacement depending",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "on patient's condition. Consult Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Infectious Disease and Orthopedics consultations are essential.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Empirical Therapy Before a Pathogen is Identified is Not Recommended.",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "If patient has sepsis or is otherwise unstable, empiric treatment before culture",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "results are obtained may be justified.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for IV treatment options.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Orthopedic Implant-Associated Infections",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date Article: Prosthetic Joint Infections: Treatment",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Osmon et al, Clinical Infectious Diseases (2013) 56.1, e1-25",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Prosthetic Joint Infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PUBIC LICE (PEDICULOSIS PUBIS)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "Text" : "Permethrin 1% lotion. Apply to affected area for 10 minutes then comb out", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 PERMETHRIN 1% LOT 10MIN 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "PUBIC LICE (PEDICULOSIS PUBIS)",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Lice are parasitic insects. Human lice survive by feeding on human blood.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "To make a diagnosis, use a nit comb, bright light, or lens to find a louse",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "living in pubic hair.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "The presence of nits on a hair shaft, especially when they are located more",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "than 6 mm from the skin, does NOT indicate active infestation.Nits may remain",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "present for months after successful treatment.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Household contacts and persons who may have come into contact with personal",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "belongings of an infested individual should be examined for evidence of lice",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "and discarded or cleaned if contaminated.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "A repeat application may be used if live lice are seen 7-10 days after",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "treatment.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "nits ($) [M]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: lice",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PYELONEPHRITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU PYELONEPHRITIS SPECIFIC PATHOGEN", "Text" : "Treatment for specific pathogens", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSJIZID CEFTRIAXONE 1 GRAM IM X1", "Text" : "Ceftriaxone 1 gm IM x 1 dose ($) [M]", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSJIZID GENTAMICIN 5MG/KG IM ONCE", "Text" : "Gentamicin 5 mg/kg IM x 1 dose ($) [R,O]", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet BID for 14 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 14DAYS 1DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID AMOXICILLIN-CLAVULANATE 875/125 MG PO BID X14DAYS", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSHZID AMOXICILLIN-CLAVULANATE 875/125 MG PO BID X14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "PSOZID2 CEFDINIR 300MG PO BID 14DAYS", "Text" : "Cefdinir 300 mg PO BID for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSHZID2 CEFDINIR 300MG PO BID 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PYELONEPHRITIS",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Most cases are caused by Escherichia coli. Resistant organisms are more likely",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "if the patient has been in the hospital for more than 48 hours or received a",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "course of antibiotics.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Obtain a urine Gram stain immediately to guide therapy. Drugs active against",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "enterococci (ampicillin, piperacillin) or staphylococci needn't be used if Gram-",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "negative bacilli predominate on the smear.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Judge severity of infection based on clinical signs and symptoms, including",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "blood pressure, pulse, mental status, white blood count, and degree of fever.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "For stable patients with mild to moderate disease, outpatient treatment may be",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "considered.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "In older men with pyelonephritis, obtain a renal ultrasound to rule out",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "obstruction. Consult urology if abnormalities are found.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treat for 7 to 14 days. In patients with a mild infection and a quick clinical",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "response, 7 days of treatment may be adequate. Severe infection, resistant",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "organisms or structural abnormality may require a longer duration. A 7-day",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "course of ciprofloxacin has been shown to be as effective as a 14-day course.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mild to moderate disease",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "An initial dose of parental agent is recommended, then complete treatment course",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "with oral agent. It is imperative to confirm susceptibility to the prescribed",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "oral antibiotic when results are reported.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Parental Therapy x 1 dose:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Complete course with oral therapy:",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Severe disease",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Sanberg et al, Lancet (2012) 380.9840:4-10",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pyelonephritis",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PYELONEPHRITIS SPECIFIC PATHOGEN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO TID for 14 days($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID LINEZOLID 600MG PO BID", "Text" : "Linezolid 600 mg PO BID for 14 days ($) [DI,O]", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSHZID LINEZOLID 600MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Ciprofloxacin 500 mg PO BID for 7 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID CIPROFLOX 500MG PO BID X 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PYELONEPHRITIS WITH SPECIFIC PATHOGEN",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treatment regimens apply to mild, moderate cases.",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Infections with enterococcus and pseudomonas require specific therapy. Refer to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Inpatient CDSS for treatment of severe cases.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "If enterococcus identified",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Alternative for vancomycin-resistant enterococci (VRE)",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "If Pseudomonas identified",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Severe Cases",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pyelonephritis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute complicated cystitis and pyelonephritis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU PYOMYOSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PYOMYOSITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1000MG PO TID", "Text" : "Valacyclovir 1000 mg PO TID for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1000MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID PREDNISONE TAPER FOR HERPES ZOSTER", "Text" : "Prednisone 60 mg daily for 7 days then 30 mg daily for 7 days, then 15 mg", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSHZID PREDNISONE TAPER FOR HERPES ZOSTER", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1000MG PO TID", "Text" : "Valacyclovir 1000 mg PO TID for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1000MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "REACTIVATION OF PRIMARY INFECTION (ZOSTER OR SHINGLES)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Zoster represents reactivation of varicella-zoster virus. After primary",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infection, virus remains latent in the sensory dorsal root ganglia.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Reactivation syndrome is characterized by painful, unilateral, vesicular,",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "dermatomal rash.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Prevention",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Vaccinate all adults greater than or equal to 50 years of age with the",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "recombinant zoster vaccine regardless of past episode or receipt of the live",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "zoster vaccine.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Give recombinant zoster vaccine x2, 2nd dose 2-6 months after the first",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Immunocompetent patients",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Treatment in persons <50 years",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment is not beneficial, none is recommended.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment in persons >=50 years",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment with antivirals can shorten duration of pain and rash in patients over",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "50 years old. Treatment must be started within 72 hours of onset.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "There is evidence that addition of corticosteroids to antiviral",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "therapy decreases pain and duration of rash and improves quality of life",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "modestly during the acute shingles episode. Corticosteroids do not decrease the",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "incidence of post-herpetic neuralgia. Some authorities recommend addition of",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "corticosteroid therapy to antiviral therapy for patients over age 50 years.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Corticosteroids are not recommended for patients at greater risk for steroid",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "toxicities (e.g., insulin-dependent diabetes mellitus, hypertension, peptic",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "ulcer disease) or for immunocompromised patients.",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Optional Recommendation:",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "daily for 7 days. ($)",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "________________________________",  "Header" : 1}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Immunocompromised patients at increased risk for complications of VZV disease",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "include: patients with malignancy, current immunosuppressive therapy, or HIV",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "infection. Treatment with antivirals shortens duration of symptoms and reduces",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "incidence of complications. In immunocompromised patients, treatment is",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "recommended to be started at any point during an active infection.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Treatment for mild to moderate disease",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease or progression from mild to moderate disease in",  "Header" : 1}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "patients <=65 years",  "Header" : 1}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "Treatment for severe disease or progression from mild to moderate disease in",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "patients >65 years",  "Header" : 1}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Kim et al. Annals Intern Med. 2018, 168(3):210-220",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Varicella-Zoster Virus",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Chickenpox and Herpes Zoster (Varicella-Zoster Virus)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX OP METRO 2GM PO X1 AZITHRO 1GM PO X1", "Text" : "Metronidazole 2 gm PO x 1 dose ($) [DI] Azithromycin 1 gm PO x 1 dose ($)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PERSISTENT OR RECURRENT URETHRITIS OR CERVICITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Retreat with initial treatment regimen if patient was non-compliant with initial",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "treatment regimen or re-exposed to an untreated sex partner. If infection is not",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "due to non-compliance with treatment regimen or re-exposure to an untreated sex",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "partner, infection is most commonly caused by M. genitalium and less commonly T.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "vaginalis.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treatment for persistent or recurrent urethritis and failure of initial",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "doxycycline treatment",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "[M]",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Failure of above treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Diseases (outpatient)",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2015) 64.3",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urethritis",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and Cervicitis",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Urethritis, Recurrent/Persistent",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute cervicitis",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Urethritis in men", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU RELIEF RX INFORMATION", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Acute Respiratory Tract Infections typically do not require an antimicrobial",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "prescription, however, patient's may be left unsatisfied. Relief Rx,",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "a symptom care pack including educational material, to ease veterans' symptoms",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "and help limit inappropriate antimicrobial prescriptions for viral infections.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Select clinics are participating in the Relief RX program with the Antimicrobial",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Stewardship Team. Please use link below to contact the team with questions",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "or to obtain more Relief RX packages for your site.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZ GTX ABX CDSS EMAIL", "Text" : "<Select Here> Contact ASP/CDSS Team", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Note: The Relief RX package does not contain medications (other than throat",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "lozenges). Provider may order additional symptomatic medications.",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "RELIEF RX =SYMPTOMATIC CARE PACK FOR VIRAL RESPIRATORY INFECTION", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU RETINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU CMV RETINITIS", "Text" : "Link to Treatment of CMV Retinitis and ARN", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 5DS 800MG PO 5X/D", "Text" : "Acyclovir 800 mg PO 5x/d for 5-7 days ($) [R]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 5DS 800MG PO 5X/D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 5DS 1GM PO TID", "Text" : "Valacyclovir 1 gm PO q8h for 5 days ($) [R]", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 5DS 1GM PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 ACYCLOVIR 7DAYS 400MG PO TID", "Text" : "Acyclovir 400 mg PO q8h for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 ACYCLOVIR 7DAYS 400MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSOZID2 VALACYCLOVIR 7DS 1GM PO BID", "Text" : "Valacyclovir 1 gm PO q12h for 7-10 days ($) [R]", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSHZID2 VALACYCLOVIR 7DS 1GM PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "RETINITIS AND ACUTE RETINAL NECROSIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Retinitis is a subset of uveitis, is rare in immunocompetent people: in these",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "individuals it is usually caused by varicella-zoster virus (VZV) or herpes",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "simplex virus (HSV). Retinitis is more common in immunocompromised patients and",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "cytomegalovirus being the most common pathogen in these patients. Other",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "retinitis pathogens include Toxoplasma gondii, Bartonella henselae, Histoplasma",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "capsulatum, and Treponema pallidum. In most cases, patients have other",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "neurological symptoms or signs.Patients with candidemia may present with 1-3",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "mm white punctate retinal lesions called cotton-wool spots. These may only be",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "visible on fundus examination. Treatment of candidal retinitisis systemic",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "antifungal therapy. Consult Ophthalmology, Infectious Diseases, or Neurology for",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "help.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "VZV and HSV cause nearly all cases of acute retinal necrosis (ARN), with a small",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "number being caused by cytomegalovirus. ARN is a rapidly progressing retinitis",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "that occurs primarily in immunocompetent people and can cause vision loss.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Treatment with intravenous acyclovir or valacyclovir is essential to halt",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "progression of ARN.",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Ophthalmology and Infectious Diseases consultation is essential",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Treatment of Non-viral Retinitis or ARN",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Refer to specific pathogen treatment recommendations of the CDSS to treat",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "underlying infection",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment of Retinitis or ARN due to CMV:",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Treatment of VZV Retinitis",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Treatment of HSV Retinitis",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Treatment of VZV and HSV Acute Retinal Necrosis",  "Header" : 1}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Ophthalmologist involvement is essential for treatment including",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "corticosteroids, vitrectomy, or laser therapy. Intravitreal foscarnet in",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "addition to a systemic antiviral may provide added therapeutic efficacy.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Duration",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Treat with intravenous therapy for a minimum of 7 days until disease has",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "stabilized then treat with or therapy for a minimum of 6 weeks",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "Lau et al, Ophthalmology. 2007, 114(4)756-762",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious causes of uveitis",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Schoenbergeret al., Ophthalmology. 2017, 124(3)382-392",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Acute Retinal Necrosis",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Herpes Simplex",  "Header" : 0}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Retinitis",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Varicella-zoster Virus (Chickenpox)", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU ROCK MTN SPOTTED FEVER", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100 mg PO q12h ($) [DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "ROCKY MOUNTAIN SPOTTED FEVER",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Rocky Mountain Spotted Fever is a tick-borne, potentially life-threatening",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "rickettsial disease. The highest incidence in the United States is in the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Southeastern and South-central states. Clinical diagnosis include fever in",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "endemic area, known or possible tick bite, with or without rash. Rash typically",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "spreads from the extremities to the trunk.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Diagnosis is difficult, consult Infectious Diseases for assistance.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consider empirical therapy with doxycycline for a patient with an undiagnosed",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "febrile illness and relevant tick exposure.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treat for 7 days.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Rocky mountain spotted fever",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Masters EJ Arch Intern Med 2003, 163: 769", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SCABIES", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 PERMETHRIN 5% CRM TOP APPL FROM HEAD TO FEET", "Text" : "Permethrin 5% cream apply from head to feet, leave on for 8-14 hours, then", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID2 PERMETHRIN 5% CRM TOP APPL FROM HEAD TO FEET", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "SCABIES",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Scabies is an infestation of the skin by the mite Sarcoptes scabiei.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "It is transmitted by skin to skin contact. Outbreaks occur in nursing",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "homes, day care centers, and residential institutions.Scabies is highly",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "contagious and meticulous infection control is needed.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment is a single application of permethrin cream.Some experts recommend",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "a second application 7-10 days after the first application if the patient is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "still symptomatic or if live mites are found at that time.Contact Dermatology",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "or Infectious Diseases for more information.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treat family members and other close contacts to prevent spread and recurrence.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Repeat application 7-10 days after the first application if patient is still",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "experiencing symptoms, or if lives mites are found.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "wash cream off with soap and water ($) [M]",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Scabies",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SECOND RECURRENCE CDIFF COLITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID2 VANCOMYCIN TAPER AND PULSE DOSING", "Text" : "Vancomycin Extended Pulse-Taper Regimen ($) [M]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 VANCOMYCIN TAPER AND PULSE DOSING", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SECOND RECCURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients with more than one recurrence of C. difficile infection are complex and",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "difficult.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Discontinue any antibiotics if possible and avoid high-risk antibiotic if",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antibiotic therapy is still needed. Discontinue antacid therapy if possible.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Second Recurrence:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Severe/life-threatening disease (shock, ileus, megacolon)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Clostridium difficile infection",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Clostridium difficile",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Clostridium difficile infection in adults: Treatment and",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "prevention",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200 MG EXTENDED-PULSE REGIMEN", "Text" : "Fidaxomicin Extended-Pulse Regimen ($$) [M]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG EXTENDED PULSE REGIMEN", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Criteria for Use: Fidaxomicin VA-PBM (11/21)",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Johnson et al, Clin Inf Dis, 2021, 73(5): e1029-e1044",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "(Fidaxomicin 200mg po bid x5days,then 200mg qother day x20days)",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "*Infectious Disease or Gastroenterology consultation is recommended*",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Third or more recurrence: Consult Gastroenterology or Infectious Disease",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 FIDAXOMICIN 200MG PO Q12H 10DAYS", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 FIDAXOMICIN 200MG PO BID 10DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "< OR>",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "(Vancomycin 125 mg PO q6h for 10 days, then taper and pulse with",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "125 mg po twice daily for seven days, then 125mg po qday for 7 days, then",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "125mg every other day for 6 weeks)",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Fulminant CDI:", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU SECONDARY PERITONITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SECONDARY PERITONITIS, INTRAABDOMINAL ABSCESS, INTRAPERITONEAL ABSCESS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPSIS, SEVERE SEPSIS, AND SEPTIC SHOCK",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH ENTEROCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Amoxicillin 500 mg PO TID ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 14DS 500MG PO TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH ENTEROCOCCI",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Administer parenteral therapy initially then can be converted to appropriate",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "oral therapy.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Duration of treatment for 2-4 weeks, depending on response",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment, MILD-MODERATE infections",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Treatment, SEVERE infections",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Inf Dis 2014, 59:e10-52", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH GNB", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO BID ($) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 14DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 LEVOFLOXACIN 14DS 500MG PO QDAY", "Text" : "Levofloxacin 500mg PO qday ($) [R,DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 LEVOFLOXACIN 14DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH GRAM NEGATIVE BACILLI (OTHER THAN",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "PSEUDOMONAS)",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Administer parenteral therapy initially for approximately 1-2 weeks",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "then can be converted to appropriate oral therapy.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Duration of treatment for 4 weeks depending on response",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Oral therapy to complete the course after intravenous therapy initially:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Up-to-date online",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Mathews CJ Lancet 2010 375:846", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH N. GONORRHOEAE", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Doxycycline 100 mg PO BID for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 100MG PO BID 7DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH NEISSERIA GONORRHOEAE",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Treat presumptively also for Chlamydia trachomatis infection",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "(asymptomatic urethritis) and test for HIV.Infection control will",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "report cases with N. gonorrhea isolated to the state department of health.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Sexual partners within 60 days should be referred for evaluation and treatment.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Parenteral therapy recommended until clinical improvement, then switch to oral",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "therapy to complete 1-2 weeks of therapy.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Susceptibility results are required to guide potential switch to an oral medicat",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment for N. gonorrheae (Plus see below for Chlamydia treatment)",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for initial parenteral treatment",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "______________________________________________________________",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Concomitant treatment for C. trachomatis",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Preferred treatment:",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Alternative treatment:",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Coakley G Lancet 2010, 375:846",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "MMWR Recommendations and Reports CDC 2015, 64:1-137", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH P. AERUGINOSA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID2 CIPROFLOX 14DS 750MG PO BID", "Text" : "Ciprofloxacin 750 mg PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSHZID2 CIPROFLOX 14DS 750MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH PSEUDOMONAS AERUGINOSA",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Administer parenteral therapy initially then can be converted to appropriate",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "oral therapy.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Up-to-date online",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Mathews CJ Lancet 2010, 375:846", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH S. AUREUS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 CEPHALEX 28DS 500MG PO QID", "Text" : "Cephalexin 500 mg PO QID ($) [R]", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSHZID2 CEPHALEX 28DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 DICLOX 28DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 DICLOX 28DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 28DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 MINOCYCLINE 28DS 100MG PO BID", "Text" : "Minocycline 100 mg PO BID ($) [DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 MINOCYCLINE 28DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH STAPHYLOCOCCUS AUREUS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Administer parenteral therapy initially for approximately two weeks",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "then can be converted to appropriate oral therapy.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Total duration of treatment 4-6 weeks depending on clinical response",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Methicillin-SUSCEPTIBLE Staphylococcus aureus",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Methicillin-RESISTANT Staphylococcus aureus",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "________________________________________________________",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Up-to-date online",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Mathews CJ Lancet 2010, 375:846",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Coakley G Rheumatology (Oxford) 2006, 45:1039", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTH STREPTOCOCCI", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "PSOZID2 AMOXICILLIN 1000MG PO TID 14DAYS", "Text" : "Amoxicillin 1000 mg PO tid for 14 days ($) [R]", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "PSHZID2 AMOXICILLIN 1000MG PO TID 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 CLINDAMYCIN 14DS 300MG PO QID", "Text" : "Clindamycin 300mg PO qid for 14 days ($) [H]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 CLINDAMYCIN 14DS 300MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT) WITH STREPTOCOCCI",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Administer parenteral therapy initially and then can be converted to",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "appropriate oral therapy.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Duration of therapy 2-4 weeks total",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Up-to-date online",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Mathews CJ Lancet 2010, 375:846", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "Text" : "Infections in bone or joint prostheses", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU BITE WOUNDS", "Text" : "Bite wounds", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "Text" : "Lyme disease", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH S. AUREUS", "Text" : "Staphylococcus aureus", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH STREPTOCOCCI", "Text" : "Streptococci", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH ENTEROCOCCI", "Text" : "Enterococci", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH GNB", "Text" : "Gram negative bacilli (other than Pseudomonas)", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH P. AERUGINOSA", "Text" : "Pseudomonas aeruginosa", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC ARTH N. GONORRHOEAE", "Text" : "Neisseria gonorrhoeae", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC ARTHRITIS (NATIVE JOINT)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : ">>For arthritis associated with a PROSTHETIC JOINT see",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : ">>For arthritis associated with a BITE WOUND see",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : ">>For arthritis associated with TICK EXPOSURE in an endemic area, consider",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Septic arthritis native joint:",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Aspirate the joint for gram stain and culture.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Use the gram stain of aspirated fluid to select initial therapy.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Use culture results to guide definitive therapy.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "In addition to antimicrobial treatment, successful managemet of acute",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "septic arthritis requires removal of intra-articular pus.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "See Inpatient CDSS for initial parenteral treatment",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Pathogen-specific septic arthritis treatment regimens",  "Header" : 1}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Duration of therapy based on pathogen and clinical response. (See pathogen)",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "If the patient has an underlying rheumatoid arthritis, 6 to 12 weeks of",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "antimicrobials may be needed, depending on clinical response.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Consult Rheumatology for more information.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Septic arthritis",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Sharff KA Curr Rheumatol Rep 2013, 15:332",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Coakley G Lancet 2010, 375:846", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEPTIC BURSITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 DICLOX 14DS 500MG PO QID", "Text" : "Dicloxacillin 500 mg PO QID ($) [DI]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 DICLOX 14DS 500MG PO QID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Doxycycline 100 mg PO BID($) [DI]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 DOXYCYCLINE 14DS 100MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID TRIMETH/SULFA 1 DS TABLET 14DS PO BID", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet PO BID ($) [R,DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID TRIMETH/SULFA 1 DS TABLET 14DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SEPTIC BURSITIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Aspiration for treatment and diagnostic confirmation should be performed",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "in all cases. Obtain synovial fluid for gram stain and culture to guide",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "therapy. Most cases are associated with Staphylococcus aureus.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Intravenous therapy is recommended. Some clinicians treat mild cases in",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "otherwise healthy individuals with intravenous therapy for part of the",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "course and then switch to oral therapy. Other clinicians treat mild cases",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "with oral therapy for the entire course. Drug selection should be based on",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "microbiological results. Close clinical follow-up is needed for all cases.",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Moderate to severe cases",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient CDSS",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Mild cases",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Treat for 14 days.",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Bursitis, Septic",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious arthritis of native joints",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Baumbach SF, Arch Orthop Trauma Surg 2014, 134:359", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A diagnosis of a sexually transmitted infection can suggest sexual activity",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Sexually Transmitted Infections (STI)",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU EPIDIDYMITIS", "Text" : "Epididymitis", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID3 GMENU PELVIC INFLAM DISEASE", "Text" : "Pelvic Inflammatory Disease (PID)", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "ORZID3 GMENU ABX SYPHILIS", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU CERVICITIS ASSOC STD", "Text" : "Cervicitis", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID3 GMENU GENITAL HERPES", "Text" : "Genital herpes", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU URETHRITIS ASSOC STD", "Text" : "Urethritis", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sexually Transmitted Infections (STIs)",  "Header" : 1}, 
{"Row" : 36, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIV-AIDS", "Text" : "Human Immunodeficiency Virus (HIV)", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "Text" : "HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Chlamydia (see Cervicitis or Urethritis or Gonorrhea)",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "Text" : "Trichomonas Vaginitis, Urethritis and Male Sex Partners", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "that could result in HIV exposure. Recommendation is for the provider to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "HIV acquisition.If the patient is interested, the provider should place a",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "consult to MRTC clinic for further discussion and evaluation for PrEP.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Pre-exposure prophylaxis (or PrEP) is a way for people who do not have",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "HIV but who are at high risk of getting HIV to prevent HIV infection by",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "taking a pill every day. When someone is exposed to HIV through sex or",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "injection drug use, these medicines can work to keep the virus from",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "establishing a permanent infection.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Per CDC, when taken daily PrEP is highly effective for preventing HIV. Studies",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "have shown that PrEP reduces the risk of getting HIV from sex by about",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "99% when taken daily. PrEP is much less effective if not taken consistently.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "As PrEP only protects against HIV, condoms are important for the protection",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "against other STIs. Condoms are also an important prevention strategy",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "if PrEP is not taken consistently.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "Text" : "Gonorrhea", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIV-AIDS", "Text" : "Human Immunodeficiency Virus (HIV)", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP NON-OCCUP MAIN PAGE", "Text" : "HIV Post-Exposure Prophylaxis Non-Occupational (Blood/Body Fluids) Outpatient", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID3 GMENU ABX PEP OCCUPATIONAL EXPOSURE", "Text" : "HIV Post-Exposure Prophylaxis Occupational (Blood/Body Fluids) Outpatient", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Sexually Transmitted Infections (STI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "A diagnosis of a sexually transmitted infection can suggest sexual activity",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "that could result in HIV exposure. Recommendation is for the provider to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "discuss with the patient Pre-Exposure Prophylaxis (PrEP) to reduce risk of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "HIV acquisition.If the patient is interested, the provider should place a",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "consult to MRTC clinic for further discussion and evaluation for PrEP.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Pre-exposure prophylaxis (or PrEP) is a way for people who do not have",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "HIV but who are at high risk of getting HIV to prevent HIV infection by",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "taking a pill every day. When someone is exposed to HIV through sex or",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "injection drug use, these medicines can work to keep the virus from",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "establishing a permanent infection.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Per CDC, when taken daily PrEP is highly effective for preventing HIV. Studies",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "have shown that PrEP reduces the risk of getting HIV from sex by about",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "99% when taken daily. PrEP is much less effective if not taken consistently.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "As PrEP only protects against HIV, condoms are important for the protection",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "against other STIs. Condoms are also an important prevention strategy",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "if PrEP is not taken consistently.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SM UNIF BAC AEROBIC BOT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SMALL PLEOMORPHIC BACILLI IN AEROBIC BOTTLE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Small pleomorphic bacilli in aerobic bottle are usually diphtheroids. These are",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "usually contaminants. Uncommonly such organisms prove to be Listeria",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "monocytogenes, which when present in a blood culture is likely a pathogen.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Listeria is more likely in patients with impaired cell-mediated immunity,",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "pregnant women, elderly and patients on immunosuppressive therapy for",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "transplantation.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Empirical treatment if there is a strong suspicion of listeria",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "__________________________________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Empirical treatment if therapy is indicated and listeria is not suspected",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Listeria Monocytogenes",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Other Coryneform Bacteria and Rhodococci",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Listeria monocytogenes",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Propionibacterium acnes",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Corynebacterium", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SM UNIF BAC ANAEROBIC BOT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SMALL PLEOMORPHIC BACILLI IN AN ANAEROBIC BOTTLE",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Small pleomorphic bacilli in anaerobic bottle usually suggest propionibacteria.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "These are often contaminants.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Treatment if therapy is indicated",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS for intravenous treatment options",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Other Coryneform Bacteria and Rhodococci",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Medical Letter Choice of Antimicrobials 2010, 8.94",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Propionibacterium acnes",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Corynebacterium", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SOFT TISSUE, MUSCLE, BONE...", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU BITE WOUNDS", "Text" : "Bite wounds", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU SEPTIC BURSITIS", "Text" : "Septic bursitis", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID3 GMENU ABSCESSES", "Text" : "Abscesses", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU CUTANEOUS ABSCESS", "Text" : "Cutaneous abscess", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU PYOMYOSITIS", "Text" : "Pyomyositis (Refer to Inpt)", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU DECUBITIS ULCERS", "Text" : "Decubitis ulcers", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU SURG SITE INFECT", "Text" : "Surgical wound infections", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ SOFT TISSUE, MUSCLE, BONE AND JOINT INFECTIONS - OUTPATIENT++",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Update/review in process Jan2019",  "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : "ORZID3 GMENU FOOT ULCER IN PT W/ DM", "Text" : "Foot ulcer in patient with diabetes mellitus", "Header" : 0}, 
{"Row" : 7, "Column" : 2, "Item" : "ORZID3 GMENU OSTEOMYELITIS", "Text" : "Osteomyelitis", "Header" : 0}, 
{"Row" : 8, "Column" : 2, "Item" : "ORZID3 GMENU DISKITIS", "Text" : "Diskitis and vertebral osteomyelitis", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "Text" : "Infections in bone or joint prostheses", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID3 GMENU SEPTIC ARTHRITIS (NAT JOINT)", "Text" : "Native joint", "Header" : 0}, 
{"Row" : 13, "Column" : 2, "Item" : "ORZID3 GMENU PROSTHESIS BONE JOINT INFECT", "Text" : "Prosthetic joint", "Header" : 0}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "Septic arthritis", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU SPLENECTOMY DAILY ANTIBIOTIC", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "HELP, additional information:",  "Header" : 1}, 
{"Row" : 2, "Column" : 1, "Item" : "ORZID2 GMENU ABX HELP PAGE", "Text" : "Help page (instructions, microbiology, etc.)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : "ORZID2 GMENU ABX DRUG INFO PAGE", "Text" : "", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "[DI]=important drug interactions, [O]=other, [M]= minimal risk)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU NEED AN ALT ABX MAIN", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "GMRCTZ INFECTIOUS DISEASE (OUTPT)", "Text" : "Consult Infectious Diseases (outpatient)", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID2 GMENU ABX COST INFORMATION", "Text" : "", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-Date online",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Daily Antibiotic Prophylaxis for Asplenia",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "The need for daily antibiotic prophylaxis and its duration is typically",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "determined individually based on patient age, immune status, history of",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "infection, potential for adverse drug reactions and other factors.",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Daily antibiotic prophylaxis is in addition to the emergency supply.",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID AMOXICILLIN 500MG PO BID FOR ASPLENIA DAILY PROPHYLAXIS", "Text" : "", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID CEPHALEXIN 250MG PO BID DAILY PROPHYLAXIS ASPLENIA", "Text" : "", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Recommended:",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin and beta lactam allergy:",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 250 MG QDAY DAILY PROPYLAXIS ASPLENIA", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Consider Prophylaxis:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "1) Approximately 1 year prophylaxis for all patients following splenectomy.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "2) Lifelong prophylaxis for patients with history of sepsis or other severe",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "infections caused by encapsulated organisms.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "3) Prophylaxis for as long as the patient is immunocompromised or for life",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "for patients with concurrent immunocompromising conditions (e.g. hematologic",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "malignancy, hypogammaglobulinemia, solid-organ transplant, advanced liver",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "disease, or HIV infection).", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SPLENECTOMY EMPIRIC ABX", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID AMOXICILLIN-CLAVULANATE 875/125MG PO BID ASPLENIA", "Text" : "Amoxicillin-clavulanate 875MG PO BID for asplenia empiric antibiotic ($) [R]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "PSOZID CEFUROXIME 500MG PO BID ASPLENIA", "Text" : "Cefuroxime 500MG PO BID for asplenia empiric antibiotic ($) [R]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID LEVOFLOXACIN 750MG PO QDAILY ASPLENIA", "Text" : "Levofloxacin 750MG PO QDAY for asplenia empiric antibiotic ($) [R,DI]", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Self-medicate Empiric Antibiotics for Fever or Other Signs of Systemic Infectio",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Patients should keep an emergency supply of antibiotics on hand to be used",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "for the development of fever or other signs of systemic infection, and",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "seek medical care immediately if these symptoms develop.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Recommendations to self- medicate:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Alternative recommendation for penicillin/beta-lactam allergy:",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Up-to-Date online",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Keenan RD, Br J Haematol 1999. 105:509", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SPLENECTOMY OPT CHART", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZ SET ABX SPLENECTOMY DAY1 THRU WEEK 8 VACCINES", "Text" : "CLICK HERE TO ORDER DAY 1 THRU WEEK 8 VACCINES", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZ SET ABX SPLENECTOMY DAY ONE VACCINES 4", "Text" : "CLICK HERE TO ORDER DAY1 ONLY VACCINES", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HIB VACCINE INFORMATION PAGE", "Text" : "Haemophilus B conjugate vaccine", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroups", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal Serogroup B vaccine", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal conjugate 13-valent vaccine", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal polysaccharide 23-valent vaccine", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroup Vaccine", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Functional or Anatomical Asplenia Vaccine Guidelines",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "ORDER SPLENECTOMY VACCINES:",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "CLICK THE INDIVIDUAL VACCINES FOR INFO & ORDER",  "Header" : 1}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Dose1______________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "day 1",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Dose3_________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "5 years",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "MMWR Morb Mortal Wkly Rep 2018:66(5)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Clin Infect Dis 2014,58:e44-100",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENB VACCINE INFORMATION PAGE", "Text" : "Meningococcal Serogroup B vaccine", "Header" : 0}, 
{"Row" : 27, "Column" : 2, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroup Vaccine", "Header" : 0}, 
{"Row" : 10, "Column" : 2, "Item" : null, "Text" : "Dose2_______________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "4 weeks",  "Header" : 1}, 
{"Row" : 13, "Column" : 2, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "Dose4__________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 2, "Item" : null, "Text" : "10 years",  "Header" : 1}, 
{"Row" : 25, "Column" : 2, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 15, "Column" : 3, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroups Vaccine", "Header" : 0}, 
{"Row" : 19, "Column" : 3, "Item" : "ORZID3 GMENU ABX PNEUMOCOCCAL VACCINE INFORMATION PAGE", "Text" : "Pneumococcal polysaccharide 23-valent vaccine", "Header" : 0}, 
{"Row" : 27, "Column" : 3, "Item" : "ORZID3 GMENU ABX MENACWY VACCINE INFORMATION PAGE", "Text" : "Meningococcal ACWY Serogroup Vaccine", "Header" : 0}, 
{"Row" : 10, "Column" : 3, "Item" : null, "Text" : "Dose2____________________________",  "Header" : 1}, 
{"Row" : 11, "Column" : 3, "Item" : null, "Text" : "8 weeks",  "Header" : 1}, 
{"Row" : 13, "Column" : 3, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 17, "Column" : 3, "Item" : null, "Text" : "n/a",  "Header" : 0}, 
{"Row" : 22, "Column" : 3, "Item" : null, "Text" : "Dose5 and above_______________",  "Header" : 1}, 
{"Row" : 23, "Column" : 3, "Item" : null, "Text" : "REPEAT every 5 years",  "Header" : 1}, 
{"Row" : 25, "Column" : 3, "Item" : null, "Text" : "n/a", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SPLENECTOMY VACCINES ABX PROPHY", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY OPT CHART", "Text" : "[click here] Place Order for Vaccines for Outpatient", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY DAILY ANTIBIOTIC", "Text" : "Daily Antibiotic Prophylaxis", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZID3 GMENU SPLENECTOMY EMPIRIC ABX", "Text" : "Self-medicate Empiric Antibiotics", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Functional or Anatomical Asplenia Vaccine & Antibiotic Prophylaxis Guideline",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Following a splenectomy there is considerably increased risk of developing",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "septicemia from invasive encapsulated organisms, namely Streptococcus pneumonia,",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Haemophilus inluenza type b and meningococcus. Key measures to prevent",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "such infections include education, vaccination, prophylactic antimicrobial",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "therapy in selected patients, and early empirical therapy for febrile",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "epsisodes. It is critically important to educate patients regarding the",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "lifelong risk of postsplenectomy sepsis, the importance of vaccinations,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "and the need for urgent action in response to a febrile episode.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Management of an Episode of Fever in an Asplenic Patient",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "*See Inpatient CDSS*",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Initiation of vaccine regimen:",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Routine vaccines should be up to date including influenza, Tdap, Zoster,",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "HPV, MMR, Varicella. See CDSS Immunization section to order.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Ideally splenectomy vaccinations should be given 10 to 12 weeks before",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "elective splenectomy.Where this is not possible they can be given up to",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "two weeks before or at least two weeks post-splenectomy.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Use of Antibiotic Prophylaxis for Asplenia:",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Use of antibiotic prophylaxis, in addition to vaccination, further reduces",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "the risk of infection and poor outcomes.",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Daily Antibiotic Prophylaxis: (in addition to emergency supply)",  "Header" : 1}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Emergency Supply Empiric Abx for Fever or Other Signs of Systemic Infection:",  "Header" : 1}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "MMWR Morb Mortal Wkly Rep 2018:66(5)",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Clin Infect Dis 2014, 58:e44-100",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Up-to-Date", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SPOROTRICHOSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID2 ITRACONAZOLE 200MG PO QDAY 90DAYS", "Text" : "Itraconazole 200 mg PO q12h continue for 2-4 weeks after all lesions", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSHZID2 ITRACONAZOLE 200MG PO QDAY 90DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "SPOROTRICHOSIS",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Sporotrichosis occurs most often in people who have had significant outdoor",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "exposure to soil.In immunocompetent people, disease is usually limited to the",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "skin.In people with decreased host defenses (eg, HIV/AIDS, alcoholism,",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "diabetes mellitus, or chronic obstructive pulmonary disease) sporotrichosis",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "often disseminates to bones, joints, or lungs.Consult Infectious Diseases or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Dermatology",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "____________________________________________________________________________",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Cutaneous infection in a patient without HIV infection",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "____________________________________________________________________________",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "resolved, usually for a total of 3-6 months ($) [DI]",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Consult Dermatology or Infectious Diseases.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "____________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Extracutaneous infection or any infection in a patient with HIV/AIDS",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "____________________________________________________________________________",  "Header" : 1}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Consult Dermatology or Infectious Diseases.",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Kaufman CA Clin Infect Dis 2000, 30: 684",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Up-to-date website", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU STAPH SCALDED SKIN SYNDROME", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "STAPHYLOCOCCAL SCALDED SKIN SYNDROME (RITTER'S DISEASE)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Staphylococcal scalded skin syndrome (SSSS) presents with severe skin",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "blistering and exfoliation resulting from toxins produced by Staphylococcus",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "aureus.SSSS is usually found in children and rarely in older adults.Obtain",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "a skin biopsy to differentiate between SSSS and toxic epidermal necrolysis.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Initiate anti-staphylococcal therapy and obtain cultures and susceptibilities.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "If cultures reveal methicillin-susceptible Staphylococcus aureus (MSSA), change",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "to nafcillin or cefazolin for better antimicrobial activity.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Staph. Scalded skin syndrome",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: The acutely ill patient with fever and rash",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Stevens DL Clin Infect Dis 2014, 59: 147",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Patel GK Am J Clin Dermatol 2003, 4:165", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SUPP ODONTOGENIC INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Amoxicillin-clavulanate 875/125 mg PO q12h for 7 days ($) [R]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 875/125MG 7DS PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID2 GMENU ABX BETA-LACTAM ALLERGY ASSESMENT", "Text" : "Assessment of Beta-lactam Reaction", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID CLINDAMYCIN 450MG PO TID 7D", "Text" : "Clindamycin 450 mg PO q8h for 7 days ($) [H,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID CLINDAMYCIN 450MG PO TID 7D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TOOTH ABSCESS AND OTHER SUPPURATIVE ODONTOGENIC INFECTIONS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Surgical drainage, scaling and antimicrobial treatment are essential and tooth",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "extraction is required in most cases. All patients should be referred to the",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "dental service for assessment and direction of treatment. Empirical coverage for",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "likely pathogens (streptococci, Peptostreptococcus, Finegoldia, Bacteriodes and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "other oral anaerobes is required. Immunocompromised patients need additional",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "coverage for Pseudomonas aeruginosa.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Consult Dental Service",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Treatment of mild to moderate disease in immunocompetent patients or step-down",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "therapy after initial intravenous therapy. Adjust duration for a total of 7 day",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "of antimicrobial therapy.",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Preferred:",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Treatment of severe disease in immunocompetent patients",  "Header" : 1}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Treatment in immunocompromised patients",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS for parenteral therapy",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Hull et al, Current Infectious Disease Reports. 2005, 7(1)17-27",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infections of the Oral Cavity, Neck, and Head",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Ogle, Dent Clin N Am. 2017, 61(2)235-252",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Reynolds et al. Lung. 2009, 187(5)271-279",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tooth, Odontogenic Infection, Ludwig's Angina",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Up-to-date article: Complications, diagnosis and treatment of odontogenic",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Infections", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SURG PNEUMOCYSTIS JIROVECII", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID TMP/SMX 1 DS TABLET QDAY", "Text" : "Trimethoprim-sulfamethoxazole 1 DS tablet QD ($) [R,DI]", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID TMP/SMX 1 DS TABLET QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID TMP/SMX 1 SS TABLET QDAY", "Text" : "Trimethoprim-sulfamethoxazole 1 SS tablet QD ($) [R,DI]", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID TMP/SMX 1 SS TABLET QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : "PSOZID DAPSONE 100MG PO QDAY", "Text" : "Dapsone 100mg PO QD ($) [O]", "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSHZID DAPSONE 100MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "ORZ SET ABX PENTAMIDINE NEB RTC LPN", "Text" : "Pentamidine 300mg Inhalation QMONTH ($) [DI,O] <AND> Albuterol 0.083%", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID3 GMENU PENTAMADINE MENU", "Text" : "Pentamidine for home administration", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "PNEUMOCYSTIS JIROVECII PROPHYLAXIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Indications for primary prophylaxis of P. jirovecii include:",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "1) HIV/AIDS patients with CD4 count <200 cells/microliter",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "2) Hematopoietic or organ transplantation patients during immunosuppression",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "3) Patients receiving Alemtuzumab, temozolomide or fludarabine",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "4) Patients receiving >/= 20mg equivalent of prednisone per day for over 1 month",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "5) Patients with acute lymphocytic leukemia, rheumatologic disease receiving",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "immunosuppressive therapy and certain primary immunodeficiencies (e.g. severe",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "combined immunodeficiency, idiopathic CD4 T-lymphocytopenia, hyper-IgM syndrome)",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Dose and duration of prophylaxis varies with the indication. Please contact",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases or Hematology/Oncology for more information.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Prophylaxis should be discontinued when host defenses are restored. In persons",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "with AIDS on highly active antiretroviral therapy, Prophylaxis should be",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "discontinued when the CD4 cell concentrations remain over 200 cells/microliter",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "for 3-6 months in patients, except that prophylaxis should be continued for",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "life in those who have had P. jirovecii disease.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Alternative when trimethoprim/sulfa is poorly tolerated or contraindicated:",  "Header" : 1}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "inhalation QMONTH ($) [M] clinic orders (call 612-467-5193 for 3V LPN",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "appointment)",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Pneumocystis pneumonia, Adult",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Treatment and prevention of Pneumocystis pneumonia in HIV-",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Uninfected patients",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Recommended FIRST-LINE prophylaxis:",  "Header" : 1}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "**Patient should be tested for glucose-6-phosphate dehydrogenase (G6-PD)",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "deficiency before starting dapsone. Individuals deficient in G6-PD",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "show about a 2-fold increase in sensitivity toward dapsone-induced hemolytic",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "anemia.",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "G6-PD lab test are resulted the same day or next day. May be add on lab.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "G6-PD lab result should be \"normal\" to start dapsone therapy.",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Alternative to the above regimens:",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "Due to efficacy and complicated logistics for administration, alternative",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "when above recommendations not appropriate for patient.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Alternative to the above preferred regimens:",  "Header" : 1}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Atovaquone is alternative for patient for clinical reason:",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "(e.g. patients with SLE, hematologic concerns, G6PD deficiency)",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Maertens J, et al. J Antimicrob Chemother. 2016, 71(9): 2397-404",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "Martin SI, et al. Am J Transplant. 2013, 13 Suppl 4:272-9",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "Infected Adults and Adolescents. AIDSinfo (2018)",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID ATOVAQUONE 1500MG QDAY PCP PROPHYLAXIS", "Text" : "", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSHZID ATOVAQUONE 1500MG SUSP QDAY PCP PROPHYLAXIS", "Text" : "", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "LRTZ G6-PD SCREEN", "Text" : "[Click here] G6-PD Screen Lab Order", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SURG SITE INFECT", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "SURGICAL SITE INFECTION",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU SYSTEMIC INFECT DIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU BACTEREMIA", "Text" : "Bacteremia", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU INTRAVASC CATH-ASSOC INFECT", "Text" : "Intravascular catheter-associated infection", "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : "ORZID3 GMENU SEPSIS AND SEPTIC SHOCK", "Text" : "Sepsis and septic shock", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "ORZID2 GMENU LEUKOCYTOSIS", "Text" : "Leukocytosis", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU FEVER OF UNKNOWN ORIGIN", "Text" : "Fever of unknown origin", "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : "ORZID3 GMENU NEUTROPENIC FEVER", "Text" : "Neutropenic fever", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZID3 GMENU LYME DISEASE", "Text" : "Lyme disease", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++SYSTEMIC INFECTIOUS DISEASES - OUTPATIENT++",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Last reviewed July 2017", "Header" : 1}
]},
{"Name" : "ORZID3 GMENU TACE IR CHEMOEMBOLIZATION", "Contents" : [
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "-Antibiotic prophylaxis in patients undergoing transarterial therapy for",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "hepatocellular carcinoma may not be routinely necessary.",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "-However, patients with an incompetent sphincter of Oddi from previous",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "surgery, sphincterotomy, biliary drainage, or prior biliary instrumentation",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "are at increased risk of infection following embolization.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "If no antimicrobial prophylaxis recommended, select below:",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Antimicrobial Pre-Procedure Prophylaxis Transarterial Chemoembolization (TACE)",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Gaba RC, et al. J Vasc Interv Radiol 2017, 28:1210-1223",  "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSJIZID LEVOFLOXACIN 500MG IV IR TACE PRE-PROCEDURE", "Text" : "Levofloxacin 500 mg IVPB once 60 minutes prior to TACE procedure", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSJIZID PIPERACILLIN-TAZO 3.375GM IV IR TACE PRE-PROCEDURE", "Text" : "", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative for penicillin allergy:",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Minneapolis VAHCS Interventional Radiology",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Recommended prophylaxis:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ GTX ABX PRE-OP TACE URL NURSE GENERIC ORDER", "Text" : "*No antimicrobial prophylaxis recommended for TACE procedure", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU THRUSH", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU FUNGI", "Text" : "Link to candida in specific pathogen", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID2 NYSTATIN SWISH/SWALLOW 5ML QID 7D", "Text" : "Nystatin swish and swallow QID for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSHZID2 NYSTATIN SWISH/SWALLOW 5ML QID 7D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID CLOTRIMAZOLE TROCHE 10MG PO 5X/D 7D", "Text" : "Clotrimazole troche 10 mg PO 5X/day for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID CLOTRIMAZOLE TROCHE 10MG PO 5X/D 7D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 200MG PO ONCE THEN 100MG QDAY 6D", "Text" : "Fluconazole 200 mg PO once, then 100 mg PO QD for 6 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 200MG PO ONCE THEN 100MG QDAY 6D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 200MG PO ONCE THEN 100MG QDAY 13D", "Text" : "Fluconazole 200 mg PO once, then 100 mg PO QD for 13 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 200MG PO ONCE THEN 100MG QDAY 13D", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "THRUSH (OROPHARYNGEAL AND ESOPHAGEAL CANDIDIASIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "For information on other types of candidal infections",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Candidal infections of the mouth, throat, or esophagus usually occur in patients",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "on corticosteroid therapy, those who wear dentures, patients treated with",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "antibiotics, chemotherapy or head/neck radiation therapy, and those with",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "cellular immune deficiency states, such as AIDS.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Oropharyngeal candidal disease may present in different patterns, like white",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "plaques in the oropharyngeal area, erythematous macules (often in patients with",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "dentures), or as pseudomembranes.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Thrush infection often recurs, especially in patients with AIDS. Consult",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Infectious Diseases (MRTC may also be consulted in the MVAHCS)for more",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "information on treatment of recurrent infection.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "Oral or pharyngeal candidiasis in patients without HIV",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Alternative for patients with HIV, or whose disease fails to respond to the",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "above therapies",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Esophageal candidiasis",  "Header" : 1}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Esophageal infection requires systemic therapy.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Candida Species",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Pappas et al. Clinical Infectious Diseases. 2016, 62(4)e1-50",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Candidiasis, Oropharyngeal",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Treatment of oropharyngeal and esophageal candidiasis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TINEA CAPITIS (RINGWORM)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 250MG PO QDAY 28DAYS", "Text" : "Terbinafine 250 mg PO QDAY ($) [R,H,DI,O]", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 250MG PO QDAY 28DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TINEA CAPITIS (RINGWORM)",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Tinea capitis is a common fungal infection of the scalp and hair. It is",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "characterized by itchy, red, raised, scaly patches often sharply defined.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "redder margins than centers create impression of ring. Tinea capitis primarily",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "affects prepubescent children, but can affect people of any age.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Treatment:",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tinea", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TINEA PEDIS (ATHLETE'S FOOT)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID2 CLOTRIM 1% CRM TOP BID 28DAYS", "Text" : "Clotrimazole 1% cream apply to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSHZID2 CLOTRIM 1% CRM TOP BID 28DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 1% CRM TOP BID 28DAYS", "Text" : "Terbinafine 1% cream apply to affected area BID ($) [M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 1% CRM TOP BID 28DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 150MG QWEEK X2-4 WEEKS", "Text" : "Fluconazole 150mg q week x 2-6 weeks ($) [R,DI]", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 150MG QWEEK X2-4 WEEKS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 250MG PO QDAY 14DAYS", "Text" : "Terbinafine 250 mg PO QDAY x 2 weeks ($) [R,H,DI,O]", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 250MG PO QDAY 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Dermatophyte (tinea) Infections",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TINEA PEDIS (ATHLETE'S FOOT), TINEA CORPORIS, TINEA MANUUM, OR TINEA CRURIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Dermatophyte fungal infections are common worldwide. Dermatophytes",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "metabolize and subsist upon keratin in the skin, hair, and nails.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Most tinea infections can often be cured with topical therapy alone.Systemic",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "therapy is reserved for severe or refractory infection, recurrent infection, or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "in immunocompromised patients.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Treat for 4 weeks",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Systemic treatment",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Up-to-date website",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tinea", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TINEA UNGUIUM (ONYCHOMYCOSIS)", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 42DAYS 250MG PO QDAY", "Text" : "Terbinafine 250 mg PO qday for 6 weeks ($) [R,H,DI,O]", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 42DAYS 250MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TINEA UNGUIUM (ONYCHOMYCOSIS)",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tinea",  "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 300MG QWEEK FOR 6 MONS TOENAIL", "Text" : "", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "Alternative oral therapy:",  "Header" : 1}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Toenail infections treat for at least 6 months",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Fingernail infections treat for 3 months",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : "PSOZID2 FLUCONAZOLE 300MG PO QWEEK FOR 3MONS FINGERNAIL", "Text" : "", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "Topical Treatment:",  "Header" : 1}, 
{"Row" : 61, "Column" : 1, "Item" : "PSOZID CICLOPIROX TOPICAL QDAY AFFECTED NAILS", "Text" : "", "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "Remove with rubbing alcohol every 7 days. ($) [M]",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "See accompanying medication pamphlet for specific instructions.",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "Treatment is continued until nail clearance or up to 48 weeks.",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "Gupta AK, et al. Br J Dermatol 2020 182(2): 287-299",  "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : null, "Text" : "Up-to-date website: Onychomycosis Management",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "Preferred Terbinafine first-line oral:",  "Header" : 1}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "Ciclopirox is a topical first-line treatment for both fingernails and toenails.",  "Header" : 0}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Complete resolution occurs in approximately 7 percent of patients treated",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "daily for 48 weeks.Ciclopirox is a well-tolerated treatment. Potential side",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "effects include temporary nail changes and local skin irritation.",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Fingernail infections treat for 6 weeks",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "Toenail infections treat for 12 weeks",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 250MG PO QDAY X12 WEEKS TOENAIL", "Text" : "", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Onychomycosis is a fungal infection of the nail that presents with yellow,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "thick, or crumbling nails. Obtain a fungal stain of nail sample prior to",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "initiating treatment. Using large nail clippers, remove as much of the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "unattached dystrophic nail as possible. Place the piece of clipped nail plate",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "in formalin jar and send to pathology for fungal stain (PAS). Treatment should",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "only be initiated if stain is positive for fungal elements. Fungal culture is",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "NOT recommended.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Cure is unlikely if the entire nail is involved, or if a portion of the lunula",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "is involved. Sometimes after treatment the fungus is cured, but the nail",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "still does not appear normal because once nail dystrophy occurs, that",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "is not reversible.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Systemic therapy is most likely to achieve a cure, especially with more nail",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "involvement. If <25% involvement topical therapy may be considered. If",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : ">50-75% involvement systemic therapy should be considered.",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Terbinafine works about 70% of the time to cure the fungus, and reinfection",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "is common, so many patients will need to do more than one course",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "of treatment.Fluconazole pulse dosing response rate is approximately 50%.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "May consider retreatment with oral therapy after one year.",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Recommend Dermatology Consult for retreatment after failure of 2 courses of",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "terbinafine or fluconazole.",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Obtain baseline labs prior to starting: CBC, liver enzymes, and serum creatinine",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "Obtain baseline labs prior to starting: CBC, liver enzymes, and serum creatinine",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Oral Treatment:",  "Header" : 1}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Toenails take 12-18 months to grow out completely, so improvement should not",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "be expected to be observed for at least 6-9 months.Continued improvement can",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "be experienced following treatment completion.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 300MG QWEEK FOR 3-6 MONTHS", "Text" : "", "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 300MG QWEEK FOR 3-6 MONTHS", "Text" : "", "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : "PSHZID CICLOPIROX 8% NAIL LACQUER FUNGAL NAIL INFECTION", "Text" : "", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TINEA VERSICOLOR", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID2 KETOCONAZOLE 2% CREAM TOP QDAY 14DAYS", "Text" : "Ketoconazole 2% cream to affected area QDAY for 14 days ($) [M]", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSHZID2 KETOCONAZOLE 2% CREAM TOP QDAY 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID2 TERBINAFINE 1% CREAM TOP QDAY 14DAYS", "Text" : "Terbinafine 1% cream apply to affected area QDAY for 7 days ($) [M]", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSHZID2 TERBINAFINE 1% CREAM TOP QDAY 14DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID2 SELENIUM LOT 2.5% 10MIN 7DAYS", "Text" : "Selenium sulfide lotion 2.5% apply to affected area, leave on for 10", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSHZID2 SELENIUM LOT 2.5% 10MIN 7DAYS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSOZID FLUCONAZOLE 300MG PO WEEKLY X2 WEEKS", "Text" : "Fluconazole 300 MG PO weekly for 2 weeks ($2.20/day) [R", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSHZID FLUCONAZOLE 300MG PO WEEKLY X2 WEEKS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "ORZID2 GMENU ABX REFERENCES", "Text" : "References", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "TINEA VERSICOLOR",  "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Pityriasis or tinea versicolor is a common superficial fungal infection.",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Patients often present with erythematous, hypo- or hyperpigmented patches,",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "usually on the trunk or extremities.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Topical antifungals can be used for limited disease.For disease that involves",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "nails or does not respond to topical therapy, use oral antifungals.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Oily skin products or exposure to hot environments often lead to recurrences.",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Return of normal skin color often takes several weeks after the treatment",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "course is finished.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment limited disease:",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "minutes, then rinse/shower thoroughly QDAY for 7 days ($) [M]",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Treatment extensive disease:",  "Header" : 1}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Up-to-date",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Tinea",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "AK Gupta AK, J Cutan Med Surg. 2014, 18:79", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TIX-CIL EUA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "Tix-Cil (Tixagevimab plus cilgavimab)",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "On December 8, 2021 the FDA issued an EUA for AstraZeneca's Evusheld",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "(tixagevimab co-packaged with cilgavimab) for the pre-exposure prophylaxis",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "(prevention) of COVID-19 in certain adult and pediatric patients.",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "The product is only authorized for those individuals who are not currently",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "infected with SARS-CoV-2 virus and who have not recently been exposed to an",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "individual infected with SARS-CoV-2. The authorization also requires that",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "individuals either have:",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "-moderate to severely compromised immune systems due to a medical condition or",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "or due to taking immunosuppressive medications or treatments and may not",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "mount an adequate immune response to COVID-19 vaccination (examples of such",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "medical conditions or treatments can be found in the fact sheet for health",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "care providers) [see link top of page]",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "[ OR ]",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "-a history of severe adverse reactions to a COVID-19 vaccine and/or component(s)",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "of those vaccines, therefore vaccination with an available COVID-19 vaccine,",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "according to the approved or authorized schedule, is not recommended.",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "-One dose of Evusheld, administered as two separate consecutive intramuscular",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "injections (one injection per monoclonal antibody, given in immediate",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "succession), reduces the risk of developing COVID-19 for six months.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "-Evusheld is NOT authorized for the treatment of COVID-19 or for post-exposure",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "prevention of COVID-19.",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "-Pre-exposure prevention with Evusheld is not a substitute for vaccination in",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "in individuals for whom COVID-19 vaccination is recommended.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Monoclonal antibodies are laboratory-made proteins that mimic the immune",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "system's ability to fight off harmful pathogens such as viruses. Tixagevimab and",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "cilgavimab are long-acting monoclonal antibodies that are specifically directed",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "against the spike protein of SARS-CoV-2, designed to block the virus' attachment",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "and entry into human cells. Tigagevimab and cilgavimab bind to different,",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "non-overlapping sites on the spike protein of the virus.",  "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "Emergency Use Authorization (EUA): Tixagevimab plus Cilgavimab (EVUSHELD)",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "Tixagevimab plus Cilgavimab combination is available via FDA Emergency Use",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Authorization (EUA) for pre-exposure prophylaxis for COVID-19 for patients",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "that meet specific criteria. They are not FDA approved drugs.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "There are no adequate, approved and available alternatives to Evusheld",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "for the pre-exposure prevention of COVID-19 in the authorized population.",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "-In patients with prior COVID-19 vaccination, at least 2 weeks are required",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "between the vaccination and the administration of Evusheld.",  "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : null, "Text" : "**PBM EUA Criteria to be completed on web link:",  "Header" : 1}, 
{"Row" : 57, "Column" : 1, "Item" : null, "Text" : "Answer to ALL of the following statements should be YES for administration:",  "Header" : 1}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "2)Patient has no known recent exposure to an individual infected with SARS-CoV-2",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "1)Patient has no symptoms consistent with COVID-19, or if any symptoms, has a",  "Header" : 0}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "a documented negative SARS-CoV-2 test within 72 hours prior to administration",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "3)Patient has moderate to severe immunocompromise per the EUA definition or",  "Header" : 0}, 
{"Row" : 62, "Column" : 1, "Item" : null, "Text" : "a documented medical contraindication to vaccination. (Note: refusal to",  "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : null, "Text" : "be vaccinated does not constitute a contraindication for the purpose of",  "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : null, "Text" : "eligibility for this drug.)",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "4)In patients with prior COVID-19 vaccination (e.g. immunosuppressed) at least,",  "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : null, "Text" : "2 weeks have passed since the last dose was given (if no prior vaccination",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "answer YES)",  "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : null, "Text" : "5)The Fact Sheet for patients/caregivers has been made available to the patient/",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "caregiver prior to administration of this drug",  "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : null, "Text" : "Note: Our staff is identifying the highest risk patients from our database",  "Header" : 1}, 
{"Row" : 72, "Column" : 1, "Item" : null, "Text" : "for this medication. We will contact patients who are currently eligible",  "Header" : 1}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "for the limited doses currently allocated.",  "Header" : 1}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Patient Criteria for Use:",  "Header" : 1}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "Important information:",  "Header" : 1}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "1)Providers approved to order: Dr. Klein (oncology) and ID Staff only",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "2)Second dose is not being scheduled/addressed at this time. We will pull",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "list of patients and assess the overall situation close to 6 month timeframe.",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "NOTES:",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Link to complete EUA documentation:",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZ GTX ABX URL LINK FOR EUA FILL OUT BY PROVIDER", "Text" : "[Click here] Pharmacist to complete EUA prior to dispensing medication", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Printable Fact Sheets for EUA:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "[Click here] Fact Sheet for Patients/Caregivers EUA Evusheld",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "[Click here] Fact Sheet for Health Care Providers EUA Tix-Cil",  "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : null, "Text" : "Minneapolis VAHCS is using the Minnesota Health Department's framework",  "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : null, "Text" : "for allocation of the medication. Our ID physicians shared in the development",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "of the plan and provides for consistency in the community.",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "3)Administration in separate area from where COVID positive patients being seen",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "4)Pharmacy dispense in original kit to clinic (decrease waste/short expiration)",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "5)Separate clinic created for patient appointments (23537 MSP 3V INJECTION)",  "Header" : 0}, 
{"Row" : 77, "Column" : 1, "Item" : null, "Text" : "[Click here] Minnesota Dept of Health-Prioritization of patients", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TOXIC SHOCK SYNDROME", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TOXIC SHOCK SYNDROME",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to Inpatient Antimicrobial CDSS.", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TRAVEL MEDICINE", "Contents" : [
{"Row" : 3, "Column" : 1, "Item" : "PSOZID CIPROFLOXACIN 500MG PO BID PRN 3DS TRAVEL MED", "Text" : "Ciprofloxacin PO 500mg BID PRN", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : "PSOZID AZITHROMYCIN 500MG PO QDAY PRN 3DS TRAVEL CLINIC", "Text" : "Azithromycin PO 500mg QDAY PRN", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "PSOZID2 LOPERAMIDE 2-4MG QID PRN TRAVEL MED", "Text" : "Loperamide 2-4mg QID PRN", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "PSOZID2 BISMUTH SUBSALICYLATE 524MG QID PRN TRAVEL MED", "Text" : "Bismuth Subsalicylate 524mg QID PRN", "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : "PSOZID2 BISMUTH SUBSALICYLATE 524MG QID 15 DAYS TRAVEL MED", "Text" : "Bismuth Subsalicylate 524mg QID", "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : "ORZ SET ABX CHOLERA VACCINE PO 100ML ONE DOSE", "Text" : "Cholera Vaccine ONCE", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "PSOZID HEPATITIS A VACCINE 2 DOSE SERIES", "Text" : "Hepatitis A 2 Dose Series", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis B 3 Dose Series", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "PSOZID HEPATITIS B VACCINE 4 DOSE SERIES", "Text" : "Hepatitis B 4 Dose High Dose Series (for immunocompromised patients)", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE 3 DOSE SERIES", "Text" : "Hepatitis A/B (Twinrix) 3 Dose Series", "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : "PSOZID HEPATITIS A/B VACCINE ACCELERATED 4 DOSE SERIES", "Text" : "Hepatitis A/B (Twinrix) Accelerated 4 Dose Series", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE 2 DOSE SERIES", "Text" : "Herpes zoster (Shingrix) 2 dose series", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "PSOZID ZOSTER RECOMBINANT VACCINE ONE DOSE", "Text" : "Herpes zoster (Shingrix) one-time dose", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZ SET ABX JAPANESE ENCEPHALITIS VIRUS VACCINE 2 DOSE SERIES", "Text" : "Japanese Encephalitis Virus Vaccine 2 Dose Series", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE ONE DOSE", "Text" : "Measles, Mumps, Rubella Vaccine ONCE", "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : "PSOZID MEASLES/MUMPS/RUBELLA VACCINE 2 DOSE SERIES", "Text" : "Measles, Mumps, Rubella Vaccine 2 Dose Series", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL B VACCINE 2 DOSE SERIES", "Text" : "Meningococcal B Vaccine 2 Dose Series", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "PSOZID MENINGOCOCCAL OLIGOSACCHARIDE CONJ VACCINE ONE DOSE", "Text" : "Meningococcal Conjugate (MenACWY) Vaccine ONCE", "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : "PSOZID PNEUMOCOCCAL 23-VALENT VACCINE ONE DOSE", "Text" : "Pneumococcal 23-valent vaccine ONCE", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID POLIOVIRUS VACCINE ONE DOSE", "Text" : "Poliovirus Vaccine ONCE", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID POLIOVIRUS VACCINE 3 DOSE SERIES", "Text" : "Poliovirus Vaccine 3 Dose Series", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID RABIES VACCINE 3 DOSE SERIES", "Text" : "Rabies Pre-exposure Vaccine 3 Dose Series", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSOZID RABIES BOOSTER VACCINE ONE DOSE", "Text" : "Rabies Pre-exposure Vaccine Booster dose", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID TETANUS/DIPHTHERIA VACCINE ONE DOSE", "Text" : "Tetanus Diphtheria Vaccine ONCE", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSOZID TETANUS/DIPHTHERIA/PERTUSSIS VACCINE ONE DOSE", "Text" : "Tetanus/Diphtheria/Pertussis (TDAP) Vaccine ONCE", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "PSOZID TYPHOID VACCINE INJ ONCE", "Text" : "Typhoid Vaccine Inj ONCE", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID TYPHOID ORAL VACCINE QOD 7DS", "Text" : "Typhoid Oral Vaccine QOtherDay 7DS", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "ORZ SET ABX YELLOW FEVER VACCINE ONCE DOSE", "Text" : "Yellow Fever Vaccine ONCE", "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : "PSOZID ATOVAQUONE/PROGUANIL 1TAB PO QDAY 24DS", "Text" : "Atovaquone/Proguanil 1Tab PO QDAY 24DS", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZ SET ABX CHLOROQUINE 500MG PO QWEEK", "Text" : "Chloroquine 500mg PO QWEEK 56DS", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSOZID DOXYCYCLINE 100MG PO QDAY TRAVEL MED", "Text" : "Doxycycline 100mg PO QDAY 30DS", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZ SET ABX MEFLOQUINE 250MG PO QWEEK TRAVEL MED", "Text" : "Mefloquine 250mg PO QWEEK 56DS", "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "Text" : "Pre-exposure prophylaxis recommendations", "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "Text" : "Post-exposure prophylaxis recommendations", "Header" : 0}, 
{"Row" : 1, "Column" : 1, "Item" : null, "Text" : "Travelers Diarrhea",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Prevention:",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Vaccines - Administered in Clinic",  "Header" : 1}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Malaria Prevention",  "Header" : 1}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "Rabies",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "Text" : "Rabies Pre-exposure Prophylaxis Recommendations", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "ORZID3 GMENU ABX RABIES POST-EXPOSURE PROPHYLAXIS", "Text" : "Rabies Post-exposure Prophylaxis Recommendations", "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Treatment:",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "ORZ SET ABX TICK-BORNE ENCEPHALITIS VACCINE ONCE", "Text" : "Tick-Borne Encephalitis Vaccine ONCE", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "ORZ SET ABX TICK-BORNE ENCEPHALITIS VACCINE 3 DOSE SERIES", "Text" : "Tick-Borne Encephalitis Vaccine 3 Dose Series", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TRAVELER DIARRHEA", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Azithromycin 1000 mg PO once ($) [M]", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 1GM PO ONCE", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "Text" : "Azithromycin 500 mg PO QDAY for 3 days ($) [M]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 AZITHROMYCIN 3DS 500MG PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 3DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID for 3 days ($) [R,DI]", "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 3DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID RIFAXAMIN 3DS 200MG TID", "Text" : "Rifaximin 200 mg TID for 3 days ($$) [M]", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID RIFAXAMIN 3DS 200MG TID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TRAVELER'S DIARRHEA",  "Header" : 1}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Acute non-bloody diarrhea (< 14 days of symptoms)",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Most cases are mild and self-limited. Reserve antimicrobial therapy for",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "patients who have severe traveler's diarrhea: pus, or mucus in stool, fever, or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "diarrhea that is incapacitating.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Bloody diarrhea can represent hemorrhagic colitis or dysentery. Antimicrobial",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "therapy and antimotility agents are not recommended in most patients with bloody",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "diarrhea due to an increased risk of hemolytic uremic syndrome when using these",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "agents. Obtain a stool sample for enteric pathogen PCR testing and reserve",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "antimicrobial and antimotility agent treatment until results are known. Enteric",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "pathogen PCR testing results are reported within 2 hours between 7am and 11pm.",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "For more information on when an antimicrobial is indicated or if the patient has",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "severe/life threatening diarrhea or is immunocompromised, contact Infectious",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Primary treatment",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Hydration and electrolyte replacement",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Empiric antimicrobial treatment for non-bloody severe acute diarrhea",  "Header" : 1}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Subacute diarrhea (>/= 14 days of symptoms)",  "Header" : 1}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Primary treatment is hydration and electrolyte replacement. Empirical",  "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : null, "Text" : "antimicrobial therapy is not indicated. Attempt to make a diagnosis with, for",  "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "example, enteric pathogen PCR testing, Clostridium difficile testing in those",  "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : null, "Text" : "who used a PPI or were treated with antimicrobials in the last 8-12 weeks, and",  "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : null, "Text" : "endoscopy. If bloody diarrhea, fever, or abdominal pain/tenderness is present",  "Header" : 0}, 
{"Row" : 46, "Column" : 1, "Item" : null, "Text" : "the case should be evaluated by Gastroenterology and/or Infectious Diseases.",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Nausea, Vomiting, and Noninflammatory Diarrhea",  "Header" : 0}, 
{"Row" : 52, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Travelers Diarrhea",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Shane et al, Clinical Infectious Diseases 2017, 65(12):45-80",  "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : null, "Text" : "Up-to-Date article: Travelers' diarrhea: Clinical manifestations, diagnosis, and",  "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : null, "Text" : "treatment", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TRICHOMONAS VAGINITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "PSOZID2 METRONI 7DS 500MG PO BID", "Text" : "Metronidazole 500 mg PO q12h for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "PSHZID2 METRONI 7DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : "PSOZID2 METRONI 7DS 500MG PO BID", "Text" : "Metronidazole 500 mg PO q12h for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : "PSHZID2 METRONI 7DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : "PSOZID2 METRONIDAZOLE 7DS 2GM PO QDAY", "Text" : "Metronidazole 2 gm PO q24h for 7 days ($) [DI]", "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : "PSHZID2 METRONIDAZOLE 7DS 2GM PO QDAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TRICHOMONAS VAGINITIS AND URETHRITIS",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Male sexual partners of women with trichomonas vaginitis will not have symptoms",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "but should be treated to prevent recurrent vaginitis in the female sexual",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "partner.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "The discharge is purulent, malodorous, and thin. The vaginal pH is greater",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "than 4.5. Nucleic Acid amplification test (NAAT) for trichomonas has improved",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "sensitivities and specifities compared to wet mount.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Treatment of Initial Episode in Men and Woman",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Pregnant women with trichomonas infection may be treated with metronidazole",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "during any trimester.",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "Treatment of Veteran Male Sex Partners (Non-Veteran Sex Partners Should Be",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "Referred to Non-VA Care)",  "Header" : 1}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "1st failure",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "2nd failure",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "3rd failure",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Consult Infectious Disease",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "________________________________________________________________________",  "Header" : 1}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Trichomoniasis",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Vulvovaginitis and cervicitis",  "Header" : 0}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "CDC STD Treatment Guidelines: MMWR (2021) 70.4",  "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Trichomoniasis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TUBERCULOSIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "TUBERCULOSIS",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Evaluation and management are complex.Consult Pulmonary and/or Infectious",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "Diseases.",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Patients with suspected or proven pulmonary tuberculosis must be in respiratory",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "isolation.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Centers for Disease Control (CDC). Tuberculosis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU TYPHLITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "NEUTROPENIC ENTEROCOLITIS (TYPHLITIS)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Refer to the Inpatient Antimicrobial CDSS", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU ASYMP BACTERIURIA", "Text" : "Asymptomatic bacteriuria", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 7 days", "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 7DAYS 1DS TAB BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 7DS 500/125MG PO BID", "Text" : "Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 7 days", "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 7DS 500/125MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : "ORZ GTX ABX IDP FLUOROQUINOLONES FDA WARNINGS", "Text" : "Fluoroquinolones FDA Serious Adverse Reactions", "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 5DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] for 5 days", "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 5DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 100MG BID 5DS", "Text" : "Nitrofurantoin SA 100 mg PO BID ($) [R,O] for 5 days, CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 42, "Column" : 1, "Item" : "PSHZID2 NITROFURANTOIN SA 100MG BID 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 44, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 3DAYS 1DS TABLET BID", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO BID ($) [R,DI] for 3 days", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 3DAYS 1DS TABLET BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 48, "Column" : 1, "Item" : "PSOZID FOSFOMYCIN 3GM SACHET PO X 1 DOSE", "Text" : "Fosfomycin 3GM sachet PO ($$)[M] x 1 dose", "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : "PSOZID2 AMOX/CLAV 500/125MG PO BID 5DS", "Text" : "Amoxicillin-clavulanate 500/125 mg PO BID ($) [R] for 5 days", "Header" : 0}, 
{"Row" : 51, "Column" : 1, "Item" : "PSHZID2 AMOX/CLAV 500/125MG PO BID 5DS", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 54, "Column" : 1, "Item" : "ORZID2 GMENU ABX IDP CIPROFLOXACIN PO", "Text" : "Select for updated Ciprofloxacin Info Page", "Header" : 0}, 
{"Row" : 55, "Column" : 1, "Item" : "PSOZID2 CIPROFLOXACIN 3DS 500MG PO BID", "Text" : "Ciprofloxacin 500 mg PO BID ($) [R,DI] for 3 days", "Header" : 0}, 
{"Row" : 56, "Column" : 1, "Item" : "PSHZID2 CIPROFLOXACIN 3DS 500MG PO BID", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 63, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 30DAYS 1 SS TAB QDAY 11RF", "Text" : "Trimethoprim/sulfamethoxazole 1 SS tablet PO QDAY ($) [R,DI]", "Header" : 0}, 
{"Row" : 64, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 30DAYS 1 SS TAB QDAY 11RF", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 66, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 2 DS TABS PO ONCE X1DAY", "Text" : "Trimethoprim/sulfamethoxazole 2 DS tablets PO x 1 dose as a single patient-", "Header" : 0}, 
{"Row" : 68, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 2 DS TABS PO ONCE X1DAY", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 70, "Column" : 1, "Item" : "PSOZID2 TMP/SULFA 1 DS TAB PO ONCE POST-COITUS 30DAYS 11RF", "Text" : "Trimethoprim/sulfamethoxazole 1 DS tablet PO x 1 dose post-coitus ($) [R,DI]", "Header" : 0}, 
{"Row" : 71, "Column" : 1, "Item" : "PSHZID2 TMP/SULFA 1 DS TAB PO ONCE POST-COITUS 30DAYS 11RF", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 74, "Column" : 1, "Item" : "PSOZID2 NITROFURANTOIN SA 30DS 100MG PO QDAY 11RF", "Text" : "Nitrofurantoin SA 100 mg PO QDAY ($) [R,O] CrCl =/>30 mL/min", "Header" : 0}, 
{"Row" : 75, "Column" : 1, "Item" : "PSHZID2 NITROFURANTOIN SA 30DS 100MG PO QDAY 11RF", "Text" : "Non-VA order for above", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "UNCOMPLICATED CYSTITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Uncomplicated cystitis refers to symptomatic bladder inflammation from bacterial",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "infection. Symptoms usually include dysuria, lower abdominal pain, urgency.",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "Bacterial cystitis in people with obstruction to urine flow, abnormalities of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "the urine collecting system, indwelling urinary catheters, or symptoms lasting",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "more than a week are considered complicated. Most cases of uncomplicated",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "cystitis occur in healthy adolescent or young adult females.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "A word about asymptomatic bacteriuria or pyuria. With just a few exceptions,",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "patients with no symptoms of cystitis should not be treated. The presence of",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "pyuria (>7 wbc/hpf) or positive leukocyte esterase, urine nitrate, or urine",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "bacteria is not a sufficient indication for antibiotic treatment. See page on",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "asymptomatic bacteriuria.",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "The prevalence of antimicrobial resistance among bacteria associated with",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "uncomplicated cystitis has increased. A urine culture should be considered in a",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "patient who has had substantial involvement with healthcare or exposure to",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "antimicrobials. If a patient fails to respond to therapy, a urine culture",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "should be done.",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "Men, preferred treatment for symptomatic cystitis",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "Alternative (weigh risk for potential serious side effects vs benefit)",  "Header" : 0}, 
{"Row" : 38, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 40, "Column" : 1, "Item" : null, "Text" : "Women, preferred treatment for symptomatic cystitis",  "Header" : 1}, 
{"Row" : 43, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 47, "Column" : 1, "Item" : null, "Text" : "Alternatives",  "Header" : 0}, 
{"Row" : 49, "Column" : 1, "Item" : null, "Text" : "<OR>",  "Header" : 0}, 
{"Row" : 53, "Column" : 1, "Item" : null, "Text" : "Alternative (weigh risk for potential serious side effects vs benefit)",  "Header" : 0}, 
{"Row" : 58, "Column" : 1, "Item" : null, "Text" : "Suppression",  "Header" : 1}, 
{"Row" : 59, "Column" : 1, "Item" : null, "Text" : "For pre-menopausal women with 3 or more episodes per year of recurrent",  "Header" : 0}, 
{"Row" : 60, "Column" : 1, "Item" : null, "Text" : "uncomplicated cystitis, suppressive therapy is indicated after infection is",  "Header" : 0}, 
{"Row" : 61, "Column" : 1, "Item" : null, "Text" : "eradicated.",  "Header" : 0}, 
{"Row" : 65, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 67, "Column" : 1, "Item" : null, "Text" : "initiated dose at onset of symptoms ($) [R,DI]",  "Header" : 0}, 
{"Row" : 69, "Column" : 1, "Item" : null, "Text" : "< OR >",  "Header" : 0}, 
{"Row" : 73, "Column" : 1, "Item" : null, "Text" : "Alternative",  "Header" : 0}, 
{"Row" : 76, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 78, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 79, "Column" : 1, "Item" : null, "Text" : "Drekonja, Dimitri M., et al. JAMA 326.4 (2021): 324-331",  "Header" : 0}, 
{"Row" : 80, "Column" : 1, "Item" : null, "Text" : "Gupta K. et. al. IDSA Clinical Practice Guidelines (2011) 52.1",  "Header" : 0}, 
{"Row" : 81, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary tract infections",  "Header" : 0}, 
{"Row" : 82, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Cystitis",  "Header" : 0}, 
{"Row" : 83, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: UTI, Recurrent, Cystitis, Urethritis",  "Header" : 0}, 
{"Row" : 84, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute uncomplicated cystitis and pyelonephritis in women",  "Header" : 0}, 
{"Row" : 85, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Acute uncomplicated cystitis and pyelonephritis in men", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU URETHRITIS ASSOC STD", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "LRTZID CHLAMYDIA/GC PCR TEST", "Text" : "Chlamydia & GC PCR/LCR test", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU RECURRENT/PERSISTENT URETHRITIS", "Text" : "Treatment of recurrent or persistent urethritis", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU CHLAMYDIA URETHRITIS", "Text" : "Treatment for chlamydial or non-gonococcal urethritis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "URETHRITIS ASSOCIATED WITH SEXUALLY TRANSMITTED DISEASES",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "The main differential in a person who presents with dysuria is between cystitis",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "and urethritis. Bacterial urethritis is more likely in people with mild",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "dysuria, onset over a few days, or recent sexual contact.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "The two most common sexually transmitted urethritis pathogens are Neisseria",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "gonorrhoeae and Chlamydia trachomatis. Nucleic acid amplification tests for",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "these pathogens are more sensitive than culture and should be used for patients",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "at risk for sexually transmitted urethritis.",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "For patients who have recently been treated for urethritis",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Initial treatment of patients and sex partners",  "Header" : 1}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "Patients and partners are often infected with both N. gonorrhoeae and C.",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "trachomatis.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 28, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urethritis",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Sanford keyword: Gonorrhea, urethritis, cervicitis, proctitis",  "Header" : 0}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "Up-To-Date article: Urethritis in men",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI) SUBMENU", "Text" : "Sexually Transmitted Infections and HIV Exposure [CLICK HERE]", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU GONOCOCCAL", "Text" : "Treatment for gonococcal infections", "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "St. Cyr S, et al. MMWR Morb Mortal Wkly Rep 2020, 69:1911-1916", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU URINARY TRACT INFECTION", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 41, "Column" : 1, "Item" : "ORZID3 GMENU UNCOMPLICATED CYSTITIS", "Text" : "Treatment for uncomplicated cystitis", "Header" : 0}, 
{"Row" : 43, "Column" : 1, "Item" : "ORZID3 GMENU COMPLICATED CYSTITIS", "Text" : "Treatment for complicated cystitis", "Header" : 0}, 
{"Row" : 45, "Column" : 1, "Item" : "ORZID3 GMENU PYELONEPHRITIS", "Text" : "Treatment for pyelonephritis", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "URINARY TRACT INFECTION (UTI)",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cystitis refers to infection of the urinary bladder, but inflammation often",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "extends into the urethra. Typical symptoms and signs include dysuria, increased",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "urinary frequency, urgency, and/or suprapubic tenderness.",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "Most cases of uncomplicated cystitis occur in pre-menopausal, non-pregnant,",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "sexually active young women.",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "Most cases of complicated cystitis are associated with Escherichia coli, but",  "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "more resistant pathogens occur, including the Gram-positive pathogens",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "staphylococci and enterococci. Urine culture should be obtained before",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "antimicrobials are given.",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Complicating conditions",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "Cystitis is considered complicated when one or more of the following is present",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "> Most men with cystitis",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "> Pregnant women",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "> Structural abnormalities (e.g. presence of obstruction, catheter or",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "nephrostomy tubes, neurogenic bladder)",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "> Metabolic abnormalities that reduce local host defenses (e.g. diabetes,",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "pregnancy, neutropenia, pelvic irradiation)",  "Header" : 0}, 
{"Row" : 26, "Column" : 1, "Item" : null, "Text" : "> Unusual or resistant pathogen",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "> Treatment failure or relapse or recurrence of infection",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "Diagnosis",  "Header" : 1}, 
{"Row" : 30, "Column" : 1, "Item" : null, "Text" : "When a patient presents with symptoms of cystitis, urinalysis should be",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "performed to check for the presence of white blood cells. Increased numbers of",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "leukocytes (usually >25) in the presence of cystitis symptoms indicates",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "inflammation and thus cystitis. The bacterial etiology is so predictable that",  "Header" : 0}, 
{"Row" : 34, "Column" : 1, "Item" : null, "Text" : "urine culture is unnecessary and empirical treatment is indicated. The",  "Header" : 0}, 
{"Row" : 35, "Column" : 1, "Item" : null, "Text" : "clinical significance of pyuria in the absence of cystitis symptoms is unclear.",  "Header" : 0}, 
{"Row" : 36, "Column" : 1, "Item" : null, "Text" : "Antimicrobial therapy is not indicated for pyuria in the absence of symptoms.",  "Header" : 0}, 
{"Row" : 37, "Column" : 1, "Item" : null, "Text" : "________________________________________________________________________________",  "Header" : 0}, 
{"Row" : 39, "Column" : 1, "Item" : null, "Text" : "Treatment",  "Header" : 1}, 
{"Row" : 48, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 50, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Urinary Tract Infection", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU UROLOGY CIPRO IN CLINIC", "Contents" : [
{"Row" : 13, "Column" : 1, "Item" : "ORZ SET ABX UROLOGY CIPRO PO ORDER AND NURSE TEXT ORDER", "Text" : "Ciprofloxacin 500 mg x1 orally ($0.10/day) [R,DI] give in clinic and nurse text", "Header" : 0}, 
{"Row" : 4, "Column" : 1, "Item" : null, "Text" : "In cases where prolonged catheterization follows a procedure, antimicrobial",  "Header" : 0}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "therapy at the time of catheter removal may be considered, since",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "colonization has likely occurred. The recommendation to treat empirically",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "depends on host factors, the duration of catheterization, and the",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "potential of morbidity or mortality.",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "Single dose of fluoroquinolone may significantly lower incidence",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "of bacteriuria for patients undergoing ureteroscopy for stone removal.",  "Header" : 0}, 
{"Row" : 2, "Column" : 1, "Item" : null, "Text" : "Urologic Clinic Procedures",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "(2008) (Reviewed and validity confirmed 2011, updated February 2012)",  "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "www.aua.org", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU UVEITIS", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "Help, legend, allergy info, consults, alternative antimicrobials and more (Opt)", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU RETINITIS", "Text" : "VZV or HSV retinitis and ARN", "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : "ORZID3 GMENU CMV RETINITIS", "Text" : "CMV retinitis and ARN", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "UVEITIS",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Most cases are non-infectious. Most infectious cases are associated with a",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "pathogen causing systemic or central nervous system infection. Diagnosis of",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "uveitis usually must be made presumptively due to the technical difficulty of",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "sampling the uvea. Cases have been associated with fungi, bacteria, viruses, and",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "protozoa like Toxoplasma gondii.",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "For treatment of posterior uveitis (retinitis) or acute retinal necrosis (ARN)",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "due to Varicella-zoster virus (VZV) or herpes simplex virus (HSV) or",  "Header" : 1}, 
{"Row" : 13, "Column" : 1, "Item" : null, "Text" : "Cytomegalovirus (CMV)",  "Header" : 1}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "Treatment of uveitis involves treating the underlying infection and is usually",  "Header" : 1}, 
{"Row" : 18, "Column" : 1, "Item" : null, "Text" : "systemic. Refer to specific pathogen recommendations for treatment of underlyin",  "Header" : 1}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "infection. Contact Ophthalmology and/or Infectious Diseases for assistance.",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "_______________________________________________________________________________",  "Header" : 1}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "References:",  "Header" : 0}, 
{"Row" : 24, "Column" : 1, "Item" : null, "Text" : "Mandell chapter: Infectious causes of uveitis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU VIRUSES OUTPT MAIN", "Contents" : [
{"Row" : 1, "Column" : 1, "Item" : "ORZID3 GMENU ABX GENERAL INFORMATION OUTPATIENT", "Text" : "", "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : "ORZID3 GMENU ABX CMV MAIN PAGE", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : "ORZID3 GMENU INFECT DIARRHEA/GASTROENT", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPATITIS A", "Text" : "Hepatitis A", "Header" : 0}, 
{"Row" : 13, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPATITIS B", "Text" : "Hepatitis B", "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : "ORZID3 GMENU ABX HEPATITIS C", "Text" : "Hepatitis C", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : "ORZID3 GMENU BELL PALSY", "Text" : "Bell's palsy", "Header" : 0}, 
{"Row" : 18, "Column" : 1, "Item" : "ORZID3 GMENU HSV ENCEPHALITIS", "Text" : "Encephalitis", "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : "ORZID3 GMENU SEXUALLY TRANSMITTED INFECTIONS (STI)", "Text" : "Genital herpes", "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : "ORZID3 GMENU HERPES WHITLOW", "Text" : "Herpes Whitlow (digit or hand", "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : "ORZID3 GMENU ABX HERPES KERATITIS", "Text" : "Keratitis", "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : "ORZID3 GMENU OROLABIAL HERPES", "Text" : "Oral lesions: Mouth, Lips (Cold sores)", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "++ VIRUSES ++",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Cytomegalovirus (CMV)",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "Diarrhea, viral",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "Hepatitis",  "Header" : 1}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "Herpes Simplex",  "Header" : 1}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "cellulitis)",  "Header" : 0}, 
{"Row" : 27, "Column" : 1, "Item" : null, "Text" : "Last reviewed 8/2018",  "Header" : 1}, 
{"Row" : 6, "Column" : 2, "Item" : "ORZID3 GMENU ABX HIV-AIDS", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 9, "Column" : 2, "Item" : "ORZID3 GMENU INFLUENZA 2021-2022 OUTPATIENT", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 12, "Column" : 2, "Item" : "ORZID3 GMENU ABX PARAINFLUENZA", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 20, "Column" : 2, "Item" : "ORZID3 GMENU ABX RSV", "Text" : "[click here]", "Header" : 0}, 
{"Row" : 23, "Column" : 2, "Item" : "ORZID3 GMENU BELL PALSY", "Text" : "Bell's palsy", "Header" : 0}, 
{"Row" : 24, "Column" : 2, "Item" : "ORZID3 GMENU PRIM INFECT CHICKENPOX", "Text" : "Varicella/Chickenpox (primary infection)", "Header" : 0}, 
{"Row" : 25, "Column" : 2, "Item" : "ORZID3 GMENU REACT PRIM INFECT ZOSTER", "Text" : "Zoster/Shingles (reactivation)", "Header" : 0}, 
{"Row" : 5, "Column" : 2, "Item" : null, "Text" : "Human Immunodeficiency Virus (HIV)",  "Header" : 1}, 
{"Row" : 8, "Column" : 2, "Item" : null, "Text" : "Influenza, Seasonal",  "Header" : 1}, 
{"Row" : 11, "Column" : 2, "Item" : null, "Text" : "Parainfluenza",  "Header" : 1}, 
{"Row" : 19, "Column" : 2, "Item" : null, "Text" : "Respiratory Syncytial Virus (RSV)",  "Header" : 1}, 
{"Row" : 22, "Column" : 2, "Item" : null, "Text" : "Varicella-zoster",  "Header" : 1}, 
{"Row" : 14, "Column" : 2, "Item" : null, "Text" : "Rabies",  "Header" : 1}, 
{"Row" : 16, "Column" : 2, "Item" : null, "Text" : "Post-Exposure Prophylaxis",  "Header" : 0}, 
{"Row" : 17, "Column" : 2, "Item" : null, "Text" : "is available in ED CDSS only",  "Header" : 0}, 
{"Row" : 15, "Column" : 2, "Item" : "ORZID3 GMENU ABX RABIES PRE-EXPOSURE PROPHYLAXIS", "Text" : "Pre-Exposure Prophylaxis", "Header" : 0}
]},
{"Name" : "ORZID3 GMENU WARFARIN DRUG INTERACTIONS", "Contents" : [
{"Row" : 26, "Column" : 1, "Item" : "ORZ GTX ABX LEXICOMP INTERACTIONS", "Text" : "Lexicomp Drug Interactions", "Header" : 0}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "DRUG-DRUG INTERACTIONS BETWEEN ANTIMICROBIALS AND WARFARIN",  "Header" : 1}, 
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "Several antimicrobials will affect metabolism or the effect of",  "Header" : 0}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "warfarin on a patient's clotting function. If possible, avoid using an",  "Header" : 0}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "antimicrobial with a significant interaction with warfarin. If you",  "Header" : 0}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "decide that an antimicrobial that interacts with warfarin is needed or",  "Header" : 0}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "you stop an antimicrobial that could interact with warfarin, you",  "Header" : 0}, 
{"Row" : 10, "Column" : 1, "Item" : null, "Text" : "should determine the INR more frequently than usual and adjust dosage",  "Header" : 0}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "accordingly. Instruct patients to inform their primary warfarin",  "Header" : 0}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "provider whenever an antimicrobial is prescribed for them.",  "Header" : 0}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "Antimicrobials can alter warfarin's anticoagulant effect by decreasing",  "Header" : 0}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "intestinal synthesis or absorption of vitamin K or by affecting",  "Header" : 0}, 
{"Row" : 16, "Column" : 1, "Item" : null, "Text" : "distribution or metabolism of the vitamin. Some antimicrobials increase",  "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "synthesis of coagulation factors.",  "Header" : 0}, 
{"Row" : 19, "Column" : 1, "Item" : null, "Text" : "Antimicrobials can decrease the rate of warfarin absorption, compete",  "Header" : 0}, 
{"Row" : 20, "Column" : 1, "Item" : null, "Text" : "with warfarin at sites of warfarin metabolism, induce warfarin",  "Header" : 0}, 
{"Row" : 21, "Column" : 1, "Item" : null, "Text" : "metabolic enzymes, or inhibit the function or synthesis warfarin",  "Header" : 0}, 
{"Row" : 22, "Column" : 1, "Item" : null, "Text" : "metabolic enzymes. Some antimicrobials displace warfarin from protein",  "Header" : 0}, 
{"Row" : 23, "Column" : 1, "Item" : null, "Text" : "binding sites.",  "Header" : 0}, 
{"Row" : 25, "Column" : 1, "Item" : null, "Text" : "Check for warfarin-antimicrobial interactions on Lexicomp:",  "Header" : 0}, 
{"Row" : 29, "Column" : 1, "Item" : null, "Text" : "References",  "Header" : 0}, 
{"Row" : 31, "Column" : 1, "Item" : null, "Text" : "Holbrook, Anne M., et al. Archives of internal medicine 165.10 (2005): 1095-",  "Header" : 0}, 
{"Row" : 32, "Column" : 1, "Item" : null, "Text" : "1106",  "Header" : 0}, 
{"Row" : 33, "Column" : 1, "Item" : null, "Text" : "Lexicomp website", "Header" : 0}
]},
{"Name" : "ORZID4 TEST OF UROLOGICAL SURGERY PROPHYLAXIS", "Contents" : [
{"Row" : 5, "Column" : 1, "Item" : null, "Text" : "**************************************************************************",  "Header" : 1}, 
{"Row" : 6, "Column" : 1, "Item" : null, "Text" : "x**",  "Header" : 1}, 
{"Row" : 7, "Column" : 1, "Item" : null, "Text" : "X* Procedure |Organisms |Prophylaxis Indicated",  "Header" : 1}, 
{"Row" : 9, "Column" : 1, "Item" : null, "Text" : "X* *",  "Header" : 1}, 
{"Row" : 11, "Column" : 1, "Item" : null, "Text" : "",  "Header" : 1}, 
{"Row" : 8, "Column" : 1, "Item" : null, "Text" : "*****************************************************************************",  "Header" : 1}, 
{"Row" : 3, "Column" : 1, "Item" : null, "Text" : "*******************************************************************************",  "Header" : 1}, 
{"Row" : 15, "Column" : 1, "Item" : null, "Text" : "",  "Header" : 1}, 
{"Row" : 12, "Column" : 1, "Item" : null, "Text" : "*******************************************************************************",  "Header" : 1}, 
{"Row" : 14, "Column" : 1, "Item" : null, "Text" : "JJKKKKKJKSP", "Header" : 0}, 
{"Row" : 17, "Column" : 1, "Item" : null, "Text" : "JJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJ", "Header" : 1}
]}
]